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ABSTRACT 
 
Research Question: What are the psychosocial factors that affect causality 
assessment in early phase oncology clinical trials? 
Methods: Thirty-two qualitative interviews were explicated with the aid of 
“Naturalistic Decision Making”. Data explication consisted of phenomenological 
reduction, delineating and clustering meaning units, forming themes, and 
creating a composite summary. Participants were members of the National 
Cancer Institute of Canada’s Clinical Trial Group Investigative New Drug 
committee. 
Results: The process of assigning causality is extremely subjective and full of 
uncertainty. Physicians had no formal training, nor a tool to assist them with this 
process. Physicians were apprehensive about their decisions and felt pressure 
from their patients, as well as the pharmaceutical companies sponsoring the trial. 
Conclusions: There are many problem areas when attributing causality, all of 
which have serious consequences, but clinicians used a variety of methods to 
cope with these problem areas. 
Key Words: Psychosocial, oncology, causality, decision-making, 
phenomenology 
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Introduction 
The Process of Clinical Trials 
 A clinical trial is defined as a prospective research study that aims to 
answer a specific health question by examining the effect and value of an 
intervention(s) on human subjects.1-3 Clinical trials are considered to be on the 
top of the health research hierarchy. Clinical trials lead the way in comparison to 
other health research methods because they address risk benefit ratios, a key 
aspect in intervention and patient safety.1,4 Clinical trials are deemed imperative 
for the study of new medications because they have strong implications for 
efficacy, safety, and clinical practice.1                                                 
Clinical trials are performed in a wide range of health research avenues 
and typically involve a large group of professionals. These professionals include 
laboratory scientists, who work to understand the epidemiology of disease, as 
well as develop treatments; front-line doctors, nurses and other health care 
professionals, who work to conduct the clinical trials tests; pathologists, medical 
laboratory staff and informaticians, who study adverse events; as well as 
epidemiologists, statisticians, and biologists, who asses the cost benefit ratio of 
the treatment.5 Beyond this, there are also organizations and personnel 
responsible for funding, marketing and post-market analysis.6 Clinical trials 
involve a lengthy and detailed drug development process, which consist of four 
primary phases, all of which are separate trials in the overall process (see Table 
1.1 below for a brief summary). The first phase of drug development commences 
the testing of the actual intervention. This intervention could be tested for the first 
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time, or could have had previous clinical trial exposure, but is being tested in a 
different medical setting (e.g., a different pathology).5 In this phase, a maximally 
tolerated dose (MTD) needs to be established.1 MTD determines the maximum 
dose of a drug that can be administered before an unacceptable toxicity level is 
reached.1 This trial is typically small, involving anywhere from 10-80 patients, 
with no control group.6 Once the safety of a drug and the MTD is determined, the 
drug development process can progress to phase II. In phase II, measurements 
of biologic activity and causality of adverse events are assessed in order to 
further establish the safety of the intervention, involving 50-300 patients, again 
with no control group.1 Phase I and phase II of the drug development process will 
be the main focus of this research study. The level of safety involved in drug 
testing increases in each phase of oncology clinical trials; therefore, more 
patients can be involved in each phase, due to the lower risk of harm.6 In phases 
I and II, a control is not required. It is typically in phase III that a randomized trial 
is first introduced. In phase III, the intervention is then tested on hundreds to 
thousands of patients.5 The focus of this trial is to evaluate the effectiveness of 
the intervention in comparison to standardized treatment methods and continue 
to monitor adverse events. 
Table 1       Stages of Drug Development 
Phase Objectives Size Control/No Control 
Phase 1 Maximally Tolerated Dose 
(MTD) is determined 
10-80 participants No control 
Phase 2 Measure biologic activity and 
adverse events 
50-300 
participants 
No control 
Phase 3 Evaluate effectiveness of the 
intervention 
100s-1000s of 
participants 
Control 
Phase 4 Long term surveillance of the 
intervention 
Unknown Control 
! $
 
The final stage of drug development involves long-term surveillance of the 
intervention.1 In this stage, the intervention is legalized and entered into the 
market.5,6 This is also known as the post-marketing analysis phase. This phase 
often goes unrecognized as a primary phase in the drug development process. It 
is typically given very little attention, unless an issue with adverse events arises, 
as resources are often limited.1,5,6  
While the focus of this review is on phase I and II clinical trials, it is 
important to review the entire drug development process and appreciate that 
each phase is subsequently reliant on the previous phase, and the quality of the 
trial, as well as the patients well-being, depend on the optimal execution of each 
and every stage. Oncology clinical trials aim to develop interventions that can be 
used for detecting, monitoring, preventing, and treating cancer.7 Clinical trials are 
also used in the field of oncology to enhance clinical practice, expand the market, 
and augment current ways of thinking about cancer epidemiology.7 In order for 
clinical trials to be successful and to have a significant impact on these various 
aspects of oncology, all phases of the drug development process need to be 
carried out to the best of their potential and as efficiently as possible. Clinical 
trials that are poorly executed result in little to no advancement in clinical 
practice, are a waste of financial resources and are criticized on aspects of 
validity and ethics.7  
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The History of Clinical Trials and their Prevalence in Canada Today 
Clinical trials have a long history, which dates back to the first reported 
clinical trial in 1747.8 James Lind, a Scottish physician, performed the first clinical 
trial while at sea onboard the H.M.S. Salisbury. He was only on the ship for a few 
months when multiple sailors became sick with what was later documented as 
scurvy.8 Lind was in search of a cure and, in doing so, conducted an experiment 
where he controlled the dietary intake of several personnel onboard in order to 
determine which diet would alleviate symptoms.8 Clinical trials have since 
progressed to include placebos, first reported in 1863, as well as randomization, 
which was introduced by Fisher in 1923 while studying pulmonary tuberculosis.8 
It was during World War II that clinical trials became a standard practice for 
evaluating medical interventions.8 Significant methodological advancements have 
been made since the first clinical trial, emphasizing patient safety, ethics, as well 
as standard protocols and procedures. However, there is still a strong need to 
continue to improve the clinical trial process.  
 Oncology clinical trials play a large role in the Canadian health care 
system. According to the Canadian Cancer Society, as of July 2010 a total of 
1177 oncology clinical trials are currently taking place in Canada (see Table 1.2 
for a breakdown by province).9 If all of these trials progress to phase II, there 
would be anywhere from 50 to 300 patients in each clinical trial, i.e., between 
58,850 and 353,100 individuals putting their lives in the hands of oncology 
clinical trials in Canada this year. This not only effects the lives of the patients 
! &
involved, but also affects oncologists, clinicians, hematologists, project 
managers, pharmacists, social workers, nurses and the patients’ friends and 
family.9 
Table 2       Current Number of Oncology Clinical Trials in Canada 
Province Number of Oncology Clinical Trials 
Alberta 158 
British Columbia 62 
Manitoba 94 
New Brunswick 26 
Newfoundland and Labrador 11 
Nova Scotia 42 
Ontario 510 
Prince Edward Island 6 
Quebec 219 
Saskatchewan 49 
Canadian Cancer Society (2010)9 
 Oncology clinical trials cost a large sum of money. The American FDA 
reported that a typical clinical trial consisting of phase I, II and III involving 3,330 
participants can cost between $6.6 million and $22.1 million.10 From 2005 to 
2006, the Canadian Cancer Society donated $5.5 million to oncology clinical 
trials in Canada.9 This was followed by a $20 million dollar donation from the 
National Cancer Institute (NCI) in the United States of America and industry.9 
Funding for oncology clinical trials also comes from a large array of sources, 
including but not limited to organizations, individuals, physicians, medical 
institutions, foundations, volunteer groups, pharmaceutical companies and 
federal agencies. This year alone the Canadian Cancer Society is giving $1.4 
million to ten investigators across Canada in support of oncology clinical trial 
research.9 In the United States, total expenditures of the clinical trial industry 
have increased drastically. In 1996, total expenditures were approximately three 
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billion dollars, increasing to sixteen billion dollars in 2003, and twenty six billion 
dollars in 2007.10 Oncology clinical trials are a major part of the medical industry 
in Canada and the United States.  
Defining and Classifying Adverse Drug Reactions (ADRs) 
 When a new drug is first administered to humans, sometimes the body 
reacts unfavorably to these novel substances, resulting in what is known as an 
adverse drug reaction (ADR). In order to assist clinicians and other professionals 
in communicating about ADRs, they are classified into five different categories 
(see Table 1.3 for summary). The first category, better known as “Type A” 
(although sometimes referred to as “Type 1”) is augmented adverse events.11-14 
These types of ADRs are most common (approximately 80 percent of all reported 
ADRs), and are defined as an exaggeration of a drug’s predicted 
pharmacological actions, a form of a toxic effect.11-14  These types of adverse 
drug reactions are often reproducible and highly drug dependent.11-14  These 
reactions also have high morbidity, but low mortality, rates and respond well to 
dose reduction.11 
 The second ADR classification is “Type B”, (sometimes referred to as 
“Type 2”), “B” standing for bizarre.11-14  These ADRs are almost the complete 
opposite of what one may expect from “Type A” ADRs. They are unexpected 
reactions that occur from the otherwise known effects of a drug, and are typically 
uncommon.11,13 These reactions are rarely dose-related and are associated with 
low morbidity, but high mortality, rates.11-14 It has been found that these types of 
reactions are most commonly counteracted with drug withdrawal.11 This does not 
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mean discontinuing the study of the drug, but rather discontinuing the 
administration of the drug to the patient experiencing a bizarre reaction.11 
 “Type C” is the third classification of ADRs and includes reactions that are 
continuous or chronic.12,14 “Type C” reactions are uncommon and arise with 
prolonged drug use.12,14 “Type D” ADRs stands for delayed reactions, which are 
also uncommon and only become apparent after using the drug for quite some 
time.12,14 
 The final two categories are less recognized as major classifications 
because they are either not directly associated with the drug or are considered a 
failure; they are “Type E” and “Type F”. “Type E” refers to those reactions that 
occur after “end of use” or withdrawal of a drug, and are relatively uncommon.14 
“Type F” is a common reaction and refers to a failure of the therapy.13 These 
types of reactions may be attributed to the dose given, but are more often than 
not due to the drug interacting with other drugs or interventions.13  
Table 3      Classification of Adverse Events 
Type Definition Commonality 
Type A Augmented Most common 
Type B Bizarre Uncommon 
Type C Continuous/Chronic Uncommon 
Type D Delayed Uncommon 
Type E End of Use Uncommon 
Type F Failure of Therapy Common 
 
Problems with Classifying ADRs 
Although ADRs can be classified, the problem lies in actually defining what 
constitutes an ADR. This can become quite difficult because these definitions are 
very dynamic and are constantly being upgraded. Current definitions of ADRs 
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have become more sophisticated with time, but still remain relatively inconsistent, 
and many definitions lack vital components.15-17 For example, the World Health 
Organization (WHO) has used a definition of an ADR for several decades that 
states, “a response to a drug that is noxious and unintended and occurs at doses 
normally used in humans for the prophylaxis, diagnosis or therapy of disease, or 
for modification of physiological function”.15 Laurence defines an ADR as, “A 
harmful or significantly unpleasant effect caused by a drug at doses intended for 
therapeutic effect (or prophylaxis or diagnosis) which warrants reduction of dose 
or withdrawal of the drug and/or foretells hazard from future administration.”.16 
 Health Canada reported that Canadian ADR reporting regulations define ADRs 
as, “a noxious and unintended response to a drug, which occurs at any dose and 
requires in-patient hospitalization or prolongation of existing hospitalization, 
causes congenital malformation, results in persistent or significant disability or 
incapacity, is life-threatening or results in death”.18 
The ‘standard’ definition by the WHO, as well as many definitions, can be 
seen as inadequate because they fail to address what can be understood as 
minor reactions, they do not account for error, and they tend to emphasize the 
‘harmfulness’ of the event. Emphasizing the harm involved in an ADR does not 
sit well with patients because they may experience ADRs that do not explicitly 
involve tremendous physical pain (“harmful”), but none-the-less are 
uncomfortable and affect their well-being.15,16,19 ADRs are often associated with 
terms such as ‘death’, ‘life threatening’, ‘prolonged hospitalization’, and 
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‘permanent disability’.20 These restrictive terms need to be questioned as they fail 
to account for many serious ADRs.20 
The most inclusive definition of ADRs to date was proposed by Edwards 
and Aronson (2000), who stated, “an appreciably harmful or unpleasant reaction, 
resulting from an intervention related to the use of a medical product, which 
predicts hazards from future administration and warrants prevention or specific 
treatment, or alteration of the dosage regimen, or withdrawal of the product”.16 
This definition is inclusive in that it accounts for minor reactions and error. 
However, none of these definitions are consistent and may lack vital 
components, such as minor reactions and error.15-18 It is evident that a 
consensus must be reached on a standardized definition of ADRs to be used 
across all clinical trials, if clinical trials are to be considered a truly standardized 
process.15-20 
Oncology clinical trials are a long and complex process. There are 
numerous oncology clinical trials currently taking place in Canada, and all are run 
over multiple years and require numerous millions of dollars, not to mention 
physician, hospital, and patient time. There are also major problems in identifying 
and classifying adverse events, which can pose major issues in early phases of 
oncology clinical trials. These issues will be discussed in depth in the next 
sections. 
Research Study 
An inclusive standardized definition of ADRs needs to be established in 
order to properly assign causality and maintain a level of true standardization 
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within the clinical trial process. Causality assessment is a process that takes 
place in the early phases of oncology clinical trials. It involves determining 
whether an adverse event (a reaction that occurs after a drug is administered) 
can be attributed to the drug or intervention being tested or if it is due to external 
causes15-20 (see Figure 1.2 for a summary of this process). This diagram (Figure 
1.2) was created by Cosby (personal communication, 2010) to delineate the 
steps that are taken to assign causality in clinical trials, and to demonstrate the 
patient-physician interaction during this process. First, there is an onset and 
diagnosis of an illness; in this case, some form of cancer. The physician then 
administers the drug or intervention to the patient. For example, the patient may 
be required to undergo to chemotherapy, or is administered a drug new to the 
market. The patient may subsequently start to exhibit signs and symptoms of a 
drug’s effect. Intended effects would include the reduction or elimination of 
disease progression, or even the eradication of the cancer from the body.  
Unfortunately, unintended ADRs may also occur, including, hair loss, weight loss 
or weight-gain, headaches, nausea etc. It is at this point when the physician must 
assign causality for the intended benefits and unintended ADRs of the 
medication. The physician needs to make a complex decision of determining 
whether this adverse event is due to the drug or intervention being tested, or due 
to an external cause, for example, the illness itself, another medication, an 
infection, or some unknown factor or element (such as stress, or a secondary 
illness not yet identified). If the adverse event is determined to be a result of the 
drug or intervention being tested, it is known as an adverse drug reaction. In this 
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case, the physician needs to determine the plan of action to be taken to deal with 
this ADR. If it is deemed that the adverse event was due to an external source, it 
remains an adverse event and no further action is taken. The process of 
assigning causality exists to determine a drug or intervention’s level of safety, the 
effect it has on the body and the illness, as well as facilitating the progress of the 
clinical trial through to the next stages. Proper methods of causality assessment 
are extremely important for both the patient and to develop an overall 
understanding of the drug's safety.  
Figure 1.      The Steps in Assigning Causality 
 
 
Purpose: The purpose of this study was to develop a psychosocial 
understanding of how clinicians assign causality in order to improve the process 
of oncology clinical trials. It was a qualitative based study of oncologists’ views on 
making these decisions, with the purpose testing and verifying Figure 1. “The 
Steps in Assigning Causality”. The research also determined if the process 
outlined in Figure 1 conceptualizes the process in oncology clinical trials. Lastly, 
the research determined what psychosocial factors affect this process, and to 
examined the roles that patients and physicians play in this process. The main 
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focus was on causality assessment and the actions taken during and after this 
process. 
Research Question: What are the psychosocial factors that play a role in 
assigning causality to ADRs?  
The Need for Qualitative Research 
This research used a qualitative approach. A recent article published on 
March 12, 2010 in the Journal of Investigational New Drugs entitled, “A 
Qualitative Study Evaluating Causality Attribution for Serious Adverse Events 
During Early Phase Oncology Clinical Trails”,21 stated that this is the first study of 
its kind to use qualitative methods to investigate causality assessment in early 
phase oncology clinical trials.21 Qualitative inquiry within the field of clinical 
oncology is not a common practice, although it is in high demand. The literature 
that supports the rationale for this study portrays that there is a strong need for 
qualitative research.9,15-21 This is amplified by Boulton and colleagues when they 
stated, “the full potential of qualitative research has yet to be realized in the field 
of health care”.22  
 A complete understanding of causality assessment in early phase 
oncology clinical trials cannot be understood through quantitative methods alone, 
and would be more appropriately investigated through qualitative methods.9,15-21 
In order to understand the decision making process of individuals, it is imperative 
that a deeper understanding of the semantics of human experience is achieved.23 
This can be achieved through a psychosocial understanding of the ADR decision 
making process. This study will also add to the accuracy and relevance of current 
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and future quantitative literature surrounding causality assessment in early phase 
oncology clinical trials.23 Quantitative analysis cannot address the how and why 
questions of human behaviour, so a holistic perspective of causality assessment 
cannot be reached without the use of qualitative measures.22  
Theoretical Framework 
 A theoretical framework is defined as the solid foundation of a research 
study.24 A theoretical framework provides the researcher with models and 
concepts to guide the data analysis stage.24 This research was not aimed at 
testing a hypothesis, but rather answering a research question, and needed a 
theoretical framework that supports this. “Naturalistic Decision Making (NDM) 
Theory” fits these criteria.24,25 It is a psychosocial theory that examines how 
professionals use the experience they have gained within their field of expertise 
to make proficient decisions within “complex real-world environments”.25,26 In 
order to understand NDM, it is important to take a look at the history of decision-
making. There are essentially three separate paradigms: formal (empiricist), 
rationalist, and naturalistic.25 The formal (empiricist) and rational paradigms are 
different from the naturalistic paradigm because they fail to account for the 
decision makers’ expertise, task complexity, as well as environmental 
limitations.25 Therefore, formal and rational paradigms cannot be applied to real 
world settings.25 The naturalistic paradigm however, represents a paradigm shift 
away from these traditional forms of thinking.27 Within the field of oncology 
clinical trials, decisions (specifically in the form of causality assessment) are 
constrained by both time and uncertainty in information (for example adverse 
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events). Naturalistic decision-making takes these issues into consideration.25,27 
Unlike other decision making theories, NDM incorporates values into the decision 
making process, making it appealing for medical decision making.28  
 There are five key components in Naturalistic Decision Making 
Research.25 
1. Emphasis on expert decision-making. 
2. A focus on the decision making process. 
3. Development of “situation-action matching decision rules”. 
4. “Context bound informal modeling”. 
5. “Empirical-based prescription”. 
The decision making process includes; a description of the information required 
to make a decision, the interpretation of this information, as well as how and what 
rules are applied to making a decision.25 The purpose of this research study is 
coherent with the purpose of NDM; to improve the decision making process. In 
order to improve causality assessment, and eliminate error, in early phase 
oncology clinical trials, it is imperative that an understanding of the decision 
making process is reached.25 In doing so, this research further aims to improve 
decision making effectiveness, aid in developing realistic decision making 
strategies, and better prepare professionals making these proficient decisions.25  
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Rationale for Research 
Summary Table of Literature Supporting Current Issues in Causality 
Assessment 
 
The following table (Table 4) is a summary of the relevant literature that 
supports the inadequacies and problems faced when assigning causality, and in 
doing so, provides a rationale for the research. The literature was systematically 
reviewed and comprised into a table format where the data is displayed in 
summarized form for a straightforward comparison. Experts agree that this 
process helps eliminate bias while strengthening the relationship between the 
research evidence and the study.27 The relevant findings were summarized into 
the following categories as rationale for this study: 
! Adverse Drug Reaction (ADR) reporting differs between databases and 
publications 
!  Improvements need to be made in detecting and preventing medical 
error; inaccurate reporting of ADRs 
! Inconsistency of key terminology used to assess causality 
! Inconsistent definition of harm; inter-rater probability (poor expert 
agreement) 
! No universally accepted tool for assessing causality, need for a 
standardized tool 
! The safety of ADR reporting needs to be revised 
! There is a need to increase patient involvement in causality assessment 
!  Under-reporting of ADRs. 
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Also see Appendix 1 for the literature search parameters used to obtain 
these data. This table includes a description of the databases or journals 
searched, the search terms used, the number of original results, the criteria used 
for selecting and eliminating certain articles, along with a list of the chosen 
articles.  
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Table 4       Review of the Literature 
See Appendix 1 for Review of the Literature Search Parameters 
 
Author(s)/Title/ 
Year of Publication Research Question Study Design Relevant Findings 
Agbabiaka, T.B., Savovic J., 
& Ernst E. 
Methods for causality 
assessment of adverse drug 
reactions  
2008 
To review and discover the 
strengths and weaknesses 
of existing causality 
assessment tools. 
Electronic databases were 
searched to find articles on 
existing causality assessment 
tools in MEDLINE, EMBASE, and 
the Cochrane  
Database including global 
introspection, algorithms and 
Bayesian tools. 
-No universally 
accepted tool for 
assessing causality 
-Inter-rater 
probability (poor 
expert agreement) 
Alsheikh-Ali, A. A., & Karas, 
R. H.  
Ezetimibe, and the 
combination of 
ezetimibe/simvastatin, and 
risk of cancer: A post 
marketing analysis 
2009 
If ezetimibe or ezetimide 
combined with sinvastatin 
increased the risk of cancer, 
would cancer-related 
adverse events reports 
reflect this? In comparison 
to sinvastatin on its own or 
other cholesterol-lowering 
drugs. 
Rates of cancer in adverse event 
reports filed with the US Food and 
Drug and Administration (FDA) 
occurring in patients on ezetimibe 
or E/S were compared to those 
patients in sinvastatin or other 
potent cholesterol-lowering drugs. 
 
-Under-reporting of 
ADRS 
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Author(s)/Title/ 
Year of Publication Research Question Study Design Relevant Findings 
Arimone, Y., Béguad, B., 
Miremont-Salamé, G., 
Fourrier-Réglat, A., Moore, 
F., Molimard, M., & 
Haramburu, F. 
Agreement of expert 
judgment in causality 
assessment of adverse drug 
reactions 
2005 
To analyze and compare 
the judgment of 5 senior 
experts using global 
introspection about drug 
causation on a random set 
of putative ADRs. 
Does a group of senior 
experts working separately 
give concordant opinions in 
the assessment of ADRs? 
What are the main causes 
of rater disagreement? 
150 drug-effect pairs were 
independently assessed by five 
experts for the probability of drug 
causation. Agreement among the 
experts was assessed using 
kappa coefficients. 
-No universally 
accepted tool for 
assessing 
causality, need for 
a standardized tool 
-Inter-rater 
probability (poor 
expert agreement) 
 
Basch, E., Jia, X., Heller, 
G., Barz, A., Sit, L., 
Fruscione, M., Appawu, M., 
Iasonos A., Atkinson T., 
Goldfarb, S., Culkin A., Kris, 
M. G., & Schrag, D. 
Adverse symptom event 
reporting by patients vs. 
clinicians: relationships with 
clinical outcomes 
2009 
How do patient and clinician 
reporting compare, when it 
comes clinical events? 
 
Patients and clinicians 
independently reported 6 Cancer 
Institutes Common Terminology 
Criteria for Adverse Events 
(CTCAE) symptoms. A time 
dependent Cox regression model 
was used to measure 
associations. 
 
-There is a need to 
increase patient 
involvement in 
causality 
assessment 
")!
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Author(s)/Title/ 
Year of Publication Research Question Study Design Relevant Findings 
Béguad, B. Martin, K., 
Haramburu, F.  
Rates of spontaneous 
reporting if adverse drug 
reactions in France 
2002 
What is the magnitude of 
underreporting from serious 
ADRs in France from 3 
different fields of 
pharmacoepidemiology 
studies? 
Estimating the magnitude of 
underreporting by comparing 
ADRs to the number of cases 
spontaneously reported to the 
French pharmacovilgance system 
during the same period and within 
the same territory. 
-Under-reporting of 
ADRs 
Betancourt, B. Y., Marrero-
Miragaya, M. A., Jiménez-
López, G., Valenzuela-Silva, 
C., García-Iglesias, E., 
Hernández-Bernal, F., 
Debesa-García, F., 
González-López, T., 
Alvarez-Falcón, L., López-
Saura, P., & the Cuban 
National Network of 
Pharmacoepidemiology 
Pharmacovigilance program 
to monitor adverse reactions 
of recombinant 
streptokinase in acute 
myocardial infarction 
2005 
Assess ADRs associated 
with intravenous 
recombinant SK in patients 
with AMI in routine clinical 
practice. 
A spontaneous reporting based 
pharmacovigilance was 
conducted, documented and 
analyzed. 
 
-Under-reporting of 
ADRs 
Coombes, M., Mukherjee, 
S., Kowaleski, B., Levine, 
M., Cosby, J., & Arnold, A. 
A tool for assessing adverse 
Understand the clinical 
reasoning behind causality 
assessment during phase 
I/II oncology clinical trials. 
In-depth interviews with 
oncologists and trial coordinators 
were conducted. 
-No universally 
accepted tool for 
assessing 
causality, need for 
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Author(s)/Title/ 
Year of Publication Research Question Study Design Relevant Findings 
events in phase I/II 
oncology clinical trials 
2007 (Abstract) 
Use this information to 
develop a causality 
assessment. 
a standardized tool 
Edwards, R., & Aronsom, J. 
K. 
Adverse drug reactions: 
definitions, diagnosis, and 
management 
2000 
To outline the definition of 
adverse drug reactions, 
outline their classification, 
and discuss ways in which 
they are diagnosed, 
managed, and monitored. 
Review. -Inconsistency of 
key terminology 
used to assess 
causality 
 
Fromme, E. K., Eilers, K. 
M., Mori, M., Hsieh, C., & 
Beer, T. M. 
How accurate is the clinician 
reporting of chemotherapy 
adverse effects? A 
comparison with patient-
reported symptoms from the 
quality-of-life questionnaire 
C30 
2004 
Are adverse events reported 
and assessed in 
chemotherapy clinical trials 
by clinicians accurate? 
Patient reported symptoms from 
the European Organization for the 
Research and Treatment of 
Cancer Quality-of-Life 
Questionnaire C30 (QLQ-C30) 
were compared to clinician 
reporting of adverse events. 
-Inaccurate 
reporting of ADRs #+!
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Author(s)/Title/ 
Year of Publication Research Question Study Design Relevant Findings 
Hubbard, G., Kidd, L., & 
Donaghy, E. 
Preferences for involvement 
in treatment decision 
making if patients with 
cancer: A review of the 
literature 
2008 
What are patients’ 
preferences for involvement 
in cancer treatment 
decision-making? 
Systematic methods were used to 
search for literature, inclusion 
(preferences for involvement in 
treatment decision making for 
cancer) and exclusion 
(preferences about decision 
making roles in cancer screening 
or genetic testing) criteria were 
applied, the quality of the studies 
were appraised. Relevant data 
from the included studies was 
selected and a narrative summary 
of this data was provided. 
-There is a need to 
increase patient 
involvement in 
causality 
assessment 
Ioannidis, J. P. A., & Lau, J. 
Completeness of safety 
reporting in randomized 
trials 
2001 
To scrutinize the 
completeness of safety 
reporting in randomized 
trials. 
Survey of safety reporting in 192 
randomized drug trials. 
-There is a need to 
increase patient 
involvement in 
causality 
assessment 
-The safety of ADR 
reporting needs to 
be revised 
Ioannidis J.P.A., Lau, J 
Improving safety reporting 
from randomized trials 
2002 
How can we improve safety 
of reporting adverse events 
in randomized trials? 
Review ADR reporting 
differs between 
databases and 
publications 
-No universally 
accepted tool for 
assessing 
causality, need for 
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Author(s)/Title/ 
Year of Publication Research Question Study Design Relevant Findings 
a standardized tool 
Kelly W.K., & Halabi, S. 
Guideline for submitting 
adverse event reports for 
publication 
2009 
The International Society for 
Pharmacoepidemiology 
(ISPE) initiated a task force 
in 2004 to examine the need 
for guidelines in publishing 
AE reporting. 
Literature review. -ADR reporting 
differs between 
databases and 
publications 
Koch-Weser, J., Sellers, E. 
M., & Zacest, R. 
The ambiguity of adverse 
drug reactions 
1977 
How ambiguous is adverse 
event reporting? 
Three clinical pharmacologists 
independently examined 500 
adverse event reports reported by 
physicians as ADRs. 
-Inter-rater 
probability (poor 
expert agreement) 
 
Mahoney, M. R., & Sargent, 
D. J. 
Adverse-event rates: 
Journals versus databases 
2007 
Is there a difference 
between adverse event 
reporting in peer reviewed 
publications and 
corresponding databases? 
 
Using the clinical data update 
system (CDUS) to compare 
adverse event data in peer 
reviewed publications and adverse 
event data reported in US National 
Cancer Institute (NCI) database. 
-ADR reporting 
differs between 
databases and 
publications 
-Under-reporting of 
ADRs 
 
McCarthy, M.  
US cancer group calls for a 
centralized review of clinical 
trials 
2003 
This article, written from the 
standpoint of the American 
Society of Clinical Oncology 
(ASCO), hopes to identify 
and improve the 
standardized review 
process, patient safety, and 
public confidence in clinical 
trials.  
ASCO calls for a review of clinical 
trials through a central review 
process, opposed to standard 
institutional review boards. 
 
-Under-reporting of 
ADRs 
-The safety of ADR 
reporting needs to 
be revised 
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Author(s)/Title/ 
Year of Publication Research Question Study Design Relevant Findings 
Molokhia M., Tanna, S., & 
Bell, D. 
Improving reporting of 
adverse drug reaction: 
Systematic review 
2009 
To evaluate methods to 
improve ADR reporting via a 
systematic literature review. 
Systematic review of the literature.
 
-No universally 
accepted tool for 
assessing 
causality, need for 
a standardized tool 
 
Ocloo J.E. 
Harmed patients gaining 
voice: Challenging dominant 
perspectives in the 
construction of medical 
harm and patient safety 
reforms 
What are the experiences of 
those who have been 
subject to medical harm? 
Interviews, focus groups and 
surveys. 
-Inconsistent 
definition of harm 
Scharf, O., & Colevas, A. D. 
Adverse event reporting in 
publications compared with 
sponsor database for 
cancer clinical trials 
2006 
Does published adverse 
event data differ from what 
adverse event data is in 
sponsor’s databases and 
study protocols of data 
collection requirements? 
 
This study compared studies that 
used a common toxicity criterion. 
Study protocols for reporting 
adverse event data were 
compared to methods cited in 
publications. Adverse event 
reports in these publications were 
then compared to adverse event 
reports in the trials’ databases. 
-ADR reporting 
differs between 
databases and 
publications 
Inter-rater 
probability (poor 
expert agreement) 
 
Trotti, A., Bentzen, S. 
The need for adverse 
effects reporting standards 
in oncology clinical trials 
2004 
Prove the need for reporting 
standards in oncology 
clinical trials. 
Review -No universally 
accepted tool for 
assessing 
causality, need for 
a standardized tool 
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Author(s)/Title/ 
Year of Publication Research Question Study Design Relevant Findings 
Westwood M., Rodgers M., 
& Sowden A. 
Patient safety: Mapping the 
literature 
2002 
What have been the goals 
of patient safety research? 
What methods have been 
used inpatient safety 
research? What types of 
studies have shown what 
kind of results? 
A mapping exercise of the 
literature on patient safety was 
performed using 15 databases 
Improvements 
need to be made in 
detecting and 
preventing medical 
error 
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Rationale for Research Continued 
The following sections will address, in more detail, the major issues with 
ADRs and causality assessment that were outlined in the literature and 
summarized in Table 4.  
The Definition of Harm 
 There are significant differences between patients’ and clinicians’ 
perspective on harm, which contribute to the variances in adverse event reporting 
between these individuals. There is great ambiguity with the term harm in any 
circumstance. Harm is a loaded term and can include physical, emotional, 
psychological, social, and economic factors.29 Harm is both objective and 
subjective, but is all too often associated with objectivity within the medical 
field.19,29 According to Ocloo (2010), “The process of defining medical harm is not 
value free, but it tends to reflect a narrow clinical interpretation of harm that 
excludes non-clinical or non-disease specific outcomes that the patient may 
consider harmful.”.19 In clinical trials, it is the patients who are exposed to harm, 
so the definition of harm needs to be more patient centered.19 The purpose of the 
research was to come to a psychosocial understanding how clinicians decide 
which adverse events are harmful and which events are not. Through this, a 
better understanding of the differences between a patient’s and a clinician’s 
definition of harm can be met. A psychosocial understanding can aid in ensuring 
that the codes and guidelines involved in clinical trials maintain a strong inclusive 
definition of harm, which will later aid in creating more accurate risk-benefit ratio, 
keeping patients safe from harm.29  
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 Seeing that patients and professionals disagree on the definition of harm, 
there can also be a large variance between what patients and professionals 
report when it comes to adverse events. Although patient reporting is not 
currently a standard practice in assessing causality of adverse events in 
oncology clinical trials, research has shown it can be quite complementary.30 
Patient reporting of ADRs is much different than what is reported by 
professionals; patients typically focus on the minute adverse events, ones that 
fluctuate on a day to day basis, whereas professionals tend to place the 
emphasis on more severe adverse events that are likely to have a strong impact 
on the clinical trial.30 Since current methods do not incorporate the patient’s 
perspective, they do not include the events that affect the patient’s daily health.31 
Evidence suggests that by including the patient in the reporting process, a more 
complete picture of drug safety can be established.31 Looking at this through a 
critical lens, it may be proposed that patient reporting is subject to bias and error; 
however, Basch et al. (2009) argue that professional reporting is biased as well.31 
When it comes to patients, the majority prefer to be highly involved in any aspect 
of treatment as well as decision-making.30 Therefore, not only would patient 
involvement aid in causality assessment, it will also allow patients to feel more 
confident in clinical trials. Through a psychosocial understanding of how 
clinicians assign causality, an understanding of the role patients play in the 
process can also be met. It is evident that patients do not play a strong enough 
role in the causality assessment process, which may contribute to the difficulties 
of professionals’ experiences. 
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 In any field of research, it is critical that there is consistency amongst its 
professionals. However, Airmone et al. (2005) compared adverse event reporting 
rates through global introspection of five senior experts and found that 
agreement between experts was poor.32 Experts indicated it was difficult to reach 
an agreement while working separately without the use of a standardized 
procedure.32 This is not new; Koch-Weser, Seller and Zacest published a study in 
1977 that reported similar findings.31 Using NDM, it is possible to develop a 
psychosocial understanding of how clinicians assign causality, the tools they use, 
and the challenges they face, which will aid in creating consistency in 
professionals’ reporting. By understanding how individual clinicians make these 
decisions, links between professionals’ decision making can be made. 
Time Constraints 
 Time constraints also influence causality assessment and adverse event 
reporting. Often, oncology clinical trials are time dependent due to drug 
development costs and federal regulations. Experts have reported that time 
restraints place added pressure on clinicians and significantly contribute to the 
under-reporting of adverse events.33-35 It has also been reported that time 
restraints serve as barriers to other aspects of clinical trials including office visits, 
recruitment and assessment of health related quality of life.36 Minor and one-time 
reactions often take up too much valuable time in the clinical trial process, and 
therefore, are often left under-reported. Time restraints can also reduce the 
quality of decision-making and the confidence in these decisions by 
clinicians.33,34 This is a major issue in clinical trials, and it is absolutely crucial that 
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this issue is prominently addressed. Clinical trials put patients’ lives at risk, so it is 
very problematic when clinicians are not confident in their decision-making 
abilities, or feel rushed while making these important decisions. Any ‘short 
cutting’ and under-reporting may benefit drug development costs and 
pharmaceutical companies, but it clearly will not provide a true reflection of the 
drug’s ability and effects, nor does it reflect the patients’ and professionals’ best 
interests.33-35 Given the time constraints placed on clinicians, it can be expected 
that errors will be made. A quote taken from Cosby’s 2010 report exhibits this 
phenomenon; “the culture of medicine creates an expectation of perfection and 
attributes errors to carelessness or incompetence”.37 The system is often the 
cause for these time pressures, but because the clinical trial system is viewed as 
'perfect', it can be very difficult to explore decision making. It is evident that time 
pressures affect clinicians’ decision making skills, but the research’s purpose is 
to understand to what extent, how, and why this happens. 
 Constraints of Error Reporting Systems  
The use of language plays a key role in defining and preventing medical 
error. In a study by Elder, Palleria, and Regan (2006), it was found that the 
definition of medical error is inconsistent, particularly between what patients and 
physicians define as medical error.38,39 A paper released by the Institute of 
Medicine in 1999 entitled, To Err is Human: Building a Safer Health System, 
defines medical error as “the failure of a planned action to be completed as 
intended or the use of a wrong plan to achieve an aim”.40 Errors can start small 
as difficulties in practice, interventions and products, and develop into system 
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errors.40 Most medical errors are actually the result of a system error, but are still 
primarily viewed by physicians as individual errors.40,41 This can contribute to the 
under-reporting of medical errors because individuals feel that they may be held 
liable for the error.37 A diagram by Rickles and colleagues (2010), illustrates how 
systems errors are actually a combination of many factors (See figure 2.).41 The 
chance of making an error is present in medical decision making, and this is 
clearly outlined by the NDM model which recognizes that these decisions take 
place in a complex real-world environment and that these decisions are often 
constrained by time and uncertainty of information.25,27 The aim of the research is 
to understand this fear of medical error through NDM and the psychosocial 
elements that coincide with it. 
System errors have a major impact on patient safety. In fact, it is 
estimated that medical errors are the eighth leading cause of death in the United 
States of America and that the American health care system is the third leading 
cause of death in the United States, right behind cancer and heart disease.40,42,43 
A startling 106,000 Americans die each year from adverse drug reactions 
alone.43 The deaths are the result of normal doses, known effects, and proper 
administration; this number is more than doubled when medical error is taken into 
account. It was also found that Americans expressed great concern about the 
risk of medical error and were open to both public and private investigation to 
reduce the risk of medical errors.42 Americans are right to express the concern 
considering the Institute of Medicine estimated that more than half of adverse 
events are a result of preventable medical errors.40  
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Figure 2.      A Multilevel Framework of Influences on Error Occurrence in                           
Organizations Systems.41 
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As evident, there is plenty of room for improvement when it comes to 
medical errors and a systematic change is needed.41,44 Drastic measures do not 
have to be taken; in fact, large improvements can be made with simple 
interventions. Examples include clinical support systems, patient monitoring and 
reminder systems.40,42,43 These little steps will have an enormous impact on 
medical errors and in turn improve patient safety. Other more drastic solutions 
include a nationwide error reporting system, which would aid in creating an active 
and standardized method of error reporting.37 Clinicians face many issues when 
assigning causality and have many concerns. It can be argued that this decision 
making process is full of imperfections, and errors are inevitable. Language and 
under-reporting of medical errors are serious issues that need to be addressed 
within the field of oncology clinical trials. A naturalistic decision making 
perspective of causality assessment can help to understand and prevent medical 
errors. 
Under Reporting of Adverse Events 
  Medical errors are often severely under-reported in oncology clinical 
trials.45,46 Unfortunately, ‘under-reporting’ has no standard definition, but there 
are several proposed definitions of under-reporting.46 For example, it could be 
that the percentage of the number of the ADRs reported does not match those 
that are suspected.47 Several studies have been performed to explore the under-
reporting of adverse-events in clinical trials. Alsheiki-Ali and Karas (2009) 
compared the rates of adverse event reporting between two drugs.48 The first 
drug was ezetimibe and the second was ezetimibe combined with simvastin, 
! $#
which is currently known to increase the risk of cancer.48 The study found that 
adverse event reporting between the two drugs did not reflect that one drug 
increased the risk of cancer over the other and concluded that adverse events 
are widely under-reported.48 Bégaud et al. (2010) compared the rates of adverse 
event reporting using three different perspectives of pharmacoepidemiology in 
France: general practitioners, inpatients, and medical departments.49 The study 
found that on average, less than five percent of all serious ADRs are actually 
reported, leading to the conclusion that adverse event under-reporting is a 
serious issue. 49 Mahoney and Sargent (2007) compared rates of adverse event 
reports of peer-reviewed publications to their corresponding databases.50 The 
study found that there was not only an under-reporting of serious adverse events, 
but also of minor and reoccurring adverse events.50  
 The prevalence of under-reporting can be attributed to a variety of 
reasons, the first and foremost being that adverse events are reported on a 
voluntary basis.51 This being said, it is not mandatory that all events are reported, 
but that only those that are seen as serious, rare, and attributable to the drug 
being tested, leaving out minor and reoccurring events.50,51 Under-reporting can 
also be attributed to the fact that physicians fear being individually blamed for 
systematic errors.40,41  
“Lippincott’s Guide to Preventing Medication Errors”, a nursing text 
published in 2003, states that reports are to be made if the drug being tested is 
responsible for: “death; life-threatening illness; initial or prolonged hospitalization; 
disability; congenital anomaly; need for medical or surgical intervention to prevent 
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a permanent impairment or injury”.52 Again, this does not include minor and 
reoccurring events. This book also includes a section on “Your responsibility in 
reporting”, in which it states: “When filling out a MedWatch form, keep in mind 
that you are not expected to establish a connection between product and the 
problem. You do not have to include a lot of details; you only have to report the 
adverse event or the problem with the drug or product.”.51 This lack of detail is a 
major issue in under-reporting.  
Under reporting can also be attributed to researcher bias; inconsistency in 
reporting standards and classification methods; incomplete and over simplistic 
reports; lack of proper training by personnel who complete the reports; and lack 
of awareness.51,52 As well, there is usually a gradual decrease in reporting over 
time once a drug has been introduced; therefore, it is likely that new drugs will 
have higher rates of adverse event reporting than older drugs.53,54 
It is also necessary to consider the external reasons for under-reporting, 
such as business rules and regulations set forth by databases, as well as 
publicity.50,55 Businesses sometimes have very specific rules that skew the 
reporting of adverse events, such as not accepting reports that contain 
incomplete or queried information, not accepting reports that make note of ADRs 
that occur during non-treatment phases, as well as not accepting “incomplete 
data mappings”.50 Therefore, if databases refuse to accept these sorts of 
information, it is likely they will never be reported in the first place. There are also 
influential differences between adverse events reported in databases and their 
respected publications, as reported by Kelly and colleagues in 2007, who found 
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that very little to no requirements are established in order to publish adverse 
events and propose that standardized guidelines be established.56  
 The high incidence of under-reporting of adverse events leads to 
inaccurate findings and has strong implications on many aspects of clinical 
trials.53,57 The first and most pressing implication is patient safety.48,51 When 
adverse events are under-reported, patients may be exposed to drug-induced 
harm because risk-benefit ratios are not accurate, affecting patients’ quality of 
life, morbidity and even mortality.33,57 This can lead to patients being 
administered toxic dosages of a drug or even exposure to a drug that should be 
withdrawn from the trial. Other implications include an ill effect of standardized 
review processes, public faith and trust in clinical trials, and financial drain on the 
health care system.16,33 The purpose of the research is to exemplify this need for 
standardized reporting procedures. It is hoped that with the aid of NDM, the 
research can actually explain why underreporting is an issue clinicians struggle 
with, and will propose reasonable solutions. 
 There are many issues associated with reporting adverse events, 
including an inconsistent definition of harm, constraints placed on professionals 
and severe under-reporting, all which can be understood and addressed through 
a NSM perspective. However, reporting adverse events is only the first part of the 
process, and is followed by the difficult decision of determining whether or not the 
adverse event can be attributable to the drug or intervention being tested. 
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Current Tools for Assessing Causality 
 There are three primary types of tools used for assessing causality of 
adverse events in oncology clinical trials; global introspection or expert judgment, 
Bayesian approaches, and operational algorithms.58 Each of the methods utilizes 
different causality categories, and therefore, uses different criteria to assess 
causality. The outcome of an undefined categorical approach delivers great 
inconsistency between methods.58 Although some methods are more commonly 
used over others, no single method of assessing causality has been universally 
accepted.58-62  
Global Introspection 
 Global introspection is the most common tool used to assess causality of 
adverse events due to its simplicity.59 This approach does not involve a 
standardized tool, but rather uses prior knowledge and experiences to assess 
causality on an individual basis.59 This method has gained popularity because it 
is very similar to clinical diagnosis, a common practice within the field of 
oncology, and is therefore seen as a more familiar and logical way of providing 
assessment.59 However, although it is relatively easy to use, this method has 
been criticized. Due to its subjectivity, it falls short of reproducibility standards 
due to the preconceived notions and background experience of the professionals 
using this tool.59,60 This often leads to missed or misinterpreted information; 
consequently the validity of this method is strongly challenged.59,60   
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Bayesian Approach 
 The Bayesian approach addresses probability from the standpoint of a 
medical equation.62 The method involves assigning ‘prior probability’ to an 
adverse reaction. To do this, prior probability is calculated from the pre-marketing 
information of the clinical trial along with prior epidemiological information.59,60,62 
This information is then used to create a ‘posterior estimate of probability’ by 
taking into account new information presented by the individual case, which in a 
sense provides a revised estimation of causality.59,60,62 The Bayesian approach is 
considered the most valid tool for assessing causality; however, it lacks 
popularity due to the complicated and involved mathematics.59,60,62 This method 
also presents challenges because the information needed to determine prior 
probability is often difficult to obtain.59,60 This information is often withheld from 
the scientific community due to confidentiality agreements between 
pharmaceutical companies and regulatory authorities.60 It is also important to 
note that even if access to this data is granted, there are often inconsistencies 
with the way the information is formatted, preventing its relevant usage in 
Bayesian approaches.60 Using such quantitative methods of assessment also 
distances the patients and limits their involvement in the clinical trials process. 
Algorithms 
 Algorithms assess causality of adverse events through operational 
methods.62 They typically consist of a series of questions, but can range 
anywhere from a non-scoring flow-chart to a long list of detailed questions that 
require heavy computer analysis.60 These methods are seen as advantageous 
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because they are transparent and have relatively high consistency rates.60 
However, these methods also hold disadvantages, in that they are relatively 
inflexible.60 The structure of algorithms is highly criterion dependent, lacks clinical 
judgment, and the use of external information.59,60,62   
 By identifying which approach (global introspection, Bayesian, or 
algorithms) the participants currently use, a better understanding of the social 
and psychological elements that play a role in the decision making process 
regarding that specific tool, can be met. This can add to the current literature 
surrounding the strengths and weaknesses of the various tools developed to aid 
in causality assessment. 
Lack of a Standardized Method for Assessing Causality 
It would make sense to assume that since there is inconsistency amongst 
professionals, inconsistency between professionals and patients, along with 
severe under-reporting of ADRs, that there is no accepted standardized 
procedure of assessing causality. Several studies have addressed these issues 
and expressed the need for a standardized procedure.59,60,62 In order to move 
forward and improve the safety of patients in clinical trials, it is critical that a 
standardized method for reporting adverse events be established.62 Airmone et 
al. (2005) indicated that it is extremely difficult for professionals, who are 
considered experts in the field, to make coherent judgments of causality.32 When 
these individuals are working independently, it is near impossible for them to 
make consistent conclusions of causality without using a standardized tool.32  
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 Ioannidis and Lau reviewed the completeness of safety reporting in clinical 
trials and had some findings of concern.34 192 clinical trials were reviewed, and 
out of that 192, over sixty percent of safety reporting was found to be inadequate 
and often times neglected.34 This review also indicated that key information 
would often be absent in the reports. For example, adverse events would be 
reported without a level of severity indicated.14 There is a strong need to develop 
a standardized tool. 
 Coombes et al. (2007) indicated the need for a standardized tool for 
assessing causality, as expressed by their participants.60 This study conducted 
interviews with oncologists and clinical trial specialists to find that, although these 
professionals used a logical system of reasoning when assessing causality, they 
still acknowledged many challenges and barriers to this process.59 The main 
challenge indicated by participants was the poor quality of information 
resources.59 There is a pressing need to highlight the importance and need of a 
standardized tool, as causality has a strong impact on intervention development, 
and patient safety.59 As Trotti and Bentzen (2004) clearly state, when it comes to 
a standardized tool, “the only harm is not trying”.63 The purpose of the research is 
to understand the tools clinicians use, and their likes and dislikes of those tools. 
Through a psychosocial understanding of causality assessment, the creation of a 
standardized tool is possible. 
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Methodology 
The study employed an interpretive-descriptive research design, i.e., the 
study was explorative in nature, and used the participants’ words and 
experiences as the primary means of data explication and interpretation.64 
Research Paradigm 
 The research was centered on an interpretive worldview. The emphasis of 
the research was on the decision making process, more so than causality 
assessment outcomes. The research was concerned with interpreting and 
understanding the unique decision making experiences of these clinicians and 
clinical trials specialists.64,66,67  
Phenomenology 
 This study assumed a phenomenological orientation; its purpose was to 
study adverse events reporting from a clinician’s point of view, a very emic 
approach.68 According to Creswell (2007), a phenomenological approach is best 
suited for this study because the purpose is to understand various clinicians’ 
experiences within oncology clinical trials. It is important to understand these 
experiences in order to improve the administration of clinical trials. 
 Edmund Husserl introduced the concept of phenomenology in the early 
twentieth century.66 Husserl believed that certainty is possible within one’s own 
consciousness, focusing on the lived experience of a particular phenomenon.66 
Other key historians in phenomenological research are Maurice Merleau-Ponty 
and Michael Polanyi.66 Merleau-Ponty and Polanyi proclaim that in 
phenomenological research, it is impossible to separate one’s experiences from 
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the world they live in. Maykut & Morehouse (1994) also established that the world 
is understood through multiple realities.66 Phenomenology is therefore a 
methodology of choice for this study because it’s purpose is to understand the 
experience of clinical trials through the multitude of experiences and perspectives 
shaped by the world in which the clinicians make decisions, and their perceptions 
of that world. The focus of this research was on Husserl’s work in which the 
emphasis was on how phenomena arise through lived experience.66 The 
emphasis was on understanding how clinicians experience decision making, in a 
clinical trial setting through conscious acts.  
 Phenomenology is also consistent with an interpretive worldview. In 
phenomenological research, the researcher can never detach him/herself from 
whatever it is that is being studied, they are always going to have some sort of 
presupposition to the data.68 The purpose of the research was to gather 
information regarding the perspective of clinicians about the phenomenon of 
causality assessment. Phenomenology recognizes that the experiences of these 
clinicians will be interpreted by the researcher, acknowledging that the 
researcher’s own predispositions will be part of this process. 
 The purpose of using phenomenological methods for this study was 
twofold. First, to improve our understanding of causality assessment and make 
these subjective experiences known and intelligible.69 Second, to find meaning in 
the shared experiences of these clinicians.69 Phenomenology was well suited for 
this study because it’s purpose is to understand several individuals’ common or 
shared experiences of adverse event reporting and causality assessment.66 
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Data Collection 
 This study analyzed data from Mukherjee and colleagues’ 2010 research 
paper entitled A Qualitative Study Evaluating Causality Attribution for Serious 
Adverse Events During Early Phase Oncology Clinical Trials.{Mukherjee, 2010 
#20} The data were collected with the intent of development a causality 
assessment tool to be used in oncology clinical trials. According to Osborne 
(1994), phenomenology based interviews are an ideal way to collect introspective 
reports, giving the researcher an opportunity to understand participants 
feelings.69 Thirty two individual face-to-face interviews were conducted in a 
private manner between the dates of May 1st, 2006 and August 31st, 2006. After 
participant permission had been granted, the interviews were digitally recorded, 
and hand written field notes were also taken during the interviews.20 All 
interviews were conducted in English by an internal researcher trained in 
qualitative interview methods. The average interview was thirty five minutes in 
length, but ranged anywhere from twenty five to fifty minutes.20 Interviews were 
preformed with the assistance of a semi-structured interview guide, consisting of 
open-ended questions, developed by the research team along with the support of 
two external researchers. The interview guide was first piloted at the Juravinksi 
Cancer Centre in Hamilton, Ontario to ensure appropriateness and clarity. (See 
Appendix 2: Interview Guide). Transcripts of these interviews were then verified, 
and an executive summary of the interview data was sent out to all participants 
for verification.  
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Participants 
 Five Canadian academic cancer centres along with the National Cancer 
Institute of Canada’s Clinical Trial Group (NCIC CTG) were used as recruitment 
sites. Purposeful sampling was employed to maximize geographical and 
organizational variations between participants.20 Key informants were located 
through the NCIC CTG Investigational New Drug (IND) committee. Participants 
experienced in early phase oncology clinical trials were selected. These 
professionals included medical oncologists, hematologists, and clinical trial 
coordinators. These participants had a range of experiences within oncology 
clinical trial settings, large scale randomized controlled trials, as well as industry 
and non-industry supported trials.20 A letter of invitation (See Appendix 3) was 
sent out by Andrew Arnold, and this was followed up by a phone call one week 
later by the study-coordinator (Megan E. Coombes). The participation rate in the 
study was sixty five percent, resulting in a total of thirty two participants whose 
characteristics are summarized in the table below.20  
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Table 5       Characteristics of Participants 
Characteristic N = 32 
Gender, n (%)  
! Female 16 (50) 
! Male 16 (50) 
  
Centre, n (%)  
! BC Cancer Research Centre (Vancouver, BC) 6 (19) 
! Juravinski Cancer Centre (Hamilton, ON) 10 (31) 
! London Regional Cancer Centre 5 (16) 
! Ottawa Regional Cancer Centre 9 (28) 
! Kingston Regional Cancer Centre 1 (3) 
! NCIC (Kingston, ON) 1 (3) 
  
Professional Group, n (%)  
! Medical Oncologist/Hematologist 21 (66) 
! Clinical Trial Coordinator (CTC)  11 (34)
  
Years as a clinical trial researcher (yrs), n (%)  
! < 5 5 (16) 
! 5 – 10 13 (42) 
! > 10 13 (42) 
 
Researcher’s Role 
In this study, as in all qualitative studies, the researcher plays a critical role 
in the research process. In qualitative research, the researcher is the primary 
research instrument used to collect and analyze data, and plays a very active 
role in the research process.70,71 Due to the fact that qualitative researchers play 
such an active role in the research, power relations are often formed in these 
settings.72 A set of experienced professionals with knowledge of the subject area, 
including an internal researcher with specific training in qualitative interviews and 
research methods conducted these interviews. The researchers made the 
purpose of the study clear and concise, and reassured the participants of their 
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valued contribution to this study. The research reported herein represents a 
secondary analysis of the data obtained by these researchers. 
It is very important for the researcher to take a subjective role when 
engaging in research.72 The researcher’s cognitive and affective subjectivity are 
critical in qualitative research. This subjectivity creates empathy within the study 
and allows the researcher to enter the world of the participant and gain an 
understanding of their perspectives.  
Explication of the Data 
Groenewald (2004) emphasizes the use of the term ‘explication of data’ 
over data analysis due to the dangerous implications that analysis can have on a 
phenomenological study.68 The term ‘analysis’ implies breaking something down 
into bits and pieces, and if this were the case, within a phenomenological study, 
the phenomenon as a whole might be lost.68 On the other hand, explication of the 
data implies that the phenomenon will remain in its entirety, but the various 
elements of the phenomenon will be revealed.68   
In order to analyze a phenomenological study, researchers suggest the 
following steps: transcribing any materials necessary, using bracketing activities 
and phenomenological reduction, gathering a sense of the whole, delineating 
meaning units, clustering meanings units and forming themes, summarizing, and 
creating a composite summary.66,68,73 These transcripts were analyzed in 
chronological order with respect to the order the interviews were conducted. 
The first stage of data explication involved transcribing any necessary 
components.72 However, for the purposes of this study, a secondary data 
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explication of pre-transcribed interviews was performed. The next stage in data 
explication was bracketing and phenomenological reduction.68,74 Bracketing 
involves, in the most literal sense, bracketing out the researcher’s preconceptions 
toward the phenomena being studied.64,75,76 Bracketing is particularly important in 
instances where the researcher has had experiences with the phenomena being 
studied, although this is not the case for this study. However, bracketing not only 
involves setting aside personal experiences, but also setting aside common 
sense, scientific foreknowledge and empirical data.72 This allows the researcher 
to enter the unique lifeworld of the interviewee and gain a true essence of the 
phenomena without being bound by prejudice.72 (Please see Appendix 4 for 
Bracketing Activity.) Phenomenological reduction was achieved by looking 
through the interview transcripts, field notes and relevant documentation. The 
data were read repeatedly until the meaning started to emerge on its own and a 
holistic sense of the data was obtained. 72,77,78 At this point, the researcher left 
the world of the researcher, and entered the world of the interviewee. The focus 
was on the meaning that was actually presenting itself. The researcher did not 
look for certain aspects of the phenomenon, but was open to the data and just let 
the meaning naturally occur.72 Once phenomenological reduction took place, a 
holistic sense of the data was gathered. This involved looking into all aspects of 
the data, and making more detailed notes on the intuitions that emerge along 
with reflexive notes.72 The purpose of this stage was to gather a holistic sense of 
what the data were portraying by staying as true as possible to the meaning 
derived from the participants’ experiences in clinical trials.72 
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 After a holistic sense of the data was established, meaning units were 
then delineated. This involved picking out statements, quotes or sentences that 
brought meaning to the phenomenon through a process known as 
horizontalization.67 Horizontalization aims to highlight data that help us 
understand how the interviewees experience the causality assessment.66 This is 
very similar to the process of meaning coding, in which the researcher will attach 
key words to represent a statement, making the statement easily identifiable.72 In 
the same manner, delineating meaning units involved creating a list of unique 
and redundant meanings, relevant to the meaning the researcher extracted from 
the data.68,74 To do this, the researcher kept track of the number of times a unit of 
meaning was mentioned in order to determine it’s significance.77 
The next stage of data explication involved clustering meaning units and 
forming themes. This stage is very similar to categorizing codes presented by 
Kvale and Brinkmann (2009), in which the researcher looks for meaning units 
that naturally group together with other meaning units to form a theme.72 A true 
sense of the essence of the clusters and the meanings they hold was 
established, and themes were developed to form an accurate representation of 
these meanings.72 (Please see Appendix 5: “Clustering Meaning Units Into 
Themes.) 
 These themes were then used to create a “textural description” of what the 
interviewees experienced in their decision making process, including “imaginative 
variation/structural description” (the context in which they experienced it).64 
These textural and structural descriptions were then used to construct an 
! %(
“invariant structure”, which is an amalgamated description that represents the 
essence of the phenomenon.67 A summary was then created that incorporated all 
themes, both those that are unique and those that are redundant, across all 
collected data, serving as the findings section of this thesis.72  
Trustworthiness 
Triangulation was used to come to a deeper understanding of the 
phenomenon by combining methods for more robust results. In this particular 
study, analyst triangulation methods were employed. This form of triangulation 
consists of using different parties to analyze data.79,80 Analyst triangulation 
reduces selective perception and reveals insight that might not otherwise be 
revealed through a single analyst approach.79,80 This study meets analyst 
triangulation by using three separate approaches. The interview data were first 
confirmed through member checking in the primary study, followed by data 
analysis by a qualitative research team, in order to develop a tool for assigning 
causality. This study then took a third approach by analyzing the interview 
content through a psychosocial approach known as naturalistic decision 
making.24,25 The researcher was completely removed from the data, as she was 
not a part of the original study, nor invested in the grant-in-aid. This distance from 
the original study further validates the use of analyst triangulation. The aim of 
analyst triangulation is not to meet a general consensus on an interpretation of 
the data, but rather to understand multiple perspectives.79,80  
Skeptical peer reviewing was also used to obtain trustworthiness within 
the study.81 My supervisor, as well as the rest of my committee served as 
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skeptical peer reviewers. They vigorously assessed the methods, meanings, and 
interpretations of this study. 
Bracketing activities were also performed by the researcher, prior to data 
analysis, to further ensure trustworthiness of the findings (See Appendix 4: 
Bracketing). This involved having the researcher set aside all foreknowledge and 
predispositions toward the phenomenon being studied in order to be fully open to 
the natural meaning within the experiences of these participants.  
Findings 
  The purpose of this study was to develop a psychosocial understanding of 
how clinicians assign causality. Using a NDM perspective, an emphasis was 
placed on expert-decision making. Through the descriptions of the participants’ 
experiences, five themes were discovered: 
! There were insufficient resources to support the decisions being made 
! Assigning causality is a task full of uncertainty  
! The process of assigning causality was full of subjective judgments  
! There was an apprehensive attitude towards causality attributions  
! There were competing goals between investigators and drug companies 
as well as investigators and their patients. 
Each main theme was comprised of several subthemes (please see Appendix 5: 
Findings Summary Table). Each one of these subthemes followed a particular 
pattern that 
1. Identified a grey or problem area 
2. Identified a strategy for coping with the issue 
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3. Provided a description of the potential consequences that may result from 
these problem areas. 
These themes serve to answer the original research questions of how these 
professionals use the experience they have gained and what psychosocial 
factors play a role in assigning causality. This extensive quote demonstrates the 
complexity of causality attributions and serves as an excellent summary of this 
study’s findings. 
 And I think a lot of things can happen under the, under the banner of 
uncertainty. You know, you can be forced to under, I think that uncertainty 
is at the heart of this, its at the heart of this. And I don’t think it’s a matter 
of honesty or dishonesty, I think it’s uncertainty and how do people cope 
with uncertainty? And I think that this actually is the measure of whether 
enterprises succeed or fail. You know, it’s how they deal with uncertainty. 
So I think for example one of the differences between successful 
businessmen and unsuccessful people in business is that the 
unsuccessful people don’t know how to deal with uncertainty. Um, 
because life is full of uncertainty and you know, it’s possible to be 
panicked into, into making a wrong decision. On the other hand it’s also 
possible to be paralyzed into not making any decision at all. [yeah] So 
when you see these kind of little human dramas played out in this situation 
as well because, but I think it’s a mistake to not allow the physician to be 
uncertain when he or she is genuinely uncertain.- S22 
 
Insufficient Resources 
No Training 
The subjective nature of causality assessment in early phase oncology 
clinical trials stems from the lack of resources available to assist professionals in 
making these decisions.  To begin, these professionals are given very little to no 
training on how to assign causality. A few interviewees mentioned that the 
pharmaceutical sponsors had training modules on adverse event reporting, but 
nothing related to causality assessment. Others have mentioned that 
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occasionally, in start up meetings, a small ‘blurb’ will be given on assigning 
causality. However, all of these experts agree that there really has not been any 
formal training. 
There hasn’t been any formal training, yeah, there’s hasn’t been anything 
formal.- S05 
 
I’ve had no formal training [no] actually.- S11 
 
There’s no formal training really, you just kind of got thrown into the 
position.- S32 
 
 
Without formal training, there are always going to be inconsistencies in reporting 
standards, which is evidently still a major issue in oncology clinical trials. These 
professionals cope with little to no training through on the job experience, 
whether it is self-training or training one another as they go. It has been 
described as a trial and error process.  
Trial and error I guess. I mean the only, the only lecture I’ve ever heard 
about is, I’ve heard A speak once, but other than that you know, really 
nothing. I mean you’d ask other more senior investigators what they would 
say for this particular event and so on. But otherwise, there was no formal 
training.- S26 
 
The Lack/Need of an Assessment Tool  
When asked if there were any tools to aid clinicians in assigning causality, 
no one could generate a response. The only answer seemed to be “no”. In fact 
when asked this question, one interviewee responded, “Are there any tools out 
there?”- S18. This statement exemplifies that the causality assessment tools are 
not made widely known to professionals.  From the various flowcharts, 
algorithms, decision-making trees, and Bayesian approaches available, not one 
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interviewee could identify a tool. There is not a universally accepted tool, and in 
most cases, these professionals do not use a variety of tools at their disposal.  
So there’s often not a lot of guidance it’s more winging it.- S01 
 
Clinicians did agree that a tool would be useful. A tool would aid in promoting 
consistent causality attributions between professionals. In order to cope with not 
having a tool to make these decisions, these professionals did state that 
occasionally they would work through the history and strength of the association 
(between the adverse event and drug administration) to make a decision. Some 
clinicians considered the investigator brochure as the closest thing to a tool they 
could think of, but indicated that they mostly use the brochure to better 
understand some of the toxicities.  
None. [no] No, well I mean, I guess I shouldn’t say that, none in terms of 
standardized criteria that’s for sure. Resources, unless you mean basically 
going back to see maybe the investigator brochure and trying to 
understand some of the toxicities.- S13 
 
…Well you can look first at the investigators brochure, you, that, that’s 
what you’re supposed to look at…- S08 
 
Lack of Resources 
With no tools being used, it is not unimaginable to assume that these 
professionals are lacking other resources as well. Physicians explained their 
need for more detailed information.  
Yeah, more detailed information I guess, other than what’s in the consent 
form, having a list of expected events and maybe, some of them put in the 
percentages of what the patients have already experienced. So yeah, I 
guess that, just a more detailed sort of, um, like I was saying we go to the 
dose modification and it will list sort of what the expected toxicities are and 
the rules to follow. So maybe to have some kind of I don’t know, chart or 
information in that area to go to, to see what we’re looking for and how 
they expect us to assign the causality.- S25 
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The consent form is an excellent start, as it has a list of expected events, and in 
some cases, the percentages of events that the patients have already 
experienced, but these often lack other supportive information, such as, dose 
modification; a listing of expected toxicities, and rules to follow. There is still no 
information as to what the expectations are in terms of standard practice on how 
to assign causality.  
Lack of appropriate information.- S06 
 
This leads to unconfident decisions being made by these professionals. In order 
to cope with the lack of resources available to them, these professionals rely 
heavily on the experience they have gained within their field to make proficient 
decisions.  
So it’s more on a, just based on the experience of taking part in the study 
and the hunch factor. I don’t actually have a tool that I use, so I think 
something like this would be very handy.- S10  
 
Vague Definitions 
Often times, the definitions of various causality assessment terminologies, 
are vague. For instance, although these professionals will be asked to identify 
whether the adverse event is certain, probable, possible, unlikely, there is no 
definitions of what these terms mean in relation to causality assessment. Some 
interviewees even felt that sponsors make the wording vague on purpose. 
Well, most of my studies are also sponsor studies and they tend to make 
the wording vague on purpose. [laughter] Probable, possible [the wording 
of what] probable, possible, definitely related, possibly related all the, so 
sometimes that can be a challenge if it’s something you haven’t 
encountered before.- S28 
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This is challenging to professionals, especially if they have never encountered 
these terms before. It is really, as one interviewee puts it, an “imprecise science”- 
S08, and it becomes extremely difficult to be certain in one’s attribution. In order 
to cope with the lack of standardized definitions, these professionals rely on their 
experience to assign causality.  
I mean it’s almost from the experience we’ve had with drugs.- S03 
 
So I think, those ones are okay because you’re basing it a bit on personal 
experience [yeah] and a little bit on what’s published.- S04 
 
Basically all one can really do is, based on experience of managing these 
people sort of know what to expect as their cancers progress and as their 
regional stages of life, as in previous experience in managing.- S06 
 
Communication Issues and the Role of the Physician  
There are also communication issues that arise when assigning causality. 
One of the main gaps in communication seems to occur between the 
interviewees and their sponsors. For instance, the interviewees often had 
questions about a certain adverse event, but found it difficult to access 
information that would allow them come to a better understanding of the drug’s 
pharmacology, beyond the investigator’s brochure. Even when writing up reports, 
interviewees felt that it would be helpful to know more about the sponsor’s data 
management. It would help them to understand their role, and understand how 
companies try to collate the information they send to them. This lack of 
communication makes it extremely difficult to come to a unanimous decision.  
Well usually there’s teleconferences and other meetings to discuss what’s 
happening with other patients. But a lot of times communication isn’t as 
good as it could be.- S07 
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Interviewees also felt like sometimes they had no idea what other investigators 
were doing.  Having the opportunity to discuss these issues, on a regular basis, 
with other investigators would aid in filling this communication gap, and lead to 
more unanimous decisions. Physicians cope with the lack of communication with 
their sponsors by searching for additional resources online, and by consulting 
with other physicians.  
 Another communication lapse lies between the physicians and the 
patients. Physicians felt that, at times, that they do not get all the information they 
need from a patient. In order to narrow this communication gap, these 
professionals cope by getting to know their patients. By coming to a better 
understanding of the patient’s personality and outlook on the trial, both of which 
are very subjective, one is better equipped to make more informed decisions 
when assigning causality. This can also help eliminate the inaccurate 
representations of adverse events from patients.  
A lot of the times I find it’s hard and I don’t think it’s an on purpose thing 
from patients, but I don’t necessarily think that we do get every single bit of 
information all the time.- S11  
 
Different things tend to be reported to different people, depending on the position 
that the person holds, whether it is a chemo nurse, clinical trials nurse, or 
physician. It is also human nature to forget things. If it is a very serious event, it is 
likely to be recorded and made known to others working in the clinical trial 
setting. However, not all patients understand that these professionals are just as 
interested in the minute events, such as the minor side effects of a treatment. 
There is a sense of disconnect in that the patients feel that they are on the 
! &&
treatment to help their cancer. Many patients decide to put up with side effects in 
hopes that they can get through the treatment, thinking that it is going to help 
their cancer, and this often translates to under reporting on the patients’ part. 
Some patients may also perceive that the staff do not want to hear them 
complaining, they do not want to be seen as ‘whiners’, so sometimes they will 
hold things back.  
…But the patients of course feel that they’re on the treatment to help their 
cancer [yeah] so there’s a little bit of a disconnect there. So they’re more 
interested in what the drug is doing for their cancer and they kind of are 
hunkered down with the idea, many of them are very stoical right [yeah] 
they say I’m going to put up with whatever side effects I have to put up 
with um, to get through this treatment because it’s going to help my 
cancer…- S19 
 
Uncertainty of the Job 
Assigning Causality 
Assigning causality in early phase oncology clinical trials is a decision 
making process that is full of uncertainty.  It is difficult for these professionals to 
know there is an explanation for an adverse event, but they rarely feel confident 
in their causality attribution. Clinicians are asked to make very important 
decisions when the situations are very vague and the answer is not clear. 
Answering the unknown is especially prevalent in the early phases of clinical 
trials. In these stages of a clinical trial, patients are typically in advanced stages 
of their disease, they have tried numerous other treatments, and some patients 
have been heavily pretreated. Therefore, a lot of these patients have complicated 
medical histories, and are more susceptible to other comorbidities and related 
symptoms that further conflict assigning causality. This makes assigning 
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causality difficult, and may lead to erroneous causality attributions. This can 
make it very difficult to determine if the developing agent is having a positive 
effect on the cancer being treated, which is the primary purpose of the clinical 
trial. 
The majority of clinicians interviewed described a basic chronology of 
decisions whenever they are dealing with patients in a clinical trial. Clinicians first 
consider the protocol drug. Typically, little is known about drugs that are new to 
the clinical setting, and they begin by gathering more information. The 
information known about these drugs is primarily based on animal testing, which 
is not entirely applicable to humans. There is not always a dose relationship 
available to aid in the decision making process. A positive dose response curve 
suggests that  the higher the drug dose, the more severe the adverse event. 
Cumulative doses are often available, but different dose administrations from 
cycle to cycle are not.  
Supposedly one of the criteria for causality is something like a dose 
response relationship whereby more of something causes more of an 
effect. And a patient typically, although we may have that in a cumulative 
dose, we don’t have different doses from cycle to cycle necessarily. So 
you can’t say when you had a little bit of this you felt a little nauseated, 
now that we’re giving you 10 times more you’re feeling really nauseated. 
So we wouldn’t have that information typically. - S01 
 
In the lives of these patients, the protocol drug is often used in 
combination with other drugs, whether it be part of the trial (to help compensate 
for certain adverse events), part of the patient’s treatment regime, or over the 
counter or complementary therapies the patient is using.  
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You always look at, I mean there are always so many other confounding 
variables in this population, especially if their disease is starting to get a bit 
worse.  They go on other medication, right which can impact, you don’t 
know what these newer agents do with any of the other medications that 
are out there.- S09  
 
When this is the case, it is difficult to distinguish which drug is causing the 
adverse reaction or if it is a combination of both. In situations where there are 
more than two drugs, causality could be assigned to a single drug alone, or to a 
combination of multiple drugs. These drugs can also have disease and food 
interactions, further complicating the situation. It is also often difficult to 
distinguish between drug reactions and the progression of a patient’s disease. In 
terms of disease progression, it could be something as simple as a patient 
becoming increasingly immobile, which could disrupt the role of proper 
functioning of the rest of the body. Distinguishing between adverse reactions and 
disease progression can be very difficult, but beyond the uncertainty of the task, 
it is crucial in determining if the developing agent is indeed working. 
Well, I guess as I’m struggling with this in the Phase 1 trials, what’s an 
adverse event. [okay] Because within the protocols they’re not defined 
very well either. So that you could get disease progression that’s an 
adverse event which when you’re coming into determining DLT’s and 
moderate toxicity if you put you know, increasing shortness of breath could 
be related to disease. But when they say it’s an adverse event that occurs 
on study, whether or not deemed related to the investigational agent you 
can potentially be putting disease progression [right] as an adverse event. 
Patients may also develop other illness during the duration of the trial, for 
instance angina or diabetes, further complicating the situation.– S09 
 
Um, yes, I had a patient who ah, developed a pulmonary embolism and 
we couldn’t say for certain it was the chemotherapy she was on. It could 
have been disease related, it could have been disease progression. There 
was a number of issues but we weren’t clear um, and yeah, we weren’t 
able to assign.- S31 
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…So I had to think this morning for example this ocular side effect, was it 
due to you know, drug A or drug B or the combination. Or was it due to 
something incidental like you know conjunctivitis or something. So you 
have to think about alternative causes, alternative explanations. I mean 
people with cancer get many symptoms from the cancer that are not 
necessarily due to the drug, they may just be due to the underlying 
disease. And of course a lot of people have comorbidities because they’re 
elderly and have a 101,000 things wrong with them. And you know, is it 
just something incidental. So I think one of the important things in the 
causal reasoning is, is to be aware of what the possible causes could 
be…- S22 
 
Determining causality is difficult because there are often confounding 
variables. There are a lot of attribution possibilities under the banner of 
uncertainty. Medical oncologists approach causality assessment in a way that 
realizes there is an entire slate of factors, which may result, either alone or in 
combination, to the adverse event under examination. 
Again, there’s, there are many factors here and um, um, and when you’re 
looking at alternative causes, that’s generally where it comes down to an 
uncertainty.- S30 
 
 It was found that clinicians often feel pressured to make the right decision, 
and that this pressure can even inhibit their ability to make a decision.  
Um, because life is full of uncertainty and you know, it’s possible to be 
panicked into, into making a wrong decision. On the other hand it’s also 
possible to be paralyzed into not making any decision at all.- S22  
 
It is evident that, in oncology clinical trials, physicians can feel genuinely 
uncertain. Uncertainty is indeed at the heart of a majority of causality 
assessments.  
However, it was found that clinicians and physicians alike use a variety of 
methods to cope with the uncertainty they are faced with in these clinical trial 
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settings. Firstly, these professionals reassure themselves that causality 
assessment is never simply black or white; there is often a grey area.  
Well because there’s a, it may help you sometimes in the dilemma where 
you in this grey zone of serious adverse event where you think about what 
to, what to assign to this SAE. If you have a clearly unrelated or clearly 
related SAE that’s easy but the, the vast majority of SAE’s is probably 
somewhere in between..- S14 
 
There always seems to be some element of doubt, and these professionals find 
comfort in the flexibility that a grey area offers in these difficult situations. There is 
tangible evidence that there is toxicity, but the reality is that indirect events can 
subsequently happen. Keeping an open mind, and changing their thinking to 
incorporate a grey area allows these individuals to feel more confident in their 
decisions, as opposed to simply saying that it is definitely related or it is definitely 
not related. 
These medical professionals also cope with the uncertainty of these 
situations by placing a strong emphasis on the timing of an event. According to 
NDM, this decision making process is seen as a matching process between 
situations and actions opposed to the generation of any possible option. These 
experts use “context-bound informal modeling” to make their decisions.!25!When 
making decisions, the professional’s knowledge and experience is specific to a 
natural context (clinical trials), as opposed to a formal decision making model 
which is context independent. 
Given that there are little resources to make these decisions, including 
inadequate dose relationship knowledge, these professionals place an important 
emphasis on the timing of an event; the proximal distance between the 
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administration of a drug and the occurrence of an adverse event. That is to say, 
the shorter the distance is, the more likely there is a causal relation.!
Yeah, and I would say timing is the most important factor. I mean, other 
factors, we don’t usually have dose as a, as a ah, we don’t usually have 
doses in the same, different doses in the same patient to be able to judge 
a dosing relationship- S01. 
 
 It was also found that these medical professionals find it so difficult to make a 
causality decision when they are with the patient, that they will often, in 
retrospect, continue to look at the data, even after the patient has left. With time, 
similar situations may develop with other patients, or may repeat themselves 
upon dose administration. This gives them a chance to reanalyze the situation, 
usually with a clearer depiction of what was going on, and make a more accurate 
decision at a later date.  
So sometimes there are grey areas and at the time it might be difficult but 
retrospectively by continuing to look at data after the fact then you’re able to um, 
to decide at a later date.- S31 
 
Clinicians also cope with uncertainty by erring on the side of caution.  
But you have to, I think you have to assume that you don’t know enough 
about the drug that it could be drug related.- S20 
  
Getting to know and understand the patient also plays a role in coping with 
uncertainty. Patients may have pre-existing conditions, or other health problems 
that may contribute to some symptoms. There is also the possibility of 
psychological factors, or changes in the patient environment that may contribute 
to adverse events.  
Say patient fatigue, ah, well that can be really difficult for instance, it could 
be related to disease, study drug, could be related to psychological 
factors, some change in the patient’s environment, who knows? And that 
could be, and you have to look at all those and figure out which is most 
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likely and then it’s you know, and have there been changes in those areas 
that might explain it? Um, and if there’s more than a couple of possibilities 
you have to kind of use your judgment which is more likely.- S20 
 
Sometimes the conflict is a result of the patient’s personality; some people may 
try to downplay their symptoms, and others may exaggerate them. Therefore, 
understanding the patient can play a key role in coping with uncertainty. 
And pre-existing conditions in the patient if they have you know, other 
health problems that could be contributory to some symptoms. You know, 
and sometimes it can be as easy as just the person themselves, some 
people will say they’re perfectly fine when they’re not. And other patients 
will elaborate on you know, how they’re feeling and might be exaggerating 
a little bit. So you know you have to try and understand the patient 
themselves as well.- S27 
 
As difficult as the process of assigning causality is, it was found that 
professionals use a variety of methods to cope with this uncertainty. Clinicians 
reassure themselves that the answer is often not black and white, that this grey 
area exists, and that is acceptable. These professionals also manage uncertainty 
by placing a strong emphasis on the timing of events, reevaluating decisions at a 
later time, erring on the side of caution, understanding the patient, and using their 
experience to make informed decisions. 
Subjective Judgments and Experience 
Causality assessment in early phase oncology clinical trials is often 
uncertain because there is rarely objective evidence. These medical 
professionals agree that most of the time they use their clinical judgment to make 
a decision. They also all agree that using one’s experience to assign causality is 
a very subjective process. 
 I have to admit that is very subjective at times.- S13 
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You know, where the same event can be attributed differently because a 
lot of things, it’s a subjective assessment. It’s not as objective as it should 
be, I think that’s what makes it a challenge.- S18 
 
Is it something that has been previously reported or associated with the 
drug from the investigators brochure or whatever information is available 
through the trial. And so you just try to gather information around that and 
then it’s a best guess.- S08 
 
 
Words used to describe clinical judgment included “common sense”- S13, 
“intuition”- S22, and “using your head”- S03. When utilizing clinical judgment, 
clinicians gather all the information they can on the adverse event and their 
patient’s status, and from there they will employ a process of elimination.  
Inter-Professional Subjectivity 
 Clinical judgment is really based on experience, and the experience level 
of each professional varies considerably. Experience can be applied to many 
aspects of the clinical trial, including experience with a particular patient 
population, a particular class of agents, or working with a particular drug 
company. 
It’s really based on experience at this, at this stage. So really it would 
depend on a, an experienced investigator who has managed a lot of the 
specific patient population to in my opinion, accurately determine if this is 
something that’s related.- S06 
 
 Given that experience levels vary, there is often inter-professional subjectivity, 
meaning it is very difficult to come to a unanimous decision. Causality 
assessment is, in many ways, intuitive and can depend on the physician’s 
interpretations of definitions, as well as their past experiences.  
Most of it is kind of intuitive you know, so I’m not sure.- S01 
 
! '$
Some professionals may have a lot of experience with a particular class of 
agents, therefore they may have particular expectations for the developing agent 
and this may bias the way they attribute causality. Their assessment can also be 
subjective in terms of the amount of background work a professional does in 
order to understand an agent. In order to cope with the varying experience levels, 
some professionals, whom are uncertain about a particular adverse event, will 
take the extra time to review the investigator brochure or protocol and talk to 
other investigators about the situation, and others will not. 
Well I think it’s based on what’s been listed in the protocol and possibly 
the investigator brochure. But really do you have time to look at an 
investigator brochure every time? No.- S08 
 
 It was also reported that when there is more than one professional involved in 
assigning causality, there is often more than one opinion, and reaching a 
unanimous decision is a difficult process. 
It would have been nice if we could have established causality 
unanimously but. [yeah] So I say going to the physician but if there is more 
than one involved there can be more than one opinion. [yes, okay] But 
generally getting a consensus is helpful if you can go to your physicians 
and they often are very good at saying well. Even when I don’t think it is, 
they’ll say no I think it was you know, the agent that caused this, this is 
definitely associated and yes we’ll say it’s, we’ll assign causality to that. So 
I don’t try to decide on my own, if I’m not sure I will go and ask [yeah] for 
other input and then we’ll try to make a decision.- S31 
 
 
 
Patient Subjectivity 
 Not only is causality assessment amongst professionals full of subjectivity, 
but patient experiences are as well. Some adverse events can be objective, for 
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example weight loss, this is easy to measure in pounds or kilograms. However, 
how a patient is feeling is very subjective, especially when it comes to pain.  
Severe pain to someone might be moderate pain to someone else, and mild pain 
to another individual. Things such as pain, nausea, fatigue, and headaches are 
very subjective, and that is where it becomes difficult for the physician.  
Um, just so there’s a general consensus and everybody can talk about it 
together to really understand what, what the patient is experiencing. Um, 
and again I think that’s very subjective for the clinician also the way the 
patient describes things.- S11 
 
But when it’s subjective, like how a patient is feeling or how sore their 
mouth is or you know, how much pain they might be experiencing, it’s all 
very subjective to each patient.- S32 
 
 
Physicians also run into situations where some patients are very detailed and 
open, they let the clinicians know exactly everything that they have been 
experiencing with their body, however mild or severe. This could possibly lead to 
adverse events being over-reported. It is also possible to have patients that do 
not want to tell the clinician anything, in fear that they are being seen as a bother, 
or complaining too much. This could possibly lead to under reporting of adverse 
events. In order to cope with patient subjectivity, physicians will often ask probing 
questions about side effects, problems, and body systems. 
So I think it definitely depends, again, very individual, depends on the 
patient, depends on your personality, what you’re asking. If you’re asking 
the appropriate questions or not, I think that that makes a big, a big 
difference too.- S11 
 
 The primary reason these subjective judgments take place is because 
there is not a systematic way to make these decisions, so these professionals 
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are left to base their decisions on hunches and feelings opposed to a rigorous 
method or measurement tool.  
Apprehensive Causality Attributions 
With limited resources to aid in assigning causality, these professionals 
are extremely apprehensive when making attributions. There is this general fear 
of making the wrong decision, which is primarily based on the very serious 
consequences of misattributions. 
If it’s done incorrectly, it’s a pain in the ass for all the trial nurses and all 
the investigators, all the trial doctors all over the world because it takes 
time to sort out.-  S03 
 
 There are two ‘mistakes’ that these professionals fear: a false positive or 
a false negative causality attribution. Any misestimating can result in risks to the 
developing agent, or to the patient.  
There’s, there’s two concerns, I think one concern is you know, over 
assigning causality. Because patients are, they can get sick, morbidities, 
multiple medications, actually a lot of reasons and it sometimes it’s easier 
to blame it on the drug. But I think my fear is that if you, if you do that 
liberally you’d be, not discrediting the drug but you’re not um, it could lead 
to dose reductions, could eventually work their way into an ineffective 
treatment schedule for that. If you saw a whole bunch of side effects that 
you thought were you know not really related to the drug and that led to 
that drug being less developed in a certain disease. Maybe you’re doing a 
dis-service to that patient population, so that’s one, that’s one concern I 
have. Perhaps over-assigning causality just because of the complications 
of some of the patients on the program is my biggest concern. And the 
other concern is, the other, completely opposite really is the not assigning 
causality and then drugs are allowed to develop. And then it’s only when 
you start getting into Phase 2, Phase 3 studies that you really, adverse 
events really show themselves. And you’re thinking well why wasn’t this 
picked up in the Phase 1 or 2 studies? [yeah] So I think you can go either 
way, you can make errors on either way, one way you might kill a drug 
that might be successful and on the other way you might let a drug 
develop not carefully enough.- S04 
 
! ''
I think there’s two big concerns. One is if you assign causality and say it’s 
related improperly then it might tarnish a good drug and stop dose 
escalation in a way that wouldn’t be appropriate. Alternatively if you ignore 
it, it might cause further toxicities in others and be potentially dangerous to 
other patients. I think it’s a very dangerous thing. I also think that 
sometimes as oncologists we tend to minimize rather then maximize 
because we’re used to toxicity with drugs and that can be dangerous.- S16 
 
Under Attributing Causality  
The fear of under attributing causality to the drug being tested stems from the 
concern for patient safety.  
Overlooking it altogether is certainly worse [yeah] but I think [it’s also 
important] a serious adverse event, if a serious adverse event is seen in 
relationship to this more often then at some point we, we report it. But I 
think the frequency may then be under reported. But the key, overlooking 
a side effect or not reporting a serious adverse event which is actually part 
of the side effect profile, that’s probably the worst, the worst thing.- S14 
 
Um, well, of assigning them poorly? It’s either you under, or whatever 
event it was so you’re compromising safety of future patients who might go 
on this treatment if you um, rule that it wasn’t related to the drug.- S15  
 
 Over looking particular side effects can allow the drug to advance to new 
phases, when it may not be safe to do so. 
So you could in one situation attribute something to an entire one set of 
the, the most serious and if it’s this and you don’t acknowledge it, that’s 
dangerous for future patients in the study.- S12 
 
 In these situations, serious adverse events may start to arise; these events may 
have not been reported in earlier phases of the trial, compromising the safety of 
future patients. In some instances, a potentially dangerous drug may progress so 
far as to be legalized into the market, harming patients, even leading to fatalities. 
It is also possible that a very small number of patients in a trial may lead to 
underestimating or under-relating particular symptoms to the drug. In order to 
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cope with this ‘fear’ of under attributing causality, these professionals will often 
err on the side of caution by attributing adverse events to the drug being tested. 
Over Attributing Causality 
 This is the opposite end of the spectrum, where causality is overly 
attributed to the protocol drug. There is a lot of pressure placed on these 
professionals to make the correct decision. However, in situations of uncertainty, 
these professionals tend to err on the side of caution, out of concern for patient 
safety, but this may be unfair to the agent under development.  
Well, I think you can overcall things that, and say that they’re related when 
they’re not. [mmm hmm] Um, and then that leads to for the drug 
companies to sort out or, or you know, whoever the sponsor is in 
determining are these or are they not? And I think um, it would be 
beneficial at some point to follow through on the other end of things to see 
what it means when you’re on that end.- S11 
 
Over attributing causality to the study drug can contaminate the entire database 
in terms of the causality of these toxicities. The onus on these professionals is 
extremely high, because they have the ability to undermine the trial by making an 
erroneous attribution. In these situations, the investigator may be forced to 
intervene in the conduct of the study, and the administration of the drug. In dose 
escalation studies, where the dose is increased based on the tolerance to 
increasing dosages, a drug may not reach the next dose level, or more patients 
may be recruited to that particular cohort level, subjecting more people to that 
drug than may be necessary. This may also cause an ineffective dose to be 
administered to a given cohort of patients, resulting in an ineffective treatment 
schedule. In some instances, it is possible to delay or even jeopardize the 
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development of the study drug, which could preclude further study of the drug, or 
stop the trial all together.  
…If you saw a whole bunch of side effects that you thought were you 
know not really related to the drug and that led to that drug being less 
developed in a certain disease. Maybe you’re doing a dis-service to that 
patient population, so that’s one, that’s one concern I have…- S05 
 
…I think one concern is you know, over assigning causality. Because 
patients are, they can get sick, morbidities, multiple medications, actually a 
lot of reasons and it sometimes it’s easier to blame it on the drug. But I 
think my fear is that if you, if you do that liberally you’d be, not discrediting 
the drug but you’re not um, it could lead to dose reductions, could 
eventually work their way into an ineffective treatment schedule for that 
population…- S04 
 
 In these instances, it is unfortunate because the trial may have been well 
proposed, with a sound hypothesis, yet one could end up rejecting the 
hypothesis by improperly assigning causality. This also risks the drug not going 
to market when it may be a potentially legitimate drug. In this case, not only the 
trial, but the entire enterprise could be undermined, which would compromise 
many years of work, money, and investment. This could also add additional costs 
for the company who developed the drug, requiring additional testing, and a 
significant amount of additional paper work. In order to cope with the ‘fear’ of over 
assigning causality, physicians will try to better understand the protocol drug and 
its sister agents in order to better equip themselves to make these important 
decisions. 
Competing Goals 
The apprehensive attitude towards assigning causality can stem from the 
competing nature of clinical trials. There are often competing goals in the process 
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of attributing causality, whether it is the workload, timeframe, the patient’s well 
being, or the development of the drug. 
Sponsor/Pharmaceutical Company Pressures 
Physicians are often apprehensive to assign causality because the trial 
sponsor has the ability to question their decisions. One of the challenges in 
oncology clinical trials is balancing patient safety and the development of the 
protocol drug. These professionals often felt pressured to attribute causality in a 
certain way to please the sponsor, but were often hesitant because they did not 
want to risk the patients’ safety. Clinicians feel pressured by these companies to 
limit toxicities. Adverse events attributable to the drug being tested can expand 
dose levels, placing a financial burden on the company, and extend trial 
durations. 
There’s an awful lot of pressure when you’re doing early phase studies 
with a small biotech company. They, there’s a lot riding on, on, you know, 
there are the issues of well are you going to torpedo their only drug or just 
from a financial point of view, with toxicities that are going to expand the 
dose level.- S03 
 
 These companies can ask clinicians to reconsider their causality attributions and 
in some instances they will, but more often than not they stick to their original 
decision. 
Um, well they come back and say well are you sure that’s related? [mmm 
hmm] right [yeah] you know. No I’m not sure but I’m not willing to say it’s 
not, you know.- S09 
 
No I haven’t because I’ve stubbornly just said well that’s my final answer, 
so I’ve never felt any, any sense of coercion. Obviously, you know, 
inherently results in more work for somebody but ah, in the Phase 1 
setting I, I, I think ultimately it’s the sponsor’s in their best interest to fully 
understand what their drug is doing and what it’s potential effects are. But 
one does have to be fairly stubborn in that regard.- S06 
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 The company makes their viewpoint well known, and will often try to persuade 
these physicians to change their decision to better suite the needs of the 
company.   
There’s an awful lot of pressure when you’re doing early phase studies 
with a small biotech company. They, there’s a lot riding on, on, you know, 
there are the issues of well are you going to torpedo their only drug or just 
from a financial point of view, with toxicities that are going to expand the 
dose level. That’s gets in and take longer for the study to complete, those 
have big financial implications.- S05 
 
Um, well there, you know, there, I think one has to fight, now this is a more 
of a perception, I don’t have any examples. But there’s a risk that the 
sponsor may want, may prefer you to go to an unlikely conclusion. That I 
disagree with.- S06  
 
Not too much, but then again I’m not the one that the sponsors contacting 
when they call you and go are you sure that this is what you think it is? 
and stuff like that. I’ve had one of those calls where they’ll call back and 
they’ll say is this the way you want it? And you just go back to the 
physician and tell them they want to reconsider. And sometimes the 
physician is, will stick to their guns and sometimes they will re-think it or 
whatever.- S07 
  
The cause of these dispositions is sometimes the difference between a primary 
and a secondary adverse reaction. Most drug companies only want the primary 
events reported as the serious adverse events; the others are to be covered in 
the description of the serious adverse events. In some instances, this may in fact 
be the case; however, where smaller reactions are a result of more serious 
reactions this may not always be the case.  
Sometimes in some places for some companies you know the serious 
adverse event would be mucusitis, diarrhea and dehydration. And other 
places and I guess the NCIC in particular, I mean our recent experience, is 
that they say well the drug doesn’t cause dehydration, the diarrhea and 
the mucacitis does.- S08 
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This places physicians in a position where they feel obligated to downplay minor 
adverse drug reactions to please the drug company. These companies have a 
tendency to label expected adverse drug reactions as serious adverse events, 
and unexpected adverse events as less serious. This may not always be the 
case, but it can influence the way clinicians feel about their attributions. 
The company sort of reports basically they, they want to downplay um, 
these and so their stock standard line is that you know, such and such a 
side effect is not listed in the investigator brochure, the implication being 
well it can’t be related. So you know they take the, so you’ve got to look at 
it with, it’s somewhat helpful but somewhat tedious. - S08 
 
With the pressure to keep the drug development process moving, the goal 
seems to be more directed towards putting patients into a study, than ensuring 
the safety of a patient in a study. In some instances, where patients experienced 
an adverse event, interviewees felt they should reduce the dose of the drug 
being administered or hold off treatment for a certain time frame, however they 
sometimes felt pressured to continue on with the study. However, in order to 
cope with the pressures from these pharmaceutical companies, these 
professionals always keep patient safety at the heart of their attributions. 
Drastic Timelines 
Other pressures stem from the extreme workload and drastic timelines. 
I guess, I guess one of the biggest challenges these days is that if we, 
people have enough time to rigorously evaluate all the possibilities in a 
very busy clinic setting. [yeah so] The time to sit down and really fully go 
over everything with the patient in terms of  what’s new by history and do a 
good physical examination.- S20 
 
Who’s kidding who, they’re busy and overworked, um, and trials are a lot 
of paper work. So I think that’s possible, I certainly don’t think there would 
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be malicious intent [no] but I, but I do think that you know, even time 
constraints that sort of thing could have, play a factor in that.- S11 
 
 
In oncology clinical trials, there is a hefty workload in reporting serious adverse 
events, including a great deal of paper work; it is a very labour intensive process. 
Interviewees feel a great deal of pressure to attribute causality in a timely 
manner, which is very difficult to do when they do not have all the information 
they need to make a secure decision.  A serious adverse event needs to be filed 
within twenty-four hours, placing time constraints on these professionals. These 
sponsors want an answer right away on what the cause of the adverse event 
may be. This can be especially difficult in situations where there has only been 
one individual who has presented this adverse event. Again, these patients 
typically have multiple comorbidities, and any of these ailments, or a component 
of them, could be causing this symptom, or it could even just be an abnormal lab 
result. So there are situations when these professionals will make an assessment 
that they will subsequently change, or it will become clearer over time, that 
something else is in fact happening, and they will change their mind. Companies 
want to know the causality assessment right away so that they can send this 
information out to other sites. However, the interviewees expressed that they feel 
pressured to be the ones to make that ultimate decision, when it might not be 
accurate. In order to cope with this, these professionals rely heavily on their 
experience to make an educated attribution. These professionals expressed the 
need for more time to make these decisions, many not understanding what the 
big rush is all about. 
! ($
I mean I think um, basically um, if we all had more time in our day it would 
probably be easier to do it. The SAE has to be filled in within 24 hours. I 
mean that’s another issue, why 24 hours? what’s the urgency? By the time 
we receive it, we send it off to the sponsor, it goes to REB, there’s going to 
be a lag time anyways.- S13 
 
In situations like these, it is imperative to have a dedicated infrastructure to deal 
with these competing goals. Drug companies want fast attributions and 
physicians want time to make accurate decisions. 
Internal Pressures 
There are also financial pressures. Drug companies will often approach a 
strong academic clinical trials group to sponsor a clinical trial. These companies 
can often offer more financially than academic investigators, so there is a 
pressure to accept funding from these companies.  
Internal pressures are also present, including competing goals between 
clinicians and patients. A patient may experience serious toxicities and the 
clinician will want to stop the drug or reduce the drug dosage; however, the 
patient can pressure the clinician to keep them on the drug. This can make 
clinicians feel forced to under-report toxicity, risking the safety of other patients. 
Clinicians cope with patient pressures by reassuring themselves that patient 
safety is their top priority. 
Yeah, that’s a very valid question, sometimes I will have a patient who is 
having a serious toxicity and I want to stop the drug and the patient is 
pressuring me to keep on the drug. And you know, if you are going to keep 
them on the drug then maybe you have to under report the toxicity.- S21 
 
…Um, so, I mean obviously patient safety is paramount…- S26 
 
Clinicians also feel pressure from the Clinical Research Associates (CRAs) 
assigned to their trial, to attribute things in a certain way. There are situations 
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where the CRAs have an opinion about what the attribution should be, but it may 
differ from other investigators’ opinions.  
Third parties, um, our CRA’s sometimes want things attributed in a certain 
way.- S19 
 
There is pressure to conform to their opinion because, by doing so, it decreases 
the amount of work for them and cuts down on the amount of time spent on that 
particular attribution, affording more time to other matters of the trial. However, 
interviewees cope with these internal pressures by using their best clinical 
judgment when assigning causality. 
Discussion 
Table 7 summarizes the main themes found in this study, and shows the 
interconnectedness between each theme. One of the main themes was the 
uncertainty of the job, which stems from the lack of objective evidence, causing 
these professionals to make subjective judgments and relying on their experience 
to do so. The subjective nature of these causality attributions stems from the lack 
of resources available to assist these professionals in making informed decisions. 
This lack of resources also leads to apprehensive behaviour towards attributing 
causality. Lastly, the apprehensive nature of causality attributions also stems 
from the competing nature of oncology clinical trials. This table also summarizes 
the subthemes that were described in the findings sections as grey/problem 
areas. 
The purpose of this study was to come to a psychosocial understanding of 
how clinicians and oncologists attribute causality in early phase oncology clinical 
trials. This was achieved through a naturalistic decision making perspective, 
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which focused on how these professionals actually make decisions in a complex 
real world environment.24,25 Table 8 revisits the themes outlined in the literature 
review, and indicates the degree that this study supports each theme. These 
results will be expanded upon in subsequent sections. 
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Table 7: Supportive Literature 
Themes in Literature Review Level of Support (Supported, 
somewhat supported, not supported) 
Inconsistent definition of harm Not supported 
Time constraints Supported 
Constraints of error reporting systems Somewhat supported 
Under reporting of adverse events Supported 
Lack of a standardized method for 
assessing causality 
Supported 
 
The literature suggests that there is great variance between a patient’s 
and a physician’s interpretation of harm, i.e., a patient experiences an adverse 
event, and may see it as a harmful reaction, but the physician does not.29  
However, this study does not seem to support this finding. There was no inherent 
discussion of the definition of harm, or how one determines which events are 
harmful, and which events are not. It was, however, evident that these 
professionals genuinely expressed concern for their patients’ safety. They were 
more likely to report an adverse event as harmful, based on their clear concern 
for their patients’ safety. It is evident that harm is a very loaded and subjective 
term, with no standard definition in the clinical trial setting; however, the views of 
these participants expressed that they are deeply concerned about the safety 
and well being of their patients, not undermining the harm a patient may feel 
subject to. 
The literature on oncology clinical trials also revealed that time constraints 
placed added pressure on clinicians.33-35  The findings of this study support this. 
Time constraints do affect the quality of these decisions as well as the confidence 
levels of the decision makers. The research aimed to discover how, and to what 
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extent, time pressures affected these professionals’ decision making abilities. It 
was found that clinicians feel as though they do not have the extra time to 
reexamine the investigators brochure, search online, or call up other centres if 
they are uncertain about an attribution. So these professionals are left feeling as 
though more effort could be put into these decisions, but the time demands on 
the trial inhibit their ability to do so, and sacrifice the confidence levels of their 
causality attributions. This study also adds to the literature because participants 
express that they did not understand the timelines in clinical trials. 
Pharmaceutical timelines typically leave these professionals with twenty-four 
hours to assign causality to an adverse event, but the interviewees did not 
understand why. There is a lack of communication between trial sponsors and 
the professionals conducting these trials, further exemplifying the need for 
change. 
Other literature on oncology clinical trials indicates the constraints of error 
reporting systems. The literature clearly indicates that medical errors are 
inevitable, and that physicians choose not to report medical errors in fear of being 
individually blamed.38,39  The findings of this study support these results. An 
exploration of the cognitive underpinnings of causality assessment through NDM 
revealed that these professionals have a lot of responsibility and can feel the 
pressures of the job.24 Although there was no direct conversation on reporting 
medical errors, the findings did show that these professionals largely feared 
making an error. These professionals were, at times, very apprehensive about 
attributing causality. A misattribution could have serious consequences for the 
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development of the drug, or the safety of their patients. Therefore, the results do 
support the constraints of error reporting systems. 
The literature in the field also conveys the severe under reporting of 
adverse events that take place in oncology clinical trials.45,46  Under-reporting can 
have severe implications on the safety of the patients in these trials..48,51 The 
findings of this study confirm that under attributing causality is still an issue in 
these trials. A naturalistic decision making perspective allowed for a detailed 
analysis of causality assessment which revealed that clinicians struggle with 
under assigning causality for a variety of reasons.24,25  Investigators may become 
largely invested in the study, choosing to minimize adverse events in order to 
help the drug succeed. There are also situations where investigators may feel 
pressured by the pharmaceutical companies to under-report, or have their 
attributions questioned by these companies. A reasonable solution would be to 
develop a standardized procedure for assigning causality in order to eliminate 
bias and prevent under reporting of the events, in turn improving patient safety. 
 Another interesting feature of the interviewees’ experiences was their fear 
of over attributing causality. It was evident in the literature that under reporting 
serious adverse events was a major issue that had serious consequences; 
however, there was little mention of over assigning causality.45,46   It makes 
sense that there would be two sides to this dilemma. Over reporting can have 
serious implications on the development of a drug, the duration of the trial, and 
can place a financial burden on the company who is sponsoring the trial. These 
experiences exemplify the constraining nature of these decisions.  
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The literature also revealed that in oncology clinical trials there is currently 
no accepted standardized tool for assessing causality, and the current study 
supported this concept.58-62  It was found that global introspection was indeed the 
most common method (in this particular study, the only method) used to assign 
causality. Global introspection does not use a tool, but instead uses prior 
knowledge and experience to make an educated decision.59  However, as 
mentioned in the literature review, and supported by the current study, this 
process is full of subjectivity, and therefore, has low reproducibility standards and 
questionable.59 In addition, this study found that these participants had a high 
interest in the development of a standardized tool. They were open to the idea of 
accepting and adapting a standardized tool. All experts agreed that a tool like this 
would be helpful, and would aid them in making more confident decisions.  
These professionals shared how assigning causality was an extremely 
subjective experience, which always seemed to be interpreted as a bad thing in 
this medical setting. There seems to be an inherent battle between subjectivity 
and objectivity in oncology clinical trials.82-84 If attributing causality is seen as 
subjective, it needs to be more objective, and if the decision is objective, it needs 
to be more subjective. Where is the balance between the two? According to the 
current study, being subjective in one’s judgments is not inherently a bad thing. 
In fact, none of the participants could identify a tool they used to attribute 
causality. In all instances, they used some form of global introspection to make 
their decision(s). However, due to its subjectivity, global introspection is criticized 
! )"
on aspects of reproducibility.59,60,85,86 However, without a standardized tool, all 
causality attributions can be seen as falling short of reproducibility standards.  
Yes, clinical judgments are based on the experiences of these 
professionals, but is that not a good thing?  Experience is a subjective feature, 
but this is one of ways these professionals cope with the uncertainty of the job. In 
fact, clinical judgment, or relying on one’s experience, was the primary strategy 
for coping with grey areas within the clinical trial. Even existing causality 
assessment tools such as, the Bayesian Approach or algorithms, can be 
criticized based on aspects of objectivity. These methods seem to distance the 
patient from the decision making process by limiting their involvement and are 
criticized for lacking clinical 
judgment.59,60,62   It is clear that 
oncology clinical trials need to find a 
balance between subjectivity and 
objectivity. 
Another surprising finding 
was the lack of education and 
training received by these 
professionals to assign causality. In 
almost all instances, the 
interviewees could not recall being 
trained, especially in a formal 
manner. Most of these professionals 
What is already known on this topic
Causality attribution is uncertain in nature 
---------- 
There is no universally accepted tool for 
assigning causality 
---------- 
Severe under reporting of adverse events
---------- 
There are often external pressures from 
pharmaceutical companies and sponsors 
placed on these professionals 
What this study adds 
Professionals use a variety of techniques 
to cope with the uncertainty of the task 
---------- 
The willingness of these professionals to 
accept and adapt a standardized tool 
---------- 
This general fear of misattributing 
including over reporting adverse events 
---------- 
There are also internal pressures placed 
on these professionals; in particular 
patient pressures 
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engaged in on-the-job training, which was, for the most part, self taught. This 
could be a reason for the high volume of professionals relying on clinical 
judgments or global introspection to make these decisions. If they had indeed 
received a formal training session on how to utilize a particular algorithm or 
Bayesian approach, their experiences may have been vastly different. Although 
clinical judgment is a well respected and commonly used tool amongst these 
professionals, training could be used to promote consistency and provide further 
validity to the approach.   
 There are no standard definitions of scale measures when assigning 
causality. This can greatly contribute to inconsistency amongst professionals and 
discrepancies between pharmaceutical companies and trial investigators. 
Clinicians are given a variety of scale measures to attribute causality. These 
mainly consist of terms such as ‘certain’, ‘probable’, ‘possible’, and ‘unlikely’. 
However, these terms are rather vague for such an important decision, especially 
when they lack standard definitions. Perhaps if formal training in regards to 
causality assessment was a common practice in oncology clinical trials, there 
would be less concern with attribution scale measures. It is proposed that 
standard terminology be developed for these scale measures. Even if a 
hypothetical situation indicating percentiles for particular attributions was 
developed, it would promote greater consistency amongst these attributions and 
allow clinicians to feel more confident in their decision making abilities.  
 After a thorough explication of the data, it is evident that a standard, more 
inclusive definition of ADRs needs to be established.  The definition needs to 
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account for minor reactions and error, as well as deemphasize the harmfulness 
of these events. A more inclusive definition of a serious ADR would be a 
response to a drug or medical intervention that significantly affects quality of life 
at doses intended for prevention, diagnosis and treatment of disease, which 
warrants changes in dose administration, including withdrawal of the product, and 
prophesizes risk from future administration. This definition is based on scientific 
research and is derived from the data explication process. This offers a more 
holistic approach to defining ADRs. 
 With reference to Figure 1- The Steps in Assigning Causality, the findings 
are in full support of the concepts presented in this diagram. The interviewees 
clearly indicated the steps that they take when attributing causality and outlined 
the role patients play in this process. While Figure 1 is a clear representation of 
the steps involved in assigning causality, the revised diagram (Figure 3) below 
presents the main themes of this study’s findings. 
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Figure 3: The Steps in Assigning Causality Revised 
!
Figure!1 
 A naturalistic decision making perspective proved to be an effected guide 
for data explication.24,25  It is evident that the participants are experienced 
professionals who are making important decisions that are constrained by time, 
uncertainty, and competing goals. These professionals use a variety of methods 
to cope with difficult decisions, but primarily drew on their experience to make 
sense of situations in order to make proficient decisions. NDM is an excellent 
decision making theory that is flexible and leaves room for individual variation, as 
well as allowing for the conclusion of complex and dynamic environments.  
Comparison to the Original Research Study 
 The original research sought to understand clinical reasoning, the tools 
used to assign causality as well as the challenges present in this process. The 
current differed in that it examined these issues through the lens of a theoretical 
framework- Naturalisitic Decision Making. NDM added a unique psychosocial 
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perspective on these various elements of oncology clinical trials serving as a 
solid foundation for this research study.  
 The purpose of the original study was to explore the perceptions and 
opinions of the participants. Being phenomenological in nature, the current 
studied purpose was to explore the lived experiences of the phenomenon of 
assigning causality. The original study conducted both a content and thematic 
analysis, and the current study increases the trustworthiness of these findings 
through analyst triangulation. Lastly, the findings of the original research study 
described the steps in assigning causality. The current study described the 
problem or grey areas that arise when assigning causality, explored the 
implications of those problem areas, and identified coping strategies for dealing 
with these issues. 
Table 8: Variances From Original Research 
Original Research Study Current Study 
! Clinical reasoning 
! Tools used 
! Challenges faced 
! Studies these things through the 
theoretical framework of 
Naturalistic Decision Making 
(NDM) – Psychosocial 
perspective 
! Explored perceptions and 
opinions 
! Explored the lived experience 
(phenomenon of assigning 
causality) 
! Content & thematic analysis ! Added validity through analyst 
triangulation 
! Described steps in assigning 
causality 
! Described grey/problem areas, 
implications, and coping 
strategies of those steps 
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Limitations and Delimitations 
Limitations 
 One of the main limitations to this study was that it was based on 
secondary data analysis. The researcher did not conduct the interviews, nor 
transcribe them. This put the researcher at a small disadvantage when it came to 
analyzing the data. Due to the fact that the researcher was not present during the 
interview and has no audio-representation of the data, the researcher solely 
relied on the transcribed data. This distance from the original content did pose a 
challenge to the researcher in terms of gathering the overall essence of the 
interviews. However, the researcher was still close enough to the data to 
minimize any decrease in sensitivity toward to phenomenon.87  Secondary data 
analysis also posed many advantages to this research study.88,89 More time was 
devoted to the data analysis stage of this research.74 Access and rapport are 
also major advantages of this secondary data analysis. The group of 
professionals who collected the data had access to major cancer research 
centres throughout Canada, as well as funding from AstraZeneca, Canada Inc. 
The data were collected with proficiency and professionalism, which would 
otherwise not be accessible to this thesis. Another advantage was that the 
questions presented in the interview guide were relevant to research questions 
proposed in this study. Secondary data analysis contributes to the likelihood that 
the data is used to its full potential.87  
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 Other limitations included that recruitment was restricted to professionals 
in academic cancer centers across Canada. The findings of this study may differ 
in other countries. 
Delimitations 
 This research aimed to come to a psychosocial understanding of causality 
assessment in early phase oncology clinical trials. This research, however, did 
not create a tool to be used to assign causality. Given the time frame required to 
complete a Master’s degree and the breadth of interview data available, there 
was not a sufficient amount of time to accomplish this. This does however, pose 
an excellent opportunity for a Doctoral thesis. With more time, a tool could be 
created, implemented, and revised with the aid of NDM, which would aid 
oncologists and clinicians in making important decisions within oncology clinical 
trials. 
Strengths/ Contributions 
As with many professionals, clinicians and oncologists are faced with 
many difficult decisions on a daily basis. They must determine whether an 
adverse reaction is due to the drug/intervention being tested, or do to external 
sources, unrelated to the trial. In doing so, they are faced with time pressures 
and bouts of uncertain information, which make it difficult for these professionals 
to feel confident and secure with their causality assessment. By coming to a 
psychosocial understanding of causality assessment in early phase oncology 
clinical trials, a better understanding of how these decisions are being made, 
what affects these decisions, and the challenges faced by the professionals 
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making these decisions, was established. Through analyzing these interviews, 
with the aid of the NDM, the present study has elicited findings that will improve 
the causality assessment of oncology clinical trials.24,25  This is critical because 
assigning causality plays a major role in patient safety, as well as the market life 
of a drug. These findings may expand beyond oncology clinical trials alone, into 
other areas of health research. The findings of this study may also be useful for 
pharmaceutical companies in terms of provided more detail in IBs, creating more 
clear expectations for causality assessment and narrowing the communication 
gap between their company and the professionals conducting these trials at 
various sites.  
It was evident in the literature that causality attributions in oncology clinical 
trials are uncertain in nature. However, this study adds a new perspective by 
identifying a variety of methods used by these professionals to cope with the 
uncertainty of the job. It was also evident in the literature that under-reporting is a 
serious issue with strong implications for patient safety. However, this study also 
found that an apprehensive attitude towards over assigning causality was 
common among professionals. These professionals did not want to jeopardize 
the agent under development. The literature clearly indicates that there is 
currently no universally accepted tool for assigning causality. However, what this 
study adds is the willingness of these professionals to accept and adapt a 
standardized tool. Lastly the literature outlines that there are external pressures 
present in oncology clinical trials, but makes little mention of internal pressures 
! )*
coming from clinical research associates and patients in the trial, which this study 
found to be a common experience. 
The results of this study will also contribute to the ongoing development 
and refinement of the NDM theory.24,25  The current research on NDM deals with 
professionals, such as firefighters, pilots, business executives, soldiers, 
technicians, and physicians.90 However, previous information on physician 
decision making using NDM dealt primarily with emergency situations i.e., 
paramedics and emergency room staff, which vary greatly from the setting(s) 
presented in oncology clinical trials. To date, no research has been found that 
examines clinicians’ and oncologists’ decision-making through a NDM 
framework. Therefore, the present study provides a noteworthy contribution to 
the literature surrounding NDM. 
Ideas for Future Research 
It is very difficult to keep consistency between professionals when there is 
no universally accepted tool to assign causality. Subsequent research includes 
using the information gathered from this study could be used to design and 
evaluate a standardized tool that can be used for causality assessment in early 
phase oncology clinical trials. With a deep understanding of the decision making 
process, the goal of designing a standardized tool is closer to reality. Such a tool 
will aid clinicians in dealing with time constraints without sacrificing the quality of 
their decision-making.  
Subsequent research can also involve developing standardized definitions 
of causality scale measures. Scale measures typically consist of terms such as 
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‘certain’, ‘probable’, ‘possible’ and ‘unlikely’. However, without standardized 
definitions, these scale measure can greatly contribute to inconsistent causality 
attributions amongst professionals.  Standard definitions would promote 
consistency between professionals and between investigators and trial sponsors. 
Other subsequent research involves developing a training program for 
causality assessment in early phase oncology clinical trials. It is hypothesized 
that the reason for the high utilization of clinical judgment stems from the lack of 
formal training. Clinical judgment is criticized on aspects of validity primarily 
because of its low reproducibility rates. If formalized training were introduced, it is 
hypothesized that this would promote greater consistency when using clinical 
judgment, and therefore raise reproducibility rates. However, if a standardized 
tool were developed, this, along with causality scale measures could become a 
standard practice for training. This future research could help eliminate error, 
improve patient safety, narrow communication gaps, promote more confident 
attributions, and promote consistency amongst professionals. 
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Appendix 1: Review of the Literature Search Parameters 
Journal/Database Search 
Parameters 
Number 
of 
Results 
Elimination/Selection 
Criteria 
Chosen Articles 
Academic Search 
Premier 
“expert 
judgment” + 
“causality 
assessment” 
1 Fit search 
parameters 
Airmone Y, Bégaud B, Miremont-Salamé 
G, et al: Agreement of expert judgment in 
causality assessment of adverse drug 
reactions. Eur J Clin Pharmacol, 61:169-
173, 2005 
Academic Search 
Premier 
“review of 
clinical trials” + 
“cancer” in TI 
Title 
6 Must contain key 
term “adverse 
event”, studies 
various types of 
cancers 
McCarthy M” US cancer group calls for a 
centralized review of clinical trials. 
Lancet, 361:1621, 2003 
Academic Search 
Premier 
“safety 
reporting” + 
“clinical trials” 
11 Only articles 
involving cancer 
subjects 
Ioannidis JPA, Lau J: Improving safety 
reporting from randomized trials. Drug 
Safety, 25, 77-84, 2002 
Google Scholar allintitle: 
“cancer” + “post-
marketing 
analysis”  
1 Fit search 
parameters 
Alsheikh-Ali AA, Karas RH: Ezetimibe, 
and the combination of 
ezetimibe/simvastin, and risk of cancer: 
A post-marketing analysis. J Clin Lipidol, 
3:138-142, 2009 
Google Scholar allintitle: 
“clinician 
reporting” + 
“adverse 
effects” 
1 Fit search 
parameters 
Fromme EK, Eilers KM, Mori M, et al: 
How accurate is clinician reporting of 
chemotherapy adverse effects? A 
comparison with patient-reported 
symptom s from the quality of life 
questionnaire C30. J Clin Oncol, 
*'!
! *(
Journal/Database Search 
Parameters 
Number 
of 
Results 
Elimination/Selection 
Criteria 
Chosen Articles 
22:3485-3490, 2004 
Google Scholar allintitle: 
“improving 
reporting of 
adverse drug 
reactions”  
3 Included review 
articles. 
Molokhia M, Tanna S, Bell D: Improving 
reporting of adverse drug reactions: A 
systematic review. J Clin Epidemiol, 
1:75-92, 2009 
Google Scholar allintitle: “safety 
reporting” + 
“randomized 
trials” 
4 Eliminated studies 
on mental health 
and antidepressants 
Ioannidis JPA, Lau J: Completeness of 
safety reporting in randomized trials: An 
evaluation of 7 medical areas. JAMA, 
285: 437-439, 2001 
Ioannidis JPA, Lau J: Improving safety 
reporting from randomized trials. Drug 
Saf, 26:77-84, 2002 
Google Scholar allintitle: 
“spontaneous 
reporting” + 
“adverse drug 
reactions” + 
“rates” 
2 Fit search 
parameters 
Bégaud B, Martin K, Haramburu F, et al: 
Rates of spontaneous reporting of 
adverse drug reactions in France. JAMA, 
288:1585-1588, 2002 
Google Scholar “completeness 
of safety 
reporting on 
randomized 
trials: An 
evaluation of 7 
medical areas” 
195 Title match Ioannidis JPA, Lau J: Completeness of 
safety reporting in randomized trials: An 
evaluation of 7 medical areas. JAMA, 
285: 437-439, 2001 
Google Scholar “methods for 
causality 
34 Eliminated studies 
looking at one 
Agbabiaka TB, Savovic J, Ernst E: 
Methods for causality assessment of 
*(!
! *)
Journal/Database Search 
Parameters 
Number 
of 
Results 
Elimination/Selection 
Criteria 
Chosen Articles 
assessment” + 
“adverse drug 
reactions” + 
“clinical trials” 
specific case report, 
looked to a more 
general analysis of 
causality tools. 
Selected articles 
whose main purpose 
was to review 
current methods of 
causality 
assessment. 
Because methods 
are continuously 
evolving, only 
articles post 2007 
were included. 
adverse drug reactions: A systematic 
review. Drug Saf, 31: 21-37, 2008 
 
Google Scholar “patient vs 
clinician” + 
“adverse event 
reporting” 
1 Fit search 
parameters 
Basch E, Jia X, Heller G, et al: Adverse 
symptom event reporting by patient vs 
clinicians: Relationships with clinical 
outcomes. J Matl Cancer Inst, 101:1602-
1603, 2009 
Google Scholar “tool for 
assessing 
adverse events” 
+ “oncology 
clinical trials” 
1 Fit search 
parameters 
Coombes M, Mukherjee S, Kowaleski B, 
et al: A tool for assessing adverse events 
in phase I/II oncology clinical trials. J Clin 
Oncol, 25:6518, 2007 
Journal of 
Clinical Oncology 
“adverse event 
reporting” + 
“publications” + 
4613 Only selected 
articles that 
contained the 
Scharf O, Colevas AD: Adverse event 
reporting in publications compared with 
sponsor database for cancer clinical 
*)!
! **
Journal/Database Search 
Parameters 
Number 
of 
Results 
Elimination/Selection 
Criteria 
Chosen Articles 
“database” search parameters 
in the title, sorted by 
prevalence 
trials. J Clin Oncol, 24: 3933-3938, 2006 
MEDLINE via 
PubMed 
“adverse effects 
reporting 
standards” + 
“oncology 
clinical trails” 
2 Eliminated the article 
based solely on 
phase 1 oncology 
clinical trials and 
toxicity reporting 
Trotti A, Bentzen SM: The need for 
adverse effects reporting standards in 
oncology clinical trials. J of Clin Oncol, 
22:19-22, 2004 
MEDLINE via 
PubMed 
“Edwards” + 
“Aronson” 
9 Only those articles 
related to adverse 
drug reactions were 
selected 
Edwards IR, Aronson JK: Adverse drug 
reactions: Definitions, diagnosis and 
management. Lancet, 356:1255-1259, 
2000 
MEDLINE via 
PubMed 
“submitting 
adverse event 
reports” + 
“publication” 
3 All the same article Kelly WN, Arellano FM, Barnes J, et al: 
Guideline for submitting adverse event 
reports for publication. 
Pharmacoepidemiol Drug Saf, 12:581-
587, 2007 
Pub Med “journals versus 
databases” + 
“adverse event” 
2 Eliminated those, 
which were drug 
specific. 
Mahoney MR, Argent DJ: Adverse-event 
rates: Journals versus databases. 
Lancet, 369: 1621, 2003 
Web of Science Title=“ambiguity” 
+ “adverse drug 
reactions” 
2 Only those articles 
related to oncology 
were selected 
Koch-Weser J, Sellers EM, Zacest R: 
The ambiguity of adverse drug reactions. 
Europ J Clin Pharmacol, 11:75-78, 1977 
Web of Science Title 
=“preferences” + 
“ decision 
making” + 
“patients with 
2 Only those articles 
related to patients 
undergoing 
treatment, including 
clinical trials were 
Hubbard G, Kidd L, Donaghy E: 
Preferences for involvement in treatment 
decision making of patients with cancer: 
A review of the literature. Europ J of 
Oncol Nurs, 12:299-318, 2008 
**!
! "++
Journal/Database Search 
Parameters 
Number 
of 
Results 
Elimination/Selection 
Criteria 
Chosen Articles 
cancer”  selected 
"++!
! "+"
!
Appendix 2: Interview Guide 
 
Semi-structured questions: 
 
1) Clinical Reasoning: 
i) Explanation of how a report of a serious adverse event is 
handled/processed 
ii) Factors considered when assessing causality? 
iii) General guidelines followed when assigning causality? 
 
2) Information Resources (e.g. Investigator’s Brochure):* 
i) Resources referred to when assigning causality?  
 
3) Tools (e.g. decision trees): 
i) Awareness of tools to help assign causality? 
ii) Tools used to help assign causality? 
 
4) Challenges / Concerns: 
i) Problems or challenges with assigning causality? 
ii) Concerns about how clinical trial researchers currently assign causality? 
iii) External influences/pressures from third parties when assigning causality?  
iv) What would make assigning causality easier? 
 
5) Education:* 
i) Formal and informal training received with respect to assigning causality? 
ii) Educational needs around causality assessment? 
 
 
* Although the domains of Information Resources and Education were explored 
in the interviews the findings are beyond the scope of what is presented here. 
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Appendix 3: Letter of Invitation 
 
 
 
 
 
 
 
May 3, 2006 
 
Dear: 
 
We are developing a tool to assist clinicians in assigning causality to adverse events (AEs) that 
occur during early oncology clinical trials. In order to ensure that this tool is useful to clinicians, 
we are conducting a research project that will identify the current decision-making processes 
used by clinicians and the criteria that are essential for an AE causality assessment tool.  
 
We would like to invite you to participate in our research through a brief in-person interview of 
approximately 30 minutes in length. The interview would focus on the clinical reasoning you use 
when assigning causality to AEs and the criteria you feel are essential for a causality assessment 
tool. Your skills, knowledge, and expertise in early oncology clinical trials would provide an 
excellent basis for our discussion and your input would greatly inform the development of the 
causality assessment tool.  
 
We appreciate that you have many competing demands on your time. However, we hope that you 
are able to spare the few minutes necessary to ensure the success of this important project. Ms. 
Coombes will contact you by telephone in the next few weeks to determine your interest in 
participating in our study and to arrange an interview time that is best suited to your schedule. 
Please let us know if you do not wish to participate and do not want to be contacted by telephone. 
 
If you have any questions, or would like to discuss our research further, please do not hesitate to 
contact either of us. We hope that you will accept our invitation to participate in this important 
research initiative. 
 
Very best regards, 
 
 
 
Andrew Arnold, MD, BS, MRCP(UK), FRCPC 
Medical Oncologist, Juravinski Cancer Centre 
Professor, Department of Medicine, McMaster 
University 
Phone: 905-387-9711 ext. 64613 
Email: andrew.arnold@hrcc.on.ca 
 
Megan Coombes, MSc 
Research Coordinator, Juravinski Cancer 
Centre 
Phone: 905-387-9711 ext. 67161 
Email: megan.coombes@hrcc.on.ca 
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Appendix 4: Bracketing Activity 
These are a composition of reflective notes on causality assessment in early 
phase oncology clinical trials. 
I personally have had no experience with cancer, clinical trials, or 
assigning causality. I have however, had personal communications with 
individuals who have been involved in oncology clinical trials. Working with the 
Canadian Cancer Society, as a hospital oncology volunteer, I have sat and talked 
to several individuals diagnosed with cancer, while waiting for their treatment. 
They have shared a variety of experiences with me including treatment regimes, 
symptoms, and changes in quality of life. However, all of these conversations 
gave me a patient perspective on the matter, and none of the experiences were 
related to attributing causality. 
 In performing a literature review, I have gained insight on the pre-existing 
empirical data on attributing causality in early phases of oncology clinical trials. It 
is evident to me, that the process of assigning causality is not perfect, and that 
there are many issues with this phenomenon. I go into this data analysis knowing 
that this process of full of inconsistency and constraints, that there is no 
standardized method to assign causality, and that error is inevitable. However, to 
the best of my abilities I will set aside these preconceived notions, in order to 
allow myself, as the researcher, to truly enter into the world of the interviewees 
and gain a true understanding of the essence of their experiences, gathering a 
holistic sense of the phenomenon at hand.  
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Appendix 5: Findings Summary Table 
Grey/Problem!Area! Coping!Strategy! Potential!Consequences!
Lack!of!Resources! ! !EA!=.3/4/4:! ^4K=M0KhA9!=.3/4/4:! _4CA4>/>=04CN!/4!.0JA.=/4:!>=3413.1>!EA!=AA@! R@3C/4:!3!>=.A4:!02JM3>/>!A4!>=.04:=M!AB!3>>AC/3=/A47!8>0!/4V0>=/:3=A.>!9.ACM8.0!
_4CA4>/>=04C/0>!90=F004!J.AB0>>/A43@>!/4!=0.2>!AB!C38>3@/=N!3>>0>>204=!
53CH!AB!.0>A8.C0>! Q0@N!A4!=M0/.!0XJ0./04C0! DM0>0!J.AB0>>/A43@>!3.0!84C0.=3/4!AB!=M0/.!C38>3@/=N!3==./98=/A4!0XJ0C=3=/A4>!L3:80!10B/4/=/A4>! Q0@N!A4!=M0/.!0XJ0./04C0! ]4C0.=3/4!C38>3@/=N!3==./98=/A4>!;A2284/C3=/A4!/>>80>?!
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Appendix 6: Horizontalization  
Significant statements were extracted from the transcribed interviews and 
made easily identifiable by attaching key words (meaning notes) 
Extracted Statement Meaning Notes 
 
So there’s often not a lot of guidance it’s more 
winging it.- S01 
 
 
No Guidelines 
Intuition 
Yeah, and I would say timing is the most important 
factor. I mean, other factors, we don’t usually have 
dose as a, as a ah, we don’t usually have doses in 
the same, different doses in the same patient to be 
able to judge a dosing relationship- S01 
 
Dose Relationship 
Temporal Relationship  
Certainty is very difficult to achieve- S01 
 
Uncertainty 
I think that the probable, possible, etc scale is 
better, it just gives more room for interpretation of 
the interpretation.- S01 
 
Interpretation 
Coping with Uncertainty 
Yeah and yes and no is desperately frustrating 
sometimes because things are grey like, you know, 
if it’s unlikely but it’s still possible then saying you 
know, is that yes or no because that’s hard.- S01 
 
Frustrating 
Interpretation 
Grey Area 
 
There is a lot of background noise in side effects, 
what side effects may be caused by other drugs, 
disease.- S01 
 
Difficult Decisions 
Uncertainty 
As previously mentioned dose, you know, often we 
don’t have a dose relationship that we can look at.- 
S01 
 
Patient Confusion 
Lack of Resources 
Supposedly one of the criteria for causality is 
something like a dose response relationship 
whereby more of something causes more of an 
effect. And a patient typically, although we may 
have that in a cumulative dose, we don’t have 
different doses from cycle to cycle necessarily. So 
you can’t say when you had a little bit of this you 
felt a little nauseated, now that we’re giving you 10 
Dose Relationship 
Lack of Resources 
! "+(
times more you’re feeling really nauseated. So we 
wouldn’t have that information typically. - S01 
 
I think it can interfere, the inaccuracy of it can 
interfere with drug development and can potentially 
in the most extreme case, kill a drug. Or I suppose 
on the other side allow a drug to go ahead when 
side effects are overlooked. Although if, if you have 
a bunch of us who are calling unlikely things 
possible, because you know, we’re not really sure 
because it’s just subjective. And the FDA looks at 
that or the investigators look at that and decide, 
you know we just have too many pulmonary 
embolisms and they’re all possible, as opposed to 
unlikely, you know, it can impact what they do with 
that drug. They may change the dose and lose 
effect or they may stop the trial or whatever. So 
there’s risk to the drug and to the patient.- S01  
 
Subjectivity 
Over Attributing 
Under Attributing 
I don’t know that I have, I think, I can certainly 
imagine however, in one’s own trial whether there’s 
going to be a bias and you don’t want side effects 
to be attributable to your drug, um. [like if you were 
the PI] Right, if you were the PI easy to imagine 
and it may or may not be conscious though. And 
on the flip side is you may have a prejudice against 
the drug because it is prior reputation, or difficulty 
of administration or something which you know. I 
can’t say that personally in short I’ve felt anything 
in particular, but it may be lack of experience to 
date.- S01 
 
Bias 
Subjective 
But we’re still stuck with you know, these vague 
situations with the problems we’ve discussed and I 
don’t, it’s not clear.- S01 
 
Uncertainty 
Most of it is kind of intuitive you know, so I’m not 
sure.- S01 
 
Intuition 
Um, sometimes it’s grey, you know, maybe could 
be and that’s the difficulty.-  S03 
 
Grey Area 
And, and ah, um, what really annoys me is when 
investigators at other sites don’t pay attention to 
this and let’s say there’s an SAE they attribute it to 
you know, very likely study drug.-  S03 
Annoying 
Lack of Attention 
! "+)
 
if it’s done incorrectly, it’s a pain in the ass for all 
the trial nurses and all the invest, all the trial 
doctors all over the world because it takes time to 
sort out.-  S03 
 
Frustrating 
Consequences of 
Misattributing 
My head.-  S03 
 
Intuition 
Just my clinical judgment.-  S03 
 
Clinical Judgment 
My common sense.-  S03 
 
Common Sense 
Well if you have, ah, ah following the patients with 
this and it takes how many minutes or hours to do 
it, it’s very costly [it adds up] it’s very labour 
intensive.-  S03 
 
Workload 
Time Constraints 
And the ICH/GCP guidelines which this is part of 
is, is, ah, is making it very, very difficult to do this 
sort of research and it’s unfortunate because you 
know, we need to study new drugs, we need to, 
yeah.- S02 
 
Difficult 
Impedes Research 
Yeah, you know, my concern is sometimes not 
enough attention is paid or they don’t understand 
sometimes what the implications are so they don’t 
give it enough time, they don’t understand it.-  S03 
 
Lack of Attention 
Times Pressures 
I mean it’s almost from the experience we’ve had 
with drugs.- S03 
 
Experience 
From a causality point of view, I mean there’s more 
stress if the adverse event is of a more serious 
magnitude in terms of determining how related it is 
to the trial medication.- S04 
 
Stress 
And I think a lot, a lot of that has to do with you 
know, how do you make the decision, it’s difficult 
sometimes, sometimes it’s pretty straight forward 
that they’re experiencing an adverse event that is 
know to occur with the study medication.- S04 
 
Difficult 
Hard to Assign Causality 
Actually not any that I know of.- S04 
 
No Resources 
So I think, those ones are okay because you’re 
basing it a bit on personal experience [yeah] and a 
Personal Experience 
Intuition 
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little bit on what’s published.- S04 
 
I can’t say that there any actual guidelines that I 
know of or that I specifically follow.- S04 
No specific guidelines 
  
So it’s more like each case, hopefully, you know, 
the fear is that you’re not consistent I guess, that 
you know, you’re scoring a patient differently, 
that’s, that’s the fear.- S04 
 
Fear of Being Inconsistent 
Patient Safety 
There’s, there’s two concerns, I think one concern 
is you know, over assigning causality. Because 
patients are, they can get sick, morbidities, multiple 
medications, actually a lot of reasons and it 
sometimes it’s easier to blame it on the drug. But I 
think my fear is that if you, if you do that liberally 
you’d be, not discrediting the drug but you’re not 
um, it could lead to dose reductions, could 
eventually work their way into an ineffective 
treatment schedule for that. If you saw a whole 
bunch of side effects that you thought were you 
know not really related to the drug and that led to 
that drug being less .- S05developed in a certain 
disease. Maybe you’re doing a dis-service to that 
patient population, so that’s one, that’s one 
concern I have. Perhaps over-assigning causality 
just because of the complications of some of the 
patients on the program is my biggest concern. 
And the other concern is, the other, completely 
opposite really is the not assigning causality and 
then drugs are allowed to develop. And then it’s 
only when you start getting into Phase 2, Phase 3 
studies that you really, adverse events really show 
themselves. And you’re thinking well why wasn’t 
this picked up in the Phase 1 or 2 studies? [yeah] 
So I think you can go either way, you can make 
errors on either way, one way you might kill a drug 
that might be successful and on the other way you 
might let a drug develop not carefully enough. 
 
Fear of Over Attributing 
Fear of Under Attributing 
I mean the biggest stress, not that I’ve had any 
stress about it, but the biggest issue is assigning 
causality that could result in a Phase 2 program 
going to a lower dose or something like that or you 
know a ineffective dose for a given cohort of 
patients is a concern, whether you’re doing the, 
Concern of Over Attributing 
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you made the call because that’s often a critical 
step in a clinical trial.- S04 
 
Oh, very little, I mean I think um, a lot of the 
pharmaceutical sponsors that we did some studies 
with, had some training modules but not 
necessarily for causality mostly for adverse event 
reporting- S04 
 
Little Training 
I normally don’t use anything particularly that 
formal.- S05 
 
No Tool 
There you’re getting, you’re, you know it’s hard to, 
to, how, how strongly are you going to implicate 
the study on the side of implicating the study drug 
just from these issues.- S05 
 
Over Attributing 
Difficult 
I think yes or no becomes very hard and we’re not 
always sure you know. And there’s always that 
element of doubt about it. But I think you have to 
be able to say how strong or weak your doubt is 
and when you have the graded scale it just gives 
you some flexibility to do that.- S05 
 
Doubt 
Uncertainty 
 
Yeah, they are really, I think in some cases we 
have to be, make sure that well, is there an 
element of doubt but clearly that’s where the 
unlikely category comes in and these are patients 
who are being said, well it’s probably related to 
their targeted agent and you know, clearly that’s 
probably likely not the case. But what that does is it 
really contaminates the whole database in terms of 
what is the causality of these toxicities. It’s a huge 
problem worldwide and we certainly see that when 
we’re having to look at data from large international 
studies where you have groups who probably don’t 
have a lot of experience with either the chemo or 
the targeted agent. And making these attributions it 
really kind of make a mess of the database.- S05 
 
Over Attributing 
There’s an awful lot of pressure when you’re doing 
early phase studies with a small biotech company. 
They, there’s a lot riding on, on, you know, there 
are the issues of well are you going to torpedo their 
only drug or just from a financial point of view, with 
toxicities that are going to expand the dose level. 
External Influences 
Time Pressures 
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That’s gets in and take longer for the study to 
complete, those have big financial implications. On 
the other hand our, our first responsibility is to the 
patient and if not I think making sure, a lot of 
pressure from the smaller companies. And I think 
the other pressure is just the sheer volume of the 
adverse events you know, here are the ones from 
the last couple of weeks. So it’s just huge volumes 
and they all, and everybody wants them done 
within kind of 24/48 hours and it just becomes 
impossible to do. On some level there needs to be, 
and a lot of these are these ones that you know it’s 
clearly the chemo drug and probably really isn’t 
related to the study drug. But there’s, probably half 
of those are those kind of things that have been 
generated, probably inappropriately because of the 
experience of the people who, it’s a problem. It’s a 
huge workload and unless we’re handling them 
consistently I’m not sure we’re going to be any 
further ahead.- S05 
 
There hasn’t been any formal training, yeah, 
there’s hasn’t been anything formal.- S05 
 
No Formal Training 
That is a challenge in that typically when patients 
go in to clinical Phase 1 trials they have advanced, 
often refractory cancers and ah, needless to say, 
significant ah, medical problems at the beginning 
and throughout the clinical trial.- S06 
 
Challenging 
Confounding Variables 
Basically all one can really do is, based on 
experience of managing these people sort of know 
what to expect as their cancers progress and as 
their regional stages of life, as in previous 
experience in managing.- S06 
 
Prior Experience 
It’s really based on experience at this, at this stage. 
So really it would depend on a, an experienced 
investigator who has managed a lot of the specific 
patient population to in my opinion, accurately 
determine if this is something that’s related.- S06 
 
Experience 
Subjective 
No I’m not aware of any.- S06 
 
No Tool 
That’s a clinical judgment based on what’s 
happened to the patient.- S06 
Clinical Judgement 
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I think it’s better to maintain a sort of a graded 
scale because I don’t think one can be that 
definitive. With the number of resources you have, 
it’s only a matter of being able to document and 
have there as a possibility.- S06 
 
Uncertainty 
Grey Area 
Um, I would say that more resources would be 
good for investigators, more resources at their 
disposal. [what sort of resources] Well, resources 
through the sponsor [for what] for information [oh 
okay] more information as to whether, you know, if 
you have questions about a certain event. And for 
example you wanted to understand the drug’s 
pharmacology better and try and determine you 
know, in some way could there be access to that 
information beyond the IB. The opportunity to 
discuss on a regular basis with other investigators, 
how the trial is going, um, through conference calls 
is a good idea.- S06 
 
Lack of Resources 
Disconnect with Sponsors 
Um, well there, you know, there, I think one has to 
fight, now this is a more of a perception, I don’t 
have any examples. But there’s a risk that the 
sponsor may want, may prefer you to go to an 
unlikely conclusion. That I disagree with.- S06  
 
External Pressures 
Sponsor Pressures 
No I haven’t because I’ve stubbornly just said well 
that’s my final answer, so I’ve never felt any, any 
sense of coercion. Obviously, you know, inherently 
results in more work for somebody but ah, in the 
Phase 1 setting I, I, I think ultimately it’s the 
sponsor’s in their best interest to fully understand 
what their drug is doing and what it’s potential 
effects are. But one does have to be fairly stubborn 
in that regard.- S06 
 
External Pressures 
Strict Decisions 
Lack of appropriate information.- S06 
 
Lack of Information 
Well I think if there’s a, I think there is a certain 
distance often between the clinical trials nurse and 
the physician.- S06 
 
Lack of Communication- 
Clinical Trials Staff 
So it is experience.- S06 
 
Experience 
The challenge is that the good Epi group who can External Pressures- Drug 
! ""$
run trials in an academic setting are going to be 
approached by drug companies. And you need a 
lot of money, those staff have to be paid and there 
are costs to the clin epi group and that’s a lot better 
then a local academic.- S07  investigator say 
getting a grant for 100,000 bucks and he can give 
you a  $1000 bucks. I think they’re, they’re, the risk 
I think comes in the academic setting when the 
institute needs to kind of step up I mean today 
that’s being done, certainly here’s its done so it’s, 
but I don’t know about other centres across the 
country.- S06 
 
Companies 
Financial Pressures 
No not really, using just yeah, anything.- S07 
 
No Guidelines 
Well usually there’s teleconferences and other 
meetings to discuss what’s happening with other 
patients. But a lot of times communication isn’t as 
good as it could be.- S07 
 
Lack of Communication- 
Communication not up to 
par 
We should be involved in as much of those 
discussions just so everybody is informed. I 
haven’t done a lot of, so I don’t know what they do 
to keep it up but sometimes you do feel a little bit, 
you have no idea what the other people are doing. 
And it would be a little insightful as to how they’re 
doing it, yeah.- S07 
 
Feel Lost 
Disconnect from other 
Professionals 
 
Problems, first of all you’re never definite, definite, 
hindsight’s always 20/20, so looking back a few 
months later you can sometimes get a more 
clearer picture of what, like analyze the situation a 
little bit more.  Sometimes when you’re right in the 
situation and you have to, you have that 
responsibility of assigning it right then and there, 
you don’t have all the information right? You don’t 
know how it’s going to end, you don’t know, um, if, 
if, why it happened or anything. You can analyze 
the situation after it occurred and everything has 
evolved then it’s sometimes easier to go back and 
go well this and this happened we can do that. So 
assigning causality sometimes at the time is 
sometimes clear cut and sometimes very difficult.- 
S07  
 
 
Uncertainty 
Time Constraints 
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Why, because you know what, um, it’s those minor 
things that can cause good quality of life issues in 
patients.- S07 
 
Concern for Patient 
Concern for Minor 
Reactions 
Well I think it’s based on what’s been listed in the 
protocol and possibly the investigator brochure. 
But really do you have time to look at an 
investigator brochure every time? No.- S08 
 
Time Pressures 
Mostly I find you know I tend, I agree with, with the 
conclusions they come to and sometimes um, I 
think there’s a tendency to over report disease-
related symptoms as being related to the 
investigational agent by the invest, you know, to be 
reported by the investigator. - S08 
 
Over Attributing 
And so in that setting there’s a discrepancy 
between what the investigator feels and what the 
medical monitor feels. - S08 
 
Over Attributing 
Conflict 
Not too much, but then again I’m not the one that 
the sponsors contacting when they call you and go 
are you sure that this is what you think it is? and 
stuff like that. I’ve had one of those calls where 
they’ll call back and they’ll say is this the way you 
want it? And you just go back to the physician and 
tell them they want to reconsider. And sometimes 
the physician is, will stick to their guns and 
sometimes they will re-think it or whatever.- S07 
 
External Pressures- 
Sponsor Pressures 
Oh, who knows, whenever you get an algorithm it’s 
always like the yes/no’s sorts of things and 
sometimes there’s a grey in-between. So 
sometimes you have to kind of think differently. 
 
Grey Area- Change 
Mindframe 
But it’s also insightful to know how the patient feels 
and how their quality of life is, is affected as well.- 
S07 
 
Concern for Patient 
Nothing formal. Sometimes in start up meetings or 
something like that they’ll, they’ll say a little blurb 
about assigning causality but they won’t really give 
like formal education as to what, we should use this 
tool or anything like that. It’s mostly a set reaction 
sort of.- S07 
 
No Formal Training- Learn 
from Experience 
! ""&
And then you have, because different companies 
will approach it differently and so then you have 
AstraZeneca with their reports. The company sort 
of reports basically they, they want to downplay 
um, these and so their stock standard line is that 
you know, such and such a side effect is not listed 
in the investigator brochure, the implication being 
well it can’t be related. So you know they take the, 
so you’ve got to look at it with, it’s somewhat 
helpful but somewhat tedious. - S08 
 
External Pressures- Drug 
Companies 
No, cause what happens, they’ll send us the report 
and then it’s up to us to how we deal with it. I mean 
they have to be forwarded to the REB and the 
internal documentation that we do is more about 
sort of thinking for ourselves whether we want to 
make consent changes. Whether we see 
something which is happening you know, with um, 
severity or a frequency that would justify making a 
change to the consent form. And that doesn’t 
happen very often, in part because you know, we 
tend to wait for, because periodically there will be 
an update to the investigator brochures and then 
they’ll considered if the consents need to be 
updated. - S08 
 
External Pressures 
Sometimes in some places for some companies 
you know the serious adverse event would be 
mucusitis, diarrhea and dehydration. And other 
places and I guess the NCIC in particular, I mean 
our recent experience, is that they say well the 
drug doesn’t cause dehydration, the diarrhea and 
the mucacitis does. So you have primary adverse 
event and then you have secondary effects from 
that [right]. And then really only want the primary 
event reported as the serious adverse event and 
then what’s secondary to that is covered in the 
description of the serious adverse event. - S08 
 
External Pressures- Drug 
Companies 
S08: [that’s a bit of a challenge] It is and some of 
that is sort of developing a better understanding of 
what individual sponsors want or expect. But on 
the other hand maybe there should be you know, 
greater consistency. - S08 
M: You find that there is variation among the 
sponsors as to what it is that they want and expect. 
External Pressures- 
Varying Sponsor 
Expectations 
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-  
S08: Yeah. 
 
Imprecise science! I am not, I mean I guess to 
have definition, I mean more clearly defined sorts 
of definitions of the terminology would be most, 
would be the thing that would be most helpful. 
[which terminology?] You know, in terms of the 
causality terminology, so more clearly define what 
people mean by unlikely, possibly, probably, you 
know definitely related. And at least people are 
using the terminology you know, in a similar 
fashion. - S08 
 
Unclear Terminology 
Inconsistency 
Well I think that there are, I mean I think you know, 
if you start sort of labeling a drug as having you 
know x, y and z side effects and in fact they’re in 
fact they’re side effects related to the disease then 
you know, um that’s a problem. But on the other 
hand does it, how does it limit development of the, 
the agents. I’m not certain, well I’m not less certain 
that it’s going to limit development of the agent. - 
S08 
 
Over Attributing- Seen as 
Problem 
No, no I’m not aware of any.- S09 
 
No Tool 
Yeah, I mean you use your clinical assessment 
and um, and it’s really process of elimination and if 
nothing else comes out.- S09 
 
Clinical Judgment 
You always look at, I mean there are always so 
many other confounding variables in this 
population, especially if their disease is starting to 
get a bit worse.  They go on other medication, right 
which can impact, you don’t know what these 
newer agents do with any of the other medications 
that are out there. There are just so many variables 
that can [yeah] affect,  drug-drug interaction you 
know and drug-disease interaction, drug-foods. I 
always make a point of asking patients are they on 
any over the counter or complimentary therapies 
because they may not think, well I’m not taking any 
medication but they’re on all these herbal or [yeah] 
just lots [lots of unknowns right?].- S09 
 
Uncertainty 
Confounding Variables 
Well, I think you can overcall things that, and say Over Attributing- 
! ""(
that they’re related when they’re not. [mmm hmm] 
Um, and then that leads to for the drug companies 
to sort out or, or you know, whoever the sponsor is 
in determining are these or are they not? And I 
think um, it would be beneficial at some point to 
follow through on the other end of things to see 
what it means when you’re on that end. [what do 
you mean on the other end?] Like a CRO getting 
this information in and saying now, you know, oh 
well what does that mean, the word, how you take 
it and what did they do with it from that point. 
Because I mean we submit the information but 
what happens on that side, but I think.- S09 
 
Consequences for Drug 
I think it would be beneficial for all of us maybe to 
spend a bit a time with them and see. Or even with 
the data management, I don’t know what they do 
with the data management part of it. [yeah] And I 
think it would help us understand part of what 
we’re doing too when you see how companies or 
CRO’s try to collate the…- S09 information we 
send to them. And then what it can do in terms of, 
you know analyzing the study or.  
No Resources 
Lack of Communication 
Disconnect with Drug 
Companies 
management  part of it. [yeah] And I think it would 
help us understand part of what we’re doing too 
when you see how companies or CRO’s try to 
collate the information we send to them. And then 
what it can do in terms of, you know analyzing the 
study or.- S09 
  
 
Um, well they come back and say well are you 
sure that’s related? [mmm hmm] right [yeah] you 
know. No I’m not sure but I’m not willing to say it’s 
not, you know.- S09 
 
External Pressures 
M: Sort of the pressure to keep the drug 
development process moving I guess. 
S09: Um, hmm, um, hmm. Yeah, very much so. 
And, and I think some of the pressures come 
around too is you know to put patients on study 
and sometimes that feels more, that’s more the 
goal rather than the safety of the patient. I think we 
rely on the companies to monitor these studies and 
when they don’t, especially the early phase 
studies, and when they don’t there’s a huge 
problem with that. I’m not perfect, and they’re not 
External Pressures- Drug 
Companies 
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either but I think they then have the responsibility 
to monitor those studies and get those forms back 
into data management so they can make the 
proper queries that will probably, that could correct 
anything that you’re not even aware of.- S09 
 
I’ll be honest and say I don’t really have any 
[really]. I don’t have any tools that I use.- S10 
 
No Resources 
I like the scale because yes/no is pretty black and 
white and often there are many scenarios where 
you’re just not sure.- S10 
 
Uncertainty 
I think the biggest implication would be that if a 
drug gets attributed to have a set of adverse 
events that are quite serious then that may 
preclude further study of that drug, that might stop 
the trial.  And if you’re looking at a dose escalation 
study where you’re escalating to your next dose 
based on the tolerated dose, you’re now saying 
that there’s some side effects. Well you might not 
go to the next dose level, or you’re recruiting more 
patients to that particular cohort level so subjecting 
more people to the drug than may be necessary in 
a clinical trial. So the issue of not, of a potentially 
very good drug not being taken further because of 
the concerns of the adverse events, that’s going 
one way. And the other way if you don’t attribute 
the causality, a potentially dangerous drug could 
come to market without the proper, or with 
concerns about adverse events.- S10 
Over Attributing 
Under Attributing 
-Concerns of… 
 
Often these patients are just, have such 
complicated histories, you know, they’re prone to 
other medical problems.- S10 
 
 
Uncertainty 
Well I think just the fact that there, there isn’t a 
systematic way to do it, that it often is based on 
hunches and feelings as opposed to a rigorous 
method or measurement tool.- S10 
 
Hunches & Feelings 
Intuition 
Well if you’re involved in industry studies then 
certainly there’s some pressure from, not so much 
for assigning causality but continuing. So if you’ve 
had someone who has had an adverse event and 
you want to dose reduce them or hold off treatment 
External Pressures- Keep 
the Drug Development 
Process Moving 
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for a little while sometimes there is that pressure to 
continue with the study. So in that sense you could 
think well maybe if you had assigned them a 
possible as opposed to a probable relationship 
then you could, you could be pushed to continue 
with the study. But you always have to keep the 
patient’s safety in mind [right] at the end of the day 
so, so that’s what you go by.- S10 
 
But I must admit I really haven’t had that much 
pressure in terms of treating the patient. It always 
comes down to the patient’s safety and that’s what 
you go by.- S10 
 
Patient Safety- Priority 
M: And then um, do you know of any tools that are 
available to help in assigning causality? Have you 
every used any sort of a decision tree or an 
algorithm or [no] something like that? No. [no] Do 
you think that would be useful? 
S11: I do think that would be useful um.- S11 
 
No Tool- But would be 
Useful to have one 
A lot of the times I find it’s hard and I don’t think it’s 
an on purpose thing from patients, but I don’t 
necessarily think that we do get every single bit of 
information all the time.- S11 [yeah] I think different 
things are reported to different people, depending 
on your position, whether that be chemo nurse, 
clinical trials nurse or the physician.- S11 
 
Missing Information 
Lack of Resources 
So I think it definitely depends, again, very 
individual, depends on the patient, depends on 
your personality, what you’re asking. If you’re 
asking the appropriate questions or not, I think that 
that makes a big, a big difference too.- S11 
 
 
Personality 
Subjective 
Oh gosh, it’s hard to say, again, every patient is 
different. Some patients, um, some patients I think 
it’s easier to leave everything open and let, just 
leave it as a blank slate, let them tell you 
everything that’s been happening. Um, some 
patients if you do that won’t tell you anything. So 
some patients, not prompting but some patients 
you need to I think go through a list of questions 
and ask them about specific side effects, problems, 
even possibly body systems and leave it open that 
Individual Variation 
Subjective 
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way for them to suggest things to you. Um, again, 
um, I find it’s, again reporting is very different from 
person to person in terms of the clinicians.- S11 
 
Um, and again I think that’s very subjective for the 
clinician also the way the patient describes things. I 
could consider it a grade 2 whereas the physician 
could consider it grade 3. - S11 
 
Subjectivity- Patient & 
Clinician 
Again, I’m not really sure that’s optimal especially 
considering how, you know, little time everybody 
has these days.- S11 
 
Time Constraints 
Um, I mean to start out with the very basics, a lot 
of, a huge workload involved, um, in doing it poorly 
and that, I mean it could be anything. Just from the 
workload involved in SAE’s, even the reporting, all 
the different avenues it needs to go through.- S11 
 
Workload 
Um, an implication could be the fact that drugs 
aren’t being marketed or aren’t moving on to 
different phases of trial because causality has 
been improperly assigned. It could also on the very 
opposite side of the spectrum, it could also lead to 
harmed patients, it could lead to death in patients. 
A whole array of things, I mean it could obviously 
affect the statistical analysis of the study, it can 
affect everything.- S11 
 
Over Attributing 
Under Attributing 
Who’s kidding who, they’re busy and overworked, 
um, and trials are a lot of paper work. So I think 
that’s possible, I certainly don’t think there would 
be malicious intent [no] but I, but I do think that you 
know, even time constraints that sort of thing could 
have, play a factor in that.- S11 
 
Workload 
Time Constraints 
I’ve had no formal training [no] actually.- S11 No training 
So if, if, there’s an SAE that, that comes out of that, 
that has So if, if, there’s an SAE that, that comes 
out of that, that has implications for notifying 
sponsors, the sponsor notifying the regulatory 
agencies and the company, there’s timelines for 
doing so. The nature of enough AEs may influence 
the conduct of the study [how does it influence?] so 
misrepresent, well a series of SAEs may [9:51].- 
S12  
External Pressures 
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So you could in one situation attribute something to 
an entire one set of the, the most serious and if it’s 
this and you don’t acknowledge it, that’s dangerous 
for future patients in the study. [right] If it’s, if it’s 
you know, this and you label it as this, you could 
be potentially closing a trial that presumably was 
well thought out and had a good hypothesis and 
the hypothesis could end up being rejected. 
[implications] Potentially [yeah] I mean if you 
polarize the extremities yeah, most of the stuff is 
not going to end up being that extreme, it’s going 
to be in the middle but.- S12  
 
Under Attributing 
Over Attributing 
It’s just very practical and if ah, I mean there is a 
bureaucratic process that is time consuming that if 
you assign an SAE versus not that somebody’s 
going to have to do a lot of work and meet 
timelines and set a whole ball rolling.- S12  
 
Time Pressures 
Bureaucratic  
I think you then have the issue of the sponsor, and 
sponsors, sponsor may influence. [okay, how so?] I 
think in general from what I’ve seen, sponsors will 
tend to, tend to things that are expected, the, if the 
consequence is an expected one and it’s tended 
less to be labeled serious adverse event even if it’s 
expected but the degree and the severity wasn’t, 
that’s a tricky one, you give an agent.- S12  
 
External Pressures- 
Sponsors 
I have to admit that is very subjective at times.- 
S13 
 
Subjective 
Um, well to be honest, not really I think you just go 
on what your best clinical judgment is or what your 
patient’s status is.- S13 
 
Clinical Judgment 
None. [no] No, well I mean, I guess I shouldn’t say 
that, none in terms of standardized criteria that’s 
for sure. Resources, unless you mean basically 
going back to see maybe the investigator brochure 
and trying to understand some of the toxicities.- 
S13 
 
No Tool- Nothing 
Standardized 
Well there’s definitely implications in serious 
adverse events, and, and association, obviously if 
Over Attributing 
Under Attributing 
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you put it wrong then there’s misinformation. If it is 
associated and you don’t think it is then that, that’s 
probably the more harm there because we need to 
be aware, particularly in Phase Is that we need to 
be aware of and people think oh it’s very unlikely 
I’m going to put it not related but then obviously 
that’s information that the physicians and the 
patients in particular need to know about. So I think 
the worst is an association that is there but one 
grades as not associated and, and harm could be 
done to patients. The other extreme is people, and 
I see this a, a lot because you have to, as the PI on 
the trials you have to signoff on all the REB 
submissions to the REB. People that put 
everything is associated creates lots of paperwork. 
Where its very clear in reading through their SAE 
this was not drug related, this was disease related. 
And to me that doesn’t do any harm to patients 
which is good but it creates extra paperwork for the 
CRAs, for the nurse, for us, for the REBs and to 
me that’s more irritating when it comes from all 
around the world, you know you get. [yeah] People 
could be, could think a little I think, I don’t know, 
think a little bit more clearer in terms of what they 
think is associated and perhaps those that are not 
associated would save the.- S13 
 
But ah, um, you know, I think it’s a very subjective 
process, that’s the problem. And subjective in 
terms of ranking them or associating but also 
subjective in how much effort people actually put 
into the work. And I won’t say I do it all the time but 
you know, I think in terms of how much 
background work one does in trying to understand 
the causality with each one trying, if you’re not 
certain, if you are certain it’s very easy. Perhaps, if 
you’re not certain are you going to spend that extra 
time to pull out the IB or talk to you’re you know, 
pull out the protocol and actually do the best.- S13 
 
Subjective 
Effort Levels 
So unrelated, definite, possible. Like what’s the 
unlikely and probable versus possible versus 
probable, you know, where do you draw the line? 
Again, it’s very subjective.- S13  
 
Subjective 
Inconsistent Scale 
Measures 
But ah, um, you know, I think it’s a very subjective Uncertainty 
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process, that’s the problem. And subjective in 
terms of ranking them or associating but also 
subjective in how much effort people actually put 
into the work. And I won’t say I do it all the time but 
you know, I think in terms of how much 
background work one does in trying to understand 
the causality with each one trying, if you’re not 
certain, if you are certain it’s very easy. Perhaps, if 
you’re not certain are you going to spend that extra 
time how much background work one doesto pull 
out the IB or talk to you’re you know, pull out the 
protocol and actually do the best [7:30].- S13 
 
Subjective 
The challenges are particularly in Phase I trials 
these are, these, they all have their advanced 
disease, they often all have been through 
numerous other treatments, some of them have 
been heavily pretreated. Many of them are not of 
the greatest performance status and so they have 
a lot of other co morbidities or symptoms that can 
merge and        play a role. Sometimes these 
brand new drugs we really don’t know. We don’t 
have a lot of information, that’s why we do the 
Phase Is. And how much weight we put on what is 
seen or not seen in dogs or monkeys or whichever 
animal work they have done it on, large animal 
work done, kind of you know, there’s not a lot of 
data there, so in the end if you don’t have a lot of 
data to work with and you have patients, it does 
become very hard.- S13 
 
Uncertainty 
Confounding Variables 
I mean I think um, basically um, if we all had more 
time in our day it would probably be easier to do it. 
The SAE has to be filled in within 24 hours. I mean 
that’s another issue, why 24 hours? what’s the 
urgency? By the time we receive it, we send it off 
to the sponsor, it goes to REB, there’s going to be 
a lag time anyways. And you don’t expect things 
to, you know, maybe grade 5 toxicities where you 
have a death, maybe that should be 24 hours. But 
I, I don’t know why an SAE can’t be 48, so you 
don’t feel that pressure to have to. Not that, I think 
we do it just because we feel a pressure, but again 
I think we just said 24 hours and that’s just been 
the rule that’s been adopted all along right. [right] I 
actually don’t see the rationale of 24 versus 48.- 
Time Constraints 
Disconnect 
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S13 
 
Well I think the only external pressures is obviously 
be accurate as possible. And so you know we’re 
part of the, part of the Princess Margaret 
Consortium and you know a couple of the NCI 
trials, you know the NCI physician from the US is 
emailing me in terms of causality, so obviously 
there are pressures to be as accurate as possible. 
But sometimes you really don’t know if it’s 
associated or not.- S13 
 
External Pressures- 
Accuracy 
Yeah, [yeah] yeah I think so. [okay why?] Well 
because there’s a, it may help you sometimes in 
the dilemma where you in this grey zone of serious 
adverse event where you think about what to, what 
to assign to this SAE. If you have a clearly 
unrelated or clearly related SAE that’s easy but 
the, the vast majority of SAE’s is probably 
somewhere in between..- S14 
 
Uncertainty 
Comfort in Grey Area 
But that is basically based on, on the situation and 
your experience and not on any formal rules or 
algorithms or whatever.- S14 
 
Clinical Judgment 
Well you can clearly overlook, worst possible thing 
would be that you actually don’t report a side effect 
which is actually a side effect, from, from the drug. 
That may really happen, but I think one of the 
existing problems is that the frequency of those 
side effects maybe under reported.- S14 
 
Under Attributing 
Overlooking it altogether is certainly worse [yeah] 
but I think [it’s also important] a serious adverse 
event, if a serious adverse event is seen in 
relationship to this more often then at some point 
we, we report it. But I think the frequency may then 
be under reported. But the key, overlooking a side 
effect or not reporting a serious adverse event 
which is actually part of the side effect profile, 
that’s probably the worst, the worst thing.- S14 
 
Under Attributing 
The opposite is true too, if you , if you report an 
SAE which is not related to the drug [mmm hmm] 
then that can cause a considerable, can have 
considerable sincere consequences for the, for the 
Over Attributing- Serious 
Consequences 
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drug and the development of the drug.- S14 
 
Worse case scenario that you delay or you stop 
the development of the drug. I mean imagine that a 
patient dies on a Phase I study and you assign the 
death as possibly related to the study drug and it 
wasn’t. Something like this can kill, kill a drug in the 
development or at least considerably delay it or 
cause a lot more costs for the, for the company or 
whoever develops the drug to do additional testing 
and stuff like this.- S14 
 
Over Attributing- Serious 
Consequences 
Well it’s so subjective, in the end, for the majority 
of SAEs which are in this grey zone of possibly or 
likely or unlikely related, it’s a very subjective, a 
very subjective thing.- S14 which is based on 
experience and, and of, of the investigator.- S14 
 
Subjective 
Grey Area 
No, not that I’m aware of, not that we use here that 
I’m aware of. 
 
No Tool 
Um, probably the sponsor wanting an answer right 
away of what the cause, because sometimes you 
don’t know, it’s hard to make a decision on one 
patient, like the first patient that presents. 
Especially if that particular patient has multiple 
problems and it’s possible that it could be their 
disease or a component of their disease that’s 
causing the symptom or the, the abnormal lab 
result.- S15 
 
External Pressures- Time 
Constraints 
Um, well, of assigning them poorly? It’s either you 
under, or whatever event it was so you’re 
compromising safety of future patients who might 
go on this treatment if you um, rule that it wasn’t 
related to the drug. Or you might over, you know if 
you say that everything is related to the um, to the 
investigational drug then you’re over, over rating it 
as to whether the drug is causing problems. So it’s 
pretty serious.- S15 
 
Under Attributing 
Over Attributing 
Well the potential ramifications of that is the drug 
might not go out to market and it might be a 
potentially legitimate drug. [okay] Because 
describe SAEs or have SAEs that might not really, 
that are manageable or might not really be 100% 
Over Atttributing- 
Rammifications 
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related to the drug. Especially if you pick a poor 
group of people who you know always get admitted 
for nausea and vomiting because they have a poor 
ECOG status. And it could be that they were just 
very poor patients initially to put on treatment.- S15 
 
Um, more information from the sponsor I guess in 
terms of um, side effects of the drug.- S15 
 
Lack of Information 
The first issue is how quickly can you really assign 
it? Often you know, you need to report within 24 
hours. Within 24 hours you may report, the person 
came in with chest pain, da, da, da, and you don’t 
have any real idea if it’s related or not.- S16 
 
Time Pressures 
I think there’s two big concerns. One is if you 
assign causality and say it’s related improperly 
then it might tarnish a good drug and stop dose 
escalation in a way that wouldn’t be appropriate. 
Alternatively if you ignore it, it might cause further 
toxicities in others and be potentially dangerous to 
other patients. I think it’s a very dangerous thing. I 
also think that sometimes as oncologists we tend 
to minimize rather then maximize because we’re 
used to toxicity with drugs and that can be 
dangerous.- S16 
 
Over Attributing 
Under Attributing 
I think sometimes, sometimes you’re in such a rush 
to get the CRF done that I think you don’t 
necessarily spend enough time. And I think one of 
the other problems is we get so many reports 
about drugs, you know like alerts [safety letters?] 
safety letters that sometimes everybody doesn’t 
know these things and may not know if it’s related 
or not. I think keeping up with the safety letters is 
hard, [just because you get so many of them?] 
mmm hmm and not really knowing the drug well.- 
S16 
 
Time Pressures 
Not Enough Time 
The timeline, it’s mainly the timeline and the 
pharmaceutical company.- S16 
 
Time Pressures 
I think most of the doctors who do a lot of clinical 
research are aware of the fact that you don’t want 
to underestimate the toxicity of a drug. But at the 
same time you don’t want to assign every single 
Under Attributing 
Over Attributing 
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adverse event to the drug some will not be due to 
the drug. So you usually end up in the, this is a 
possible to probable consequence of the drug if it’s 
in the grey area where there could be many 
reasons why the patient had an adverse event.- 
S17 
 
One always worries if an investigator who is on, 
perhaps working with a drug company may wish to 
minimize adverse events because they really want 
this drug to be a success or acceptable. And it 
need not necessarily be driven by egregious 
opportunities around receipt of research funds, it 
may be because they get sort of um, too invested 
in the drug itself and wanting it to succeed or 
wanting their career to succeed or something of 
that nature. But that can induce investigator bias. 
Um, on the other hand you can have some 
investigators who um, will always attribute 
causality to the drug because they rather 
simplistically think if anything bad happens it must 
be the drug.- S17 
 
Under Attributing 
Over Attributing 
Are there tools out there? [laughter] no I don’t. 
[okay].- S18 
 
No Tool 
You know, where the same event can be attributed 
differently because a lot of things, it’s a subjective 
assessment. It’s not as objective as it should be, I 
think that’s what makes it a challenge.- S18 
 
Subjective 
Lack of Objectivity = 
Challenging 
Um, I think any time with an investigational agent, 
like I said your antenna are fairly high up and you 
probably are more likely to ah, to lean on the side 
of, you don’t want to harm a patient or subject to 
harm to assign causality where it may not have. 
Like assign a higher level of attribution even if it 
may not have been. So you know, when in doubt 
the diagnosis of exclusion is going to be that it’s, 
it’s the investigational agent. [yeah] So, and that 
may be unfair to the agent under development 
right. [mmm hmm] So it’s just your level of, you 
scrutinize it more, like I said a more conservative 
approach to when in doubt, better to say it’s 
possibly related than not. Those are, and no tool.- 
S18 
Over Attributing 
Hesitant 
! "#)
 
That’s where I think issues of attribution become 
very difficult.- S19 
 
Uncertainty 
I think it’s human nature to forget things [okay, 
forget] and obviously if it’s a very serious event, it’s 
going to be recorded and you’re likely going to 
hear about it in some way. But not all patients 
understand that in a clinical trial that we’re also 
interested in the side effects of the treatment. And 
in a Phase I actually toxicity is your primary 
endpoint. [mmm hmm] But the patients of course 
feel that they’re on the treatment to help their 
cancer [yeah] so there’s a little bit of a disconnect 
there. So they’re more interested in what the drug 
is doing for their cancer and they kind of are 
hunkered down with the idea, many of them are 
very stoical right [yeah] they say I’m going to put 
up with whatever side effects I have to put up with 
um, to get through this treatment because it’s 
going to help my cancer. And I think that’s, that 
translates sometimes to a lack of reporting of 
events. I think that some patients may also 
perceive that you know, the doctors or nurses don’t 
want to hear them complaining right, they just feel 
that they’ll sound like whiners right.- S19 
 
Lack of Information 
Patient Bias 
And if you’re so busy or have not done your 
homework in terms of reading about the drug, or 
don’t have the time to go look it up. So you know, 
basically just having a busy clinic and being busy 
at work can lead you to mis-attribute these things 
right.- S19 
 
Workload 
Time Constraints 
Third parties, um, our CRA’s sometimes want 
things attributed in a certain way.- S19 
 
External Pressures 
Yeah, I was just thinking they’re, when you look at 
attribution of adverse events, I mean they’re 
basically the people you’re working with [yeah and 
they want] you think you’re filling out a CRF and 
then um [they] they want an attribution level. And 
ah, sometimes they have their opinions about what 
the attribution is and they’re different from [yours] 
mine. You know, not a lot but um, that just in terms 
of explaining to them and then they have to change 
External Pressures 
Workload 
! "#*
their forms [yeah, yeah] and if they’ve already 
submitted the forms a certain way. Ah, in affect 
you’re creating more work for them, ah, so that 
does, I don’t like to create more work for the 
people I work with. So I do feel a little but of 
pressure there, but ah.- S19 
 
Besides the patient, family members, maybe 
differences in behaviour, maybe some psychologic 
or neurologic issues associated with the 
medication because we just don’t know enough 
about them, ah lab work, imaging results 
sometimes [okay] and the physical examination.- 
S20 
 
Lack of Information 
Lack of Communication? 
No. I think we basically use our medical judgment 
and the sources of information.- S20 
 
Clinical Judgment 
But you have to, I think you have to assume that 
you don’t know enough about the drug that it could 
be drug related.- S20 
 
Uncertainty 
Err on the Side of Caution 
I think a lot of it sometimes is the background noise 
from patient or the disease. And how do you know 
the symptoms are not related to the cancer or to 
underlying symptoms from other comorbidities 
from other chronic diseases the patient may have? 
- S20 
Uncertainty 
Confounding Variables 
Well sometimes it’s difficult, somebody, say 
somebody with chest pain who has plural 
metastasis it’s really hard sometimes to know 
whether this is related to pulmonary embolism. 
Then basically have to do the appropriate 
diagnostic imaging which in that case would 
probably be a spiral CT scan to try and sort some 
of that out. Um, what other symptoms? say patient 
fatigue, ah, well that can be really difficult for 
instance, it could be related to disease, study drug, 
could be related to psychologic factors, some 
change in the patient’s environment, who knows? 
And that could be, and you have to look at all those 
and figure out which is most likely and then it’s you 
know, and have there been changes in those areas 
that might explain it? Um, and if there’s more than 
a couple of possibilities you have to kind of use 
your judgment which is more likely.- S20 
Difficult 
Uncertainty 
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I guess, I guess one of the biggest challenges 
these days is that if we, people have enough time 
to rigorously evaluate all the possibilities in a very 
busy clinic setting. [yeah so] The time to sit down 
and really fully go over everything with the patient 
in terms of  what’s new by history and do a good 
physical examination.- S20 
 
Time Pressures 
Um, I think everybody’s under severe time 
pressures these days and it makes it, it’s um, you 
need to have a dedicated infrastructure to do good 
Phase I and II studies.- S20 
 
Time Pressures 
Nothing formal.- S20 
 
No Training 
No, it’s kind of, for me it’s like an intuitive process, 
and I should also say that sometimes the CRA’s do 
it.- S21 
 
Intuition 
Just that there’s more than one possible 
explanation for a lot of toxicities that you see. So 
as you say, PE can be due to the drug or it could 
be due to the cancer and maybe they would have 
had that PE even if they weren’t on the drug or 
because they’re immobile or any number of 
factors. I guess it’s just that there are multiple 
factors at play. I’d say that’s the most difficult 
aspect of it. And plus the fact that they may be on 
other treatments, like they may be on something 
for their hypertension or their diabetes [yeah], 
they’ve got often multiple medical problems aside 
from the cancer.- S21 
 
Uncertainty 
Difficult 
I probably don’t give it as much thought as, as I 
should. I mean, I guess the real risk is that if 
people are falsely ascribing SAEs to the drug when 
it’s really the cancer then you could potentially 
throw out a good drug.- S21 
 
Over Attributing- Risks 
And I guess the converse is true too that if you 
don’t, if you don’t adequately report the toxicities 
then you might be introducing a drug to the market 
that is dangerous.- S21 
 
Under Attributing 
Yeah, that’s a very valid question, sometimes I will Internal Pressures- Patient 
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have a patient who is having a serious toxicity and 
I want to stop the drug and the patient is 
pressuring me to keep on the drug. And you know, 
if you are going to keep them on the drug then 
maybe you have to under report the toxicity.- S21 
 
No, I don’t, I don’t think so, no, it’s mainly the 
example I can think of is patient’s pressuring me to 
keep them on a drug when I’m not sure that’s to 
their, you know in their best interest.- S21 
 
Internal Pressures- Patient 
Zero.- S21 
 
No Training 
I guess, I keep coming back to this, but keeping it 
simple and brief because there are a lot of 
competitors for a trialist’s attention, you know, like 
there are a lot of time constraints and something 
more simple that would be best.- S21 
 
Time Constraints 
Need for Simplicity 
And then it becomes difficult for me, but then 
you’re forced to make some kind of a decision.- 
S22 
 
Difficult 
To the causality [oh the causality yeah] because 
you have to react in some way. So I had to think 
this morning for example this ocular side effect, 
was it due to you know, drug A or drug B or the 
combination. Or was it due to something incidental 
like you know conjunctivitis or something. So you 
have to think about alternative causes, alternative 
explanations. I mean people with cancer get many 
symptoms from the cancer that are not necessarily 
due to the drug, they may just be due to the 
underlying disease. And of course a lot of people 
have comorbidities because they’re elderly and 
have a 101,000 things wrong with them. And you 
know, is it just something incidental. So I think one 
of the important things in the causal reasoning is, 
is to be aware of what the possible causes could 
be. You know, it’s due to the experimental drug, it’s 
due to some other drug the patient may be taking 
or may have just started taking. It could be due to 
the underlying cancer, it could be due to some 
other illness that may have occurred or that may 
have already existed like diabetes or angina or 
something you know. So I think critical in the sort 
Uncertainty 
Conflicting Alternative 
Attributions 
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of, the kind of cognitive approach is the realization 
that there’s a whole slate of things which could 
possibly either alone or in combination have 
resulted in this phenomena.- S22 
 
On the other hand you don’t want to be paralyzed 
by uncertainty because if you’re in a busy clinic 
you can only tolerate paralysis for so long [right] 
you have to make some kind of a decision.- S22 
 
Time Constraints 
But every now and then it’s tough, like what 
happened this morning for example, it was difficult, 
it wasn’t clearly obvious to me what was going on.- 
S22 
 
Difficult 
You might argue you know, causality is difficult, 
causality is not simple. [no] You know, there’s 
different kinds of causality, there’s the kind of 
relationship where something is sufficient on it’s 
own. [right] There’s another kind of relationship 
where something by itself is not sufficient on it’s 
own but it’s necessary. [and then there’s] And 
there’s relationships that are where you have it’s 
neither sufficient nor necessary but it nonetheless 
contributes. So it’s actually, on the one hand you’re 
saying well just attribute causality but there’s 
actually a more profound and fundamental 
understanding of causality with respect to well 
what type of causality? Um, which is important I 
think because it does help you manage the 
situation you know, so sometimes I don’t think it’s 
possible to be 100% sure.- S22 
 
Difficult 
Uncertainty 
You know, this is caused by drug X or it’s not. And 
in a sense I don’t like that because, I know, I just 
don’t think it represents the reality and the reality is 
sometimes there is an element of uncertainty.- S22 
 
Uncertainty 
But, but even if you stumble on a strategy that’s 
effective it doesn’t necessarily mean that there 
aren’t other strategies that are also effective. [sure, 
yeah] So this just speaks to the complexity of this, 
especially when you’re dealing with two drugs.- 
S22 
 
Complex 
M: So definitely dealing with two or more drugs in Challenging 
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combination is a challenge [yeah] in terms of 
assigning causality, are there any other 
challenges? - S22 
 
Well I think you know, they have to make a 
judgment in a hurry, so there’s a concern straight 
away, they’re on the busy machine in the clinic and 
they have to, you know, somebody puts some form 
in front of them and they kind of, you know, they’ve 
got two pens, one pen in their left hand and one 
pen in their right hand and they’re hitting the 
typewriter with their nose and looking at the screen 
and trying to do four things at once and the 
telephone is ringing and so on. It really is a zoo as 
you know, so they have to make hurried decisions, 
so that’s my one, that’s my number one concern.- 
S22 
 
Time Constraints 
Stressful 
Um, I think it’s a long way from engineering right 
now and I think a lot of it is gut feeling and kind of 
intuition.- S22 
 
Intuition 
But it may not be quite that easy to do with 
chemotherapy, even in the, even off trial, but it’s 
particularly difficult to do that on a trial because 
you know that you might sabotage you know, the 
intent of the study by just unnecessarily stopping. 
You know, I think the onus on an investigator and 
somebody who’s responsible for treating the 
patient on a trial is quite high really because they 
have the ability to undermine the trial by making a 
fallacious attribution. You know because 
something might have happened you know, they 
got gastro because they ate something at some 
restaurant or something and then you say well it’s 
the drug and you take them off the drug. Well then 
you undermine the whole enterprise you know 
which isn’t just that trial, it stretches back over 
probably 15 years of work and money and 
investment. And it’s so easy to undermine it by 
making, by casually making the wrong attribution.- 
S22 
 
Over Attributing 
Difficult Decisions 
So there’s two kinds of mistakes you can make. 
You can make a false positive attribution or you 
can make a false negative lack of attribution, when 
Under Attributing 
Over Attributing 
! "$%
in fact you should have.- S22 
 
So it’s, you know, these things are in a way 
matters of life and death, they can be.- S22 
 
Serious Decision 
And I think a lot of things can happen under the, 
under the banner of uncertainty. You know, you 
can be forced to under, I think that uncertainty is at 
the heart of this, its at the heart of this. And I don’t 
think it’s a matter of honesty or dis, I think it’s 
uncertainty and how do people cope with 
uncertainty? And I think that this actually is the 
measure of whether enterprises succeed or fail. 
You know, it’s how they deal with uncertainty. So I 
think for example one of the differences between 
successful businessmen and unsuccessful people 
in business is that the unsuccessful people don’t 
know how to deal with uncertainty. Um, because 
life is full of uncertainty and you know, it’s possible 
to be panicked into, into making a wrong decision. 
On the other hand it’s also possible to be 
paralyzed into not making any decision at all. 
[yeah] So when you see these kind of little human 
dramas played out in this situation as well 
because, but I think it’s a mistake to not allow the 
physician to be uncertain when he or she is 
genuinely uncertain.- S22 
 
Uncertainty 
The real, the really difficult issue is where you 
would have a situation where you would have to 
stop the study drug or reduce the dose of the study 
drug. There I think it becomes particularly difficult 
and particularly important that the correct decision 
is made. If you’re simply going to say well you can 
treat this with a bit of Imodium or some heparin or 
something it doesn’t really matter. But where 
you’re forced to interfere with the conduct of the 
study and the administration of the new drug that’s 
where it becomes acutely important to do the right 
thing.- S22 
 
Over Attributing 
Pressure to Be Accurate 
I have seen situations where some pressure, let’s 
say that the pharmaceutical company maybe had a 
different viewpoint about what was said, you know 
without being specific I’ve certainly seen that. I 
think most people have, most people that deal with 
External Pressures- 
Pharmaceutical Companies 
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pharmaceutical companies realize that they’re 
obviously coming from a certain angle. And that 
they may have a different interpretation, 
sometimes, I think sometimes they’re right. I think, 
I’m not saying they’re always wrong but certainly 
they have a viewpoint [sure] which they express 
you know.- S22 
 
I think you know, if a patient is sick in a way that 
taxes the resources of the cancer center and the 
hospital, I think you know, there’s certainly 
pressure not to carry this on beyond what’s 
reasonable. And you know, that’s, that’s 
understandable and inevitable.- S22 
 
Internal Pressures 
Well more so but there was a lot of problems with 
some of the toxicities as well, all the patients were 
having serious adverse events. But they were also 
very ill patients and it’s very hard to separate that 
out at times.- S23 
 
Difficult Decisions 
Time, the physician’s time.- S23 
 
Time Pressures 
Well it’s the companies they want to get their drugs 
to market and sometimes you get a little pressure 
from them you know? [to do what?]  Well to just to 
confirm yes this is related particularly if it’s nasty, 
nasty stuff. There’s a couple of companies out 
there that don’t think twice about picking up the 
phone, you know, asking you to review with the 
physician, that’s fine we’ll review it but ultimately 
we’re not here for the trial. Well we’re here for the 
trials, but we’re here for the patients and so we’re 
not going to cause them any harm if we can help 
it.- S23 
 
External Pressures- 
Pharmaceutical Companies 
Minimal at best [okay] basically on-the-job training. 
I think all the CRAs we basically self-train or train 
each other as we go.- S23 
 
Minimal Training 
Yeah, um, yeah, obviously we haven’t received 
any training for it but um, I’m not sure that we’re 
the ones who are actually expected to come up 
with that determination. - S24 
 
No Training 
Nothing in particular pops up, I mean I can see Uncertainty 
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there are some areas that obviously are a little 
grey as to which way the assignment should go, 
whether it’s definitely related or somewhat related. 
- S24 
 
Grey Area 
So the physician meets with the patient [mmm 
hmm] and afterwards they come out and they 
dictate what sort of went on. [mmm hmm] And 
often times it’s not extremely detailed, is that what 
you’re saying? - S24 
 
Lack of Detail 
Lack of time probably. [just time pressures, yeah, 
okay that would seem reasonable].- S24 
 
Time Constraints 
Um, ah, well just that, that, it’s always, you never 
know whether something, there could be that 
chance that you don’t know whether something 
could be related if it’s a new event if it’s happening 
with our patients.- S25 
 
Uncertainty 
Yeah, more detailed information I guess, other 
than what’s in the consent form, having a list of 
expected events and maybe, some of them put in 
the percentages of what the patients have already 
experienced. So yeah, I guess that, just a more 
detailed sort of, um, like I was saying we go to the 
dose modification and it will list sort of what the 
expected toxicities are and the rules to follow. So 
maybe to have some kind of I don’t know, chart or 
information in that area to go to, to see what we’re 
looking for and how they expect us to assign the 
causality.- S25 
 
Lack of Info 
Lack of Communication- 
Expectations 
Yes I guess, um, I was going to say something 
similar to that, that they might be making decisions 
quickly without really going to source, some sort of 
source or really knowing.- S25 
 
Time Constraints 
Um, well I find the companies, well they don’t 
always agree and then ah, [with your 
assessment?] with our assessments. And you see 
that often in safety reports that come through, it’s 
tends to be always a possible or probable 
assessment when it really may not be necessary. 
But not a major pressure other than they want to 
know what the causality is you know, with that 
External Pressures 
Time Constraints 
! "$(
initial, if it’s an SAE for example [yeah] they want to 
know that right away because they have to send 
that out to other sites. [yeah] So you know, that’s 
the pressure there to sort of um, get that answer 
quickly. And because we don’t want to make that 
ultimate decision they may be getting our 
assessment initially that might not be the correct 
one so I guess that would be a concern or a 
pressure for me [yeah] to get the physicians 
ultimate decision on [right]. Because they want the 
information quickly right with an SAE so.- S25 
 
Ah, yeah, they could do that for sure, they might 
phone us, or during monitor visit they might um, 
sort of query it and ask questions about why we, 
thought it was related or not. And then give us their 
reasons why they think it should be different and 
want us to change it and we might not always want 
to. So there’s, there’s always that happens, usually 
they would speak with the physician, we’d have 
them speak directly with them so they would 
discuss their reasons for their assessment. But it 
does happen.- S25 
 
External Pressures 
Question Decisions 
But other than that um, as far as education as to 
how to assess the causality [yeah] I would say 
that’s really minimal to none.- S25 
 
No Training 
Well I guess one of the things that I’ve always had 
a difficult um, thing to grapple with is that there are 
too many, often there are too many categories of 
relatedness. [okay] You know, like definite, 
probable, possible, unlikely or not, do you see what 
I mean? [yeah] And I think that those are fairly 
subjective definitions that will vary from person-
person. You know, what I think is unlikely is not 
necessarily what you might think to be unlikely 
[mmm hmm] and so um, again the assigning of 
causality there could be sort of chance depending 
on the interpretation of the definition by the 
individual physician.- S26 
 
Subjectivity 
Confounding Variables 
Ah, none [can you recall a time?] none really, I 
mean there’s, the only pressure that you feel um, is 
the sort of sense of urgency of, because you know 
you have to fill out the SAE report within 24 hours 
Time Constraints- Make for 
Difficult Decisions 
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and all this sort of stuff. You may not have all the 
information and you may make an original, you 
may make an assessment that subsequently you 
change or becomes clearer as time goes on that 
something else is in fact happening and you want 
to change your mind about something. Which is, 
which is fine and you do, do that but I think that 
sometimes, I don’t know that you should 
necessarily have to assign the causality right away. 
I mean I think reporting the SAE right away and 
saying this is what’s happening and we’re 
monitoring the patient and these are the steps 
we’ve taken. And we’ll, you know, as things evolve 
we’ll let you know what we think actually 
happened, rather than saying yes we think this is 
study drug related within the first 18 hours when 
you don’t, you may not necessarily have all the 
facts yet.- S26 
 
Well as I said I think sometimes it’s arbitrary and it 
depends upon the physician’s interpretations of the 
definitions of you know, these different things. I 
think it depends a little bit on the physician’s past 
experiences, expectations and biases with respect 
to the class of agents and so on.- S26 
 
Subjective 
Arbitrary 
Like I think that whole 24-hour, like I understand 
that we need to report the event but I think the 
causality part of it should be delayed until after you 
have the facts. And then you can say okay really I 
think this is you know.- S26 
 
Time Constraints 
Trial and error I guess. I mean the only, the only 
lecture I’ve ever heard about is, I’ve heard A speak 
once, but other than that you know, really nothing. I 
mean you’d ask other more senior investigators 
what they would say for this particular event and so 
on. But otherwise, there was no formal training.- 
S26 
 
No Training- Nothing 
Formal 
Well I guess just trying to determine which drug 
could be causing the adverse event, you know if 
it’s, you know they could both be causing it, it could 
be one or the other so you need to do.- S27 
 
Uncertainty 
Multiple Variables 
And pre-existing conditions in the patient if they Uncertainty 
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have you know, other health problems that could 
be contributory to some symptoms. You know, and 
sometimes it can be as easy as just the person 
themselves, some people will say they’re perfectly 
fine when they’re not. And other patients will 
elaborate on you know, how they’re feeling and 
might be exaggerating a little bit. So you know you 
have to try and understand the patient themselves 
as well.- S27 
 
Patient Subjectivity 
Well, most of my studies are also sponsor studies 
and they tend to make the wording vague on 
purpose. [laughter] Probable, possible [the wording 
of what] probable, possible, definitely related, 
possibly related all the, so sometimes that can be a 
challenge if it’s something you haven’t encountered 
before.- S28 
 
Lack of Information 
Disconnect with Sponsors 
So anytime they asked for anything to be changed 
I would leave those queries up to him and 9 times 
out of 10 he would not change them. [oh that’s 
good] Because, but then it gets annoying and then 
you start to second guess and wonder why are 
they even asking if the investigator is ultimately 
responsible for the data and not some data entry 
person a million miles away who has no idea what 
is really going on. Why are they second guessing 
this, what are they really after?- S28 
 
External Pressures 
Annoying 
So quite often I think it can be multi-factorial, it may 
not be just due to the one thing [yeah] so it’s 
complex, pain is complex. So I don’t think you can, 
sometimes it might be obvious, I mean if someone 
has bone mets and they come in and they have a 
fracture. That’s pretty straightforward, it’s their 
disease, but it may not always be that 
straightforward.- S29 
 
Uncertainty 
Pain- Subjective 
No. [no eh, you don’t use any?] No, in fact I think 
people tend to lean towards putting it, like when 
they’re not sure, and most people are never 100% 
sure, they’ll say you know either probable or could 
be. And I think we see a lot of “could bes” more 
than any other.- S29 
 
No Tool 
Err on the Side of Caution 
Well we probably don’t pay as much attention to it Lack of Attention 
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as we should. I mean a lot of the initial information 
is prepared by the CRAs or the study nurses and I 
think in a practical everyday busy clinical 
environment we have these things coming across 
our desks to be signed almost on a daily basis. 
And I’m not sure if we think about it as much as we 
should, if we give it as much attention as we 
should, because it’s just another thing to be 
signed. [mmm hmm, yeah] And there’s been sort of 
very little attention paid to it in sort of the clinical 
research area.- S29 
 
Like pain, pain is subjective, fatigue is subjective, I 
mean you can try and quantify it but if you think 
that the study, that the causality, that fatigue is due 
to the study drug you’re not going to have objective 
evidence. [true] Weight loss, well I guess if you 
have weight loss you can measure them in pounds 
but it’s not always going to be there.- S29 
 
Subjective 
Not Always Objective 
Evidence 
Because I think you can falsely label a drug with all 
sorts of um, toxicities that have nothing to do with 
it.- S30 
 
Over Attributing 
So it’s really, it’s, there’s, it’s a combination of 
factors when you’re making decisions, when you’re 
designating causality.- S30 
 
Uncertainty 
Um, and it can go both ways, if you only see a very 
small number of patients you may underestimate 
or under-relate particular symptoms to, to the drug. 
And the same thing can also happen where if, if 
you just decide that every bad thing that happens 
to a patient is going to be possibly attributable 
then, then not only do you jeopardize the 
development of a drug but you also, those things 
all get added to patient consent forms and they 
muddy the waters for patients.- S30 
 
Under Attributing 
Over Attributing 
Well with smaller drug companies you tend to get 
more queries about why did you assign this as 
attributed or not attributed? You know, what do you 
think the underlying pathophysiology is? and so 
you know, smaller drug companies particularly 
when their entire livelihood depends on, on a 
single agent will, will be, will, I don’t know if 
External Pressures- Drug 
Companies 
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pressure is the right word but they will definitely 
discuss extensively how and why you’ve chosen 
that something is related.- S30 
 
So sometimes there are grey areas and at the time 
it might be difficult but retrospectively by continuing 
to look at data after the fact then you’re able to um, 
to decide at a later date.- S31 
 
Uncertainty 
Grey Area 
It’s tangible evidence that there is a toxicity. But 
something that is not a direct result but could 
subsequently happen is I think a grey area, and it 
could probably, it might have been, we don’t know 
for sure. [yeah] So that’s why I say it’s kind of a 
grey [yeah] a grey area.- S31 
 
Uncertainty 
Comfort in grey Area 
So you’re assigning causation when maybe it’s not 
it may be something else. So as a company I think 
they’re obligated to list that as a part of their um, 
their package. Maybe not, maybe they don’t take 
into account certain timeframes. Maybe they have 
a tool.- S31 
 
Over Attributing 
Timing 
No.- S31 
 
No Training 
It would have been nice if we could have 
established causality unanimously but. [yeah]  So I 
say going to the physician but if there is more than 
one involved there can be more than one opinion.- 
S31 
 
Subjective 
So sometimes it’s hard to attribute it to exactly one 
specific thing. You kind of have to say it could be a 
combination of their con-meds and their study 
medication and the chemo, so it’s harder to give a 
causality. So usually a lot of times we just, we have 
to answer unknown because we’re not, we can’t 
specify exactly, possibly, could be related you 
know.- S32 
 
Difficult 
Uncertainty 
A study drug that may have that same adverse 
effect. So trying to directly relate causality to that 
sometimes is difficult when you know that it could 
be experienced in two, two different, or three 
different medications.- S32 
 
Uncertainty 
Difficult 
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But when it’s subjective, like how a patient is 
feeling or how sore their mouth is or you know, 
how much pain they might be experiencing, it’s all 
very subjective to each patient. So severe to one 
person might be you know, moderate to another. 
So those kinds of things I find, unless you can 
assign a number value to it I find that hard to 
grade. Because some things are very subjective, 
pain, those things are, in my, I find personally hard 
to grade.- S32 
 
Subjective- Patient 
There’s no formal training really, you just kind of 
got thrown into the position.- S32 
No Training 
Note: S= Subject 
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Appendix 7: Clustering Meaning Units to Form Themes 
Units of Meaning Themes 
 
No Guidelines (3) 
Uncertainty (31) 
Grey Area (3) 
Confounding Variables (1) 
Difficult (14) 
 
 
Coping with Uncertainty 
Personal Interpretation (1) 
Intuition (4) 
Subjective (13) 
Clinical Judgments (6) 
Common Sense (1) 
Personal Experience (5) 
Hunches and Feelings (1) 
Personality (1) 
Individual Variation (1) 
 
Subjective Judgments 
No Guidelines (3) 
Unknown Dose Relationship (3) 
No Resources (9) 
No training (13) 
No tool (7) 
Lack of Communication (4) 
Unclear Terminology (1) 
Lack of Support (1) 
Missing Info (1) 
 
Insufficient Resources 
Fear of Under Attributing (14) 
Fear of Over Attributing (24) 
 
Apprehensive Causality Attributions 
Time Constraints (24) 
External Pressures (25) 
Internal Pressures (3) 
Workload (4) 
 
Competing Goals 
Frustrating (2) 
Patient Confusion (1) 
Annoying (1) 
Lack of Attention (4) 
Stress (1) 
           Inconsistent (1) 
Non-Redundant   
(Incorporate throughout) 
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Feel lost (1) 
Concern for Patient (3) 
Serious Decisions (1) 
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Appendix 8: Transcript Characteristics 
Interview Center Position Specialization Time 
Subject 01 JCC Medical 
Oncologist 
Lung 22 Minutes 24 
Sec. 
Subject 03 JCC Medical 
Oncologist 
Breast 31 Minutes 31 
Sec. 
Subject 04 JCC Hematologist Blood (Lymphoma, 
Myeloma) 
26 Minutes 39 
Sec. 
Subject 05 JCC Medical 
Oncologist 
Gynecologic 22 Minutes 26 
Sec. 
Subject 06 JCC Hematologist Melanoma, Non-
Hodgkin’s 
Lymphoma 
24 Minutes 27 
Sec. 
Subject 07 JCC Clinical Trials 
Nurse 
Hematology, lung 24 Minutes 47 
Sec. 
Subject 08 JCC Medical 
Oncologist 
Breast, lung 29 Minutes 04 
Sec. 
Subject 09 JCC Clinical Trials 
Nurse 
Breast 38 Minutes 10 
Sec. 
Subject 10 JCC Medical 
Oncologist 
Breast, GI 24 Minutes 31 
Sec. 
Subject 11 KRCC Clinical Trials 
Nurse 
Hematology 38 Minutes 40 
Sec. 
Subject 12 NCIC Hematologist Hematology 29 Minutes 3 
Sec. 
Subject 13 BCCA Medical 
Oncologist 
Breast, head & neck 18 Minutes 20 
Sec. 
Subject 14 BCCA Medical 
Oncologist 
Gastrointestinal, 
genitourinary  
24 Minutes 28 
Sec. 
Subject 15 BCCA Clinical Trials 
Nurse 
Ovarian, lung, 
breast, GI, head, 
neck, melanoma 
22 Minutes 55 
Sec. 
Subject 16 BCCA Medical 
Oncologist 
Breast 22 Minutes 55 
Sec. 
Subject 17 BCCA Medical 
Oncologist 
Breast, lymphoma 25 Minutes 45 
Sec. 
Subject 18 BCCA Medical 
Oncologist 
GI 22 Minutes 14 
Sec. 
Subject 19 LRCC Medical 
Oncologist 
Unknown 46 Minutes 18 
Sec. 
Subject 20 LRCC Medical 
Oncologist 
Unknown 38 Minutes 32 
Sec. 
Subject 21 LRCC Medical 
Oncologist 
Unknown 29 Minutes 34 
Sec. 
Subject 22 LRCC Medical Unknown 54 Minutes 03 
! "%'
Oncologist Sec. 
Subject 23 LRCC Clinical Research 
Associate  
Unknown 25 Minutes 40 
Sec. 
Subject 24 ORCC Clinical Research 
Associate 
Prostate 31 Minutes 30 
Sec. 
40Subject 
25 
ORCC Clinical Research 
Associate 
Unknown 40 Minutes 37 
Sec. 
Subject 26 ORCC Medical 
Oncologist 
Lung 37 Minutes 21 
Sec. 
Subject 27 ORCC Clinical Research 
Associate 
Head, neck 34 Minutes 43 
Sec. 
Subject 28 ORCC Clinical Research 
Associate 
Lung, ovarian 30 Minutes, 58 
Sec. 
Subject 29 ORCC Medical 
Oncologist 
Breast, lung 34 Minutes, 20 
Sec. 
Subject 30 ORCC Medical 
Oncologist 
Colorectal  31 Minutes 41 
Sec. 
Subject 31 ORCC Clinical Research 
Associate 
Brain, breast 36 Minutes 54 
Sec. 
Subject 32 ORCC Clinical Research 
Associate 
Breast, GI 29 Minutes 29 
Sec 
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Appendix 9: Memoing 
Subject 01 
S01: So am I going to get a consent form for this? 
 
M: Laughter, yes, you just signed it remember and then threw it in your recycling 
bin? [oh right yeah] So let’s start, so even the most experienced clinicians find 
assigning causality to adverse events challenging. And many groups, such as 
industry sponsors, clinical trial cooperative groups and research ethics boards 
they all expect prompt and sensible causality assessments. But, assigning 
causality is not straightforward and if done poorly it can have large implications 
for patient safety and drug development. So what we’re interested in doing is 
developing a tool to help clinicians efficiently and reliably assign causality during 
Phase 1 oncology trials. And we feel that by better understanding your needs as 
a clinician we can make our tool more relevant to you the clinician. So have you 
got any questions before we start?  [ No]  No, okay great. So let’s say one of your 
Phase 1 clinical trial patients has just reported experiencing an adverse event. 
Can you please walk me through how the situation is handled? 
 
S01: So you gather whatever details you can and I think with any side effects 
you’re thinking about you know, general issues of causality such as you know, a 
temporal association with the taking of the medication. (Pays attention to 
timing) Is this something that is mechanistically plausible from what we 
understand of the drug? Is it something that has been previously reported or 
associated with the drug from the investigators brochure or whatever information 
is available through the trial. And so you just try to gather information around that 
and then it’s a best guess. 
 
 
M: So what sort of, when you say temporal association, what is it that you’re sort 
of looking at?  
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S01: Ah, are there any, you know, was the medication taken, the experimental 
medication taken prior to the adverse event? Were there other agents, ah, 
experimental or otherwise that were taken concurrently with that? So did the 
patient get an experimental agent plus some sort of standard chemotherapy that 
may also be implicated? Or were they taking other over the counter medications 
or prescribed medications that maybe, may offer an alternative explanation and 
started at a similar time. 
 
M: So what are the resources that you refer to when you’re assigning causality? 
 
S01: I mentioned the investigators brochure or the protocol itself, mostly looking 
at prior side effects and mechanism. You know, if the patient has hemoptysis and 
is on an anti-ontogenesis drug and you know, you’re, you’re more likely to 
accept. Um, I suppose occasionally colleagues would come into play asking if 
they had seen a particular side effect, it would be less common. I, you know, any 
literature that may already exist is kind of overlapping the other sources but you 
know if you’ve read any trials or abstracts related to the drug that indicates side 
effects previously seen. 
 
M: Are there any tools that you use to help you when assigning causality? 
 
S01: No [no] like, no, I don’t think I’m even aware of any tools. [no, okay] 
 
M: And would you use one if one was available? 
 
S01: If a tool was not cumbersome [yes] yes then it would be. 
 
M: What sort of general guidelines do you follow then when you’re assigning 
causality? You run through all these sort of gathering the details and 
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S01: Yeah, I mean I don’t have, in, in kind of the literal sense I don’t have a 
guideline set, that I refer to you know. I’ve been, protocols actually, typically it’s 
not that explicit as it is to what to look for except for timelines, up to 30 days after 
last taking a drug or something. So there’s often not a lot of guidance it’s more 
winging it. 
 
M: Do you think the protocols could be a little bit more helpful that way? 
 
S01: Yeah, I guess so, if they could be helpful. 
 
M: What do you consider to be the most important factor when assigning 
causality? Temporality? 
 
S01: That’s probably the strongest, the strongest of the factors. [yeah] Yeah, that 
would outweigh mechanism which we often don’t understand, you know, other 
drugs which. (Not a lot is known about protocol drugs) Of the alternative 
explanations still I think you have to give the benefit, we tend to give the benefit 
of the doubt to the experimental agent as being the, being toxic or being the 
adverse agent. 
 
M: You tend to err on the side of caution and ascribe it to the experimental drug. 
 
S01: Yeah, and I would say timing is the most important factor. I mean, other 
factors, we don’t usually have dose as a, as a ah, we don’t usually have doses in 
the same, different doses in the same patient to be able to judge a dosing 
relationship. And sometimes we’re in a position where you stop the drug and re-
start it and you get a repeat occurrence of the drug so that kind of reinforces the 
temporal association. 
 
M: I would just like to ask you now to consider the following scenario. [okay] Let’s 
say you’re treating a 65-year-old female patient who has a confirmed diagnosed, 
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a confirmed diagnosis of metastasic breast cancer. And she’s in a Phase 1 
clinical trial with a new investigational drug and she experiences a pulmonary 
embolism. How would you assign causality to the study drug if there was a 75% 
chance that the adverse event was related to the study drug and a 25% chance 
that it was related to other factors, such as adjuvant treatment, disease 
progression [are you asking on that little cause of probably, likely] Yeah, if the 
categories were certain, probable, possible or unlikely. 
 
S01: I would put it as probable. [probable] Certainty is very difficult to achieve. 
 
M: When would you use certain? 
 
S01: Um, I think, if, if I, you know, certain things are more obvious like a 
pulmonary embolism is just something, as you mentioned, a common cause of 
metastasic disease, chemotherapy administration. But a rash for example may, a 
peculiar rash may you know, without other new drugs being started may be more 
associated or something else, well rashes aren’t rare but um. So probably 
something up around you know 90/95% I would consider it to be sufficiently 
certain in human terms to call certain for a trial. [yeah] Now 80% I would still say 
is probable. 
 
M: How about if there was a 50% chance that it was due to the study drug and a 
50% chance it was due to other causes or factors would it still? 
 
S01: I would call that possible. [possible] 
 
M: And what about if there was a 20% chance that it was due to the study drug 
and an 80% chance it was due to other factors? 
 
S01: If the other categories underneath possible are unlikely and not? 
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M: Certain, probable, possible or unlikely. 
 
S01: Um, so 20% chance [mmm hmm] oh, that’s tricky I think I would still call it 
possible. [yeah, okay] I would stick unlikely may be down around 5 or 10% but I 
don’t know. 
 
M: So given the choice, would you prefer to grade causality as certain, probable, 
possible and unlikely or as a yes related to the study drug or no not related to the 
study drug. 
 
S01: I think that the probable, possible, etc scale is better, it just gives more room 
for interpretation of the interpretation. Look at a series of adverse events and see 
how people judge them and get the general impression from, you know, from that 
information about, about where to go. If you read a clinical vingette about a 
patient, you can get an impression and make an assessment like I did. But if 
you’re the clinician who is taking care of the patient and has even more detail 
and maybe a more accurate gestalt then I think you can assign a slightly more 
accurate value. (A closer relationship to a patient yields more accurate 
causality attributions) It may be um, you know, it may still be incorrect but it’s 
going to be probably a little bit better. So it, it let’s you see what they saw or it 
gives you their impression second hand, I think it’s better. Yeah and yes and no 
is desperately frustrating sometimes because things are grey like, you know, if 
it’s unlikely but it’s still possible then saying you know, is that yes or no because 
that’s hard. [right] 
 
M: What would you say are some of the challenges or problems with assigning 
causality? 
 
S01: We don’t know mechanism often. There is a lot of background noise in side 
effects, what side effects may be caused by other drugs, disease. Um, temporal 
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associations are often surprisingly difficult to tease out and you sometimes 
cannot be sure that the onset of symptom was actually after drug administration. 
 
M: Why is it difficult to tease out? 
 
S01: patients can sometimes be unclear or maybe our questioning is unclear but 
they have so much going on that something that may have been a minor 
nuisance or low grade symptom that suddenly becomes more evident. You know, 
it’s also difficult for them to tell I think sometimes, if they’ve you know, felt a little 
tired and achy but they had a couple of other side effects and some anxiety that 
was masking that. They might not realize that until you know, afterwards, 
symptoms change over time and so it can be unclear to the patient. Um, what 
else? [concerns, problems when assigning causality] As previously mentioned 
dose, you know, often we don’t have a dose relationship that we can look at. 
 
M: What do you mean when you say that? 
 
S01: Supposedly one of the criteria for causality is something like a dose 
response relationship whereby more of something causes more of an effect. And 
a patient typically, although we may have that in a cumulative dose, we don’t 
have different doses from cycle to cycle necessarily. So you can’t say when you 
had a little bit of this you felt a little nauseated, now that we’re giving you 10 times 
more you’re feeling really nauseated. So we wouldn’t have that information 
typically. That’s all I can think about right now. 
 
M: What are your concerns about how clinicians currently assign causality?  
 
S01: I think it can interfere, the inaccuracy of it can interfere with drug 
development and can potentially in the most extreme case, kill a drug. (Concern 
for protocol drug) Or I suppose on the other side allow a drug to go ahead 
when side effects are overlooked. Although if, if you have a bunch of us who are 
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calling unlikely things possible, because you know, we’re not really sure because 
it’s just subjective. And the FDA looks at that or the investigators look at that and 
decide, you know we just have too many pulmonary embolisms and they’re all 
possible, as opposed to unlikely, you know, it can impact what they do with that 
drug. They may change the dose and lose effect or they may stop the trial or 
whatever. So there’s risk to the drug and to the patient in each way of 
misestimating. [any other concerns] No 
 
M: What external pressures from third parties have you felt when assigning 
causality? 
 
S01: I don’t know that I have, I think, I can certainly imagine however, in one’s 
own trial whether there’s going to be a bias and you don’t want side effects to be 
attributable to your drug, um. [like if you were the PI] Right, if you were the PI 
easy to imagine and it may or may not be conscious though (Feels that PI’s 
want to drug to succeed). And on the flip side is you may have a prejudice 
against the drug because it is prior reputation, or difficulty of administration or 
something which you know. I can’t say that personally in short I’ve felt anything in 
particular, but it may be lack of experience to date. 
 
M: From your perspective, what would make assigning causality easier? 
 
S01: When you gave me the percentages I realized how poorly I estimate. How I 
had not considered the relationship between the terms and the percentages. And 
that might be an improvement, giving numerical ranges, at least we’d all be 
speaking the same language, I think, although maybe even that has difficulty. 
Um, I guess I’m not being very creative at the moment but I can’t think of [no 
that’s good] I can’t think of tool that would make it easier. I mean we have a list 
and most of us have been in a class somewhere where the, you know, some of 
the elements of causality have been discussed so we know kind of what we are 
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looking for. But we’re still stuck with you know, these vague situations with the 
problems we’ve discussed and I don’t, it’s not clear. 
 
M: Maybe just making that a little more systematic. 
 
SO1: Yes or, in a, yeah, no point in suggesting research but [or what] well no, I 
don’t know, I think, could one go and look back at, at these factors that we’re 
talking about, you know, temporal association, dose, other um, other factors, 
competing factors or explanations. Could you actually go back and look at a 
series of SAE’s and see how those are, which of those played the greatest role. 
And ultimately based on what happened to the drug in the future, which of those 
was the best criteria to rely upon. [hmm] I don’t know. [that’s a good idea, cool] 
 
M: What I’d like to do now is just give you a list of 10 questions that were 
developed by a researcher named Naranjo, and I don’t know if you’re familiar 
with Naranjo’s algorithm to help clinicians assign causality to adverse events. So 
what I would like if you could just carefully read the questions and cross out any 
that feel are not relevant to the Phase 1 oncology clinical trial setting. [okay] 
 
S01: I think they’re all relevant, two are a little bit more difficult, number 7 was the 
drug detected in blood in concentrations known to be toxic. That’s not always 
going to be feasible. And 10, was the adverse event confirmed by any objective 
evidence, I’m not sure what that means. If that means, was the PE pulmonary 
embolis you know, diagnosed by a VQ scan or pulmonary angiogram. We aren’t 
really sure what the adverse event was what that means exactly. But otherwise it 
all seems relevant. 
 
M: You’re thinking objective evidence means some sort of imaging or something 
is that right? 
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S01: Yeah, I guess so, was the adverse event confirmed by any objective 
evidence. Adverse event, if it’s a rash, how are you going to confirm it, you see it. 
Pulmonary embolism, you do an image so I’m not really clear what they mean. I 
mean if we call it an adverse event, I think we typically use some sort of objective 
measures, it seems redundant. I shall strike it off, good-bye. [get rid of it] 
 
M: Okay, so now would you be able to just rank the remaining questions then in 
order of importance to assigning causality. [okay] So 1 would be least important, 
10 would be most important 
 
S01: I only have 9. [that’s okay] Okay, a little bit arbitrary but, because some 
things are not too dissimilar to importance I think. So a lot of the temporal stuff 
here for example, did it disappear, did it, sorry, was it temporally associated, did it 
go away when we stopped the drug and did it come back when we re-
administered it. They are all kind of the same temporal category, but they’re all, 
they add something each I think. 
 
M: Okay, did the reaction reappear when the placebo was given, you ranked that 
as 3. 
 
S01: Yeah, I think that, I mean, it’s important, it just doesn’t happen that often, 
just like detection in the blood. You know, typically in a phase 3 study it’s not 
going to happen so in terms of what’s most relevant and practical I would say that 
you’re not going to be able to give somebody [in a Phase 1 study] and you don’t 
know the placebo typically. [right] So it’s, it’s nice, but I wouldn’t want to have to, 
you know if I was trying to, if I was thinking about a tool then it’s just not practical, 
it doesn’t happen so I would get rid of it. [yeah, in this situation you wouldn’t need 
that] Right. And the other thing, item 7 detected in blood [so what’s the problem 
with that one] in, in a Phase 1 study and say higher doses and you would run into 
dose limiting toxicity. But in a Phase 2 or 3 study you probably don’t have blood 
levels, unless you meant this to be explicitly Phase 1. 
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M: Yeah, well we’re thinking, yeah, Phase 1 primarily and 
 
S01: The other thing is some patients have you know some patients get reactions 
to drugs that are really uncommon. So it wouldn’t surprise me if some patients 
could get reactions at lower concentrations than other patients. So we’d find, you 
know, and we’d still be left with, well you know maybe you’re particularly sensitive 
and we don’t really understand a lot of that stuff so I would still rank it probably 
where I did as the weakest. 
 
M: And are there any questions on here, like anything that was missing that you 
think maybe should be added or anything come to mind that you think oh that’s 
not in it at all. 
 
S01: No, I don’t think any of the things I mentioned in the discussion were 
outside of that, we just did some of it. 
 
M: So lastly I would just like to ask you a little bit about your experience as a 
clinical trial researcher. So in which cancer(s) do you specialize? 
 
S01: Ah, lung normally, I’ve done some head and neck as well and here I’m 
doing GI but that doesn’t happen till next week. [okay, so not a lot there] 
 
M: So you have a Bachelors, like you have MD right [yes] and what year did you 
get that? 
 
S01: 96. 
 
M: And do you have a Masters or PhD [no] or anything? And when did you get 
your medical oncology license? 
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S01: I guess, I didn’t get a license to independent practice until, I mean I’ve had 
resident’s licenses for a long time but I, 03. 
 
M: And what year did you become involved in clinical trials as a researcher? 
 
S01: I guess it would be 01. 
 
M: Overall, what percentage of your work time would you say is devoted to 
clinical trials?  
 
S01:  50%? 
 
M: And what percentage of that is devoted to Phase 1 or 2 clinical trials? 
 
S01: Probably, most of it’s Phase 2 so 35%, I mean, of this [yeah, of that 50] of 
that 50% [yeah] 70% [70% of that time and then the other 30 would be Phase 3] 
Phase 3 yeah. 
 
M: Have you ever been a local PI? 
 
S01: Yes. [yeah okay] 
 
M: And have you received any other training? 
 
S01: Do you mean local PI as in here locally or just [no because you just arrived 
here right] right [so in your experience as an investigator] yeah, right 
 
M: And can you tell me about any training that you’ve received specifically with 
respect to assigning causality? 
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S01: Nothing formal. I did a Trials Fellowship at the NCI Canada but it would just 
have been incidental, nothing formal. 
 
M: When did you do the Trials Fellowship? 
 
S01: 01 to 02 [that was at NCIC] yeah. 
 
M: And so what did you learn in that, like did they actually talk about causality? 
 
S01: No, it was just incidental nothing formal. 
 
M: So you just sort of had to teach yourself along the way or? 
 
S01: Yeah, you know, reading protocols, writing protocols, seeing what was in 
there. 
 
M: What additional education about assigning causality do you feel needs to be 
made available to clinicians? 
 
S01: I don’t know that the list that was just given, imagined list or whatever, most 
of that, most of that I think we’ve seen and have a sense of so I’m not sure how 
much education would help with the accuracy. Most of it is kind of intuitive you 
know, so I’m not sure. And if there was to be a session, probably 5 minutes 
would be enough just to say you know, remember these are the criteria and to 
maybe, to better define you know, likely, unlikely, possible. 
 
M: Great, so those were all the questions I have, is there anything, oh the last 
thing is there anyone else you recommend that I speak to. I don’t know if you, 
you just started here so have you. 
 
S01: Yeah, probably no one that you haven’t already had contact with. 
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M: What about, have you, you haven’t started any trials here have you [no] 
because we’re actually would like to speak to clinical [no I don’t have one yet] 
you don’t have one yet. Great thank you. 
Subject 03 
M: Even the most experienced clinicians find assigning causality to adverse 
events challenging. And many groups, such as industry sponsors, clinical trial 
cooperative groups and research ethics boards all expect prompt and sensible 
causality assessments. But, causal, assigning causality isn’t straightforward and 
if done poorly can have large implications for both patient safety and the 
development of new drugs. So we’re interested in developing a tool to help 
clinicians efficiently and reliably assign causality during Phase 1 oncology clinical 
trials specifically. And we feel that by better understanding your needs as a 
clinician we can make our tool more relevant to you. So do you have any 
questions about this before we start?  [ No]  No, okay great. So let’s say one of 
your Phase 1 clinical trial patients has just reported experiencing an adverse 
event. Can you walk me through how the situation is handled? 
 
S03: Well I don’t do a lot of Phase 1 trials [anymore right] no [did you ever do 
any] no, A will tell you I’m a Phase 3 guy. [okay] But we’re, but I have done 
Phase 1 trials and we’re about to start a Phase1/2 trial in the same situation. So, 
if the patient um, had an adverse event, it depends whether you mean adverse 
event or serious adverse event, there’s a big difference. [yes] Unfortunately, 
many of the cancer patients because of the nature of their disease, underlying 
disease um, have lots of adverse events, you know, nausea, vomiting, pain, blah, 
blah, blah, blah blah that are not necessarily related to the study medication and 
most likely are not related to their study medication. Similarly, many of the 
hospitalizations in these patients, which is by definition an SAE, um, are not drug 
related. So I think you need to be more specific with your question [okay] 
because if a patient has an AE um, for example they have a little bit of nausea, 
that’s a grade 1 AE, I don’t give a shit, excuse the expression A, explicative. (No 
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concern for minor reactions) I mean so what, they all have toxicity, I don’t see 
that as a, as a, as a, I wouldn’t bother with that, it’s a mild um, situation unlikely 
related to the drug. So I wouldn’t, you have to be more specific in your question. 
[okay]Are, are you, you know, if, if there is a situation where there’s a more 
severe um, adverse event, like a 3 or 4 toxicity. 
 
M: Alright then lets talk more specifically about a serious adverse event. [yeah, 
an SAE] 
 
S03: So what I do, well I don’t do much, the clinical trial nurse does everything. 
(Clinical trials nurse is more actively engage in causality attribution over 
medical oncologist) But basically the, what’s supposed to happen is that it’s 
supposed to be documented first on the report form and also by the nurse on a 
SAE form. Usually most sponsors have their own type of SAE form. And then um, 
um, then that’s forwarded onto the sponsor.  I think that where the difficulty lies is 
attributing the SAE to study medication or not and that, that, what, what, what we, 
what I try to do in many of the studies that we, my group coordinates is that we 
actually try to put in the protocol that any, any, um, SAE or such that is clearly 
attributed to the tumor or the underlying cancer is not, not necessary to report as 
an SAE or etc, etc. [yeah] (Doesn’t bother reporting AEs attributable to the 
disease) The FDA doesn’t always buy that, Health Protection Branch, TPD will, 
but the FDA hasn’t when we’ve tried it a couple of times. So I mean what you do, 
you fill out the forms, I don’t fill them out, the nurse fills them out and you sign 
them, investigator and it goes off to um the sponsor and then the sponsor 
decides. I think where the difficulty is attributing um, whether it’s related to the 
drug. And um, I mean sometimes it’s clearly not related, like patient commits 
suicide [right] patient gets hit by a car, it’s clearly not related [right]. Or it’s clearly 
you know, a complication of an operation, you know, it’s not drug related. Um, 
sometimes it’s grey, you know, maybe could be and that’s the difficulty. And, and 
ah, um, what really annoys me is when investigators at other sites don’t pay 
attention to this and let’s say there’s an SAE they attribute it to you know, very 
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likely study drug. And let’s say, and they also tick off unexpected, you know, 
which is if an SAE is related and unexpected that’s reportable to regulatory 
authorities. And then when you look at the patient, and it’s happened at another 
site, across the world in another study, another trial that sponsor is doing and 
then you get and you’re, you get this piece of paper and it says you’re supposed 
to give it to you REB and you read it, you say, my goodness, this has nothing to 
do with the study medication, it’s due to X, Y or Z. (Annoying when different 
sites are working on the same protocol drug, differing opinions) But you are 
obliged to send it to your REB with a covering note saying what your own opinion 
is. [right] (Opinionated process) So an investigator has to pay particular 
attention to the um, the relevance of the reaction or the toxicity to the drug. You 
gave me two reasons at the beginning but the, one patient safety and the second 
I forget what you said, but the third reason is, if it’s done incorrectly, it’s a pain in 
the ass for all the trial nurses and all the invest, all the trial doctors all over the 
world because it takes time to sort out. (Misattributing can have serious, 
global consequences) [yeah] So there’s a long-winded ah, but that’s what I do. 
 
M: So when you’re trying to assign causality what are the resources that you 
refer to? 
 
S03: My head. Well you can look first at the investigators brochure, you, that, 
that’s what you’re supposed to look at. You, you look at also what you know 
about the underlying disease, ah, discuss it with clinical trial nurses, you discuss 
it with the local PI. And if you’re really not sure you can go to the PI for the whole 
study. (Uses personal experience and knowledge to make decisions) 
 
M: Any other resources that you use? 
 
S03: Um, the web, if you think, you are saying Phase 1 so there’s not going to be 
anything on the web for Phase 1 study. But if it’s, if it’s Phase 3, Phase 2 or 3 
there might be stuff if you do a literature search? 
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M: Are there any tools that you use to help you in assigning causality such as 
flow charts or algorithms or you know? 
 
S03: Just my clinical judgment. 
 
M: What sort of  
 
S03: And you can, A as you know, I’m always right. [laughter] 
 
M: And what general guidelines do you follow then when you’re assigning 
causality?  
 
S03: Well I look at the, well first I look at the protocol, and I, and I look at what the 
protocol specifies for in terms of causality. Often, each company or each sponsor 
may have slightly different wording for, I’ve noticed that. So whether its related or 
not related, the various gradations in-between may be slightly different wordings 
in English. So you have to be careful, so I read the protocol, I look at what the 
protocol says, that’s my starting point. (Cautious Protocol) 
 
M: Any other sort of general guidelines to do with causality, rules of thumb that 
you use? 
 
S03: My common sense [yeah]. 
 
M: What do you consider to be the most important factor when you’re assigning 
causality? 
 
S03: I don’t know what you mean. 
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M: So presumably there’s many things that come into play when you’re assigning 
causality maybe the patient’s, you said their underlying disease, maybe what you 
know about the drug. 
 
S03: Which is the most important? Do I have to give you the most important? 
 
M: Well if you don’t think there’s any one that’s most important then. 
 
S03: I think it’s a constal, it’s an assimilation of timing, severity, in, in other words, 
you know, by severity I mean, is it, is it, have I never seen this before like the 
rarity. I don’t know what the right word in English is [yeah, yeah, yeah] rarity I 
guess, severity, timing, um, is it, is it something that can be explained by 
something else. Those are the types, some types of things that I look at. 
(Seeking explanation for cause and effect) 
 
M: Now I would just like to ask you now to consider this scenario. [scenario, sure] 
Let’s say you’re treating a 65-year-old female patient with a confirmed diagnosis 
of metastatic breast cancer. [yes] She’s in a Phase 1 clinical trial with a new 
investigational drug and she experiences a pulmonary embolism. How would you 
assign causality to the drug if you knew that there was a 75% chance that the 
adverse event was due to the study drug and a 25% chance that it was due other 
factors, such as adjuvant treatment, disease progression, concomitant illness, 
concomitant meds and the grades were certain, probable, possible or unlikely. 
 
S03: Okay, so first of all the patient has metastatic breast cancer and she’s on a 
Phase 1 study. She presumably because she’s on a Phase 1 study she’s 
probably had other therapies for metastatic disease so she’s pretty, she’s got 
advanced disease. People with metastatic breast cancer um, um, metastatic 
cancer are prone to PE. So, you, you, you know she could have gotten the PE 
and it had nothing to do with the drug. On the other hand there are some Phase 
1 drugs that are anti-VEGF, anti-angiogenic that appear to be associated with, 
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with pulmonary embolism. So I think I would use your third one down which I 
think was possible [probable] no, no, no [there was certain, probably, possible or 
unlikely] possible. 
 
M: Okay, even though there was a 75% chance that it was due to the study drug 
and 25% chance it was due to other factors. 
 
S03: Well I don’t know how you, you can decide that unless you have other, um, 
other information from other Phase 1 studies [yeah], is that what you mean by the 
probability? [yeah] Like if you said to me 
 
M: Just based on, it’s really an unlikely scenario really, because you never know 
what those probabilities are [well] but we’re just trying to get a sense of what you 
would attribute to 
 
S03: But if you said to me this Phase 1 drug was an anti-angiogenic agent or an 
anti-VEGF, I would, and maybe that’s what you mean by 75 probability % you 
know. It would be more helpful for me to answer the question if I knew what the 
drug was targeting because anti-VEGF or anti-angiogenic drugs appear to be 
associated with thrombosis. So if you told me that was the Phase 1 drug then I 
would say very possibly. But it’s, it’s very difficult without, maybe that’s what 
you’re getting at by saying it’s a 75% probability because that’s the only, that’s 
you know… 
 
M: We didn’t have any drug in particular in mind for this, it’s just trying to get a 
sense of you know, what your thresholds are for calling it possible, versus 
probable versus unlikely. 
 
S03: But where’s the probabilities come in, that’s what I’m not understanding. 
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M: I know, it’s hard, it would be nice if we knew what those probabilities were all 
the time right but we don’t necessarily. 
 
S03: Well I’m going to stick with what I did. 
 
M: That’s fine, I’m not asking you to change your answer at all. [right, right, right] 
But let’s say there was a 50% chance that it was due to the study drug and a 
50% chance it was due to all those other factors would that change your? 
 
S03: No, no. 
 
M: You would still say possible. [mmm hmm] 
 
M: And what if there was a 20% chance that it was due to the study drug and an 
80% chance… 
 
S03: I still say possible. [still say possible] 
 
M: So what would it take for you to say it was probably related to the study drug 
or was unlikely related to the study drug? 
 
S03: Well again, if you told me what it was [this is just hypothetical] yeah, well I 
think on the bottom side probably about 5% from possible to not. And on the top 
side you gave me 75% to start at the top, [mmm hmm] probably about 80% [for it 
to be probable] yeah, yeah. 
 
M: And so given the choice would you prefer to grade causality as certain, 
probable, possible or unlikely or as a yes related to the study drug or no not 
related to the study drug? 
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S03: No, no, no, it has to graded [you need a scale] you need a scale. Because 
then you’re going to, by just having it categorical to yes or no you’re going to end 
up um, okay well wait a minute by yes and no do you mean, but you have to, like 
yes means like yes, definite. Is that what you mean by yes? 
 
M: Yes related to the study drug or no not related to the study drug. 
 
S03: It’s never like that [it’s never] oh you know out of every 100, it’s a, it’s a slam 
dunk, I think that’s not a good that I, I mean it’s so rarely a slam dunk that’s, I, I, 
you need a gradation. (Certainty is rare) 
 
M: What would you say are some of the problems or challenges with assigning 
causality? You mentioned just the complexity of these patients [yeah] with 
advanced disease. 
 
S03:  Reproducibility so that, by reproducibility I mean not only interobserver, you 
know different people rating causality but also the same people, am I consistent 
over time, probably not, but it’s both inter and intra so that those are problems. 
(Feels they are inconsistent) Um, the whole, I mean probably the whole thing is 
overkill, that we end up having to grade causality probably is irrelevant for over 
90% of all the AE’s. [why do you think?] Because any, as I said to you earlier, 
many of the AE’s, everybody who has cancer on treatment is fatigued. So do you 
fill out a, do you fill out, do you bother doing an AE for mild fatigue? There are 
lots of people with breast, bone, always have pain but they live with it. So many 
of the AE’s, I get such a push back from the clinical trial nurses when, when, on 
this subject of mild AE’s, many patients have and they have them all the time. Do 
they have, they’re tough you know, why bother filling them out, so the whole 
process has gotten out of hand. (Feel reporting mild AEs is a nuisance) 
 
M: But if it’s just a matter of recording them in the case record form. 
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S03: Well if you have, ah, ah following the patients with this and it takes how 
many minutes or hours to do it, it’s very costly [it adds up] it’s very labour 
intensive. (Feels reporting minor AEs wastes time) 
 
M: Well what about if a patient has a number of low-grade toxicities which overall 
is really hard on them? 
 
S03: Right, but they’re probably not, first of all they’re probably not related to the 
study medication. [okay] (Feels minor reactions are not hard on patients) 
They’re probably related to the underlying disease and yet you’re not 100% sure 
that you can’t attribute in part, a little tiny bit and you’re sort of chasing your tail. 
Because they certainly could be explained by the disease of interest, um, not by 
the drug but if the product monograph says nausea how do you know if the 
nausea is due to the cancer or you know what I mean? [mmm hmm] so it’s gotten 
to the point now in my own view that the whole bureaucracy of this is unwieldy 
and it’s getting worse not better. (Feels clinical trials are failing in terms of 
causality attribution)[yeah] And ah, it’s actually going to kill, it’s going to, it’s 
going to kill clinical research, the whole administrative bureaucracy that’s 
involved. And the ICH/GCP guidelines which this is part of is, is, ah, is making it 
very, very difficult to do this sort of research and it’s unfortunate because you 
know, we need to study new drugs, we need to, yeah. 
 
M: What are your concerns about how clinicians currently assign causality? You 
mentioned the concern with the REB’s receiving reports. 
 
S03: Yeah, you know, my concern is sometimes not enough attention is paid or 
they don’t understand sometimes what the implications are so they don’t give it 
enough time, they don’t understand it. This whole problem of inter, people, 
different people don’t agree on the categorization so that something I would call 
unlikely, they might call likely. And the whole again gets these, if something is 
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reported as serious related and unexpected it sets off a whole chain of reactions 
around the world. 
 
M: What external pressures from third parties have you felt when assigning 
causality? 
 
S03: None. 
 
M: From your perspective, what would make assigning causality easier? 
 
S03: No, because these patients are often so sick. What we’ve done as I said to 
you, but it’s not assigning, well it is, we’ve tried to, like we get the protocols, 
we’ve tried to get statements put into the protocols saying, if, I’ll show you. I’ll see 
if I’ve got some stuff here, what have I got. [the safety section] Okay, so here’s 
what we put in one of our studies that I coordinate. In terms of the SAE definition, 
hospitalizations exceptions, criteria for hospitalizations not related, reported as 
SAE’s, planned as per protocol medical surgical procedure okay. [right, obviously 
yeah] Planned chemotherapy, routine health assessment, you know dah, dah, 
dah, like colonoscopy. Medical surgical admission for purpose other than 
remedying ill, ill health state, in other words they were planned ahead of time 
[plans] admission to account for other health circumstances that has no bearing 
on health status. So I mean, we’ve actually with other people gotten more 
extreme um, in terms of um, had language sort of saying if it was an admission 
for the underlying cancer it’s not an SAE you know, that sort of stuff. So those, 
you can, you can put exceptions in so that if people think about them ahead of 
time, it, it does cut down, a little bit on the bureaucracy [yeah the administrative 
burden] right, so we’ve tried that. Um, for our radiation trials, where, where, 
where um, radiation trials sort of haven’t yet got on the radar screen of the 
regulatory agencies because it’s not investigational drugs. Um, we’ve really um, 
we do AE’s and SAE’s but very modified, only related to the radiation therapy, 
only severe grade 3 and 4 [right] much more practical approach.  So that’s made, 
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I mean it’s almost from the experience we’ve had with drugs and what’s bad 
about the AE/SAE reporting of drugs we’ve done some nice templates for the 
radiation trials which are really much more practical. You know, really zeroing in 
on toxicity related to radiation, organ system toxicity related to radiation and that 
sort of stuff [right] very practical. But that’s not a tool for grading or categorizing 
AE’s and SAE’s. 
 
M: No but that’s definitely something that’s making it easier. [yes, definitely yeah] 
 
M: What I’d like to ask you now is to do a little exercise for me if you don’t mind. 
So I’d like you to read these following questions cross out any that you feel are 
not related to or are not relevant to the Phase 1 oncology setting. This was a tool 
that was developed by a fellow named Naranjo, he developed an algorithm to 
help clinicians assign causality. 
 
S03: They’re all good. 
 
M: Okay, great, then now would you be able to rank them in order of importance 
in terms of, [laughter], I know it’s quite an exercise, 10 would be most important 
and 1 would be least important. [okay] Great, so I see that you’ve crossed out 
number 6 and why did you decide to cross that one out? [well because] Did the 
reaction reappear when a placebo was given? 
 
S03: I think it’s a stupid thing, stupid because I can’t, I don’t think it’s ethical in a 
Phase 1 trial that if you have an adverse reaction to the drug to try to trick. I 
mean basically what you are saying with the placebo is that it’s a psychosomatic 
type thing. You can give the placebo and the reaction still comes out. I’m, I’m not 
sure in a Phase 1 study it’s that important to ascertain that sort of thing by 
rechallenging the patient with a placebo. There’s all sorts of ethics involved with 
that so I had a little difficulty thinking it was particularly helpful. 
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M: And that’s not usually done is it? [yeah] You ranked um, was the adverse 
event confirmed by any objective evidence as 3 which is fairly low. What did you 
understand to be, objective evidence [well] what was your impression of that? 
 
S03: Let’s say, because I think many of the, I mean there are, when I think of 
adverse reactions so you’re thinking of the, I guess why I had difficulty with that is 
some adverse reactions are very lab dependant or diagnostic dependant. Say 
let’s say a drug causes lung toxicity, well you’d like to see it on a chest x-ray, you 
can’t just say because someone is short of breath. On the other hand, if a patient 
develops severe anaphylactic that’s a, you don’t need any tests, that’s a clinical 
history and physical, you know. So I wouldn’t, just because, if I had, if a patient 
experienced what I thought was a you know, a, a severe adverse reaction and I 
didn’t have a lab, a blood test or chest x-ray to back it up, you know. They’re 
admitted, basically patients um, you know, drops their blood pressure in their 
boots and is admitted to the hospital with shock with no blood pressure, that’s a 
clinical diagnosis. I mean, I mean I don’t really interpret a history and physical as 
objective evidence. I mean a physical exam is objective so I don’t think it’s a 
good question but if said. [okay] 
 
M: Was the reaction more severe when the dose was increased or less severe 
when the dose was decreased. You ranked that as 4 [mmm hmm] that’s not as 
important as other things. 
 
S03: Because if you suspect, again, if you suspect it’s a bad drug reaction you’re 
going to stop the drug. And again it’s a little bit like the placebo thing, you’re not 
going to sort of for a Phase 1 study try to demonstrate a dose response 
relationship. So that, that, I didn’t dismiss this totally outright, but I think it’s really 
the issue in a Phase, for a severe drug reaction does, does it come out on 
rechallenge that’s the, that’s important. Not by fooling around with the dose, big 
ethic issues with that. 
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M: And then whether it was detected in the blood in concentrations known to be 
toxic, you rated that quite low too, what was your reasoning for that? 
 
S03: Generally, um, in many of the Phase 1 studies they collect blood for 
pharmacokenitic and pharmacodynamics. Those are frozen, batched and done 
six months later, well the patient is dead by then (little emotional attachment to 
patient) [yeah you don’t] so they’re useless, it’s useless to, it’s not very 
important. 
 
M: You just don’t have that information at the time [yeah] when you’re assigning 
[yeah] causality. [yeah, yeah] 
 
M: Great, that’s and then were there any questions that you thought should be 
here but just weren’t on this list? 
 
S01: I really hadn’t thought about it. [okay, just let me know if you think of any] 
 
M: And then lastly I would just like to ask you a little bit about your experience as 
a clinical trial researcher and I know this could take some time. So, you 
specialize in breast cancer right. 
 
S03: Yes. 
 
M: Any other special areas you specialize in? 
 
S03: Thrombosis. 
 
M: When did you get your MD? 
 
S03: 1976. 
 
! "(#
M: And your oncology license? 
 
S03: I don’t know, um, I started, I started, 1981. [81] 
 
M: And I see that you did the Masters in ClinEpi here at Mac, when did you do 
that? 
 
S03: 1982. 
 
M: And is there any other education that you have that I should know about? 
 
S03: No. 
 
M: Any other certifications, clinical trials that you’ve done? 
 
S03: A lot of clinical trials. 
 
M: And what year did you become involved as a clinical trials researcher? 
 
S03: 1982. [1982] 
 
M: What percentage of your work time would you say is devoted to clinical trials?  
 
S03: [27:34 – skipped – did not hear answer 70%] 
 
M: Of that what percentage of the 70% is related to, is spent doing Phase1/2 
trials. 
 
S03: 0%. 
 
M: So it’s virtually all Phase 3 [yeah]. 
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S03: Oh wait a minute, wait a minute. See the problem is I coordinate a trials 
group, so some of the work we do, actually we’ve got a couple of Phase 1 
studies. Well I better fix that up there [okay] probably, it’s probably 10% Phase 1 
[okay, 10 and 60] 60 yeah. 
 
M: And you’ve been a local PI obviously before yes? 
 
M: And can you tell me about any training that you’ve received specifically with 
respect to assigning causality? 
 
S03: I think the, you know, every time you, you write a protocol you come up into 
the administrative section and each sponsor does it differently. So just by reading 
and writing the protocols you learn about it. Um, second, for example, as the 
local PI for a trial that we’re about to open, this one here, [oh yeah] I wasn’t, I had 
to go onto the sponsors website and do um, a course, ah, ah and questions 
related to ICH guidelines and, and one of those, part of it was on AE’s and all 
that crap. It was very good actually, it was excellent. [which one, who was the 
sponsor for that one] BMS [BMS] yeah, that was..[so there were questions and a 
little exam] yeah, yeah, yeah. So I flunked them first and then I did the whole 
course and I passed after, it was good, it was good.  
 
M: What additional education about assigning causality do you think should be 
made available to clinicians? 
 
S03: I think that sort of thing. [that sort of thing] I also had to, you know, the third 
thing I did was, all of us who hold, what the hell is it called, you have an 
investigator number with the US [NCI] NCI and to um, initially get that number 
you have to do an online course related to regulatory issues and all that stuff. It 
was very similar to the BMS thing, so I, I had to do that a number of years ago to 
get the NC to get the regu, the investigator number with the NCI. [and then that 
! "(%
was their, was there anything about causality?] There was, there was, this is an 
AE, this is an SAE, these are the criteria to grade them, that sort of stuff. [yeah, 
nothing specifically about how] how, no [how to assign] yeah. [maybe that could 
be incorporated] I think a little, a little, I know A is crazy about electronic stuff, a 
little CD or a little thing, a web-based thing where you went into and ah, you 
know, with Microsoft multimedia or something like that. You could do a really nice 
little [tool] tool with some examples and a test and all that sort of stuff. It could be 
kind of, I think that would be very useful. [great] 
 
M: Is there anyone else you recommend I contact with respect to, we’re also 
speaking to clinical trials nurses so if there’s anyone you recommend. 
 
S01: I don’t know who you’re talking to but um [I’ve pretty much talked to all the 
investigators here at the JCC] okay but have you done any on the radiation side. 
 
M: Well we purposely excluded the radiation oncologists. If not that’s okay. 
 
S01: Yeah, I don’t think, yeah you’ve done the trials nurses I think. 
 
M: Yeah, we’ve got a sample of them. Okay great, well I really appreciate the 
time you spent with me today because I know I’ve gone over and I know you’re 
very busy, but yeah, thank you. 
Subject 04 
M: Okay, so I’ll just ask the question again. [sure] Let’s say one of your Phase 1 
clinical trial patients has just reported experiencing an adverse event. Can you 
please walk me through that situation. [okay]  
 
S04: So do you want to know from a practical point of view how it’s handled [um] 
or do you want to know from a [yeah] causality point of view how we might 
assign. [both would be great] Both, so I guess practically ah, it will depend on the 
nature of the adverse event, if it’s something that seems fairly mild often we’ll for 
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all intensive purposes deal with, deal with it over the phone. Um, if it’s something 
that needs assessment in the clinic then we’ll kind of bring them in for a face-to-
face assessment. And some of the decisions sometimes rest with where they are 
in the treatment protocol. If they’re already on active therapy then we will see 
them physically face-to-face. If they’re, they’re during a week where they’re off 
therapy or in some sort of a follow-up phase then we’ll, probably we’ll deal with it 
over the phone. So that’s kind of practically how we deal with it. From a causality 
point of view, I mean there’s more stress if the adverse event is of a more serious 
magnitude in terms of determining how related it is to the trial medication. And I 
think a lot, a lot of that has to do with you know, how do you make the decision 
(the decision making process is very important), it’s difficult sometimes, 
sometimes it’s pretty straight forward that they’re experiencing an adverse event 
that is know to occur with the study medication. Sometimes though for a lot of 
these newer drugs we don’t know what the side effect profile is necessarily [right] 
and so you take that into account. Sometimes you have to know their underlying 
co morbidities, whether or not there is some other underlying illness that the 
patient has that could be creating the side effect. I think between those two you 
kind of try and figure out is it related to the drug or not. I, for ones that are clear-
cut, known to be associated with the drug from other experience I would tend to 
rate those as being more causal if it’s fairly straightforward. (Errs on the side of 
caution)I think if it’s not straightforward, I kind of, I put the causality as 
somewhere in between possible or [2.27 not sure if skipped]. For one’s there is 
clearly an explanation, a patient’s co-morbidity disease or some other co-existing 
illness then I’ll clearly put them as unlikely. I think the ones that are, I think the 
ones that are easier to score are the ones that are clearly not related to the drug 
because of those reasons or the ones that are clearly related to the drug based 
on ones own experience and the literature on that agent. The ones that are 
difficult are the ones that are in between, that’s, it’s difficult in that sense. 
 
M: Can you give me an example of one that would sort of be in between? 
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S04: We’ve had a lot of experience recently doing Velcade® studies bortezomib 
which is a proteasome inhibitor. It typically causes fatigue and peripheral 
neuropathy and low blood counts and change the bowel habits usually causes 
either constipation or diarrhea. Those patients are challenging because some of 
them already have neuropathy left over from their previous therapy, it’s often mild 
but it’s ah. So if that neuropathy clearly gets worse during the study then I would 
ascribe it to the drug itself. Some of them have diabetes too or they’ve had 
shingles and it’s really hard to know whether, if their neuropathy is getting worse. 
I mean it may just be their underlying disease rather than the drug itself. For 
those situations I would tend to assign causality to the drug less ah, directly. So 
that, that was a common theme in the Velcade studies. And the other thing in the 
Velcade studies was you know, changes in bowel habits and that because these 
patients are on narcotics, so they’re already taking medication known to cause 
constipation. They’re on Velcade as well which can cause constipation, also 
longstanding left over from their previous treatments. So it’s really hard unless 
the grade of bowel disruption is very high or it’s obvious that things have gotten a 
lot worse and nothing else has changed then I’ll say it’s probably the drug. But in 
the setting of day-to-day variations say in someone’s bowel habits it’s really hard 
to know I’ll tend to be less causal in terms of the connected side effect. 
 
M: What are the resources that you refer to? 
 
S04: Actually not any that I know of. I mean for drugs that we have personal 
experience with that are just being used in a new way or in a new dose schedule 
or a new disease then those are a little bit easier because you do have some 
experience and there’s a bit of literature already about the potential adverse 
effects. So I think, those ones are okay because you’re basing it a bit on personal 
experience [yeah] and a little bit on what’s published. For the really new drugs 
[yeah, say in a Phase 1 study] in a Phase 1 nobody has any experience with 
then, you are kind of stuck, you’re going on what’s in the files, monograph, the 
study design in terms of anticipated risks and side effects basically. [yeah, they’re 
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outlined in the IB] Yeah exactly. But apart from that I don’t know of any other way 
of getting more information than what’s there for a drug that’s really early on in 
Phase 1. At times you know, we’ll do Phase 1 testing of combinations of drugs 
that are more known and I think in that situation too sometimes it can be a little 
bit tricky trying to figure out what’s happening in the combination, what side 
effects, maybe is there one drug that’s more responsible than another. [right] 
Those are definitely, other than the brochure, really there’s nothing I know of. 
 
M:  What sort of tools do you use to help you assign? 
 
S04: Tools in terms of um, 
 
M:  Decision trees, Algorithms, are there any sort of general guidelines that you 
follow, you mentioned when you are more likely to assign probable and possible. 
 
S04: I can’t say that there any actual guidelines that I know of or that I specifically 
follow. So it’s more like each case, hopefully, you know, the fear is that you’re not 
consistent I guess, that you know, you’re scoring a patient differently, that’s, 
that’s the fear. (Afraid of inconsistency) So I think I don’t use specific 
guidelines, I try and, I try to be mindful to score the causality in a similar way. 
Because some of the side effects keep popping up in different patients, for the 
Velcade example, constipation and fatigue and neuropathy they’re like recurring 
events that the nurses have scored. So I try to be consistent in terms of you know 
well, did they have neuropathy when they started or what medications have they 
been on, where are they in their treatment. I try and use all that information to 
assign causality, I don’t know, I don’t know, I don’t use anything directly any other 
way. (No tool to ensure consistency) 
 
M: Where they are in their treatment, what do you, how is that important? 
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S04: Like if the adverse event came up and it was after the treatment or 
depending on the chemo schedule, was it, was it on their week off or [trying to 
get at the timing like how soon after] yeah [the drug was administered?] yeah. 
Kind of like nausea, vomiting for example in their treatment week, that would be 
you know, more likely to be drug related. Rather then saying nausea, vomiting 
that occurred in their week off [right] in their third week of a three-week regimen. 
(Use timing to cope with uncertainty) 
 
M: What do you consider of those to be the most important factor of all those 
things that you mentioned? 
 
S04: In assigning causality? [mmm hmm] Oh I think timing is, I think timing would 
have to be the most important thing. [why?] Well, I guess it kind of makes intuitive 
sense, that if a drug is given on day one and there’s a certain schedule to it 
which is based on some pharmacokinetic principals. You know that drug might 
be, out of the circulation by day 7 so you might expect any adverse events in the 
first few days after the administration. (places strong importance of timing of 
event to cope with uncertainty) Where it gets tricky though is if it’s given on 
day 1 could cause some of neutropenia like fevers or that can happen later on as 
well that are related to the drug [link back a few steps] link back yeah. But I think 
timing is important and I think, well that’s probably the most important. And I think 
the magnitude of the event probably has something to do with it. Somebody that 
has a little bit of nausea that grumbles up and down are obvious if they had, you 
know, they get the drug on day 1 and on day 2 or 3 they have [when you say 
magnitude you mean severity] the grade, the severity yeah. [okay] I think timing 
will probably be the number one. 
 
M: What I would just like to ask you to consider this scenario. So let’s say you’re 
treating a 65-year-old female breast cancer patient and she’s been diagnosed 
with metastatic breast cancer. [okay] She’s in a Phase 1 clinical trial with a new 
investigational drug when she experiences a pulmonary embolism. [okay] And 
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you don’t know anything about the study drug [right, okay]. How would you 
assign causality to the study drug if there was a 75% chance that the adverse 
event was due to the study drug and a 25% chance that it was due other factors 
 
S04: 75 versus 25% how would I assign causality? 
 
M: Yeah, if the grades were certain, probable, possible or unlikely. 
 
S04: I would say probable for that one [okay] that’s the second one from the top. 
[yes] I would have to say probable. 
 
M: Let’s say you knew there was a 50% chance that it was due to the study drug 
and a 50% chance it was due to… 
 
S04: Same grade, I would go one level below probable which would be what 
possible [possible] yeah. 
 
M: And what if there was a 20% chance the adverse event was due to the study 
drug and an 80% chance it was due to… 
 
S04: I would still go with possible [yeah] part of it is [can you elaborate there] 
yeah, part of it is, I mean it seems logical to just go down one more step and say, 
I don’t know, what’s below possible [unlikely] unlikely. And say well of the issue is 
where, you know, where to draw the cutoff in the numbers, is 20% unlikely, is it 
10%, is it 18%, 25 and I guess. So that’s one issue, and the other issue that 
might, that might trump the number a little bit is the, is the adverse event itself. 
So like pulmonary embolism is, could be life threatening. [yeah] So, if, if a certain 
drug was associated with a side effect that could be life threatening I would be 
inclined even at lower rates of probability to assign it as being more likely than 
just based on the number itself. (err on the side of caution with serious 
adverse events by attributing it to the druf) So with the pulmonary embolism, 
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so I might go down to 10% even, to be kind of [that would sort of be your cut off 
rate] yeah. In terms of to just make sure there was a potential warning there. 
[10% or less would be unlikely for you] Right, if it was like nausea and vomiting 
say, I’d be, I’d probably not be as likely to assign causality and that’s to do with 
the severity of the side effect. 
 
M: And given the choice would you prefer to grade causality as certain, probable, 
possible and unlikely or as a yes related to the study drug or no not related to the 
study drug? 
 
S04: Um, I do like the grading because it gives you a little bit of leeway and you 
could argue about what each term means, but I do like the multi-level grading it 
gives you a bit more choice. 
 
M: What’s not good about the yes or the no, is there any… 
 
S04: Well the yes is, I mean, worthwhile knowing whether the drug is highly likely 
to cause an adverse event, or possibly or unlikely rather than just yes or no. Like 
I find that information useful, whether it’s kind of possible or probable or likely. 
 
M: So you think it would be that, that, having that gradation is more useful to your 
colleagues also probably [yeah] they would find it more useful. [I would say so] 
 
S04: Because we don’t, we all think in statistics anyway, we all think, even in 
day-to-day care of patients there’s the mindset of different levels of, that the 
patient, given a certain treatment for disease x that their probability of survival, 
it’s not just 100% or 0, there’s always some probabilities of, so like we, what I’m 
trying to say is we talk in probabilities all the time. [yeah] So rather then just 0, 
like on or off. (uses a statistical mind frame) 
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M: What would you say are some of the problems or challenges with assigning 
causality?  
 
 
S03: Oh, I think um, the fundamental problem is really, for a new agent that’s 
being tested is hard to get around, obviously if, if there are disastrous side effects 
then I think it would be easy to assign causality. But in the absence of that I think 
it’s around the lack of experience is difficult. [with the new drug] Right. Often you 
know, part of the dilemma is when you’re dong Phase 1 or Phase 2 studies, 
particularly Phase 1 I guess, there could be multiple Phase 1 studies done for a 
given agent. Unless you are in the loop with people and talk about things offline, 
there’s really nothing printed to go on to say that the side effect in this given 
patient has never been reported before. (lack of info on protocol drug, use 
communication to cope) It could be that other people have seen it but it’s not 
something that’s been published in any formal way. So I think part of the 
challenge is getting people who do Phase 1 studies to really communicate with 
one, with each other to try and get a sense of some of the adverse effect profile 
of some of these newer agents if possible. But you know, when you talk casually 
to colleagues at other centers who are working on similar drugs you might you 
know, review cases with them. And say you know, have you ever seen this with 
this drug, it’s kind of an informal way of, not really assigning causality. Because I 
mean you’re [?14:07] it on that given case but it gives you a sense of whether 
other people are seeing similar problems. 
 
M: What are your concerns about how clinicians currently assign causality?  
 
S04:  There’s, there’s two concerns, I think one concern is you know, over 
assigning causality. Because patients are, they can get sick, morbidities, multiple 
medications, actually a lot of reasons and it sometimes it’s easier to blame it on 
the drug. But I think my fear is that if you, if you do that liberally you’d be, not 
discrediting the drug but you’re not um, it could lead to dose reductions, could 
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eventually work their way into an ineffective treatment schedule for that. 
(Apprehensive to make causality attribution) If you saw a whole bunch of side 
effects that you thought were you know not really related to the drug and that led 
to that drug being less developed in a certain disease. Maybe you’re doing a dis-
service to that patient population, so that’s one, that’s one concern I have. 
Perhaps over-assigning causality just because of the complications of some of 
the patients on the program is my biggest concern. And the other concern is, the 
other, completely opposite really is the not assigning causality and then drugs 
are allowed to develop. And then it’s only when you start getting into Phase 2, 
Phase 3 studies that you really, adverse events really show themselves. And 
you’re thinking well why wasn’t this picked up in the Phase 1 or 2 studies? [yeah] 
So I think you can go either way, you can make errors on either way, one way 
you might kill a drug that might be successful and on the other way you might let 
a drug develop not carefully enough. (error- strong term) 
 
M: What external influences or pressures from third parties have you felt when 
assigning causality? 
 
S04: Pressures from third parties, none, I don’t think so, I haven’t you know, I 
haven’t really personally felt the pressure to assign or not assign causality. I 
mean the biggest stress, not that I’ve had any stress about it, but the biggest 
issue is assigning causality that could result in a Phase 2 program going to a 
lower dose or something like that or you know a ineffective dose for a given 
cohort of patients is a concern, whether you’re doing the, you made the call 
because that’s often a critical step in a clinical trial. But I don’t feel particularly 
stressed about it, I think you just call it as it is and then if it means the dose gets 
reduced for the next cohort or they stay the same, I mean so be it. I think Phase 
1 studies are carefully crafted, to look at significant adverse subjects for example. 
So other then that I don’t think there’s any… (little concern for minor AEs) 
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M: From your perspective, what would make assigning causality easier? 
 
S04: Um, I think if there was some sort of road map to use it might be, I don’t 
know how that would look. I mean you’re looking at an interplay of you know, 
patient factors, specifics about the clinical trial, I don’t know how you would build 
that into some tool that clinicians could use. (designing a tool would be 
difficult) If there was something to use to go on to say well this case, given what 
I know about the patient and their comorbid diseases and the medications they’re 
taking, what I know already about this drug, then I should score this event as a 
likely, or a possible or a probable. So having a bit of, guidance about those 
specific terms because I suspect people interpret them differently. (need for 
more guidance) 
 
M: With this roadmap, how could we be assured that you would use it, you know 
best fit into your day-to-day? 
 
S04: Well anything else, like day-to-day I think, I mean you’re talking about more 
causality in a clinical trial setting. [yeah] So we’re, we’re already pretty used to 
using other tools, sort of you know, other scales and measuring for hematological 
toxicities for example using gradings. So I’m used to using scales in clinical trial 
patients, so I think having, having something printed or on paper that one could 
refer to wouldn’t be a burdeon in that situation. And I think where it becomes 
much more loser is assigning causality casually say in the clinic on patients 
receiving medications, like not on trial. Where it’s much more, there’s probably 
the, the margins in that situation are probably much wider in terms of what people 
will call because they’re not under that clinical trial scrutiny, they don’t have to 
make the causality so. (reporting isn’t taken as seriously outside the trial) 
[how’s that different] Well it’s different in the sense that well you know, like say 
you have a drug that’s been used for years, you kind of know the side effect 
profile and you think so the patient has an adverse event and you think, well it’s 
probably it, it’s probably related to the drug but if it’s mild he’ll continue on. I 
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mean it’s, you don’t, you don’t generally get to worried about, now if it’s severe 
you know, you’ll deal with that. (little concern for mild AEs) But for, you’re not 
going to worry too much about whether it’s, for mild events, whether it’s going to 
be highly likely or probable or possible or unlikely. You do what you need to do 
for that patient’s treatment. [right] 
 
M: In a clinical trial, even the mildest adverse events are, you have to assign a 
causality. 
 
S04: You have to assign a causality, you need to know when it started, when it 
stopped, there’s a bit more rigor. Whereas in the clinic I think things are a little bit 
more loser, maybe from a more bookkeeping point of view, that way they are a 
little different. 
 
M: What I’d like to do now is ask you to do a little exercise for me. [sure] So I was 
just wondering if you could read those questions and cross out any that you feel 
are not relevant to the Phase 1 oncology setting.  
 
S04: Just cross them out if I feel that they’re not relevant? [yeah, cross any out 
that you don’t feel are relevant] On Phase 1 I guess, I mean there’s not often 
placebo in a Phase 1 study. I’m going to cross that one out because I can’t 
imagine a situation where, where the treatment is placebo, I can’t imagine. And 
the drug detected in the blood in concentrations known to be toxic. I don’t know 
about number 8, the reaction being more severe depending on the dose, I mean 
it’s hard to know. Probably that’s going to depend on whether there’s any 
knowledge about a dose effect of the drug. I don’t know, I might put a line 
through that one. I think the other ones are relevant. 
 
M: And then, of those remaining ones could you just rank them now in order of 
importance [okay] so 1 being least important [I see okay] . 
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S04: 1 is least and 10 is most important right [yeah]. 
 
M: So just to give me a sense of which ones you think. 
 
S04: Previous conclusive reports probably should be on the list first so I might 
have to cross, rearrange them a little. [sure, that’s okay, take your time] Okay [all 
done] rank the other two I guess, okay. 
 
M: Excellent. And so number 7 you ranked the lowest, was the drug detected in 
the blood [blood levels] why was that? 
 
S04: Ah, I don’t know, I think, many drugs, I think there’s, there’s a disconnect 
often between what you might be able to measure in the blood and what the side 
effect might be and I’m not sure that that’s been worked out. I’m sure there’s 
drugs that, that holds very true levels and, I’m sure, my, my impression is for 
many drugs it’s we don’t really know toxicity and blood levels that they go very 
well together. [yeah] 
 
M: Great, that’s wonderful, can I keep that [yea] thanks. Then were there any 
other questions on here or questions that you thought should be on here that 
weren’t included? 
 
S04: No actually it was a good list. 
 
M: Any thing that came to mind. It was actually a tool developed by a researcher 
named Naranjo and ah, he made this to try and help investigators when they’re 
assigning causality. 
 
S04: It’s actually, I mean it’s a comprehensive list. I mean you could see for some 
of the drugs that we use, you could easily run through this list and fairly quickly 
come up with yes and no’s for each of these. Placebo thing might not be 
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relevant, blood concentrations may not be known so that might be, so some of 
these could be quickly irrelevant, I mean just speed right through it. So that’s, it’s 
an interesting list, I have to admit I’ve never seen this before. 
 
M: Now the last thing I would like to ask you a little bit about your experience as a 
clinical trials researcher. [yeah] so in which cancers do you specialize? 
 
S04: Ah, all the blood cancers, so mostly lymphoma, myeloma. 
 
M: What year did you get your MD? 
 
S04: 93. 
 
M: And what year did you get your medical oncology license? 
 
S04: That would be hematology, so that would be in [sorry, hematology] 97. 
 
M: And do you have a Masters or PhD at all in any? 
 
S04: A Masters, Masters of, Masters in Science, yeah. 
 
M: Okay, where did you do that? 
 
S04: Here at Mac. 
 
M: That was the ClinEpi program [yes] yeah. What year did you finish that? 
 
S04: Oh it should say it back here, 2004 I think, when did they actually grant me 
the, 2004, hematology actually, what did I say. [you said 97] Actually 98, sorry 
yeah. 
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M: And what year did you become involved in clinical trials as a researcher? 
 
S04: Um, I probably started here in 90, 2001 probably. [2001] 
 
M: So overall, what percentage of your work time would you say is devoted to 
clinical trials?  
 
S04: 10% say. 
 
M: Yeah, and of that 10% what percentage is devoted to working on clinical, or 
Phase1 or 2 trials. 
 
S04: Phase 1 and 2 would be probably half of that. 
 
M: and then the other half is on Phase 3 [Phase 3 yeah]. And have you ever 
been a local Principal Investigator for a trial? [yes] 
 
M: And lastly I just want to ask you a little bit about the education you’ve received 
around assigning causality? So can you tell me about any training that you 
received specifically? 
 
S04: Oh, very little, I mean I think um, a lot of the pharmaceutical sponsors that 
we did some studies with, had some training modules but not necessarily for 
causality mostly for adverse event reporting. Mostly, particularly for serious 
adverse events, mostly for clinical trials nurses to meet regulatory requirements, 
reporting quickly and that type of thing. But specifically causality in terms of the 
grading system, nothing really. [how to do it no?] No. 
 
M: What additional education about assigning causality do you feel needs to be 
made available to clinicians if any? 
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S04: I don’t know if there is any education, I don’t know what even exists out 
there. [let’s say there’s nothing out there] If there’s nothing out there? [yeah] then 
I think we, I think there has to be some way of teaching people perhaps how to 
score causality if it’s on a 5 or 6 point scale. What’s the best way of doing that I 
don’t really know. 
 
M: What would work best for you? 
 
S04: I mean, me usually it’s, an interactive session would probably work the best 
[like a face-to-face] face-to-face or working with something on a CD Rom, some 
sort of interactive program. Rather than a lecture or something like that, case-
based, that type of thing [yes] that would probably be the best I think. [great] 
 
M: Well I really appreciate all the time that you spent with me today. [no problem] 
I don’t have any other questions and ah, the only other thing is I just wanted to 
know if there’s anyone else you recommend I speak to, so we’re talking to not 
only oncology [?]. 
 
S04: Yeah, either, well are you doing all this, this week. 
 
M: Well over the next few months. 
 
S04: Well, a few months, I mean, the two clinical trials nurses are TH and KH, 
they would both be, they are basically the two that run the vast, vast majority of 
the hematology trials, both of them would be good. [great] 
Subject 05 
M: Okay, so as you know, we’re looking at how investigators assign causality 
[right] to adverse events that occur in clinical trials, specifically Phase 1 clinical 
trials. Even the most experienced clinicians find assigning causality to adverse 
events challenging and many groups expect prompt and sensible causality 
assessments. But assigning causality isn’t straightforward, and if done poorly it 
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can have large implications for patient safety and also new drug development. So 
we’re interested in developing a tool to help clinicians efficiently and reliably 
assign causality during Phase 1 oncology clinical trials. And we feel that by better 
understanding your needs as a clinician we can make our tool more relevant to 
you. Do you have any questions before [no] we begin, no okay. So first of all let’s 
just say one of your Phase 1 clinical trial patient has just reported experiencing 
an adverse event. Can you please walk me through how the situation is handled? 
 
S05: Yes, I guess the first thing is in terms of trying to sort out, I mean I think the 
issue is is it really related to the patient’s underlying disease, the study 
medication or some other cause? Then based on what the temporal pattern is 
and what we know from the mechanism of the study drug you know, is it possible 
that, that. I mean clearly having to review a lot of these SAE’s coming from 
everywhere, it’s really a big mess in terms of  whether it’s a strong indication that 
the study drug is involved when clearly when you look at everything else. (Very 
hard decision to make when there are confounding variables) What I 
normally will try, the problem with Phase 1 drugs is, is that we don’t necessarily 
know everything that we’re going to expect in human beings so that, that the 
information that’s in our expectations of toxicity don’t always predict everything 
you’re going to see. On one level I think you have to, to accurately reflect you 
know, whether it’s study doing, study drug doing something that we think is in 
keeping with how you expect the drug to behave. On the other hand you have to 
be really able to capture kind of the unusual stuff that may not have anything to 
do with the way we think the drug works but still be able to capture that and do 
that in a way that you’re not necessarily torpedoing a drug for things that may be 
you know, very tenuous in terms of their association. So that’s kind of the, the 
way I try to approach when I’m, I’m seeing these kinds of things. (copes with 
uncertainty by considering the known effects of the drug and paying 
attention to unique AEs) So first of all you know, is there a temporal 
relationship, then assigning, depending on what we think the strength of that 
relationship is, definitely, probable, possible, unlikely. 
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M: What are the resources that you refer to when you’re assigning causality? 
 
S05: Well most importantly, when we see the patients we assess them so getting 
and the various lab parameters so, and the background information about the 
drug. So you have the investigate, the investigator brochure of the background 
and clinical data on the drug. (patient history and history of the drug play a 
strong role) 
 
 
M: What tools do you use to help you? 
 
S05: In terms of specific algorithms you have in mind or? [yeah, or decision 
trees]. I normally don’t use anything particularly that formal. It’s really just going 
through the information and the history and strength of the association. 
 
M: What guidelines do you follow?  
 
S05: We’re usually using, we’re usually given in terms of assigning the grade or 
are you asking something else? 
 
M: Not necessarily, because I know there’s the RECIST criteria. 
 
S05: Yeah, the RECIST is more for assessing response [to tumors yeah] so for 
grading toxicity [right] we often use the NCIC criteria or, or the NCI or the WHO 
toxicity criteria are the ones we use most commonly just in terms of you know, 
whatever grade that is, whatever the cause. (No consistent criteria to grade 
toxicities) 
 
M: But when you’re actually assigning causality [yeah] like unlikely, probable, 
what guidelines do you use for doing that? 
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S05:  Well it’s really again just looking at, at the particular situation at hand and 
really putting together um, what we know about the agent and what the patient’s 
reaction is and you know, what actually makes more sense. You know, I think 
the, the big issue always is in most cases is it due to underlying disease 
problems giving disease related symptoms or is the drug doing that. That to 
some extent you have to get a sense of you know, the history of the patient, their 
disease, the extent of their disease in terms of might that be causing. I’ll give you 
an example [okay] so today we had a, had a one of our Phase 1 patients come in 
he’s on a, on a ?? now, this was his fourth cycle. And all of a sudden his liver 
function tests were elevated, they had gone up dramatically, and they had been 
quite normal before so. This fellow has colorectal cancer which we know can 
metastasize to the liver, so the question for him was, do we think this is related to 
the study drug or related to something else? So how do you sort that out, so the 
first issue was from the history point of view, well he’s had the study medication, 
he’s had this for his previous three cycles and it hasn’t changed so why should 
something suddenly change in the fourth cycle. So that didn’t look like a strong 
possibility, is he on any other medications that might have caused this? Well, the 
other medication he’s been on he’s been on a long time so that seemed unlikely. 
Then the issue was well perhaps this is his disease progressing rather quickly 
and we looked at his CAT scan from two weeks ago and that turned out to be 
perfectly clear. So at the end of the day we’re left with somebody who’s got 
progressively abnormal liver function tests and what’s the likelihood this is his 
study medication. My sense with the information we have is that it’s unlikely, he’s 
had it before, he’s had the same dose three previous times. We have no other 
obvious explanation for it so can we say that it’s absolute? Definitely not. I think 
it’s unlikely but I think we have to leave the door open to say well maybe when 
patients are on this drug for more than three cycles there’s there are cumulative 
effects on the liver. But you know, based on what we know, how, how strong is 
that, that association. So we’re left in a situation where this guy has abnormal 
liver function tests and at the end of the day with all the things we’ve done, we 
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don’t have anything we can say absolutely it’s this. But based on what, what we 
know he’s been through what his disease is, what the drug does, make some 
assumptions to say the likelihood that this is causality. It’s clearly not a situation 
where you’ve got it black … (copes with uncertainty through process of 
elimination) 
 
M: In that case what did you assign? 
 
S05: We’re, it’s going to be unlikely at this point in time. But obviously you know 
we’ll have to re-evaluate that with time, it would be nice to have something that, 
that we can hang our hat on or eventually to say this is the cause. 
 
M: What do you consider the most important factor then when assigning 
causality? In that example, it sounds to me that you didn’t have any objective 
evidence of liver mets. 
 
S05: It’s got to be something other than disease, I think it depends on you know, 
what you know about the potential toxicity of the drug and guessing how could 
you definitively get an answer from this, well, he’s stopped the drug now, does 
the toxicity start to reverse, ideally if you have the opportunity to rechallenge, 
things off again, obviously there’s a question if somebody is quite ill from the 
toxicity it’s probably not ethical. But in terms of the best way of actually trying to 
sort that out, that would be scientifically the cleanest way. Clearly if they’re very ill 
and you’re rechallenging then, that’s obviously not ethical. But I think the most 
important strengths are if it occured right or shortly after they started the study. 
(Place a strong emphasis on timing of an event. There are clear ways to 
determine causality, but they are unethical) 
 
M: What I would like to do now is just ask you to consider a scenario. Let’s say 
you’re treating a 65-year-old female patient with a confirmed diagnosis of 
metastasic breast cancer. And she’s in a Phase 1 clinical trial with a new 
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investigational drug and she experiences a pulmonary embolism. How would you 
assign causality to the drug if there was a 75% chance that the adverse event 
was related to the study drug and a 25% chance that it was due to other causes 
given the scale of certain, probable, possible or unlikely. 
 
S05: Who made up that question, that’s a tough one…..scale geez[laughter] 
that’s a good, I mean that’s the reality, that’s exactly the kind of situation we face. 
And what was my scale? [certain, probable, possible or unlikely] Yeah, so I think, 
you know, I think really you have to be careful in terms of the extremes there I 
think because somebody with metastasic breast cancer certainly if they are on a 
new treatment has a possibility of having that kind of a problem. But I think given 
the high likelihood of the drug causing those kinds of problems I think you have 
to weigh it heavily on you know, very likely that it’s caused by that so I would put 
probably there related to. And also include possibly underlying breast cancer. 
Again I think you need to get a sense of exactly when the patient started the 
study medication and when this happened. I think that would give you stronger 
evidence in terms of saying you know, if it started a short time after the patient 
went on this drug. (Stresses emphasis on timing of an event) 
 
M: Now what if there was a 50% chance that it was due to the study drug? 
 
S05: That’s tough. Again, I think I would probably um, I would call it probably 
related to study medication. There you’re getting, you’re, you know it’s hard to, to, 
how, how strongly are you going to implicate the study on the side of implicating 
the study drug just from these issues. Probably drug, possibly underlying 
disease. (worried about implicated study drug) 
 
M: Now what if the, there was a 20% chance that it was due to the study drug 
and an 80% chance it was due to other factors? 
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S05: Yeah, then I think you’re starting, the strength of the other drugs association 
is starting to drop so I would say possibly study drug and probably underlying 
breast cancer. [right, great] 
 
M: And then given the choice, how would you prefer to grade causality as certain, 
probable, possible or unlikely or as a yes related to the study drug or no not 
related to the study drug. 
 
S05: No, I think you have to kind of have a graded scale. I think yes or no 
becomes very hard and we’re not always sure you know. And there’s always that 
element of doubt about it. (Lack of confidence in attributions) But I think you 
have to be able to say how strong or weak your doubt is and when you have the 
graded scale it just gives you some flexibility to do that. 
 
M: What would you say are some of the problems or challenges with assigning 
causality? 
 
S05: Yeah, I think it’s um, you know what, if you have a drug and a known 
mechanism of action and it’s causing toxicity with those known mechanisms, 
that’s actually fairly straightforward. So you know, you’re giving the drug that has 
that known toxicity, the patient is taking it, the likelihood is it’s the drug causing it. 
It’s when you have, have side effects that you aren’t expecting that, that may well 
be related to the drug just because it’s being studied in a species that it ‘s never 
been studied in before and you want to be sure that you are not missing 
toxicities. And I think it’s easy to ah, often these things only come out in the wash 
you know. And a good example of this is the um, the lung toxicity that we saw 
with the Iressa type of drugs and in fact that wasn’t expected. But when you treat 
enough patients and if people had reported all of those as unrelated to study 
drug, that likely would never have come to light. (Always need to have 
unexpected reactions as possibly attributable to the drug, so many 
unknowns) But it was being flagged as possibly related to study medication then 
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when you’re analyzing patients then you say, oh look 50 or more patients. So I 
think it is important [interruption for signature] [so you were talking about the 
Iressa example] yeah, so if you have kind of uncommon tox. And another one is 
these, funny, reversible, neurovascular events on Avastin  so as  we’re treating 
more patients these events are coming up. We have to have a mechanism to 
make sure that if there’s some question of whether there’s a relationship that we, 
we can at some level capture that. And I think that’s really the trick of making 
sure that we include those. 
 
M: Can you tell me a little more about, you said, was it Avastin? 
 
S05: Avastin it’s bevacizumab it’s, I can’t remember the terminology, basically 
there’s reversible vascular, it basically causes vascular [  ]  been on the Avastin it 
is related to some events where you know, even if, you know the choice of it is or 
it isn’t, if it isn’t then you’ve kind of lost them but only in a very small way. And the 
other problem we have is, see, you know one of the problems with some of these 
studies where you, where you’re looking at chemotherapy drugs combined with 
targeted agents that don’t have, and it’s really a question of, you’re giving chemo 
drugs that we know have side effects. And then you’ll see the reports come back 
where a patient is getting classical chemotherapy related toxicity and then they 
attribute this as probably related to the targeted drug that likely has no role at all 
to play and that’s very frustrating. (inconsistency amongst professionals is 
frustrating) Because you get these reams of toxicities that we as investigators 
on other studies with these agents have to deal with that are just you know [… 
chemotherapy]. Yeah, they are really, I think in some cases we have to be, make 
sure that well, is there an element of doubt but clearly that’s where the unlikely 
category comes in and these are patients who are being said, well it’s probably 
related to their targeted agent and you know, clearly that’s probably likely not the 
case. But what that does is it really contaminates the whole database in terms of 
what is the causality of these toxicities. It’s a huge problem worldwide and we 
certainly see that when we’re having to look at data from large international 
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studies where you have groups who probably don’t have a lot of experience with 
either the chemo or the targeted agent. And making these attributions it really 
kind of make a mess of the database. (Misattributions can have serious 
consequences) [right, right] 
 
M: So that would be one of your concerns about how clinicians are assigning 
causality. 
 
S05: Yeah, we should have, I think it’s important we have a standardized 
approach to answering causality, you know, if there was a standard algorithm you 
could be very famous if this works out. [well A could] Oh don’t let him take all the 
credit. (understands the importance of a standardized tool) 
 
M: Any other concerns about how clinicians assign causality? 
 
S05: Those are kind of my major concerns, spectrum that we should have and 
don’t do right now that I think would really be. (Believes we should have a 
standardized tool) 
 
M:  Any external influence or pressures? 
 
S05: There’s an awful lot of pressure when you’re doing early phase studies with 
a small biotech company. They, there’s a lot riding on, on, you know, there are 
the issues of well are you going to torpedo their only drug or just from a financial 
point of view, with toxicities that are going to expand the dose level. That’s gets in 
and take longer for the study to complete, those have big financial implications. 
On the other hand our, our first responsibility is to the patient and if not I think 
making sure, a lot of pressure from the smaller companies. And I think the other 
pressure is just the sheer volume of the adverse events you know, here are the 
ones from the last couple of weeks. So it’s just huge volumes and they all, and 
everybody wants them done within kind of 24/48 hours and it just becomes 
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impossible to do. (time constraints affect confident decision making) On 
some level there needs to be, and a lot of these are these ones that you know it’s 
clearly the chemo drug and probably really isn’t related to the study drug. But 
there’s, probably half of those are those kind of things that have been generated, 
probably inappropriately because of the experience of the people who, it’s a 
problem. It’s a huge workload and unless we’re handling them consistently I’m 
not sure we’re going to be any further ahead. (apprehensive about assigning 
causality because of the large implications a misattribution can have on a 
study, need consistency) 
 
M: The next thing I’d like to ask you is just to do a little exercise, I’m wondering if 
you go read over the following questions and then cross out any that you don’t 
feel are relevant to the Phase 1 oncology trials. 
 
S05: I think those are all relevant questions. 
 
M: Okay, so would you be able to just rank them then in order of importance. 
 
S05: I was afraid you were going to ask that. [I know, late in the day] And some 
of them are kind of going to be hard, they are all, many of them [you can use 
more than you know, if any are equally important then you can just] I’m just going 
to kind of star the most important ones. [okay] In Question 10, um, adverse event 
confirmed by evidence of the toxicity or what are you talking about there? 
 
M: That’s a good question. What do you interpret that as? 
 
S05: I’d like to have it if you are saying they have hepatic toxicity and the liver 
function tests are going up. That’s how I’m interpreting what they’re meaning. 
[yeah] Because I would say I mean they’re kind of, it’s hard to kind of split them 
up into kind of you know, ranking them 1 to 10 but I’m just going to arbitrarily put 
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some numbers down, 6 & 7 they’re pretty close in terms of the order you put 
them in. I’ve done this backwards, will do this. [okay, super] 
 
M: One is least important and 10 the most important. You ranked number 7 the 
lowest, was the drug detected in the blood. 
 
S05: I mean I think that of those factors, I think they were all on some level 
important, I just think, um, we’re, we’re often not clear when we’re doing these 
studies. In humans, what are important drug levels, I mean we are often, have 
information on levels in, in, in animals or the, the models they’ve been studying 
but those don’t necessarily correlate. So I, I put less weight on that than some of 
the others things. Just that we can be fooled by what we think are toxic levels 
are… 
 
M: And did the reaction reappear when a placebo was given, you rated that one 
fairly low as well. Why is that? 
 
S05: Again, I think in terms of the other ones, I think are stronger, is that 
important? Yeah, I think if it’s happening when you’re giving them placebo it 
makes it less likely it’s your study drug. But I, I think all 10 of them actually are 
things you should use to consider, it’s just a question of do I think that’s as strong 
as if you actually give the study drug and something happens. I think that just 
gives me stronger evidence that’s all. 
 
M: Is there anything that, or that wasn’t here that you felt should be included in 
this list? 
 
S05: I guess something about the mechanism of action of the drug. There’s 
nothing that would suggest that, that toxicity that you are seeing would be in 
keeping with that. [excellent, thanks] 
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M: And just lastly I would just like to ask you a little bit about your experience as a 
clinical trial researcher. [mmm hmm] So in which cancer(s) do you specialize? 
 
S05: Gynecologic cancers. 
 
M: You have your MD and what year did you receive your MD? 
 
S05: 1980. 
 
M: And what year did you receive your oncology license? 
 
S05: 1985. 
 
M: And have you got any other [no] anything else like that, any education to do 
with clinical trials? 
 
S05: Yeah, there isn’t anything no [no okay great] 
 
M: And what year did you become involved in clinical trials as researcher? 
 
S05: Really once, so 1986. 
 
M: Overall, what percentage of your work time would you say is devoted to 
clinical trials?  
 
S05:  I would say probably about um, about a half. [50] 
 
M: And then of that 50 percent how much of your time is devoted to clinical trials? 
 
S05: Um, I would say ¾ of that. 
 
! #++
M: Okay and 25% is Phase 3. [yeah] Just roughly yeah. 
 
M: Have you ever been a local PI  [mmm hmm] for a trial yeah. And can you tell 
me about any training you received specifically with respect to assigning 
causality. 
 
S05: There hasn’t been any formal training, yeah, there’s hasn’t been anything 
formal. 
 
M: What kind of informal training have you had? 
 
S05: We’ve had, certainly going to the American Society of Clinical Oncology and 
go to there they often have educational days where you know a lot of these 
issues are discussed and their, their sessions around the conduct of clinical trials. 
Certainly informal teaching sessions that, that I have gone to that have reviewed 
those aspects. ASCO is particularly the one, the other one would be the 
Molecular Target in Therapeutics meeting where they talk about clinical trials and 
they’re particularly looking at is it the agents and which one of the agents is it. 
And so it’s very complex and clearly people have given it a lot of thought. 
 
M: What additional education about assigning causality… 
 
S05: Well I think what would really be nice is to have, people have a 
standardized approach and that there are standard decision making tools that I 
think are accepted as you know, to make those decisions. And I think that’s the 
problem because it’s a dog’s breakfast out there now. 
 
M: We are also interviewing clinical trial nurses. Is there anyone else that you 
recommend I contact? 
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S05: Yeah, in terms of the nurses that I work with any one of the Phase I nurses 
A, S, M, S, H and the data manager, Y. [great, thank you] 
 
M: That’s all the questions I have. I just want to thank you for all the time you 
spent with me today. 
 
S05: What’s going to happen in terms of the information you’re gathering. So at 
the end of the day what’s the plan? 
 
M: So this information, we’d like to do sort of a qualitative analysis of this data 
and use that to first of all inform this tool that we are developing and help us in 
developing that tool. And also, I mean these interviews also serve the purpose of 
raising awareness down the road. So what we’re going to do is we’ll definitely 
give you an executive summary once we’ve got things summarized.  
 
S05: Is the plan ultimately to develop a tool for this [yes] or to use a tool that’s 
already existing. 
 
M: Well you know, yeah, that’s sort of what we’re looking at now, the Naranjo tool 
is just one that’s out there and A felt that it needs to be modified so we might just 
modify the Naranjo tool. Okay. 
 
S05: Good, excellent. 
Subject 06 
M: Alright, so even the most experienced clinicians find assigning causality to 
adverse events challenging and many groups, such as industry sponsors, clinical 
trial cooperative groups, research ethics boards, they all expect prompt and 
sensible causality assessments. But as you know, assigning causality isn’t that 
straightforward, and if its done poorly it can have large implications both for 
patient safety or drug development. So we’re interested in developing a tool to 
help clinicians efficiently and reliably assign causality specifically during Phase 1 
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oncology clinical trials. And we feel that by better understanding your needs as a 
clinician we can make our tool more relevant to you. Do you have any questions. 
[no] No alright. So let’s just say one of your Phase 1 clinical trial patient 
experiences an adverse event. Can you please walk me through how the 
situation is handled? 
 
S06: So in the Phase 1 setting our priority is to document toxicities and so I’ll 
have an emphasis on assessing patients on a fairly frequent basis for a variety of 
toxicities through using. And so any, obviously any grade 3 or 4 toxicities are 
picked up so the trial needs to be set up in such a way that you’re carefully, 
frequently assessing people so that you can document any 3 or 4 grades of 
toxicity and then make a determination. We will tend to document and report 
most of them, basically even if most of them are unrelated. (not all Aes are 
documented) That’s, we’re kind of in a spirit of or an atmosphere of well the 
majority are unrelated. (mindset that AEs are not related) 
 
M: And so how do [so we err on the side of caution] yeah. How do you actually 
determine causality when you’re thinking about those adverse drug events? 
What sort of thinking do you use? 
 
S06: That is a challenge in that typically when patients go in to clinical Phase 1 
trials they have advanced, often refractory cancers and ah, needless to say, 
significant ah, medical problems at the beginning and throughout the clinical trial. 
(assigning causality is difficult) So, so definitely is a challenge, um, often times 
patient’s cancers are progressing resulting in symptoms, problems that if you 
send somebody out um and they have grade 3 or 4 toxicities because of 
progressive cancer or because, basically all one can really do is, based on 
experience of managing these people sort of know what to expect as their 
cancers progress and as their regional stages of life, as in previous experience in 
managing. And then if a new toxicity comes up that one hasn’t seen before you 
would tend to look at the intervention. It’s really based on experience at this, at 
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this stage. So really it would depend on a, an experienced investigator who has 
managed a lot of the specific patient population to in my opinion, accurately 
determine if this is something that’s related. (Feels experience plays a crucial 
role) 
 
M:  Do you look at what is … 
 
S06: So, sorry, the mechanisms I’ll look at is the timing of the event. The 
relationship to the administration of the drug, whether it’s, whether the toxicity 
has been previously, seen at previous cycles of the drug but in a milder form. 
And also in my mind I assess whether the event seen is related to a short-term 
effect of the drug or potential long-term effect of the drug. Short-term effects tend 
to be easier because there is that temporal relationship. The longer term effects 
of the drug, aren’t you know the first weeks I think are more challenging. (places 
strong emphasis on temporal relations) 
 
M: Can you give me an example of a longer term? 
 
S06: Um, I mean an example would be of um, Adriamycin, a chemotherapy drug 
resulting in heart failure from toxicity. But you know, if you were investigating you 
probably wouldn’t be seeing it on each cycle, it would only be after the fact. But I 
think one, one breaks it down into short-term and long-term effects that need to 
be documented and. And I think trials are often set up more for short-term. 
 
M: What are the resources you refer to when assigning causality? I guess 
knowledge of working with that patient population, any other resources? 
 
S06:  Well, I mean if, to investigate the adverse event, I mean as a clinician I 
have to treat the adverse event because I’m responsible for managing the patient 
so I would use the lab, the um, um, any you know pre-clinical ….Pubmed to 
determine if it’s related. (assumes responsibility for patient) Sometimes I’ll go 
! #+%
to other investigators on the trial to see if they’ve seen if they’ve seen similar 
events. [your local investigators here or at other sites?] well it depends, yeah at 
other sites. Yeah, just send out a broad email to [with email yeah] Yeah. [do you 
find they’re generally pretty helpful] Yeah, I think, I think in a clinical situation if 
you, if you, you know, I have a patient whose developed a certain problem, has 
anyone seen this?, people are often very willing to give their opinions. And often 
times someone will say yeah, that’s funny we’ve seen that as well. (seeks 
support/confirmation from others) I think also if one’s running a trial, sort of 
frequent investigator conference calls just to hear those types of words are, is 
very helpful.  If someone has a sense about something you can kind of discuss it 
that way. So I very much think working as an investigator, working in isolation. 
(feels isolated, seeks support) 
 
M: Do you use any tools, or what sort of tools do you use to help you assign 
causality, do you use a formal algorithm? 
 
S06: … or list, no I’m not aware of any. 
 
M: What sort of general … 
 
S06: Sorry, to back up on that one I do, we do sort of adhere to a dose finding 
study process in that if somebody develops grade 3 or 4 toxicity we will either 
treat at that dose for another group of patients or reduce the dose. I mean one 
follows the protocol for dose limiting toxicity. So one does work within those. 
 
M: What general guidelines do you follow when assigning causality, are there any 
rules of thumb that you tend to use?   
 
S06:  Well I, I follow, as dictated in the protocol I follow the you know, the 
notification and the definitions in the protocol for ah, so it will be, will be, that 
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information will be present in, in definitions in the protocol. So I will go back to the 
protocol and read. 
 
M: Does the protocol sort of give you guidelines on how to assign causality? 
 
S06: No, no, well it just gives definitions, so um, [what’s an SAE, what’s an AE, 
when to report, what the timelines are] the timing and who, specifically who 
needs to be called. So that the um, um, [flipping paper] there must be one here, 
you know um, again the definitions for adverse reaction to therapy, unexpected 
adverse reaction to therapy, expected adverse reaction to therapy, what is an 
SAE, results in death, is life threatening, requires in-patient hospitalization or 
prolongation of existing hospitalization, results in persistent or significant. So I, I 
do tend to go to the protocol and, and determine the clinical situation and how it 
fits into those definitions. That’s about all I’ll do though, I don’t have any other. 
(considers process of attributing causality to be minimal) 
 
M: No real guidance on assigning causality, that’s sort of left up to you. 
 
S06: That’s a clinical judgment based on what’s happened to the patient. 
 
M: You said that you know, you tend to err on the side of caution. 
 
S06: I think whenever, whenever a grade 3 or 4 toxicity is documented this one 
little, I’ll, I’ll try it, especially in Phase 1, you know, onset date, resolution date, I’ll 
try to document all those things. Often it’s not just the one case but a series of 
cases over time and when there’s a review by the protocol safety committee if 
there’s something going on it gets picked up. I don’t have anything at the bedside 
where I can, a tool that I can look at and sort of help me determine …. (no tool, 
but it would be helpful) 
 
M: Do you think that would be helpful?  
! #+'
 
S06: Mmm hmm. 
 
M: Yeah? [yeah] What do you consider to be the most important factor when 
you’re assigning causality? 
 
S06: Timing. (again strong emphasis on timing on an event) 
 
M: Could you sort of expand on that, can you give me an example of when the 
timing would… 
 
S:06: Well it depends on the nature, the nature of the drug and mechanism of 
how it works but, but I mean certainly if the drug is given and in 8 hours 
something occurs I would want to tend to think it’s the drug. Somehow it’s had a 
role in what’s going on, I think that’s the most important. Second would be, you 
know, what is the mechanism of action of the drug? So if a drug is an angio, 
angiogenic drug and all of a sudden I’m seeing bad neuropathies then I know in 
my mind that the two are related based on the mechanism of action of that drug. 
 
M: Now I would just like to ask you to consider the following scenario. [okay] Let’s 
say you’re treating a 65-year-old female patient with a confirmed diagnosis of 
metastasic breast cancer. And she’s on a Phase 1 trial with a new investigational 
drug and that’s all you know but she experiences a pulmonary embolism. How 
would you assign causality to the study drug if you knew that there was a 75% 
chance that it was due to the study drug and a 25% chance that it was due to 
other factors, concomitant [10:12 not sure if finished]. [um] Sorry and given, I’m 
sorry I didn’t give you the grading scale, but let’s say the scale is certain, 
probable, possible or unlikely. 
 
S06: I mean it’s, obviously that’s a tough question because metastasic cancer 
patients are at risk of PE, so in itself then I think that has to be documented as an 
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SAE. In terms of defining causality you have to have the patient’s history, the 
various risk factors beyond their cancer for pulmonary embolism, risk of 
pulmonary embolism based on other medical history. To me that, that, this [?] 
something the patient was ultimately at risk for having a PE [11:00] [So probable] 
 
M: Let’s say there was a 50% chance that the adverse event was due to the 
study drug and 50% chance it was due to other factors? And given the same 
scale, certain, probable, possible or unlikely. 
 
S06:  It would still be probable [11:14] 
 
M:  That’s actually my next question, let’s say there was a 20% chance it was 
due to the study drug and an 80% chance it was due to other factors? Possible? 
 
S06: Possible. 
 
M: What, what would it take then for you to say that it was unlikely? What would 
be your percentage? 
 
S06: Oh, I mean in the cancer setting it would be clearly due to progression, 
something that clearly in my mind is related to the existing cancer then I would 
call it unlikely, everything else would be called possible or probable. It’s just that 
the Phase 1 mentality is pretty much to overcall everything and then review that 
data. (mindset to err on the side of caution and attribute AEs to the drug) 
You know, if you’re not calling it possible then you’re not going to see it and one 
of the side effects of the drug called Thalidomide we use for multiple myeloma is 
PE, and that really wasn’t recognized until the drug was well into use. And I think 
your example is a good one I think people could easily brush it off and if a bunch 
of people do that, you never realize that actually 20% of the people on 
Thalidomide get it and that’s why you get overcalling. 
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M: In the case of Thalidomide it didn’t get discovered until much later? 
 
S06: Yeah, it was kind of discovered through you know trials being completed 
and then people looking saying, boy that’s a lot of clots and then the drug is 
being used now for a decade and it’s really only in the last two years people have 
been taking steps and it’s because, PE is a good example, it’s something that 
happens in the cancer setting and clearly it’s an example where if one had called 
it SAEs and all the people participating in the Phase 1 studies had called it an 
SAE possibly related then it would have been picked up much earlier. (reporting 
improves patient safety) 
 
M: And they’re using thalidomide to treat which type of cancer? 
 
S06: Multiple myeloma, among others, the primary one for us is multiple 
myeloma [when did they start using that again?] 13:12 
 
 
M: Given the choice, would you prefer to grade causality as certain, probable, 
possible and unlikely or as yes related to the study drug and no not related to the 
study drug. 
 
S06: Um, I’m comfortable with the previous one, the first one [the scale] yeah, 
um, it provides a bit more information. But at the same time you’re right, is it or 
isn’t it? I think it’s better to maintain a sort of a graded scale because I don’t think 
one can be that definitive. With the number of resources you have, it’s only a 
matter of being able to document and have there as a possibility. (never really a 
concrete answer) 
 
M: What would you say are some of the problems or challenges with assigning 
causality? 
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S06: Um, I would say that more resources would be good for investigators, more 
resources at their disposal. [what sort of resources] (not enough resources 
available) Well, resources through the sponsor [for what] for information [oh 
okay] more information as to whether, you know, if you have questions about a 
certain event. And for example you wanted to understand the drug’s 
pharmacology better and try and determine you know, in some way could there 
be access to that information beyond the IB. The opportunity to discuss on a 
regular basis with other investigators, how the trial is going, um, through 
conference calls is a good idea. (need for an open forum between 
investigators) And you know, I don’t know how a tool is, is formulated, there’s 
nothing to my knowledge to say a meta, you know a 65 year old metastatic 
breast cancer patient, what is her risk of a pulmonary embolism by any drug? 
[yeah] But you know, that, that would be my, in determining causality, that would 
be my first step. And so if the chance of her having a PE was 2% then I would 
lean towards giving the drug more. If the chance of that was 80% as you had 
said, but getting that information available to you is [basic baseline risks and] . 
Yeah, for, for various SAEs, what is the risk of ah, ah,  how often do metastatic 
cancer patients get severe headache, how often doe they get um, the other 
SAEs that are involved. 
 
M: Any other problems or challenges that you’ve encountered when you are 
trying to assign causality? 
 
S06: Um, well there, you know, there, I think one has to fight, now this is a more 
of a perception, I don’t have any examples. But there’s a risk that the sponsor 
may want, may prefer you to go to an unlikely conclusion. That I disagree with. 
(feels pressured by sponsors) 
 
M: Have you ever personally felt that? 
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S06: No I haven’t because I’ve stubbornly just said well that’s my final answer, so 
I’ve never felt any, any sense of coercion. Obviously, you know, inherently results 
in more work for somebody but ah, in the Phase 1 setting I, I, I think ultimately it’s 
the sponsor’s in their best interest to fully understand what their drug is doing and 
what it’s potential effects are. But one does have to be fairly stubborn in that 
regard. [interruption, taking a quick call] (Feels they need to defend their 
decisions) 
 
M: So what are some of your concerns about how clinicians currently assign 
causality? 
 
S06: Lack of appropriate information. (not enough resources) 
 
M: What kind of appropriate information? 
 
S06: Well information about the patient. 
 
M: They just might not have enough details about the patient why is that? 
 
S06: Well I think if there’s a, I think there is a certain distance often between the 
clinical trials nurse and the physician. Clinical trials nurses at least locally do a 
fantastic job of being very involved in the patients. I think there’s a risk of um, 
them not seeing the big picture on certain issues or missing. So information is 
important about the patient about the drug about the situation. (need a holistic 
perspective on the trial) 
 
M: Is that just because the clinical trials nurse hasn’t collected it or it’s just not 
available or? 
 
S06: Well they pretty much have to collect it if they’re using the Common Toxicity 
Criteria tool, they have to document ah, certain things, not all of them. I’m not 
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always sure if the PI of a trial is available to get that information always in a 
timely way. And when it’s an obvious adverse event then yes, but it’s the smaller 
ones that I’m not sure are always being, I’d say the first thing is information, 
patient information, information about the event. All the literature that goes 
around the risks of that patient having that event on their own and then all the 
information about the drug , the pre-clinical, investigator drug brochure and 
communication with other investigators and company. [yeah, a lot of things go 
into it] So all of those things need to happen and all of them sort of intrinsically 
have their own, not show stopping, but little obstacles that don’t prevent it so. 
Okay, well tell me about the drug, okay, where’s the IDB, why isn’t it in my office. 
I want to talk to the sponsor about the drug, oh they’re on holidays, they’ll be 
back in two weeks, okay, well who’s covering them. (run into obstacles, slows 
down causality assessment) You know, then we have a conference call about 
the study with all the investigators from other sites [right] and if they were 
happening frequently then there would be you know, a venue to be able to 
discuss these things. [right] (lack of communication) 
 
M: From your perspective then what would make assigning causality easier then 
regular conference calls. 
 
S06: Access to information, I mean I think a tool would make it easier, I’m just, at 
this stage don’t have a vision of what, a, a, phenotype of that tool, how it would 
be. Would it be a, purely information based, the patient has toxicity A in the 
setting of disease B, plug into a formula, what is the risk of this happening. If it’s 
greater then 10% it’s probably the disease if it’s less then 10% it could be the 
drug. [right] I, I suppose, although I can’t sort of envision how, that would be a 
huge database to capture all the potential toxicities or adverse events in a setting 
of a specific cancer type, maybe, I don’t know. But that would be helpful yes. 
 
M: What I’d like you to do now is a little exercise for me. I’d like you to read the 
following questions and then just cross out any that you feel are not relevant to 
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the Phase 1 oncology clinical trial setting. [and put a number] Well after that I’m 
going to ask you to rank them in order of importance, so 1 would be least 
important [so cross out the ones that aren’t important] yeah. So first just cross out 
whatever ones you think aren’t important. [okay] And then if you could just rank 
the remaining questions in order of importance, so 10 would be most important 
and 1 would be least important. [right, I don’t know what 10 means] Just that 
that’s most important to you as a, as a consideration when you’re assigning 
causality. [okay] Okay, great, thank you. Okay, so I see that you crossed out 
number 6, did the reaction reappear when a placebo was given, why did you 
cross that one out. 
 
S06: I don’t think I’d, that would be done [no] that doesn’t make sense to me. You 
wouldn’t have a drug, a patient on a study drug, they have a reaction and then 
give them a sugar pill to see if they have the reaction. 
 
M: What about number 8, was the reaction more severe when the dose was 
increased, or less severe when the dose was decreased, I mean. 
 
S06: So if a person had a reaction to a certain drug, you wouldn’t go back and 
give them a higher dose of the drug. 
 
M: Would you decrease the dose and see if? 
 
S06: If, sometimes the protocol would specify if there was concern to give half 
the dose, um, but that implies that their reactions were completely dose related 
and often times reactions aren’t dose related. It’s not always a dose phenomenon 
so I don’t see that as relevant. 
 
M: Alright, and the one that you ranked the highest was number 8, was the drug 
detected in the blood? [oh I’m sorry I did it backwards] oh you did it backwards. 
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S06: Well I saw the scale and you said rank and I thought, I thought the scale 
was going to happen later. So you’ve got to do them all backwards now. 
 
M: Okay, I won’t make you do it again. So in your mind then number 2 is the most 
important did the adverse even appear after the suspected drug was 
administered? [yeah] Okay, alright, great. And was there anything on this scale, 
any questions here, or anything that you thought that was sort of missing that 
maybe should have been included that wasn’t there? 
 
S06: I thought that was pretty comprehensive, those seemed to be the right 
questions, except for 6 and 8. 
 
M: So lastly then I would just like to ask you a little bit about your experience as a 
clinical trial researcher. [mmm hmm] So you’re a hematologist and what cancers 
do you specialize in? 
 
S06: Multiple melanoma, Non-Hodgkin’s lymphoma. 
 
M: And what year did you receive your MD? 
 
S06: 1988 
 
M: And what year did you receive your hematology license? 
 
S06: 1991 
 
M: And have you ever taken a Masters in Clin Epi? 
 
S06: No 
 
M: Is there any other research related education that you’ve had? 
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S06: A three-year fellowship. 
 
M: And when did you complete that? 
 
S06: That was 96. 
 
M: Where did you do that, was that NCIC? 
 
S06: It was an NCIC fellowship. 
 
M: And what year did you become involved in clinical trials as researcher? 
 
S06: 98. 
 
M: Overall, what percentage of your work time would you say is devoted to 
clinical trials?  
 
S06:  20%. 
 
M: And of that what percent of that is devoted to working on Phase 1 or 2 trials? 
 
S06: 80% 
 
M: And then the other 20% would be Phase 3? 
 
S06: Ah, Phase 2 or 3. 
 
M: Okay, so 80% is strictly Phase 1.[Yeah]  
 
M: And have you every been a local PI? [yeah] 
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M: So now I’d like to ask you a little bit about the education that you’ve have 
received specifically around assigning causality to adverse events. So can you 
tell me about any training that you’ve have received specifically with respect to 
assigning causality [none] to adverse events? Anything informal? 
 
S06: Oh, through the clinical trials methodology group, I’ve had interactions in 
working with them [the group here] yeah, through M L. When I write protocols, I 
see more of a science, scientist phenotype and as a translational researcher and 
writing and designing protocols that first hand experience is valuable in the 
processes. [so that group has really helped you out] yeah [in doing that] yeah. 
 
M: Any additional education about assigning causality that you feel needs to be 
made available to clinicians? 
 
S06: Well I think, you know it’s, I think, I think the process of understanding the 
Phase 1 study and toxicities and documentation and reporting SAEs probably 
would lend itself to some form of workshop or short course so that people do 
understand the general principals and how things need to be done. Um, in terms 
of actually running the trial you know the devil is in the details you would have to 
have it all set up appropriately so that basically everything runs on auto pilot once 
you have a protocol there. And not sure if one is you know, doing a Masters in 
Epi, I’m not sure you learn those specific details of, you know, you know, that’s 
the realities and those are the details you need to focus on. So it is experience. 
And I think you know, REB boards need you know, have to be the guardians of 
protocols that you know, there is some recognizing that this trial, especially if it’s 
a local investigator trial has the necessary infrastructure in place to be able to 
document and capture all the information. I think, you know, I think the academic 
institution at the same time should be able to provide that infrastructure at least in 
support, if not through collaboration with the groups. The challenge is that the 
good Epi group who can run trials in an academic setting are going to be 
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approached by drug companies. And you need a lot of money, those staff have 
to be paid and there are costs to the clin epi group and that’s a lot better then a 
local academic investigator say getting a grant for 100,000 bucks and he can 
give you a  $1000 bucks. I think they’re, they’re, the risk I think comes in the 
academic setting when the institute needs to kind of step up I mean today that’s 
being done, certainly here’s its done so it’s, but I don’t know about other centres 
across the country. (funding plays a major role)  
 
M: So we’re also interested in interviewing clinical trial nurses [mmm hmm] is 
there anyone you could recommend I speak with. 
 
S06: The two I work with are KH and TH. 
 
M: I think that’s all the questions I have so thank you very much. 
Subject 07 
M: Alright, so even the most experienced clinicians find assigning causality to 
adverse events challenging and many groups, such as industry sponsors, clinical 
trial cooperative groups, research ethics boards, they all expect prompt and 
sensible causality assessments. [mmm hmm] But as you know, causality, 
assigning causality isn’t that straightforward, and if done poorly it can have large 
implications both for patient safety and also new drug development. [mmm hmm] 
So we’re interested in developing a tool to help clinicians efficiently and reliably 
assign causality to adverse events that occur during Phase 1 oncology clinical 
trials. And we feel that by better understanding your needs as a clinician we can 
make this tool more relevant to you. [okay] Do you have any questions then 
before we start? [no] No okay. So let’s just say one of your Phase 1 clinical trial 
patient has just reported experiencing an adverse event. [mmm hmm] Can you 
please walk me through how the situation is handled? 
 
S07: So you interview them, you ask them what the side effect was you would 
immediately grade it, 1, 2, 3, 4. Um, then depending on the severity you treat it, 
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usually 1, 2 you don’t, it all depends what it is right. But the higher, the higher the 
causality probably the more attention you pay to that particular adverse event. 
[the greater the severity] The greater the severity. (more attention paid to 
severe AEs) So you make sure the person is safe and that um, you treat that. 
Now do you want to get into notifying the sponsors and things like that. [right] So 
what you would do [if it was a serious adverse event] yes, serious adverse event, 
obviously you would look to the protocol as to how you’re going to report it right. 
Some grade 3, 4 toxicities if they’re unrelated, um, they don’t want to know about 
it but usually in Phase 1 they want every single detail. So if it’s a serious adverse 
event obviously you follow protocol and notify the company within the 24-hour 
time required. If, you know, if it’s a non-serious but you know, whatever, if it’s a 
non-serious event you look to the protocol to see whether you’re supposed to 
stop the drug, if you’re supposed to reduce the drug and sometimes they give 
guidelines so you have to look to the protocol to see. 
 
M: What about in terms of assigning causality? 
 
S07: Assigning causality is some, I would say a combined event between the 
investigator and the study nurse. (assigning causality is a tem effort)I think 
both parties can, give valuable information as to their insights into the, into the 
whole situation. Obviously the principal investigator has sort of ultimately 
authority as to how he or she wants to assign, assign that causality. However, I 
really feel that, like we kind of work together to assign that particular causality. If 
the patients comes with grade 2 shortness of breath or something like that well 
why are they having the shortness of breath. [right] And is it just because it’s pre-
existing or is it because of what we’re doing to them and we’ll have a discussion 
about that. [so it’s a joint effort] Yeah, I would say so. 
 
M: What are the resources you refer to when assigning causality? 
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S07: The ah, book [oh, when you’re grading you mean?] yes [okay, so that’s for 
grading the adverse event] grading the adverse event. And you said resources to 
assign causality? 
 
M: Yeah, when you’re actually thinking about whether the drug is related to that 
adverse, whether that adverse event is actually related. 
 
S07: If it was actually related to it or not? You would look at the protocol and look 
at the research that has been done on the drug to see if this is something that 
has been reported before. And if it, that, that would be the major resource. [and 
most of that’s in the protocol?] Yeah, usually in the protocol, or usually the PI has 
articles that they have. And also, the resources being past experience as well in 
this particular drug which was kind of similar to this one. 
 
M:  Now in terms of, you mentioned the common toxicity criteria which is sort of a 
tool that you use to grade [mmm hmm] the adverse event. What tools do you use 
to help you assign causality? 
 
S07: Assign causality, didn’t we just sort of answer that? [yeah, yeah] Using the 
protocol, using the research. 
 
M: Those are the resources that you go to, that you refer to. 
 
S:07 How do you come about to assign causality? 
 
M: Yeah, do you use any sort of flow sheets or decision trees? 
 
S07: No we just kind of go is it related, is it not related, is it somewhere halfway 
in-between and sometimes it’s, it’s obvious. You know, the person had a pre-
existing asthma or something like that. And usually you take a base, the way we 
usually do it is we take what they were at baseline and if we’ve made them worse 
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we have to then decide, okay, is that because of the drug, the disease or just 
them right? But as for decision trees and things like that no. 
 
 M: And then are there any sort of general guidelines that you follow when you 
assign causality, any rules of thumb that you use?  [laughter] 
 
S07: No not really, using just yeah, anything. 
 
M: Let’s say for example it’s, let’s say it’s an adverse event that has occurred with 
a patient with a headache say [mmm hmm] and they reported that they had the 
occasional headache at baseline [mmm hmm] and these seem to be maybe 
more frequent how would you sort of [how would you assign causality to that?]. 
Yeah, like is there [so you] any sort of general rules that you might use? 
 
S07: Well, has it happened before [right] if it’s happened before and you’ve kind 
of got these cluster headaches and if it is definitely increasing intensity, the 
adverse event is increasing we would, that kind of raises the red flag that it could 
probably either be possibly or, or probably related to the particular study 
medication. We’re always concerned when anything increases, is it because of 
the study drug or not? Or is it just because of the nature of their disease? If you 
have brain mets and their disease is increasing you’re going to have more 
headaches. So you kind of have to take the whole picture of what’s happening 
with the patient and their disease as well as their response to the medication as 
well as their pre-existing whole picture [right] when assigning causality. (need 
holistic perspective) 
 
M: Of those factors, what do you feel is the most important factor when assigning 
causality? 
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S07:  Um, [or is it hard to say] I think you have to take the whole picture, I think 
you have to take the person and their pre-existing disease and the study 
medication. 
 
M: When you say study medication, what is it about the study medication that 
you’re… 
 
S07: Any kind of side effects [that is known about it] that is known about it yeah. 
 
M: Now I would just like to ask you to consider a scenario for me. [okay] Let’s say 
you’re treating a 65-year-old female patient [mmm hmm] and she’s got a 
confirmed diagnosis of metastasic breast cancer. [mmm hmm] And she’s in a 
Phase 1 clinical trial with a new investigational drug and she experiences a 
pulmonary embolism. [mmm hmm] Now how would you assign causality to the 
study drug if there was a 75% chance that the adverse event, the pulmonary 
embolism was due to the study medication and a 25% chance that it was due to 
other factors say [have cancer or whatever] yeah, disease progression, 
concomitant meds, concomitant illness. [mmm hmm] And the grade was, the 
scale is certain, probable, possible or unlikely. 
 
S07: I would probably say probable, just because you can’t be certain because 
you have the 75 versus the 25 and the 3 to 1 sort of thing. And because it’s 3 to 1 
it’s more probable that it’s the study medication itself. 
 
M: Now what if there was a 50% chance that the adverse event was due to the 
study medication and 50% chance it was due to other factors? Then using that 
same scale how would you… 
 
S07: Then you would go somewhere in the middle there, possible [one down 
from probable] one down from probable. 
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M: And then let’s say there was a 20% chance that the adverse event was due to 
the study medication and an 80% chance it was due to other factors? 
 
S07: Third one right because you don’t want to, and that’s, I would probably go 
unlikely/possible. It’s an 80/20 but you always want to be on the cautious side, 
well maybe, you have to look at other patients as well, how many of those are 
getting blood clots as well. So when assigning causality it’s kind of hard because 
you don’t know what’s happening with the other patients as well. So anyway, 
we’ll go unlikely. 
 
M: What would you say then is your threshold for you know going somewhere in-
between possible and unlikely. What is the percentage chance for unlikely? 
 
S07: To assign it to unlikely, yeah, probably about 20% and lower yeah, probably 
yeah. Like, hindsight is always 20/20 right. You can assign causality but you 
know if every single person on the study is getting a blood clot then obviously 
then you would, you would relook at your causality as well. It’s really hard at the 
time to go definitely for sure this is unlikely related. [yeah] But anyway. 
 
M: You said it’s important to know what’s going on with the other patients [mmm 
hmm] in the trial, how do you keep abreast of that? 
 
S07: Well usually there’s teleconferences and other meetings to discuss what’s 
happening with other patients. But a lot of times communication isn’t as good as 
it could be. (lack of communication) 
 
M: Who are those teleconferences with? 
 
S07: The principal investigators usually. The PMH consortium is quite good with 
their teleconferences. NCIC as well is that, study nurses are usually not as 
involved with the NCI. 
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M: But you get to sit in on the ones in the PMH? 
 
S07: Yeah we actually get to um, yeah so I think that’s kind of insightful. We 
should be involved in as much of those discussions just so everybody is 
informed. I haven’t done a lot of, so I don’t know what they do to keep it up but 
sometimes you do feel a little bit, you have no idea what the other people are 
doing. And it would be a little insightful as to how they’re doing it, yeah. (feels 
uninvolved in certain aspects of the trial, secluded) 
 
M: And given the choice, would you prefer to grade causality as certain, 
probable, possible and unlikely or as a yes related to the study drug or no not 
related to the study drug. 
 
S07: Oh I love grey areas so the first one. The other one seems too definite 
[yeah] it’s really hard to say yes or no because you don’t really know, it’s just one 
of those could be couldn’t be, yeah. 
 
M: What would you say are some of the problems or challenges associated with 
assigning causality? 
 
S07: Problems, first of all you’re never definite, definite, hindsight’s always 20/20, 
so looking back a few months later you can sometimes get a more clearer picture 
of what, like analyze the situation a little bit more.  Sometimes when you’re right 
in the situation and you have to, you have that responsibility of assigning it right 
then and there, you don’t have all the information right? You don’t know how it’s 
going to end, you don’t know, um, if, if, why it happened or anything. You can 
analyze the situation after it occurred and everything has evolved then it’s 
sometimes easier to go back and go well this and this happened we can do that. 
So assigning causality sometimes at the time is sometimes clear cut and 
sometimes very difficult. (easier to assess over time) 
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M: Do you ever have to go back and change your? 
 
S07:  Oh absolutely, where we, something may have been unlikely or and then 
we decide later on that no it’s probably related to the study drug. 
 
M: And what are some of your concerns about how clinicians currently assign 
causality. 
 
S07: I don’t think we pay a lot of, as much attention to the importance of it as we 
should. I think a lot of times, causality is, is the minor things, the minor things that 
nobody kind of pays attention. Major things are usually, if  it’s an SAE you can 
pay a lot of attention to is it related, is it not, but the grade 2 things sometimes the 
nurse just kind of assigns causality and the physician will look at it and may 
change something. But as study nurses we try the best we can to assign 
causality, um, with the physicians, like obviously we’re going to ask for the 
guidance but for the minor things we don’t. (feels not enough attention is given 
to minor reactions) 
 
M: So in your experience then do you tend to only go to the physician when it’s a 
serious adverse event or do you discuss causality with the investigator for all of 
the adverse events? 
 
S07: For all the adverse events no. [just adverse events] Just adverse events, 
anything grade 3ish, we definitely, ah, 3 or above, definitely I would consult the 
physician. It’s those grade 1, 2’s  that I usually assign causality based on the 
information available on that particular agent. (feels they need to seek 
consultation for more serious AEs, minor AEs are not an issue) 
 
M: What do you think the implications are of that, like why are you [hopefully we 
are right] yeah, but why are you concerned about that? 
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S07: Why, because you know what, um, it’s those minor things that can cause 
good quality of life issues in patients. And if somebody has bone pain because of 
a particular medication, one bone pain is, two bone pain, that’s starting to 
implicate on quality of life issues. And if we’re kind of assigning bone pain, you 
know that could have issues and we may not like notice the issue until later on in 
the development of the drug. So I think it is important to have a good idea if a 
drug causes a certain side effect or not, no matter if it’s mild or severe. We’re 
always concerned about the moderate to severe but we’re not.. 
 
 M:  Have you ever, or what external influences or pressures from third parties 
have you felt when assigning causality? 
 
S07: Not too much, but then again I’m not the one that the sponsors contacting 
when they call you and go are you sure that this is what you think it is? and stuff 
like that. I’ve had one of those calls where they’ll call back and they’ll say is this 
the way you want it? And you just go back to the physician and tell them they 
want to reconsider. And sometimes the physician is, will stick to their guns and 
sometimes they will re-think it or whatever [Do you find that seems to differ 
depending on the PI?] totally [does it?] I think so, some principal investigators are 
um, much more involved in assigning and how ? they are about the particular 
agent or their prior experience and back down, or if they’ll stick to the way they 
originally assigned the causality. (individual variation when dealing with 
sponsors) 
 
M: Any other influences or pressures that you [no] when assigning causality. [no] 
And from your perspective, what would make assigning causality easier? 
 
S07: You know, actually, the way, when you said like a, having a tool, like a 
flowsheet sometimes to kind of guide you through causality. Everybody has their 
own kind of mental picture of when they’re going through causality. But 
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sometimes something solid on paper, but given that though, sometimes there are 
always exceptional cases where you kind of have to think outside the algorithm 
[right] or things like that. So you always, like even you may have an algorithm for 
a particular situation as well, so it would be helpful, but it shouldn’t kind of stifle, it 
shouldn’t stifle the way you assign causality. (tool won’t always apply- 
exceptional situations) 
 
M: What would sort of stifle it? 
 
S07: Oh, who knows, whenever you get an algorithm it’s always like the yes/no’s 
sorts of things and sometimes there’s a grey in-between. So sometimes you have 
to kind of think differently. (need to change mind frame when assigning 
causality) 
 
M: Okay, what I’d like to ask you now is if you wouldn’t mind taking a read, 
reading over these questions and then crossing out any that you feel are not 
relevant to the Phase 1 oncology clinical trial setting. That’s great [okay] yeah, so 
these questions are to be used sort of when you are assessing causality in a 
Phase 1 oncology clinical trial setting. 
And now if you could just rank them from sort of least important to most important 
if you don’t mind, so 1 is least important, 10 is most important. 
 
S07: And you can assign them, it doesn’t have to be 10, 9, 8 [no they don’t have 
to be] okay that’s fine. I think they’re all 10, I have to think about it, okay. 
 
M: That’s good, okay, great. 
 
S07: Yeah sure, instead of just making them all 10’s. 
 
M: So you think they’re all pretty important. 
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S07: Yeah, I think they’re all very important. 
 
M: And then the one that you ranked the lowest was did the reaction reappear 
when a placebo was given? And why, why did you rank that one lower? 
 
S07: Why did I, because something had to be lower. You know, it’s still important 
to know, like I didn’t actually rate this, like power of the mind is huge right, so you 
tell somebody they’re going to get a skin rash and you give them a placebo and 
they get a skin rash right. You know, it’s the power of the mind so it’s, I think it’s, 
yeah, that would be important but usually, sometimes in Phase 1 trials you don’t 
have the placebo right, so you don’t know. [right] 
 
M: Now, what additional questions do you feel should be added here? 
 
S07: Does the patient feel, how does the patient feel and their side effects. Does 
the patient feel that this happened before or is this something, a totally new 
experience for them? And now granted, the power of the mind is, is, is there and 
that if you give them a consent form and tell them they’re going to get all these 
side effects they’re going to be worried about that. But it’s also insightful to know 
how the patient feels and how their quality of life is, is affected as well. 
 
M: Great, that was actually a tool that was developed by a researcher named 
Naranjo [mmm hmm] and we’re considering potentially using something like this 
and maybe modifying it a bit so that it’s applicable to the Phase 1 oncology [oh 
very good] setting. 
 
M: So then lastly I would just like to ask you a few questions about your 
experience as a clinical trials researcher. [sure] So in which cancer(s) do you 
specialize? 
 
S07: Hematology, lung, those are the major ones right now. 
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M: You have a Bachelors in Nursing? 
 
S07: Yes. 
 
M: And when did you get that one, what year? 
 
S07: 95 [95] 
 
M: And when did you get your license, your RN license? 
 
S07: 95. 
 
M: And you’re working on your nurse practitioners? 
 
S07: Acute care nurse practitioners, my Masters. 
 
M: And so when do you hope to have that one finished. 
 
S07: Next year [2007] yeah. 
 
M: And is there anything, any other sort of certifications or fellowships, anything 
that you’ve done related to clinical trials? 
 
S07: I have the oncology nursing certificate. 
 
M: When did you get that? 
 
S07: The CONC, that was 99. 
 
M: So what year did you become involved in clinical trials as researcher? 
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S07: 99 [99] 
 
M: Overall, what percentage of your work time would you say is devoted to 
clinical trials?  
 
S07:  100% [100%] yeah. 
 
M: And then what percent of that is devoted to work on Phase 1 or 2 trials? 
 
S07: Right now about 25, 25 to 50, it varies. 
 
M: Okay and the other 75 would be on Phase 3.  
 
S07: Let’s just see what I have right now, ah, right now 50% I would say, I would 
say 50% right at the moment. 
 
M: And then lastly I would just like to ask a little bit about the education you have 
received specifically around assigning causality. [mmm hmm] So can you tell me 
about any training you have received with respect to assigning causality to 
adverse events specifically? 
 
S07: Nothing formal. Sometimes in start up meetings or something like that 
they’ll, they’ll say a little blurb about assigning causality but they won’t really give 
like formal education as to what, we should use this tool or anything like that. It’s 
mostly a set reaction sort of. 
 
M: Anything, any other sort of informal education you can think of? 
 
S07: You know, sometimes NCIC meetings or something like that, um, I can’t say 
I’ve ever been to one. 
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M: So what sort of additional education about assigning causality do you feel 
needs to be made available to clinicians? 
 
S07: Just the importance of it. Um, I think a lot of times we give them the case 
report forms and they just sign it. There’s a few physicians that will check the 
causality that has been reported, they’re kind of few and far between. I think for 
the majority of physicians they just sign the piece of paper. (feel physicians do 
not put in enough effort) 
 
M: What about for people such as yourself, clinicians such as yourself? 
 
S07: Um, be more aware of the drug side effects. Usually through start up 
meetings or whatever like that, we as nurses, we have to be aware of the side 
effects, how to manage them and what is expected and not expected. And 
having a more formal decision meeting with them or something like that in which 
we can be in the process as well. 
 
M: We’re interviewing both clinical trial nurses and medical oncologists and 
hematologists. I think we’ve probably interviewed or approached most of the 
people at JCC [mmm hmm], is there anyone that you can recommend that I 
speak to in addition to Dr. W and  Dr. .L [hmm you have them] too busy.  
 
S07: Dr. W she does some clinical studies and in the Hamilton area or are you 
just 
 
M: Well we’re also going to go to some other sites but for now we have ethics 
approval here, in Kingston and BC, [oh, that’s awesome] yeah I just need to get 
them all lined up in the same week which is difficult. [yeah, that’s all I can think of] 
 
Subject 08 
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M: So I’ll just explain to you what it is we are doing. We are looking at the way 
investigators assign causality to adverse events that occur in specifically Phase 1 
oncology clinical trials. And as you know, even the most experienced clinicians 
find assigning causality challenging and, but many groups, such as industry 
sponsors, clinical trial cooperative groups, research ethics boards, they all expect 
prompt and sensible causality assessments. But assigning causality is not always 
straightforward, and if done poorly it can have large implications for patient safety 
and/or new drug development. So we’re interested in developing a tool that will 
help clinicians efficiently and reliably assign causality during Phase 1 oncology 
clinical trials. And so we feel that by better understanding your needs as a 
clinician we can use that information to make our tool more relevant to you. Do 
you have any questions before we start? [no] No? okay. So first I would just like 
to better understand the clinical reasoning that you use when assigning causality. 
So let’s say one of your Phase 1 clinical trial patients experiences an adverse 
event. Can you just walk me through [yeah] how the situation is handled? 
 
S08: Um, you mean how do I think about the issue of causality? I mean the first 
thing really is, is there a temporal relationship, so I mean, does the side effect 
appear at a time that is reasonably related to the administration of the drug. I 
mean the second thing is does it fit in um, because often I mean if we’re talking 
about Phase 1, it may be a Phase 1 trial just with a new agent on it’s own, or it 
maybe a Phase 1 of a new agent in combination with existing agents. So is this 
an expected side effect from the existing agent. [okay] You know, is this 
something that’s already been observed, so is it expected from the, the 
experimental agent. Is this something that you might expect to happen as a result 
of the disease, so you know, is it more a disease related symptom rather then an 
adverse event from the, from the drug. But the, the bottom, the difficulty is that 
often, you know, particularly the Phase 1 trials that I’ve been involved with have 
often looked at combining a new agent with chemotherapy. And so you have 
overlapping toxicities and you’re left with ultimately a situation where if a patient 
experiences an adverse event and if you’re not sure, sometimes you think, well 
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okay, this is, these are side effects we see with treatment and so you think well it 
is possibly related or probably related. But then there are things that happen that 
aren’t necessarily related to the disease, um, aren’t necessarily known side 
effects. And you sort of think or left thinking well maybe they are totally unrelated 
but you end of saying it’s possibly related because you can’t rule out the 
possibility. So sometimes it comes down to you really don’t know and you know, 
my approach is if I really don’t know and there’s not a clear cut explanation then I 
have to say that it’s possibly related.(Errs on the side of caution and attributes 
to the drug when unsure) And the difficulty is that sometimes some Phase 1 
trials give you the option of saying you know, unlikely, possibly, probably, 
definitely you know, or unrelated. And then others it’s just a simple yes/no[right] 
and the yes/no’s are hard because you know, unless you can say it’s definitely 
unrelated then it’s yes and you know, that doesn’t give you the gradation. 
 
M: Yeah, so you definitely prefer the scale then? [hmm mmm] 
 
S08: Um, and then there are some things that add strength to the sort of 
associations and so if you treat somebody, you know, particularly if somebody is 
getting sort of cyclic treatment instead of continuous treatment and they get the 
same things happen with each cycle of therapy then it’s much easier, you know, 
to say there’s an association with the treatment you’re giving. So I guess re-
treatment or re-challenge is clearly a fact that helps in determining causality but it 
doesn’t necessarily help the first time it happens. 
 
M: What sort of resources do you refer to when you’re assigning causality? I 
know you said you think about whether it’s expected 
 
S08: Well I think it’s based on what’s been listed in the protocol and possibly the 
investigator brochure. But really do you have time to look at an investigator 
brochure every time? no. (lack of time to use the resources that are available) 
The other thing I guess is being, you know, what is on my desk here, a series of 
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adverse events. And I would think, you know I have two or three trials that 
generate enormous numbers of these MedRA reports. [right] So you know, that 
helps build the perception of the sort of side effects that are being experienced 
so. And there’s a variety of resources, but do I go and look up every time I, you 
know something happens do I go back and look up you know in the investigator 
brochure probably not. [no]  
 
M: And that’s usually because of time constraints or [yes] any other reasons? 
 
S08: Well and sometimes you know you’ve seen the same things happen in other 
patients [you don’t really need to] so you don’t really need to yeah. 
 
M: Can you talk to me a little bit about these safety reports that you get, I, I’ve 
heard in other interviews that it’s a bit of a, an issue just sort of the way the data 
is presented and. 
 
S08: I mean they vary, some of them are, like this one, this is, these just came 
today, so these are from, from BMS or from Imclone, now these seem to be fairly 
detailed reports which is good and bad in a sense because if you’re trying to look 
through 10 of them and you’ve got a couple of pages of detail. Like, 3, 4 pages, 4 
pages of text, um, you know, it becomes difficult to you know, in a time 
constrained environment [right] to read that in a lot of detail. (not enough time to 
pay attention to details) So you are going to skim it and sometimes it’s 
apparent because a lot of them are complicated patients, you know, people that 
come in and have multiple things go wrong and you know really that it’s going to 
be very difficult to sort out. The whole issue of causality because there are 
multiple contributing factors. So sometimes you just look at it and think well yes 
it’s possible you know, it’s related. And what I find if there’s a good succinct 
summary then you know, that’s, that’s very helpful and the reports are easy to 
look at. Mostly I find you know I tend, I agree with, with the conclusions they 
come to and sometimes um, I think there’s a tendency to over report disease-
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related symptoms as being related to the investigational agent by the invest, you 
know, to be reported by the investigator. (tendency to over attribute protocol 
drug) It’s my sense in particularly in a series of things we are you know, reports 
that I got that related to a study of interferon and a drug called CCI-779 in renal 
cell cancer. And so in that setting there’s a discrepancy between what the 
investigator feels and what the medical monitor feels. And then you have, 
because different companies will approach it differently and so then you have 
AstraZeneca with their reports. The company sort of reports basically they, they 
want to downplay um, these and so their stock standard line is that you know, 
such and such a side effect is not listed in the investigator brochure, the 
implication being well it can’t be related. So you know they take the, so you’ve 
got to look at it with, it’s somewhat helpful but somewhat tedious. (Pressure 
from drug companies) 
 
M: Okay, so um, that, that would seem like a bit of a pressure then that you’re 
getting from the sponsors. So do they actually write back to you in writing and 
say? 
 
S08: No, cause what happens, they’ll send us the report and then it’s up to us to 
how we deal with it. I mean they have to be forwarded to the REB and the 
internal documentation that we do is more about sort of thinking for ourselves 
whether we want to make consent changes. Whether we see something which is 
happening you know, with um, severity or a frequency that would justify making a 
change to the consent form. And that doesn’t happen very often, in part because 
you know, we tend to wait for, because periodically there will be an update to the 
investigator brochures and then they’ll considered if the consents need to be 
updated. [right] 
 
M: One of your concerns that you mentioned was that there was a tendency to 
over report disease related symptoms as being related. [mmm hmm] Why do you 
think that is? 
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S08: That, I mean, I don’t want to sound like I’m being judgmental but there’s, 
there’s a propensity for that to happen in, from reports that come out, particularly 
out of Eastern Europe. [oh really, okay] So I think that there’s geographic 
variation in, in the way in which things are attributed. And so I you know, 
particularly in Eastern Europe I’m more skeptical of, about the assessment of 
causality. But that’s a very broad comment, that’s not universal. 
 
M: And do you think it’s just a tendency to be overly cautious or not 
understanding the disease well? 
 
S08: I don’t know, I think that would be very difficult for me to answer [yeah, 
yeah] or hazard to guess at people’s thought processes. [sure] 
 
M: So what external pressures from third parties have you felt when assigning 
causality then? 
 
S08: I don’t think I felt any external pressure [no?] no. 
 
M: You haven’t felt um, you mentioned sort of AstraZeneca wanting to downplay. 
 
S08: Well that’s in terms of these reports, we [oh you mean, what you’re referring 
to] [11:05] we receive, not necessarily the [at the bottom where they have their 
company comment?] yeah, not necessarily the ones that we generate. But not, I 
mean never been, I mean there have been times when we’ve had queries come 
back about um, about reports, but not. I mean I’ve never sort of had someone 
say we have to change something [okay] that would probably just make me dig 
my feet in I think. Um, I mean there’s a difficulty because again, the way that um, 
the expectation for serious adverse event reporting seems to differ a little. [yeah] 
And for instance the [how so] well let’s say you have someone that has diarrhea, 
mucusitis and then becomes dehydrated. Sometimes in some places for some 
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companies you know the serious adverse event would be mucusitis, diarrhea and 
dehydration. And other places and I guess the NCIC in particular, I mean our 
recent experience, is that they say well the drug doesn’t cause dehydration, the 
diarrhea and the mucacitis does. So you have primary adverse event and then 
you have secondary effects from that [right]. And then really only want the 
primary event reported as the serious adverse event and then what’s secondary 
to that is covered in the description of the serious adverse event. (Difficult to 
know what sponsors want report and how they want them reported) So 
someone that gets um, you know, febrile neutropenia, who gets febrile 
neutropenia, sepsis, renal failure, pneumonia, and dies. I mean it may be that the 
only adverse, the only thing that might be considered the serious adverse event 
would be the febrile neutropenia. Um, so you know, it becomes a little confusing 
at times trying to figure out what should be on and I think the, um, the biggest 
problems that we’ve had in recent times in submitting SAEs has been you know, 
questions about what should be listed in terms, as the serious adverse events. 
[that’s a bit of a challenge] It is and some of that is sort of developing a better 
understanding of what individual sponsors want or expect. But on the other hand 
maybe there should be you know, greater consistency. 
 
M: You find that there is variation among the sponsors as to what it is that they 
want and expect.  
 
S08: Yeah. 
 
M: Now you mentioned that when you’re thinking about causality you think of a 
number of things, you think about temporality, you think about whether the event 
is expected or not and you look at all the other possibilities and consider the 
drug. What do you consider to be the most important factor when you’re 
assigning causality? Anything, any one thing in particular that sort of is most 
important? 
 
! #$'
S08: Is it a known effect of either the drug or other treatment as being received 
[yeah] would be I guess the most important thing. 
 
M: Now I would just like to ask you to consider a scenario for me. [mmm] Let’s 
say you’re treating a 65-year-old female patient with a confirmed diagnosis of 
metastasic breast cancer.  And she’s in a Phase 1 clinical trial with a new 
investigational drug when she experiences a pulmonary embolism. How would 
you assign causality to the study drug if you knew that there was a 75% chance 
that it was related to the study drug and a 25% chance that it was related to other 
factors such as her disease progression, or chemotherapy or? 
 
S08: I mean something like that I would say, I mean to say that there’s a 75% 
chance that it’s related to a study drug would indicate that there’s a pre-existing 
um, you know, that it’s already known that the drug causes thrombolic disease. 
And if that were the case then I would say it’s probably related. 
 
M: Okay, so your scale is certain, probable, possible or unlikely and you’d say 
probable [probable] okay. 
 
S08: Because I mean it can be disease related as well. You’re never going to be 
able to tease out a Phase 1 trial that it’s definitely, definitely related. (feels there 
are no concrete answers) 
 
M: And what about if those percentages were changed so that you knew there 
was a 50% chance it was related to the study drug and 50% chance that it was 
due to other factors?  How would you grade causality then given the same scale? 
  
S08: That’s not a real life situation you’re never going to know [no I know] so I 
mean I don’t think I could answer what you’re asking because you know, you’re 
never going to have that degree of certainty about you know the likelihood. And 
you’re left with a situation where you know that metastatic breast cancer is 
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associated with a risk of thrombolic disease. And if your investigational agent has 
been said to have an association as well then you know, it’s, it’s always going to 
be a, you know, a probably or possibly. If there’s a clear knowledge that it causes 
thrombolic problems I’d probably say probably and if it was unclear I’d say 
possibly. Sorry to be difficult but you know there’s no point in answering [yeah] a 
hypothetical question that’s irrelevant. 
 
M: Would you ever assign, can you give me an example of where you’ve ever 
assigned causality as unlikely [in any] yeah, sure, can you provide me with an 
example. 
 
S08: Well someone that’s on combination chemotherapy and a new agent where 
um, you know where you already have a high likelihood of getting neutropenia, 
you know, severe neutropenia then the patient gets grade 3 or 4 neutropenia 
then, on the combination then I would probably attribute it to the chemotherapy 
and say it’s unlikely to the investigational drug. Unless there’s already, you know, 
unless single agent studies of the investigational drug have been shown to cause 
neutropenia. 
 
M: So in a case like that you’d feel fairly certain that it wasn’t the study drug that it 
was the chemotherapy and that there was. 
 
S08: Well I mean how do you be fairly certain about anything in a Phase 1 trial? I 
mean you’re talking about a drug for which you have limited experience in 
humans by and large. The only way to know clearly whether the addition of your 
new agent to the chemotherapy causes an increased risk of, of side effects that 
are associated with chemotherapy is when you do a randomized comparison of 
chemotherapy alone versus chemotherapy plus new drug. Um, then you’ll know 
what the true increased incidence is, for instance when you look at studies of 
Avastin and chemotherapy, I mean this is relevant to what we’re doing currently 
in, with a trial in lung cancer with carboplatin, taxol and AZD2171. You know 
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that’s a drug that blocks vascular endothelial growth factor. And you know, we’ve 
been faced with neutropenia and febrile neutropenia concerns and we’ve largely 
said that it’s, you know it’s been largely said that it’s unrelated to the study drug. 
But on the other hand when you look at the studies of, of chemotherapy plus 
Avastin, a randomized trial, and Avastin is a similar class of drug, then the rate of 
neutropenia and febrile neutropenia is probably double that of chemotherapy 
alone. So there’s some increased risk in related drugs and yet we’re tending in 
Phase 1 to sort of say well okay it’s probably not related. But the only way to 
know truly if the rates are increased is when we do a randomized comparison. So 
you’ve got to, there’s a lot of imprecision in, in um, trying to tease out toxicities 
when they overlap with other drugs you’re giving. I think to, to, you know, to 
suggest otherwise is um, is fraught with problems. 
 
M: From your perspective then what would make assigning causality easier? Or 
do you just resolve yourself to the fact that it’s an imprecise science. 
 
S08: Imprecise science! (key term) I am not, I mean I guess to have definition, I 
mean more clearly defined sorts of definitions of the terminology would be most, 
would be the thing that would be most helpful. [which terminology?] You know, in 
terms of the causality terminology, so more clearly define what people mean by 
unlikely, possibly, probably, you know definitely related. And at least people are 
using the terminology you know, in a similar fashion. (lack of consistent 
definitions) You’re always going to have difficulty in teasing out um, disease 
related symptoms. And you know, if you’ve got other treatments there you’ll have 
difficulty in teasing out you know, concerns about overlapping toxicities. 
 
M: So better defining the grade, the terms on the scale [yeah], anything else, 
what else would make it easier? 
 
S08: Honestly, I don’t think anything else would make it easier. You know, this is 
not, um, it’s not something that there will be an epiphany and we’ll say, oh this is 
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how to do it. [right] Because you know, of the nature of, of that, it’s, it’s evolution, 
it’s knowledge in evolution, by definition. And because of the fact that you have 
limited experience in humans either of that drug alone or of that drug in 
combination. It may in fact be wrong to take away that um, that imprecision 
because the process needs to evolve really with each, maybe not with each 
patient but with each group of patients. I mean the, the knowledge of what the 
potential toxicities are evolves. [need to have room to evolve] (imprecision 
leaves room to evolve) 
 
M: Okay, what I’d like to do now is just ask you to quickly read over these 
questions and cross out any that you think are not relevant to the Phase 1 
oncology clinical setting.  
 
S08: Phase 1, well there’s no placebos in Phase 1. Just put a line through the 
whole one. [yeah sure just cross it right out] 
 
M: Oh great, thanks, super. Is there anything here that you thought was missing? 
Anything that could have been added that wasn’t there? 
 
S08: I don’t think so, I mean, well anything there that’s not there is um, it’s sort of 
there it says, I mean it’s sort of there because it says are there alternative causes 
other then the drug that had, that could have caused the reaction. Um, I think you 
need to, to separate out you know, disease, you know, related symptoms and 
also the possibility of you know is this a Phase 1 trial of a new agent plus 
standard chemotherapy? Because if it’s a new agent alone then it’s easier to look 
at then if it’s a new agent plus chemotherapy where you have to consider the 
expected toxicities of the, the chemotherapy or other therapy they received. 
[okay, good] 
 
M: What do you think the implications are then, I just want to go back to, I think 
you bring up a really interesting point about it being an imprecise science and 
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that you know, you don’t want to stifle that evolution of knowledge. On the other 
hand, what do you think the implications are of assigning causality poorly? 
 
S08: Well I mean if you’re assigning causality poorly I mean you start to get a 
profile of side effects, I mean, because the real issue in Phase 1 is does the drug 
go forward or not? And how, I’m not sure how often a drug ah, fails to proceed in 
development because of toxicity. More often you know, there are issues about 
ah, lack of efficacy or lack of perceived efficacy because again, it’s more difficult 
to asses efficacy in that setting. (efficacy is an issue) 
 
M: So, you don’t really feel that there’s huge implications in terms of the drug 
moving forward? 
 
S08: Well I think that there are, I mean I think you know, if you start sort of 
labeling a drug as having you know x, y and z side effects and in fact they’re in 
fact they’re side effects related to the disease then you know, um that’s a 
problem. But on the other hand does it, how does it limit development of the, the 
agents. I’m not certain, well I’m not less certain that it’s going to limit 
development of the agent. (not sure what the consequences of over 
attributing are) 
 
M: Okay, are there any other, like can you give me an example of a, of a drug 
that was sort of halted because of safety issues? 
 
S08: Um, always when put on the spot, because a lot of these things are 
numerically identified at this point so they don’t have um, [easy to remember 
names?] easy to remember names, but some of the um, there’s at least one of 
the, the agents active against VEGF I can’t think of which one it was, but not one 
that we were personally involved with. But there are some examples of some 
drugs in recent times that have just proved too difficult to administer. Whether the 
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anticipated toxicity of the drug, like the dose limiting toxicities occur at doses that 
are below what are thought to be biologically effective doses. [okay] 
 
M: Now I guess I would just like to ask you a little bit about your experience as a 
clinical trials researcher. So which cancer(s) do you specialize in? 
 
S08: Breast and lung. [lung and breast okay] 
 
M: You have your MD obviously, what year did you get your MD? 
 
S08: 198… it’s on the wall isn’t it, 1988. 
 
M: 88 and you also have a PhD is that right? [yeah] and in what year? 
 
S08: In 2000. 
 
M: In 2000, and that was here at Mac right? 
 
S08: No, that was in [Australia] Australia. Well I have a Masters in Clinical 
Epidemiology [okay and what year] that was in 199-- I graduated in 1998. The 
PhD was Health Services Research and it was all sort of based in Australia. 
 
M: Any other education? When did you get your Medical Oncology License? 
 
S08: 1995 [95] 
 
M:  And any other sort of research related education or? 
 
S08: I don’t think so, that’s enough isn’t it? [yeah, I think so] I mean I’ve got 
Canadian Certification but that’s not, that didn’t require additional training so it 
probably doesn’t really count. 
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M: So what year did you become involved in clinical trials as researcher? 
 
S08: In earnest when I arrived here, so 2000 is probably the simplest thing. I 
mean I was exposed to clinical trials all through my training. So really from 199, 
well from 1993 onwards. But as a primary researcher, 2000 onwards. 
 
M: And what percentage of your work time would you say is devoted to clinical 
trials?  
 
S08:  That’s a hard question isn’t it [yeah] I mean do you count the time in, I think 
maybe 10%. 
 
M: And of that 10% what percentage do you spend in Phase 1 and 2 trials? 
 
S08: Maybe 30% of it. 
 
M:  And then the other 70% would be [would be in Phase 3] okay. 
 
S08: You know, but it varies from time to time [yeah] I mean there’s such a big 
fluctuation [yeah] depending on what’s happening. [yeah, it’s just an estimate] 
 
M: And you’ve been a local PI [yeah] for a trial. Can you tell me about any 
education you’ve received specifically to do with assigning causality to adverse 
events? 
 
S08: I did some causality, we did some causality things in the clin epi program, 
not necessarily causality associated with adverse events in phase one trials, but 
um, more looking at the issue of causality in general. 
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M: What did you learn about? Bradford Hills criteria? [yeah] Any other training 
specific to assigning causality in trials? 
 
S08: No, just the protocols will come with, so some definitions about what they ah 
[what they expect] what they expect yeah. But nothing in terms of formal 
education, training, I’m not sure anything exists. 
 
M: Do you think there’s a need for something like that? 
 
S08: I think there’s a need for people to have some training in clinical trials, the 
conduct of clinical trials yeah. But I’m not sure limiting to just assigning causality 
in Phase 1 trials. 
 
M: I think that’s, those are all the questions that I have. [okay] Have you got any 
questions for me? 
 
S08: No I don’t think so. 
 
M: If I have any additional questions later on is it alright if I come back. 
 
S08: Sure that’s fine. 
Subject 09 
M: So, I’ll just explain what it is we are doing again. So even the most 
experienced clinicians find assigning causality to adverse events challenging and 
many groups, such as industry sponsors, clinical trial cooperative groups, 
research ethics boards, they all expect prompt and sensible causality 
assessments. But assigning causality isn’t always that straightforward, and it can 
have large implications for both patient safety and new drug development. So 
we’re interested in developing a tool to help clinicians efficiently and reliably 
assign causality during Phase 1 oncology clinical trials. And we feel that by better 
understanding your needs as a clinician we can make this tool more relevant to 
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you. So do you have any questions before we start? [no, it’s clear] Good. So let’s 
say one of your Phase 1 clinical trial patients has just experienced reporting, or 
she’s just reported experiencing an adverse event. Can you just walk me through 
how that situation is handled? 
 
S09:  Well, I guess as I’m struggling with this in the Phase 1 trials, what’s an 
adverse event. [okay] Because within the protocols they’re not defined very well 
either. (struggle to determine even what constitutes an adverse event) So 
that you could get disease progression that’s an adverse event which when 
you’re coming into determining DLT’s and moderate toxicity if you put you know, 
increasing shortness of breath could be related to disease. But when they say it’s 
an adverse event that occurs on study, whether or not deemed related to the 
investigational agent you can potentially be putting disease progression [right] as 
an adverse event. So I think clearly defining what you mean by an adverse event 
upfront and what you mean by moderate and dose-limiting toxicity. But generally 
if somebody calls in with, say the call in with, you know, they’ve been short of 
breath, well they got the drug on Monday and today they’re short of breath. So 
you go through clinically you know, what their symptoms are, like is it something 
that, if they’ve got plural effusions are they more short of breath? Is it something 
related to disease? have they got a fever? So you go through all those diagnostic 
type things first. And then from, based on that, you kind of algorithm out which 
way you’re going to do. And it can be related to drug and you’re always looking at 
the time, when their dose of drug was versus the onset of symptoms. [okay] If it’s 
um, if it’s listed as an expected in the IB, an expected toxicity in the 
investigational brochure um, versus disease under study, those I think are the 
three triggers. (strong emphasis on IB and timing of an event) The challenge 
with the Phase 1 studies when you’re on these, doing these agents that are first 
in man you don’t know. (uncertain) And a lot, I think we tend in practice to um, 
be over-cautious and possibly assess attribution if you’ve ruled out the other 
things and you have to say ah, possibly related to drug um, and then go from 
there. (err on the side of caution when uncertain) And it then it becomes, if 
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it’s, I mean a bad enough toxicity where you stop the drug then you, if there’s a 
re-challenge that happens and then you see if it re-occurs versus if it doesn’t. 
[right] And, and, certainly even with, in the animal model, not all humans get the 
same side effects that animals do so [right] you know [so there’s limitations to 
that] there’s limitations [right]. That’s okay and some of it too is, it’s something too 
that you notice over time because you might not pick it up in one patient, buts it’s 
only as you think so and so had that and we didn’t think it was related, well 
maybe it is. And I guess that’s the limits of the phase one studies when you’re 
dealing with a small number of patients. [yeah] And ah, I find it a challenge too 
when you’re doing the accelerated titration design studies where they put one 
patient on per cohort [yeah] that you’ve only got one patient on that dose level. 
And we know that not all compounds work the same way in all disease type so it 
may not be effective in somebody with colon cancer but it may be toxic to 
someone with a lung malignancy. (uncertainty- individual variation) 
 
M: Right, so that’s a real challenge then when you don’t have a large number of 
patients you can’t 
 
S09: So the first one may not have had a problem and you move on and you 
double the dose and that person may not, and then because a lot of them are 
open to patients with any malignancy, it’s not geared to one specific disease site. 
So you’re not putting the same patient with the same diagnosis on the study. 
[okay] 
 
M: You mentioned that there needs to be better definitions of what is an adverse 
event, [mmm hmm] and I guess also better definitions of what is disease 
progression, right? [yeah, very much so] So you used the example of increasing 
shortness of breath, so that’s sort of one of those ones that’s difficult to tell 
whether it’s [it is] an adverse event or a disease progression. 
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S09: I mean it’s, because if you’ve got someone with say a lung with plural 
effusion or a metastatic breast patient that’s got plural effusions or whatever and 
they worsen the disease. But a lot of them don’t have biopsy that they’re 
malignant effusions. And there’s always the thing that’s at the back of your mind 
that is, we always hope the compounds that we are developing target the 
malignant cells. But we know that they can target normal cells, so are they 
causing these patient’s disease to take off? [right] and speed up the metastatic 
process with you know, and that’s still back there with it. I’ve had 5 patients on 
and they’ve all progressed pretty quickly, was that the drug? [yeah, that’s really 
difficult] 
 
M: You mentioned that one of the resources that you use when assigning 
causality is the IB to check if the adverse event was an expected adverse event 
based on what you know [right] about the drug and in a Phase 1 study that’s not 
too much. What other resources do you refer to then [for] when you’re assigning 
causality? 
 
S09: Well first of all it’s usually, it’s the PI’s responsibility [so you refer to them] 
that’s right. (hierarchy) Again it’s the experience with the compound as you go 
along really, ah, if there’s been similar compounds that are out there, um, that 
have been used. But in Phase 1 you’re really, you’re flying by the seat of your 
pants. (interesting expression) [flying by the seat of your pants?] Well you are I 
mean you don’t know right, you don’t know. [yeah] I mean they always start the 
Phase 1 studies at a tenth of a dose where they saw toxicity in the animal model, 
but that can be way too toxic right. [yeah] Then you know, I’ve got a study now 
where we’re going backwards, the first dose was wrong so we’re going 
backwards. [yeah, okay] It’s mainly the IB and just what the patient had before 
they started study and if they don’t have it before, if they don’t have an adverse 
event before they start study then it’s probably drug related. You have to, you 
have to say that, you know, you really do, so… [okay] 
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M: Are there any flowcharts, algorithms, decision trees, any sort of tools that you 
use to help you when you’re assigning causality? 
 
S09: No, no I’m not aware of any. [none that you use personally to help you out] 
No, again, I, I go with what the patient presented with at baseline [yeah] and what 
grade that was at baseline and then any change [yeah] is whether it’s disease 
under study or drug. Other like you know the hot humid weather, everybody is 
short of breath and has swollen ankles. I think when we dictate we, well 
personally, if I’m, if we are leaning towards a few things that could have caused 
something, then we say could be related to this or this or drug and then we’ll 
continue to monitor, And it’s only over time you see a pattern or you don’t. (hard 
decision to make on the spot) So you may assign causality in week three of 
possibly related but when you get to week seven something else may have come 
around and you think oh you know what? that back there wasn’t. In hindsight it 
was like early disease progression or they were septic or something else will 
come out. [So it’s ah, your knowledge sort of evolves over time] yeah, I mean you 
use your clinical assessment and um, and it’s really process of elimination and if 
nothing else comes out. And then as you get more patients on then the pattern 
either develops or not. [okay] That’s why I always tell patients to on a Phase 1 
study that anything they feel like don’t feel it’s too trivial [yeah] if you usually have 
a bit of heartburn and now you have more heartburn, you need to let me know 
because it could be the drug. [yeah] Right, you know, just any change in your 
normal so that they know and it kind of [you can look at it] yeah, and it kind of, 
and I also pick on things that they might, or try to think of things that they might 
think are trivial or you know [yeah]. Like I usually say if you usually burp once a 
week and now you’re burping every day. [laughter] it could be my drug and not 
you. [that’s good you want them to pay attention to those things right?] Yeah. 
 
M: So what do you consider to be the most important factor then when you’re 
assigning causality? Is there any one thing that um? 
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S09: In terms of the drug [yeah] it’s probably like the temporal relationship, is that 
what you mean? [sure like of all those things that you look for. You think the 
timing is the most?] the timing. (significance of timing) I mean if it comes on 
within an hour of drug or within a day of drug or you know, there definitely has to 
be something around that temporal relationship. And then you always see what 
happens when you stop the drug and if it goes away [yeah] you know. 
Sometimes, and again, it depends on the severity of the AE whether you 
rechallenge or not. And things often, I mean we don’t know in terms, even with 
Phase 1 studies, some of them are, patients can continue on as long as they 
have stable or um, improving disease. So how long is too long? So they may 
have nothing in cycle 1 but then in cycle 4, so is it drug? [right] (concern for 
patients) You always look at, I mean there are always so many other 
confounding variables in this population, especially if their disease is starting to 
get a bit worse.  They go on other medication, right which can impact, you don’t 
know what these newer agents do with any of the other medications that are out 
there. There are just so many variables that can [yeah] affect,  drug-drug 
interaction you know and drug-disease interaction, drug-foods. I always make a 
point of asking patients are they on any over the counter or complimentary 
therapies because they may not think, well I’m not taking any medication but 
they’re on all these herbal or [yeah] just lots [lots of unknowns right?] (so many 
unkowns) 
 
M: Now I was just wondering if you could consider a scenario for me. [mmm 
hmm] Let’s say you’re treating a 65-year-old female patient with a confirmed 
diagnosis of metastasic breast cancer. And she’s in a Phase 1 clinical trial with a 
new investigational drug when she experiences a pulmonary embolism. How 
would you assign causality to the study drug if you knew that there was a 75% 
chance that it was related to the study drug and a 25% chance that it was related 
to other factors, say adjuvant treatment, disease progression, concomitant 
illness, concomitant meds. [hmm] Your scale is certain, probable, possible or 
unlikely. 
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S09: If there’s a 75% chance then I would say possibly.  [yeah, okay] 
 
M: Now what if there was a 50% chance that the adverse event was due to the 
drug and 50% chance it was due to other factors?  
 
S09:  I would still say possibly [yeah] because I would say possibly drug and 
possibly disease under study. [yeah, okay] Again you would have to look at what 
else, I mean if they’ve just recently been on a trip to Australia and in a plane for 
[right] you always digging for what else they were and I mean cancer patients are 
more at risk for that. 
 
M:  And what if there was a 20% chance that the adverse event was due to the 
study drug and an 80% chance it was due to other factors? [and what was it 
possible] Certain, probable, possible or unlikely. 
 
S09: Probably and unlikely, or possible. The first one should be probably when 
you’re saying [oh the 75%] yeah, yeah, 20% I would still say possible. 
 
M: So what do you think would be your lower threshold where you would say 
unlikely? 
 
S09: I mean 20% is 1 out of 5, so I don’t think that’s unlikely and I don’t think 
that’s an unlikely thing for someone to get. I would think if it’s a couple of 
percentage points then I would say unlikely. But when you’re looking at 1 out of 5 
I think that’s pretty high. [yeah] So I wouldn’t be comfortable saying in that 
situation that an AE is unlikely related. [so you said a couple of percent] Because 
even if we do um, we do our consents, um, when you’re explaining risk ah, 
common is 20% or more [right, okay]. So and then rare, you know there’s 
common, less common and rare and so if less common is less then 10% and 
rare is a couple of percents so [mmm hmm]. You know, if you were to say there’s 
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a rare chance that you would get a PE so I’m thinking low, like 1 or 2%. [okay] So 
I, I do kind of think back to that, that comes from the IB as well and what we know 
but yeah. [okay] (uncomfortable stating the AE is unlikely due to the 
protocol drug) 
 
M: Now given the choice would you prefer to grade causality as certain, probably, 
possible and unlikely or as a yes related to the study drug or no not related to the 
study drug? 
 
S09: I wouldn’t like yes or no. [you prefer the scale] Mmm hmm [why?] Just 
because you have that room to say that possibly, probably definitely and I think 
that helps overall than just saying yes or no. [mmm hmm, a bit of wiggle room] 
You need wiggle room and I would hate to say, if I only have yes or no then I’m 
probably going to pick yes more times then not.(errs on the side of caution) 
And I, I don’t know in terms of the drug development, I mean I’m sure there’s 
triggers for if you’re getting people saying probably, probably, probably versus 
unlikely, what you’re going to do right. [mmm hmm] So I wouldn’t say yes and no. 
[the scale maybe is a little bit more informative]. I think it’s more informative, it’s 
more informative for me. 
 
M: So what would you say are some of the problems or challenges when 
assigning causality? 
 
S09: You don’t know, in Phase 1 you don’t know what’s related to drug. In the 
later Phase trials you, you’ve got more data behind you but in the early Phase 
trials you don’t. So that can be, I think that’s a big challenge. [yeah] 
 
M: Any other challenges? Even logistical challenges or anything? 
 
S09: Well, I think you can overcall things that, and say that they’re related when 
they’re not. [mmm hmm] Um, and then that leads to for the drug companies to 
! #&"
sort out or, or you know, whoever the sponsor is in determining are these or are 
they not? And I think um, it would be beneficial at some point to follow through on 
the other end of things to see what it means when you’re on that end. [what do 
you mean on the other end?] (unknown consequences on the drug 
companies end- in terms of over attributing to the drug) Like a CRO getting 
this information in and saying now, you know, oh well what does that mean, the 
word, how you take it and what did they do with it from that point. Because I 
mean we submit the information but what happens on that side, but I think. (need 
for communication) 
 
M: So you think it would be nice to have some feedback and understand better 
how they? 
 
S09: Yeah, I mean, say you look at a company like you know AZ or Pfizer, 
Aventis, Novartis, any of the ones that we deal with a lot is to be in there and see 
what happens, what happens when they get all these AE logs in and what does it 
mean and. And having the source documentation there to support everything that 
you’re doing. 
 
M: Yeah, no, it’s an interesting question actually [good] that’s. 
 
S09: I think it would be beneficial for all of us maybe to spend a bit a time with 
them and see. Or even with the data management, I don’t know what they do 
with the data management part of it. [yeah] And I think it would help us 
understand part of what we’re doing too when you see how companies or CRO’s 
try to collate the information we send to them. And then what it can do in terms 
of, you know analyzing the study or. [yeah] 
 
M: What external influences or pressures have you felt from third parties when 
you’re assigning causality? 
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S09: Um, well they come back and say well are you sure that’s related? [mmm 
hmm] right [yeah] you know. No I’m not sure but I’m not willing to say it’s not, you 
know. 
 
M: Have you ever felt that you, have you ever been asked directly to change your 
causality assessment? 
 
S09: Yep, we have. 
 
M: How does that play out? 
 
S09: Well, that’s the investigator’s call [yeah] yeah. 
 
M: Any other pressures from third parties? 
 
S09: Not that I can think of off the top of my head. I think all of us are very aware 
that the fact that the information we submit is what um, you know, can carry that 
compound further or not, you know. And how important that is and how important 
that is that we gather it properly as it is specified in the protocol to get all that 
information in. Even missing lab work can be important because you could miss 
someone’s peak in liver function tests or whatever that could be a drug-related 
event. 
 
M: Sort of the pressure to keep the drug development process moving I guess. 
 
S09: Um, hmm, um, hmm. Yeah, very much so. And, and I think some of the 
pressures come around too is you know to put patients on study and sometimes 
that feels more, that’s more the goal rather than the safety of the patient. 
(pressure to progress study drug) I think we rely on the companies to monitor 
these studies and when they don’t, especially the early phase studies, and when 
they don’t there’s a huge problem with that. I’m not perfect, and they’re not either 
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but I think they then have the responsibility to monitor those studies and get 
those forms back into data management so they can make the proper queries 
that will probably, that could correct anything that you’re not even aware of. 
[yeah, okay] (mistakes are inevitable) 
 
M: From your perspective then what would make assigning causality easier? 
 
S09: If you knew up front whether it was related or not. [laughter] [to know the 
impossible of course] To know if was or not. [if we only had a glance] Well I think 
that’s, I don’t know in the early phase studies if I knew how to make it easier, I 
don’t know if there is a, you know. I think you look at the temporal relationship, 
that’s the big thing in Phase 1, if it was around when they got the drug well, looks 
like a duck, walks like a duck, talks like a duck, it’s probably a duck. [laughter] I 
don’t know, I don’t know how you would make it easier to assign causality. 
(extremely difficult process)You know like I say you go by the consent and the 
IB and, but I guess for everybody is to be aware of, you have to ask the 
questions and you have to dig. You can’t just say to the patient well did you have 
any toxicities related to the drug?, because they don’t know, they don’t know 
what their looking for you know. [right] (a lot of work involved-probing) The 
same thing if you’re looking for thinks like nail changes or something, well how do 
they know that they broke two nails last week that, that was just because they 
broke two nails or if that was because their nails are getting dry and brittle from 
the drug. [yeah] So you have, you’re always thinking of you know everything. 
Like, I just had a lady on a study who’s been on a Phase 1 study for nearly 3 
years [wow], yeah, she has a really slow growing tumor. But she um, has noticed 
over the last probably six to nine months that her hair was getting thinner. Um, so 
is it drug related?, I don’t know, it’s not listed in the IB, it’s not listed in the 
consent but nobody was on that drug either for nearly 3 years. So is it drug 
related?, you have to say possibly because [you just don’t know] you don’t know. 
So she said, so did the mice lose hair? she said, well we don’t know because it 
was tested on nude mice. [laughter] You tested a chemo drug on nude mice?, 
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how could you?, how will you ever know if we’ll lose hair?. She was just floored 
that the drug was tested on nude mice. 
 
M: And the mice probably didn’t get the drug for 3 years either. [that’s right] 
 
S09: So again, I don’t know. Is that, people as they get older their hair gets 
thinner [yeah] is that a part of it? I don’t know. But we have to say at this point in 
time that’s it’s possible related to drug long term, I don’t know. 
 
M: But it’s good that you’re recording it as that because it’s hard to get that long-
term data. [yes, that’s right] 
 
S09: And then if somebody else somewhere has that person and has another 
person on maybe they’ll see the same thing I don’t know. (others rely on 
reporting) 
 
M: So what I’d like you to do now is to read over the following questions and 
cross out any that you don’t feel are relevant to the Phase 1 oncology clinical 
trials setting.  
 
S09: What do you mean by conclusive report, do you mean by an AE or SAE, 
what do you mean? 
 
M: Um, well I didn’t actually write these questions. [oh okay] Um, these, this was 
a tool developed by a researcher named Naranjo [mmm hmm] to help clinicians 
assign causality [mmm hmm] and so I guess it’s however you would interpret it. 
So previous conclusive reports would be yeah I guess 
 
S09: Like from an SAE whether they felt there was some, a definite relationship? 
[I guess yeah] Okay, I wouldn’t cross out any. 
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M: You wouldn’t cross out any? okay. So now then would you mind just ranking 
them in order of importance, so 1 would be least important, 10 would be most 
important. [laughter] 
 
S09: Some of this you wouldn’t have when assigning causality [what is it] like I 
wouldn’t know there are conclusive reports and I might not know the 
pharmacokenetic [number 7 if the drug was detected in the blood?] mmm hmm. 
[okay] See we, when I’m assessing causality it’s kind of on the information I have 
at the time and you know you may not, you may not know this. 
 
M: And what about the previous conclusive reports, would, you wouldn’t know 
that? 
 
S09: No, you might not, you might not have them. [okay] 
 
M: I guess it comes back to how you interpret that right [yes] because you could 
just say oh well that means if it’s in the IB in which case you might, you would 
have that. [right] But, you’re thinking in terms of the safety letters? [mmm hmm 
you might not have it] okay, fair enough. [So ] It’s good to keep in mind yeah. 
There are no right or wrong answers it’s sort of a general. 
 
S09: They’re all pretty well, like all of these I would, I would think they’re pretty 
well part of  
 
M: You can assign them the same number, they don’t have to have all different 
numbers if you think they’re equally important. 
 
S09: I ranked them but [ok good] I wouldn’t, I think a lot of them could be the 
same. I would think this and these are like really important. [yeah, okay] And if 
there pharmacokinetic data is right up there that will really [that helps] oh yeah [if 
it’s available] if it’s available. Because actually usually when we see some toxicity 
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on there then we’ll ask for the PK samples to be shipped. And then we’ll look at 
them to see what, but then when I’m doing that note that day in clinic do I have 
that?, no. [right, right] And they want something assigned at that point in time, so 
that’s why I think you overcall them because you have to, again for the safety of 
the patient be, be over cautious and say possibly or probably related. (err on the 
side of caution) [yeah] Although you may modify it at that point in time and I 
think that, maybe that’s part of the time pressures is that you have to make a, an 
assessment call on that day that you see the patient with the, the data that you 
have at hand. Not looking into it you know down the line. [okay, good that’s great] 
 
M: Then lastly [mmm hmm] I would just like to ask you some questions about 
your experience as a clinical trials researcher.  So in which cancers do you 
specialize? 
 
S096: Breast. 
 
M: Now you have your, do you have a Bachelors then [yeah] in nursing. And 
when did you receive that? 
 
S09: 99. 
 
M:  And do you have a Masters?  [no] When did you receive your RN license? 
 
S09: 79. 
 
M: Do you have a diploma in nursing as well? [yeah] yeah and when did you get 
that? 
 
S09: Well ah 79. 
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M: And is there, are you a nurse practitioner? [no] no. Do you have any other sort 
of? 
 
S09: Certification in Oncology, yeah [is that the CANO?] yeah. 
 
M: And what year did you get that? 
 
S09: Oh, 2002/2003, 2003 I think. 
 
M: And what year did you become involved in clinical trials as a researcher? 
 
S09: Here? [well how long have you being doing] 95. [95 okay] 
 
M: So what percentage of your work time would you say is devoted to clinical 
trials then?  100%? 
 
S09: Well yeah. 
 
M: And then what percent of that is devoted to Phase 1 or 2 trials? 
 
S09: Well I was going to say because up here I do breast and I backup neuro but 
because I do Phase 1, I do them all. [oh okay] So I don’t consider myself an 
expert in all of them but I deal with a lot of [different types of cancers] yeah, yeah. 
So what was your other question, sorry. 
 
M: What percentage of your time is devoted to working on Phase 1 or 2 trials? 
 
S09: Right now, 80. 
 
M: 80% and then the other 20% would be Phase 3? 
 
! #&)
S09: Well actually, some of my breasts are Phase 2, 80 yeah [yeah] yeah. 
 
M: And then is the rest of your time spent on Phase 3? 
 
S09: Yeah [yeah, okay] 
 
M: Now, lastly I’d just like to ask you a little bit about the education that you’ve 
have received [mmm hmm] with regards to assigning causality. So can you tell 
me about any training that you’ve received specifically with respect to that? [with 
respect to causality?] Yeah, assigning causality. 
 
S09: Um, I guess it would just be at the start up of each trial, in terms of a formal 
course related to causality? [mmm hmm] I mean, they have sessions on it at the 
NCIC Spring meeting and you know different conferences that you go to. You 
know like the San Antonio Breast Cancer but I mean, that’s probably about it. I 
think that’s probably a huge gap [yeah] mmm hmm. (believes more training is 
need) 
 
M: So at each study start you receive some training? 
 
S09: They go over what, they go over adverse events and what they are [and 
that’s from the sponsor?] yeah. [so what an adverse event is] What an adverse 
event is, how they get logged in the form, you know, assigning grade, you know, 
even in terms of causality, I don’t even really know that they go over that much in 
causality, it’s just the fact that [they don’t go over it too much?] they really don’t, 
the fact that it’s more if it occurred on study or if it’s something new you know, 
then it’s an, call it an adverse event. But do they say assigning causality, it’s 
actually pretty poorly defined. Because I think even as you were looking for it the 
other day, it’s not even in there, over [definitions of the terms in the scale?] mmm 
hmm [yeah]. So I think that’s something that industry needs to, well not industry, 
it wouldn’t be industry, but all of us need to [come to some sort of consensus] 
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consensus on yeah. How do you assign not possibly or probably [yeah what do 
those terms mean] yeah. (feels there is a need for consistency) 
 
M: So what additional education about assigning causality do you feel needs to 
be made available to clinicians? So we just talked about the definitions [mmm 
hmm] on the scale. 
 
S09: And I guess what does it mean to the sponsor? When they’re, when they 
want, when they ask for unlikely, possibly, probably, what is the criteria that they 
are [yeah] wanting you to use to assign, to make that decision? What are they 
asking you to make that decision based on? (more communication needed 
with sponsor) 
 
M: So I think that’s all the questions that I have for you, do you have any for me. 
[no] Well thank you for the time you spent with me today. 
Subject 10 
M: So, what I’ll do is I’ll start by explaining exactly what it is we are doing [mmm 
hmm]. We’re looking at the way investigators, clinicians assign causality to 
adverse events in Phase 1 oncology clinical trials. And even the most 
experienced clinicians find assigning causality to adverse events challenging. But 
many groups, such as industry sponsors, clinical trial cooperative groups, 
research ethics boards, they all expect prompt and sensible causality 
assessments. But I’m sure as you know it’s not always straightforward and if 
done poorly can have large implications. So we’re interested in developing a tool 
to help clinicians efficiently and reliably assign causality during Phase 1 oncology 
clinical trials. And we feel that by better understanding your needs as a clinician 
we can make our tool more relevant to you. Do you have any questions before 
we begin? [no] Okay, so let’s say one of your Phase 1 clinical trial patients 
experiences an adverse event. Can you just walk me through how that process is 
handled? 
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S10: So normally they would be brought into clinic for an actual assessment, so a 
history and physical, so detailed questions of what the adverse event is, when 
did it occur, what are the specifics of the event in terms of the severity. What 
treatments if any have already been tried by the patient and if they have seen 
their family doctor for example. So what sorts of interventions have already taken 
place for the ah, adverse event. So just a, basically a thorough history in terms of 
the actual symptoms that they’re having and the treatment to date. And then a 
focused physical examination related to what the ah, adverse event is and um, 
so that’s what we would do in terms of seeing the patient in the clinic. And do you 
want it detailed right to the end? 
 
M: And then I guess you would have to assign causality at some point. 
 
S10: Yeah, so I would want to do some investigations, depending on what the 
adverse event is. And then depending on the ah, findings, assign the causality. 
[okay] 
 
M: And how do you go about assigning causality? 
 
S10: So I look to see what the adverse event is, is it something that is know. I’m 
assuming this was a drug trial, yeah, is it something that is expected from as a 
known side effect of the treatment. (assumes its a result of the drug) Um, 
temporal relationship to, to the drug. 
 
M: Now can you explain what you mean when you say a temporal relationship? 
 
S10: When did it occur, so if it occurred before they even got the drug well then 
that ‘s not going to be related to the, to the drug. However if it occurred a few 
hours after and it’s happened repeatedly after taking the drug then you can see 
that it’s associated with a certain time element related to taking that medication 
and that sort of temporal association makes you more likely to suspect that, that’s 
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related to the, to the medication. (use of temporal association) So those are 
the two big things in terms of the, assigning causality. And then just looking to 
see how severe it is [okay] and what intervention needs to take place from our 
end to deal with that. You know, stopping the drug or supportive treatments. 
 
M: And so what are the resources you refer to when you’re assigning causality?  
 
S10:  I’ll be honest and say I don’t really have any [really]. I don’t have any tools 
that I use, I just know from taking part in the studies that you ah, look at the key 
features that have already been mentioned in terms of the relationship to the 
study drug, timing, reproducibility, that sort of thing. So it’s more on a, just based 
on the experience of taking part in the study and the hunch factor. I don’t actually 
have a tool that I use, so I think something like this would be very handy. [okay] 
(uses own experience, but feels a tool would be helpful) 
 
M: When you’re determining the expectedness of the adverse event though 
[mmm hmm] you’d probably have to… How would you determine that? 
 
S10: Well it depends on the pre-clinical information, what we know already from 
um, earlier studies. From patient volunteers who have been on the study, who 
have been on the drug, so if you know that rash has been seen in patients before 
this, this study then that’s something you can expect. Or from other agents that 
are similar, if you’re testing drug x and drug y is similar to it and it’s been reported 
that it has a rash for example then it’s not unexpected. Knowing the mechanism 
of action of the drug, you can postulate that there are certain expected side 
effects if you have a drug that affects your blood vessels and bleeding is 
something that you could logically expect would be an adverse event. [mmm 
hmm] So ah, just based on the biological plausibility factor as well in terms of 
assigning the, the adverse events.  
 
M: Do you refer to the IB at all? 
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S10: Yeah, yeah that would be available. 
 
M: What general guidelines do you follow when you’re assigning causality, are 
there any sort of rules of thumb that you, you know, you said you sort of go by 
your … . 
 
S10: You can look at it in terms of unexpected, probable, possible, the usual five, 
unrelated and what not. 
 
M: And do you personally have any kind of [how do I assign?] yeah. 
 
S10: Not that I can admit to quite honestly. It’s basically just that you know, if it is 
something that’s recorded in the IB or in previous studies then yes we would put 
that as expected or probable. Otherwise if there’s any kind of concerns, then 
possible, you know if they got it, if they got the adverse event before they even 
got the medication or there doesn’t seem to be a temporal relationship, then 
unexpected. 
 
M: Now of all those things that you mentioned you consider when you’re 
assigning causality, what do you feel is sort of the most important factor? 
 
S10: To put a weight on it, I think more the biological plausibility, is there a 
mechanism that you can see as to why you would have that reaction? It makes 
scientific sense that this could be an adverse event related to that particular drug. 
And the temporal association, the timing of the reaction. Often sometimes with 
people, you do a little bit of a drug challenge where you see if it comes again. 
Like if they have the reaction and it’s a drug that they’re getting daily, well you 
stop it for a little while and see if the reaction goes away and then you re-
challenge and if after a couple weeks it comes back, well then you’ve got your 
temporal association right there, relationship there. [okay] 
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M: I just wanted to ask you now if you could consider a scenario for me. So let’s 
say you’re treating a 65-year-old female patient with a confirmed diagnosis of 
metastasic breast cancer. And she’s in a Phase 1 clinical trial with a new 
investigational drug and she experiences a pulmonary embolism. [mmm hmm] 
How would you assign causality to the study drug if you knew that there was a 
75% chance that it was due to the study drug and a 25% chance that it was due 
to other factors, say disease progression, concomitant illness, [mmm hmm] 
concomitant meds and the  scale is certain, probable, possible or unlikely? 
 
S10: I would say probable, just based on the 75% likelihood, but with her 
underlying malignancy she’s at risk for developing a DVT, pulmonary embolism 
regardless I wouldn’t say certain based on that feature.  [okay] 
 
M: And what if there was a 50% chance that the adverse event was due to the 
study drug and a 50% chance it was due to other factors, how would you assign 
it then? [so with certain, probable] possible or unlikely. 
 
S10:  I think I would still say probable in that situation. 
 
M:  And what if it was a 20% chance that the adverse event was due to the study 
drug and an 80% chance it was due to other factors?  
 
S10: Possible. [possible, yeah] 
 
M: And you know, what sort of, I know that you never really get these 
percentages in real life, it’s very hypothetical but what would sort of be your 
threshold for unlikely? Can you think of [in terms of percentage?] yeah. 
 
S10: 10 [10 or less yeah] mmm hmm. 
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M: Just to get an idea of where people are coming from, it’s purely hypothetical. 
 
M: And given the choice would you prefer to grade causality on a scale like I just 
gave you [mmm hmm] or a yes related to the study drug or no not related to the 
study drug? 
 
S10: I like the scale because yes/no is pretty black and white and often there are 
many scenarios where you’re just not sure. 
 
M: What would you say are some of the implications of assigning causality 
poorly? 
 
S10: I think the biggest implication would be that if a drug gets attributed to have 
a set of adverse events that are quite serious then that may preclude further 
study of that drug, that might stop the trial.  And if you’re looking at a dose 
escalation study where you’re escalating to your next dose based on the 
tolerated dose, you’re now saying that there’s some side effects. Well you might 
not go to the next dose level, or you’re recruiting more patients to that particular 
cohort level so subjecting more people to the drug than may be necessary in a 
clinical trial. So the issue of not, of a potentially very good drug not being taken 
further because of the concerns of the adverse events, that’s going one way. And 
the other way if you don’t attribute the causality, a potentially dangerous drug 
could come to market without the proper, or with concerns about adverse events. 
(consequences of attributing causality poorly) 
 
M: Have you every seen anything like this before or can you give me an example 
of anything? 
 
S10: Well I mean you can think about the whole issue of the Cox 2 inhibitors in 
terms of the cardiac events and the whole issue of attributing causality perhaps if, 
in the earlier studies that was something that was strictly monitored it might not 
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have gotten to the point where Vioxx had to be pulled off the market for example. 
A lot of those events only came to light once the drugs were well into the 
community. So that would be the big one that comes to mind. 
 
M: And what about personally within your area of oncology, have you every 
witnessed anything like that or … not, not like the Cox 2’s but just you know 
maybe experienced a trial that was halted? 
 
S10: Well I can think of the ah, one particular study ah, letrozole plus CCI779, 
one of our Wyeth industry studies where it was stopped because of lack of 
efficacy, concerns of some adverse events I believe. It’s the only one, recent one, 
that comes to mind. 
 
M: And were there causality issues around that? 
 
S10: Not that I know of, I wasn’t ah, I was on maternity leave when that study got 
stopped so I’m not sure of the circumstances around it. Kind of heard about it 
second hand when I came back to work and said I think I have a patient for it and 
learned that it was closed. [oh, right, okay] 
 
M:  What would you say are some of the challenges when assigning causality? 
 
S10: I think the biggest thing is determining the actual act of assigning causality. 
(big statement) You’re never really 100% certain so the whole issue of probable, 
possible, you know, I think we kind of have an idea of which way it swings, it ‘s 
just the degree of certainty. [mmm hmm] Whether you think it is attributable to the 
medication at hand. 
 
M: So it’s difficult to even know what your degree of certainty is? [mmm hmm] 
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S10: Often these patients are just, have such complicated histories, you know, 
they’re prone to other medical problems. Particularly I find the difficulty is with the 
thrombotic events is a big one in terms of, is that because of their underlying 
cancer where they’re already prone to clotting issues as opposed to the 
medication. And how much is the medication increasing their already baseline 
risk of having those kinds of events? [yeah, yeah, okay] Older patients with 
cardiac events, the same sort of thing, if you’ve got someone with diabetes and 
high blood pressure and other cardiac risk factors, the same issue of how much 
is the medication increasing their baseline risk for a coronary event. 
 
M: What do you think might help in that situation? 
 
S10: Boy wish I knew [tough question] yeah. I mean certainly for the coronary 
events if you had an assessment perhaps by a cardiologist you could say that 
this is their baseline risk of a cardiac event. And if you knew that beforehand that 
would certainly help with, with that side of things. Certainly from the cardiac point 
of view I could see that would be helpful but for most events I don’t know that you 
could get a similar assessment and say you know this person’s risk, baseline risk 
is x% and the drug will increase it by 20% or 30%. 
 
M: What are your concerns about how clinicians are currently assigning 
causality? 
 
S10: Well I think just the fact that there, there isn’t a systematic way to do it, that 
it often is based on hunches and feelings as opposed to a rigorous method or 
measurement tool. 
 
M: Can you give me an example of when something you know, when you assign 
causality based on a hunch or a feeling? 
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S10: Well I can think of one where the person had a lot of diarrhea after their 
chemotherapy, but mind you they had had quite extensive bowel surgery so 
they’d had some difficulty with diarrhea before they even came on the study. Yet 
diarrhea is a known side effect of the medication that they were on so you know, 
how much was it increased from their baseline? So that was more based on a 
hunch in that situation. [yeah] 
 
M: And how did you assign causality in that case? 
 
S10: Well probable, because of the, the knowledge that that particular drug, 
diarrhea was something that was seen. 
 
M: And what external influences or pressures from third parties have you felt 
when assigning causality? 
 
S10: Well if you’re involved in industry studies then certainly there’s some 
pressure from, not so much for assigning causality but continuing. So if you’ve 
had someone who has had an adverse event and you want to dose reduce them 
or hold off treatment for a little while sometimes there is that pressure to continue 
with the study. (feels pressure to move drug forward) So in that sense you 
could think well maybe if you had assigned them a possible as opposed to a 
probable relationship then you could, you could be pushed to continue with the 
study. But you always have to keep the patient’s safety in mind [right] at the end 
of the day so, so that’s what you go by. (however, patient safety is most 
important) 
 
M: So if the patient, if the SAE was downgraded from a probable to a possible 
[mmm hmmm] that would mean the difference between the patient continuing on 
or 
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S10: Continuing on the study or possibly coming off the study, that again would 
depend on the side effect, and the severity of it, depending whether it’s treated or 
resolved, the outcome of the, the adverse event. But I must admit I really haven’t 
had that much pressure in terms of treating the patient. It always comes down to 
the patient’s safety and that’s what you go by. [okay] 
 
M: From your perspective what would make assigning causality easier? You said 
you know, maybe a tool would help [mmm hmm] that would sort of make it a bit 
more systematic. 
 
S10: I think more information about, and it’s difficult because these are Phase 1 
studies so this is the first time you are testing it in patient, patients. Better pre-
clinical data in terms of the data of these mechanisms of these medications so 
that you could, the whole biological mechanism of action so that you can think 
that well maybe this is something that makes sense and foreseeably cause some 
of these adverse events. That certainly would be helpful for assigning causality. 
[yeah] Does that mean more pre-clinical studies or better assays or information in 
terms of the, the way these drugs work? Because often times we really don’t 
know, we think it’s one particular way and then these other side effects come to 
light. And you’re wondering well, that doesn’t make sense, why would they get 
this side effect and then you do some more bench top work and find out that well 
okay, it may also be affecting this pathway and so that makes sense in terms of 
the side effects. 
 
M: Now I would just like to ask you if you wouldn’t mind completing a little 
exercise for me. So if you could just read over these questions and cross out any 
that you think aren’t applicable to the Phase 1 oncology clinical trial setting.  
 
S10: They’re all pretty relevant. 
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M: Then, now if you could just rank them from least important to most important 
from your perspective, there’s no right or wrong answer. 
 
S10: Should I just put the numbers right here? 
 
M: Yeah, if you don’t mind, so least important is 1 and most important would be 
10 and you can just kind of arrange them in order. [so most important is 10?] 
Yeah. Okay awesome. So number 10, question number 10 you ranked the 
highest as being the most important. So was the adverse event confirmed by any 
objective evidence, what, what did you interpret objective evidence to mean 
there? 
 
S10: Well actually any physical findings for example. 
 
M: So could you give me an example of something like that? [like a rash] okay, 
so if you actually saw the rash or something [mmm hmm] okay, good. And then 
the lowest one you ranked was did the reaction reappear when a placebo was 
given [mmm hmm], why did you rank that one lowest? 
 
S10: Thinking that sometimes you can have a reaction, I mean because they 
have a placebo for example, let’s stick with the rash scenario, you can get a rash 
from two completely different drugs, it doesn’t matter that, I mean you get a 
reaction to drug x and a reaction to drug y. The reaction to drug y doesn’t 
necessarily have anything to do with the other. So for example they could be, in 
that example they could be someone who is prone to rashes or that drug brought 
it out so. It was more that in the grand scheme in all these points it seemed to be 
the least important to me in terms of the causality. [okay, great] 
 
M: And then are there alternative causes (other than the drug) that could on their 
own have cause the reaction?, that wasn’t too important either. 
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S10: Again, important but just out of all the others felt it to be lower. [okay, good, 
great, thanks] 
 
M: This is actually a tool that was developed by a researcher named Naranjo. 
[mmm hmm] And the thought is that maybe we might modify this [mmm hmm 
that’s very good] to make it more relevant to the oncology setting. Were there any 
questions here that you felt were missing, there should have been something 
here that wasn’t. Something that you think about when you’re assigning causality 
that you didn’t see there. 
 
S10: Nothing that comes to mind off hand, it’s pretty thorough. 
 
M: Then I just need to ask you a little bit about your experience as a clinical trials 
researcher. [mmm hmm]  So in which cancers do you specialize? 
 
S10: Breast and GI [breast and GI] 
 
M:  So you have your MD [mmm hmm] what year did you get that? 
 
S10: 1996[1996] 
 
M: And when did you receive your medical oncology license? 
 
S10: Um, 2000, sorry 2001 [2001] 
 
M: And do you have any other, do you have a Master’s in ClinEpi [yes I do] yeah, 
what year did you get that? 
 
S10: 2004 [was that here at Mac?] Yeah. 
 
M: And then any other sort of education that you have to do with clinical trials? 
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S10: No. [no] 
 
M: And what year did you become involved as a researcher in clinical trials? 
 
S10: It would be about 2001 on my own?, because part of my fellowship I was 
doing research so would I include that [oh okay] as well? [sure yeah] so that 
would be about 2001. 
 
M: And then overall what percentage of your work time would you say is devoted 
to clinical trials then?   
 
S10: About 30%. 
 
M: And then of that, what percent is devoted to Phase 1 and Phase 2 trials? 
 
S10: Um, Phase 1 and Phase 2, about half. 
 
M: Okay, so 15% and then the other 15% would be for Phase 3? [yeah] 
 
M: And have you been, you’ve been a local PI before [mmm hmm] on a trial? 
[yeah] 
 
M: And now, lastly I’d like to ask a little bit about the education that you’ve have 
received specifically to do with assigning causality. [mmm hmm] So can you tell 
me about any training that you’ve received specifically for assigning causality for 
adverse events? 
 
S10: Just basically the investigator meetings related to some of the studies [okay] 
There was a little bit of a workshop attached to the meeting in terms of the basic 
science background of the drug, the mechanism of action, what the expected 
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side effects are from other studies of the agents. And going through the causality 
forms. Quite limited. [mmm hmm, okay] (feels training was limited) 
 
M: What additional education about assigning causality do you feel needs to be 
made available to clinicians? 
 
S10: I think having a workshop that’s independent of any particular study or study 
sponsor, just in general on oncology drugs and assigning causality would be, 
would be useful. 
 
M: And do you think that would be good for just clinicians or all [anyone involved 
in conducting clinical trials] clinical nurses too [trials yeah]. What would be 
covered there then in that sort of a workshop, what would be helpful. 
 
S10: The key things to look for in terms of assigning causality that’s ah, what are 
some causality tools, those are the two big things. [okay great] 
 
M: Well I think those are all the questions that I have, I really appreciate the time 
that you’ve taken to speak with me today. And um, is there anybody, we’re also 
interviewing clinical trials nurses to so, is there anyone that you recommend we 
speak to? 
 
S10: In terms of the Phase 1 studies [yeah] I know ST is involved in a lot of my 
Phase 1 studies or AI and then any of the Phase 1 trial nurses, you can get that 
list from B in terms of [yeah, I think I have] probably have them. [yeah, I’ve got S 
and I’ve got A so that’s good, thank you] 
Subject 11 
S11: I find it is a little bit tough sometimes just because, yeah, I mean that’s 
where all my training is and I can’t use that so I do find that a bit frustrating.  
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M: So you’ve got that nursing background but [exactly] in this model of care 
you’re not able to. 
 
S11: No and which ah, I have since found out and I am very, still relatively new to 
the department, I’ve been here for just 10 months. [yeah] Um, and since I’ve met 
so many other people from different centers at meetings that I’ve gone to, our, 
like you said, our model is much different [yeah] than other centers. We don’t 
have “clinical trial nurses” that just work in clinical trials [right] and just do, except 
of course, for myself. So in that department it’s much different, when we take on 
Phase I studies and things of that nature we have to find the most appropriate 
hands-on nurse down in the clinic who tends to be Dr. B’s primary nurse, his 
name is xxx xxx. So he has agreed to work with her and myself on the early 
phase studies. [okay] So again, it’s a little bit different, he is not a clinical trials 
nurse he has just agreed to work with us when there are trials that need 
somebody to dedicate essentially most of their time to them. [oh, okay] So it’s a 
little bit tricky, it’s a little bit tricky and there are a lot of hands in the pot but a lot 
of the times, just because we have to coordinate everything together instead of 
me just performing those functions. [right] Which I am qualified to do but can’t. It’s 
just a bit tough, it’s a little bit tough in that way [okay] yeah. 
 
M: So can you just explain to me then what happens or how you handle, just 
walk me through the situation of one of your Phase I clinical trial patients [okay] 
who has just reported experiencing an adverse event. How, how does that work 
in your model? 
 
S11: Just so you know, the one Phase I study that we’ve opened since I’ve 
actually been here, we haven’t been successful at accruing anyone. [okay] Um, 
but it would be very similar to any of the other trials. I’m currently doing a couple 
of Phase II, and I just got done an IND trial. So essentially the person would 
report back to me and probably also D and Dr B as well, three different times. 
Typically I like to see the patient first so that they, sorry, D would actually see the 
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patient and initially bring them into the clinic or doing what he would be doing 
with them. I would see them next and then the physician would see them last. 
Um, after the time we had, each person had seen the patient, when we come 
back out into the clinic area, the physician and I as well as the nurse would 
discuss what the patient had told us. And at that point it would be, usually at that 
point it would be determined, do we concur or does the physician think that it is 
attributed to study drug or not. So it’s usually right after we see the patient we 
would discuss it and make the causality at that time [right, okay] so. 
 
M: And so what are the factors that you’re considering when you’re making that 
assessment? 
 
S11: Baseline, um, typically, so what they’ve reported at baseline or their 
previous medical history. Um, anything that they had been experiencing up to 
that time as well as have we been seeing um, I mean depending of course, on 
what cycle they’re in, or how many treatments they’ve received, is this something 
brand new that we can actually say it seems to be coinciding with the infusion or 
injection of drug. Is this something that each week when they get that infusion it’s 
been getting worse, it’s been getting better. Um, good example, like I said, I just 
finished an IND study and we had a gentleman, liver cancer was his primary, um, 
never had problems with rashes, itchiness, that sort of thing, and day one after 
his first infusion he developed a rash desquamation. Um, and each time it 
actually, each time he got his infusion every three weeks, it again would 
reappear, um, actually the severity would increase each time. Um, so at first our 
process, in that instance, at first we didn’t know, we thought possibly but it was 
unknown. The second time it was, well you know, now it’s a possibly we’ve seen 
it twice now, and it seems to be getting worse with each infusion and essentially it 
went up to, he ended up getting only four infusions but at that point it was 
definitely related because he hadn’t, he didn’t experience it in-between. It was 
just the first four days following the infusion, it would go away and again once he 
got the infusion, four days following he would get it again. Um, so a lot of timeline 
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things, a lot of timeline things and checking back in their medical history to see is 
this something they’ve experienced before or is it brand new with the infusion of 
the investigational drug? [okay, that’s great] (timing of AEs plays a crucial role) 
 
M: Are there any other things you consider when you’re assigning causality? 
 
 
S11: Again, unfortunately it’s not really my department, ah, um, the IB of course, 
you know, what’s expected to be related to these drugs. Um, if nothing is 
mentioned I do, and again this is something that separates me a little bit from my 
coworkers in just, I will also check out the class of drug. Are there any sister 
drugs or closely related drugs that produce similar or that are expected toxicities 
for that? (feels she goes beyond coworkers, but looking into the class of 
agent) 
 
M: And where do you go to look that up? 
 
S11: CPS, I use a lot of, also our Cancer Care Ontario Handbook, I search 
MEDLINE Plus, there are a couple of cancer websites that I use also. Um, I don’t 
know the name of them off hand. But in terms of chemical make up I will look into 
that too. Of course I don’t get to make that decision but I make those suggestions 
to the PI, is this a possibility that it could be related to the drug? [okay, great] 
 
M: And then um, do you know of any tools that are available to help in assigning 
causality? Have you every used any sort of a decision tree or an algorithm or [no] 
something like that? No. [no] Do you think that would be useful? 
 
S11: I do think that would be useful um. (feels a tool would be useful) 
 
M: When wouldn’t it be useful? 
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S11: Um, it’s hard to say, I mean everybody is so very individual right. So even 
though it’s nice to have algorithms and schemas, that sort of thing um, everyone 
is going to react to everything differently. (hard to compensate for individual 
variation within a tool) And of course it depends on the medications they’re 
already taking, their con-meds and pre-existing conditions. Um, so I can’t really 
think of a specific, a specific time that it wouldn’t be appropriate, but of course it’s 
going to be, you can’t lump everything into one big catchment area, it would have 
to be individual for each patient, unfortunately, which [mmm hmm] I’m not sure 
would be feasible. [right] (feels tool needs to be focused around the 
individuality of each patient) 
 
M: What do you feel are some of the major challenges to assigning causality? 
 
S11: Um, I mean the chemical makeup of the drugs and I mean it’s not 
necessarily, I mean I’m certainly not claiming to know every drug off hand and 
what, even common side effects, things like that. I think being just that little bit 
removed, my entire department, not just myself but my co-workers also in that 
um, again I’m the only one with oncology training per se. Um, but even myself 
it’s, it’s not always possible to know exactly each drug and all the drugs and all 
the new drugs that are coming out. Every year there are new regimens as well as 
anti-emetic regimens that go with specific chemotherapy regimens. Um, yeah, so 
again everything is, is so highly variable even you know, what treatment did you 
get before in combination with this one? A lot of the times I find it’s hard and I 
don’t think it’s an on purpose thing from patients, but I don’t necessarily think that 
we do get every single bit of information all the time. [yeah] I think different things 
are reported to different people, depending on your position, whether that be 
chemo nurse, clinical trials nurse or the physician. 
 
M: So how does that differ, can you just give me an example of a time when 
that’s happened? 
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S11:  It happens quite a bit you know where the patients will tell us in clinical 
trials that they feel great, a little bit of pain here and there, that’s sort of thing. 
And then you read the physician note or you discuss with the physician after their 
meeting with the patient and they’ve been having nausea, swelling, you know, 
intermittent boughts of cough, that sort of thing. So I think it definitely depends, 
again, very individual, depends on the patient, depends on your personality, what 
you’re asking. If you’re asking the appropriate questions or not, I think that that 
makes a big, a big difference too. 
 
M: So getting sort of consistent and reliable information from patients [yes] is a bit 
of a challenge [yes] in assigning causality. 
 
S11: I think so, I think so, I would like to think that that’s just not here, that, that 
would be everywhere. [you’re not the first person to say that, don’t worry] Um, 
even working on the in-patient floor, it’s very different, even nurse-to-nurse, even 
minute-to-minute. Um, you know, one person might go on break and lo and 
behold you know, something new pops up that you know the actual attending 
nurse had no idea about. Um, I think, personally I think rapport is one of the, the 
biggest things and whichever, whichever clinician that may be. I don’t know how 
you would actually streamline that into making sure that everybody is getting all 
the same bits of information. [mmm hmm, a challenge] I don’t know that, that 
would be possible, [yeah] human nature, right so. [right] 
 
M: Any other challenges that you can think of when it comes to assigning 
causality? 
 
S11: Well I mean I think it’s tough too when the drugs are so new and there’s not 
a whole lot of things known about them. I think it’s very, very different what a drug 
has been showing in the lab or with test animals as opposed to humans. Um, I 
think even site to site things are very, very different.  
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M: How so? 
 
S11: I think, again I think that processes, process is pretty huge in things. So 
actually your centre and our centre I think are very, very different in that, I 
believe, and correct me if I’m wrong, that nurses in your chemotherapy centre are 
trained to put in pic lines and things like that. [mmm hmm] Here that’s not done, 
it’s actually done in interventional radiology, it’s a surgical procedure, it all goes 
through there. [okay] So I know at the Juravinski Centre they’re showing some 
sort of side effects and again we haven’t put any patients on. Some side effects 
I’m not sure how that’s being attributed to the study drug but I have to wonder if 
certain processes maybe show different things. 
 
M: So you’re wondering because the nurses can put in pic lines [that’s just the 
only example I can] yeah, that’s a good one [yeah] but could that somehow 
explain some things. [exactly] 
 
S11: All, I know very little about what’s actually going on at your centre only 
because, obviously we are so far apart and your girls are so busy there working 
because they have quite a few patients on study. Um, but I do know that quite a 
number of people have had pic (PICC?) line infections and that sort of thing and 
have had to come off study drug. And I would be very interested to see if it’s the 
same thing here. Um, so again I don’t know how causality has been, like how it’s 
been determined or what it has been determined to be in, at Juravinski. But I 
would really like to know and I’m interested to see what happens here. And do 
those, they’re underlying processes that we might not be considering, but do 
those things, whether it be procedures done by intervention or even past, past 
procedures, does that have an effect on how patients react to the drugs and do, 
are we taking that into consideration when we’re assessing causality? [yeah, 
mmm hmm] Because I think every centre is so very different and I think we all 
don’t really realize it until we visit another site. [that’s a real challenge] 
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M: So what do you think would help in assigning causality, what sort of things do 
you think would help? [yeah] Let’s just talk about the differences in the processes 
between sites. 
 
S11: Um, for me it’s been nice, again, I haven’t had any patients on our Phase I 
study but for me it is nice that A takes it upon herself to call me and let’s me know 
what’s happening with her patients. And I know again, that’s not very feasible 
when you’re running studies that are multi-centre and quite multi-centre, 10 or 
more. I mean it might not be possible to correspond on a regular basis. 
 
M: Are you referring to the clinical trials nurse at the JCC? [yeah] Axxx [yes, 
yeah] 
 
S11: So I mean, we, there are only three sites that are participating. I know that 
they have been having teleconferences every Thursday morning I believe, um, 
where they discuss things. A she has [announcement 14:14] called me and 
we’ve discussed what’s been going on with her patients, do you have any hints 
or tips I can tell my patients? For me that’s great in terms of well maybe we 
should be watching out for these certain things. Again, I didn’t ask her about 
causality but maybe she wasn’t aware either. [right] Um, I find personally that 
correspondence from site to site [really helps] yes, it makes a big difference. Now 
in terms of the investigators, I don’t know how much difference that would make 
for them. (feels communication from site to cite is more beneficial to clinical 
trial nurses) So here they would be the ones actually assessing the causality. 
But for me it’s nice, it’s nice to know, kind of a heads up as to you know this could 
happen, it’s happened here it could happen there. That would be helpful I think, 
just having some sort of a streamlined process into, coordination and 
communication with other sites. That’s really the only other study I’ve been 
involved in where I’ve had the opportunity to do that on a fairly, not really, a fairly 
regular basis. So it’s nice, it’s a nice option. [good] 
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M: What about in terms of gathering information from patients and kind of 
overcoming that challenge, what do you think would help there? 
 
S11: Oh gosh, it’s hard to say, again, every patient is different. Some patients, 
um, some patients I think it’s easier to leave everything open and let, just leave it 
as a blank slate, let them tell you everything that’s been happening. Um, some 
patients if you do that won’t tell you anything. So some patients, not prompting 
but some patients you need to I think go through a list of questions and ask them 
about specific side effects, problems, even possibly body systems and leave it 
open that way for them to suggest things to you. Um, again, um, I find it’s, again 
reporting is very different from person to person in terms of the clinicians. So I 
have to wonder would it be detrimental or beneficial to go in together in terms of 
clinical trials nurse or clinical trials associate as well as physician? Go in and do a 
small portion of the assessment together [mmm hmm] even if it’s an AE or 
toxicity assessment before the physician does their full physical, things like that. 
Um, just so there’s a general consensus and everybody can talk about it together 
to really understand what, what the patient is experiencing. Um, and again I think 
that’s very subjective for the clinician also the way the patient describes things. I 
could consider it a grade 2 whereas the physician could consider it grade 3. I 
realize here that the physician overrides our opinion obviously, which makes 
totally, total sense. [mmm hmm] Um, but again, if it’s very different [yeah] grade 1 
to grade 3 it’s hard to, to determine where it’s really falling [yeah] one extreme or 
the other or right in the middle like a grade 2.Um, so I wonder if maybe 
collaborating a little bit more in terms of doing the AE assessment together if that 
might make a difference. [okay] 
 
M: Is there anything else that you think might be helpful in terms of making that 
whole causality assessment process a little bit easier or streamlined? 
 
S11: Um, yeah, depending on how much you know about the drugs specifically 
and whether that be through the IB or safety reports or what have you. Um, I 
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think giving the patient a little bit of background knowledge first and giving them 
an idea as to, you know, instead of just leaving it very broad category, well you 
might experience some nausea, but maybe making it a little more specific in that, 
not too specific because obviously they have a lot of their plate. But more specific 
in you know, essentially what, what we would consider being very serious. Not 
that we don’t do that already, but maybe just making the lines between, that 
might be hard to do, between gradings. [mmm hmm] You know, there is a really 
big difference between feeling a little bit nauseous in the morning and feeling 
nauseous to the point that you’re vomiting 14 times a day. But actually explaining 
to them those differences and why we consider them so different. And how 
important it is to tell us all those little things, things that you know precluded it or 
made you feel better, that sort of thing. The professional asking the patients 
questions can really impact the decisions being made by the information 
they solicit) But being, I think maybe just a little bit more specific with the 
explanation of things to patients. Again, I’m not really sure that’s optimal 
especially considering how, you know, little time everybody has these days. And 
again, a lot of these patients, it’s, it’s fairly new in that, they’ve either just been 
told their palliative or that they even have this disease or that sort of thing. Like 
maybe it’s not appropriate at that time. So I think that, that would be a little tough, 
but maybe giving the patient a little bit more information to work with [right] might 
make it a little bit easier to understanding how important it really is for us that 
they tell us everything. [mmm hmm] I think that, that’s um, and I think a lot of 
patients don’t want to disappoint which I think is really too bad. And you can say 
it over and over that we need to know for your own safety, but I find that a lot of 
patient’s they [who don’t they want to disappoint?]. I think their physicians they 
don’t want to disappoint, um even probably clinical trials they don’t want to 
disappoint. I also think too um, in Phase I situations where, not always, but a lot 
of the patients are end stage palliative, they’ve, a lot of them have come to a 
point where there aren’t any other treatment options. I think it’s a distinct 
possibility that they could very well minimize things because what they’re thinking 
is I’m not going to have another treatment option if this fails me. Which is part of 
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what I experienced with, with one of my IND patients, um, [tell me about that]. He 
was actually the gentleman with the rash. He found out, not even a year ago that 
he had essentially stage IV liver cancer, young guy, early 50’s, was finding it 
really hard, even though he had a history of cancer in his family, was finding it 
very hard to come to terms with the fact that he was sick. Very much a go, go, go 
type person, worked every day, all day, never slept by choice, just because he 
liked to keep busy and do as much as he could with his life. Um, so once the IND 
study failed him, um, I mean he told me every reason in the book why, even 
though according to our, our measurement criteria, he understood that he had 
progressed according to the study. But he felt great, you know, I don’t feel 
unwell, I don’t have pain, I’m not sick from the chemo, I have, you know, could 
we not just do one more, could we not do more? Um, so I think in terms in 
patients coming to terms of what that means to them, especially, again, 
especially in early studies where you want the least sick of the sickest people. It’s 
a tough population to round up in a place like this because we are a relatively 
small centre in the realm of things. (Patient education would aid in attributing 
causality) Um, you know, have a huge population like that but like I said, I think, 
you know, having younger patients who essentially are told they don’t have any 
other treatment options, I think that’s tough for them especially when you’re going 
to be taken off treatment because of toxicity. I think that’s hard [yeah] I mean I 
think it’s hard for everyone involved, but for a patient to admit you know, even 
something as simple as nausea or something we might take for granted like 
vomiting. Um, that can easily take you off study but for a patient who knows there 
is nothing else out there I think that can be pretty devastating. [yeah] So I could 
[so that would maybe lead to them minimizing] I think possibly [the adverse 
events that they’re experiencing?] I wouldn’t be surprised if it didn’t. [okay] 
 
M: I just want to talk a little bit about, what do you think the implications are to 
assigning causality poorly? 
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S11: Oh, I think there are huge implications, huge. Um, I mean to start out with 
the very basics, a lot of, a huge workload involved, um, in doing it poorly and that, 
I mean it could be anything. Just from the workload involved in SAE’s, even the 
reporting, all the different avenues it needs to go through. Um, an implication 
could be the fact that drugs aren’t being marketed or aren’t moving on to different 
phases of trial because causality has been improperly assigned. It could also on 
the very opposite side of the spectrum, it could also lead to harmed patients, it 
could lead to death in patients. A whole array of things, I mean it could obviously 
affect the statistical analysis of the study, it can affect everything. I think that’s 
huge to be quite honest with you, I think that there would be (misattributions 
have serious implications) 
 
M: What are your concerns about how clinician are currently assigning causality, 
do you have any concerns? 
 
S11: Um,  not specifically, nothing specific but I think it would be very possible 
and again I don’t know again exactly how other centers work. Um,  
 
M: Just in your experience have you had any concerns about how it’s been 
done? 
 
S11: I think it could be possible that maybe things could get not necessarily 
overlooked but a very quick look, take a quick glance at you know, maybe what 
somebody else has written. [mmm hmm] Um, and you know it’s very easy to just 
sign your signature and walk away. (feels those you sign off on attribution 
don’t give the study the attention it deserves) Um, I think that, that could be a 
problem, um, I also think it could very well be problematic if things get lumped 
together. Oh, patient A experienced this and I thought it must be related so if 
patient B is experiencing it, it must be related too. And again, I don’t know how 
often physicians do that but I think it would be a possibility. [mmm hmm] Who’s 
kidding who, they’re busy and overworked, um, and trials are a lot of paper work. 
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So I think that’s possible, I certainly don’t think there would be malicious intent 
[no] but I, but I do think that you know, even time constraints that sort of thing 
could have, play a factor in that. 
 
M: What do you think we could do to make it sort of less time consuming or how 
could we ensure that it’s not done too quickly? 
 
S11: Um, I don’t know, I think that again is an individual physician thing. I think 
each physician has different interests in different areas and studies for different 
reasons. [yeah] Um, I think some are just more motivated than others, um again, 
every person is just so very different, that’s the problem with medicine is 
everything is so individual. So I’m not really sure, in terms of, again schemas and 
that sort of thing for known causality or what’s expected in terms of a trial that 
would be great. Even in terms of the IB and having, just something that was a bit 
more comprehensive. You don’t necessarily have to read through an entire 
paragraph to figure out that nausea is related to cisplatin. I mean if you had 
tables that were easy to read instead of actually having to read everything which 
is great when you want to read it it’s there. But if you just want a quick reference 
that that’s available for you also. I know in terms of my work and again it’s not 
causality, it’s other things, but I know that it’s a big timesaver. But to have it 
maybe printed right, right in the IB I think is just a bit more surety [mmm hmm] 
you know. You know that it’s right there and it’s visible and accessible. [yeah, 
okay] 
 
M: Let me see, now I guess, I know you don’t attribute causality yourself [yeah] 
but I’m sure you’re familiar with the various causality scales and the way it’s 
attributed right? [yeah] So can I just ask you then to consider a scenario for me? 
[okay] Okay, let’s just say you’re treating a 65-year old patient with a confirmed 
diagnosis of metastatic breast cancer [okay] in a Phase I clinical trial and she 
experiences a pulmonary embolism. [okay] How would you assign causality to 
the study drug, and I recognize that you [laughter] don’t have a lot of information 
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[right] to go with, but let’s say there was a 75% chance that the pulmonary 
embolism was due to the study drug [okay] and a 25% chance that it was due to 
other factors like [okay] concomitant meds, concomitant illness, disease 
progression. [okay] And your scale is certain, probable, possible or unlikely. 
 
S11: Okay, so how would I, like my thought process in going through that or just 
what would I, right now what would I grade it? Like what would I give it in terms of 
causality? 
 
M: Tell me a little bit about your thought process, yeah. 
 
S11: Um, I mean essentially you just go back, the basic things, patient history, 
essentially the things you just mentioned, concomitant meds as well as 
intercurrent illness. Um, other things too, do they have a pic line, do they have a 
central line, have they had a bout of coagulapathy before. Um, so essentially all 
the very basic things that you know, any of us clinicians do in assessing a 
patient. Ah, um, even just going and asking a patient history, what have they 
noticed, is there anything different/, um, when did certain things start? Was it you 
know, did you have shortness of breathe before the infusion, after the infusion? 
and that sort of thing. Um, I think in this situation, I mean, 75% against the 25% 
and not knowing a whole lot about the patient’s history obviously, um, I think it 
would be very easy to jump in and say probable or certain. I think it’s actually 
more appropriate at this point to say, possible. Um, [so that would be] I would 
probably say possible [yeah] of course you would have to take in all the other 
factors into account but it’s, it’s a distinct possibility. Even regardless of what her 
past history is or not it’s a possibility. 
 
M: And what if the percentages were changed to a 50% chance that it was due to 
the embolism and a 50% chance it was due to all those other factors [right] would 
you change your assessment then? 
 
! #)'
S11: Um, at this point probably not, just with the information I have I would have 
to say no, again, possible, possibly not but again it’s possible. 
 
M: Okay, and what if it was a 20% chance it was due to pulmonary embolism and 
80% chance is was due to other factors. And I know that it’s a very hypothetical 
situation [yeah] very difficult to say, but. 
 
S11: Um, 20% chance, I would probably stick with the same but again investigate 
a bit. If other things came about clinically that, I mean you could definitely 
pinpoint it to not likely, then that’s probably the way I would go. I mean if she had 
some sort of a history of coagulapathy I would definitely, I would go more to the 
not related end. But if there was absolutely nothing and it was just very middle of 
the road 50 or 20/80 and still nothing else, I would still say possible. 
 
M: We’re just trying to get a sense of um, [yeah] how people assign to those 
categories [sure] and you know try to quantify [yeah] what they mean. 
 
M: What I’d like to do now is just ask you a little bit about your experience as a 
clinical trials researcher. [okay] In which cancers do you specialize? 
 
S11: I am hematology [yeah] currently I am doing the hematological studies, I do 
the melanoma studies. I do, I was doing the liver studies and prostate. 
 
M: And you have a Bachelor’s in Nursing. 
 
S11: I do. 
 
M: And what year did you get that? 
 
S11: Graduated in 2003. 
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M: And you have your RN license? 
 
S11: I have my RN license as of [what year did you get that] 2003 [the same] as 
well as my um, certification in oncology nursing in Canada [ is that CANO] CONC 
is what the, my designation is. 
 
M: And what year did you get that? 
 
S11: Just, 2006 [good for you] thank you. 
 
M:  And so what year did you become involved as a clinical trials researcher? 
 
S11: 2005 
 
M: And what percentage of your work time would you say is devoted to clinical 
trials, 100%? 
 
S11: In terms of, what else would I be doing? [laughter] 
 
M: Well I guess you’re pretty much a dedicated clinical trials nurse. 
 
S11: 100% dedicated yeah. 
 
M: And of that, what percentage of your time is devoted to Phase I and II trials 
and what percentage to Phase III? 
 
S11: I would say right now and this could very well shift quickly once we start to 
accrue onto the Phase I. But Phase I/II I would say right now is [just roughly] I 
would say right now approximately between 25 and 30%. 
 
M: And the other 75% would be Phase III? [yes] 
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S11: Like I said though I think will actually be the opposite come about a month 
from now. [so things could change] Yes, very much so. 
 
M: And can you tell me about any training you’ve received specifically with 
respect to assigning causality to adverse events. 
 
S11: I’ve had no formal training [no] actually. 
 
M: So how have you learned about it? 
 
S11: I think just my past experiences, personally and again I don’t know any 
different. But being a nurse and working on the floor and giving a lot of cancer 
drugs, um, the huge variation of cancer drugs to a huge variation of individuals, 
all adults, mind you I was never in peds. Um, but ranging in age from 18 to 100. 
You know, just my past experience, what I’ve seen, I’ve learned you don’t jump to 
things too quickly but assessment is the most important part of your clinical work. 
Um, and whether that be assessing causality of something or just assessing 
symptoms. [mmm hmm] I am a very firm believer that, that is the most important 
part of your day. And, and researching into that and taking nothing for granted 
and you don’t take somebody else’s word for things. And you certainly don’t take 
credit for something you didn’t do. So I’m very much into, you know I have to look 
that up, it’s not, you know, you never stop learning and it’s not something you 
can take for granted. Even if it’s something you’ve seen, you know, 100 times 
over it’s still worth investigating each and every time [yeah] so. (certainty is 
difficult to achieve, even for those with experience)  
 
M: What additional education do you feel would be helpful to clinicians like 
yourself? 
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S11: Um, having some sort of formal training in that. Um, we get lots and lots and 
lots of formal training in good practice guidelines and I personally have had lots 
of other training in doing ECG’s and even how to fill out CRF’s. I mean almost 
every other aspect of the trials that I think we do here we get lots of training in. In 
terms of that I think because we’re not responsible for that, I think it kind of gets a 
little bit overlooked. [okay] Which personally I do not think is, the most optional 
approach. I think it would be extremely beneficial to have, for the CRA’s (Clinical 
Research Associates) here at our centre, I think would be extremely beneficial 
to have more formal training in causality. Even for myself, even though I think I 
have a bit of more broad knowledge base in specific chemotherapy drugs or 
classes of drugs. I think that that would be very important, even 
 
M: What would that look like then? 
 
S11: The actual training you mean? 
 
M:  Yeah, what would you think should be the content of it? 
 
S11: I think, gosh that’s asking so much, almost, almost quite honestly almost 
like a pharmacology course, um. Essentially to teach you know, different types of 
drugs, different classes of drugs. But also in what types of cancers, disease sites, 
you know histological types, you know what are we treating with what and why?  
Um, even how they’ve proven to be effective, um, I think really understanding 
what they effect, how they effect, if it’s the cell cycle, you know protein synthesis. 
Whatever it is, I think it’s very important to have, I mean at least bare minimum a 
small amount of knowledge in that to be able to make fair assessment in that sort 
of a situation. 
 
M: Yeah, so like the biological mechanism. 
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S11: Yeah, well definitely because each mechanism affects the person’s body 
differently. And again, I don’t think that, I don’t think that as a group we know 
enough about that, I think we’re very lacking in that area. [yeah] 
 
M: And what sort of, what do you think would work best in terms of a forum? 
 
S11: It’s hard to say. I personally am a more visual learner myself. You know, I 
take quite well to lectures, I like that sort of thing. Lectures, handouts, even you 
know, online courses, I think that would be very valuable. Actually just coming 
back to what do I think would be valuable, assessment skills I think would be very 
valuable in improving skills in causality. And you know not necessarily to 
determine causality itself but just to get a full assessment of whether it be each 
body system or each AE. I think that there’s, again, I think there’s a lot of room 
for error in assessment skills and I think that, I mean everybody is going to be 
different but I do thing that you know, teaching the proper avenues or even types 
of questioning I think could maybe improve things quite a bit for our department 
specifically. 
 
M: Yeah, no that’s, I think you’ve touched on something important there, 
definitely. Okay, um, I think those are all the questions that I have for you. Do you 
have any questions for me? 
 
S11: I don’t think so [no] no, I think it’s definitely worthwhile. Again, I think our 
department is very different from all the other places you’re going to visit and all 
the other people you’re going to talk to. [yeah] So it’s, I think it’s probably tough 
to modify what you have to fit us too. [yeah] But it’s, it should be interesting 
hopefully for you in that we are so very different from everybody else [yeah] and 
the way that we do things here. 
 
M: Well, I don’t really see that as a barrier [great] I mean I think there’s probably 
going to be a lot of similar needs despite the differences. I think there’s probably 
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going to be quite a [good] you know it could work in any model. [great] Okay, well 
great, thank you.    
 
Subject 12 
M: So I’ll just start with a little bit about what it is that we’re doing. We’re 
interested in how investigators assign causality to adverse events specifically that 
occur in the Phase I oncology clinical trial setting. And the idea is that by 
gathering a little bit more information about that whole reasoning and thought 
process and the issues surrounding it we can potentially develop a tool that might 
help to sort of systematize that process a little bit better. And so um, yeah so we, 
and the goal with the tool is that it would sort of help clinicians efficiently and 
reliably assign causality. [good] We feel that by better understanding the needs 
of clinicians we can make this tool more relevant to clinicians. And I understand 
that you’re not maybe practicing as a clinician [yeah] at this stage, is that correct? 
[yeah] You are still?  
 
S12:  Oh yeah, I still have, not like before but ah, a half-day clinic a week but 
that’s only, very busy before then. 
 
M: Right, okay, so you’ve got lots of experience then and would have lots of good 
insights in this. So that’s sort of what we’re trying to do and um, so I guess I’ll just 
start then [yeah] is that alright? [sure]. So let’s say for example you’re an 
investigator on a Phase 1 oncology clinical trial and a patient has just reported 
experiencing an adverse event to you.  Can you just walk me through how that 
situation is handled and the reasoning you go through when you’re assigning 
causality? 
 
S12:  The ah, I guess there are several components that have to be considered, I 
guess first is getting a clear description of what the event is, the nature of the 
toxicity and what the severity of it is. What the series of biological consequences 
are, in other words a problem that can result in a respiratory component, a kidney 
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problem occurring etc. So the systems of the body are linked. So basically you 
want to define the scope and the severity of the problem. You then, I think want 
to understand result from diseases. The nature of the disease in terms of the 
problem that is occurring. Is there a potential linkage where the problem relates 
to the disease? Secondly, sort of linked to that what’s the status of the disease? 
[right]. Is the problem that you’re being faced with in fact a toxicity, but in fact it’s 
a manifestation of the disease. Am I talking too much? [no, you’re doing really 
well, I just wanted to make sure it was still working] Is it a manifestation of 
progressive disease as opposed to not due to, or the intervention? The sort of 
next level is somewhat related to that and there are sites, groups that would have 
problems with that, but within hematology part of the disease process you often 
face consequences with an infection [right]. Infection is a common part of the 
disease process. So you’ve got primary problems of the disease, problems of 
progressive disease and then sort of downstream consequences that occur as a 
result. (Many confounding variables to consider) Next step I think would be to 
look at the nature of the treatment received and have they received single 
modality, multi-modality, if it’s a single modality it could be a single agent or multi 
agent. In the context, in the Phase I study, often Phase I studies are single agent, 
but you do Phase 1 studies with combinations. So then you have the whole issue 
of what’s the investigational drug versus what are the known consequences of, of 
the other components of the treatment. You have to understand the potential, the 
potential toxicities of, of those drugs and what would be expected versus would 
be unexpected. Under expected you probably still have varying degrees of 
severity, so one problem may be [4:10 skipped] with a given level of severity you 
may be seeing in your individual patient dispropionate to what’s expected. So 
through the sort of disease status, the disease indirectly, the nature of the 
treatment, what’s expected from the treatment, standard parts of the treatment. 
What would be expected as part of the investigational agent. So if it’s anticipated 
that or if the investigational agent is well known to cause neutropenia or whatever 
and you’re seeing neutropenia it wouldn’t be hard to imagine a cause-effect. One 
of the final steps then is um, looking at timelines and surrounding circumstances. 
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So you’ve got a problem, a clinical problem does it fit a logical timeline with 
respect to exposure to the drug or possible timeline of exposure to the drug? 
(again, timing plays a major role in attributing causality) Secondly, have any 
other things in terms of co-interventions been done in terms of management of 
problems that have come up along the way. For instance, if a person gets a skin 
rash, they got a drug, they, they may or may not have had an infection, they got 
put on an antibiotic and they got a skin rash. So you’re, you’re situation is now 
confounded by that. It’s important that you look at it in terms of temporal 
relationships but other relationships with co-interventions. So I may have left 
some stuff out but those are probably the major parts. (there are other smaller 
factors that play a role when assigning causality) 
 
M: When you’re going through all of that thought process do you use any tools to 
help you or is it just something that you kind of go through mentally in your mind? 
 
S12: The tool, well um, okay, if, if we back up in terms of the effects of the 
disease, there’s probably not tools about, you know, you’re supposed to know 
the disease you are looking after and if you look after lymphoma or myeloma 
there’s content knowledge there. (feels responsible for knowing the disease 
without the support of a tool) I suppose there, there could be rare instances 
ah, cerebellar degeneration is an extraordinary consequence of having ??, so 
you know, if you weren’t to know that and they got a therapy and is it blame the 
therapy? Some of the tools you might use would be a lit search type of in terms 
of the feature and, and of the event itself as a downstream effect of the disease 
the argument would probably still be the [6:41] the um, consequences of the 
drugs, standard drugs or investigational drugs, um, you would have, if you were 
in doubt, I guess the first tool would be the protocol, the study protocol would 
have aspects of that. (tools are a source of support when in doubt) If it’s new 
and uncertain, the study protocol, nurse assistant, clinical trials nurse, knowledge 
of the study protocol, coordinating centers’ knowledge of previous experiences, lit 
search. 
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M: When you say the coordinating centre do you mean like the sponsor? 
 
S12: Yeah [yeah] sponsor’s aspect. 
 
M: Would you sort of, would you call them up? 
 
S12: Not necessarily first off, I’d probably go to the protocol, the investigator 
brochure, ah, their collaborator, ah, their collaborators that have, if we’re the 
centre, then myself and the study coordinator. If  I’m not the PI, I would speak 
with the PI at that centre to deal with that but in terms of other tools they’d be the 
protocol itself, the investigator brochure, lit search material, the sponsor, CTEP, 
the provider in terms of the nature of the toxicities in terms of severity, you know 
the standard grading and those are probably … (identified many resources but 
no distinct/standardized tool) 
 
M: And what about for actually assigning causality? Do you ever, I know there’s 
like the criteria for grading severity as you mentioned, um do you have any sort of 
a tool like that for assigning causality, are you aware of anything? 
 
S12: Not in terms of grading, in terms of definite. [yeah] I mean schemas for that 
and assistance for, other tools that [8:23] in finding those, in terms of the focus of 
the study to be honest with you. 
 
M: Can you give me an example of a schema, you said there are schemas for the 
probable, possible or just the actual scale itself [that’s right] that’s in the protocol. 
 
S12: In the criteria, yeah [laughter] there’s variation in filling in, of the criteria 
people would use. And I’m sure there’s [8:46] 
 
M: That can lead to, you know is that a concern for you? 
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S12: Um, yeah, obviously in terms of the integrity of the study, the generation of 
serious adverse events and bringing the implication of  who should report them, 
the consequences of reporting it in terms of the potential outcomes influencing 
study design to capture it [what implications] in case there’s something of high 
risk. (feels reporting comes with consequences) 
 
M: You mentioned the potential fall out in the study design, can you just 
elaborate on that? 
 
S12: So if, if, there’s an SAE that, that comes out of that, that has implications for 
notifying sponsors, the sponsor notifying the regulatory agencies and the 
company, there’s timelines for doing so. The nature of enough AEs may influence 
the conduct of the study [how does it influence?] so misrepresent, well a series of 
SAEs may [9:51] 
 
M: Have you every experienced something like that, can you give me an example 
or tell me about it? 
 
S12: Um, we’ve, we’ve ended up closing the study to accrual because we had 
frequent dose-limiting toxicities which in themselves are not events, they were 
potential consequences brought to a more profound degree and the dosage 
required adjustment. But along the way with that, we had an SAE, one of the 
consequences a patient became, the first person to start with it got a bad disease 
etc, etc, a subsequent death occurred and study treatment was attributed to that. 
Had the DLTs not already closed the trial to accrual to start and having to re-
design, the SAE would have. That was sort of the freshest in terms of [10:40]. 
Now if you were to turn that situation around, if he had been very ill, and met the 
eligibility criteria but is a high risk person and you attributed the subsequent poor 
outcome to their disease and unrelated to the treatment, that would be a stretch. 
I mean things are truly unrelated that would just you know, blow over. So you 
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could in one situation attribute something to an entire one set of the, the most 
serious and if it’s this and you don’t acknowledge it, that’s dangerous for future 
patients in the study. [right] If it’s, if it’s you know, this and you label it as this, you 
could be potentially closing a trial that presumably was well thought out and had 
a good hypothesis and the hypothesis could end up being rejected. [implications] 
Potentially [yeah] I mean if you polarize the extremities yeah, most of the stuff is 
not going to end up being that extreme, it’s going to be in the middle but. 
 
M: Have you any concerns about how causality is current assigned? 
 
S12: Um, yeah, I think sort of along the lines of what we’ve just talked about 
[yeah] that um, 
 
M: How about the way in which clinicians assign causality, feelings of 
 
S12: Yeah, I don’t think the, the I don’t think amongst clinician investigators that, 
that a sufficient set of details to consider would be uniformly[12:20] constructive.  
 
M: When you say category what do you mean? 
 
S12: Unrelated versus definite or possible, what’s the difference between 
possible and probable? [right] 
 
M: So those terms aren’t very clearly defined. [no] What do you think would help 
in assigning causality, that might be one thing I guess, to better define those 
categories. 
 
S12: I think what probably needs to be, I mean you can make errors in either way 
right, assigning it when it’s not present and not assigning one when it is present. 
So there probably needs to be a philosophical agreement as to which type of 
error it is conceivable that, that could the error change in different situations. In 
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prevention trial the bar for causing no harm is set very, very high. In hormone 
replacement therapy in women you know, the bar would be set very high, 
because harm, that’s going back, it’s going to play out to a lot of people. If you 
have somebody with acute leukemia where you know, say relapsed acute 
leukemia, where the life expectancy is 12 weeks and the benefits of treatment 
are debatable. Do you have a complex disease and a complex set of 
circumstances for comorbidities based on a, you know, the type of error would 
vary in the situation. So I think there’s a, overall there’s a set of principles as to 
[13:54] (I wish this didn’t skip) about making that maybe and so there has to 
be.  Once you understand which is the sort of area  within given. 
 
M: I see where you’re coming from, just depending on philosophical standpoint 
and your willingness to accept harm or [yeah] yeah [yeah]. 
 
S12: I mean that’s life, that’s risk and benefit and acceptance of taking greater 
risks. (feels they need to accept risks in order to get the job done) 
 
M: What external influences from third parties have you felt when assigning 
causality? 
 
S13: Um, the most, um, the first and most immediate is the work the clinical trials 
nurse is going to have to do. [okay] It’s just very practical and if ah, I mean there 
is a bureaucratic process that is time consuming that if you assign an SAE versus 
not that somebody’s going to have to do a lot of work and meet timelines and set 
a whole ball rolling. So that’s, it’s not an external pressure but there’s a reality 
[right] that, that you have to factor in. You , I think you deal with that one pretty 
quickly and, and you do the right thing and if somebody has to do more work 
then so be it. But, that, that’s the first most immediate one. I think you then have 
the issue of the sponsor, and sponsors, sponsor may influence. [okay, how so?] I 
think in general from what I’ve seen, sponsors will tend to, tend to things that are 
expected, the, if the consequence is an expected one and it’s tended less to be 
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labeled serious adverse event even if it’s expected but the degree and the 
severity wasn’t, that’s a tricky one, you give an agent [can you give an example 
of that?] Oh, to make an exaggeration, you give a drug and it’s know to cause a 
low white count, neutropenia. An average duration of that’s going to be five to 
seven days and it would be very unusual for it to last more then 10 to 12 days. If 
it’s a new agent and you get neutropenia that lasts 25 days, that expected, is it 
expected or not expected. Well the neutropenia was expected, the severity was 
not. Now I suspect some people would argue with me, an extreme group would 
argue with me on was it serious etc. But I’ve polarized it with an exaggerated 
example. And you know at what point, well if it was 13 days, 15 days you know, 
sort of where’s your cut point [sure] before you say it’s expected versus 
unexpected. (difficult to grade severity) And I think it’s in that degree of 
gradations that, that you can get debate and [differences] differences in 
interpretations. 
 
M: So the sponsor would tend to oh that’s expected. 
 
S12: I think on the, yeah. Now I’m doing, I’m looking at if from a standpoint of 
clinical trials. For prevention trials, I don’t know, I haven’t done prevention trials. 
And what I said at the outset about philosophy, and which is the greater error, I’d 
have to see how that played out. [yeah, yeah] 
 
M: Any other external influences or pressures that you felt? 
 
S12: Not that I felt, I mean I can imagine things in terms of the hospital, the REB, 
if the sponsor is not a pharmaceutical, if you’re studying a drug but the sponsor 
is, like the CTG and not the drug company. The drug company, they’re all 
potential stakeholders within it. But I can’t say I’ve sort of felt pressured, I think 
you’re original question was have you felt influenced by them, personally I 
haven’t. But in, in, theory could you?, I suppose you could. The Regulatory 
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Agency itself [yeah] Health Canada, could you? yeah, yeah. (suggesting others 
may have felt pressured) 
 
M: Have you ever heard of a tool developed by a researcher named Naranjo? 
There’s a researcher named Naranjo who developed a tool to help clinicians 
assign causality to adverse events. And what I would like to do is have you take a 
look at it if you don’t mind, and um, it’s here somewhere, here it is. If you could 
just take a look at it and then just cross out any, any points there that you feel 
aren’t relevant to the Phase I oncology clinical trial setting. There’s no right or 
wrong answer [mmm hmm, no] 
 
S12: They’re all potentially relevant, um, I mean, any that are not relevant? [yeah] 
Um they’re all potentially possibly [okay] um. 
 
M: Are there any that you feel are more important than others. [yeah, yeah] Okay, 
so would you be able to just rank them along the side then, so 1 would be least 
important and then 10 would be most important and you could just sort of [can 
any of them have the same number or not?] sure, whatever you feel, 1 is least 
important and 10 is most, sure. 
 
S12: I don’t have to do them in order I can just give sort of a ballpark figure [yeah] 
as I muddle along. [great thanks] 
 
M: So did the adverse event appear after the suspected drug was administered 
you ranked that as 10, that has to do with temporality. 
 
S12:  Yeah, if the adverse event occurred [it’s pretty obvious] before that’s a 
tough sell. I mean could you, could it have occurred and then been made worse 
by the offending agent. There’s even interpretation about that one but. But it is 
occurred in it’s full blown form before the drug was given the temporal profile 
[10:53] 
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M: Was there anything here, like did you think that there were any questions that 
were missing that maybe should be added. You mentioned the worsening which I 
don’t think is in here. 
 
S12: Well it’s talks about test/re-test doesn’t it and it talks about dose, which is, is 
there. [anything else that should be added?] Would probably [20:18 #5] in terms 
of the disease, so that the scope of what’s considered alternate explanation. 
[yeah, that’s a good point] That’s ah, some of them, like the drug concentration in 
the blood, if you have that, that’s potentially helpful information as a rule. Not 
having it, like even having blood tests with non-toxic levels would barely 
persuade me compared to other things [right]. So you have to sort of read some 
of these very carefully [sure] in terms of how they would [20.55] I’m not sure that 
ah  
 
M: Okay, but you’ve never seen this Naranjo scale before? [no] Okay, this is the 
thinking that maybe we could adapt something like this to the oncology clinical 
trial setting and. What do you think about, do you think this would be used by 
clinicians? Do you think something like this would be helpful or do you think it’s 
too cumbersome? 
 
S12: I think it would, I think it could be useful and so it would be desirable to have 
something like this to, to um. (finds the concept of a tool desirable) Let me 
backtrack, I think it would have to be tested [yeah definitely] and is it, could you, 
is there enough reason to hypothesize it might be beneficial if adapted. Ah, I 
think that’s a good hypothesis. The difficulty is each question you go through 
here, I mean, are you, are you just sort of downloading degrees of interpretation 
and variation around interpretation into additional components. So you know, it 
would have to be tested that it actually does lead to consistency. You know, you 
would almost have to have a two-sided statistical test, could it lead to more 
inconsistency? it’s not impossible. Because you could interpret, you know, you 
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could have degrees of interpretation here and it’s kind of like um, you know, 
assessing quality of life you know, do you ask two questions to get an overview 
of quality of life. Or do you ask 40 questions that test domains, and what’s the 
truth? [yeah] And what leads to more variation than the other. [right] And is 
someone’s you know, is there a process where overall Gestalt could be made 
more consistent, or is this a bunch of components. I think you’d have to test it. 
[mmm hmm] But, but I’d be open to you know, I think it would be rational to think 
this would lead to more consistency and is worthy of testing. Now would, if the 
test and test circumstances showed that it was, that led to more consistency that 
would be great. Would people actually use it?, that’s a separate question. It’s um, 
just reading through it here in terms of test purposes, it’s, you have to think [yeah] 
a lot about this. And to sort of go, now, it may be helpful to have the actual 
example in front of you right now that it’s easier in the context of a given example 
and so forth that you go through it quickly. But for sort of  [23.33]  
 
M: Yeah, definitely. Okay thanks. And then the last little thing I’d like to ask is a 
little bit about your clinical, your experience [sure] as a clinical trials researcher. 
So you said you specialized in [hematology] hematology right. And you have your 
MD obviously right? [yeah] And what year did you get that? 
 
S12: 78. 
 
M: And when did you get your medical oncology license or sorry hematology 
license? 
 
S12: It was 84. 
 
M: And do you have any other Masters or PhD or clinical trials, no. 
 
S12: I did some Masters courses but I didn’t finish the program [at Mac?] yeah 
[yeah, okay] 
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M: The ClinEpi [yeah I did the coursework] A was the same actually, [yeah he 
was] that’s okay you still got the education [that’s right] And what year did you 
become involved as a clinical trials researcher? 
 
S12: Where you’re actually responsible, 84.  I mean you would be exposed or 
exposed would have been as a resident even before then and 84 when you 
actually had to [24:40] 
 
M: And when did you do the ClinEpi course work [um late 24:44] Okay. And I 
know this has sort of changed recently, but what percentage of your work time 
would you say is devoted to clinical trials? 
 
S12: In terms of answering, for the purposes of answering this question you 
should probably use my old life [okay] because that’s the experience, that’s 
what’s formed the basis of [yeah] not all but most, I mean I have learned stuff in 
the last [25:07] but if you look at that. Clinical trials [yeah, what percentage of 
your workload] depends how you, because I was a site chair in terms of for NCIC 
for hematology so I operate in, actual putting patients on trials versus developing 
trials, overall conduction of trials [everything] analysis. Everything [yeah] I was 
probably a day a week, 25, 20 to 25%. 
 
M: And then of that, how much of that time was spent in Phase I, Phase II trials 
versus Phase III. [  ] Like out of that 25% [25] of the time yeah. [less than 5] 
Okay, then the rest of it was Phase III [Phase III].  
And you’ve been a local PI obviously [yeah] before, yeah. 
Then, I just want to ask a little bit about the education that you received, 
specifically to do with assigning causality. Can you tell about me anything you 
have received, any kind of training? How did you learn about it? 
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S12: Just by being around, it’s informal, [okay] being exposed to certain (learn 
through exposure) 
 
M: What additional education do you think needs to be made available to 
clinicians about assigning causality? 
 
S12: Probably [26:29] other than that? To participate in USNCI studies you have 
to go through a web based, and certificate at the end, otherwise you can’t be an 
investigator let alone a principal investigator. There’s probably, there’s similar 
training that’s going to take place in terms of GCP clinical practice in terms of 
conduct of trials. [it’s not in place yet] It’s not in place yet [but it’s coming] it’s 
coming. There’s probably modules within overall conduct of clinical trial aspects 
like that, as opposed to a specific education experience of learning about 
causality and assigning of events. It’s probably a module in a broader sense of 
being an investigator and what the responsibilities of an investigator are. 
 
M: So the Canadian investigators they do the, the USNCI training [for ethics] oh 
okay. 
 
S12: We have, actually it was through this office, through LS downstairs has 
developed something that will be on the web 
 
M: Okay, so the GCP is being developed here in Canada [yeah 27:37] yeah, that 
was, in previous interviews people had mentioned this type of education and 
thought that it would be really great to have something like this [yeah] as a 
module or on it’s own to do with assigning causality. 
 
S12: This is sort of a handbook on GCP and I’m just wondering what’s [are those 
the ICH guidelines?] yes, I’m just wondering what’s in here   [skipped] but I will, 
I’ll have to   [they tend to define adverse events, serious adverse events] 
separately but I was interested to see because this is the type of module where 
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that type of training would be part of, now that’s so regulatory driven I’m not sure 
that it’s academic enough to incorporate things like this. On the other hand 
ultimately these are the things that go to regulators [that’s right] so it would be 
reasonable [yeah] 
 
M: Okay, great, I think those are all the questions that I have for you. [good] do 
you have any additional questions for me then?  
 
S12: I don’t think so [no, okay] that’s a good idea. I remember A telling me about 
this, we sat beside each other and he was saying he was going to do this so it’s 
neat to see that it’s unfolding. Those were great questions. 
 
M: Good, thank you. 
Subject 13 
M: So even the most experienced clinicians find assigning causality to adverse 
events challenging. Groups such as industry sponsors, clinical trial cooperative 
groups, they all expect prompt and sensible causality assessments. But as you 
know, it’s not always that straightforward and if done poorly it can have large 
implications for patient safety and new drug development. So we’re interested in 
developing a tool to help clinicians efficiently and reliably assign causality. We 
feel that by better understanding your needs as a clinician we can make our tool 
more relevant to clinicians. Do you have any questions? No, okay. First let’s say 
one of your patients who is enrolled in a Phase 1 oncology clinical trial has just 
reported experiencing an adverse event. [okay]  Can you just walk me through 
how that situation is handled? 
 
S13:  You mean mechanistically how it is handled? [sure] So for, do you mean an 
adverse event or serious adverse event? [lets say serious adverse event] So if a 
patient on a Phase I trial here gets, I become aware of a serious adverse event, 
then basically what I do is I contact the clinical [1:00] attempt to. Or, if for 
instance they come, they call us for something or they come in, and we obviously 
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see them here immediately and do the appropriate investigations. So we try to 
obtain all the documentation necessary to understand what the adverse event is, 
and fill out the SAE form and fax it to the appropriate um,  
 
M: You said you gather all the pertinent information, so what sort of information 
are you looking for? 
 
S13: Um, why, what event actually happened so the diagnosis, what diagnosis 
was made, so any supporting blood work, imaging, treatment the patient received 
and um, what consequences or what [1:36] 
 
M: So you have to complete the adverse, the serious adverse event form [mmm 
hmm] and you have to assign causality. Can you just walk me through how you 
go about doing that, what you’re thinking about causality? 
 
S13: Um, well I guess,  I mean, yeah, the bottom line is besides documenting the 
event, I have to admit that is very subjective at times [1:55] and how one goes 
about it or at least how I go about it is to understand what the known side effects 
of the agents are. (helps to understand the agent under development) What 
the possibility is in terms of if that drug could have caused that event. For 
instance if the patient is admitted for febrile neutropenia and the drug is known to 
cause neutropenia, and there are no other precipitating agents like the patient 
has not taken any treatment that they’re not allowed to on the trial or any other 
unknown treatments, lets say naturopathic. Then it’s almost an association by 
exclusion, so you exclude other things and then you basically make a judgment. 
(it’s really a process of elimination) So again if a new Phase I 
chemotherapeutic agent is known to cause neutropenia and it happens in a 
timeframe that you would expect and there is no other agent or other agents the 
patient has been exposed to then I think you would have to say it’s related. Part 
of the issues in terms of associations is there are various I guess gradations of 
association unrelated to related but then there’s, possibly, probably or kind of, 
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you know, it depends on the grading or it depends on the association. That’s very 
vague in-between. Two extremes are more, is easy perhaps to understand. 
Probable or unlikely always makes it very subjective. 
 
M: Are there any sort of guidelines that you following when it’s sort of that in-
between? 
 
S13: Um, well to be honest, not really I think you just go on what your best 
clinical judgment is or what your patient’s status is. Um, what their co morbidities 
are and how their cancer is affecting them and what their pre-treatment 
symptoms are. You know if something clearly gets to the underlying, because 
really the problem is really sorting out is it related to their underlying disease or is 
it related to the treatment or something else which is less likely unless the patient 
is taking (no tool to aid in uncertainty) [right] 
 
M: What resources do you refer to when you’re assigning causality? 
 
S13: None. [no] No, well I mean, I guess I shouldn’t say that, none in terms of 
standardized criteria that’s for sure. Resources, unless you mean basically going 
back to see maybe the investigator brochure and trying to understand some of 
the toxicities. I guess sometimes going, I think when it comes to a serious 
adverse event then more attention is definitely made to try to ?? that with 
whatever documentation you have. For adverse events, all the other adverse 
events grades 1-2, not only Phase Is but Phase IIs, there is no way that um, you 
get through every single one with the time constraints that we have. (minor AEs 
are not reported due to time constraints) 
 
M: Is there any implications to that? 
 
S13: Well there’s definitely implications in serious adverse events, and, and 
association, obviously if you put it wrong then there’s misinformation. If it is 
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associated and you don’t think it is then that, that’s probably the more harm there 
because we need to be aware, particularly in Phase Is that we need to be aware 
of and people think oh it’s very unlikely I’m going to put it not related but then 
obviously that’s information that the physicians and the patients in particular need 
to know about. (feels professionals err on the saide of caution and attribute 
causality to the drug) So I think the worst is an association that is there but one 
grades as not associated and, and harm could be done to patients. The other 
extreme is people, and I see this a, a lot because you have to, as the PI on the 
trials you have to signoff on all the REB submissions to the REB. People that put 
everything is associated creates lots of paperwork. Where its very clear in 
reading through their SAE this was not drug related, this was disease related. 
And to me that doesn’t do any harm to patients which is good but it creates extra 
paperwork for the CRAs, for the nurse, for us, for the REBs and to me that’s 
more irritating when it comes from all around the world, you know you get. [yeah] 
People could be, could think a little I think, I don’t know, think a little bit more 
clearer in terms of what they think is associated and perhaps those that are not 
associated would save the (more attention and effort need to be put into 
causality attributions)   [right, okay] 
 
M: And what about, you mentioned that you know with the lower grade AEs you 
just don’t have the time to do the, to think about those ones do you think there 
are implications 
 
S13: Um, obviously you want to have the most accurate information so 
implications aren’t good data to come out. Um, I don’t know, I mean I think we all 
try our best to see what we think is related or not. And I don’t know, as clinicians 
we pay that much attention to grade 1 as we pay to grade 3 or 4. So I don’t think 
the ramifications are as you know, anything [6:33] 
 
M: Do you have you any concerns about the way causality is assigned,  you sort 
of talked about over assigning causality? 
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S13: Over or under assigning, well I think the concerns, I mean I think concerns 
are definitely in this area that I think there is room if possible to be a little bit more 
standardized and rigid about associations and how we go about it I don’t know. 
Maybe you guys can figure that out if that’s what you’re looking at. But ah, um, 
you know, I think it’s a very subjective process, that’s the problem. And subjective 
in terms of ranking them or associating but also subjective in how much effort 
people actually put into the work. And I won’t say I do it all the time but you know, 
I think in terms of how much background work one does in trying to understand 
the causality with each one trying, if you’re not certain, if you are certain it’s very 
easy. Perhaps, if you’re not certain are you going to spend that extra time to pull 
out the IB or talk to you’re you know, pull out the protocol and actually do the 
best [7:30] (feels some people don’t but enough effort and time into properly 
assigning causality) 
 
M: What would you say are some of the problems or challenges when assigning 
causality? 
 
S13: The challenges are particularly in Phase I trials these are, these, they all 
have their advanced disease, they often all have been through numerous other 
treatments, some of them have been heavily pretreated. Many of them are not of 
the greatest performance status and so they have a lot of other co morbidities or 
symptoms that can merge and        play a role. Sometimes these brand new 
drugs we really don’t know. We don’t have a lot of information, that’s why we do 
the Phase Is. And how much weight we put on what is seen or not seen in dogs 
or monkeys or whichever animal work they have done it on, large animal work 
done, kind of you know, there’s not a lot of data there, so in the end if you don’t 
have a lot of data to work with and you have patients, it does become very hard.   
[8:24] (animals studies don’t correlate perfectly with results on humans) 
 
M: Do you think more pre-clinical work needs to be done? 
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S13: I wouldn’t necessarily say so because I think that um, um, I would like to 
see things being moved along in an expedited manner but I don’t necessarily 
know that more work. I mean I think um, basically um, if we all had more time in 
our day it would probably be easier to do it. The SAE has to be filled in within 24 
hours. I mean that’s another issue, why 24 hours? what’s the urgency? By the 
time we receive it, we send it off to the sponsor, it goes to REB, there’s going to 
be a lag time anyways. And you don’t expect things to, you know, maybe grade 5 
toxicities where you have a death, maybe that should be 24 hours. But I, I don’t 
know why an SAE can’t be 48, so you don’t feel that pressure to have to. 
(doesn’t understand why there is a 24 hour rule, not well explained) Not 
that, I think we do it just because we feel a pressure, but again I think we just 
said 24 hours and that’s just been the rule that’s been adopted all along right. 
[right] I actually don’t see the rationale of 24 versus 48. If there was somehow, 
there was, maybe you know, particularly for Phase IIs because there would be a 
lot of data. But if there was somehow a unified international database where you 
could almost punch it in and see if things have occurred with that before then you 
would almost get a better sense that um, what the causality is (no international 
database to aid in decision making) Because if it’s never been reported before 
for something, um, then who knows. I’ll give you an example where we did a 
Phase I trial of an oral EGFR inhibitor, Tarceva, at a higher dose once or twice a 
week and a subject developed grade 3 effusions, pericardial and pleural 
effusions. I don’t know if it was related or not, all I could really say was possibly 
because it could have been related. But again if there was a worldwide database 
for physicians who were the PI’s on these trials to have their CRA punch in that. 
And if in the database there has never been a report of it then you probably have 
to say it’s unrelated or unlikely. [mmm hmm] Versus if there were multiple reports 
of it, but they’re all scattered, particularly at the higher doses and then you go 
well actually it could be related. So you know, that would be helpful because 
otherwise I’m going on an experience of N of 1 versus you know, if there’s more 
literature. 
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M: Okay, anything else that you think might help? 
 
S13: Um, I don’t know, I don’t know if they have um, I’m thinking rather than, 
rather than 5 different associations, I’ve got one here for NCI US, but again, you 
know, have um,  [oh, the causality scale] yeah, unrelated, unlikely, possible, 
probable, definite. I mean I don’t know if all of them are used the same or 
not.(unsure if there are consistencies in grading measures) But again, you 
have five relationships, do you really need to have five? Can you simplify it to 
three? So unrelated, definite, possible. Like what’s the unlikely and probable 
versus possible versus probable, you know, where do you draw the line? Again, 
it’s very subjective. So simplification would make it easier. (too difficult) I think 
simplification would make it easier in that regard. I think that um, particularly you 
know we get a lot for these Phase II/Phase III trials we get industry with drugs, 
particularly that have already been registered we get tons of these, for instance 
for capecitabine or herceptin from the sponsor we get lots of these coming to us 
and if they perhaps did a better job of screening them. If they saw something and 
they said this is definitely not related they would just go back to their PI at the site 
and say ‘you know what correct this, this is not related so you don’t need to 
generate an SAE’ and you don’t have to generate it from all around the world, do 
I really need to particularly if I don’t think they’re related. And you’re basing, 
you’re basing it on what a physician in a different country, who knows what 
experience they have in clinical trials or with the drug attributing a relationship? 
It’s a huge amount of paperwork from it [the safety letters that you get] 
 
M: Have you ever felt, or what external pressures or influences have you felt 
when assigning causality? 
 
S13: Well I don’t think I had any, well I think the only external pressures is 
obviously be accurate as possible. And so you know we’re part of the, part of the 
Princess Margaret Consortium and you know a couple of the NCI trials, you know 
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the NCI physician from the US is emailing me in terms of causality, so obviously 
there are pressures to be as accurate as possible. But sometimes you really 
don’t know if it’s associated or not. (pressure to accurately assign the 
inaccurate) 
 
M: So when they email you about your causality assessment are they asking 
you? 
 
S13: Asking for clarification and they’re making suggestions and they could, ‘to 
us this doesn’t seem related’. Which I think is not a bad thing, it’s probably a 
good thing to be clearer on these. These tend to be, these tend to be more 
serious ones, dying after study treatment. I mean there are pressures to be as 
accurate as possible, try to get as much information, have autopsies and if 
they’re dying in a different hospital you know, even though they are off study 
treatment but they’re within the four weeks and so some information is not 
necessarily available. So there are some pressures, but I think, I don’t feel they’re 
undo pressures by any means, I think if anything that’s a better way to go, 
obviously anything to be more. 
 
M: Have you ever heard of an algorithm that has been developed by a fellow 
named Naranjo? I just want to ask you now if you wouldn’t mind reading over 
these questions. This is the algorithm that was developed by Naranjo [you want 
me to cross them out or what?] Yeah just cross out any you feel are not related 
or not relevant to the Phase I oncology clinical trial.   
 
S13: Not relevant, you mean not what I wouldn’t want on there. 
 
M: Well yeah, if you don’t think it’s, if you don’t think it’s sort of relevant to the 
Phase I setting. So now if you’re done, with the remaining ones if you could try to 
think what you feel are the most important. Most important would be a 10 and 
least important would be a 1. Great, thanks. Can you just explain why you 
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crossed out 6 and 7, did the reaction reappear when a placebo was given. And 
number 7, was the drug detected 
 
S13: I don’t think most of the pks have a threshold dose as toxic. 
 
M: And most important was whether the reaction improved when the drug was 
discontinued. 
 
S13: If there’s an antagonist you can reverse it now that’s very rare but obviously 
 
M: And least important was were there previous conclusive reports is that right? [ 
] oh that’s an 8, sorry [that’s okay] was the adverse event confirmed by any 
objective evidence? What did you understand objective evidence    [       ] I wasn’t 
either when I read it. I think it needs to be made clearer for sure. [yeah] 
 
S13: I guess, lab work or some imaging, something to confirm it with I guess. 
 
M: Yeah, so this was one of the things we were thinking might help, you know 
because I think investigators tend to do this in their minds [yeah] but maybe not 
everyone so it might be good to have something to think about each of these 
things. 
 
S13: The problem is if you are talking about an SAE you’re not going to have a 
lot of that information in the first 24 hours and that’s when you have to assign 
initial causality for an SAE. So usually, by the time, we’re supposed to do it within 
24 hours of knowing it so it could be later than that if it happens on a weekend 
and we don’t know about it. (could be more accuaret in causality attributions 
if given more time) Reality is that it’s generally pretty soon after an event 
happens, a lot of the improvements or things like that we’re not going to know 
about. I think you’re right, most of us do use those criteria to assess causality in 
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a, perhaps not in a systematic way or a consistent way but we all that’s how we 
all [think about it] attribute it. 
 
M: And were there any questions that you thought weren’t here that should have 
been? [16:20] 
 
M: Lastly, I’d just like to ask you a little bit about your experience as a clinical 
trials researcher. So in which cancers do you specialize, breast? 
 
S13: Breast, head and neck and Phase I. 
 
M: And when did you receive your MD? 
 
S13: I think I got mine in 1995. 
 
M: And your oncology license? 
 
S13: MD must be 93 and oncology is 99. 
 
M:  Do you have any other certifications [16:46] 
M: What year did you become involved as a clinical trials researcher?  [1999] 
Overall, what percentage of your work time would you say is devoted to clinical 
trials?[16:55]  [clinical work or all other associated work?] Anything to do with 
clinical trials? 
 
S13: 25% 
 
M: Of that, what percentage of that 25% [probably two thirds]  and then the other 
third would be Phase III. Have you ever been a local PI? [yeah] And can you tell 
me about any training that you’ve received specifically with respect to assigning 
causality. [laughter] 
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S13:…….to be honest most of it’s pretty common sense right, particularly with 
causality, definitely not. It’s just here’s the AE’s, sometimes you go ask people if 
you don’t really know. It’s pretty common sense, it’s just information that’s all it is. 
(just sees determinants of causality as information, nothing deeper) 
(distanced from the meaning of the trial) 
 
M: Do you feel that there’s, it would be beneficial to have any education? 
 
S13: I think um, you know in general, it’s probably not a bad idea, most things we 
have to do are based things or CD based you know just a few things in there   
[17:48] just as important. Making people aware of how significant it is.  People, I 
think, they just tick off one or the other just because it’s the first thing [] without 
thinking about all the ramifications particularly all the safety reports that comes 
out of something like that. Yeah, I think it’s not a bad idea, it should be done. 
 
M: Those are all the questions that I have for you. [okay] Do you have any other 
questions for me? I really want to thank you for taking the time, I know you are 
very busy, that was great, thanks very much.  
Subject 14 
M: So even the most experienced clinicians find assigning causality to adverse 
events challenging. Groups such as industry sponsors clinical trial cooperative 
groups, research ethics boards all expect prompt and sensible causality 
assessments. But as you know, it’s not always that straightforward and if 
assigning causality is done poorly it can have implications. So we’re interested in 
developing a tool to help clinicians efficiently and reliably to adverse events that 
occur in Phase I oncology clinical trial. We feel that by better understanding your 
needs as a clinician we can make the tool more relevant to you. So do you have 
any questions [no] before we begin? [no] Okay, great, so let’s say one of your 
Phase I clinical trial patients reported experiencing a serious adverse event. Can 
you walk me through how that situation is handled? 
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S14: How that situation is handled? [yeah] So the patient has reported with a 
serious adverse event. [yeah] What do you mean by handled, the formal 
process? [yeah, what are the next steps that you take?] Oh, well we usually take 
a precise and detailed history of the, of the event and then we usually dictate a 
report. And then it goes through the SAE reporting system that is determined by 
the study protocol and we have to assign a causality. 
 
M: Okay, and what sort of thought process do you go through when you’re 
assigning causality? 
 
S14: What the process, my personal process is? [yeah] Well, um, it very much 
depends on, on the situation of the patient and the drug. If this is a side effect or 
a serious adverse event which clearly has been recognized as a possible side 
effect of this drug and the patient has no reason to have a symptom like that then 
causality is usually easy to assign because then it’s very likely the event was 
driven by the drug. It’s more complicated if the patient is in a situation where he 
can develop certain side effects by, caused by his disease and his personal 
situation. For example, if somebody develops a thrombosis and has extensive 
metastatic cancer and the thrombosis occurs at the same time on a drug which is 
known to cause that, then its usually a question. But, but at the end of the day it’s 
always about drug. If I’m uncertain whether it’s related or not I tend to, for safety 
reasons, to decide to call it a drug related possible SAE rather then not. 
(attributes to drug when uncertainty- method of coping with uncertainty) 
[okay] If, if it is an SAE which is clearly independent because the drug is known 
not to cause those side effects or because it’s obvious from the patient’s situation 
that it’s related to the patient’s situation and disease then we assign unlikely. 
That’s probably the exception in a Phase I situation. [good] 
 
M: So as a general rule you tend to attribute the causality, if you’re unsure. 
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S14: Um, well at least you have to assign a possible [yeah] I mean because you 
cannot really, you have to be honest and you cannot really rule it out. Even so 
that you often get the question back, are you sure that this is possible. Well yeah, 
it’s possibly related or possible that there is a relationship because you cannot 
prove the opposite. [right, okay good] 
 
M: What are the resources that you refer to when you’re assigning causality? 
 
S14: Um, history and depending on what the SAE is, additional tests, imaging 
studies, lab tests, which we, we utilize to try determine whether or not it’s drug 
related. (did not identify tool) 
 
M: Any tools to help you when you’re assigning causality? [tools?] Like any 
decision trees, flow charts or algorithms. [no] Do you think something like that 
would be useful or? 
 
S14: Yeah, [yeah] yeah I think so. [okay why?] Well because there’s a, it may 
help you sometimes in the dilemma where you in this grey zone of serious 
adverse event where you think about what to, what to assign to this SAE. If you 
have a clearly unrelated or clearly related SAE that’s easy but the, the vast 
majority of SAE’s is probably somewhere in between. And then as I explained 
before, you have to, to somehow try to get as much information as possible and 
then put everything into perspective and then assign a causality. But that is 
basically based on, on the situation and your experience and not on any formal 
rules or algorithms or whatever. (clinical judgment) 
 
M: In order for a tool like this to be useful for you what, what would it have to, 
what criteria would it have to meet? 
 
S14: I think it should have all the, the legal implications in it, like, like GCP 
guidelines or whatever, certain definitions of certain, like the definitions for what 
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is a possible, possibly related serious adverse event, what is a related event and 
these things. And then, then probably cover the main categories [the main?] of 
those, of those events. Well I’m wondering whether you can develop a tool which 
helps you with certain situations. [can you give me an example of a situation?] 
Well if you have a patient with whatever, abdominal lymph nodes and the patient 
develops a thrombosis and is on a drug which, which has, is thormbogenic. Well 
is it because you have the lymph nodes compressing the vein or is it because of 
the drug? [right] That’s one of those typical situations where I think, hmm, can be 
disease related, can be drug related. So you cannot rule out that the drug 
contributed to this so you have to assign a possibly or possible, relationship 
possible. And this, this is this grey zone where I think a lot of where those serious 
adverse events fall into and where you really don’t have a good tool to help you. 
It’s, as I said more experience and judgment of the situation. And I’m not sure we 
can develop a tool because what would a tool do in a situation like this? [yeah] 
It’s difficult. [yeah it is a challenge definitely, okay] 
 
M: What do you feel are the major challenges associated with assigning 
causality? 
 
S14: Exactly that, exactly the situation where you, where you have different 
reasons on the drug side and the patients side for this particular adverse event. 
And you have to judge what is indeed the main cause for the adverse event. 
[yeah] 
 
M: How do you sort of do that now? 
 
S14: Well as I said, you try to get as detailed picture as possible so that you can 
really take into account every little piece of information. And then you have to 
weigh the two sides against each other. And if you, if you cannot assign a clear 
unrelated, then you have to go with the possibly related right away. I think in a 
Phase I trial you only should assign an unrelated or an unlikely only if you are 
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really, if you really have a good enough reason to believe that it is unlikely. 
(seems fearful of stating that AE is unrelated) 
 
M: What do you think are the implications of assigning causality poorly? 
 
S14: Well you can clearly overlook, worst possible thing would be that you 
actually don’t report a side effect which is actually a side effect, from, from the 
drug. That may really happen, but I think one of the existing problems is that the 
frequency of those side effects maybe under reported. 
 
M: What’s worse, overlooking it all together or 
 
S14: Overlooking it altogether is certainly worse [yeah] but I think [it’s also 
important] a serious adverse event, if a serious adverse event is seen in 
relationship to this more often then at some point we, we report it. But I think the 
frequency may then be under reported. But the key, overlooking a side effect or 
not reporting a serious adverse event which is actually part of the side effect 
profile, that’s probably the worst, the worst thing. 
 
M: Any other implications do you think? 
 
S14: The opposite is true too, if you , if you report an SAE which is not related to 
the drug [mmm hmm] then that can cause a considerable, can have considerable 
sincere consequences for the, for the drug and the development of the drug. 
(there are always consequences to misattributing) 
 
M: What kind of consequences? 
 
S14: Worse case scenario that you delay or you stop the development of the 
drug. I mean imagine that a patient dies on a Phase I study and you assign the 
death as possibly related to the study drug and it wasn’t. Something like this can 
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kill, kill a drug in the development or at least considerably delay it or cause a lot 
more costs for the, for the company or whoever develops the drug to do 
additional testing and stuff like this. 
 
M: Do you have any experience with something like that, can you tell me about a 
time when something like that happened or are you aware of anything like that 
happening? 
 
S14: I have not had a case that ah, a serious adverse event was reported, 
wrongly, wrongly. No, I cannot. 
 
M: Or just a time when a drug was sort of halted in it’s development because of 
um, 
 
S14: I’ve seen death on Phase I’s [yeah] um, and, and  that usually causes a lot 
of emails, a lot of regulatory things. And I’ve seen studies where the, the drug 
went back to pre-clinical studies even. The clinical development was put on hold 
for a year or two to get the drug back on, in the lab and do further testings there. 
 
M: What are your concerns about how clinicians currently assign causality? 
 
S14: Well it’s so subjective, in the end, for the majority of SAEs which are in this 
grey zone of possibly or likely or unlikely related, it’s a very subjective, a very 
subjective thing which is based on experience and, and of, of the investigator. 
[mmm hmm] (sees subjectivity as a concern) 
 
M: Why is that a concern? 
 
S14: Well because things can be wrongly assigned [yeah] with all the 
consequences. If you assign a possible, that’s different from being unlikely so 
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that can have implications on the further course of the study and the side effect 
profile. 
 
M: Any other concerns about how causality 
 
S14: I was just thinking but  ?????? 
 
M: What external influences or pressures from third parties have you felt when 
assigning causality? 
 
S14: Laughter, boy you feel a lot but, you sometimes get, you sometimes get, 
sometimes, a lot of companies these days are actually very sensitive, I find, with 
these things and they, they are very open to discuss these things. Sometimes 
you get more than usual amount of emails with, do you really think this is related 
or not? But I never felt pressured, probably because I don’t let it put pressure on 
me. [mmm hmm] I just tell them, that’s how it is and that’s how I think it is and 
that’s how I think it is. [right] But I can imagine that, that happens. I also think 
things have changed a little bit. [yeah, how come?] Well I think a lot of companies 
are more sensitive for these things because the process is more open than 10 
years ago. [yeah, how is it more open?] It’s more open and more controlled, I 
don’t know what, I’m from Germany and so I don’t know about Canada. But in 
Germany the whole process is now much more monitored, much more detailed 
and has much more regulations on it. 
 
M: You think that they’re sensitive just because they’re being watched? 
 
S14: No, I also think because if, if they assess something like this wrongly [yeah] 
and it happens in the future they can have a big problem [yeah] by not having 
reported that and really, clearly outlined the process how they handled this. And 
especially in the US that can be very expensive, a very expensive thing. One of 
the examples is this Celebrex, Vioxx thing, where apparently some side effects 
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were kind of very generously [swept under the carpet] well, or at least not put 
open, put openly on the table and discussed. And ah, and ah, I mean that was a 
huge disaster. [yeah] And if they had done that before the drug would probably 
still be on the market and the benefit/cost ratio is probably still in favour of the 
drug but just by not doing this, for whatever stupid reason, caused a big mess I 
would think. [yeah, that’s right] 
 
M: Have you ever heard of a researcher named Naranjo? [no] He did an 
algorithm to help clinicians assign causality and I have it here and I was just 
wondering if you could take a look over it and see if there is anything, any of 
those questions that you feel are not relevant to the Phase I oncology clinical trial 
setting. And then you can just cross out any that you don’t feel are relevant. 
 
S14: That are not relevant? [yeah] Are there any previous conclusive reports on 
this reaction? That’s certainly relevant. I would say two questions would be less, 
less important for me. [okay, which one’s?] Whether the drug was detected in the 
blood in concentrations known to be toxic. [okay, why?] Well we talk about a 
Phase I situation so you can have unusual reactions to, to unusual drug levels. 
So I would, I would take that into account but I would not put my judgment on it 
and say you know, the concentration was very small, we should not do that. I’ve 
seen patients reacting in weird ways to drug levels that we thought would be 
completely safe. [right] So that would be something that I would be very cautious 
about. And the same applies to, was the reaction more severe when the dose 
was increased or less severe when the dose was decreased? [okay] We 
sometimes, in Phase I studies you can see reactions just happening to the same 
extent regardless. Just because the patient is exposed to the drug, it does not 
necessarily have a [not necessarily a dose-response] a dose-response 
relationship. So those two questions I would certainly, they’re relatively important, 
but the others are good questions. And that’s what we usually try to rely on, are 
there previous reports?, is there a timely relationship between drug and reaction? 
If you re-expose the patient do they have the same?, I just had two patients with 
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this, where we, one of the patients we did not re-expose him because the 
situation was too severe. Another patient insisted on continuing and we did and 
so far it did not re-appear. But I have still do not have a good explanation why he 
did have the adverse event in the first place. So but yeah. 
 
M: So would you be able to rank the, so you’re crossing out 7 and 8. 
 
S14: I would not cross it out I would just not put that, not as much emphasis as 
on the others. [oh I see, so those would be less important] yeah, yeah. 
 
S14: I mean, clearly one of the most important questions is if you have similar 
reports on this drug in similar situations. [yeah] I mean that’s the first thing you 
look at, is this a known side effect? 
 
M: How would you, how do you figure that out? [what do you mean?] How do you 
know if there has been previous reports of that reaction like that? What resources 
do you refer to? 
 
S14: Well, investigators brochure [yeah] current literature um, personal 
communication with other investigators, the whole nine yards. Sometimes if you 
have other drugs from the same class of drugs which are further developed you 
can at least try to make a cross conclusion if there is a class effect. 
 
M: Now you said you personally communicate with other doctors, is that usually 
other doctors here at the site or do you [no no] talk to other investigators? 
 
S14: Other investigators who participate in the study [in the trial] or have 
experience with these kinds of drugs. That’s not restricted to the centre, [okay] 
we live in a very global world. [you would just give them a call and say, have you 
ever seen?] Phone call, email. 
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M: Are there any questions on this list that weren’t there that maybe should have 
been? 
 
S14: Not anything obvious. I think, I think it pretty much has the, the 10 questions 
that you usually go through in your head when you try to assess causality. 
 
M: Do you think something like this would be useful [yeah] if it was implemented 
more widely? 
 
S14: Yeah, you would certainly not miss anything and you would have a constant 
reminder what kind of points you have to, to tick off. 
 
M: So now I would just like to ask you a little bit about your experience as a 
clinical trials researcher, we’re almost done. In which cancers do you specialize? 
 
S14: Gastrointestinal, genitourinary. 
 
M: What year did you receive your MD? 
 
S14: In Germany [what year was that?] oh, 1993 
 
M: And do you have a Masters or a PhD or anything?   
 
S14: No. 
 
M: What year did you receive your oncology license? 
 
S14: When? [yeah, laughter] 2002 
 
M: What year did you become involved as a clinical trials researcher? [sorry?] 
What year did you become involved as a clinical trials researcher? 
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S14: That would be 1997. 
 
M: You didn’t have your license until 2002? 
 
S14: That’s the  German system. You start, we have a six-year internal medicine 
residency program and then a two-four year combined hematology/oncology 
fellowship program. [oh okay] And it’s not a program like here where you, like a 
two-year fellowship and then you get kicked out, it works a little differently. [right] 
And you have one or two year leeway doing exams, sit your board exams or not. 
[right] But in Germany you start doing clinical research basically doing your 
residency. So in 1997 I started a residency position at a university hospital and 
got involved with clinical trials. [okay] So that’s the difference. 
 
M: Do you have any other certification then to do with clinical trials or any other? 
 
S14: What do you mean qualifications? 
 
M: Like any other certifications, any other course work or any education around 
clinical trials. 
 
S14: Yeah, I have, I, I, I ah, did a training to, for, for clinical trials physicians in 
Germany. It’s a course you have to take, contains all the different aspects of 
clinical trials, ethics, data monitoring, whatever you need, GCP and regulation 
things. [okay] So I’m, so I have basically a certificate of attendance. 
 
M: Good, and what year was that. 
 
S14: That was in, around 2000. 
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M: So overall, what percentage of your work time would you say is devoted to 
anything to do with clinical trials? 
 
S14: Anything to do with clinical trials? [yeah, even writing protocols or whatever] 
Physican working hours [yeah] or all of the working hours? [laughter] I would say 
it’s probably, right now [yeah] maybe 80/20 [80% trials?] no, no, 20 [20% trials] 
just because we have a big chunk of regular clinical work so. 
 
M: And then of that 20%, what percentage is devoted to Phase I and II trials. 
 
S14: So 20% would be a day a week, yeah 70/30, I would say 70/30. 
 
M: And of that 30% what percentage is devoted to Phase I, Phase II trials as 
opposed to Phase III. 
 
S14: 80 [80%] at least 80% is Phase I/II [and 20% to Phase III] 
 
M: And have you ever been a local PI? [yeah]  
 
M: Can you tell me about any training that you received specifically with respect 
to assigning causality to adverse events? 
 
S14: You mean overall or specifically for trial. 
 
M: Specifically on  
 
S14: Because I did receive the training as a clinical trials doctor, which had some 
training in there for assigning causality. But otherwise I’ve never received I think 
formal training for assigning causality. 
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M: What additional education do you think should be made available about 
assigning causality to clinicians? 
 
S14: I think a training tool would be helpful, especially if you start in a clinic like 
this, I imagine it would certainly be helpful for, [so if you are just starting out] 
junior, junior staff members who just start in this field. 
 
M: What would that look like? 
 
S14: I think it gives an overview of what the different categories are [when you 
say categories you mean probable, possible?] yeah. And what, what kind of 
assays fall into the different categories and then it probably should contain a fair 
number of samples and examples. And then something like the questions you 
showed me, something like this. [okay, great] 
 
M: What do you think would be the best way to implement something like that, 
what would be, web-based or CD Rom or lecture, workshop? 
 
S14: Web-based [yeah] A workshop you have to get together and probably not a 
day filling thing, it’s probably a couple of hours or so. So I think a web-based 
thing would be the best, like the Ethics Course you have to take.[oh the ethics 
course like the NCIC ethics?] Yeah, it’s web-based too and you just sit and you 
get, you get the explanations on the way through the, through the [great] 
 
M: Well I think that’s all the questions I had for you today. Do you have any more 
questions for me?  
 
S14: No, let me know about the outcome. 
Subject 15 
M: So what we’re looking at doing is, we want to know a little bit about the 
decision making or the rationale that goes or the reasoning that goes behind 
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physicians assigning causality to adverse events that occurred, specifically 
Phase I clinical trials. The reason we are interested in this is we want to see if 
there is a need for a tool or some way to systematize that process a little bit 
better. And um, just want to talk a little bit about those, those issues. Even the 
most experienced clinicians find assigning causality to adverse events 
challenging. And sponsors, clinical trial cooperative groups, research ethics 
boards they all expect prompt and sensible causality assessments. But I’m sure 
as you know, it’s not always that easy or straightforward and if done poorly can 
have some implications. So we’re interested, like I said in developing a tool to 
help clinicians make assigning causality a little bit more reliable. We feel that by 
better understanding your needs as a clinician we can make the tool more 
relevant to you. [mmm hmm] So do you have any questions [no] about what 
we’re doing? [no, that’s pretty clear] Okay, good. So first of all let’s just say one of 
your Phase I clinical trial participants reports experiencing an adverse event, let’s 
say it’s a serious adverse event. Can you walk me through that situation, how 
that situation is handled? 
 
S15: How that situation is handled? [yeah] Well it can present itself in a number 
of different ways, number 1) a patient can phone in to say that they’re having this 
problem. And based on what they tell us over the phone in terms of what they’re 
experiencing we might ask them to come in to be assessed. [okay] So once 
they’re, when they are assessed, basically it’s the patient describing what’s going 
on and, and what they’re what they’re presenting with in terms of symptoms, vital 
signs, lab test results. We look at everything and then we make a decision on the 
severity of what the patient is experiencing. [okay, yeah] So an SAE is a patient 
being admitted to hospital, so it might, it’s, it’s severe in the sense that it’s 
reported as an SAE because they are admitted to hospital. And so usually an 
admission to hospital is usually at least a grade 3 or 4 that we would admit them 
for. And in terms of how we decide whether they’re, a physician makes that 
decision to admit and assigning causal, ah relationship or severity. We use the 
common toxicity criteria for assigning the severity. Causality, whether it’s the 
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drug, you take into consideration the patient’s past history. It maybe a symptom 
that they were having before that was poorly controlled. For example, if it’s their, 
their pain, it could be maybe that their disease is progressing or it could be 
because of the medication that’s causing it. [okay] 
 
M: So you look at other factors like whether it’s the progression of their disease. 
 
S15: Well it could be their disease, it could be you know, you have to take 
everything [beeper] you take everything into consideration. You take everything 
into consideration, you have to put everything together, it’s not just necessarily 
the patients symptoms, you have to look at their lab values, look at their 
medications they’re on, what’s, what’s causing the problem. (a lot of work) 
 
M: So now do you actually do the assigning of causality or how does that work? 
 
S15: It’s basically a, an investigator, I mean I’m a nurse, I’m oncology trained, I 
have lots of experience, giving chemotherapy and looking after patients who are 
on chemotherapy. Lot of experience in looking after different types of patients, 
cancer patients, so you know, my experience does help in, in terms of identifying 
whether it is related to the drug or not. That’s part of my job to know what the 
side effects are or potential side effects are of the medication. If it’s combined 
treatment, I know what the side effects of chemotherapy are but um, and you 
know what the expected, potentially what the side effects are of this new drug 
because of the type that it is. So a lot of it has to do with um, knowing the drug 
and what potentially could be a problem. But really it is the physician’s 
responsibility to assign causality. [okay] 
 
M: Do you sort of give him, this is my opinion and then he’ll sort of say yes or no, 
I think you’re right or well, let’s look at this further or you know. 
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S15: Um, it’s kind of a, you know really it is the physician and I might ask the 
question because I want to know or you know, just for my own benefit in terms of 
becoming more acquainted in the drug, I’ll ask more questions [yeah] about why 
you think it is, why it isn’t. Try to figure out what their rationale is just because 
down the road that will help me to better assess other patients that come along 
as well. [right, okay] But it’s usually kind of, I mean not necessarily obvious but 
you know, you get to know the patient pretty well so if it’s something totally way 
out of left field that’s happened and quite surprising and there’s no real other 
explanation for it because you kind of try and figure out, okay, is there another 
explanation for why this patient is experiencing this certain symptom. And um, 
you know, you kind of rule out everything else before you kind of point the finger. 
[could you turn that off just so I can answer this pager?] (process of 
elimination) 
 
M: So what are the resources you refer to when you’re assigning causality, when 
you’re looking at when you’re assessing the patient and those factors? 
 
S15: Um, I will, one of the resources that I use we have on our computer, it’s 
called, Up to Date. So basically if a patient is on some medication that I’m not 
familiar with I might look it up to see what the side effects of that particular 
medication is, is that the patient’s on to see if maybe it’s because of the new 
dose that we’ve prescribed for him. 
 
M: Now does that include investigational drugs too from the database? [no, not 
investigational] So sort of like a CPS? 
 
S15: Yeah, it’s more than a CPS, it even talks about, like if there’s a condition 
that a patient has, say they’ve got some weird, let’s say they’ve got Lupus as 
well. I might look that, because I’m not familiar with it. I might look it up to see 
what symptoms the patient might experience if they had an exacerbation of their 
disease just to see if maybe that’s what’s happening with the patient. [so it has 
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information about diseases and drugs?] Diseases and drugs yeah.  I’ll use that 
as a source and then of course I use the protocol um, as a source of information 
in terms of side effects and [how helpful is the protocol usually?] um, it’s helpful 
enough for me that. Um, like there will be a red flag in the um, in terms of the pre-
clinical and clinical, initial clinical experience that they have with the drug in 
patients so it is helpful to me that way. I know that there is an investigator 
brochure which has more detailed information and in my particular role I don’t 
have time to read the investigator brochure. [okay] So, but that would be the PI 
would, the PI knows more because they do read the investigator brochure about 
the drugs and potential, potential side effects. But um, yeah, with an 
investigational new drug, I mean lots of times you just don’t know. I mean if a 
patient walks in and their LFT’s are you know, they’ve been throwing up and you 
look and their LFT’s are totally out of whack. And they were perfectly normal 10 
days ago before they had the investigational drug and there’s no other reason 
for, you know, they didn’t go on a drinking binge, don’t have a history of liver 
disease, then you pretty much know that the drug has probably caused, you have 
to assume it was the drug that caused that problem. 
 
M: When you’re looking at this whole causality question are there any tools that 
you use, algorithm, flow chart? [no] I know when you’re grading severity you’ve 
got the CTC guidelines, anything like that? 
 
S15: No, not that I’m aware of, not that we use here that I’m aware of. (No tool) 
 
M: Do you think that would be useful, something like that? 
 
S15: Um, yeah, could be if it wasn’t too cumbersome [okay] because you know 
that is the one thing about any of, it has to be, it has to be something that’s easy 
to use. (tool needs to be simple and easily accessible) 
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M: Can you kind of explain, like too cumbersome how? Like what would, what’s 
too cumbersome? 
 
S15: Well if it’s like an octopus, like at the end of the day if it looks like an 
octopus, that’s too cumbersome. I prefer yes/no, yes/no kind of thing and you just 
kind of very logically follow it through then that, that would be helpful to me. 
[okay] 
 
M: And do you think something electronic or paper-based would be better? 
 
S15:  Um, it has to be easy to use in eitheir way [ just has to work well in your 
setting] yeah, mmm hmm. 
 
M: And you use the computer a lot so. 
 
S15: Yeah, use the computer a lot, not always easy to get at in clinic but we do 
use it a lot yeah, more so than I ever used to for sure. [yeah] yeah [but not in the 
clinic] In the clinic I do it’s just hard to get to one, there’s lots of computers it’s just 
the matter of getting to one. [because you’re sharing them] mmm hmm yeah. 
[okay] 
 
M: What do you think are some of the problems or challenges with assigning 
causality? 
 
S15: Um, probably the sponsor wanting an answer right away of what the cause, 
because sometimes you don’t know, it’s hard to make a decision on one patient, 
like the first patient that presents. (sponsor placed pressure on making a 
quick decision) Especially if that particular patient has multiple problems and it’s 
possible that it could be their disease or a component of their disease that’s 
causing the symptom or the, the abnormal lab result. Um, as opposed to knowing 
for sure that it’s, you know if a patient comes in and they’re like you and me and 
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you give them a drug and all of a sudden they’re sick and you’ve, you’ve just 
treated a perfectly healthy person. It’s easy to say yes it was the drug because 
there’s nothing in the patient’s history since giving them the drug that made them 
sick this way. [right] But when you have a patient that has multiple problems, it’s, 
it’s harder to assign causality. Especially if it’s happened in that one person and 
it’s the first time you’ve seen it. [mmm hmm] You, you, so sometimes we have left 
that box blank you know for a couple of visits until we know for sure that it was 
the drug or wasn’t. 
 
M: And the sponsor’s don’t particularly like that. 
 
S15: Well no, they, you know, for them, a possible, you know, any time you have 
an inkling it might be related you have to go with that possibly. So is it or isn’t it 
you know? [mmm hmm] 
 
M: But if there is any question you usually say possibly? [yeah] 
M: What are your concerns about how clinicians currently assign causality? 
 
S15: Um, I don’t have any concerns really, it’s all, you know, um, kind of logically 
thought out um, and reasonable. 
 
M: You mentioned feeling the pressure from sponsors to provide a causality 
assessment quickly. What other external influences or pressures have you felt 
from third parties when it comes to? 
 
S15: Well even the sponsor, that’s kind of going over the top a bit, they don’t 
really pressure you, but ah, there aren’t any other pressures. 
 
M: What do you think are the implications of assigning causality? 
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S15: Um, well, of assigning them poorly? It’s either you under, or whatever event 
it was so you’re compromising safety of future patients who might go on this 
treatment if you um, rule that it wasn’t related to the drug. Or you might over, you 
know if you say that everything is related to the um, to the investigational drug 
then you’re over, over rating it as to whether the drug is causing problems. So it’s 
pretty serious. (apprehensive about consequences of causality attributions) 
 
M: And so what does, how is that, if you’re over scoring what are the, what’s the 
potential ramifications of that? 
 
S15: Well the potential ramifications of that is the drug might not go out to market 
and it might be a potentially legitimate drug. [okay] Because describe SAEs or 
have SAEs that might not really, that are manageable or might not really be 
100% related to the drug. Especially if you pick a poor group of people who you 
know always get admitted for nausea and vomiting because they have a poor 
ECOG status. And it could be that they were just very poor patients initially to put 
on treatment. [mmm hmm] 
 
M: So then from your perspective what would make assigning causality easier? 
 
S15:  Um, more information from the sponsor I guess in terms of um, side effects 
of the drug. 
 
M: Do you think there needs to be more pre-clinical work done or? Or is it just 
that you’re not getting the information? 
 
S15: No, no, we’re getting the information, I guess to get more information about 
the investigational drug would be more pre-clinical work. But at the same time I 
think that these drugs are put out there for in Phase I trials and it’s reasonable to 
use them at that, and not to wait any longer. I mean just to give an answer I 
would say that [mmm hmm] but at the same time I think drugs that are going out 
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now for Phase I trials I think it’s, the sooner you get it out to the patient in a 
Phase I study, the sooner it will get offered. (the drug development process is 
rushed) 
 
M: Have you every heard of an algorithm, the Narjano algorithm, a researcher 
named Narjano and he’s created an algorithm  to help clinicians assign causality. 
You’ve never heard of anything like that? [never of heard of it, no] I was 
wondering if you wouldn’t mind just looking over these questions and cross out 
any that you don’t feel are relevant to the Phase I oncology clinical trial setting.  
 
S15: So the ones that are not relevant. [yeah if there’s any there you think are 
not relevant] And so now I have to assign a number, okay.  
 
M: Yeah, and then the remaining ones if you could rank them from most 
important to least important. 
 
S15: Oh, so I have to rank them like 10, 9,8, 1 [sure] 7, 6, oh that’s going to be 
tough, this is going to take a long time. 
 
M: That’s okay, there’s no right or wrong answer and it doesn’t, you don’t have to 
over analyze it, just whatever you think. 
 
S15: Yeah, because these are all kind of inter-related, yeah okay. 
 
M: You can, if you know think some are the same, of the same importance you 
can give them the same number. We just want to get a sense of what you feel 
are the most important factors when you’re assigning causality. [okay] Great, 
thanks. Good. So the most important was whether there were previous 
conclusive reports on the reaction. And the least important was #6 Did the 
reaction reappear when a placebo was given? [mmm hmm] Okay, great. 
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S15: I picked that last one because if it’s a Phase I study you don’t often get 
placebo.  
 
M: Exactly yeah, some people have crossed it off just because it doesn’t really 
apply in the Phase I setting. Now is there anything here, like was there anything 
that came to mind that you thought oh, something should be on here that wasn’t, 
any questions that, things you think about that weren’t included here? 
 
S15: No none that came to mind but I thought they were very applicable 
questions, yeah. 
 
M: One of our thoughts was that we might just try to modify this Narjano 
algorithm to try to make it more suitable for [yeah] the Phase I oncology clinical 
trials setting. Do you think this is too cumbersome, like you mentioned. 
 
S15: No, no, they were, yeah, they totally made sense in relation to these I trials 
yeah. 
 
M: And you think it might be helpful in sort of systematizing you know the process 
and making sure that you know. 
 
S15: Well basically like all of those things we do consider [yeah] it’s you know, 
they’re very applicable to Phase I studies. I mean we don’t really think that that’s 
what we’re doing but when I was reading them all I was thinking oh yeah, that is 
what we do when we’re assigning causality. 
 
M: Lastly I would just like to ask you a little bit about your background as a 
clinical trials researcher. So which cancers do you specialize in, all of them in 
Phase I? 
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 S15: Yeah, pretty much. In Phase I it’s any tumor site, so ovarian, lung, breast, 
prostate, GI, it’s pretty much everything, melanoma, it’s everything [head and 
neck?] head and neck, everything. [wow, everything] GU is my primary, so 
basically I do GU and Phase I trials so those are my two, two areas that I work in. 
 
M: And do you have a Bachelor’s in Nursing? [yes] And where, what year did you 
receive your Bachelor’s in Nursing? 
 
S15: In 1989. I’m also a certified oncology nurse. 
 
M: Oh CANO, you have a CANO certification? [yeah] and what year did you get 
that? 
 
S15: The first year, was it 95 or 96 it was the first year that they did the CANO 
oncology nursing certification. Yes, you can write 95, 95 or 96 I can’t remember 
when. 
 
M: And when did you get your RN license, was that in 
 
S15: 79 
 
M: Oh 79 okay, so you also have a diploma then in nursing. 
 
S15: Yeah as well, yeah I also have a diploma that when I graduated in 79 and 
then I went back to university [oh good] and graduated from University in 89 [oh 
good for you okay] 
 
M: And do you have any other like Masters, any other clinical trials training? 
 
! $$(
S15: I have, yeah, I was, I’ve let my certification lapse but I was, I did have my 
SOCRA CCRP, certification, it’s the clinical, oh gee, research, Certified Clinical 
Research Professional. 
 
M: Okay and what year did you get that? [1999] 
 
M: What year did you become involved as a clinical trials researcher?  
 
S15: 97. [1997 okay] mmm hmm 
 
M: Overall, what percentage of your work time would you say is devoted to 
clinical trials? 
 
S15: 100% [100%] yeah. 
  
M: And then of that, what percentage is devoted to working on Phase I and II 
trials? 
 
S15: Oh, Phase I and Phase II? [yeah] oh 100% [so no Phase III?] That’s 
because I don’t have any Phase III trials, [You’re the specialists]. 
 
M: Can you tell me about any training you’ve received, specifically with respect to 
assigning causality to adverse events? 
 
S15: On the job training.(no formal training) 
 
M: On the job, from other nurses, investigators? 
 
S15: Um, mostly the investigators. 
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M: What additional education do you think should be made available to clinical 
trial nurses? 
 
S15: If there was an assigning causality course out there that would be helpful. 
Um, probably some, I don’t know, you know, there’s not much out there because 
clinical trials is kind of a narrow. I go to um, I go to our medical oncology rounds 
and basically I just kind of learn about new drugs and upcoming drugs just from 
attending medical rounds, just learning about what’s up and coming. But yes, in 
terms of  
 
M:  You’ve been doing this awhile now but do you think maybe something earlier 
on when you were just starting to try and figure out this whole clinical trial thing 
might have been helpful? 
 
S15: Well it’s kind of hard to say because when I started working on clinical trials 
were very different then they are now. 
 
M: Okay, how so? 
 
S15:  In just terms of the severity of patients that you’re seeing and the type, the 
types of drugs that are out there now are much more complex than the ones that 
were there when I first started working in clinical trials. It was a much simpler life 
back then. (clinical trials have become more complicated) 
 
M: Patients you are seeing now are a lot more complex because they’ve got 
additional co-morbidities and that sort of thing? 
 
S15: They’ve usually been multiply treated with you know, yeah, they’ve had 
multiple treatments as opposed to when I first started working [oh you mean now 
they’re on to 3rd line therapy] yeah, 4th, 5th, 6th line. Just the types of drugs that 
are out there now is significantly different than the types of drugs in terms of the 
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family that they come from [they’re more targeted therapies] exactly, so that’s 
really changed. 
 
M: And um, with respect to education around causality do you think it might be 
worthwhile to sort of include a module or, maybe in your, what about in your 
CANO, that’s not specifically clinical trials though is it? 
 
S15: No it’s not. You know you could do something like with NCIC but um, I 
mean if there was, even like a self-learning module that would, yeah, that would 
be helpful. 
 
M: I think that’s all the questions that I have for you [okay]. Have you got any 
additional questions for me. [no] 
Subject 16 
M: Even the most experienced clinicians find assigning causality to adverse 
events challenging. Many groups such as industry sponsors, clinical trial 
cooperative groups, research ethics boards they all expect prompt and sensible 
causality assessments. But I’m sure as you know, it’s not always [mmm hmm] 
that straightforward and if done poorly there’s implications. So we’re interested in 
developing a tool to help clinicians more efficiently and reliably assign causality to 
Phase I oncology clinical trials. We feel that by better understanding your needs 
as a clinician we can make the tool more relevant to you.  So do you have any 
questions? [no I don’t] Okay, I will just start by asking you, let’s just say one of 
your Phase I patients reports experiencing an adverse event, let’s say it’s a 
serious adverse event. Can you just walk me through how that situation is 
handled? 
 
S16: Well if the patient let’s say, there are different kinds of things, if the patient 
phones in, the patient would phone the nurse, who is a clinical trials nurse we 
would then see the patient, we would then assess them. Let’s say it’s a serious 
adverse event and we are going to then admit them and fill out the CRF’s you 
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know and putting something in. [and what about] Alternatively they might present 
to an emergency room, so they might present to an emergency room with a 
serious adverse event and then we get called by the emergency room. How do 
we assign causality? [mmm hmm] I think that’s interesting, because there are 
different issues around assigning causality. The first issue is how quickly can you 
really assign it? Often you know, you need to report within 24 hours. Within 24 
hours you may report, the person came in with chest pain, da, da, da, and you 
don’t have any real idea if it’s related or not. The second issue is deciding if 
they’re on a chronic therapy, do you continue drug or not? Because if this isn’t 
drug related then you may continue drug, if this is drug related then you don’t. 
Generally in most Phase Is regardless of whether you think it’s related or not you 
would stop drug, you know, if it’s chronic dosing. The third issue around this 
serious adverse event is sometimes you know, if it is a life threatening event is, 
there you have somebody on a clinical trial where most of the time in Phase Is 
they’re in cancer patients, they’re end stage patients you know, in that they don’t 
have curable disease, you wouldn’t go to heroic measures often. Yet in the face 
of the Phase I you may want to do more heroic measures than not. And this can 
become a problem in the night or on the weekends if the person who most 
understands the trial is not around for those decisions. So there’s also the 
decision-making around causality of, you know, you want to keep that person 
alive because number 1, if it’s related to drug and iatrogenic or whatever then 
you want to try to get them over that because you might have caused this. 
Number two, if it’s related to drug you want to see if you could reverse it because 
you might learn more about the drug. Um, number three, if you do, do heroic 
measures you might also be able to further establish is this due to drug or not? 
So then I think you get into this whole situation too of assigning causality to make 
those decisions. Having said that if this is a person with widespread metastatic 
disease it might not be appropriate to do very heroic measures. So you’re in a bit 
of a bind so you want to be able to quickly assign causality. If it clearly is a 78 
year old guy who, that man up there was in a Phase I, that guy who’s standing in 
the white suit. He was on a Phase I study and he had a massive heart attack, 
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Phase 1 study. [right] And um, on the one hand was it just due to a heart attack, 
due to being an elderly guy, in which case, it wasn’t a bad escape for a guy with 
metastatic cancer. On the other hand if it was a heart attack due to the drug I was 
giving him then maybe it wasn’t a good end. [right] I mean I think it’s a difficult 
area. I’m going around in circles. How do I assign causality? I usually assign 
causality by looking at the symptom, is it something that could be expected from 
the class of drugs that we’re looking at? Is it something we’ve already seen in the 
trial? Is it something that’s coming on a temporal basis where it could be 
unusual? So I think the first thing is that if it is something that’s already been 
seen in the trial, if it looks like it it’s temporally related, if it’s something that could 
be expected then I think that, although it might be definite, their white counts 
have fallen and they’re septic definite. More often you might not assign as a 5 
you might assign it a 4 as probably or a 3 as possibly, you know [mmm hmm] in 
terms of that. I think if it’s a brand new symptom, particularly if it’s a first in man 
drug, a brand new symptom that you don’t have any expectation of and that you 
can’t necessarily relate to temporally. Let’s say it’s a three-week schedule and 
this is on day 8 or day 10, it’s not necessarily predicted, I think it’s very, very 
difficult and I think there’s two big concerns. One is if you assign causality and 
say it’s related improperly then it might tarnish a good drug and stop dose 
escalation in a way that wouldn’t be appropriate. Alternatively if you ignore it, it 
might cause further toxicities in others and be potentially dangerous to other 
patients. I think it’s a very dangerous thing. I also think that sometimes as 
oncologists we tend to minimize rather then maximize because we’re used to 
toxicity with drugs and that can be dangerous. (err on the side of caution) 
 
M: Can you give me an example of when you’ve seen that? 
 
S16: Well I think even neutropenia you know, low white counts, we can deal with 
low white counts, so we ignore things like that often. I think we get used to 
dealing with that neuropathy in some drugs. I think that we would rather have a 
drug that works and deal with toxicity. So that in a Phase I you often don’t know if 
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the drug works but I think you’re going to accept a reasonable amount of toxicity. 
I also think it behooves us, often in cancer centers we don’t have all the facilities 
necessarily right at hand to characterize. So you know, if indeed you get cardiac 
toxicity, you’re not an intensive cardiac unit and how many of our patients would 
be accepted to it? And that’s where the heroic measures come in because you 
know, it may be that we need to have them accepted to an intensive cardiac unit 
to assess if there is really cardiac damage in a way that’s much more rigorous 
than we might assess cardiac damage in the cancer hospital where we’re not 
assessing cardiac damage, you know, it’s a different level. [phone rings] Does 
that get to you what you wanted? [yeah, yeah that’s, that’s great, so what about] 
So how do you assign causality? I think you assign causality by number 1, 
looking at is it something expected?, number 2, is it temporally related?, number 
3, is there any possible way, erring more on the side of ... You know, number 4, 
is it something that was related to a pre-existing condition or is there something 
obvious that can explain it? And finally erring more on the side of assigning 
causality to drug than not because it’s the safer way to go.[right] 
 
M: And what do you think are the implications then of assigning causality? You 
mentioned earlier 
 
S16: I think one poor, I think one problem is if you have too many DLT’s, you can 
stop dose escalation in a Phase I drug and maybe kill a good drug because you 
[54] 
 
M: Have you [55] can you give me an example? 
 
S16: Well it’s hard to know because you never know if they were going to be a 
good drug, okay? [yeah] you know? I think there’s situations where dose 
escalation has stopped but you know, you can’t really say it was a good drug 
because you don’t know because you’ve never gotten there. But I think there are 
sometimes you know where you stop drug development. [okay] And you know, 
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one example, it’s an old example but you know, you even look at Taxol, first 
Phase I study of Taxol had some doubts and then it took them a couple of years 
before they were able to figure how to give it. And you know Taxol has been 
widely used since then. Now they did eventually figure out you know, and the 
causality was true that it was due to hypersensitivity but it did stop the 
development of the drug for a couple of years and in another situation they might 
not have gone back to it. [right] 
 
M: Do you use any tools to help you when you’re assigning causality or do you 
think decision trees, algorithms of something like that would be useful? 
 
S16:  Um, possibly as a training mechanism, you know, sort of going through if 
this, then … you know, it could possibly but. You know, most of the time you 
have to do this fairly quickly, it’s not like a teaching tool. So it could be helpful in 
terms of teaching residents how to think about things, but I don’t think you’d use 
it in the real world. It could be helpful to teach nurses how to think about it. 
Ultimately it’s almost an intuitive sense of you know is this related? (doesn’t 
think a causality assessment tool is applicable in oncology clinical trials) 
 
M: What are your concerns about the way in which clinicians currently assign 
causality? 
 
S16: I think sometimes, sometimes you’re in such a rush to get the CRF done 
that I think you don’t necessarily spend enough time. And I think one of the other 
problems is we get so many reports about drugs, you know like alerts [safety 
letters?] safety letters that sometimes everybody doesn’t know these things and 
may not know if it’s related or not. I think keeping up with the safety letters is 
hard, [just because you get so many of them?] mmm hmm and not really knowing 
the drug well. 
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M: A mentioned something about you guys had developed some sort of a system 
for safety letters [mmm hmm] can you describe that for me? 
 
S16: What we were trying, we do everything electronically. What we do is we 
have a Phase I ah, meeting every two weeks and what we try to do at those 
Phase I meetings is talk about the recent alerts. And one person, the PI that 
would be assigned for that safety alert but we would then summarize it say, once 
every two weeks for all the Phase I docs so that everyone is up to date. Because 
like if A is the Phase I doctor and there are 4 other people working with him, he’s 
the only one that gets those safety letters so how do the other 4 people know 
about them? (lack of communication between clinical trials staff) 
 
M: So do you have them all in a database [mmm hmm] that’s made available to 
all the other investigators on the trial or? 
 
S16: Well yeah, we’re setting that, we actually don’t have the database set up, 
well there is a database you can go to but we’re setting up an easy database [oh, 
okay] so there will be an itemized thing. So let’s say I’m doing a study of drug X, 
we’ve talked about it let’s say at the meeting but as well as talking about it, let’s 
say I’ve just come in as a new nurse on the trial and somebody comes in with 
cough. I can go there and I can look up and oh at Hamilton there was a cough 
reported and in another study in New York there was a cough reported. I could 
go back and you know, or I might look it up and say oh well there’s been no 
alerts about this and there’s been no dose-limiting toxicity at all and no serious 
adverse events on this drug. I might say I don’t have anything to help me with the 
cough you know. You’ll be able to go back, ploughing through the whole thing. 
So what there is going to be is just a, a grid, so there would just be a grid. So let’s 
say for Phase I, X you know, you know X, there would be a grid saying you know, 
05 November, cough, grade 3 you know [right] 06 February you know, 
neutropenia, 06 March neutropenia and then I’d be 06 June, oh you know I’ve got 
another cough so that’s, I’m going to put in something you know. I can look back 
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and say well cough has already been reported with this drug. It wouldn’t have a 
lot, it would just have you know, and then, and then it would be linked so that you 
could then go to the link and you could go to the safety alert thing that’s on the, if 
you wanted to. [oh, I see] So if I said cough, I wonder if that cough is similar to 
the cough that I’m seeing today, I could then you know click on the thing, I would 
get into the safety alert letter from the drug company. Unproductive cough 
coming on, you know treatment dah, dah, dah, oh and I’d say that’s exactly like 
what I’m seeing. 
 
M: Okay, so when you receive the paper-based letter from the company you scan 
it in [yeah, mmm hmm] somehow? okay, I see. 
 
S16: We do it, well we ask for everything electronically [oh I see, so the company 
is sending it to you electronically?] they are starting to send it yeah, otherwise we 
scan them in yeah. Because otherwise you wouldn’t know you know? [yeah, 
yeah] 
 
M: And you use that in conjunction with the investigator brochure [mmm hmm] 
right? [mmm hmm]. 
 
S16: Well the investigator brochure isn’t, isn’t updated regularly. [yeah, ah ha, 
twice a year or something right?] mmm hmm. (IB not always reliable, not up to 
date) 
 
M: What would you say are some of the problems or challenges of assigning 
causality? 
 
S16: We’ve been through those, I think I already said. Challenge is figuring out if 
it really is related or if it’s due to underlying disease of the patient. If it’s brand 
new, I’m figuring out you know, it doesn’t make sense to be related to the drug. 
[so when you say] And doing it on a tight, tight time schedule. And also 
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sometimes doing it without the benefit of all the fancy investigations that you 
might have related to that site of disease. So that’s what I said, we’re in a cancer 
hospital so if someone comes in and tells me they’ve got chest pain, it’s not like 
I’m in the middle of a cardiac centre. So then I have to send my person over for a 
cardiac assessment but meanwhile the drug company wants me to assign 
causality within 24 hours. The other challenge is if they go to a different hospital 
and making sure all the right tests have been done. Often we’re assigning 
causality in a bit of a void because we haven’t necessarily sent the patient right 
then. You know, as a PI you’re asked to but let’s say it’s a Saturday and they 
went to another hospital, you know. [yeah] Or the resident saw them, you know, 
you’re assigning causality without necessarily having been right there. 
 
M: What external influences or pressures do you feel from third parties? You said 
the timeline factor. 
 
S16: The timeline, it’s mainly the timeline and the pharmaceutical company. 
 
M: Any other influences or pressures? 
 
S16: I think one could say the IRB is going to be a pressure but I don’t think it 
really is, it’s a good pressure.  
 
M: What’s their pressure? 
 
S16: Well just to make sure you’re following all the rules that you said you would 
with Health Canada or what have you. I guess the only other pressure would be 
you know making sure you can book all the tests you need to get booked. 
 
M: Right, so that comes down to availability of health services? [Exactly] 
 
M: So from your perspective then what would make assigning causality easier? 
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S16: I think tools like having all the previously known side effects of the drug 
readily available. I think that’s the biggest tool [like your database that you’re 
developing?]. Yeah, yeah, I think the second thing is being able to prioritize 
Phase I early drug patients for extra testing if you them, like if you need a heart 
scan or you need something you are able to get those done in a timely fashion. 
And I think the third thing is, always having more time for all these things is the 
other thing, but the third thing is being able to possibly inform the company as to 
the procedure. So we first inform them that something’s going on, we do this 
sometimes you know, we’re investigating it but don’t have to assume final 
causality until [8:52] which we do but it’s a lot more paperwork. So they want a 
causality right away so you might say probable and then fill out another form and 
you say no it’s not related. And they say well I want 5 forms on why did you said 
probable before and now you say not? [Yeah, more streamlined 9:08] Yeah, a 
little more fluid. (changing your causality attribution creates extra work and 
issues with pharmaceutical companies) 
 
M: Do you have any,, do you have any initiatives underway right now in terms of 
prioritizing those Phase I patients so that they can get to those tests? 
 
S16: Well we try to do it but you know, it’s not a formal system but it’s [9:25] 
 
M: Now um, what about in terms the way causality is graded because I know that 
[ the 5 grading?] well you’re mentioning 5, now which grading scale are you 
referring to? 
 
S16: Well the one we usually use is, I don’t remember what the name of it is but I 
thought it was from NCIC, definite is 5, probable is 4, possible is 3, probably not I 
think is 2 and not, definitely not is 1. I think that’s what we tend to use. The other 
one is a four one which is not, possible, probable, definite. I think we tend, most 
of our studies are 5. 
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M: Because I’ve noticed it seems to vary depending on the study and what’s sort 
of outlined in the protocol. 
 
S16: So it would be nice if there was one. I think actually you know, I think 
definite, probably, possible are the three that are most important, and not are the 
three, are the four that are most important. When can you say definite? You can’t 
say definite sometimes, probable is better some of the time, you know. Then 
when you’re writing up a paper or looking at assigning, you know possible is in 
this grey zone. But I think it’s very hard with a Phase I study to say definitely not, 
there are lots of possibles where you want to have that scale though. 
 
M: What do you understand possible to mean? 
 
S16: I understand possible to mean that there are a lot of other factors that I can’t 
assign it, but that I can’t totally rule it out. So if I said, if I did a cough and I said 
possible and this woman had no other factors, got this drug, possible. And then 
you know, the next patient in Montreal had a cough and then somebody in 
Hamilton had a cough. We could then say no, the Hamilton one by then A might 
assign probable to it. But it’s a fluid, it’s an evolving thing. So we just had a study 
where a drug, it was an NCIC early Phase II study where a drug caused 
pneumonitis and it wasn’t picked up by the first few. A number of people had 
cough and a number of people had pneumonitis and it didn’t get picked up. 
Although this class of drug could cause, the parent drug could cause 
pneumonitis, the next drug that was developed didn’t really cause a lot of 
pneumonitis and we had more experience with that and this was a new drug, a 
newish drug which hadn’t been reported to cause pneumonitis. So the first few 
were possibles, possibles and now when we see one it’s a probable or a definite. 
So it’s, it’s got to be fluid. Now should we go back? yes, in our database at NCIC 
we’ve gone back and reviewed those ones that were possible and now have 
made a lot of them you know, probable. But at the time, at the moment when this 
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causality was being assigned you couldn’t say it was probable. So that’s what I 
understand by possible. 
 
M: Are you familiar with the algorithm that was created by Narjano [no] to help 
clinicians assign causality? [no] Okay, this is it and it’s a series of 10 questions 
and I guess what I’d like you to do is if you wouldn’t mind having a read over 
those 10 questions and then cross out any that you don’t feel are relevant to the 
Phase I oncology clinical trial setting.  
 
S16: Um, Phase I, I don’t think placebo is you know. So should I just do an X on 
the side here [well just cross it right out, that’s great] I think most of these we 
wouldn’t have, I think for Phase I, already previous, that’s important, did the 
adverse appear after, that’s important, improved when discontinued but not 
usually possible, causality usually needs to be considered earlier you know [you 
have to make a call] than a washout you know. Alternative can cause reaction, 
yeah, was the drug detected in blood, usually do not have enough pk data to be 
useful, so you know, detected in blood and then we usually don’t have the pk 
data and then usually only decrease dose per patient. And then we have to rank 
them? [yeah just sort of] Most important okay. [yeah most important would be 10] 
So are they, that would be a 9 I think, now did you want them [no that’s fine]. 
 
M: And the one that’s the lowest that you ranked was number 3, did the adverse 
reaction improve when the drug was discontinued. 
 
S16: Usually we don’t have an antagonist, and discontinue, I don’t think we 
usually have enough time for that I think we’re assessing causality before that 
you know [yeah, excellent] okay. 
 
M: So I guess the thought was that we might try to modify something like this 
[mmm hmm] for use as a [yeah, yeah, good] Whether it be for a training tool or  
[or whatever yeah] 
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M: Lastly I would just like to ask you a little bit about your experience as a clinical 
trials researcher. So you’re the head of the IND program here right [yeah] and 
what cancers do you specialize in? 
 
S16: Breast cancer these days, I do HIV, some HIV malignancies and I do Phase 
I and breast. So I see everything with Phase 1. 
 
M: So what year did you receive your MD then? 
 
S16: 79 
 
M: And what year did you receive your medical oncology license? 
 
S16: 84 [84] 
 
 M: And do you have any other clinical trials, do you have a Masters or PhD? 
 
S16: No, I did the work in England, the training in England. [clinical trials 
training?] mmm hmm. [when was that] Oh, 88 and 89. 
Phone rings 
Subject 17 
M: Even the most experienced clinicians find assigning causality to adverse 
events challenging. Many groups such as industry sponsors, clinical trial 
cooperative groups, research ethics boards they all expect prompt and sensible 
causality assessments. But I’m sure as you know, assigning causality isn’t 
always that straightforward and if done poorly there are implications. So we’re 
interested in developing a tool that will help clinicians assign causality in the early 
Phase I oncology clinical trials. We feel that by better understanding your needs 
as a clinician, we can make the tool more relevant to you, to clinicians.  So do 
you have any questions then about what it is that we’re doing before we start? 
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[no] No, okay great. So let’s just say one of your Phase I clinical trial patient has 
just experienced an adverse event, a serious adverse event. Could you just walk 
me through how you assign causality in that situation? 
 
S17: Well typically it depends on the disease the patient has and typically in 
Phase I studies the patient has advanced disease in the cancer research milieu. 
Because that may have a direct effect on whatever problem they’re experiencing. 
So the immediate question is always is this a disease related event or is it a drug 
related event? Or is it something completely unrelated to either disease or drug 
and perhaps to some other underlying medical condition? I typically will base my 
opinion on a combination of patient’s history regarding this particular symptom, 
their, their examination in terms of confirming the nature of the problem and any 
relevant laboratory work. And then I will pause and reflect and think about what is 
the likeliest thing to be going on. (takes time to reflect on the situation) Very 
frequently in Phase I studies one tends to attribute any adverse outcome to the 
investigational drug or a combination of the investigational drug with other 
conventional treatment which maybe ongoing as part of the cancer treatment 
plan. exam, lab tests and basing the decision on your understanding of And only 
attributed to disease if it is very evident that the patient is having say a rapid 
progression. So the sort of examples might be, if a patient with bone mets from 
breast cancer on a Phase I trial gets started on a drug yesterday but comes in 
with a fractured femur today which has broken through a large lytic lesion I will 
very clearly attribute that to disease because there is no way the drug could have 
done that kind of damage. On the other hand if the patient comes in febrile and 
septic or they come in with respiratory problems where they previously had none, 
I would be inclined to attribute that either to the drug per se or as probably 
attributable to the drug because we’ve always got a gradation. [mmm hmm] Is 
this definitely attributable or is probably or possibly attributable on the scale? So 
one errs on the side of caution in that you do not want to underestimate the risk 
that the drug might have caused an adverse event. So it’s very much based on 
gathering the knowledge from as I said, patient history, patient their disease and 
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their drug and the balance of probabilities, which is a qualitative assessment as 
to whether you think the drug is responsible. Frequently it’s clear-cut and 
sometimes it isn’t. [mmm hmm] 
 
M: And you said that um, it’s a balance of probabilities [yeah] but that’s qualitative 
[yes] rather then quantitative. 
 
S17: Yeah, the quantitative elements factor in, but in the end you have to make a 
judgment based on probable distribution of risk. And whether you call that 
qualitative or quantitative I think there is a component of quantitative evaluation 
of the probability of the drug is responsible. But there is also some qualitative 
judgment based on your years of experience as a practitioner. More often then 
not we will attribute either definite causality or probable or possible causality to 
the drug if there is no other reasonable explanation. [right] 
 
M: And how do you differentiate between probably and possibly and definitely, 
you know, what sort of? 
 
S17: Sometimes it’s difficult. I think a very good example might be a patient with 
advanced cancer has begun a Phase I drug and sometime later, it could be a 
week or several weeks later the patient gets the deep vein thrombosis and a 
pulmonary embolis. Now you know patients with advanced cancer have a high 
risk of getting those types of adverse events so you will classify it as an adverse 
event. I think when it comes down to assigning causality as to whether it’s 
disease, I think you can only say that there’s either a probable or possible 
relationship to the drug. You can’t exclude there being a relationship but nor 
could one unequivocally assign the accountability to the investigational drug. 
[mmm hmm] (rare and difficult to assign ‘definitely’) And one only sorts out 
those sorts of questions when you eventually get to Phase III randomized trials 
where there will be adverse events in both groups and you are looking at the 
relative incidence [right] in both groups. [right] A classic example would be 
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hormone treatment for breast cancer. [right] I, I think most of the doctors who do 
a lot of clinical research are aware of the fact that you don’t want to 
underestimate the toxicity of a drug. But at the same time you don’t want to 
assign every single adverse event to the drug some will not be due to the drug. 
So you usually end up in the, this is a possible to probable consequence of the 
drug if it’s in the grey area where there could be many reasons why the patient 
had an adverse event. (apprehensive to make an attribution outside the grey 
area) 
 
M: What are your concerns about how clinicians currently, how they currently 
assign causality? 
 
S17: I think the concern inevitably has to be consistency. For example, if you 
have a Phase I trial with multiple investigators or it’s taking place in multiple sites 
their level of attribution of causality to the drug may vary between investigators. 
One always worries if an investigator who is on, perhaps working with a drug 
company may wish to minimize adverse events because they really want this 
drug to be a success or acceptable. And it need not necessarily be driven by 
egregious opportunities around receipt of research funds, it may be because they 
get sort of um, too invested in the drug itself and wanting it to succeed or wanting 
their career to succeed or something of that nature. But that can induce 
investigator bias. (researcher bias is a concern) Um, on the other hand you can 
have some investigators who um, will always attribute causality to the drug 
because they rather simplistically think if anything bad happens it must be the 
drug. Now an experienced investigator, and none of the people doing Phase I 
clinical trials are inexperienced, usually they are the most experienced, they are 
very unlikely to over attribute causality to the drug. Sometimes with Phase III 
trials where you’ve got inexperienced investigators who are born pessimists 
perhaps. So in reality there needs to be a dialogue between investigators about 
how they do it, or even a tool as you’re discussing, as to how you try and do the 
attribution. [mmm hmm, mmm hmm] Internal consistency, that’s what I mean 
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[right] not only, there has to be a reliable and reasonably accurate approach to 
consistency as well. You can be consistently bad at it [that’s right] if you’re not 
careful. [ that’s right, reliable but not valid right] That’s right you could be 
consistently invalid [yeah] yes. (consistency isn’t always a good thing) 
 
M: What would you say are some of the problems or challenges with assigning 
causality? 
 
S17: Um, the principal problem is the multi-factorial nature of the adverse events. 
In an ill population with advanced cancers to whom a number of adverse events 
would naturally accrue even if you didn’t give them any treatment. So it’s the 
difficulty in discriminating between disease versus drug. And this can be 
particularly the case if you see abnormal liver function tests, abnormal renal 
function, non, non-specific pulmonary infiltrates in patients who may have a 
predilection to become infected, which could be drug, could be disease, you 
know, I’m thinking of lymphoma, myeloma patients. The biggest difficulty is that 
sometimes it isn’t clear and it never will be clear. (there may never be a clear 
cut answer) Sometimes it becomes clearer over a period of time when you do 
investigations and you finally give your best assessment. But these are all 
evaluations that take time to come to a reasonable conclusion. You may have, 
you may send in an immediate adverse event notification form because the 
patient is very sick today and you may not know why completely, but over the 
course of the next week or so you may have a much clearer idea and then you 
can further clarify that. But in reality it comes down to investigators conducting 
appropriate evaluations and appropriate management. (first time management 
is mentioned)And investigators having clinical expertise as well as being simply 
able to look at [9:07]. So you need a degree of balance analytical thought and 
you need a degree of [9:14]. 
 
M: What do you think would make assigning causality to make it easier then? 
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S17: It’s not easy to make it easier. [laughter] I’m somewhat skeptical that this is 
going to get any easier and I’m not even completely convinced a tool will make it 
easier. But I would very much welcome any thoughtful presentation on making 
assignment easier. My sense is that if a tool is developed or any other strategy it 
should be a means of enhancing the dialogue between investigators. (lack of 
communication) Not only for a single study but between investigators who 
collaborate across a range of studies. [okay] Say at the National Cancer Institute 
of Canada level and so on. So it might need some high level thinking by the 
leaders in a clinical trials organization and some dialogue that perhaps could be 
based on a communication tool that would be a prompt to them in trying to define 
causality into different categories. 
 
M: What do you sort of envision this communication, I know you’re thinking, 
you’re probably thinking this is best left to the higher ups in the, sponsors. 
 
S17: Oh no, no I think um, in some ways one could evolve a tool that has some 
relationship to, for example the National Cancer Institute of Canada or other 
clinical trials toxicity criteria. So you could base it on toxicity criteria which are in 
well described categories, of you know, what do you call it performance status, 
renal, hepatic, pulmonary, those sorts of things. And you could potentially go 
through those and say well, under which circumstances are we likeliest to see 
adverse events in this category based on causality related to the drug? Under 
other circumstances are you likely to see them? In reality you would have a 
different assignment for different [  ]. A communication tool that would address 
dialogue between investigators would be essentially helpful. But it could also be 
quite complicated. And a tool that would, facilitate the assignment at the time of 
the event I think will be quite challenging to design so I think it will be interesting 
to see what other people might come up with. [mmm] And it would have to be 
practical and useful to the clinicians in order to be greeted warmly by them. 
[mmm hmm, great] (tool will not be readily accepted by clinicians) 
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M: Given the choice, would you prefer to grade causality on a scale or as a yes 
related to the drug or no not related to the drug? 
 
S17: You cannot possibly do it on a yes or no. A scale however shouldn’t be a, I 
don’t think a 1 to 10 scale is a good idea. The vast majority of causality 
assignments are on a scale and they usually are categorized as unrelated or 
related which is a yes or no and at least two in-between, so possibly and 
probably. And I’m very comfortable with that because I honestly do not think it’s 
easy to get down to a much more detail than that. [mmm hmm] Plus it gets pretty 
hard to garner all that information as part of the reporting to ethics comities and 
to applications that come out of clinical trials. So about four categories is fine for 
me which is the type of modified scale. [mmm hmm] 
 
M: Have you ever heard of an algorithm that was developed by a researcher 
named Narjano? [no] No, he’s developed an algorithm to help clinicians assign 
causality and this is it here. I was wondering if you could just have a look over 
those questions [mmm hmm] and cross out any that you don’t feel are relevant to 
the Phase I oncology clinical trial setting.  
 
S17: Why would you want to know did the adverse event appear after the 
suspected drug was administered, there’s no, we’re not in the business of 
reporting events that occur before the drug is administered, that’s stupid. That’s 
okay. Any previous conclusive reports on this reaction? This is vague, reports on 
this patient or reports on this drug, that needs to be much more specific. [mmm 
hmm] Drug reports, patient reports, sloppy question. Um, did the adverse 
reaction reappear when the drug was readministered? That’s highly relevant. Are 
there alternative causes that could have?, yes that’s relevant. We do all this 
automatically. Did the reaction reappear when a placebo was given? It is not 
routinely giving a placebo to monitor for a reaction so this is impractical, might do 
it in certain at both ends. Was the drug detected in the blood in concentrations 
known to be toxic? This is occasionally helpful. Helpful but, I think it’s not relevant 
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in a Phase I clinical trial because you don’t know what a toxic dose level is. [right] 
I’ll put a tick but I’ll but dubious here. Was the reaction more severe when the 
dose was increased, or less severe when the dose was decreased? You’re not 
going to be increasing the dose if you got a severe reaction. Are these severe 
reactions or not severe reactions? If it’s trivial you might, for example, low white 
count, might not necessarily spur you to reduce the drug if you don’t think it has 
an adverse effect on the white blood cell. So this is, this is probably relevant. Did 
the patient have a similar reaction to the same or similar drug in any previous 
exposure? This is not helpful in a Phase I setting, because really how many 
Phase I trials is any one patient going to do, or classes of the same drug? Now in 
the fuzzy wuzzy Phase I world of pretty harmless drugs for well volunteers is a 
different situation, which is why this was written. For example, there’s a lot of 
healthy volunteers where you can try anti-depressant A for Phase I and they’ll 
come back and you pay them some more money and they’ll do anti-depressant B 
or analgesic. So they may have had a similar reaction in a similar class of drugs 
but truly on the oncology clinical trials and this says oncology here, I think it’s 
unhelpful because you’re not likely to be offering Phase Is in the same class to a 
variety of patients. [mmm hmm] And one rarely offers Phase Is in the cured 
patient setting or the well patient setting. Not that it’s impossible but it’s a rare 
event [yeah] in Phase Is. Was the adverse event confirmed?, yeah this has to be. 
So this is a pretty useless scale, I wouldn’t put any investment into that one. 
[okay] The things that are ticked as yes you would automatically do, so that kind 
of thing is unhelpful. The things that are silly one would be horrified if one was 
asked to do them because they’re a complete waste of your time. So that type of 
scale is useless. [okay, good, that’s good feedback] I’d be interested to know 
after we finish this interview what everybody else thought of that scale. [laughter] 
But don’t tell me now, it might prejudice the rest of my replies. [laughter] 
 
M: So were there any questions on here that you felt, you know, in a tool similar 
to this were there questions that maybe should be on here but weren’t? 
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S17: Yeah, lots of questions, poor tool, weak, important questions left out. And 
I’m not going to try and design it for you because it would take me too much time. 
So the sort of thing for example, if you have a patient, this might not be for a 
Phase I trial but, if you’re testing out something that causes hot flushes in people 
who are post-menopausal and have hot flushes anyway, um, that’s not a serious 
adverse event but it may be a toxicity. And it’s such a common event in that 
natural phase of their lives that it’s not even related to disease, it may be a 
completely separate physiological process that’s ongoing and not related to the 
drug either. So I think that you need to have some clear thinking around how you 
accumulate toxicity data in a range of clinical trials. It needs to be developed 
specifically for what the disease entity stage of the disease and the type of drug 
that you’re studying. So the one size fits all is going to be quite challenging I think 
yeah. [yeah] (each situation is unique) 
 
M: Lastly I’d like to ask you a little bit about your experience as a clinical trials 
researcher. [mmm hmm] In which cancers do you specialize? 
 
S17:  Currently breast cancer, previously lymphoma. [okay] 
 
M: And you have your Bach, MD, what year did you receive your MD? 
 
S17: 1976 
 
M: And what year did you receive your medical oncology license? 
 
S17: 1982, 82, 82 
 
 M: And do you have any other degrees, Masters, PhD any other fellow, clinical 
trials related education? 
 
S17: Clinical trials  
! $&*
 
M: What year did you become a clinical trials researcher? 
 
S17: So I joined in 1982 and I’ve been doing clinical trials ever since. [okay, 
great] Yes, so that would mean, yes that is 24 years of clinical trials [yeah that’s a 
lot] mmm, hmm. And I’ve done Phase I, Phase II and Phase III. 
 
M: And so what percentage of your workload would you say is devoted to clinical 
trials? 
 
S17: Well it depends on how you ask the question. In term of my own patients, 
very little these days, probably 10%. But I’m in overall charge of all clinical 
research for the BC Cancer Agency and I’m the acting Medical Oncology. So 
everybody doing clinical trials is responsibility, is responsible to me for their 
academic performance and their clinical standards and their clinical research. So 
a lot of my day-to-day activities is oversight of clinical research, 25%. [okay] So 
that’s not me directly doing it, it’s 10% direct and 25% oversight and leadership. 
 
M: And of your direct clinical trials [mmm hmm] what percentage of that is Phase 
I, Phase II? 
 
S17:  Nowadays I do principally Phase II and Phase III because I’m too busy in 
my leadership position to do Phase I, so I’m doing 0 Phase Is at the present. 
[mmm hmm] In the past I used to do a very small volume of Phase I patients. 
 
M: What percent is Phase III? 
 
S17: Um, it’s probably 50/50 Phase II, Phase III. [okay, so 5% Phase II] yeah, 5% 
of the time [yeah, sorry, I’ve just confused myself] that’s okay. 
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M: Can you tell me about any training that you’ve received specifically with 
respect to assigning causality? 
 
S17: Um, directive training I don’t know that any of us has received much 
directive training. But we’re all collaborators in cooperative groups where we 
spend a lot of time discussing causality. So through our participation on 
committees at the National Cancer Institute of Canada and in the case of some 
other investigators here, NSABP. We are involved in the discussions and the 
formulation of the reporting systems for a variety of clinical trials activities. We’re 
all very well educated, but it’s been learning on the job rather than signing up for 
a course. [mmm hmm] And also participating as leaders there. 
 
M: What additional education about assigning causality, if any, do you feel needs 
to be made available to clinicians? 
 
S17: I think it would be extremely helpful to have an educational forum for young 
new investigators as they begin their careers on staff. Not so much for residents 
because they’re not filling in these forms as residents and I think it would be too 
much information for them at that point. But as soon as people join a medical 
oncology academic facility, even a community oncology facility where they are 
conducting trials I think that could be helpful. And I think best run through 
cooperative groups like NCIC. And I think if it’s funded through a variety of 
different mechanisms there would be some specific courses for young 
investigators on causality. Or indeed completion of, of clinical report forms for 
clinical trials in general. [mmm hmm] Now some of this evolving, like for example, 
we all have to qualify that we’ve done certain ethics committee, ethics training in 
order to be qualified investigators. So there’s some on, online tools you can use 
for education around ethics. And you also have to prove that when you’re audited 
by Health Canada that you have a comprehensive understanding, we’ve just had 
a Health Canada audit, understanding all aspects of clinical trials and doing the 
causality issues. So I would think the most useful tool to be developed wouldn’t 
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be an assessment tool, it would be an educational tool. [mmm hmm] (feels 
training and education is more important than trying to incorporate a tool) 
And an educational tool that would be an online tool as, would be helpful as well 
as potentially some educational forum, perhaps once a year at, nationally, I 
wouldn’t hold this regionally, or through universities, they’ll never get their act 
together. But a national approach under the auspices of NCIC or the Canadian 
Strategy for Cancer Control or CAPCA would be I think a reasonable thing to do. 
An educational tool I think would be very helpful. 
 
M: What’s CAPCA? 
 
S17: Canadian Association of Provincial Cancer Agencies, they are the people 
who hire all the people doing all the investigations. [okay] 
 
M: I think those are all the questions that I have for you. Do you have any 
questions for me? 
 
S17: Oh yes, completely unrelated to the survey, I’d like to see, hear what 
everybody else’s response was to that tool that you showed me. 
 
M: Yes, so what we’re going to do is we’re going to compile all the information 
[mmm hmm] that we’ve gathered through these interviews and we’ll be providing 
each of the participants with an executive summary of the results. [mmm hmm] 
And our goal is to present at the Fall NCIC meeting [okay] and, and, we also 
hope to write this up as a qualitive study. [mmm hmm] And then of course this will 
inform whatever tool becomes developed. But ah, a lot of your comments were 
quite, you know, many people have, have said similar things. Like a lot of people 
have crossed out this placebo question [laughter] not relevant at all. I definitely 
agree with you that there are, it’s very vague, some of the questions are 
extremely vague and need to be better defined. [yeah] Um, I think overall most 
people feel that this is sort of thing that would be helpful if it’s not too 
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cumbersome and not too administratively burdensome and um. It’s really varied, 
um, in terms of what questions people think are, would be useful. You know 
things, pk values people said we just don’t have that information [precisely it’s 
pointless]. So you know, maybe further on down the line [yeah] we might look 
back 
 
S17: Months later when all that data comes in say wow, that guy’s really high 
level, maybe that’s related to whatever happened you know. [yeah] But at the 
time it’s very hard to make that assignment. 
 
M: So, but I think this is very valuable information and I think you know, this, this 
needs to be heard by regulators or the people that are making these [yeah] these 
sorts of  
 
S17: Regulators need to hear it, some sponsors of trials need to hear it, the role 
of the clinical organization ought to be able to provide I think some educational 
opportunities. And I do not know whether anything is evolving through the 
national NIH or the National Cancer Institute in the United States because they 
do have some online educational things. It’s something that I think J or R may 
have at NCIC. So I think it does help to improve the, but honestly a tool of the 
nature of the one you showed me is just a joke because any clinician who 
pauses to think at all can do better than that at first pass you know [right]. So, so 
a tool has to enhance our capability and not be too dumbed down that it’s not 
helpful or contain questions that are not relevant. So I think the delivery tool is 
quite a challenge to develop, the educational tool I think would be quite. 
 
M: Okay, well that’s great, I really appreciate the time. 
Subject 18 
M: Even the most experienced clinicians find assigning causality challenging. 
Many groups such as industry sponsors, clinical trial cooperative groups, 
research ethics boards they all expect prompt and sensible causality 
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assessments. But I’m sure as you know, assigning causality isn’t always that 
straightforward and if done poorly it can have implications. [yeah] So we’re 
interested in developing a tool to help clinicians more efficiently and reliably 
assign causality to, during the Phase I oncology clinical trials setting specifically. 
[yeah] We feel that by better understanding the needs as a clinician we can 
develop a tool that is more relevant to you. So do you have any questions then 
before we start? [no] No, okay. So let’s say one of your Phase I clinical trial 
patients experiences an adverse event, [mmm hmm] let’s say it’s a serious 
adverse event. Can you just walk me through the thought process you use when 
you’re assigning causality to that serious adverse event. 
 
S18: Um, I think the thing with Phase I most investigators, and I’m no exception, 
are fairly conservative. So when in doubt, you know, it’s kind of a diagnosis of 
exclusion but if there aren’t a lot of confounding factors, it’s a low threshold to 
attribute it as a possible or probable association. And so usually I kind of look at, 
multiple things, I’ll look at temporality, like was there sort of a before and after 
thing related to administration of the agent, so time sequence or temporal course. 
I’ll look to see whether, you know, if it’s something that improved with withdrawal 
of the agent. So you know, sometimes you can’t make that in real time because 
the event has happened and you’ve withdrawn it. I try, and that’s harder again 
with the Phase I to see if it’s biologically plausible. So if I have an anti-VEGF 
agent and I get someone with malignant hypertension and even though it’s a new 
agent but that’s the mechanism and I know that’s the experience in that class 
[yeah] I kind of will think okay it’s plausible that would have happened. Um, and 
then, I mean those are kind of the, and then you obviously exclude other obvious 
confounders. So the workup would include excluding you know, you’re of 
differential things that could cause whatever that toxicity would be. And then you 
basically, the composite of that and decide, I have to admit, it’s infrequent that I 
can say definite unless it’s a scenario where there’s really nothing before and the 
person is well from that systems point of view and there’s no confounders and 
they get the drug and it happens right after you know. So a definite would be like 
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an infusional reaction and you know that that’s happened. But more common it 
falls in the possible or probable. I don’t think I’ve ever, to be quite honest, had a 
serious adverse event and been able to say absolutely not, like there was no 
association in, in a Phase I. That’s not true for other things where you have more 
experience with the agent. (the less developed an agent, the more it is 
attributed) 
 
M: How do you, how would you differentiate between possible and probable, like 
what, what? 
 
S18: Just index of suspicion so, um, I don’t know, nothing fancy. I think for me  
probably of all of those the biggest thing is the time sequence, like the 
temporality of it. I don’t have a you know, if it meets one of my three criteria I say 
possible and 2 of the 3 I say probable, it’s more of a gut feel. [ah ha, okay] 
(intuition) 
 
M: What are the resources you refer to when you’re assigning causality? 
 
S18: Resources, so I will, so if someone has had a serious adverse event, you 
grade the severity and usually we use the NCIC CTC criteria so. And typically we 
don’t usually that vigorously assign causality unless it’s 3 or 4. And then I’ll look 
at the investigators brochure or the protocol to see if this was like a described or 
known effect. (more serious toxicities are assigned more carefully) 
 
M: What do you mean when you say don’t vigorously assign causality [well 
usually] unless it’s a 3 or 4? 
 
S18: Well those are the scenarios where you have to do it right away, because if 
it’s a serious adverse event, it’s not that you don’t do it after the fact, you have 
time. If it’s a grade 1 or 2 you have time to follow it and then see what happened 
with it, like if you withdraw the agent and it worked. But usually with a serious 
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adverse event we often have to report it within 24 hours and we have to give 
some idea of what happened. And often you’re asked to give an attribution of 
what we think is the likelihood of it being related to the drug and make a decision 
if the patient is staying on or coming off, those kinds of things so. [yeah] It’s, so 
the grade 3/4’s are more pressing ones is what I [right] should say. Um, but the 
resource basically it’s looking at the, trying to grade the severity of the toxicity 
and then looking to see what information you have on that agent you know. So if 
it’s an agent that has, whether it’s a lit review or the other Phase Is that are 
available for it [okay] yeah, that’s about it. 
 
M: Where would you get the other Phase I data information from? 
 
S18: Usually do um, abstract searches, Pub Med, often, because they’re not 
really, by the time they’re published, you’re onto a Phase III. [yeah, so abstract 
searches] So abstract searches or speak to colleagues or other investigators who 
have studied the drug. 
 
M: And usually your other colleagues are here or elsewhere [wherever] wherever, 
yeah, okay. 
 
S18: There’s a fairly small community in Canada for people like you know, so if 
it’s a Phase I being done at multiple sites so let’s say it’s being done through 
PMH and we’re doing it here then we would contact you know PMH. Or if it’s 
being done through NCIC we’d contact the NCIC office and see if this has been 
reported. [right, okay, good] 
 
M: Are there any tools that you use when you’re assigning causality? 
 
S18: Are there tools out there? [laughter] no I don’t. (demonstrates the 
seriousness of this issue) [okay] No, other than the attribution scale that just 
sort of, that tells you how to rank it, it doesn’t. I mean there’s, like there’s those 
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five, those principals of association versus causality and that’s what you follow 
and I already talked about that. Time sequence, dose response, withdraw it and it 
goes away [how did you learn about those?] biologic possibility. [you know, do 
you]  I think we all learn it at some point, I don’t know where but, it came up at 
some point in my training I’m sure [in med school or something] yeah, yeah. 
[what did you call them, principals of?] Well there’s a, I don’t know what the, if 
you asked me for a reference I couldn’t. But there are sort of 4 or 5 criteria that 
you use when you sort of say there’s something a potential association versus 
assigning actual causality to it. And the more criteria is satisfied the more you can 
assign causality to it. And it’s usually related to like exposure, risk of expose and 
an outcome. [mmm hmm] So you know, smoking causes lung cancer [yeah] [so 
like the Bradford Hills criteria] I don’t know the name [yeah, yeah]. But the idea is 
supposed to be you know, so then they, the example is smoking again, if you, it’s 
biologically possible if you, usually the smoking happens before the lung cancer. 
If you stop smoking you decrease your risk of lung cancer [mmm hmm] and 
there’s a dose the, the more you smoke the more likelihood you have of getting 
lung cancer [right, a dose-response yeah] and there might be another one but I 
can’t. But those are the, I think that’s the context in which it was initially 
presented to me somewhere [yeah] but I use it for that. I mean it’s for the same 
idea and it kind of fits, but a tool would be nice. As far as, it’s interesting, as you 
try to articulate the rationing, the reasoning, you know, I’m like well, that’s very 
hocus-pocus. But that’s, there isn’t, I’m not aware of a refined clinical tool in the 
trial setting that helps assign attribution. [okay, good] (again, reiterates the 
seriousness of the situation) 
 
M: What would you say are some of the problems or challenges with assigning 
causality? 
 
S18: I think, um, the, the challenge is what we were just talking about, it’s not ah, 
it’s probably not reproducible, like there’s a lot of bias, it’s probably and there’s 
sort of intra-investigator variability. (reiterates what was found in the literature: 
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low reproducibility of clinical judgment) You know, where the same event can 
be attributed differently because a lot of things, it’s a subjective assessment. It’s 
not as objective as it should be, I think that’s what makes it a challenge. (feels 
the process is too subjective) Um, I think any time with an investigational 
agent, like I said your antenna are fairly high up and you probably are more likely 
to ah, to lean on the side of, you don’t want to harm a patient or subject to harm 
to assign causality where it may not have. Like assign a higher level of attribution 
even if it may not have been. So you know, when in doubt the diagnosis of 
exclusion is going to be that it’s, it’s the investigational agent. [yeah] So, and that 
may be unfair to the agent under development right. [mmm hmm] So it’s just your 
level of, you scrutinize it more, like I said a more conservative approach to when 
in doubt, better to say it’s possibly related than not. Those are, and no tool. 
[laughter]  
 
M: That’s one of the challenges. [one of the challenges] So you think a tool would 
be useful then? 
 
S18: I think, I mean [what would] I mean something that’s standardized, 
something that, that at least, so there is, like some, potentially less variability in 
how we assign, um, because I don’t think it is standardized. I mean there, I have 
to admit, there are sometimes when um, I will be reviewing SAEs for other 
agents. Like if it’s a trial and we are asked to decide if we are going to submit it to 
our REB, that kind of thing. And you look at them and they’re so obviously not 
related or they’re so obviously related and then they will often tell you in the little 
synopsis what the investigator felt. And you’re looking and thinking, how, how did 
you come to that conclusion? Because based on the clinical information 
provided, it either totally doesn’t make sense or, and so you. So clearly people 
are interpreting it quite differently and so, I think it really isn’t, isn’t standardized. 
[phone rings] And it’s taken for granted that people know how to do it. Do you 
mind if I get that? [sure]. (major inconsistencies due to lack of 
standardization) 
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M: So with this tool then, what do you think, what sort of criteria should it, what 
should it um, look like? 
 
S18: I think ideally, I would think of it like, you know a set of criteria, like 6 or 8 or 
10, points and then you could say that if you had, let’s say it’s a 10 point scale, if 
you decided there were 10 criteria, if you have 8 or more is definite and 5 to 7 it’s 
probable and 3 to 5 it’s possible. Like that kind of a [yeah] something objective, a 
scoring system I think is probably, something that, something that would be 
helpful. [mmm hmm] And it has to have some measure of flexibility because 
people may not have all the information available to be able to do it. Like in the 
scenario where I said if you have to report it right away, although you can go 
back and change what your attribution was but it has to be a little bit flexible and 
should be simple and easy to remember [laughter] and that kind of thing. [yeah] 
So maybe not ten points. [laughter] 
 
M: What are your concerns about how clinicians assign causality right now? You 
already sort of touched on that briefly. 
 
S18: Um, I think my concern is I don’t know how they do it. (big statement) And 
so you know, we have to trust each other’s judgments when we kind of determine 
the safety profile of something or are presenting it to a patient. So I think, it’s just 
I don’t, I don’t know how they do it. My concern is that people may be too, may 
be not as rigorous in pursuing whether it’s related to the drug or, or, you know I 
just don’t yeah, I don’t know what the, there’s no accountability for it, we just 
assign and that’s about it. Usually, I mean for industry sponsor I don’t know, for 
industry-sponsored trials the company will also try to look at it and put it into 
some context. But the company is not a completely unbiased perspective and so 
you have to kind of decide for yourself. [yeah, okay] 
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M: What external influences or pressures from third parties have you felt when 
assigning causality? 
 
S18: I haven’t had any. [no?] No. 
 
M: What I’d like to do know is just give you a quick, what this is, this is a tool that 
was developed by a researcher named Narjano to help clinicians assign causality 
to adverse events. I’m just wondering if you wouldn’t mind reading over the 
questions and then crossing out any that you don’t feel are relevant to the Phase 
I oncology clinical trial setting. Have you ever seen this or heard of this before? 
[no] 
 
S18: The ones that I feel are not necessary? [well just not relevant to the Phase 
1 setting] Probably the only one is the placebo question [number 6, yeah]. You 
don’t have a lot of dose going up and down in a Phase I either, number 8, I don’t 
know how, but it does depend on the trial, sometimes there are dose escalations 
done within a single patient so I suppose that’s possible. But this, this, like I said, 
the flexibility thing it would have to be, for something like this there would have to 
be an option to say not applicable like [yeah] something like the scale should be 
80% of whatever denominator you have left. That kind of a scale versus absolute 
numbers. Confirmed by any objective evidence [you don’t know what that 
means?] Was adverse event confirmed by any objective evidence? [yeah I think 
it’s a bit vague too] yeah [needs to be better defined]. I think if, yeah, I think it 
needs to be defined a bit more, like a rash and did you actually see it? or. [I think 
sort of what yeah, that means] That needs a bit of clarity. Everything else makes 
sense yeah. 
 
M: Are there any things that you think are more important than others, should be 
weighted more heavily?. 
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S18: I think, to me the whole before and after time sequence I would put a lot of 
weight on that. [so is that 1 and 3] So 2 and 4 [sorry, 2 and 4 yeah] appear after 
and then I’d probably say did it disappear for 3 would be the next one, 2, 4, 3. 
 
M: Would you be able to just rank these [oh sure yeah] so 10 would be the most 
important and 1 would be the least important. [1 is least important] Okay, great, 
thank you very much. Now is there anything here you think is missing [10 is most 
right right] yeah, 10 is most important. 
 
S18: Anything missing, no I think this about covers it, I think so. [yeah] 
 
M: And do you think something like this would be too cumbersome or? 
 
S18: If there was some way to collapse it, maybe, because as I look at it, 10 is 
probably too many points. So if it could be fewer, like some of these are 
overlapping questions, like the does it get better when you stop is overlapping 
with the was it worse when you had more drug or less? Like these are, these are 
kind of overlapping questions, 8 and 3, yeah, they’re asking the same thing and 
there might be ways to collapse them into, into one. [mmm hmm, alright, great] 
 
M: Now I just wanted to ask you a little bit about your experience as a clinical 
trials coordinator. So, in which cancers do you specialize? 
 
S18: GI [GI] 
 
M: And um, you have your MD? [mmm hmm]  What year did you receive that? 
 
S18: 96, 10 years [good for you] 
 
M: And ah, your medical oncology license, when did you receive that? 
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S18: It was 2001. 
 
M: And do you have any other Master’s, PhD or? 
 
S18: Public Health. 
 
M: Oh yeah, where did you do that? 
 
S18: I did it at Boston [okay, the Harvard] Harvard program yeah. 
 
M: What year did you complete that? 
 
S18: 2003. 
 
M: How did you like it? 
 
S18: It was good, a good program, it’s good for clinicians I think, its geared 
towards it’s not esoteric, I was able to, you can do it in the summers, that’s the 
beauty of it you know, so it’s a good program. [good] 
 
M: Any other certifications or qualifications related to clinical trials? 
 
S18: I mean I did a sort of clinical research fellowship after, from 2001 to 2003 in 
GI and that was, so that included protocol, writing protocols, involvement in trials 
and that was at Mayo. 
 
M: So what year did you become involved as a researcher? 
 
S18: Here? So officially, like independent [mmm hmm] 2003. 
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M: And what percentage of your worktime would you say is devoted to clinical 
trials? 
 
S18: Oh, you mean actually seeing patients on trials or writing trials and doing 
trials [all related to trials] all of it, 25%. [25%] 
 
M: And then what percentage of that is Phase I, Phase II versus Phase III? 
 
S18: Oh um Phase I, it’s probably, I mostly do Phase II so I would probably say 
50 Phase I and II and then 50 Phase III. 
 
M: And have you been a local PI ever here? yeah. And can you just tell me about 
any training you’ve received, specifically with respect to [background noise] do 
you mind if I close this [no] this recorder will pick every little sound up. [oh that’s 
okay] So can you tell me about any training that you’ve received specifically with 
respect to assigning causality to adverse events. How did you learn how to do it? 
 
S18: Formally, I don’t have any recollection of any formal training. Now, we have 
to, we have to do, other than when we sign up to be investigators through NCIC 
you have to make sure you’ve done the ethics for. I mean the ethics for 
conducting human clinical trials, the online web thing [yeah] but I don’t think we 
have to do anything that relates to GCP, like Good Clinical Practice, assigning 
attribution formally. I don’t think there’s anything. So I don’t think, there wasn’t 
very much else unless I slept through that class or I missed it, if there was I 
haven’t done any. [no] 
 
M: I think something is actually in the works [yeah] with NCIC for developing 
some sort of ah, GCP thing. 
 
S18: That would be good because they have a new investigators workshop, 
that’s really about, this is the NCIC, it’s not really about some practical 
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information about how to like conduct clinical trials. [yeah] And I have to admit 
the, both through my Fellowship and the Harvard Program there are courses on 
design and conduct of trials and stuff. But most of them focused on like 
developing a trial and writing up a protocol. There’s not much emphasis on the 
actual execution part of, of the protocol. So I, I, I don’t think there has been that 
formal training. 
 
M: what additional education about assigning causality do you feel should be 
made available? You know, do you think something like that would be useful? 
 
S18: I don’t think it requires a whole course. I think a tool. Practically speaking if 
you look at the breadth of people who are involved in enrolling patients to clinical 
trials and are investigators. I don’t think everyone needs to take a formal, I think 
that’s why tools are helpful and the questions are fairly intuitive, like when you 
read it, it does make sense so so I think it just needs to be standardized. If there 
was something that everyone had to do that related to GCP and include that and 
it could be a web based type. Make sure you’ve gone through that, understand 
what, what it means when you, like even the grades of attribution and what it 
means when you assign causality. But I’m not sure it needs to be a big course. 
[no] Yeah. [yeah, okay, great] 
 
M: I think those were all the questions that I have. [excellent] Thanks very much, I 
really appreciate your time, I know how busy you guys are. 
 
S18: Yeah, it’s a good, good effort I think that, that we do need something at the 
NCIC level. I’m surprised, I’m surprised there aren’t, are there tools out there that 
are in use [not in use] that in the groups, nothing [no]. (big statement) 
 
M: This, this is one that’s been developed and there have been others that have 
been developed but it just doesn’t seem like, based on the people that I’ve talked 
to, nobody is really familiar with it [yeah] don’t even know that it exists [yeah] 
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never mind using it you know. So I think it would be really good if we could try 
and get something like this, just, especially for young investigators who are just 
starting out and really aren’t sure how to do this. [yeah] I think once you get to a 
certain level you, you know [yeah] it becomes second nature but. 
 
S18: Because many of us learn from seeing what other people, like you, it’s just 
very off the cuff and I think a tool would be useful.  It’s a huge hole. I can’t believe 
it. (big statement) 
 
M: Well that’s encouraging, that’s good, great, thanks. 
Subject 19 
M: I will just give a little background about what it is we’re doing. We’re interested 
in knowing how clinicians assign causality to adverse events during Phase I 
oncology clinical trials. [okay] And, um, so even the most experienced clinicians 
find assigning causality to adverse events challenging. But some groups such as 
industry sponsors, clinical trial cooperative groups, research ethics boards, they 
all expect prompt and sensible causality assessments. [mmm hmm] But 
sometimes it’s not always straightforward [mmm hmm] and if done poorly it can 
have some large implications. [mmm hmm] So we’re interested in developing a 
tool that can help clinicians efficiently and reliably assign causality during Phase I 
oncology clinical trials. And we feel that by better understanding the needs of 
clinicians we can make the tool more relevant to the people using it. So do you 
have any questions [no] before we start? 
 
S19: No, I completely understand where you’re, the issue. 
 
M: Okay, so first I’d like to better understand the reasoning that you’re using 
when assigning causality. So let’s say one of your Phase I clinical trial patients 
experiences a serious adverse event [yeah] can you just walk me through how 
you think about the situation when you’re assigning causality? 
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S19: Yeah, I guess there are probably, I mean first of all there’s not some rigid 
schematic that I follow and I don’t know that there’s one that anybody follows. 
(believes no one uses a systematic tool) Um, so there’s, as far as I know 
there’s not an existing template for assigning causality. [okay] I think what I do is 
typically, obviously Phase Is almost by definition are using new agents [mmm 
hmm] and so I will look at the protocol or information I have about the new agent. 
Um, to just see what the expected adverse effects are both common and 
uncommon with that agent. So the first thing is, you know, is it, is this episode or 
event something that you aren’t surprised to see? You know, is it typical of what’s 
been reported with the drug so far? Um, the second part of it I think is, and 
another part is the temporal relation, you know, to the, to the drug [what do you 
mean?] in terms of time. So if it wasn’t something that was happening before and 
it’s now happening now that they’re on the drug. I mean that is something I think 
figures prominently in terms of attributing causation, particularly with drug 
infusions. So um, someone gets a drug and they almost immediately have a 
reaction, I mean that’s obvious. But I mean even if it’s within a few days or even 
within perhaps a week, I think that gives you a stronger basis for causation. 
[okay] And it’s harder with things like chronicly administered oral medications 
right, where the onset of an adverse event maybe delayed as the blood levels of 
the drug you know, gradually equilibrate in the person. Um, and I think the third 
factor I consider is the patient and their underlying disease process. Because I 
think where I have the most problem assigning causation is where it’s something 
that you could blame on the cancer or blame on the drug [right] so I think that’s 
where it’s most difficult. 
 
M: Can you give me an example. 
 
S19: I think, I mean, the example to me that comes immediately to mind is ah, is 
DVT or blood clots, right. So those can occur in cancer patients, especially 
people with metastatic disease who are typically the ones in Phase I trials I mean 
they just happen you know. But they also can be related to the study drug you 
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know, and ah, so when someone develops a blood clot when they are on the 
study drug, would it have happened anyway?, is it related to the drug? That’s 
where I think issues of attribution become very difficult. [right] If it’s neutropenia 
well then it’s probably, it’s almost certainly due to your study drug unless you 
know they’re getting bone marrow infiltration from the cancer or something like 
that. So I think attribution of something fairly obvious like that is a lot easier. 
[yeah] So I guess, I guess you know, if there’s a fourth criteria, so it’s the, it’s the 
person’s cancer situation and I guess the fourth criteria is it’s the type of adverse 
event, right, [yeah] which I didn’t count because it’s kind of self-evident. You 
know there are some that are more difficult to attribute and some that are easy, 
you know, myelosuppression, low blood counts, it’s almost always due to study 
medication. It would be very rare that you would attribute that to something like 
the disease process unless you’re treating, unless the patient has leukemia or 
something like that. [paused for phone call]. 
 
M: Okay, so you were mentioning that sometimes it’s important to look at the type 
of event. 
 
S19: Yes, recapping, basically it’s the type of event, clinical event, is it obviously 
related to the drug?, or obviously related to the cancer?, right. [yeah] And there 
are some events that I think obviously are, like neutropenia, unless the person 
has leukemia or something is almost always related to the drug you know, if it’s a 
chemo cytotoxic agent. Where you know, um, a rash, with some of these drugs 
have a rash, you know, you give them a pill and they’re covered in a rash all of a 
sudden, you know, those are obviously related to the drug. And there are some 
things that are obviously related to the cancer, like pain. You know, sometimes I 
see pain listed as an adverse event and you know, drugs rarely cause pain, they 
can do it, but usually that’s a sign that the cancer is progressing or something 
right. (believes pain is attributed to the disease not the agent under 
investigation) And then there’s the timing, so there’s the, you know, if it’s 
obviously, you were well one minute and then you took the drug and this 
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happened it’s pretty hard to argue that there’s not some causality there. [right] 
Although occasionally that can be coincidence, but most of the time the temporal 
relationship in terms of time quite useful. But there do remain some things like 
fatigue, blood clots, nausea, you know these types of things that are not always 
easy to clearly attribute to the ah, to the drug or to distinguish from the underlying 
disease process, right. [yeah] Um, sometimes it’s really helpful to really carefully 
evaluate those symptoms at baseline right. So what is the level of, and we don’t 
always do that, so what is the level of nausea or fatigue at baseline? And often 
when you look back you find, yeah the patient did have some nausea even 
before they started the drug right. You know, they’re on narcotics or something 
that was causing nausea. Whereas if they had nothing like that, then I think it 
makes the attribute, attribution of those types of you know, sort of experiential 
symptoms of the patients easier to attribute to the drug. [yeah] Where you know, 
so I guess that’s sort of how I do it. [okay] 
 
M:  And what resources do you refer to when you’re assigning causality? You 
mentioned you check the protocol. 
 
S19: Well typically you will have information about the drug itself or drugs under 
study in some form. It maybe the study protocol, or some, it maybe the 
investigator’s brochure, um, I mean sometimes you might have to go to other 
resources like the CPS or go on the Internet .You may sometimes have to call up 
the principal investigator you know, um, I’ve haven’t, I mean I probably have 
done that but that’s rare. Um, so there’s and, and pharmacists as well [yeah] you 
know, if it’s an experimental drug they may sort of know as little about it as you 
do you know. [yeah] But if you’re giving drug combinations for instance, that 
contain more standard agents that can sometimes be helpful to rule out 
attribution to the other agents and be able to attribute it to the investigational 
agent. (have to get information on the protocol drug from a variety of 
sources, a lot of work) 
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M: So if you were doing a study when there’s a combined therapy.  
 
S19: Yeah, most of the Phase I studies I’ve been involved with, because we don’t 
do first in humans very often here at our centre. [mmm hmm] When I’ve done a 
Phase I it’s typically been ah, adding a new drug, molecular agent onto a 
standard chemo drug. [regimen yeah] You know that type of Phase I. [okay, 
good] 
 
M: And, um, what tools then do you use when assigning causality, are there any 
sort of tools that you are aware of or that you use, any kind of? 
 
S19: Tools, well you know, I’m always asking my CRA’s um, what, I mean, I don’t 
know what they’re called, but there’s these quality of attribution scales. [okay] 
Like, and I don’t like these are the things like definitely related, probably related, 
um, you know, possibly related [yeah, yeah], unlikely to be related, unrelated, 
those types of scales. I’m not sure if those are standardized, my perception is 
that there’s some variability in those scales. (suggesting standardized 
measuring criteria) And in some trials almost a yes or no [yeah] you know, is it 
related or not? and you know if there is any uncertainty that makes attribute, I 
think that brings a lot of potential for misattribution in. But also, to miss, when I 
say mis- attribution I mean, attributing it wrongly to the drug or not attributing, 
missing attribution as well as mis-attribution. Um, some had a DVT for instance 
that could be related to the drug and if you had to say yes or no, oh this person 
had cancer, this is related to their cancer, it’s not related to the drug. But that 
might be an important attribution that we miss. So when you don’t have a, when 
you’re forced to yes or no it um, I think that can bring in a lot variability in 
attribution. (sometimes feels forced to make a decision when they are 
genuinely uncertain) 
 
M: So you prefer the scale? 
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S19: I think a scale is much better but I think there is also variability in the scales 
too. I’m not sure if there is a standardized attribution scale or not. You know, we 
have standardized toxicity scales in terms of grades for toxicity [for grading] yeah, 
and those are quite useful. But then when you want to attribute the toxicity you 
don’t know exactly what you’re going to get and you have to sort of look and use 
whatever is on the CRF right. [yes, okay] So it would be nice if there was a 
standardized attribution scale. I personally like the ones that have a number of 
gradations of attribution, um, you know, likely, probably, possibly, definitely, you 
know that’s my own preference. Because it still allows you to be black and white 
about it if you’re sure it’s the drug, it’s definitely related or it’s unrelated. But also 
there’s you know, for some of those other types of events I talked about, 
mentioned earlier it allows you to kind of grades of attribution where you’re not 
quite sure. [yeah, yeah, okay, great] (takes comfort in having the flexibility of 
scale attributions) 
 
M: What I would like to do know and just ask you to consider a scenario for me. 
So let’s say you’re treating a 65-year-old female breast cancer patient with a 
confirmed diagnosis, sorry patient with a confirmed diagnosis, she actually has 
metastatic breast cancer. [okay, yeah] And she is in a Phase I trial [mmm hmm] 
with a new investigational drug and she experiences a pulmonary embolism. 
[okay] Sound familiar? [yeah, I called it] How would you assign causality to the 
study drug if there was a 75% chance that the adverse event was due to the 
study drug and a 25% chance it was due to other factors. So lets say adjuvant 
treatment, disease progression. 
 
S19: Well that’s a typical dilemma isn’t it? [yeah] I would in that case say 
probably but not definitely. [okay] Because metastatic breast cancer patients do 
get blood clots and they do get PEs. But where, how I translate that information is 
this drug is associated with thrombosis because you’re saying 75% and therefore 
that is important in terms of the data you collect from this trial that, that event is 
associated with the drug in some way where you can’t be definite. I don’t think I 
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would say it’s definitely associated though, I just don’t think you could do that um, 
in that clinical scenario. There is some uncertainty that this patient might have 
developed, had the PE anyway. [mmm hmm, okay] 
 
M: Now what if those percentages were changed so that there was a 50% 
chance that the adverse event was due to the study drug and a 50% chance it 
was due to other factors. [50/50] Yeah and the scale is certain, probable, 
possible or unlikely. 
 
S19: Certain, probable, possible, unlikely, it’s either probable or possible. Again I 
would because the person is in a trial I would probably say probable if it’s a 50/50 
toss up. And that would be because my bias for a person on an experimental 
drug is to report any adverse events that could be related to the drug. And I think 
if you said possible there, you wouldn’t be wrong in accuracy, but it slightly 
downplays the importance of the severity of this event. You know pulmonary 
embolism is a severe adverse event and if it’s, if it’s even possibly related to the 
drug um, I think that’s important to document and publish in the results of the 
study. So I would say probable. [great] 
 
M: Now what if there was a 20% chance it was due to the adverse event [20%] 
and an 80% chance it was due to other factors? 
 
S19: Then I’d say possible. 
 
M: Then you’d say possible [yeah] okay, great. Just trying to get a feel of how 
people are interpreting [yeah] those terms you know. [yeah] 
 
M: Now what would you say are some of the problems or challenges with 
assigning causality? 
 
S19: Well I think one problem is simply documenting events. 
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M: Why is that? 
 
S19: I don’t think patients always tell you everything that happens to them. Um, 
then there’s (feels there is a disconnect with the patient) 
 
M: Why is that do you think? 
 
S19: I think it’s human nature to forget things [okay, forget] and obviously if it’s a 
very serious event, it’s going to be recorded and you’re likely going to hear about 
it in some way. But not all patients understand that in a clinical trial that we’re 
also interested in the side effects of the treatment. And in a Phase I actually 
toxicity is your primary endpoint. [mmm hmm] But the patients of course feel that 
they’re on the treatment to help their cancer [yeah] so there’s a little bit of a 
disconnect there. So they’re more interested in what the drug is doing for their 
cancer and they kind of are hunkered down with the idea, many of them are very 
stoical right [yeah] they say I’m going to put up with whatever side effects I have 
to put up with um, to get through this treatment because it’s going to help my 
cancer. And I think that’s, that translates sometimes to a lack of reporting of 
events. I think that some patients may also perceive that you know, the doctors 
or nurses don’t want to hear them complaining right, they just feel that they’ll 
sound like whiners right. [right] And now there are some people who are more 
than happy to talk to you for a long, long time about everything that’s bothering 
them. [yeah] So you know, it’s just this sort of spectrum of human nature, it’s just 
how people are. Um, they’re, and some people are you know, very 
obsessive/compulsive in their personalities, they keep diaries and they can show 
you day-by-day what their side effects were. And other people are not like that at 
all and they just don’t record it and then they forget, there’s just that difference in 
personalities. I think then there’s, assuming that the patients report the events, 
there’s the recording of the research people or nursing staff, right [yeah] or the 
physicians themselves. So there’s actual, I mean you just may forget to write 
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down an event, especially if the patient is having a lot of side effects you know it 
just may be missed. (human nature adds bias to the trial) So I think basically 
recognizing and recording that this adverse event actually occurred is something 
that happens you know. So that would be a barrier to you know, attributing it if 
you don’t even know it happened. Um, other barriers to attribution. 
 
M: Just, just problems or challenges yeah. 
 
S19: Well I think you know when you’re dealing with a lot of new drugs and doing 
a lot of drug trials it’s hard to keep track of some of the idiosyncratic or unique 
adverse effects of some of these drugs. So you have to, as I mentioned earlier, 
knowing the drug and it’s potential side effects, um, you know is sort of key in a 
way to attributing. (you really need to know the drug well) And if you’re so 
busy or have not done your homework in terms of reading about the drug, or 
don’t have the time to go look it up. So you know, basically just having a busy 
clinic and being busy at work can lead you to mis-attribute these things right. (but 
time pressure take away from this) So care has to be taken you know, in terms 
of both the identification recording and attribution. Um, I guess another potential 
barrier is sometimes when you’re dealing with Phase I drug trials, new side 
effects occur that haven’t happened before right. And you just may not think it’s 
due to the drug, you know, you look in your documents and that’s never been 
reported [mmm hmm] and um, I mean you have to realize something like a blood 
clot would be typical because um, typically in a Phase I trial the drug has not yet 
been studied enough in humans to know if it increases the risk of thrombosis 
right. [yeah] Which may happen in 5% of people treated, but if only 50 people 
have ever got the drug before, none of them may have actually experienced that. 
And then when you see it in a patient, ah, you know, you’ll look at your 
information and say well this has never been reported with this drug, this drug 
doesn’t cause clots. But in fact it does and it’s just an issue of you know, a very 
infrequent but serious event [yeah] that, that’s you’re seeing the first event of it. 
And that’s always with Phase I trials, that’s always the thing I worry about when I 
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see something strange, is this, you know this hasn’t been reported with this drug 
before, but is it due to the drug? And ah, um, and so I think that can lead to mis-
attribution as well you know [right] people will think, oh doesn’t cause clots and 
it’s definitely not related to the drug when in fact it is. [yeah] And as time passes 
and more people see it then the idea of attri, the awareness of that attribution 
becomes you know, ah, prominent. But, but you know when you see it the first 
few times people may just wave it off [yeah]. What else, so it’s about what 
impedes attribution was your questions right? 
 
M: Well just any problems or challenges [Challenges, challenges] that you 
encounter when trying to assign causality. 
 
S19: Yeah so [that’s pretty good] I’ve covered all the bases there. Patients don’t 
report it, doctor’s don’t record it and doctor’s don’t know what, know of it, either 
because they haven’t read it, or are not familiar with the drug or it hasn’t occurred 
before. I think those are the main things. Um, I think um, other drugs can confuse 
the issue too, make attribution difficult. 
 
M: Other study meds? [just other medications] yeah any other meds. 
 
S19: And other medications yeah, concomitant medications, I think that’s it, that’s 
everything. 
 
M: What are your concerns with how clinicians currently assign causality? 
 
S19: Um, well I think, I think there is some variability in that. I think clinicians 
may, and that is due to a number of factors, I’ve mentioned some already but I 
think some physicians whether it’s business or lack of care don’t know enough 
about the new drugs that they’re giving to people to appropriately assign 
causality. They don’t have a clear cut attribution scale, I think there may be 
differences in what one person thinks is probable and another person thinks is 
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probable, you know what I mean? [mmm hmm] We don’t get any education about 
this right so as a part of GCP training we are taught about serious adverse 
events and yada, yada, yada, but no one ever goes over the difference between 
definitely, probably and possibly, you know. And ah, I mean I think I know what it 
is, but that maybe very different than my colleague next door [that’s right]. So I 
mean we’re assuming everyone is using the same definition of those terms but 
I’m not so sure. I mean I think you already illustrated with the earlier questions 
where my sort of cutoff is between possibly and probably but that may be 
different for somebody else right. [right] So if you only consider events probably 
or definitely related, that difference between physicians and those labels could be 
important right. [yeah] Um, yeah I think um, I think those are the main things I’d 
mention there. [okay, great] (lack of consistency with grading scales, leads to 
inconsistencies in attributions) 
 
M: What external influences or pressures from third parties have you felt when 
assigning causality? 
 
S19: Third parties, um, our CRA’s sometimes want things attributed in a certain 
way. 
 
M: Really? [yeah] how, how attributed in what way? 
 
S19: Well, they’ll often, I think they often do a lot of the causality assignments, 
sorry the attribution type of assignments [phone rings] 
 
M: Okay, so you were saying that um, the CRAs tend to attribute causality. 
 
S19: Yeah, I was just thinking they’re, when you look at attribution of adverse 
events, I mean they’re basically the people you’re working with [yeah and they 
want] you think you’re filling out a CRF and then um [they] they want an 
attribution level. And ah, sometimes they have their opinions about what the 
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attribution is and they’re different from [yours] mine. You know, not a lot but um, 
that just in terms of explaining to them and then they have to change their forms 
[yeah, yeah] and if they’ve already submitted the forms a certain way. Ah, in 
affect you’re creating more work for them, ah, so that does, I don’t like to create 
more work for the people I work with. So I do feel a little but of pressure there, but 
ah (feels pressured to conform to certain causality attributions in order to 
create less work for others) 
 
M: Now is it usually that they want you to attribute it a little more one way than 
another way? 
 
S19: No, no, it’s usually that they’ve made an attribution and because it was say 
serious they had to submit a CRF immediately and for whatever reason they had 
to do that, maybe I wasn’t around [yeah]. It just had to be done and they and then 
when we go over the event my opinion of the attribution is actually different so 
then we have to revise their paper work right. [right] So you know, there’s a small 
bit of, do I really feel this is important enough or strongly about this distinction 
that it’s worth putting this person I work with through revising their paperwork 
right. [right] You know, this doesn’t happen often, but that would be, if I think 
about it off the top of my head that’s the only time I’ve felt pressure about 
attribution. [yeah] Um, um, but that’s, but that’s not a pressure where I feel I’m 
being under duress to, to ah, mis-attribute something if I think it’s the right, the 
wrong thing I will change it. [yeah] Because ultimately as the PI I’m responsible 
for all the, what’s in the CRFs. And they do their best and usually they’re right, 
but these are very infrequent disagreements. [yeah, okay] 
 
M: Any other pressure [no] influences from third parties? 
 
S19: No, no that’s it. 
 
M: So from your perspective what would make assigning causality easier? 
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S19: Um, well I think some type of very accessible documentation about the 
adverse events of the medication. I often actually look at the letter of information 
that was given to the patients [the consent form] the consent form yeah. Because 
it’s there, it’s summarized in a fairly succinct way and often it’s put into common, 
less common and rare [yeah]. And ah, as a physician I really don’t get that from a 
protocol. In a protocol, the toxicity, you’re reading from off of several pages of 
material, so just what do we know?, what are the bad things that we know this 
drug does, commonly, uncommonly and rarely? That would be nice, because as I 
say the first part of this is distinguishing is this due to the drug or is this due to the 
disease? And the second part would be a commonly, a universal scale of 
attribution that once you learn it, you know it and you have some comfort that all 
physicians are using it in a similar way. [yeah] Just like we use grading for the 
NCI toxicity scale, you know what a grade 3 neutropenia is. Um, so, you know, 
basically common definitions and gradations of attribution I think would be useful. 
[okay] 
 
M: Anything else? 
 
S19: Um, well I guess the only other thing would be good recording and reporting 
of adverse events. Um, we use a PAR form here, which is sort of four pages of 
questions listed, you know, the gradation of toxicity across the top and the types 
of toxicity along the side. And just circles and comments about the duration and I 
find that very useful. I don’t think that’s in use at all centers [no] but in terms of 
recording so you know it cues the person doing the forms whether it’s the nurse, 
the CRA or the doctor to ask these questions. So it’s less likely a patient, and it’s 
fairly comprehensive and it asks at the end anything else basically that we 
haven’t asked you know, so open-ended. [mmm hmm] And ah, it would be hard 
for me to imagine that you know, unless a patient was making a concerted effort 
to not tell you about something, that you wouldn’t pick up an adverse event using 
this tool. And you have the toxicity right there and theoretically as well you have 
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the timing. So with that piece of paper um, it helps me a lot in terms of attribution 
you know, just having an accurate and useful record of the timing, severity and 
type of adverse event and all of the adverse events recorded. So, I think um, 
obviously recording and documentation is critical. [very good] It’s harder when 
people get hospitalized and you know with a, you know, away from, out of town, 
hospitalized in Stratford with some event and that often creates a nightmare of, of 
ah, recording side effects and timing and severity and whether or not they’re due 
to the drug. 
 
M: And why is that, is that just because it’s difficult to get the records? 
 
S19: It’s, it’s the documentation aspect. When you’re doing it retrospectively right, 
the patient has been admitted somewhere else, they come in and see you days 
later or a week later and you’re just trying to go through it all, to get the timing 
down, the severity and going from written medical records. It just, it doesn’t 
happen often but it’s a lot of work when it does happen so it’s to be avoided. [yes, 
laughter] (maybe due to time pressures) 
 
M: What do you think is essential then for a causality assessment tool? What are 
some of the most important things you know, in order for you to use it? 
 
S19: Causality assessment tool. Well I think a couple of them we’ve already 
touched upon, one is it has to have gradations of causality because it’s clear 
there’s a grey area, often a big grey area for some of these types of events. 
(deals with uncertainty by scaling) So it has be gradation, it’s can’t just be yes 
or no, black or white, a dichotomous type of instrument. Um, it’s um, it’s um, it’s 
got to use definitions of causality in terms of the level of causality if you will um, 
that are understandable and for which there is pretty universal agreement. Or 
where you could even put in the definition of what it means, probable means, you 
know, that there is at least if you know if you do this questionnaire on 100 
physicians and they all say at 50% I still call it probable but any less it’s possible. 
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Then you could write in probable means that there’s at least a 50% chance this 
problem occurred due to study drug right. [right] So theoretically you could 
quantitatively define probable, each of these definitions, that would be nice. Um, 
and ah, and what else? Gradation …, and that you know it’s used all the time 
right, so that from study-to-study, drug-to-drug you’re not using a different scale, 
you know a different causality assessment instrument or tool. [yeah] Um, those 
would be the main things. [great] 
 
M: What I’d like to do now is just a quick exercise. If I could just ask you to read 
over these questions [mmm hmm] and cross out any that you do not feel are 
relevant to the Phase I oncology clinical trial setting. 
 
S19: Not relevant to assessing causality to Phase I oncology clinical trials. Yeah, 
I think they’re all relevant. 
 
M: Okay, now would you be willing to just grade them from most important to 
least important? So most important would be 10 and least important would be 1. 
[okay] Yeah, just rank them in order of importance. 
 
S19: Rank in order of importance in assessing causality. This is hard, it may take 
me some time here, you may want to go for coffee and come back in 10 minutes. 
 
M: It’s just a general guide, you know, there’s no right or wrong answers. [okay 
that’s my gestalt] So least important was whether there were any alternative 
causes that on their own could have caused the reaction. [right] Why did you rank 
that as least important? 
 
S19: Um, because I think I always assume the reaction, if someone is on a 
clinical trial I assume the event is related until proven otherwise. [okay] So the 
fact that there might, you know if someone has a massive PE, the fact that 
they’ve got cancer I consider that a possible cause. But until, but I assume that 
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it’s due to the drug until proven otherwise, you know for a serious type of adverse 
event. [okay] 
 
M: And most important was did the reaction reappear when a placebo was given. 
 
S19: Yeah, we almost never, never do that, but ideally that is what you do either 
re- challenge either with a drug or with a placebo. So we do re-challenge people 
with drugs and I think some of the other comments there were you know, re-
appears with re-administration. But we don’t actually re-challenge people with 
placebos, I’ve never done that. [right] But if someone had an event and it re-
appeared with a placebo that would rule out I think that it was due to the study 
drug right. But we don’t do that experimental design. So optimally you might want 
to do that with some reactions, like nausea for instance or fatigue or things like 
that. Those one’s in the grey area, in a way, if you could give n of 1 placebos 
infusions. But you’re talking about Phase 1 trials here which are usually 
uncontrolled right [yeah] you don’t have a comparison arm where you can, so 
um, in those type of trials you, I’ve never have one where you’d give a placebo 
infusion to rule out attribution to study drug, but it’s a good idea. [okay, great] 
 
M: Um any other, did you have any other thoughts as you were going through 
this? 
 
S19: Well I think the idea of re-challenging you know, um when I have to attribute 
something it’s usually at the time okay. [yeah] And so I think an important point 
that came up after reading that, was yes attribution, you should be able to revise 
it with time. So typically after the first cycle of a drug um, you’re asked for an 
attribution if someone has an adverse event. But as you go on with the treatment 
and you modify the dose and re-challenge the patient with the drug, that may 
give you more information over time. You know, as it says in here, by increasing 
the dose, decreasing the dose or even just re-administering the dose. That gives 
you more information about attribution right. So someone got a rash, you 
! $*+
thought, ah that’s nothing, and then you said it’s unlikely to be study drug. And 
then you re-administer it the second time around and they get the same rash and 
it’s a little bit worse well suddenly now it’s not possibly or probably related right. 
[yeah] Where at the first cycle you weren’t sure and you were and because it was 
a minor sort of thing, tending to probably under-attribute it right. So I think from 
reading that, that’s 
 
M: It’s important to be able to revise your causality. [yeah, right] 
 
S19: But we don’t actually, I don’t think we actually do that very often, right it’s 
causality at that time, at that cycle, at that point-in-time, right then, right [yeah]. 
As opposed to, over the course or treatment did it change the causality? Now 
sometimes I do, I have been asked to revise causalities in that way, 
retrospectively, okay, retrospectively reassessing causality [by who? by the 
sponsor?] typically by, presumably the monitors right. [okay yeah] You know, 
monitors ask the CRA’s and then I look over the chart and the history and I go oh 
yeah, I guess I wasn’t sure about that the first time but now it seems to be related 
right. [right] So yeah, so the repeated treatments, I think you’re right, can give 
some, a lot of insight into attribution. [okay, great] (may be a result of time 
constraints) 
 
M: Were there any questions that you felt weren’t on here that should be 
included, anything that’s important but not there? 
 
S19: Ah, I don’t think so, I mean I think, pre-clinical evidence is covered, previous 
conclusive reports, that can be in animals or humans, confirmed by objective 
evidence. So pre-clinical aspect, you know, if it causes it in monkeys and dogs 
and rats and you see it in humans then you know, you are probably going to 
attribute it to the drug right. [yeah] So I think that covers those points. Um, yeah, 
that’s about it. [okay, good] 
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M: The last thing I want to ask about then is education around assigning causality 
and you did mention this briefly. [mmm hmm] Can you tell me about any training 
you’ve received specifically with respect to assigning causality to adverse events. 
 
S19: Just the school of hard knocks [laughter] just doing clinical trials. I haven’t 
received any specific training about that. [okay] 
 
M: What additional education about assigning or attributing causality do you feel 
should be made available to clinicians? 
 
S19: Um, well I think some of those points that you raised up there in those 
questions were good ones, did it, you know, changing drug dose, did it get 
worse, did it get better you know with repeat infusions, by stopping the infusion, 
those types of observations. Some people are pretty scientifically minded and 
others are not right. You know, they’re just not in that frame, I can’t assume that 
all clinicians have the same level of um, observational skills with their patients, 
you know what I mean. (mind frame, individual variation) [mmm hmm] In terms 
of how closely they observe what’s going on. So I think that just, if it’s really a 
scientific experiment, you know, when you’re giving a Phase I drug to a patient 
you know, I don’t know that all clinicians have that, have been trained with those 
sets of observational skills [right] right. Um so I think emphasizing, you know just 
going, those points of what to look for, don’t assume anything, record it, thorough 
documentation. (feels a stronger level of observational skills needs to be 
achieved) Um, and then you know, issues about the definitions of attribution you 
know, what does probable mean?, what does possible mean?, what does 
unlikely mean? [yeah] that type of thing. [okay great] 
 
M: Well that’s all the questions I have for you. I was just wondering though does, 
is there anyone else that you recommend I speak to while I’m here? 
 
S19: Um, you’ve got V. You should probably talk to MM. 
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M: Is she a Phase I investigator? [yeah] 
 
S19: She’s actually trained in Hamilton and she sort of wants to get involved 
more. She’s our drug development person, she’s new. 
 
M: So she’s a clinician, she’s actually a medical oncologist. 
 
S19: She’s a medical oncologist yeah [okay, great] definitely talk to her. So V, 
me, M um, you’re talking to T [yeah]. You could um, W next door has done a lot 
of trials during his career, he’s an older guy, I mean I don’t know, I mean if you’re 
looking for more rather then less you could interview him. [great] Anybody else 
um,  
 
M: That’s good, we’re just looking at, I know you guys don’t do a lot Phase I trials 
here [yeah] anyway. 
 
S19: It’s pushing it if it’s about Phase I really [yeah] 
 
M: Perfect, that’s great. 
Subject 20 
M: I will just give a little background about what it is that we’re doing.  I’m working 
with Dr. A at the Juravinski Centre, you know him [right]. We’re interested 
assigning causality to, how clinicians assign causality to adverse events that 
occur in patients during Phase I oncology clinical trials. [I or Phase I and II]  
Yeah, Phase I, Phase I/II. 
 
S20: Because I don’t have any experience in Phase I. 
 
M: No, so early oncology clinical trials [okay] when very little is known about the 
drugs [yeah] just sort of finding, looking into the toxicity of the drug more or less. 
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But as you know even the most experienced clinicians find assigning causality 
challenging and many groups such as industry sponsors, clinical trial cooperative 
groups, research ethics boards, they all expect prompt and sensible causality 
assessments. And that’s not always straightforward and if done poorly can have 
large implications.  So we’re interested in developing a tool to help clinicians 
efficiently and reliably assign causality to adverse events during Phase I 
oncology clinical trials. And we feel that by better understanding your needs as a 
clinician we can make the tool more relevant to you. [okay] So do you have any 
questions [no] about what we’re trying to do? Okay, so first I’d like to better 
understand of the clinical reasoning that you use when assigning causality. So 
let’s say one of your Phase I clinical trial patients reports experiencing a serious 
adverse event, or Phase I, Phase II clinical trial patients experiences, reports 
experiencing an adverse event. Can you just walk me through how that situation, 
you know, the reasoning you use when you’re assigning causality to that SAE? 
 
S20:  Well I think what you’ve got to look at is the relationship to the 
administration of the medication. For instance, if it is an event that the patient has 
a symptom that they never had before so it can’t be easily related to any previous 
disease the patient’s had. Ah, or if um, this is something that is, is, um happens 
shortly after the medication has been administered I would be more concerned 
that this might be related. (temporal association) 
 
M: What do you mean when you say shortly, how shortly? 
 
S20: Well that’s a good question, if it’s during the administration of the drug then 
obviously there’s a potential possibility that it could, I mean I say at least possible 
that it could be related to the study medication. [yeah] If it’s after the drug 
administration, um, again this is probably something that’s a little bit difficult, it 
would be, I guess, what could we say, if we knew in animal studies that there 
were certain side effects and we saw similar side effects in people, obviously 
there’s more likelihood that there would be at least a possible causality. [okay] 
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Um, if there were side effects in animal models and say animals had some 
transient um, myocardial changes for instance[okay] or say pathology and the 
patient say has a, say for argument sake, the patient didn’t have any history of 
angina, but say he had high cholesterol and hypertension and developed um, 
some arrhythmias I would say it’s possible this could be related to the medication 
at least [based on what was seen in the animal study] based on what was seen 
in the animal study. (baseline is important) So I think you would have to infer a 
little bit from the animal data. If the patient say has had a previous history of 
arrhythmias and develops an arrhythmia, I think it’s going to be difficult. I think it if 
occurred during the administration of the study drug you couldn’t rule it out. If it’s 
something that occurred a couple of weeks later ah, it would depend possibly on 
what are the pharmacokinetics of the study drug, what’s the half-life of the study 
medication. [okay] I think that’s all. 
 
M: So you look at the timing, the relationship to the administration and you also 
look at whether it’s been seen before in animal studies. [right] 
 
S19: The other question might be does the severity of the side effect, would that 
play a role? You know if somebody had a sudden death that was unexpected 
that would be a concern and you would have to say it’s a possibility. Um, if 
there’s a serious event, the patient developed pneumonia you would have to look 
at some of the extraneous factors. Maybe there was a virus going around in the 
community and the patient has a previous history of bronchitis. In that type of 
situation, especially if the drug didn’t have a side effect such as neutropenia or 
any impact on the immune system, you might say well less likely this is related to 
the study drug and you would probably say unlikely. So severity doesn’t 
necessarily mean it’s related to the study medication, but obviously that would 
have to be looked at very carefully. Um, if the, I think I mentioned this, I think if 
there is any absolutely new symptoms, the patient has never had any before 
[yeah] that would be and if it’s persisting in particular, that would make me 
suspicious. [okay] 
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M: What do you mean when you say persisting, persisting for how long? 
 
S20: Well you could have say somebody who has transient heartburn, that might 
be one thing but if somebody has persistent heartburn lasting for a week or so 
after the medication and especially if they required some sort of intervention, that 
would be [yeah], that would be fairly significant and you would have to say it’s 
possible. [okay, alright, great] 
 
M: What are the resources you refer to when you’re assigning causality?  
 
S20: The most important one is the patient, the history. (Feels knowledge of the 
patient is more useful than information on the agent)  
 
M: Sort of what they tell you, their oral history? 
 
S20: Absolutely and we get that by um, ah, the patient has a, has a, self-
questionnaire that they fill out, a patient assessment review form [mmm hmm] 
called a PAR form. And we, I will then actually focus in as well and ask the 
patients in more detail about those symptoms. Um, also I would normally, again, 
just to make sure things are covered, ask the patient are there any other, other 
things, even if they may have answered negatively just in case there is 
something not fitting on the PAR form that they may have noticed. Besides the 
patient, family members, maybe differences in behaviour, maybe some 
psychologic or neurologic issues associated with the medication because we just 
don’t know enough about them, ah lab work, imaging results sometimes [okay] 
and the physical examination. 
 
M: Okay, any other resources when you’re assigning causality when you are 
thinking about whether the event is attributable to the drug? 
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S20: Um, well I’ve talked about how I might, think this might be causal, I think I 
pointed out most of the information sources I would use, I think those are. 
  
M: Okay, that’s, there are no wrong answer here. What tools do you use when 
you are assigning causality, I mean, you talked about resources? 
 
S20: Sorry the other thing I didn’t mention is the other source of information 
would be the nurses in the chemo suite administering the chemo also. [okay, 
good] 
 
M: And what about any tools, are there any sort of tools that you use when you’re 
assigning causality? 
 
S20: I’m not sure I know what you mean by tools. (not well known even 
amongst experienced professionals working in the field) 
 
M: Okay, say like a flow chart or an algorithm or a decision tree. 
 
S20: No, no. 
 
M: No, are you aware of any? 
 
S20: No. I think we basically use our medical judgment and the sources of 
information. [okay] 
 
M: What I would like to do now is just ask you to consider a scenario for me. 
[sure] So let’s say you’re treating a 65-year-old female patient with a confirmed 
diagnosis of metastatic breast cancer. [okay] And she is in a Phase I/II trial with 
an new investigational drug and she experiences a pulmonary embolism. I am 
sure this is probably a pretty typical scenario for you. [mmm hmm] How would 
you assign causality to the study drug if you knew that there was a 75% chance 
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that the adverse event, the pulmonary embolism was due to the study drug and a 
25% chance it was due to other factors, such as disease progression, other study 
medication … 
 
S20: I would have to related, it would have to be causal. 
 
M: Okay, so the scale is certain, probable, possible or unlikely. 
 
S20: Probable. 
 
M: You would say probable, okay and why is that, you seem pretty certain about 
that. 
 
S20: I think just because, although pulmonary emboli are associated with 
metastatic disease in particular we know that administration of drugs can also 
increase the risk of pulmonary embolism. I think you have to err on the side of 
caution when you’re ascribing, particularly a potentially serious event to a study 
medication. Um, I think, and the other, the other thing is that some study 
medications maybe associated with various line placements that maybe 
implicated. And I guess we have to look at the 
 
M: Line placements, what do you mean? 
 
S20: that’s a PIC line placement may result in a thrombus for instance, going 
quite, say involving the subclavian vein occasionally, especially with Phase I 
drugs that’s not that uncommon. Um, I realize that things like pulmonary 
embolism may not be related to the study medication but that, that just has to be 
compared with other Phase II data realizing that some of this is part of the 
underlying baseline noise that patients with metastatic disease as well. But you 
have to, I think you have to assume that you don’t know enough about the drug 
that it could be drug related. [yeah, okay good] 
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M: Now what if there was a 50% chance that it was due to the study drug and a 
50% chance it was due to other factors.  
 
S20: You still have to relate that it’s probable. 
 
M: Given that same scale, certain, probable, possible or unlikely. You’d still say 
probable. 
 
S20: It’s either possible or probable. I would say probable. [okay] 
 
M:  And what if there was a 20% chance that it was due to the adverse event and 
an 80% chance it was due to other factors would that change anything? 
 
S20: Well then you’re getting into, I guess the first question I would ask is how do 
you know when you’re doing a Phase I trial that it’s a 20% probability? 
 
M: I know, it’s a very hypothetical question, it’s really not realistic at all, but I 
guess we’re just trying to get a sense [yeah] of how you understand those terms. 
 
S20: Yeah, so then I mean obviously it’s less then 50% so it’s not probable but 
it’s possible [okay] if you’re looking 50% as the cutoff. 
 
M: And that would sort of be your cut off? 
 
S20: Yeah. It would make sense to me. 
 
M: What would you say are some of the problems or challenges with assigning 
causality? 
 
S20: I think a lot of it sometimes is the background noise from patient or the 
disease. And how do you know the symptoms are not related to the cancer or to 
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underlying symptoms from other comorbidities from other chronic diseases the 
patient may have? 
 
M: Is there anything you sort of use as a general rule to help you sort that out? 
 
S20: Well sometimes it’s difficult, somebody, say somebody with chest pain who 
has plural metastasis it’s really hard sometimes to know whether this is related to 
pulmonary embolism. Then basically have to do the appropriate diagnostic 
imaging which in that case would probably be a spiral CT scan to try and sort 
some of that out. Um, what other symptoms? say patient fatigue, ah, well that 
can be really difficult for instance, it could be related to disease, study drug, could 
be related to psychologic factors, some change in the patient’s environment, who 
knows? And that could be, and you have to look at all those and figure out which 
is most likely and then it’s you know, and have there been changes in those 
areas that might explain it? Um, and if there’s more than a couple of possibilities 
you have to kind of use your judgment which is more likely. [yeah] (process of 
elimination) 
 
M: Okay, any other problems or challenges when it comes to assigning 
causality? 
 
S20: Um, yeah if you were looking at, at, lab testing, is um, worsening anemia is 
it related to the study medication or is it related to bone marrow infiltration by 
tumor? Um, that could be extremely difficult to sort out and I think what we have 
to do then is okay, let’s look at what was happening maybe before the patient got 
on the study medication. Was there worsening ah, bone marrow functioning 
beforehand and if this is just a continuation of what was happening beforehand, 
probably more likely related to the disease than to the study medication. If this is 
something that’s relatively new, um, then you’ve got to look at the disease 
process and find out whether there’s been some recent new progression of 
disease in the bone that would corroborate this as probably disease related or if 
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there isn’t then I may be a bit more suspicious that it’s medication related. Other 
things that could interfere that you have to check out as well, for instance, 
nutritional causes of marrow function, the patient may be becoming folate 
deficient, vitamin deficient in some way, maybe having some blood loss for 
another reason. So you have to kind of look at everything. [yeah, okay] 
 
M: What are your concerns about how clinicians currently assign causality? 
 
S20: [laughter] I guess, I guess one of the biggest challenges these days is that if 
we, people have enough time to rigorously evaluate all the possibilities in a very 
busy clinic setting. [yeah so] The time to sit down and really fully go over 
everything with the patient in terms of  what’s new by history and do a good 
physical examination. (see time as the most significant constraining factor 
on causality assessment) 
 
M: So you’re concerned that might not be being done right now? 
 
S20: Um, I think everybody’s under severe time pressures these days and it 
makes it, it’s um, you need to have a dedicated infrastructure to do good Phase I 
and II studies. 
 
M: So what’s involved in that, infrastructure, what do you mean? 
 
S20: Um, I think you need good clinical trials nurses, good experienced clinical 
trials nurses. Um I think you need to have appropriate time in the clinic to assess 
the patient. Ideally you should, we should have things like clinical trials fellows to 
facilitate in the research. Um, I think ideally what would be really nice is to have a 
clinical trials kind of organization, Phase I or II organization where people could 
meet regularly to, so that they are aware of some of the issues to keep the quality 
assurance of the clinical trials as high as possible. 
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M: Hmm, that’s an interesting idea.  
 
S20: It’s a bit of thinking out of the box [good for you, okay]. 
 
M: What external influences or pressures from third parties have you felt when 
assigning causality? 
 
S20: None [no] I’ve never felt any. [no, okay] 
 
M: And from your perspective what would make assigning causality easier? [Ha, 
ah] Other than the obvious, having more time. 
 
S20: That’s an interesting question. I’m not sure if there’s any shortcuts to this. 
Um, maybe others have thought about it a bit more than I have but I, I think you 
need to um, you need to have a good history from the patient each time. You 
need to have a good physical examination, and you need to have experienced 
people involved in the clinical trials. Um the more you have of that, the more you 
have some protected time to do that, the more accurate the information you’re 
going to get. Um, I, I, the um, there are too many, especially now that they are 
moving into molecular treatments and biological treatments and when we start 
using that in combination with other agents there are too many unknowns. And 
especially, I mean, the data that I’ve seen not too long ago where we’ve seen 
information from animal studies that suggest that combinations of agents seem to 
be well tolerated. And we moved to the human setting and get a completely 
different result. I don’t, I think it’s very difficult to try and make any assumptions. 
 
M: Can you give me an example of something like that? 
 
S20: Well there was a neat, there was a neat presentation at the I believe, San 
Antonio Breast Cancer meeting in 2004. And I’m trying to remember the name of 
the fellow, I think it was a guy that used to practice, who used to be at the 
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University of Toronto and he’s now in one of the facilities in Texas. And he 
presented a neat ah, um, um, antidote about some mouse studies using 
combinations of biological agents where the mice seemed to be doing pretty well, 
they had really good results in terms of tumor regressions. And they started doing 
the Phase I and Phase II trials in humans they had all these unexpected 
toxicities. 
 
M: You don’t remember the name of the drug though eh? 
 
S20: Ah, it was a combination of tyrosine kinase inhibitors and stuff, it was a bit of 
a cocktail [okay] I don’t have it at my fingertips. [no I’m sure there’s so many] 
 
M: Yeah, so that’s, that’s definitely a challenge when you’re using these 
biological targets and they don’t perform as expected. 
 
S20: In oncology, the one thing you realize is there’s always going to be 
surprises [yeah] and I think we just have to, I think we basically have to make 
sure we have our eyes and our ears open a lot. [yeah, okay] Anyway. 
(unpredictablility of the job) 
 
M: What I’d like to ask you to do now is if you wouldn’t mind just taking a read 
over these questions and crossing out any that you do not feel are relevant or 
appropriate for the Phase I oncology clinical trial setting. 
 
S20: Causality in Phase I [reading questions] What, I cross out 
 
M: Anything you don’t think is relevant [okay] or useful for assigning causality. 
Specifically thinking about Phase I or early oncology clinical trials. Fell free to 
think out loud. 
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S20:  Well there’s just one, did the reaction reappears when placebo was given? 
[mmm hmm] that’s a bizarre question, [yeah in the early stages] I wouldn’t even 
think [cross it out if you don’t think it’s] well, that are not relevant. Well it’s not 
really relevant, whether a patient gets placebo or not I don’t think should impact 
on causality [right] that’s just a red herring. Um, was the drug detected in blood or 
other fluids in concentrations known to be              toxic?, could be relevant. Was 
the reaction more severe when the dose was increased or less severe when the 
dose was decreased?, that’s possible. Did the patient have a similar reaction to 
the same or similar drugs in any previous exposure?, ah, that’s causality 
potentially. Was the adverse event confirmed by any objective evidence? So the 
patient was dizzy, then it happened in the clinic or say in the chemo suite and the 
patient was dizzy and they took their blood pressure and it was way down, yeah 
that makes sense. So I guess the only one I would cross out would probably be 
six. [okay] 
 
M: Okay, and then of those remaining ones, would you be able to sort of rank 
them in order of importance. So what you feel are higher levels of evidence 
versus less important.  
 
S20: So put the number beside these? 
 
M: Yeah, 1 would be least important and I guess 9 would be most important. 
 
S20: Okay, well this is going to be tough, ah, let’s go my most important first, let’s 
see. Um, should I start from 10 and work down [sure] or go from 1 to 9 [whatever 
you like, whatever you’re comfortable with] alright. Um, I think did the adverse 
reaction reappear when the drug was re-administered that would probably be a 
10 [mmm hmm]. Did the patient have a similar reaction to the same or similar 
drugs in any previous exposure, that’s probably the next most common one. And 
8, was the reaction more severe when the dose was increased or less severe 
when the dose was decreased is probably the next important. Um, did the 
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reaction improve when the drug was discontinued or a specific antagonist was 
administered, ah, I guess that’s 7. Did the adverse reaction appear after the 
suspected drug was administered, that’s probably 6. I’m not sure where to put 
was the adverse event confirmed by objective evidence because most of the stuff 
I would say would be ah. Trouble is objective evidence, it could be, so they’re 
talking about something that’s kind of I guess observed or was a lab test which 
could be related to the treatment or disease or something else. So I would put 
that probably in the middle somewhere. 
 
M: Yeah, I know it’s sort of a vague term, objective evidence. I tend to ask people 
what they think that means because [yeah] it wasn’t clear to me when I first read 
it either. 
 
S20: Um, are there previous conclusive reports on this reaction? I would 
probably, I put that lower down mainly because I’m more concerned about what 
I’m seeing in the patient, so I put that as a 4. Um, are there alternative causes 
other than the drug that could have caused the reaction? perhaps the question is 
not relevant, it’s not saying it’s definitely associated with causality it’s just for the 
relevance. Ah, okay, probably put this as, yeah, I’ll put this as 3 and put this as 2, 
okay. [alright, good stuff, great] 
 
M: Sorry I know that’s taxing for a Friday afternoon [laughter] Actually this was 
developed by a researcher named Naranjo and ah, as an algorithm to help 
clinicians when deciding causality. Did you do, had you ever seen this before? 
 
S20: No. 
 
M: No. Do you think something like this might be useful if you sort of had this as a 
you know, to run through when you’re assigning causality? You can be honest, 
you won’t hurt my feelings. [laughter] 
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S20: I think basically it kind of intuitively we kind of think about a lot of this 
already and even though I may not have mentioned all the keys points in this but 
I think about that anyway. [yeah] Um, it might be helpful for someone first doing 
clinical trials, but if you’ve basically got a little bit of experience under your belt 
this is probably something we do anyway. [yeah, okay that’s good to know] (use 
clinical judegement) 
 
M: Then lastly I would like to ask you about any training you’ve received with 
respect to assigning causality to adverse events. What sort of training? 
 
S20: Nothing formal. 
 
M: Nothing formal. What about anything informal, anything you can think of? 
 
S20: I worked, well I worked, it didn’t have anything really to do with causality but 
I did do a Fellowship for a year with NCIC Clinical Trials Group. But that wasn’t 
really related to that much to this. Um,  
 
M: So how did you figure it all out, how did you learn how to assign causality? 
 
S20: I think we basically um, I think we work with our clinical research associates 
and nurses and we, we um, I think we attend NCIC Clinical Trials Groups 
meeting. We go to oncology meetings where um, there is discussions on Phase II 
trials. Ah, we read oncology journals. So I think its basically picked up, maybe 
have a discussion occasionally with our colleagues. 
 
M: What do you, like when you’re discussing it with colleagues, what are you 
usually talking about there? That’s not how you, did you learn from each other? 
 
S20: Well I think, that’s kind of, I don’t think that happens on a regular basis but if 
you have a situation where, that’s really bizarre I mean, and um, I’m just trying to 
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think, um, well there may be something for instance that somebody may not be 
totally aware of. But say somebody, and this hasn’t happened to me personally 
but you could argue about, but somebody’s head and neck protocol and they 
were getting an infusion of 5-FU with a study medication um and they were 
having severe chest pain. And gee could this be related to the study drug and 
what’s going on and then you might see well infusional 5-FU can be associated 
with coronary artery spasm. So maybe it’s, you know, so how do you assign 
causality there? So you go well it’s possible it’s related to the 5-FU infusion or the 
study drug. So that’s a tough one because it’s serious enough you really don’t 
want to expose the patient to this again, it could cause severe symptoms. So 
what do you do, do you drop the 5-FU and continue with the study drug or do you 
just drop everything? And that would probably, that’s something that sometimes 
you might, it’s tough, but you might have to say okay, maybe I should discuss this 
with the medical chair of the study because you just can’t make a decision. [yeah] 
That’s a tough one. [yeah, sounds like it] 
  
M: What additional education about assigning causality if any, do you feel should 
be made available to clinicians? Do you think there’s a need? 
 
S20: Yeah, I think it would be very interesting to do an experiment where you had 
a clinical scenario. Ah the patient is on, say a study drug where you could 
develop a profile, here’s the animal toxicology, here’s the medical status of the 
patient before going on the study, the type of malignancy. And present a scenario 
that the patient has developed such and such side effects. And it would be very 
interesting to see in that scenario with experienced clinical investigators and also 
say um, people who have just finished their residency program in medical 
oncology and fellows and um, maybe nurses. How would they ascribe causality 
to such and such an event. I think it might be an interesting eye opener. I suspect 
that’s been done, maybe that’s why the survey is out there, I’m not sure. Have 
you seen anything published? [no] Neither have I. So it might be a bit of an eye 
opener, it would be like the scenario of what was done 20 or 25 years ago at 
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PMH and I think a couple of other places where they had okay, how good are we 
at assessing response rate? And you had a bunch of different size metal balls 
that were covered with foam and you had the residents and the experienced 
clinicians measure these balls and found out how much a discrepancy there was 
in the measurements. And then measure them later on and find out how many 
times there was a false response rate when you’re measuring the same size ball. 
[really?] Fascinating data on that. 
 
M: Okay so, PMH, that was a study done at PMH? 
 
S20: Yeah, I think Ian Tannock was involved in that probably about 25 years ago 
and I’ve seen that replicated somewhere else a few years later. 
 
M: What was the last name [Tannock]. 
 
S20: And, and ah, basically I think opened a lot of clinicians eyes that you know, 
our, our ability to assess response rate, we’ve got to be very careful, especially 
with smaller lesions where there’s more margin for error. [mmm hmm] And, and 
you know, I think we have to take response rates as an endpoint in terms of 
making decisions about the effectness of treatment with a grain of salt there may 
be harder outcomes that, that may be more appropriate to look at. And the 
response rates are only one bit of information that we should be looking at. 
[yeah] (feels the need to be very cautious when attributing causality) 
 
M: And that was in breast, was it in breast? 
 
S20: Um, this was you know, this was not breast cancer, this was basically 
different size metal balls [right] this was just a simple experiment [could have 
been a tumor anywhere really right?] yeah, yeah. [okay] 
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M: I’m going to look that up, that sounds good. Okay and how did they, you’ve 
peaked my interest now, okay, I’m going to look that one up. Was that done at 
like a medical conference or something. 
 
S20: This was, if I remember correctly it was published in one of the first issues 
of the Journal of Clinical Oncology. 
 
M: Yeah, but how did they actually get all of these investigators, they must have 
something to do with a conference or something. 
 
S20: No, it was, I think it was a bunch of clinicians and residents at the Princess 
Margaret Hospital and they had a room where they had these balls covered with 
foam and you had to go around and measure them. And, and they probably had 
maybe 10 or 15 people do it. [yeah] And then they came back, I think they came 
back maybe a day or two latter and remeasured and said okay let’s see how you 
measure up. 
 
M: Excellent, that’s good, simple but to the point. Okay, great, well those are all 
the questions that I have for you. [That was relatively painless] Good I’m glad it 
was. [hope it wasn’t too painful for you].  
Subject 21 
M: I will just explain a little bit about what it is that we’re doing.  [mmm hmm] 
We’re interested in the way investigators assign causality to adverse events, in 
oncology, early Phase oncology clinical trials. [sure] As you know, many groups 
such as industry sponsors, clinical trial cooperative groups and research ethic 
boards, all expect prompt and sensible causality assessments. But it’s not always 
that straightforward and if done poorly can have large implications. So we’re 
interested in developing a tool to help clinicians efficiently and reliably assign 
causality during Phase I oncology clinical trials. And we feel that by better 
understanding your needs as a clinician, we can make this tool more relevant to 
you. [mmm hmm] So, do you have any questions? [No I don’t think so] So first 
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we’d like to get a better understanding of the thought process that you use when 
assigning causality for adverse events. So let’s say one of your patients in an 
early Phase I oncology clinical trial experiences an adverse event and report that 
to you and you have to assign causality, let’s say it’s a serious adverse event. 
[mmm hmm] Can you just walk me through how that situation is handled and 
what your thought process is when you’re assigning causality? 
 
S21: Sure. So I make sure that I’m aware of the potential adverse effects that 
have been described previously reported, like in the investigators brochure or in 
previous Phase I trials. And then I also look at the disease the patient has and 
whether or not the disease itself could have been responsible for the SAE. And 
then you know, if the patient has received any other interventions. 
 
M: Any other interventions like other study medication or? 
 
S21: Or if they’d had radiation or if they had a procedure like a biopsy or 
something that could be responsible. [okay] So I guess first I would consider the 
drug, you know it’s mechanism and the reported side effects. 
 
M: And where do you go to get the information about the mechanism of the drug? 
 
S21: Usually back to the protocol and to the investigators brochure. [okay] 
 
M: And do you always refer back to the protocol and the IB when you’re 
assigning causality? 
 
S21: I can’t say that I always dig it out but sometimes you know that you’re 
working with drug X and you know that similar drugs have caused certain SAEs 
before. So sometimes it’s just my memory of, of what is likely to be an adverse 
event with that drug. And then if its a less common side effect that I wasn’t 
particularly expecting then I would go back to the IB and to the protocol and see 
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if there was any evidence for that from previous work. (only uses IB for 
uncertain situations) 
 
M: Are there any other resources that you use when you’re 
 
S21: Oh sometimes I look on ASCO.org or 
 
M: What are you looking for when you go there? 
 
S21: Well I’d look at previously published abstracts on ASCO.org and see if there 
are any other Phase trial, Phase I trials and see if the SAE that I’m looking at has 
been described previously. [okay] Sometimes I just go to Google [laughter]. 
 
M: That’s great, a lot of researchers use Google. Yeah, it’s a wonderful tool. 
Okay. Are there any tools that you use when you are assigning causality like flow 
charts or algorithms or decision trees. 
 
S21: No, just what knowledge I have in my head and in the IB and sometimes on 
the net. (use of clinical judgement) 
 
M: Do you think a tool would be helpful? 
 
S21: I do as long as it wasn’t, didn’t take a long time to do, that’s the bottom line. 
[laughter] As long as it wasn’t too complex. (time constraints) 
 
M: What are you thinking of when you’re thinking of the complexity of it like? 
 
S21: If it was more than one page I would be unlikely to do it. [okay] Because 
there’s already a lot of documentation required for early Phase Clinical Trials. 
And ah, you know, if I thought it was truly helpful I would do it but if I saw it as just 
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another piece of paperwork I probably wouldn’t do it. [yeah, yeah, okay] 
(overwhelmed with paperwork) 
 
M: Are there any other criteria that you think, you know, for this tool, do you think 
it should, what other? 
 
S21: I guess it would have to be fairly general to be able to extrapolate it to every 
possible SAE and every possible drug and disease. [yeah] 
 
M: I suppose it would either have to be really general or it would have to be um, 
very specific and individualized. 
 
S21: Right, exactly. 
 
M: Are there any general guidelines that you follow when you’re assigning 
causality? 
 
S21: No, it’s kind of, for me it’s like an intuitive process, and I should also say that 
sometimes the CRA’s do it. [okay] And actually in fact, just very recently in the 
past month or so we changed our reporting forms here so that they never used to 
have a column for attribution and now they do. So now that it’s on the form that I 
see in the clinic, I’m more likely to fill it out. [oh I see] Whereas previously the 
CRAs would just come to me if, if an attribution wasn’t straightforward [oh I see] 
and then often they would be doing it themselves. 
 
M: And did that cause problems at all or? 
 
S21: No, I probably wasn’t thinking about attributions as much as I should have 
been. And part of that’s because I don’t do any Phase I, I just do Phase II so you 
know, attributions are more important in Phase I than they are in Phase II when 
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the toxicities have already been described. And so just because of the trials that I 
do it hasn’t been as much in the forefront of my mind. 
 
M: But that additional column in that [makes me think of it more] chart, makes 
you [yeah]. 
 
S21: Yeah, the way the form is set up now it will say, it will have the CTCAE or 
whatever that abbreviation is for the Common Toxicity Criteria, you know, it will 
say rash and it will have graded it from 0 to 5 or whatever. And then right next to 
that it will say attribution from you know, not at all likely to highly likely or 
something like that. [okay] 
 
M: Actually I’m going to be talking to one of your CRAs later today and I’ve asked 
her if she could show me that chart [yeah] because I’ve heard good things about 
it. 
 
S21: Yeah, I think it is going to add something to the accuracy of our data. [yeah, 
good] 
 
M: What I would like to do now and just ask you to consider a scenario for me. 
[sure] So let’s say you’re treating a 65-year-old female patient with a confirmed 
diagnosis of metastatic breast cancer. [mmm hmm] And she is in a, let’s say 
she’s in a Phase I clinical trial with a new investigational drug when she 
experiences a pulmonary embolism. [mmm hmm] How would you assign 
causality to the study drug if there was a 75% chance it was due to the study 
drug and a 25% chance it was due to all other factors, say disease progression, 
adjuvant treatment, concomitant illness, concomitant meds. 
 
S21: I would probably mark that as probable. 
 
M: Okay, and the scale would be certain, probable, possible or unlikely. 
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S21: Probable. [probable, okay] 
 
M: Why is that? Just because you think that [75 is] pretty high [yeah]. 
 
S21: Yeah, I mean it’s not certain but it’s more than likely, more than 50/50 so. 
[yeah, okay] 
 
M: And what if it was 50/50? 
 
S21: Then I would say possibly. 
 
M:  And what if there was a 20% chance that it was due to the adverse event and 
an 80% chance it was due to all other factors, or sorry due to the drug? 
 
S21: So, I’d say less likely or unlikely. [unlikely?] 
 
M: I’m just trying to get a sense of how people understand those terms and you 
know, trying to link some percentages [sure] and probabilities to that because. 
And I know in a real life situation you would never probably have those 
probabilities but just to try and understand how people interpret those terms. 
[yeah] 
 
M: What would you say are some of the problems or challenges with assigning 
causality? 
 
S21: Just that there’s more than one possible explanation for a lot of toxicities 
that you see. So as you say, PE can be due to the drug or it could be due to the 
cancer and maybe they would have had that PE even if they weren’t on the drug 
or because they’re immobile or any number of factors. I guess it’s just that there 
are multiple factors at play. I’d say that’s the most difficult aspect of it. 
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(uncertainty is the hardest part) And plus the fact that they may be on other 
treatments, like they may be on something for their hypertension or their diabetes 
[yeah], they’ve got often multiple medical problems aside from the cancer.  
 
M: So it’s pretty complex. [yeah] Are there any other challenges you’ve 
encountered with assigning causality? Maybe even just like logistical or um? 
 
S21: Just the kind of  ‘pain in the ass’ factor [laugher] the paper work, that kind of 
thing. [yeah, okay] (hates paper work) 
 
M: So it’s just sort of one other thing that you have to do. 
 
S21: Or if it’s a totally unexpected new toxicity and sometimes that hasn’t really 
been described in the IB or previous Phase I trials and you don’t know whether or 
not that was due to the drug if it hasn’t previously been described. 
 
M: What do you do in that case? 
 
S21: I think about the mechanism of action of the drug and make my attribution 
assessment from that. Or sometimes you know, like if the toxicity is severe then 
you’ll stop the drug and if the adverse event abates then you’ll have to conclude 
that it was the drug. 
 
M: Sometimes you have to attribute your causality and then you stop the drug but 
you’ve already made your causality assessment and you don’t yet know what 
[mmm hmm] is going to happen with that patient, you don’t know the outcome. 
[right]  
 
S21: I guess you may have to go back and modify you’re attributions. 
 
M: So you’ve done that before? 
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S21: I probably did that in Hamilton but I don’t think I’ve done it here. And that’s 
probably because up until very recently the CRAs have been doing almost all of 
the attributions. [right] 
 
M: Any other problems or challenges that you’ve encountered with assigning 
causality? 
 
S21: I don’t think so, like on the whole like most of the adverse events that I see 
have been described in the IB or in previous trials, so if I have them on a tyrosine 
kinase inhibitor and they get a rash well that’s expected. [yeah] So most of the 
time it’s not rocket science. [yeah, that’s nice] 
 
M: What are your concerns about how clinicians currently assign causality? 
 
S21: I probably don’t give it as much thought as, as I should. (feels they could 
put in more of an effort) I mean, I guess the real risk is that if people are falsely 
ascribing SAEs to the drug when it’s really the cancer then you could potentially 
throw out a good drug. 
 
M: So why is it that you just don’t give it as much thought as you should? 
 
S21: Probably because up until recently it hasn’t been on the form. And also 
because you know, I don’t do Phase I trials here, so you know, it’s not, it’s not the 
primary endpoint of the trial. It’s not to describe the toxicities it’s to describe the 
response rate so you know, it’s kind of a secondary thing to document the 
toxicities for most of the trials that I do. [yeah] And you know when I was in 
Hamilton I was doing Phase I trials there then obviously it’s more on your mind. 
And also because the nurses there would come to me and ask me to do the 
attributions [yeah, yeah] but not so much here because we’re not doing Phase I 
trials here. 
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M: Now you said that obviously if you were to over-assign causality there’s the 
potential to throw out [mmm hmm] potentially a good drug. Do you have any 
examples of you know, when that’s happened in the past? 
 
S21: Oh, for instance maybe you could see a problem, I can’t think of a specific 
example in the past but I could foresee that maybe you know, you might throw 
out a drug if you saw an abnormally high rate of pulmonary emboli or something 
when that’s something that’s going to happen with cancer anyway so that could 
happen. And I guess the converse is true too that if you don’t, if you don’t 
adequately report the toxicities then you might be introducing a drug to the 
market that is dangerous. I mean I guess you could look at the Vioxx example for 
that, you know, maybe there was under reporting of cardiovascular incidents with 
Vioxx in the beginning. Because probably everybody said oh well, all these 
patients are old, they have arthritis, they’re old so and old people get strokes and 
heart attacks so. And then it was only when it had been on the market and 
millions of people are taking it that you see that event. [mmm hmm yeah, that’s a 
perfect example isn’t it]? You know, I have a particular concern for one drug that 
I’m using for kidney cancer that I’ve seen a lot, a lot of really negative outcomes 
with it. And yet when I look at the data that is on you know, the ASCO website 
and I even have written to the PI of the trial saying you know, my impression of 
this drug isn’t all as safe as what it’s cracked up to be. 
 
M: What drug is that? [sunitinib] Good, alright so those are your concerns then, 
that you could potentially throw out a really good drug or on the other hand you 
might introduce a new drug to the market that is not [as safe] as safe as originally 
thought. [yeah] Any other concerns about how clinicians assign causality? 
 
S21: I guess the other thing is that you know, sometimes a drug is safe if given in 
the study, in the right population, you know what I mean. I’m thinking of the 
sunitinib example of that, you know, I’ve had some really bad outcomes with that 
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drug and I think maybe my patients weren’t the right, you know, their 
performance status was too bad. Maybe that was my fault, that I was trying to 
extrapolate data from a study to a general population and you can’t do that. I 
think maybe you know, if attributions were, you know, if that was more a focus 
then I would have said, alright this is a dangerous drug. I don’t know if I’m making 
a lot of sense. (Fears being individually blamed for misattribution and the 
consequences that may arise) 
 
M: But then on the other hand right, I mean once this drug does hit the market 
and becomes available to everyone [yeah] there will be people receiving it [yeah] 
that maybe shouldn’t or don’t have the greatest performance status [exactly] 
 
S21: Yeah, that’s my concern that, that particular drug was only suitable for fit 
patients [yeah a very clean study population] Yeah, and when I tried to use it in 
my kind of borderline patients well they definitely died early. 
 
M: And that was kidney cancer patients? [yeah] 
 
M: What external influences or pressures from third parties have you felt when 
assigning causality? 
 
S21: Yeah, that’s a very valid question, sometimes I will have a patient who is 
having a serious toxicity and I want to stop the drug and the patient is pressuring 
me to keep on the drug. And you know, if you are going to keep them on the drug 
then maybe you have to under report the toxicity. (new perspective-patient 
pressures) 
 
M: Okay, so the patient wants to stay on.  
 
S21: Yeah, I’ve had that happen several times that the patient does not want to 
discontinue the drug even though they’ve got substantial toxicity. 
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M: And then you mentioned that, that might cause you to want to under report 
[yeah] toxicities thereafter. 
 
S21: Maybe I call it a grade 2 when it was really a grade 3.(change grading of 
causality attribution to suit the demands of the patient) 
 
M: So that’s to do with um, that’s to do with the severity. [yeah] What about your 
causality assessment would that sort of change at all? 
 
S21: No, I never really tinkered with that. 
 
M: Have you felt any other external influences or pressures? 
 
S21: No, I don’t, I don’t think so, no, it’s mainly the example I can think of is 
patient’s pressuring me to keep them on a drug when I’m not sure that’s to their, 
you know in their best interest. 
 
M: So, we talked a little bit about this, so from your perspective what would make 
assigning causality easier? You know, we’re going to try and develop this tool, 
but is there anything else? 
 
S21: A cleaner patient population you know [sorry?] a cleaner patient population 
[yeah, making] that’s never going to happen but if you had a patient that wasn’t 
as at high risk for PE or for a decline in their functional status or whatever then 
that makes it easier to say that it’s the drug. If they were quite fit when they came 
on the drug and then something happened, it’s probably the drug. 
 
M: And unfortunately we’re usually testing these drugs in [yeah] metastatic 
cancer patients right. 
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S21: Other than that, I can’t really think of anything. 
 
M: What I’d like to do now is ask you to take a look at this algorithm that was 
developed by a researcher named Naranjo. [mmm hmm] So there’s 10 questions 
there, he developed this algorithm to help clinicians assign causality to adverse 
events. I was just wondering if you wouldn’t mind crossing out any that you do 
not feel are relevant to the Phase I, specifically Phase I oncology clinical trial 
setting. So if you don’t think they’re useful or relevant, just cross them out. 
 
S21: I think they’re all relevant. 
 
M: Okay, so now would you be able to rank them for me, so 10 would be most 
important [okay] and 1 would be least important, so just sort of in your order of 
importance, what you think? 
 
S21: So does there have to be one, can there be two that are marked 10 [oh 
sure] or are they supposed to be 1, 2, 3, 4 [no, if you would like to do it that way 
that’s fine] 
 
M: Okay, great thank you, that’s perfect. So I guess the least important then was 
whether the drug was detected in the blood in concentrations known to be toxic. 
Why did you rank that one so low? 
 
S21: Because some patients maybe had an allergic type reaction and just 
needed a small amount of the immunogen to cause a reaction. 
 
M: So it doesn’t necessarily have to be a highly toxic level [no] for them to react. 
 
S21: No some patients may have enzyme deficiencies make them more 
susceptible to the effects of some drugs. 
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M: And then was the adverse event confirmed by any objective evidence you 
ranked that fairly low. 
 
S21: Yeah, I have to believe a patient if they tell me that their feet are painful or 
whatever even though I can’t see it. 
 
M: Yeah, that’s a good example, yeah pain is a really tough one [yeah] you can 
only go by what patients are saying. And then most important was did the 
adverse event appear after the suspected drug was administered. 
 
S21: That makes sense [it makes sense yeah, it can’t happen before] 
 
M: Did you have any thoughts, like as you were going through this what did you 
think? 
 
S21: I thought somebody made this up based on Hills criteria [yeah] isn’t that true 
[yeah, it’s very like, yeah, it’s a lot like Hills criteria] yeah, but that’s about all I. 
 
M: Were there any questions that were missing that you thought should have 
been here? 
 
S21: Nothing I can think of no. [okay, great] 
 
M: Do you think something like this might be useful as a tool to help clinicians? 
 
S21: I think it yes, as long as it were fairly brief and user friendly and also it 
depends I guess on the level of experience. Somebody new to clinical trials that 
would probably be helpful but somebody that already has that thought process 
engrained in their memory might not need it as much. (time constraints 
discourage clinicians from using a tool, which is design to help them) 
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M: Yeah that’s what I think too and I’ve received that feedback from other people 
too that it would probably be good for somebody just starting out. [yeah] 
 
M: So lastly I would like to ask you about the training you’ve received [sure] 
specifically with respect to assigning causality to adverse events. So have you 
received any training? 
 
S21: Zero.  [no eh] 
 
M: Not necessarily formally, but informally? 
 
S21: No, the first time I had to do it was when a nurse came to me and said 
you’ve got to do this [laughter] [and how did you even know how to do it] I said, 
are you sure that’s my job? [laughter] So I mean it was just kind of logic, you 
know, in my mind I guess I was using something like your checklist, you know, 
looking for a temporal relationship and a dose response relationship. You know, 
and a biological plausability relationship. 
 
M: Right, so you recalled your Hills criteria. [exactly] [laughter] And where did you 
learn about the Hills criteria? 
 
S21: In my epidemiology course [in the epi course you took at Mac?] Yeah. 
 
M: But not all MDs get that do they? 
 
S21: No, most wouldn’t no. But I mean, I think there’s a certain logic to it you 
know, I think everybody, anybody is going to know well it’s not the drug if the 
reaction happened before the drug. [yeah, yeah] And anybody’s going to 
conclude that it’s more likely the drug, if you stop the drug and the reaction calms 
down. I don’t think you, I think you can kind of describe what you’re thinking 
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better if you know about Hills criteria but you don’t necessarily have to have that 
teaching to reach the same conclusion about causality. [yeah] 
 
M: What additional education about assigning causality do you feel would be 
helpful to clinicians?  
 
S21: Well you know, I guess like something like running through that checklist 
would be helpful, particularly as I said to somebody who is new to the process. 
 
M: Is there anything else that you can think of that might be helpful in terms of 
education? 
 
S21: I guess, I keep coming back to this, but keeping it simple and brief because 
there are a lot of competitors for a trialist’s attention, you know, like there are a lot 
of time constraints and something more simple that would be best. 
 
M: I know, you guys are super busy. Okay, I think those are all the questions that 
I have for you then. Do you have any questions for me? 
 
S21: Yes, I’d like to hear how it all turns out. 
 
M: Yes, definitely, so the plan is once we analyze all this interview data we will be 
sending the participants an executive summary [oh that would be good] of the 
results. And we’re also hoping to present at the fall NCI meeting although I’m not 
sure, it might end up being in the Spring [yeah]. We would like to present at an 
NCI meeting. [yeah that would be interesting] Yeah, yeah, I think, I think there’s 
some good stuff coming out of these interviews for sure. Okay and so do you 
have anything else you would like to add? 
 
S21: I don’t think so. Good luck with your project. 
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M: Thank you very much for your time. 
Subject 22 
M: Even the most experienced clinicians find assigning causality to adverse 
events challenging. Many groups such as industry sponsors, clinical trial 
cooperative groups, research ethic boards, all expect prompt and sensible 
causality assessments. But I’m sure as you know, it’s not always that 
straightforward and there are implications. [mmm hmm] So we’re interested in 
developing a tool as I mentioned to help clinicians efficiently and reliably assign 
causality to adverse events that have occurred in early Phase oncology clinical 
trials. And we feel that by better understanding your needs as a clinician, we can 
make that tool more relevant to you. [okay] So, do you have any questions? [No I 
think I understand what the study is about] So first I’d just like to get a better 
understanding of the clinical reasoning, the thought process that you use when 
you’re assigning causality to an adverse events. So let’s say one of your Phase I 
or II patients comes in and reports experiencing an adverse event, let’s say it’s a 
serious adverse event. Can you just walk me through the thought process that 
you use when you’re assigning causality to that event? 
 
S22: So I think the first thing obviously is to describe the event, you know, how 
severe, exactly what it consisted of, is it something that’s well recognized, is it 
something that’s entirely novel or unusual? The next thing I think is to look at 
when it occurred with respect to going on the study, did it occur before starting, 
you know, is there evidence that this was kind of brewing prior to starting the 
treatment? [okay] So we look at the temporal association, we look at the, you 
know, the course of what happened. Did the patient stop the drug? For instance, 
if it’s an oral medication that he’s taking continuously he would have the 
opportunity to stop the drug and then see if it got better. On the other hand if it’s 
a kind of one off, intravenous every 3 weeks kind of thing then the patient doesn’t 
have the opportunity to stop the drug. But sometimes if it’s oral, and increasingly 
these new drugs are oral, they may phone up and say hey, you know, my tongue 
has turned blue what do I do you know? And the nurse is going to say well gee 
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maybe you should stop the medication. So you may have temporal evidence 
about what happened depending on if the patient stopped the drug or not. [yeah] 
So I guess this is kind of the initial process, just to describe the event, try to work 
out a temporal association between going on the trial and maybe stopping the 
medication.(cope with uncertainty by placing a strong emphasis on 
temporal association) Restarting it and seeing if it comes up again you know, 
that sort of thing, trying to look for cause and effect relationships really. 
 
M: You mentioned trying to understand if it’s well recognized or if it’s something 
that’s novel [right] how you do determine that? 
 
S22: Well we have a, everyone that goes on trial here has a PAR form and that 
stands for patient something, something report form, patient adverse event report 
form or something. But basically it’s a series of standard common side effects or 
adverse events which are kind of stereotyped you know, diarrhea, mucousitis, 
neutopenia, rash, hand-foot syndrome, vomiting, nausea, that sort of thing. So 
there’s a whole list of these things, which most adverse events that are related to 
drugs will fall into. However if something novel occurred like for example, this 
occurred this morning where somebody got ocular irritation, he was on a drug, a 
drug combination that was novel this was, this is not something that you see all 
that commonly and as a result it’s not on the PAR form. So it has to be recorded 
separately on the back of the PAR form where there’s space for the CRA or the 
nurse to write this kind of stuff out if it doesn’t fall into a simple category. You 
know, like diarrhea grade 2 or something, something that’s unusual or novel our 
system allows the nurse or the clinical trials associate to write it out on the back 
so that firstly there is a permanent record of it. And secondly it alerts me to the 
fact that something, a) something’s happened and b) that it’s not the usual kind 
of thing. [mmm hmm]. And then it becomes difficult for me, but then you’re forced 
to make some kind of a decision. (feels a decision must be made- feels 
forced, very hard to do- complexity and uncertainty of the situation) 
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M: With respect to what? 
 
S22: To the causality [oh the causality yeah] because you have to react in some 
way. So I had to think this morning for example this ocular side effect, was it due 
to you know, drug A or drug B or the combination. Or was it due to something 
incidental like you know conjunctivitis or something. So you have to think about 
alternative causes, alternative explanations. I mean people with cancer get many 
symptoms from the cancer that are not necessarily due to the drug, they may just 
be due to the underlying disease. And of course a lot of people have 
comorbidities because they’re elderly and have a 101,000 things wrong with 
them. (almost too many confounding variables to deal with) And you know, is 
it just something incidental. So I think one of the important things in the causal 
reasoning is, is to be aware of what the possible causes could be. You know, it’s 
due to the experimental drug, it’s due to some other drug the patient may be 
taking or may have just started taking. It could be due to the underlying cancer, it 
could be due to some other illness that may have occurred or that may have 
already existed like diabetes or angina or something you know. So I think critical 
in the sort of, the kind of cognitive approach is the realization that there’s a whole 
slate of things which could possibly either alone or in combination have resulted 
in this phenomena. (have to have an open mind, be open to possibilities) 
[right] On the other hand you don’t want to be paralyzed by uncertainty because 
if you’re in a busy clinic you can only tolerate paralysis for so long [right] you 
have to make some kind of a decision. (time constraints) So that’s 
 
M: So in that case, what did you? 
 
S22: I would say 95 to 98% of the things that happen, it’s, you know, it’s kind of, 
to an experienced clinician you know, without wanting to entrench, you know and 
have my own prejudices confirm themselves. (uses experience to cope with 
uncertainty) But I think that. My sense is that 95 to 98% of the things that the so 
called toxicities or adverse events we can generally, going through this kind of a 
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process make the correct kind of attribution. But every now and then it’s tough, 
like what happened this morning for example, it was difficult, it wasn’t clearly 
obvious to me what was going on. (some decisions are very difficult, even for 
the most experienced clinicians) 
 
M: And so what did you attribute, what was your attribution in that case? 
 
S22: Well I thought at the end of the day that it was likely due to the drug, so 
without specifics … 
 
M: And what was that based on? 
 
S22: Without going into the specifics, the patient was being treated with two 
different types of drug. One is a common chemotherapy that’s been used for 
years and the other one is a novel drug that’s also been used but has been used 
separately as a single agent. 
 
M: So this was the first time it was being used in combination with the chemo. 
 
S22: In combination, exactly right. And so it was this unusual ocular side effect 
which has rarely been described before with the chemotherapy, the old fashioned 
chemotherapy but not commonly. And has been described with this novel drug 
but not quite in the same way. So my sense is that it’s probably something to do 
with the two of them together. [right] But certainly I think the novel drug was 
necessary. You might argue you know, causality is difficult, causality is not 
simple. [no] You know, there’s different kinds of causality, there’s the kind of 
relationship where something is sufficient on it’s own. [right] There’s another kind 
of relationship where something by itself is not sufficient on it’s own but it’s 
necessary. [and then there’s] And there’s relationships that are where you have 
it’s neither sufficient nor necessary but it nonetheless contributes. (verifying 
types of causality make the decision even more complex) So it’s actually, on 
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the one hand you’re saying well just attribute causality but there’s actually a more 
profound and fundamental understanding of causality with respect to well what 
type of causality? Um, which is important I think because it does help you 
manage the situation you know, so sometimes I don’t think it’s possible to be 
100% sure. Except I think it’s usually possible to be reasonably sure that a drug 
has got something to do with it. [mmm hmm] But I think at the end of the day you 
may just have to reconcile yourself with you know, an attribute of say probably as 
opposed to certainly. Because it may not be possible, it maybe kind of fatuously 
accurate like you know, what’s the distance between here and Ottawa or here 
and Hamilton, well it’s approximately 160 kilometers. But there’s no point in 
saying it’s 161.2357 kilometers it’s kind of speciously accurate you know what I 
mean. [yeah] So I don’t think that we should attribute causality more than we can, 
you know because we feel some obligation you know, to fill in some category in a 
form. (feels obligated to make a decision, even in cases of uncertainty) So I 
think an intelligent approach doesn’t demand that you be more accurate than you 
can. Because I think I’ve been in some situations where it doesn’t, you know it 
either is or it isn’t and it only gives you two possibilities. You know, this is caused 
by drug X or it’s not. And in a sense I don’t like that because, I know, I just don’t 
think it represents the reality and the reality is sometimes there is an element of 
uncertainty. And I think that the best kind of, the best kind of forms that you have 
to fill in, when you fill in these, allow you to designate if there is some uncertainty 
or not. [right, yeah] 
 
M: That was actually one of my questions, yeah, so you definitely prefer to have 
sort of the gradation rather than 
 
S22: Yeah, I prefer the gradation and having said that I mean, I think the 
gradation is, is not the end of it, I think it’s perhaps the beginning of an intelligent 
insight into it. But I don’t think that, you know, in terms of what we were talking 
about where something might be necessary but you know, the necessity and the 
sufficiency of it. I’m not sure that, that emerges immediately from, from a kind of 
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graded scale. So the kind of graded scale if you like, where you’re on the one 
hand on the one extreme you are certain that this is not due to the drug, on the 
other hand you are certain that it is due to the drug. But then in-between you’ve 
got, you know, possibly and probably. I mean the simple thing would be a 4 point 
scale where it’s definitely not, possibly is, probably is and definitely is might be. 
But you know even once you fill that in to the best of your ability you don’t really 
know whether the, what the, you don’t really have a lot of insight into the precise 
causal relationship. [mmm hmm] You know, whether the drug was just one of the 
factors for example that led to the event. [right] (type of causality is most 
difficult) 
 
M: So for example in your case where you think that it’s a combination of the 
chemo with the drug, not just the study drug on it’s own. That’s really not 
reflected when you’re attributing causality is it? 
 
S22: So I say for example, if I had to put down on the thing I would say that this is 
probably due to the new drug. But that doesn’t give you any information as to the 
fact that probably the other drug contributed something. [yeah] And that probably 
if we reduce the dose of the novel drug that you wouldn’t get this problem. [right] 
So that not only was it due to the drug, it was due to the drug being delivered at a 
certain dose, so, you know what I’m saying. [yeah] So an in depth understanding 
of the causality, let’s say for example, let’s say in this case the ocular toxicity was 
due to the presence of the other drug, plus this new drug given at a certain dose. 
And that we could do, in order to get rid of it, which is really what you’re trying, 
the whole purpose of this is to get rid of the toxicity, you could do one of two 
things. You could get rid of the, the old-fashioned chemo drug, that might solve 
the problem. Or you could keep the chemo drug in and lower the dose of the 
novel drug which is what we elected to do. [right] And both of those things might 
actually solve the problem. So in a way what we are getting at here in studying 
causality in-depth is what is the strategy we have to adopt to get rid of the 
problem? Because when you successfully get rid of the problem in a way you 
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might just be trying things on an ad hoc random empirical basis. But if you 
stumble on some strategy that gets rid of the problem [mmm hmm] it does give 
you, not total insight but more insight into the precise nature of the causality. But, 
but even if you stumble on a strategy that’s effective it doesn’t necessarily mean 
that there aren’t other strategies that are also effective. [sure, yeah] So this just 
speaks to the complexity of this, especially when you’re dealing with two drugs. 
You know, if you’re dealing with one drug it’s somewhat simpler but I think you 
know, you may want to address this in the tool, when you’re dealing with two 
drugs, which I think is often the case in oncology, two or more drugs it then 
becomes quite important to but also more difficult to understand the precise 
causal relationships that are operating. [yeah, definitely] And I think, we’re in a 
situation quite often in oncology where you have mild to moderate, let’s say 
ocular toxicity, it’s not life threatening but irritating and it definitely impairs quality 
of life. [yeah]  But it may not be a sufficient priority of the academic community 
that they will specifically design trials to sort this out. But in fact you may need to 
design a whole lot of different trials, or at least different strategies to sort out 
these kinds of you know, low level irritating toxicities. Such as for example, the 
hand/foot syndrome with a drug called capecitabine, which is not life threatening 
therefore people will say well let’s throw in some peridoxine or maybe try some 
dose reduction. Dose reduction always works but you know peridoxine is felt to 
alleviate it but nobody really knows for sure because it hasn’t been felt to be a 
sufficiently high priority to actually design a proper study to, to evaluate 
peridoxine. So you just don’t know you know, whether, if you do dose reduction 
plus peridoxine, it seems to kind of get better, was it the peridoxine, was it the 
dose reduction? If you gave the peridoxine maybe you don’t have to have a dose 
reduction and that would be you know, potentially quite an important piece of 
information. (trial and error in trying to eliminate toxicity) But because this is 
not regarded as the most, as the highest priority of the academic community, you 
know. Despite the fact that capecitabine has been on the market for 5 to 7 years 
we’re still in the situation where we don’t really know how to manage [what’s the 
best] what’s the best strategy of what in fact is the commonest side effect of 
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capecitabine which is the hand/foot syndrome. So we don’t know, you know, we 
just don’t know. 
 
M: So definitely dealing with two or more drugs in combination is a challenge 
[yeah] in terms of assigning causality, are there any other challenges? 
 
S22: Well I think you know, part of the problem is that um, some of the toxicity is 
pharmacogenomic, you know, is based on individualized differences at the 
genomic level which we’re not aware of you know. So firstly, we know that these 
genomic differences exist but we don’t really know because they aren’t measured 
so we don’t have the information available to us. (lack of resources) And also 
what may, what may be important is genomic differences that exist that we don’t, 
which we don’t know about you know. Single nucleotide polymorphisms with 
respect to genes that may affect you know you skin or your bladder or your brain 
or something that are hidden from us right now because we just don’t know that 
they exist. [mmm hmm] And you know, obviously you know, the whole western 
tradition of thinking is mechanistic thinking. You know, we don’t believe in magic, 
we don’t believe in, I mean quantum physics is a challenge to the western 
mentality because it seems that at a quantum level [requires a leap of faith] 
things happen without any immediate cause. You know, a radioisotope decays, 
we know that statistically you know the half-life of plutonium maybe 60 years or 
100 year, whatever it is, or 1000. I don’t know what it is but you know that at 1000 
years, let’s say it’s 1000 years half of the plutonium atoms that are going to 
decay will decay in 1000 years on average. But you don’t know on a Tuesday 
afternoon at 3:00 [how many] what one is or isn’t [yeah]. Because it seems to be 
inherently unpredictable which is an afront to the western way of thinking. But at 
the level of toxicity you know, we have a sense because of the way we think and 
approach science that everything at this kind of level, at the macroscopic level is 
explicable. [yeah] We, we know and this is really one of the things that drives us 
and irritates us is that we know that there had to be an explanation why Mr. xxx 
got 3 grade diarrhea five days after starting his chemotherapy. You know, there is 
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a causal chain of events and it’s not random, it’s not unpredictable but we just 
don’t know enough about it to predict. So one of the things that interests me for 
example, is the prediction of toxicity. I actually have a website called 
www.predictpatientevents.com [oh really] which makes available to functioning 
clinicians through the Internet mathematical models which just require 
parameters being put in for say anemia in ah, in the adjuvant treatment of breast 
cancer or the advanced non-small cell lung cancer setting. With nausea and 
vomiting across a range of different disease situations, chemotherapy-induced 
diarrheas, the latest one we’ve put up about two weeks ago. So you can input 
data um, parameters with respect to age, gender, you know, line of treatment, so 
on and so forth that we have just empirically found to be associated and 
predictive of chemotherapy and have this updated cycle by cycle. So that you 
can get a report that you can share with a patient that in a way might look like a 
weather report saying you know, the risk of precipitation this afternoon is 53% 
and you can decide what you’re going to do about it. [right] But we give you a 
prediction on a percentage basis of you know, significant grade 3, grade 4 
diarrhea associated with this cycle of chemotherapy with either say FOLFOX 
which is oxaliplatin, 5-flurouracil and leucovorin or irinotecan, which is a regimen 
called FOLFIRI.  So we’re able to do this and we think that these um, this kind of 
prediction system is significantly better than, than a crap shoot than a random 
you know, it may or may not happen kind of thing which really happens now 
[yeah] it may or may not happen. So that, I mean, our belief is if you know with a 
greater degree of certainty whether or not you are going to get serious toxicity 
that you can do something about it before it happens. [yeah] So we’re interested 
in explanations as well but from a slightly different point of view because we’re 
interested in identifying um, parameters if you just use a general word that are 
associated reliably with the presence or absence of some toxicity, such as 
chemo-induced diarrhea. [right] Now we don’t, from our limited point of view, 
don’t really care whether they’re causally implicated in the mechanism. But we 
just want to isolate these things because they’re reliable indicators that it’s going 
to happen. So it’s like the red sky at night, do you know that? [sailor’s delight], so 
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the red sky doesn’t actually cause the weather the next day [no] but it’s a signal 
as to what the weather is going to do next day. And it’s obviously related in some 
deep way to the causality but by itself it may not be the explan, the cause, in the 
causal chain of events. [yeah] So for instance, your performance status is highly 
correlated with the appearance of many different kinds of toxicity. Um, but the 
performance status itself is not what causes the toxicity, it’s the underlying 
physical status of your body that manifests as a performance status. And there’s 
elements of that which cause the toxicity. So you know, we’re interested in it here 
as well but we’re interested in the predictive ability of parameters. Now obviously 
if we can isolate the causal events that would probably, presumably increase the 
reliability of the prediction. [right] So when, when we look for a model, we look 
initially for things that might be associated causally. So let’s say we’re interested 
in neutropenia, one of the things we would be interested in is how much radiation 
[have they received] have they received to what percentage of their bone 
marrow, you know, the skeleton that carries the bone marrow and that casually 
would be associated with myelosuppression subsequently because you’ve 
eliminated part of your bone marrow, therefore it makes sense it would be more 
prone to getting myelosuppression. But other things maybe unpredictably 
associated, like you know, your creatinne or your alkaline phosphatase or 
something it just might come up as a signal and we, we would incorporate it in 
the model because it’s useful. Not necessarily because it’s causal but just 
because it’s useful as a flag. [yeah] So we’re also interested in this [great that 
sounds wonderful] so just at it from a slightly different perspective. 
 
M: Wow, yeah, I’ll definitely check out your website [check it out]. Have you 
written some papers about it? 
 
S22: Yeah, there’s an article published in Lancet Oncology and several others in 
abstract and others that are being submitted um, you know that, that you might 
want to look at. [definitely] We’re encouraging oncologists to try and use them. 
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M: I think that’s useful information to give to patients and you can, like you said, 
maybe try to preempt some of these events from happening. 
 
S22: It’s the preemption that we’re interested in.  So that we think that a lot of the 
downside of chemotherapy is actually unnecessary [yeah] and that if you knew 
what was going to happen before it happened [you could take some measures] 
you could do something about it. [increase your fluid intake say or]  Or go on 
GCSF or whatever, or don’t take that holiday to Florida or, there’s a lot of things 
that you might do differently. But one of the things you might do differently is you 
might give the chemotherapy at a lower dose or you might prescribe a supportive 
care medication. Or you might instruct the patient on early monitoring and 
intensify the educational and monitoring efforts. So there’s a lot of things that you 
might do if you knew about it, which right now we pretend in a way that we don’t. 
And you know, we give toxic chemotherapy knowing that up to 33% of people will 
get serious, sometimes life threatening side effects. But the question is, what 
makes that ethical? The only thing that makes that ethical is you don’t know in 
any group of 100 patients who are the 25 to 30 patients [who are going to make 
it], so the whole basis, well who in fact will get ill. [yeah] The only reason that 
you’re allowed to do that, first of all the rationale is you over treat a minority in 
order not to under treat the majority. I mean that’s the only reason why we do it. 
So, but if you knew that this person was going to get grade 4 diarrhea if you did, 
if you prescribed it you wouldn’t do it. The only reason it’s acceptable ethically is 
because it’s anonymous okay, but the minute you knew somebody, this was 
going to happen to somebody, you would be forced as a, you know good medical 
practice to do something different. Either lower the dose, prescribe Octreotide, 
you know, whatever, whatever you know, do something different. So it becomes 
something important to the whole reputation of chemotherapy and the 
improvement of chemotherapy in going forward is that we should view it the way 
the airline industry views accidents, they have a zero tolerance policy basically. 
[right] So if we had, obviously if you are trying new drugs and so on, some toxicity 
is going to happen, you can’t, but once chemotherapy becomes mature and 
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incorporated into the standard, there’s still an appalling amount of toxicity. And 
what we should, if we said as a society we’re going to have zero tolerance to this, 
it really means that you have to understand it much better than we do now. (feels 
there is still so much to learn in terms of even known toxicities, lack of 
knowledge in these areas)  
 
M: And then if you were to add in a novel agent in combination with that 
chemotherapy it would be much easier to sort out what to do to the novel agent. 
 
S22: Exactly, because it would be much better defined, you know, what, what 
you would expect [from the chemo] especially by the way if you could 
individualize the risk. So what our website does is that is doesn’t just give you 
know, like the literature risk it individualizes the risk. And of course in a Phase I 
study you are dealing with individual patients. So you know, if you got some 
standard drug plus some new drug, um, somebody gets neutropenia or whatever 
it may not help you all that much to know that the sort of published literature 
incidence of neutropenia is you know, 16% because you know, did it or didn’t it? 
you don’t know. But it might help you to know that the individualized risk of 
neutropenia for that patient may have been 1% or 70%. Then you could put the 
other drug in much better context. [yeah, yeah, interesting] 
 
M: Well maybe we could somehow work together here [maybe, maybe] you 
never know. Okay, well this is great, I’m learning a ton. 
 
M: What are some of your concerns about the way clinicians are currently 
assigning causality; you sort of touched on it a little bit. 
 
S22: Well I think you know, they have to make a judgment in a hurry, so there’s a 
concern straight away, they’re on the busy machine in the clinic and they have to, 
you know, somebody puts some form in front of them and they kind of, you know, 
they’ve got two pens, one pen in their left hand and one pen in their right hand 
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and they’re hitting the typewriter with their nose and looking at the screen and 
trying to do four things at once and the telephone is ringing and so on. (time 
pressures on top of busy workload) It really is a zoo as you know, so they 
have to make hurried decisions, so that’s my one, that’s my number one concern. 
Number two is the options that are placed in front of them are different depending 
on the trial. You know, some trials allow you to, to grade this kind of level of 
certainty that we were talking about before. Other trials force you to make some 
kind of premature commitment one way or the other. 
 
M: You mean the options on the actual causality scale? 
 
S22: They maybe limited, this is due to this or it isn’t, I’ve seen that before, that 
sort of disturbs me. (disturbing that some scale measures are not flexible) 
 
M: Well it disturbs me too, actually I think that let’s be consistent, how can we 
expect to be consistent if we don’t use the same scale across the board? 
 
S22: Right, that’s right, so it’s the consistency of the scale that’s different. Now, 
on the other hand, we don’t want people, we don’t to stop people experimenting 
with new scales that might be better. But I certainly don’t want older scales that 
are worse. So those are my two concerns just off the top of my head. And the 
other concern I have is do, are people sufficiently educated in casual attribution? 
 
M: Let’s just talk about that for a minute. Um, how did you become educated in 
assigning causality? 
 
S22: Well I just, I’m curious I suppose about explanations, I’m curious about 
scientific explanations and it seems to me that the only way that we’ve really 
made progress, the best way to make progress is to understand something in a 
way that an engineer understands something. And I think medicine gets better 
when, as it turns into engineering. Um, I think it’s a long way from engineering 
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right now and I think a lot of it is gut feeling and kind of intuition. But I think that 
we will make progress as we turn it from an art into a science and ultimately 
applied science is engineering. And I think that engineering does mean a very 
precise understanding of mechanistic relationships if you think about a machine 
you know um, you know I think um, the things we understand best are machines 
that we construct and build. And I think we’re, this whole enterprise of medicine 
really is an attempt to reduce the human body to, to a machine in a very, very 
complicated web of, probably multiple machines at multiple different levels. But 
really that’s what this whole goal, this whole thing is directed towards. (sees 
human body as machine) 
 
M: Yeah, that’s, I would agree. So you’ve learned how to attribute causality 
because you’re curious and you just self-taught or? 
 
S22: Yeah, well I think, if you’re interested in logic, you know, it’s, it really 
becomes obvious that there’s different possibilities in terms of the causality you 
know, firstly at the crude level did or didn’t? And if it didn’t what else did because 
something certainly did. [yeah] And then you feel obligated as a physician you 
know, to know why this happened to your patient because even at a non-curious 
level, even at a functional pragmatic level in order to give people appropriate 
medical advice, if you really don’t have the faintest idea why something 
happened to them it’s very difficult to give them the appropriate advice. (feels 
obligated to give patient a concrete explanation, frustrating because there 
often isn’t one) [that’s right] Especially if they’re on a drug that might have 
caused it but on the other hand might also be helping. [yeah] So it’s not a trivial 
thing to say well just stop the treatment. I mean if you’re treating somebody for 
acne or you know, mild headaches or something like that or you know, chronic 
arthritis. It’s very easy to say, stop this anti-inflammatory, stop this topical 
medication and just see if something gets better because that’s an obvious way 
to do it [sure] from a causal point of view. [yeah] But it may not be quite that easy 
to do with chemotherapy, even in the, even off trial, but it’s particularly difficult to 
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do that on a trial because you know that you might sabotage you know, the intent 
of the study by just unnecessarily stopping. You know, I think the onus on an 
investigator and somebody who’s responsible for treating the patient on a trial is 
quite high really because they have the ability to undermine the trial by making a 
fallacious attribution. You know because something might have happened you 
know, they got gastro because they ate something at some restaurant or 
something and then you say well it’s the drug and you take them off the drug. 
Well then you undermine the whole enterprise you know which isn’t just that trial, 
it stretches back over probably 15 years of work and money and investment. And 
it’s so easy to undermine it by making, by casually making the wrong attribution. 
(apprehensive about assigning causality due to serious consequences it 
can have on the trial) 
 
M: Do you have any examples of that, like can you think back to a study that was 
or a drug that had been halted in it’s development because of? 
 
S22: I mean I don’t you know, you could think about it the other way as well in 
fact where something happened. Let’s say, there is a class of drugs where an 
incidence of pneumonitis has emerged in lung cancer which was not made 
necessarily, we didn’t necessarily, we weren’t, it wasn’t immediately apparent to 
the investigators that this, this side effect might occur. So it’s possible that this 
side effect occurred earlier on but somebody did not attribute it to the drug. So I 
think, I think it’s, now of course you’re dealing with somebody people with lung 
cancer and it’s not a surprise that some of them might get pneumonitis and may 
even die. But you kind of wonder whether somebody thought hmm, this is a little 
unusual but may not have did, I don’t know if anybody did or didn’t. But 
somebody may not have attributed it when in fact they should have. [mmm hmm] 
So there’s two kinds of mistakes you can make. You can make a false positive 
attribution or you can make a false negative lack of attribution, when in fact you 
should have. So, 
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M: Do you remember the name of that drug? 
 
S22: Well it’s a drug called Iressa which is a drug that later on it became clear 
that there was an element of pneumonitis, now I don’t think it’s very common [no] 
but nonetheless I have seen it personally. And we nearly lost somebody, not on a 
trial but just you know and had to be ventilated and two weeks on the ventilator. 
And the intensive care people are saying this is cancer, we should write it off, we 
should stop the ventilation because this is obviously cancer. And I said no it’s not 
it could quite possibly be the drug and indeed it was the drug. And two weeks on 
the ventilator she cleared and came off. [wow, that’s] So it’s, you know, these 
things are in a way matters of life and death, they can be. (attributions can be 
as serious as life and death) Now, you know, we’re told the incidence is 1 to 
2%, maybe 4% in the western the world and 1% in the orient. And you know, I’m 
not pointing fingers but it is something that occurs at a low frequency that might 
be expected in the population anyway. And I think it’s just interesting if you’re 
looking at a case history to go back and say well what is the history of this 
attribution, when did it become, when do people really know about it? Is it 
possible that people under attributed it earlier on? You know, were there 
accusations that there was over attribution? You know, because, I’m not saying 
this company is an ethical company but they’re, but is it possible that some 
company with some drug might pressurize people not to make the attribution? 
[sure] You know, what do you do under these circumstances, what is your 
responsibility? And I think a lot of things can happen under the, under the banner 
of uncertainty. You know, you can be forced to under, I think that uncertainty is at 
the heart of this, its at the heart of this. And I don’t think it’s a matter of honesty or 
dis, I think it’s uncertainty and how do people cope with uncertainty? And I think 
that this actually is the measure of whether enterprises succeed or fail. You 
know, it’s how they deal with uncertainty. So I think for example one of the 
differences between successful businessmen and unsuccessful people in 
business is that the unsuccessful people don’t know how to deal with uncertainty. 
Um, because life is full of uncertainty and you know, it’s possible to be panicked 
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into, into making a wrong decision. On the other hand it’s also possible to be 
paralyzed into not making any decision at all. [yeah] So when you see these kind 
of little human dramas played out in this situation as well because, but I think it’s 
a mistake to not allow the physician to be uncertain when he or she is genuinely 
uncertain. But what I don’t see is like, you know, a highly refined scale about 
uncertainty. Like if you say okay, you’re uncertain. I don’t see a scale that then 
says well quantitate your uncertainty and do you think, how is uncertain, how 
certain are you that this, or what do you think is the probability in percentage 
terms that this drug caused this side effect? And I’ve never seen that ever. So if 
you say for example, there’s a category of possibly, one of the things that you 
might consider is once you click, once you tick possibly due to this then give me 
your, try and put a quantity on your, on your sense that this has actually caused 
this. Is it 30%, is it 40%, is it 50, 60, 70%? And that might be quite interesting to 
go through as an exercise. To actually allow people to be uncertain and then 
make them quantitate what they think the likelihood is that it actually did that it 
actually did cause. 
 
M: Well actually, that’s quite interesting, can I just ask you to, I just want to 
describe a scenario to you and we can just sort of walk through it. So let’s say for 
example you have a, a you have a female patient who has been diagnosed with 
metastatic breast cancer and um, she’s just reported and she’s in a Phase I 
clinical trial with an investigational trial and she’s just experienced a pulmonary 
embolism. How would you assign causality to the study drug if you knew that 
there was a 75% chance that it was due to the study drug and a 25% chance it 
was due to other factors, say um… 
 
S22: Well I would say it’s probably [probably] probably. Yeah, I’d think you’d have 
to, if probably was an option [yeah]. 
 
M: So the scale would be certainly, probably, possibly or unlikely. 
 
! %%+
S22: Then I would say that it was probably due. But I’m not sure that I would 
know necessarily that the underlying, that it was 25/75 [yeah, so you would never 
know those percentages] I would never know those percentages. Unless I, 
unless somebody could tell me what is the risk of people on chemotherapy with, 
not chemotherapy, people with metastatic breast cancer, getting a pulmonary 
embolis off of chemotherapy. Because I presume she’s not on chemotherapy, 
she’s just on the new drug. So the question is what is the likelihood that this 
would have occurred anyway had she not had the drug? And it comes back, it 
comes back to our predictions to, and the answer is we don’t know. So if for 
example, this knowledge was available to the physician when he was asked to 
make the attribution [right] that the incidence of pulmonary embolism, the woman 
on, with metastatic breast cancer, independent of treatment is you know 16% 
lifetime, you know during, from metastasis to death. There is a 16% incidence 
which I would say might be quite accurate, I don’t know but it’s probably around 
that order, maybe even higher. Um, so how does that help you? Well I think it 
does help you to a certain extent because you know it’s not 80%. If it was 80% 
then you might be inclined to say well it’s probably not due to the study drug and 
therefore I’m inclined not to stop the study drug. But if it’s say 10% you’d say well 
I’m inclined to believe that it might be due to the study drug, um, and therefore I 
might be inclined to do something about it. Now in this case probably what you 
would do is put the patient on anti-coagulation and carry on with the study drug. 
It’s probably what you would do, just like you would do with conventional 
chemotherapy. The real, the really difficult issue is where you would have a 
situation where you would have to stop the study drug or reduce the dose of the 
study drug. There I think it becomes particularly difficult and particularly important 
that the correct decision is made. If you’re simply going to say well you can treat 
this with a bit of Imodium or some heparin or something it doesn’t really matter. 
But where you’re forced to interfere with the conduct of the study and the 
administration of the new drug that’s where it becomes acutely important to do 
the right thing. (uses the term forced again) And that’s where I suspect that 
people need help. So one of the things you might want to think about is maybe 
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you shouldn’t let the physician by himself decide or at least have total ah, I mean 
I think the physician is ultimately responsible at the end of the day. But maybe 
there ought to be some centralized mechanism whereby some brain, artificial or 
real helps the physician make a decision, rather than just stop the drug or, you 
know, arbitrarily do something. One of the things that does concern me that I 
didn’t tell you about before is where junior physicians particularly seeing patients 
in a clinic on trial will just say oh my goodness stop the drug you know, just do 
the wrong thing out of, sometimes out of fear, something bad has happened. You 
can imagine, you know, [it could be scary for someone brand new] yeah, 
because they see two weeks ago somebody started a new drug, now you know, 
the patient’s skin is falling off. You know you get scared, what am I going to do. 
The safe thing to do is to stop you know. I mean this happened to me, again a 
couple of weeks ago, some patient came in with some really weird rash, weird 
rash and it wasn’t like trivial, it was like you know, open oozing areas, this kind of 
thing. And the question was what, what could possibly be doing this you know. 
[right] And they were on an experimental drug at the time and we had to get a 
dermatology opinion and even a biopsy to try and sort out what was going on you 
know. And we did in fact stop the drug because I had not seen this before, it 
looked potentially quite serious. So you know, I think under those circumstances I 
think in a way you had little choice. But you can imagine there were many 
borderline situations where you know. And I think, I think if there were some 
central and I think the Internet can enable this, if there were some enabling 
technology where the principal investigator of the study could make a decision 
together with the treating physician rather than just some junior person stopping 
the drug or mistakenly carrying it on. So that also, that also worries me, the way 
decisions are made with respect to stopping or starting or reducing the dose of 
the experimental drug. (worried about the authenticity of certain attributions) 
That inexperienced people in a bind, in a clinic, in a busy clinic feel forced to 
make a decision. Whereas we now live in an age you know, with the Internet that 
you know some kind of advice [yeah] that you know was semi-quantitative or at 
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least more insightful. That this responsibility might be shared and a more rational 
decision could be made. 
 
M: That’s, yeah, I think there’s a lot of work that can be done to improve a lot of 
the processes for sure. [yeah] That’s a good idea. You mentioned that 
uncertainty is sort of at the heart of this and that the unsuccessful ones don’t 
really know how to deal with ah, with the uncertain um. The companies that are 
unsuccessful are the ones that don’t know how to deal with that uncertainty and I 
guess sometimes that can lead to pressures. Have you ever, you know, what sort 
of external influences or pressures have you ever felt? 
 
S22: Well yeah, I would say, you know, just without 
 
M: Not necessarily from companies either, just any sort of third parties. 
 
S22: Yeah, I think that companies, consisting of human, they’re all human beings 
you know and they tend to, they tend to drink their own kool-aid you know. Um, 
they sort of believe their own propaganda in a way and they’re very nervous 
about putting reports out with respect to side effects. So, there’s no doubt you 
know, I’ve seen situations where, you know, people writing up papers or 
abstracts have been monitored quite closely by the companies with respect to 
what they say about side effects. 
 
M: So if the PI of the trial is writing up the, the study results? 
 
S22: Yeah, I have, especially interim reports more so than with final reports, 
certainly interim reports. I have seen situations where some pressure, let’s say 
that the pharmaceutical company maybe had a different viewpoint about what 
was said, you know without being specific I’ve certainly seen that. I think most 
people have, most people that deal with pharmaceutical companies realize that 
they’re obviously coming from a certain angle. And that they may have a different 
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interpretation, sometimes, I think sometimes they’re right. I think, I’m not saying 
they’re always wrong but certainly they have a viewpoint [sure] which they 
express you know. [laughter] 
 
M: Any other pressures when you assign causality or from third parties? 
 
S22: I think you know, if a patient is sick in a way that taxes the resources of the 
cancer center and the hospital, I think you know, there’s certainly pressure not to 
carry this on beyond what’s reasonable. And you know, that’s, that’s 
understandable and inevitable. 
 
M: So that would be sort of from the cancer center? 
 
S22: Yeah. You know, let’s say a drug causes profound anemia and somebody 
has to be transfused over and over and over again. Is this, you have to think 
about, you know, no man is an island, no person has got an exclusive claim on 
the resources of society ad infinitum. So I think we have to make judgments 
about whether they’ve crossed some kind of threshold of reasonability. [yeah, 
yeah] You know, and I think you know, some of the, some of the new stuff, some 
of the new drugs that we test inevitably are going to make some people seriously 
ill, even if it’s a small minority of people who are seriously ill. They’re going to be 
in intensive care units, they’re going to extract, they’re going to use a lot of 
resources. So I think doing clinical trials is actually a resource intense occupation 
that can really only be afforded in quite wealthy countries actually. [definitely] You 
know, to do it properly and to look after people on the downside. I was just 
watching TV last night about these 6 people in the UK [oh right] I don’t know if 
you’re familiar with that story. [yeah, just this past March] Yeah, I don’t know 
exactly what they’ve got and what went wrong but it didn’t look good from the 
report on the BBC. Life long side effects you know, eradication of their immune 
system you know [previously perfectly healthly] previously perfectly well. [healthy 
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people yeah] So, how come, how come 6 of them, you know, why wasn’t it 
picked up on the first one? Was there an under attribution problem? 
 
M: I think in that case what happened was they started infusing one and then half 
an hour later they started infusing the next one and then the next one and they 
didn’t leave enough time. 
 
S22: So there’s a thought you see about how these, about how it’s spaced out. 
So that once something happens, should a mechanism kick in to permit sufficient 
time to evaluate [definitely] before they treat the next section? 
 
M: I’m not sure how that trial passed through you know to be performed in that 
manner. 
 
S22: Well yeah, again, I don’t want to point fingers because all of us have to 
learn as we kind of, as we go along. But I think it’s just important that we do learn 
[yeah from our mistakes] from our mistakes. [definitely] I think that’s the least you 
owe people is to learn from mistakes. [definitely] 
 
M: Well I don’t want to keep you anymore, this has been wonderful. I really, really 
appreciate the time that you spent with me. 
Subject 23 
M: I will just explain a little bit about what it is that we’re doing.  Even the most 
experienced physicians find signing causality to adverse events challenging. And 
many groups such as industry sponsors, clinical trial cooperative groups and 
research ethic boards, they all expect prompt and sensible causality 
assessments. But I’m sure as you know it’s not always very straightforward and if 
done poorly there are implications to that. So our thought was that we would like 
to develop a tool to help clinicians more efficiently and reliably assign causality to 
adverse events that occur specifically in the early phase oncology clinical trials 
setting. And we feel that by better understanding your needs as a clinician, we 
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can make this tool more relevant to you, the end user.  So, do you have any 
questions about that? [No] Sounds pretty good? [sounds like a wonderful idea] 
Okay great.  So first I’d just like to get a better understanding of the, the clinical 
reasoning that you use when you are attributing causality. And this is going to 
sort of help to inform the development of the tool.  So let’s say one of your early 
clinical trial patients, let’s say they are an early phase oncology clinical trial 
patient, reports experiencing a serious adverse event. Can you just walk me 
through your thought process? 
 
S23: Well the first thing is if it’s a drug we have used fairly regularly we would 
kind of relate it back to whether or not we had seen it previously, or ah, in the 
letter of information and consent, if it’s listed as a likely side effect of the drug. 
Other than that, especially for serious adverse events, we get all the information 
we can get from the hospital where the patient has been admitted and go to the, 
fill in the form as much as we can and then basically sit with the physician. 
 
M: Sorry what do you do with the physician? 
 
S23: Sit with them and, and review it with them. 
 
M: Okay, so you review it with the physician, yeah. 
 
S23: Because you can mess up a lot of you’re, when you’re messing with Phase I 
causality, it can make quite a difference. I mean 20 years from now they go back 
you know, the drug has been shelved because of it, so it can have a lot of 
repercussions. [right] 
 
M: Have you ever experienced that where a drug has just not made it past the 
Phase I stage or? 
 
S23: Um, occasionally with some of the IND drugs that we use yeah. 
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M: Can you give me an example or? 
 
S23: There was one we used in melanoma a few years ago and then we used 
CCI779 and in the site we were using it in, it was not effective. 
 
M: What site was that? [Melanoma] Okay. So I guess it was halted because of 
lack of efficacy more so.  
 
S23: Well more so but there was a lot of problems with some of the toxicities as 
well, all the patients were having serious adverse events. But they were also very 
ill patients and it’s very hard to separate that out at times. 
 
M: Okay, so you look at whether the event has been seen previously, do you 
mean in previous trials that you’ve done? 
 
S23: Well we try not to cross trials because sites can make such a difference too. 
So we try to stay [disease sites] yes, stick to the same sites so if we’re doing a GI 
trial in colon and we see a side effect we will look back on the other patients that 
have been on that study. And also at the letter of information and consent, the IB 
basically, and ah, from there go to the physician. Usually if there’s a lot of doubt 
we go with possible and go back and forth with the company. 
 
M: What do you mean go back and forth with the company? 
 
S23: Well we’ll fax it off and they’ll say, you know, they’ll come back and say why 
is this a possible relation? and the physician will say the reasons he thinks that it 
could be because he doesn’t know that it isn’t so he will do a possible. And 
occasionally we change that either to probable or unlikely but normally we stand 
pretty firm with what our initial gut is. (goes with their intuition) 
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M: So it’s not uncommon then for the company to ask you to justify your causality 
assessment. [mmm hmm]  
 
M: And so you mentioned that some of the resources you refer to is the IB, the 
consent, form. Any other recourses that you use? 
 
S23: Those are the primary ones I use and then to the physician after that. I 
guess occasionally with drugs that we use a lot and there’s something odd I’ll go 
online and see you can find any reference that but we certainly don’t base it on 
that because that’s usually on an individual case basis. 
 
M: What sort of tools do you use to help you when you are assigning causality do 
you have any? You mentioned this PAR form. 
 
S23: We’ve got this PAR form. [okay let’s talk about your PAR form] Okay. We 
just developed this lately and it’s based on the version 3.0. And what we’ve done 
is we’ve gone through the toxicities, the most common toxicities we see across 
the board because we use it in every site. So for nausea we’ve kind of gone 
through and thought well almost every, it’s mostly for chemotherapeutic agents. 
Almost every drug causes some form of nausea or vomiting or something like 
that. And so if we start with this as a baseline and we have a good feel for the 
patient, it’s a lot simpler obviously to give the relationship to the drugs. The 
problem we’re running into with this form right now is first of all, the physicians, 
because it’s new, they’re not being very helpful in clinic, because obviously 
they’re used to their old ways. Quick glance at the PAR, see what’s going on and 
with the patient and back out again. And the other thing is because we’re starting 
this mid-stream for a lot of the patients it’s very difficult to say in clinic alright well 
do we call it a 3 or a 4, what have we been calling it? Because we don’t obviously 
have the CRFs with us right. So a lot of them have been left blank right now, so I 
don’t know how to fix that. [right] 
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M: So ideally you would want to start this form when you’re [at the initial stage] 
assessing them at their initial visit. [mmm hmm, mmm hmm] And um, now is this, 
is this based on, was this developed in house? [mmm hmm] yeah. And is this 
using the common toxicity criteria grading [yeah, yeah] for the severity. And this 
causality scale, who’s scale is that? 
 
S23: That’s basically just, I don’t even know where that comes from but that’s 
basically the one that all the CRFs use so that’s why we pull it out. I’m sure 
there’s a reference for it someplace. 
 
M: Because I have seen different causality scales used and just wondering if this 
is sort of the NCIC scale or the. 
 
S23: I guess if we had to go back it would probably be NCIC that we started with. 
[yeah, yeah] 
 
M: Okay, so this looks great. So these are just sort of the most common ones 
that you’re likely to see [mmm hmm]. And then what about if there’s one that are 
less common, what do you do? 
 
S23: We have a section at the back. 
 
M: Okay, here we go, oh, so you’ve just left some blank so they can fill it in [and 
some white space so that they can clarify those]. And so then each, one of these 
is done for each visit [yeah] okay, great. Will I be able to keep this? [mmm hmm] 
yeah, that’s great. Very, very good, because I think that it would be definitely 
useful to the CRAs at the JCC. I’m not sure what sort of things they’re using right 
now but I haven’t seen anything this good before. 
 
S23: Windsor has one as well [do they] but they’ve got a lot more, not quite as 
much blank space on it so it was very difficult to follow along. And I think they’re a 
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smaller centre so they have more time with the physicians and I think that was 
reflected on the form as well [yeah, yeah, okay, good, excellent, thanks] (larger 
centers have less time with physicians)  
 
M: So that’s one of the tools that you use, are there any other tools that you use 
when you’re assigning causality? 
 
S23: Um, really there’s not a lot out there so we try to stay very specific for the 
protocol with the IB, the letter of information, past experience with those types of 
patients. [yeah] 
 
M: What do you think would help make assigning causality easier? 
 
S23: Well that’s a very good question but I don’t really have an answer because 
every drug of course is different. And you’re going to run into a whole slew, 
especially for Phase I’s of things that you don’t know, don’t expect. [yeah] 
 
M: What would you say are some of the problems or challenges with assigning 
causality? 
 
S23: Time, the physician’s time. (time constraints, initial reaction) 
 
M: The physicians don’t have enough time [mmm hmm] they’re too busy? 
 
S23: Oh they’re clinics are crazy. Dr. xxx when he was running in he was just 
finishing up a morning clinic that was supposed to end way before noon and we 
never do, we go through lunch every week. [really] And that’s how all the 
physicians work around here anymore. [yeah] (everyone is overworked) 
 
M: So they just don’t have enough time [mmm hmm] to properly assign causality? 
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S23: Not in clinic, a lot of the times it’s retrospectively. Obviously if there is 
something that’s greater than a grade 2 we have to stop and review because we 
obviously have to do dose reductions etc. [okay] 
 
M: Any other problems or challenges that you found with assigning causality? 
 
S23: Um, well I guess not really because we do have really, if you go back to the 
IB and it’s not there and it’s something really unusual, it’s the physicians 
discretion at that point so. I think we rely on the physicians ultimately and their 
tools and their knowledge of it. [okay] 
 
M: Do you have any concerns about how physicians assign causality? 
 
S23: Not usually no, because usually they talk it out you know, like this is what 
you said in your note and this is what’s happened to the patient, so we just kind 
of talk it out so not usually. Our physicians, well most of them have been here a 
long time so they’re pretty experienced, well Dr. xxx is new but she’s got a  lot of 
Phase I’s in her past as well.  
 
M: Now are there any other external pressures or influences that you felt when 
ah, when assigning causality? 
 
S23: Um, they’re there but we basically ignore them [okay, and what are they?], 
because ultimately. Well it’s the companies they want to get their drugs to market 
and sometimes you get a little pressure from them you know? [to do what?]  Well 
to just to confirm yes this is related particularly if it’s nasty, nasty stuff. There’s a 
couple of companies out there that don’t think twice about picking up the phone, 
you know, asking you to review with the physician, that’s fine we’ll review it but 
ultimately we’re not here for the trial. Well we’re here for the trials, but we’re here 
for the patients and so we’re not going to cause them any harm if we can help it. 
(patients are the main priority) 
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M: Yeah, that’s the right attitude I think. 
 
M: What I’d like to ask you to do now, if you wouldn’t mind is read over these 10 
questions and cross out any that you do not feel are relevant to assessing 
causality in the Phase I clinical trial setting.  
 
S23: Did the adverse event appear after the suspected drug was administered? 
A lot of companies still make you do a serious adverse event even if the drug 
hasn’t been administered. [really?] Yeah, a patient walks out the door and falls 
and breaks their leg it’s a serious adverse event because they’ve consented to 
the study. [oh my gosh] It happens very regularly. [and they haven’t even 
received the first dose yet] Exactly. Usually it’s the smaller companies that are 
trying to make their mark I think and they’re being overly cautious. [long pause] 
Half of it. 
 
M: Oh great, now if you could just rank them, you probably already read it. If you 
could just rank them from most important to least important [mmm hmm], so 10 is 
most important. [okay] 
 
M: Great, thanks. So I see that you crossed out number 6, and oh [just part of 
that one] just part of number 8. 
 
S23: Just we would never increase the dose if there was a serious adverse event 
[okay, no, but you would decrease it] potentially decrease and continue yeah.  
 
M: And then number 10 was most important, was the drug detected in the blood 
in concentrations known to be toxic. 
 
S23: We do a lot of PK’s in Phase Is. 
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M: And then next was, was the adverse event confirmed by any objective 
evidence? [mmm hmm] What did you understand that to be? 
 
S23: A lot of them actually, a lot of them could be clumped together rather than 
[yeah]. 
 
M: So which ones would you kind of clump together? 
 
S23: Well not so much those, any objective evidence on physical exam or, or 
blood results that came back. Or heaven help us if we actually had a CT right 
when something was going on. [yeah, okay, something like that alright] 
 
M: And then least important was did the adverse event appear after the 
suspected drug was administered, why did you? 
 
S23: Oh, I’m sorry, I read that wrong, sorry, no that should be up there a little 
higher than a 1 [oh, okay] well maybe a 7 and a half. [okay good] 
 
M: So then are there alternative causes other than that drug that could have on 
their own caused the reaction, that was what you marked as lowest [mmm hmm] 
why was that? 
 
S23: Well, yes because something else may have caused it but we don’t know 
that this particular drug didn’t cause it as well, especially if it’s in early Phase I. 
And that’s probably where we would go with the possible relationship as opposed 
to probable or anything else. [okay]  
 
M: So what did you think of this overall as a tool, do you think something like this 
would be helpful? 
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S23: Well it makes you stop and think, yeah it does, especially to try and rate 
them, it’s very difficult. It would depend definitely on ah, well the patient to some 
extent, the physician you are working with. 
 
M: Do you think something like this, it would be feasible to complete something 
like this at the time when you’re assigning causality? 
 
S23: I think if we made part of our, especially for serious adverse events, part of 
the whole process that would make it a little easier. 
 
M: So what do you mean when you say make it part of the? 
 
S23: Well when we start the serious adverse event form, the physician, this 
would be part of his responsibility to review this with us. [okay] 
 
M: So you usually fill out the SAE form with the physician there? 
 
S23: Usually do most of it and then go to him at that point [okay] all the 
background stuff and con meds and . [yeah] 
 
M: So this would be something useful to take with you when you go to the 
physician [mmm hmm] and say let’s just work through this and do it together. 
 
S23: Yeah, on an individual basis you know, it’s a lot easier than just going, you 
know, trying to rate that. [yeah, yeah, okay] 
 
M: What do you think, are there any other criteria for a tool that you think would 
be important, that you think it should or shouldn’t be or what it should or shouldn’t 
look like. 
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S23: Um, I think the simplest is always the best, everybody is always in a hurry, 
so something like a little tick box or check list, minimal writing, minimal 
instructions. (time constraints don’t allow room for exaggerated tool) 
 
M: What about if it was on the computer, sort of computer-based would that work 
in your environment? 
 
S23: It would work for me, it wouldn’t work for all our physicians [no] no, they, 
some of them just don’t use the computer [they don’t use the computer] not very 
often. [okay] I work with two physicians that, that don’t. [okay, great] 
 
M: Now lastly I would just like to ask you a little bit about your education [mmm 
hmm] that you’ve received, specifically to do with how to assign causality. So can 
you tell me about any education that you’ve received with respect to you know, 
how to assign causality to adverse events? 
 
S23: Minimal at best [okay] basically on-the-job training. I think all the CRAs we 
basically self-train or train each other as we go. So as new people come on and 
basically if I’m training somebody I always tell them the investigator’s brochure 
and the letter of information. Usually go to the letter of information first, and the 
investigator’s brochure and if there are any questions straight to the physician. 
[okay, right] 
 
M: Do you think some more education around this might be useful? 
 
S23: Oh, definitely, but I’ve never seen anything. [no] 
 
M: What, what do you think would be good in terms of education in this, you 
know, can you think of what? 
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S23: Well it depends how you go about it I suppose, I don’t know how you would 
actually do it. I would think in classroom in small groups would be ideal because 
then you get a number of CRAs together and you get chatting and you learn 
more there then actually from any classes. Do you know if people have 
developed tools that they are using? 
 
M: Um, I don’t know of any at this point, but yeah we’re thinking especially for the 
CRAs this would be really useful. You know, just to try to, maybe even just going 
through some case studies [mmm hmm] or you know, that kind of thing. Whether 
it would be sort of in a small group setting or whether it would be an instructional 
CD Rom or something I don’t know. But yeah, we’re thinking we’d like to develop 
something along those lines. 
 
S23: Even a CD Rom would be excellent because you could stay on site and do 
it amongst yourselves with the CRAs. It’s amazing, even when we were 
developing the toxicity form, of how many people, you think you know, everybody 
is doing the same but how, how little variances go over the years. And some of it 
would not, would not hold up. (subjective) 
 
M: How, can you give me an example of how some people were doing things 
differently? 
 
S23: Well it’s just how they were assessing the patients as well, the PAR is built 
on this is the patient’s norm so it’s a variance from the norm. People were 
actually grading constipation as a grade 2 and in actual fact that was a normal for 
the patient so they didn’t actually go up in grades. [oh okay] So a bit more 
education and you just kind of I think when you don’t revise things enough people 
kind of fall by the wayside. (education could aid in limiting individual 
variation) 
 
M: Just having those continual reminders about 
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S23: I would think it would be the same with something like this. 
 
M: Yeah, yeah, okay, great. Um, let me just check here, I think that’s pretty much 
all the questions that I have. Do you have any more questions for me? 
 
S23: Not really. [no] But if you develop this I certainly would be interested in it. 
 
M: In piloting it? [mmm hmm] Yeah, well what we would like to do is yeah, 
develop some sort of a tool and then we want to try and test it out in a clinical trial 
setting. It may, it may just be tested out at the JCC for now but um certainly what 
we’re going to do is once we’ve interviewed all the people that we intend to 
interview we’re going to summarize and put it into sort of an executive summary 
and send it out to all of the participants. So we’ll let you know what comes out of 
these and stay tuned for the tool. 
 
S23: Are you going across Ontario to all the centers or? 
 
M: Well I’ve actually been out to the BC Cancer Agency, to here to this site, to 
the Hamilton, obviously, and then in a couple of weeks I’m going to be going to 
Ottawa. We tried to go to PMH but the ethics was just a nightmare so it wasn’t, it 
wasn’t coming together for PMH and I’ve been out to Kingston as well. [the larger 
sites] Yeah, the larger cancer centers. 
 
S23: Kitchener or Windsor might be an idea because they’re small they might 
handle things a little differently, may have a little more feedback. 
 
M: Okay, great well thank you [you’re welcome] I appreciate that. 
Subject 24 
M: I will just briefly go over what it is that we’re doing.  As I mentioned, the 
researchers that I’m working with we’re, we’re interested in how causality is 
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assigned to adverse events that occur during clinical trials. In the hopes of 
potentially developing a tool that will make things a little bit easier for, for people 
who have to assign causality. [sure] You know, even the most experienced 
clinicians find assigning causality challenging. But unfortunately many groups 
such as industry sponsors, research ethics boards, clinical trial cooperative 
groups, they all expect prompt and sensible causality assessments. [mmm hmm] 
But I’m sure as you know it’s not always that easy and if done poorly there are 
implications. So as I said we’re interested in developing a tool. And we done 
about, well I’ve done over 20 interviews now [okay]. And I’ve been told initially the 
CRA tends to assign causality. Can you give me an example of a time where 
you’ve had to assign causality or make that decision? Or do you even agree with 
that statement? 
 
S24: Um, I’m not so sure about that. 
 
M: No, not even initially? 
 
S24: No, no, usually we just read through the progress notes, or find out from the 
clinician, clinician themselves. 
 
M: Oh, okay. So I mean every centre seems to do it a little bit differently. [mmm 
hmm] How does it work here in your centre? Can you tell me about an SAE that 
you’ve had that has occurred recently and walk me through how causality was 
assigned? 
 
S24: Recent SAE, um, I actually don’t get a whole lot of them in my particular trial 
because they are Phase III prostate patients and they usually don’t die off too 
quickly. [that’s good] We did have a case fairly recently where the patient died 
suddenly at home in his sleep. The problem with causality with that was that 
there was no autopsy done. [right] So there’s just a lot of guessing and there 
really wasn’t one assigned for that. [so um,] Prior to that, we had a lady who was 
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admitted to hospital with ah, severe cystitis a result of her bladder cancer. [right] 
But again, that was just going through the progress notes, the ah, and discussing 
with the principal investigator and coming up with the causality to assign to it. 
 
M: Okay, so you sort of work together as a team [that’s right] to decide how to 
assign causality. [yeah, yeah] Can you think of anything that would have helped 
you in making that decision? 
 
S24: Nothing comes to mind. Um, [can you walk me] since I’m really not the 
person who actually sees the patient to and diagnose the patient, I’m really on 
the outside of that, so there’s really nothing I can do. [okay, okay] 
 
M: So when you, your patient who experienced the severe cystitis and she was 
admitted to hospital [mmm hmm] how did you become aware of that serious 
adverse event? [um] Was it at her next visit that she told you about it? 
 
S24: No, actually just kind of by accident really, just going through trying to figure 
out when she was supposed to come back, they’re supposed to come back at 
pre-determined times and it just happened to pop up that she was actually 
admitted to the hospital. [oh okay] 
 
M: So she missed her next appointment or? 
 
S24: No, no, we just ah, soon after they’re seen we know when they’re supposed 
to come up, um, because we have these flow sheets and it says okay, they’re 
supposed to be seen on this particular day so that’s when it’s usually written into 
the notes we know they’re scheduled. Um, so she was coming, she was due in a 
few days, so I just sort of checked to make sure that she was still coming in for 
this one and I just happened to notice she was admitted. [mmm hmm, so she 
was] We used to get lists of all the patients who were admitted to the hospital but 
they stopped doing that about a year or so ago so it is just hit and miss now. 
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[okay, I see] (must be very difficult not being notified if you’re patient is 
admitted to the hospital) 
 
M: So this comes up on your computer screen and alerts you that she’s been 
admitted to the hospital [that’s right] and then you have to start the process of 
completing the SAE form is that right? [that’s right]. And so then you try to collect 
all of that data and 
 
S24: Go over there and go through the patient’s notes and [so luckily she was 
admitted to this hospital] yes, yeah. Um, and then just read through the notes 
and discuss it with the primary care giver and see what’s going on. And we sort 
of follow her for at least a couple of days before we make any definitive diagnosis 
or what is going to happen with her. 
 
M: So in that case, how did you assign causality? 
 
S24: um really it was just in the progress notes that she had developed severe 
cystitis and she was started on antibiotics. [okay] 
 
M: And was that felt to be related to the study drug? 
 
S24: It would have been related to the radiation she had received yes, she was 
receiving a combination of radiation and chemotherapy for her bladder cancer. 
[okay] 
 
M: So you guys determined that it was likely due to the radiation therapy. 
 
S24: That’s right. 
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M: So how did you come to that, how did you come to that decision? What were 
some of the factors that you were looking at when you were thinking what was 
sort of ? 
 
S24: Um really I didn’t, I just read it off the notes. 
 
M: Oh I see, so in the notes it actually said [yes] that they felt that it was probably 
due to the radiation [that’s right], okay I see, good. So that one seems to be a 
fairly straightforward SAE [yes] where, you know, the investigators felt it was 
clearly related to the radiation therapy. [that’s right] Can you give me an example 
of a serious adverse event that was maybe a little less straightforward that you’ve 
had in the past? 
 
S24: Not, really, they’ve been pretty straightforward. [yeah] My patients, they 
usually don’t die of their prostate cancer, I’d say about 90% of my cases are 
prostate cancer. [yeah] It’s usually from something else, a cardiac event which is 
usually pretty obvious, or they develop a secondary malignancy in the lungs or 
they have a new primary to the brain. So they’re usually pretty straightforward. 
 
M: So they’re usually due to disease progression. 
 
S24: Not necessarily progression of the prostate cancer but a new primary pops 
up somewhere. 
 
M: Oh, a whole new primary okay. 
 
S24: My studies haven’t gone far enough along to see death from disease 
progression. [okay, yeah, yeah] 
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M: I have been really surprised actually to hear that CRA’s haven’t received very 
much training with regards to assigning causality. Can you maybe tell me a little 
bit more about that or would you agree with that statement? 
 
S24: Yeah, um, yeah, obviously we haven’t received any training for it but um, 
I’m not sure that we’re the ones who are actually expected to come up with that 
determination. 
 
M: Okay, so you don’t see that as being a big problem. 
 
S24: Not really no. 
 
M: Do you think that would be helpful to you in your job or that’s just? 
 
S24: I guess, I guess it would depend on institute policy. I mean really we’re 
supposed to discuss with the co-investigator and investigator and come up with 
the causality and it’s usually them that come up with it as such. [okay] 
 
M: Are there any resources that you use when you’re assigning causality? 
 
S24: Other than the scans that the patients have, the tests and the progress 
notes, that’s pretty much it. [okay] 
 
M: And, and just based on that information you’re able to sort of determine 
whether it’s related to the drug or not? 
 
S24: Usually for the most part yeah. 
 
M: What about tools, are they any sort of decision trees, or flow-charts or 
algorithms or anything like that you use? 
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S24: No, not that I’m aware of. [okay] 
 
M: Are there any sort of general guidelines that you tend to follow when you’re 
assigning causality, any sort of rules of thumb? [loud sound] Oh my gosh, there’s 
some noise coming from the next room. [starting windows] Is there a computer 
class next door? 
 
S24: No, they’re probably just starting up the projector that they have over there. 
[okay, okay] 
 
M: It’s just the recorder is highly sensitive to sound so it will pick that up probably. 
 
M: What I would like to do now is just ask you a little bit about what you feel are 
some of  the problems or challenges with assigning causality? Have you ever 
encountered any? 
 
S24: Particular problems with it? [yeah] 
 
M: Is there anything that’s kind of tough in assigning causality? 
 
S24: Nothing in particular pops up, I mean I can see there are some areas that 
obviously are a little grey as to which way the assignment should go, whether it’s 
definitely related or somewhat related. (certainty is difficult to achieve) 
 
M: Okay, what makes that difficult? 
 
S24: We just usually decide with past experience with the drug. I guess it might 
just be a question of, maybe there’s just the history is a little vague or the tests 
weren’t 100%. I can see those sorts of things popping up but I haven’t actually 
experienced those sorts of things yet. [okay] 
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M: So you said that sometimes assigning causality is a little bit grey and I’ve 
actually heard that from quite a few other people that it is a bit of a subjective 
process. But can you explain to me a little bit more about what you mean when 
you say it’s grey, I’m trying to get a better understanding of that. 
 
S24: Um, just a question of how likely was the event related to the study drug. 
Um, it may be a little ambiguous in terms of the results of the tests that the 
patient has had, they may not be quite definitive. 
 
M: Okay, can you give me an example of a test that wasn’t definitive or? 
 
S24: Um, nothing that’s related to an SAE that I’ve had [okay] but I mean some of 
the scans just don’t pick up things as well as others, you have to probe a little bit 
deeper sometimes, they just don’t. 
 
M: Yeah, so just the type of scan or? 
 
S24: Yeah, we question whether it’s a CT or an MRI or something like that. Some 
of them are more sensitive than others for picking up certain processes. [okay] 
 
M: And so you know, you have these test results but you can’t rely on them 100% 
[um] is that what you’re saying? 
 
S24: Yeah, um, in terms of what shows up or what the physician who is actually 
looking at the scan and dictated the note comes up with, sometimes they’re kind 
of short with their dictations and some of them are quite extensive in detail. It 
varies from physician to physician. [right, okay] 
 
M: You mentioned that sometimes the history is sort of vague, like the patient’s 
oral history that they’re giving you, is that what you mean? 
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S24: Um, not my, not the one that I would take, say one of the physicians maybe, 
some physicians are quite short in the dictations and so may not catch 
everything. [okay] (time constraints) 
 
M: So the physician meets with the patient [mmm hmm] and afterwards they 
come out and they dictate what sort of went on. [mmm hmm] And often times it’s 
not extremely detailed, is that what you’re saying? 
 
S24: I wouldn’t say it’s often, but yeah, sometimes. 
 
M: Sometimes it’s not really detailed. [yeah] Okay, and do you know why that 
could be or? 
 
S24: Lack of time probably. [just time pressures, yeah, okay that would seem 
reasonable] (time pressures seem to be a major trend) 
 
M: So those sort of things all combine to make it difficult to determine how likely 
the event was [mmm hmm] related to the drug? [yeah] 
 
M: What are your concerns about how clinicians currently assign causality? 
 
S24: Can’t say that I’ve actually had any myself [no] no real concerns for it [no] 
no. [okay] 
 
M: Some people have said that maybe it’s done a little too quickly or it’s, it’s not 
really well thought out. Would you tend to agree with that? 
 
S24: No, not in my experience no. [okay] 
 
M: What external pressures or influences from third parties have you felt when 
ah, when assigning causality, have you felt any? 
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S24: No, not in my studies, very little um, pressure from any of the drug 
companies that we deal with. [okay] But then again mine are more local studies. 
 
M: Okay, that are initiated by local PI’s? 
 
S24: Local PI’s yeah, they may get some funding from some of the drug 
companies but not like some of the other CRAs that work here where they deal 
primarily with sponsors and drug companies. [okay] So they would probably have 
more pressures. (drug companies may place added pressure on causality 
attribution) 
 
M: So then from your perspective what would make assigning causality easier? 
Can you think of anything that might make the process easier? 
 
S24: Um, if there were any courses or literature on how to define it or come up 
with better ways then yeah, I would certainly be willing to take them. [mmm hmm] 
But I haven’t heard anything about that. 
 
M: So courses or literature on how, on just sort of how to do it or? 
 
S24: Yeah, how to do it or guidelines, because I don’t think there’s anything 
really written in stone as to how to assign it or how, the process to actually do it, I 
mean the physicians usually just sort of come up with something. (lack of 
standardized tool) 
 
M: Is it a kind of a mystery to you how they determine the causality or does it 
seem fairly, clear? 
 
S24: No, it’s usually fairly clear. [yeah] But then again I don’t have the medical 
background that they do so. 
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M: Do they usually take the time to explain to you why they have assigned it a 
certain way? [it varies] It varies by physician? [yeah] 
 
S24: Sometimes it’s fairly clear-cut and it’s kind of obvious and I don’t ask, but 
other times I will ask, they’re usually pretty good about it. [okay] 
 
M: What I’d like to do now, is take a look at an algorithm that was developed by a 
researcher named Naranjo. And, ah, it’s a series of 10 questions that might help 
in thinking about how to assign causality. I’m wondering if you could just give 
those a read over [sure] and cross out any that you feel are not relevant to the, 
specifically the Phase I, but if there are any that you feel, I know you mostly 
specialize in Phase III. [mmm hmm] Any that you don’t feel are relevant, 
especially to the oncology clinical trial setting. [sure]  
 
S24: Not sure how often number 6 happens [number 6] does the reaction 
reappear when a placebo was given? [okay] I don’t have a lot of studies, or 
actually I have no studies in Phase I. [yeah] 
 
M: Well feel free to cross it out. You know, this tool wasn’t developed with 
oncology in mind [mmm hmm] so if you don’t feel it’s relevant. 
 
S24: Yeah, I don’t know that it actually would happen in practice here on a study. 
 
M: Yeah, that’s, many people have said that. [yeah] So is that the only one or 
were there others to cross out? 
 
S24: No I think that’s about it [okay] I can see that they might do this in a Phase I 
study but I don’t have a lot of experience with that so. [okay] 
 
M: Now I’m just wondering with the remaining questions. 
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S24: I think that would just be cruel [yeah to re-challenge with the placebo] yeah. 
So you want me to rank them in order of importance. 
 
M: yeah, if you could just rank them, and 1 is least important and 10 is most 
important. So yeah just how important you feel those other factors are. 
 
S24: So not an order as such, more of a rank. [yeah] 
 
M:  Great, okay, so number 9 you’ve ranked the lowest, did the patient have a 
similar reaction to the same or similar drugs in any previous exposure, why was 
that? 
 
S24: Um, I wouldn’t say that if they had a similar reaction it was indicative of 
having a problem this time around. [right] You know, I’d say they’re all fairly 
important just that one was the lowest. 
 
M: And now number 2 and 3 you ranked as highest. [mmm hmm] Did the adverse 
event appear after the suspected drug was administered and did the adverse 
reaction improve when the drug was discontinued or a specific antagonist was 
administered? Why did you rank those the highest? 
 
S24: They just seemed the most obvious without having a problem. Just the 
events started when they actually started the drug then more than likely they are 
having a problem. 
 
M: So if there’s a temporal relationship [mmm hmm] there’s a timing [yeah] okay, 
if the timing makes sense yeah. So that’s sort of, that would be the most 
important evidence [mmm hmm] to your causality assessment. [yeah] Okay, 
great. Now was there anything on here that you felt was missing or should have 
been there but wasn’t? 
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S24: No, it’s pretty complete. 
 
M: What did you think of it as a tool, you know going through these series of 
questions would be useful for every SAE that you have or? 
 
S24: Yeah, I would say so, but most of the time you’re going through those in 
your head anyway [you’re sort of thinking through it] maybe not all of those but 
yes. For the most part when you are going through, okay when did it happen, 
timing of events, that sort of thing yeah. [okay] 
 
M: Alright, is there anything else that you think might be useful, sort of as 
opposed to this or what sort of, you know, if we are to develop a tool [mmm hmm] 
you know, what are the criteria, how should it look and what should it? What 
purpose should it serve, how would it fit into your daily routine? 
 
S24: In terms of what layout or how it would look or? 
 
M: Yeah, well I guess just more sort of, we want to make sure that this is 
something, you know, that you’re going to find useful [mmm hmm] and want to 
use every day or every time you have an SAE. You know we don’t want to create 
additional paperwork [yeah] or you know, that kind of thing, we want it to be 
useful. You know, maybe if it could pull other information in or, I don’t know. 
 
S24: What are you thinking of having this as a computer type thing or? 
 
M: Yeah, we could, definitely. 
 
S24: Pulling it from various sources or? 
 
M: Yeah, it could potentially be an internet-based type tool or. 
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S24: That would probably be of most benefit. I guess what, if it could pull similar 
events from ah, that particular drug automatically. 
 
M: Okay, sort of events that have happened [mmm hmm] in the past [mmm hmm, 
yeah]. 
 
S24: I don’t know how we can tie that in with any other tests that have been 
performed as such. That would be quite daunting I would think. 
 
M: Oh you mean like linking it to the patient’s history? [yeah] Well maybe, [good 
luck with that] down the road. 
 
S24: Specific lab tests that you could punch in or something like that. [mmm 
hmm] 
 
M: Okay, great. Now what’s the scale that you use when you’re assigning 
causality? 
 
S24: Since I don’t really do it? [laughter] 
 
M: On the SAE form there should be some sort of a scale. 
 
S24: Yeah, there’s usually, what is it ah, likely, unlikely, definite, not at all, there 
might be one more. [okay] 
 
M: And do you prefer to have that, that scale or would you prefer a yes it’s related 
to the drug or no it’s not related to the drug. 
 
S24: No, I think definitely the scale. (leeway in scale measures is comforting) 
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M: Why is that? 
 
S24: I think sometimes it is a little ambiguous as to is it really caused by the study 
drug or procedure, it’s nice, it would be nice if you could say definitely [yeah] but 
it’s not always the case. [no] 
 
M: Can you give me an example of a time when it was sort of ambiguous and you 
needed that scale? 
 
S24: If it was, could be attributed to a number of different factors then yeah you 
really can’t say whether it’s definitive for whatever you’ve given. 
 
M: So what would be some of the other factors? 
 
S24: The patient’s condition, if they were somewhat frail to begin with, if they 
already had a cardiac history and did the chemo drug induce that or was it just 
some event that was going to happen anyway? [right] There’s a lot of things that 
come into play, it’s not always a case where you can say yes. [right] 
(confounding variables) 
 
M: So is it the, so all of those factors kind of are what makes it grey [mmm hmm] 
what makes it ambiguous. [yeah] 
 
S24: I mean if the patient didn’t have any cardiac history or any neurological 
history then you could say, sure this is definitely attributed to, but this patient 
population is elderly and there is always something going on [yeah] at the same 
time. (assumes comorbidities with their patients) 
 
M: Great, well I think those are all the questions that I have, do you have any 
other questions for me? [no]  No, okay, well thanks very much for your time, I 
really appreciate it. 
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M: So basically I’m working with some researchers at the Hamilton Cancer 
Centre and they’re very interested in how causality is assigned to adverse events 
during clinical trials, specifically oncology, or early Phase oncology clinical trials. 
[okay] And even the most experienced clinicians find assigning causality 
challenging. And um, many groups such as industry sponsors, clinical trial 
cooperative groups, they all expect prompt and sensible causality assessments. 
[mmm hmm] But I’m sure as you know, it’s not always that straightforward and if 
it’s done poorly it can have some large implications. [right]  So our interest is in 
developing a tool to help in assigning causality more efficiently and reliably. But 
we feel that by better understanding your needs [mmm hmm] we can make this 
tool more relevant to you. [okay]. So do you have any questions then before we 
start? [um, no not at this point] Okay. Did you want to say anything about the way 
things work here or your role as a CRA? 
 
 S25: My role as a CRA? sure um, I guess step-by-step would be the physicians 
identify patients here that they think would be a candidate for a study. [yeah] And 
in turn they would contact us and together we would review for eligibility. Um, we 
sort of work together with the physician to enter patients on the trial. Once the 
patients are actually on the study we see them every cycle or every visit while 
they’re on treatment and in follow-up. And we, we usually see them before the 
physician, we’d just go in and chat with the patient while they’re waiting and sort 
of go over um, any sort of symptoms or adverse events that they have 
experienced. And then we would review with the physician at that visit and 
together talk about what’s happening with the patient’s after each cycle of 
treatment, even, well during follow-up too. And then together just 
 
M: And then if there’s been a serious adverse event [right] how, what happens in 
that case? 
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S25: So if there’s a serious adverse event, depending on how we find out about it 
or when. Um, if we found out about it, if they were admitted to the hospital, 
usually the physicians would phone us, they usually find out and phone us. Or we 
would let them know if a family member contacts us or something. And then we 
report it um, the initial event, we would report that right away, what we know to 
have happened right away. And then as soon as we get any follow-up 
information or as soon as the patient is discharged from the hospital then we 
would complete the event. 
 
M: So we’ve done a little over 20 interviews now [right] and um, what some have 
said at least initially anyway, a lot of time the CRA assigns the causality because 
there is that tight deadline of 24 hours. [right] Would you tend to agree with that? 
 
S25: Definitely happens for sure, definitely, because we’re doing that initial 
submission that we may. Often the physicians sign off the report, not always the 
initial, but if we, if we’re with the physician, if we can talk to them at that time that 
we have to submit it then we would try to find out. But yeah, often we would go to 
whatever tools we have to try find out if it may possibly be related. (do try to 
make use of the tools available to them) 
 
M: What are some of the resources you use then when assigning causality? 
 
S25: Well definitely we would go to the protocol, the investigators brochure, um. 
 
M: What are you looking for when you’re looking in there, in the IB what are you 
going to look for? 
 
S25: Um, looking for events that may have already happened in previous studies 
that they think may have possibly been related. We look at the consent form. 
 
M: What are you looking for on the consent form? 
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S25: Any adverse events that might be listed, whether or not they think they’re 
possibly, most of the companies now put whether there’s a chance that it might 
be related or not, so we look through that as a tool. [okay] 
 
M: And the protocol how does that help? 
 
S25: Um, some, some of the study, or sorry the companies, not all of them 
mention, but do actually have tools right now where they would give some 
examples or sort of pointers I guess to help us out in, in assessing causality to 
the event. Things we could follow through like, I don’t know how to, it’s been 
awhile since I’ve had a tool like that. But it’s very rare, I can think of one company 
that has it, even [someone comes in room], yeah, they just have a tool to help 
you, to guide you in whether or not the event might be related or not. 
 
M: Do you remember the company? 
 
S25: I think it’s AstraZeneca that has a tool like that, it’s been so long since I’ve 
done anything with them, I’ve only come across it once. 
 
M: And what does the tool do? 
 
S25: It’s just sort of gives you pointers in, in different events and what to look for 
and what may possibly be related and not related. [mmm hmm] But the other 
protocols we would just look um, same thing like the consent, and what they think 
might be a possibly related event. Mostly the consent form has that information 
for us. [right] There’s not a whole lot to go to. [yeah] 
 
M: So what would sort of help you then in making that decision? 
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S25: Um, I think something similar to what that one company I was talking about 
has, I, I think for us we keep in our patient charts right now for example, um, all 
the dose modification rules for stopping the drug. If, if an event happened, um, so 
we sort of follow through with that, and that even lists what events to look for to 
do the dose modification or 
 
M: Okay, so where are you getting those documents from? 
 
S25: In the dose modification information. 
 
M: And where does that come from? 
 
S25: In the protocol, sorry [okay]. So we copy that information, we keep that right 
in the patient’s chart. So if something was to happen, if they experience some 
event we can go right to that information. And um, usually the, the companies will 
list what they know to be the more common events so we can go right to those. If 
it’s something that we know is expected, I mean the physicians with any 
chemotherapy know what’s expected of our standard chemotherapies. So we 
could go to that for example and then it would give rule as to what to do with the 
drug. So I think in maybe that section of the protocol um, there could be some 
type of a tool, where they could list, it’s already kind of listed like that, I’m just 
trying to think of a good way [what’s already listed] what’s some of the more 
common events [to expect] to watch for, to expect. (list of common toxicities is 
not sufficient enough, need for something greater) 
 
M: With the new drug or with the standard chemo? 
 
S25: With the new drug, sorry, the protocol drug. So I’m just trying to think of 
some kind of guidelines for us to follow, like what to look for. [mmm hmm, yeah 
that’s good] Something to add to that section of the protocol, maybe that… 
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M: Yeah, so that would make assigning causality a little bit easier [yeah, yeah] if 
it was more readily available and clearly laid out. [right, yeah] 
 
M: Are there any tools that you use to help you when assigning causality, like any 
sort of, I’m thinking more like a flow chart or a decision tree or some sort of 
algorithm? 
 
S25: Just the, we photocopy, like I said the sheet we take right out of the 
protocol, we copy the dose modification information. 
 
M: So that’s the only decision-making tool. 
 
S25: That’s really our, that’s really our tool that we use. [yeah] Other than the 
consent form where it lists all the different events to look for or to expect the 
possible side effects. [okay, good] Yeah, that’s pretty much it. 
 
M: Are there any sort of general guidelines that you tend to follow when you’re, 
when you’re assigning causality? 
 
S25: Well definitely we don’t make the ultimate decision so the physician will 
always make that ultimate decision. We have a um, when we see the patients in 
the clinic we do have a standard sheet we use, an assessment sheet and we um, 
on the back of the sheet it lists um, probably about 10 standard sort of events 
that patients would experience with chemotherapy. Things like nausea, vomiting, 
diarrhea and then we leave quite a few blank spaces so that when we assess the 
patients and they tell us what’s happening during their cycles, we keep track of all 
that, we grade them, put the start and stop dates. And then we have a section for 
causality, so initially we may put the cause but then we always go to the 
physician and they’ll review it and sign off on it. [okay, that sounds good] And I 
think for them, I don’t want to speak for physicians, but the same thing, from 
knowing the protocol, reviewing the background of the drug we’re using, going to 
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the meetings. They have an idea of what to expect from the drug, but again, 
there are always new things that are happening so. But ultimately it’s always the 
physician that makes that final [right okay] decision. [okay, good] 
 
M: What I’d like to do now is ask you to consider a scenario for me. [sure] So let’s 
say you’re treating a 65-year old female patient with a confirmed diagnosis of 
metastatic breast cancer [okay] in a Phase I clinical trial with a new 
investigational drug when she experiences a pulmonary embolism [okay] So 
obviously an SAE. How would you assign causality to the study drug if there was 
a 75% chance that it was due to the study drug and a 25% chance it was due to 
other factors? 
 
S25: So probably related, all the companies have different [different scales] yeah 
different scales to use. So I’m saying probably but it depends on the scale they 
have. 
 
M:  Okay, so let’s say I give you the scale of certain, probable, possible or 
unlikely. 
 
S25: Probable [you would say probable] definitely. 
 
M: Okay, why would you say probable. 
 
S25: You said probable, sorry can you just read them again? 
 
M: yeah, certain,  [right] probable, possible or unlikely. 
 
S25: Okay, I was going to say I didn’t hear definite but that’s certain. So probable 
because it’s not 100% chance that it would be related [mmm hmm] but 80%, or 
75% is a pretty good chance that’s it’s definitely. [mmm hmm 75 is pretty high] 
And then ultimately again I would let the physician make that decision but it 
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would depend, there’s always a chance it could be a disease related event too. 
[yeah] 
 
M: Alright, now let’s say there was a 50% chance the adverse event was due to 
the study drug and a 50% chance it was due to other factors. How would you 
assign it given the same scale again? 
 
S25: So possible. [possible okay] It’s the same scale you said right? [yeah, same 
scale] Okay. 
 
M: And now let’s say there was a 20% chance the adverse event was due to the 
study drug and an 80% chance it was due to other factors. How would you 
assign it then? 
 
S25: So we have unlikely, possible, probable and certain, just the 4 [yeah] and 
it’s 20%, I would probably still say possible [yeah] yeah, I’m kind of in a tossup 
there but yeah. (goes with intuition) 
 
M: And what would be, what would be sort of your lower limit then to say that it 
was unlikely? 
 
S25: Hmm, I would have to go with the physician’s assessment, just if they really 
thought it was more disease related than something that was caused. I’d have to 
sort of read a little bit more into it to say it was unlikely, I’d have to have a little 
more information I guess. Because there’s always that one chance, I know 
unlikely there’s still that chance, but I guess until I had more information or spoke 
to the physician I would still say possible. [yeah] (feels comfortable consulting 
with physician) 
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M: And can you tell me, tell me a little bit about how you determine whether you 
should call it probable or possible, like how do you, how do you make that 
distinction, between probable and possible? 
 
S25: Well again, like I said, I’d have to have more information to make that 
decision. But if it’s something that is um, there’s a big percentage of that event 
occurring with the study drug, for example, and this is something that the patient 
experienced. Depending again on the timing and when it happened to her and 
what disease, or what disease the patient had then I would definitely go with 
probable over possible. Unless it was something that was happening with this 
particular patient with her disease, you know, then I would definitely say 
probable. [yeah, if you know that it’s] With a large percentage of patients on this 
particular study drug where this event is occurring, that’s, me personally how I 
would base that. (very subjective) [yeah] It’s hard though without more 
information, I know the initial sort of, I think, I guess it’s better to go on the higher 
end of the scale because it’s a study drug, you know, to be safe [yeah] until we 
have more information, when you’re doing that initial causality. [yeah] You know, 
because it’s a safety thing that you’re sending out there so I guess that’s the way 
I would go with it. [sounds good to me] 
 
M: So you said if there was [It’s hard to think about how you do all this] yeah, and 
so you said if there were a high number of patients on the trial that were 
experiencing that same event [right] then that would more likely be possible or 
[probable right] probable. And how, how do you know about that, how do you 
know if there’s other patients? 
 
S25: From other events, safety events that are coming to us from other sites, or 
the company, any of that sort of correspondence that’s coming through to us. Or 
information from previous trials, it maybe something that’s already known when 
we start the study. [in which case it would be in?] It would be in our consent form 
or protocol, that’s right, something that we would already know starting. [yeah] 
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But again, for that initial for me, if, if, I wouldn’t base it solely on um, she had the 
event and she’s on a study drug so it’s probable. I wouldn’t base it solely on that 
because she’s got a disease and I don’t really know any information. So I would 
definitely go to my other sources first to make that [yeah, yeah] causality, before I 
just said oh yeah, it’s probable, because she’s on a study drug, I wouldn’t do that. 
[no, no, no] 
 
M: And this is just a very hypothetical scenario. 
 
S25: Yeah, definitely I would um, yeah, that’s how I would do it. [okay good] And 
of course if it’s something that we thought was probable we would be in contact 
with the physicians to try and figure it out as well from their point of view [oh 
yeah, yeah] as a safety issue so. (safety is a prominent concern) 
 
M: What would you say are some of the problems or challenges with assigning 
causality? 
 
S25: Um, ah, well just that, that, it’s always, you never know whether something, 
there could be that chance that you don’t know whether something could be 
related if it’s a new event if it’s happening with our patients. Um, you know, 
getting in touch with the physicians here just to work as a team to try and figure it 
out. [is that] And as you said, it’s the source, where to go to other than the 
consent or the protocol to know, you know, what we’re looking for. 
 
M: So sometimes you find it difficult to get information? 
 
S25: Yeah, more detailed information I guess, other than what’s in the consent 
form, having a list of expected events and maybe, some of them put in the 
percentages of what the patients have already experienced. So yeah, I guess 
that, just a more detailed sort of, um, like I was saying we go to the dose 
modification and it will list sort of what the expected toxicities are and the rules to 
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follow. (lack of detail in IB) So maybe to have some kind of I don’t know, chart 
or information in that area to go to, to see what we’re looking for and how they 
expect us to assign the causality. (little known about the expectation of 
causality assessment) 
 
M: And you mentioned getting in touch with physicians sometimes is a 
challenge? 
 
S25: Yeah, sometimes it is a bit challenging, but um, you know, with holidays and 
being away that’s sometimes a challenge [yeah]. But for the most part I would 
have to say here our physicians are pretty ah, pretty available. And we always 
have sub-investigators if we really needed to, to get some information. So I 
wouldn’t say that’s a huge problem. [okay] 
 
M: So the biggest problem then is the ah, just, you never know and it’s 
sometimes difficult to get the detailed information about what’s expected. 
 
S25: Yeah, we can have, they do provide, companies do provide information as 
to what you know, what they’ve seen previously but there’s always that unknown. 
So yeah, it would be nice to sort of have something, I don’t know what kind of a 
tool you would make though with um, so many different studies and different 
drugs, how you would make something generic. Or if you’re looking at study 
specific, I don’t know what you’re, what sort of tool you’re. 
 
M: Well that’s the thing [that’s a challenge] yeah, it is a challenge trying to decide 
um, I think ideally we would like to do something generic that would work over 
many different studies and many different therapeutic areas. But we might just 
need to focus in on you know, one particular [yeah] area for now. [yeah] 
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S25: Yeah, that’s just it, all the different sites, there’s always a different toxicity 
with all the different drugs and the different cancer sites so I’m not sure how you 
would… 
 
M: But if they’re using the same drug at different centers right [yeah] it should 
be… 
 
S25: The same drug, but I’m just talking about all the different, because you’re 
looking for some type of a generic tool for different Phase I studies is that what? 
 
M: Yeah, yeah, just for Phase I studies yeah, for all Phase I studies. So you think 
that would be challenging why? 
 
S25: Well I’m just wondering if for the different drugs how you would um, I’m just 
wondering how you plan, like what ideas you already have [yeah] to do this sort 
of tool. 
 
M: Well actually why don’t I just ah, I’ll get you to do this exercise and this might 
help [yeah, sure] clarify a little bit about one way that we’re thinking [okay] of 
doing it. So if you wouldn’t mind just reading over these 10 questions. This is an 
algorithm that was developed by a researcher named Naranjo and he didn’t 
develop it specifically with oncology in mind. But we’re thinking maybe we could 
tailor it more to you know, the Phase I oncology clinical trial setting. [okay] So if 
you could just read through those questions and cross out any that you do not 
feel are relevant to the Phase I oncology clinical trial setting that would be good.  
 
S25: And cross out any that are not relevant, previous conclusive reports 
[reading out loud]. So just put a check or an x or something. 
 
M: Just cross out any that you don’t feel are really relevant. 
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S25: Oh I see put the numbers up here. 
 
M: Oh, so you’re done [yeah] so with the rest of them if you could just rank them 
according to the level of importance in making the causality assessment. [long 
pause] 
 
S25: Sorry, this is taking long. 
 
M: That’s okay, take your time, okay great. So um, was the adverse event 
confirmed by any objective evidence, you ranked that the lowest, as being least 
important, why was that? 
 
S25: I just felt the other ones more important because with a Phase I, with the 
dose increasing I just felt that that and um, what else did I put here [whether it 
was detected in the blood] yeah, doing the blood and then whether or not the 
event would reoccur after the drug was administered. Or after it was administered 
to me might show you whether or not it was actually drug related or not because, 
what did I put for 8?, or whether or not it could have been another cause like 
disease or something else. I just felt that was more [those were more relevant] for 
a Phase I for me. [more important yeah] 
 
M: What did you understand objective evidence to be? [um] How did you interpret 
that? 
 
S25: Um, providing objective evidence, um, I guess, well I guess I could have 
rated that higher, like doing any other sort of, other testing, for me that’s what I 
thought it meant [mmm hmm, yeah] scans or other blood work, things like that. I 
guess that to me, well yeah, I guess that could have been more up here with this 
one, if it was due to any other causes. 
 
M: No, I don’t want you to change 
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S25: No, no, it’s hard to number them because there’s so many of them [I know] 
for Phase I that we’re allowed. But I guess the way I look at it and it’s so hard to 
do this because in every situation is different. [yeah, yeah] So whether the 
patients, they may automatically do some test that’s, that would prove right away 
that it was something else and then they may not re-administer the drug. So I 
guess I was looking at it with Phase I because you know, we’re increasing the 
dose, that, and whether or not it happened before or after, during, to me would 
sort of prove if it was, it would give you some sort of idea about causality. It’s a 
hard scale to [yeah] for me to do. [no, it’s is, it’s a tricky exercise, no question] 
Yeah because after you sort of read them, that’s why I was having a hard time 
putting the numbers, you might switch your numbers around so. But this one for 
me would be sort of testing [yeah, okay] for example, if they were admitted for 
some event um, they might do some testing and they might rule out right away 
that it’s [yeah] you know. If not then … 
 
M: They would rule out right away that it was due to the drug? 
 
S25: If they could rule out right away that it was due to disease or another cause. 
But I guess that’s why I put these as higher numbers for me for a Phase I, I 
guess, what was the other one here, ah, this one here I guess I should have put 
as a higher [number 3] did the reaction improve when the drug was discontinued 
or antagonist was administered. Between that one and did it happen, did it 
become severe when the dose was increased. I guess in a Phase I those would 
give you some kind of inclination if you already knew of an event that might be a 
probable or possible [right] event to look for. 
 
M: Now I see you crossed out number 9, did the patient have a similar reaction to 
the same or similar drugs in any previous exposure? How come you crossed that 
one out? 
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S25: Um, I guess with the Phase I they wouldn’t have had this drug before so. 
Typically they shouldn’t have already received that drug if they’re going on, that’s 
why I crossed it out. [because usually patients] That’s the way I interpreted it so 
[it’s a brand new drug so they wouldn’t have received it before] yeah, that’s how 
I’m interpreting that one. 
 
M: And then number 1 you crossed out, are there previous conclusive reports on 
this reaction. Why did you cross out that one? 
 
S25: Yeah, I guess because it’s Phase I and it’s new and they’re trying to find the 
different events for a Phase I [yeah] yeah. [okay, great] 
 
M: Yeah, so that’s sort of the idea of something that we’re thinking about maybe 
developing. [yeah] What, what did you think? 
 
S25: Yeah, it’s ah, like the same, like you would make it the same idea you mean 
for different, I see so you’re not going specifically to. 
 
M: Yeah, this is very generic but maybe just ah,  
 
S25: I think they’re all good questions and I think they’re definitely questions that 
we have in our mind already when we’re trying to assess causality. [mmm hmm] 
Um, so it might be a good little reminder tool for us you know of what sort of 
questions to ask, definitely. (feels reminders would be helpful) Like I said, I 
think there are things that we already ask ourselves when we’re [mmm hmm] 
 
M: What would make it more useful? [this tool?] Yeah, or any tool? 
 
S25: Hmm,  
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M: What about if it was something that was sort of Internet based and you know, 
sort of thinking big, we could really try to bring in some other information or you 
know. 
 
S25: Yeah, well I mean, Internet is always a good tool, it’s quick, you know, easy 
access tool for us so that, yeah it’s hard [what do you]. I think the questions are 
good you know, good little reminders for us. 
 
M: And if you were to go through and answer all these questions, do you think 
this could help you in assigning causality on that scale, causality scale? 
 
S25: Definitely, yeah, I just have a hard time answering it because every situation 
for every patient is different. [right] But I think based on the patient situation, 
these would be easier to answer because then you could say yes or no. You 
know, that would definitely help out. It’s hard to number them for me when I don’t 
know what the situation is, what the event is. 
 
M: So you would actually have to try out the scale and see how it would work. 
 
S25: Yeah, I would have to try it, but I think for me personally I think it would be 
easier to do this um, with the actual event, knowing what the event is. [okay] But I 
do think it is a good scale. [yeah, so that’s great] 
 
M: Were there any questions that you felt were sort of missing that should be 
included on there that weren’t? 
 
S25: Ah, no, not that I can think of off the top of my head. [good] 
 
M: And now lastly I just want to ask you if you have any concerns, what are your 
concerns  about how clinicians assign causality? [Um, concerns] About how 
causality is being assigned right now. 
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S25: Do I have any concerns [some people have said] sorry, go ahead. 
 
M: Well some people have said that they think it’s done a little too quickly [too 
quickly] or maybe it’s not done as thoroughly as it should be. 
 
S25: Yes I guess, um, I was going to say something similar to that, that they 
might be making decisions quickly without really going to source, some sort of 
source or really knowing. (make decision when based on time constraints) I 
mean, I find here though, we’re pretty good to go back, we may make that initial 
decision but then we’re pretty good to go back and discuss. So I hate to say that 
they make sort of hasty decisions. I mean, they’re educated with the patient’s 
disease so I would hope that they go to all of their sources [mmm hmm]. But 
yeah, maybe initially they make that decision and then ah, don’t, don’t review 
everything later and make a change that might be necessary. The cause maybe 
already assessed and it maybe incorrect. Other than that though, I don’t really 
have a major concern about that. [okay] 
 
M: What external influences or pressures from third parties have you felt when 
assigning causality? 
 
S25: Um, well I find the companies, well they don’t always agree and then ah, 
[with your assessment?] with our assessments. And you see that often in safety 
reports that come through, it’s tends to be always a possible or probable 
assessment when it really may not be necessary. But not a major pressure other 
than they want to know what the causality is you know, with that initial, if it’s an 
SAE for example [yeah] they want to know that right away because they have to 
send that out to other sites. [yeah] So you know, that’s the pressure there to sort 
of um, get that answer quickly. And because we don’t want to make that ultimate 
decision they may be getting our assessment initially that might not be the correct 
one so I guess that would be a concern or a pressure for me [yeah] to get the 
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physicians ultimate decision on [right]. Because they want the information quickly 
right with an SAE so. [yes] (pull and push between time and certainty) 
 
M: So you said that the companies they, you know, you send them in your 
causality assessment sometimes they don’t always agree. [yes] Do they come 
back to you and ask you to change it? 
 
S25: Ah, yeah, they could do that for sure, they might phone us, or during 
monitor visit they might um, sort of query it and ask questions about why we, 
thought it was related or not. And then give us their reasons why they think it 
should be different and want us to change it and we might not always want to. So 
there’s, there’s always that happens, usually they would speak with the 
physician, we’d have them speak directly with them so they would discuss their 
reasons for their assessment. But it does happen. [okay] 
 
M: Any other pressures? 
 
S25: No, not that I can think of. [okay, great] 
 
M: Lastly, I would just like to talk to you about the education you’ve received with 
respect to assigning causality to adverse events. I was actually, I’ve been 
actually fairly surprised that a lot of people who I have spoken to have said that 
there really isn’t much education out there [no there isn’t] in terms of how to 
assign causality to adverse events. [no] 
 
S25: No, I’m just trying to think of what would be an actual, you know, education 
that we’ve had. But other than when we go to the investigator meetings and we 
review the protocol they, they sort of have their own charts with their different 
assessment tools. Other than that we just  
 
M: What sort of assessment tools? 
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S25: Well you know, your, your points there where it’s either probable, definite, 
those sort of. 
 
M: So they’ll go over the causality assessment scale that they want you to use? 
[yeah] 
 
S25: But other than that um, as far as education as to how to assess the 
causality [yeah] I would say that’s really minimal to none. [yeah] 
 
M: Do you think something like that would be useful? 
 
S25: Sure, for sure. [yeah] I think for new CRAs or somebody who hasn’t had any 
sort of training, definitely. It’s kind of like on the job learn as you go really [yeah] I 
mean there really isn’t any specific training to that. [yeah] It definitely would be a 
helpful thing for new people starting. (feels education/training in causality 
assessment would be beneficial to new staff, no mention of current staff) 
 
M: What do you think would be the best way to deliver training like that to new 
CRAs? 
 
S25: Like what sort of tools or what sort of setting? 
 
M: Yeah, what sort of setting, like do you think a little CD Rom might work well or 
something over the Internet or something in person? 
 
S25: Maybe something like that, I know workshops work well. I know when we go 
to NCI meetings they always have their workshops for the new CRAs and 
something like that might be helpful. Not everyone takes part in NCIs and if they 
didn’t they would miss out on that. So maybe a CD, Internet definitely would be 
[yeah] that might be more, um, people might be more attentive to something like 
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that than a reading material. [yeah] That’s why workshops are always good too 
because then there can be open discussion. [yeah] 
 
M: And what would, what do you think should be the content of something like 
this, like what would be, you know, what should be covered? 
 
S25: I think your scale was good, something to go over different questions you 
might ask yourself when assessing the causality. [okay, anything else?] I guess 
the reasons why, you know, go over the reasons why we do it, the importance of 
it. [okay, good] 
 
M: Excellent, that’s really helpful. Those are all the questions I have for you then, 
do you have any questions for me or any thoughts, final comments? 
 
S25: No, it’s definitely a challenging undertaking for sure so I’ll be interested to 
see what you come up with. 
 
M: So will I, no, that’s great yeah. 
 
S25: It isn’t an easy topic for sure. 
 
M: Yeah, I think it’s, I agree, it’s challenging but a lot of people have definitely 
shown a  lot of interest in it. [that’s good] So I think that there is a need there. 
 
S25: There is, it’s a difficult thing that’s um, I would be more worried that it’s 
being done properly so it might be helpful for sure. [yeah, yeah] ( worries about 
how causality is currently assessed) 
 
M: Good, well thank you very much for your time. 
Subject 26 
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M: So I’ll just explain a bit about what it is that we’re doing then. As I mentioned, I 
am working with some researchers at the Juravinski Cancer Centre and we are 
very interested in how clinicians assign causality to adverse events in early 
phase oncology clinical trials, so specifically you know, Phase I. And um, but 
even the most experienced clinicians find assigning causality to adverse events 
challenging. And many groups expect prompt and sensible causality 
assessments. I’m sure as you know it’s not always that straightforward and if 
done poorly there are implications. So we’re interested in developing a tool to 
help clinicians more efficiently and reliably assign causality to adverse events 
during Phase I oncology clinical trials. And we feel that by better understanding 
your needs as a clinician we can make the tool more relevant and useful to you. 
You look like you had a question there. No, okay, so no questions then before I 
start? [no]. No, okay. So first I would just like to get a better understanding of the 
reasoning that you use, the thought process you use when assigning causality to 
adverse events. And I’m wondering if you can just recall a serious adverse event 
that occurred recently and just walk me through how you assigned causality to 
that. 
 
S25: Okay, let me think, um, I’m just trying to think of some patients of mine that 
are on clinical trials. Alright, well I had a patient on a clinical trial, who ended up 
getting admitted ah, she was on a clinical trial of chemotherapy plus, either a 
study drug or a placebo. And she got admitted following the first cycle of 
chemotherapy with ah, weakness, and um, dehydration, diarrhea and um, sort of 
new focal neurologic findings. And it turned out that on MRI she’d had a series of 
strokes actually that explained the new focal neurologic findings [sorry the new 
focal] neurologic findings. Um, so obviously because of the severity of the 
symptoms on admission, that was a serious adverse event. And the problem was 
assigning causality to either the chemotherapy or to the study drug/placebo or to 
both, or whether it was unrelated to anything. Um, we know that the diarrhea and 
dehydration is an expected toxicity of the study drug and so we thought that was 
a reasonable, you know, there was a reasonable possibility that that’s, what had 
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caused that particular problem. The strokes we weren’t too sure of, we thought 
that there was multiple things that could have contributed to that, including just 
the cancer itself which makes people more prone to these sorts of things. 
Chemotherapy which increases your risk for thrombotic events, but thrombotic 
events have also been associated with the class of, with agents in the class that 
the study drug was in as well. 
 
M: What was the class? 
 
S26: Angiogenesis inhibitors. And so we thought that there was a possibility that 
it could have been related to both chemotherapy or the study drug/placebo. 
 
M: So in that case it could either be the study drug or it could be the study drug in  
combination with the chemotherapy. 
 
S26: In combination with the chemotherapy or it could have been the 
chemotherapy itself or it could have been, I suppose it could have been 
unrelated. I mean patients with lung cancer who stroke, or who smoke are at risk 
of having strokes and so on you know. [was this a lung cancer patient?] Yeah a 
lung cancer patient, so there’s always the possibility that this could have been 
bad luck and unrelated to anything that was going on at that particular time. And 
so, and also the whole fact that she was dehydrated and so on probably made 
her hypercoagulable again and again made her predisposed to thrombotic events 
and so on. So I suspect it was all inter-related, but teasing out you know which of 
those treatment things was ultimately responsible for the stroke was difficult and 
is difficult. [right] (although all inter-related, it is very difficult to pin point the 
primary toxicity) 
 
M: Yeah, so when it’s a constellation of factors [yeah] and trying to figure out 
which is the most important. 
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S26: Important and which is the one that is ultimately to blame, you see what I 
mean? And I don’t think that, these are not, I don’t think there’s a right answer to 
that, I don’t think that you could know with 100% certainty which of those, which 
of the factors is ultimately responsible. Because likely if you’d taken away any of 
them it may not have happened. [right, right, very tricky] 
 
M: So what do you think would have helped you then in that, when you were 
making that decision? 
 
S26: Well I guess you know, knowing what the baseline risk of somebody with 
lung cancer who’s on chemotherapy of having a stroke in the middle of their 
chemotherapy. Like, how often does that happen?, you know what I mean. [mmm 
hmm] So is that something that occurs you know in a small proportion of patients 
anyway?, right. [right] Um, and what proportion of patients with lung cancer who 
are not on active treatment have a stroke?. You know, so that you can see the 
increased risk just with chemotherapy itself. And then what proportion of people 
on these, this class of agents stroke, and what proportion of people on this 
agents in combination with chemotherapy stroke? [mmm hmm] So I mean 
knowing, knowing that may have helped assign causality I suppose in terms of 
the balance of probabilities if the likelihood of having a stroke on chemotherapy is 
less than 1%. But if the likelihood of having stroke on chemotherapy and one of 
these drugs is 10% then it makes it much more likely that it’s the study drug 
that’s, you know contributing and so on. [yeah] At least in my mind that’s how I 
would, how I would logic it out. (copes with uncertainty through process of 
elimination) [right] So I guess you know, knowing some background features of 
exactly how common certain toxicities are in untreated patients. Because you 
know bad things happen to patients with cancer even without treatment right 
[yeah] they do funny things all the time. And then what the likelihood is with 
certain chemotherapies, particularly agents in the class, in the same class as the 
study drug and then that might help. [yeah okay] 
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M: Is there anything else that might have helped you in coming to that decision? 
 
S26: Not that I can think of at the moment. 
 
M: Were there any other challenges that you’ve come across when you assign 
causality? 
 
S26: Well I guess one of the things that I’ve always had a difficult um, thing to 
grapple with is that there are too many, often there are too many categories of 
relatedness. [okay] You know, like definite, probable, possible, unlikely or not, do 
you see what I mean? [yeah] And I think that those are fairly subjective 
definitions that will vary from person-person. You know, what I think is unlikely is 
not necessarily what you might think to be unlikely [mmm hmm] and so um, again 
the assigning of causality there could be sort of chance depending on the 
interpretation of the definition by the individual physician. I think you know, in 
some ways it might be better if these things were done by consensus rather than 
by one, one person. Um, [consensus among?] consensus among other people 
who do Phase I trials in oncology, you know what I mean? (lack of team 
work/group cohesion) 
 
M: So that everybody who is an investigator on the trial comes together to 
decide? 
 
S26: Not necessarily everybody on the trial but at least the investigator who is 
involved, plus the principal investigator, plus maybe one other person either from 
the cooperative group or whatever. I don’t know, I’m just trying to think of ways, 
and I think it would be good too to decrease the number of categories and to 
make the categories fairly explicit in terms of what the likelihood is. [okay, alright] 
 
M: What external pressures or influences have you felt from third parties when 
you’re assigning causality? 
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S26: Ah, none [can you recall a time?] none really, I mean there’s, the only 
pressure that you feel um, is the sort of sense of urgency of, because you know 
you have to fill out the SAE report within 24 hours and all this sort of stuff. You 
may not have all the information and you may make an original, you may make 
an assessment that subsequently you change or becomes clearer as time goes 
on that something else is in fact happening and you want to change your mind 
about something. Which is, which is fine and you do, do that but I think that 
sometimes, I don’t know that you should necessarily have to assign the causality 
right away. I mean I think reporting the SAE right away and saying this is what’s 
happening and we’re monitoring the patient and these are the steps we’ve taken. 
And we’ll, you know, as things evolve we’ll let you know what we think actually 
happened, rather than saying yes we think this is study drug related within the 
first 18 hours when you don’t, you may not necessarily have all the facts yet. 
[right] (finds time constraints to limit accuracy of assessment) 
 
M: Now would you tend to, would you say that you tend to be more cautious 
initially when you don’t have all the information? Or are there you know, any kind 
of guidelines that you follow when you have to make that initial assessment 
under that time pressure? 
 
S26: No, I mean, cautious, by that do you mean more likely to attribute? 
 
M: Yeah, like, I’ve done over 20 interviews now and one of the things that I’m 
kind of gathering from speaking to people is that they tend to err on the side of 
caution in the interest of patient safety. [yeah] And I guess I’m just wondering 
where there is that time pressure, that 24-hour time where you have to report and 
assign causality in that timeframe and you don’t necessarily have all the 
information. Are you more likely to say yeah it could possibly be related to the 
drug but we just don’t know yet? Or, or are you more likely to say well I’m not 
ready to attribute it to the drug just yet because we don’t know, you know? 
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S26: Yeah, I don’t know that I necessarily go either way [yeah] I mean I try to 
look at what has happened and look at what is known about the drug and what 
the drug has been reported to do in the past. You know, if it’s a fairly typical 
toxicity of the medication, like if the person has been admitted with diarrhea and 
dehydration and that’s, that’s a known side effect of that class of agents then I’m 
more likely to say, yeah that’s probably what it is, it’s probably drug related. 
Whereas as if, if, it’s something like a stroke and I don’t really know what’s 
happening or what’s going on and that’s, that may have been reported in the past 
with that class of drug, but it’s highly unlikely, highly unusual or whatever. I mean, 
I would, I would go more with what’s already been reported for that class of 
agents. (copes with uncertainty by assigning similar causality attributions) 
[right, okay] Um, so, I mean obviously patient safety is paramount but I, I’ve not 
been in a situation yet where I think something is definitely drug related that has 
profound safety implications, you know what I mean, that, that really the trial 
should be put on hold. You know, these sorts of things because I think this is a 
toxicity that’s definitely related to study drug that could be you know, life 
threatening to other patients. 
 
M: Have you ever worked on a trial where it’s been halted because of safety 
issues? 
 
S26: Oh yeah. 
 
M: Can you give me an example or tell me a little bit about that? 
 
S26: Well ah, well I mean one of the, the clinical trial that I talked about before 
was put on hold by the data safety monitoring committee after they looked at the 
first bit of data to decide that you know, perhaps the toxicities were too great. 
 
M: Which trial was that? 
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S26:  BR24. 
 
M: Okay, which drug was that using? 
 
S26: It’s using an angiogenesis inhibitor. [okay] 
 
M: So that trial was put on hold. [yeah] And has it restarted? 
 
S26: Now some of this information is confidential. [yeah] Yeah, the trial has, the 
amendment has been approved and it’s been approved by Health Canada and 
the Data Safety Monitoring Committee and all that sort of stuff and the trial is up 
and running again. [okay] With an amendment obviously to try to protect patient 
safety. [okay, right] 
 
M: But I guess that just sort of happens if you’re not expecting certain toxicities. 
 
S26: Yeah, I mean I think that’s the whole point behind having a Data and Safety 
Monitoring Committee right? [right]. In fact it was the investigators, it was us, that 
asked for an earlier review of the toxicity because we felt that perhaps we were 
seeing too high a rate of toxicity compared to what one would expect from the 
chemotherapy regimen itself. So we thought that the study drug was probably 
adding a certain degree of toxicity that perhaps wasn’t safe. [right] 
 
M: So you guys actually asked for an early investigation of it  [yeah] before the 
Data and Safety Monitoring Board caught on? 
 
S26:  Yeah, they weren’t due to meet, we’d asked for an earlier review and we’d 
let them know that we were concerned so that they would look at the data with 
greater care. [that’s good] Yeah, so I think that you know, investigators are, are 
highly attuned to the need for, for vigilance in patient safety. [yeah, yeah, okay] 
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M: So you talked about the sense of urgency in terms of assigning causality to 
the adverse event within 24 hours. Any other influences or pressures that you 
felt? 
 
S26: No, I’ve never been ah, I’ve never been asked to change my causality or 
anything like that you know. [okay] Um, you know, sometimes people will ask for 
clarification and say you know, is this what you mean?, is this what you really 
think happened?, you know that sort of stuff, that sort of stuff. But I don’t call that 
pressure [mmm hmm] I just see that as people seeking to understand you know, 
my, my line of thinking and logic and so on. [yeah, okay, great] (has no issues 
defending their causality attribution) 
 
M: Do you have any concerns about how clinicians assign causality? 
 
S26: Well as I said I think sometimes it’s arbitrary and it depends upon the 
physician’s interpretations of the definitions of you know, these different things. I 
think it depends a little bit on the physician’s past experiences, expectations and 
biases with respect to the class of agents and so on. And I think that if you are 
unfortunate and the first couple of patients that you have on um, on a study or 
with a class of drug happen to have significant toxicity, which occasionally 
happens. Then I think that your viewpoint might be a bit skewed, which is why I 
think that having you know, a consensus approach to, to building you know, 
relatedness and so on may be better. Because you’d be able to have other 
people say well actually I’ve given this drug at that dose to this type of patient 
and so on and haven’t seen that, so maybe there is something else going on. Or 
maybe it is a true toxicity related to this drug but it isn’t as common as you would 
think and, and so on. I think hearing other people’s experiences with a similar 
agent will allow you to put what’s happened to your patient into a bigger context. 
[right] (subjective) 
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M: Now some participants have actually mentioned that sometimes the 
communication isn’t that great among investigators in a trial, would you tend to 
agree with that? 
 
S26: Yes. 
 
M: Yeah, you think that could be something that could be improved? 
 
S26: Yeah, and again I think that’s where it gets down to the whole you know, 
consensus building approach to looking at toxicities and so on. 
 
M: Can you think of anything else that might help in terms of, like you said putting 
that SAE into a broader context, so being able to sort of step outside of your 
personal experience and look at you know, look at it from a broader entire trial or 
drug history you know perspective in terms of the history of the drug and the trial 
that it’s been used in thus far, that kind of thing. 
 
S26: Yeah, I know, it would be interesting if you could do some sort of database 
search or something yourself, you know, and say okay look there’s been x 
number of reports. But I mean, I doubt any drug company in the world will allow 
you to do that. You know, I’m sure all that stuff is kept very, that’s all closely 
guarded secrets. [mmm hmm] 
 
M: Now as I mentioned, we’re looking to develop a tool that’s going to help 
investigators in assigning causality. Um, what, what are some of the key features 
of a tool that you would require you know, for it to be useful and practical for you 
to use? 
 
S26: Can you give me an example of what you mean? 
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M: Well I just know that you guys are really busy and some people have said you 
know, it can’t add to my administrative burden. You know, I guess I would like to 
get a sense of if we were to develop some sort of a tool how would it best fit into 
your day-to-day working environment. [right] 
 
S26: Well I think that it would have to be ah, clear and you know, I think that the, 
the definitions would have to be you know, not really subject to a lot of inter-
investigator interpretation, you know what I mean. So that what I think is likely is 
the same as what you think is likely and so on, based on the definitions. [yeah] I 
think that it would have to, ah, I mean, I don’t know, either like a little pocket card 
from a practical point of view [yeah, sure] that would be sensible you know, but 
not overwhelming. Right, I think it has to be simple and either you know, a pocket 
card that you whip out to look at the rule. Or you know, you can get on the 
Internet or you know, on your computer or something like that. It would have to 
be something that, that is not complicated and could be understood by everybody 
involved in the clinical trial, not just the investigator but the, the research nurses 
and research associates and all that sort of staff as well. (tool needs to be 
simple, efficient and accessible if t is to gain popularity) Um, like what sort of 
tool do you foresee? [okay] if you told me that then I could tell you, you know how 
I could see that fitting in. [mmm hmm]  
 
M: Well one of our thoughts was, I don’t know, are you aware of any decision 
making tools right now? 
 
S26: Well I know that A gave a presentation once and he did say that there were 
some sort of algorithms to follow but they’re not sort of widely used in oncology. 
They’re, you know, it talks about you know, does it make biological sense, you 
know, these sorts of things and has it been described with this drug before and is 
there a rechallenge phenomena. I can’t remember all of them. 
 
M: And have you ever used those tools? 
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S26: No. Again, I don’t know that anybody does in oncology. Have any of your, 
other than A, have any of your other people said yes? (feels no tools are used 
in oncology clinical trials) 
 
M: No, no. [laughter] And in fact, you know, thinking back to their medical training 
and whatnot they’re not even familiar with them. This one was developed by a 
fellow researcher named Naranjo and what I’d like to ask is if you wouldn’t mind 
just reading over these 10 questions and crossing out any that you feel are not 
relevant to the Phase I clinical oncology setting. The idea was that maybe we 
might be able to slightly modify the Naranjo tool and make it more applicable to 
the oncology setting. [pause] Okay, that’s great and then with the remaining ones 
if you could just rank them in order of importance, so 10 would be most important 
and then you can just kind of work your way down from there. In terms of you 
know, factors that you consider when you’re assigning causality. Ones that are 
more important, there are probably some that are more important than others. 
 
M: Great, okay so you crossed out number 6, that’s pretty common, most people 
cross that one out. And then number 8, was the reaction more severe when the 
dose was increased, you crossed that out obviously because [you wouldn’t do 
that] that rarely happens in Phase I right. 
 
S26: Yeah, I mean that would be if you thought there was a possibility that they’d 
suffered an adverse event related to the drug, I think it would be unethical to 
[yeah] give them a higher dose. [laughter] 
 
M: Absolutely. Did the patient have a similar 
 
S26: But you don’t have to, but less severe when the dose is decreased, I think 
that might be okay [mmm hmm] do you see what I mean, just half of the question. 
[yeah that’s important good] Yea. 
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M: And then did the patient have a similar reaction to same or similar drugs in 
any previous exposure. I guess you’re thinking this is a brand new agent 
 
S26: Right, it’s unlikely that they would have seen it and you know, the, um, I was 
just thinking that, one of the things that was going through my mind that this was 
first cycle toxicity you know what I mean. And so they wouldn’t have had 
[previous] previous exposure, see what I mean and so that doesn’t seem 
particularly relevant to Phase I. And I mean, usually patients aren’t allowed to go 
on some trials [right] if they’ve had a similar drug in the past, you know what I 
mean, so. [okay, good] 
 
M: And then most important to you was whether there were conclusive reports, 
previous conclusive reports on this reaction. Um, what did you interpret that to 
mean, sort of previous conclusive reports? 
 
S26: Um, I just thought that that meant that it was established that you know, that 
there was a toxicity profile of the drug and that it, it’s known that this drug can do 
x, y and z to patients. And if the patient had y and it’s been described that x, y 
and z have happened then that, that for me goes a long way in saying okay, well 
this is a reaction that’s known to happen with this drug. 
 
M: Okay, so then are you thinking it would be in the IB [yeah] consent form. 
 
S26, Exactly, exactly, that’s stuff that’s known about the, the agent already. 
[okay, great, alright] 
 
M: And then least important, was the drug detected in the blood in concentrations 
known to be toxic, why was that? 
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S26: Because you don’t get that information for ever, I mean, when, when um, 
like you may do a lot of pharmacokinetic studies with blood draws and so on but 
those samples are batched and sent off to God knows where to be analyzed and 
you don’t see that data for months. [right] And so it’s not relevant to actually 
assigning the causality at the time the event has happened. 
 
M: Yeah, yeah, quite a few people have actually said that, okay. And then was 
the adverse event confirmed by any objective evidence, again that, that’s a 
vague term isn’t it, objective evidence? 
 
S26: Yeah, and I’m not sure what they mean by that. To me if a patient 
complains of a symptom that to me is sufficient, I believe what patients tell me 
[yeah] I mean if they say this is happened to them I don’t necessarily need 
objective evidence. 
 
M: What would you consider objective evidence [well] if you actually see it 
happen? 
 
S26: Well yeah, exactly, like I don’t need to watch them vomit to ah, you know, 
what I mean. If they tell me they threw up 10 times, then they threw up 10 times. I 
mean people may exaggerate a bit but if they say they threw up 10 times then 
that’s good enough for me, you know what I mean. [right] Now obviously if 
something really weird has happened like the patients had an MI and some 
selective drug causes cardiac ischema or you think that that’s what’s happened 
then obviously you’d want to check for evidence that that’s actually what’s going 
on. But for the most part a lot of this is going to be symptomatology and your, 
your physical examination of the patient [okay] so, so I don’t think you necessarily 
need anything more than, than that. 
 
M: Was there anything on here, that wasn’t on here that you thought maybe 
should have been included or anything that was missing? 
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S26: Not that I can think of at the moment no. 
 
M: What did you think of it in general [this, tool? I think that] what was your first 
impression? 
 
S26: I think, well I think it’s actually the um, I mean these are things that we, I 
think go through in our minds anyway without, without necessarily having it quite 
so systematized as this. But these are the types of things that I ask myself right, 
like is this known to happen with this drug? is the time sequence right? Like 
obviously if it started before the drug it’s probably not the drug unless it got 
worse, you know what I mean. [mmm hmm] You know, did it get better when we 
stopped? if we rechallenged the patient did it come back? I mean these are all, 
those are all sort of common sense things that we probably work through in our 
minds anyways. [mmm hmm] 
 
M: So in terms of this as a tool, what do you think [I think] worthwhile or? 
 
S26: Well the only thing about it is it, if you could somehow link it to the different 
categories of causality, see what I mean. Like if you felt that some of these were 
worth more points than others, see what I mean. And then you could um, you 
could say okay if you answered these yes, no, maybe, for a yes you get 2, maybe 
you get 1, no you get 0 and if you add up all the points and if you come up with a 
score of between this and this then it’s probable. And if you come up with a score 
between this and this then it’s possible, you see what I mean. [yeah] That would 
be the way I could see that because again unless you can, I mean if, a tool to me 
implies that there’s a measurement like afterwards, or some sort of hard end 
point. Um, but if you go through this and at the end of the day it’s still up to the 
investigator to make a judgment call having used that, then, then I don’t know if 
we’re any further ahead. Do you understand what I’m saying? [yeah, definitely] 
Um, so unless you can get people to interpret this all the same way and, and 
! &+%
then translate the answers to those questions into a measurement that you then 
apply to the event so that you come up with a probability statement. Like it’s x% 
likely that this event was caused by the drug, then I don’t know that it would 
change anything about our decision making now. I think the one thing that has to 
change that would help the most is the time pressure. Like I think that whole 24-
hour, like I understand that we need to report the event but I think the causality 
part of it should be delayed until after you have the facts. And then you can say 
okay really I think this is you know. (good idea reporting event, then assigning 
causality later, when it is more clear) 
 
M: I guess the challenge with that is though, you know the safety letters, the 
regulations state that if it’s serious, unexpected and causally related then a safety 
letter goes out to all investigators [yeah] in all trials with the drug right. [yeah, 
yeah] And I guess that’s why they need that causality assessment [right] within 
that first 24 hours. [yeah] So that would be tough to change. 
 
S26: Well that would require you know, [ICH guideline changes] yeah, and I 
appreciate that. I’m just saying that, that actually, and I recognize that’s for 
patient safety and of course therefore you should err on the side of attributing it 
to the drug. But I’m not sure necessarily that’s best for science and the best for, 
for your purposes in assigning causality. [yeah, yeah, agreed] 
 
M: Alright, the last thing I want to ask you about is, can you tell me about any 
training you’ve received specifically with regard to assigning causality to adverse 
events. How did you learn how to do it? 
 
S26: Trial and error I guess. I mean the only, the only lecture I’ve ever heard 
about is, I’ve heard A speak once, but other than that you know, really nothing. I 
mean you’d ask other more senior investigators what they would say for this 
particular event and so on. But otherwise, there was no formal training. [yeah] 
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M: Yeah, that’s what I’ve heard. Now do you feel that that’s something that would 
be useful? 
 
S26: Um, I guess, but are there, is there a consensus out there on how to do it 
anyways? 
 
M: Well exactly, first you need to know what to teach people right? 
 
S26: Well exactly, I mean, I mean, who would teach what, you know what I 
mean. Yes, I think all investigators should be taught how to do it but if there’s no 
agreement on how to do it and if there’s no standardized way of doing it then 
what’s to teach? [yeah] So A can become the world’s expert and teach us all and 
if we all agree on how to do it I think that would be great. Um, but until that time 
then [fire alarm] that’s okay though, when it speeds up then you think about 
packing up and then there’s a third level where you really should get out of the 
building. [laughter] So we’re alright for the moment. 
 
M: Right, we have these go off in our building too. And actually it’s good because 
we’re done now, so thanks very much, I really appreciate the time. 
Subject 27 
M: So as I mentioned assigning causality to adverse events is sometimes 
challenging, even for the most experienced investigators. And um, but groups 
such as industry sponsors, clinical trial cooperative groups, research ethics 
boards, they all expect prompt and sensible causality assessments. But I’m sure 
as you know, it’s not always that straightforward and if it’s done poorly there are 
some implications.  So we’re interested in developing a tool to help clinicians 
more efficiently and reliably assign causality, specifically during early phase 
oncology clinical trials. And we feel that by better understanding your needs we 
can make that tool more relevant to you. So do you have any questions then  [no] 
before we get started?  So can you think back to maybe a recent serious adverse 
event that has happened with one of your patients? If you could just recall a 
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serious adverse event for me, tell me a little bit about it and how causality was 
assigned to that serious adverse event. 
 
 S27: Um, unfortunately working with the brain tumor patients they end up being 
hospitalized due to their disease more so then they do to um, a drug related 
SAE. [right] Um, I’m just trying to think of, there was one patient a while back, a 
head and neck patient that was admitted to hospital and it was drug related SAE. 
It had to do with gemcitabine and it was documented in the investigator brochure 
that this was a potential AE that could happen. 
 
M: What was the AE, why was the patient hospitalized? 
 
S27: She, um, you’re testing my memory [laughter] um, I can’t recall the 
specifics. 
 
M: Okay, but it was an expected event. 
 
S27: It was an expected event. 
 
M: So it was in the IB for gemcitabine. [yes] Was the patient receiving just 
gemcitabine or were there other. 
 
S27: No, they were just receiving gem. 
 
M: Okay, and in that case did you assign the causality or um? 
 
S27: I, I anticipated what it was but I confirmed it with the investigator before 
[right] yeah, before putting it on the report. 
 
M: So is that usually how it works then? 
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S27: Yeah, unless it’s very blatant, um, we usually go over those types of things 
with the investigator just to make sure. It’s their ultimate responsibility, so I want 
to make sure that they’re in on the whole thing. [yeah, okay] 
 
M: So obviously in that case you referred to the investigator brochure [mmm 
hmm] were there any other resources you referred to? 
 
S27: Well in the protocol as well they usually list um, what the expected AEs can 
be and um, so that, that’s usually my first, the first place I go to, the protocol just 
to review what they have and then if, if I don’t get the answer then I’ll go to the 
investigator’s brochure. [okay] 
 
M: And um, are there any other tools that you use when assigning causality, 
decision-making tools to try to determine whether it’s due to the drug or due to 
other factors? 
 
S27: Well usually when we set up, like our sheets that we use, our CTO 
assessment sheets that we use. 
 
M: What’s CTO? 
 
S27: Clinical Trial Office, it’s just, it’s just our own [lingo] lingo yes. It’s an 
assessment sheet that we use and usually when we’re starting up a new study 
we refer to the protocol and we can use our own add or subtract whatever we 
want on these. So on the backside of the sheet we have AEs, so nausea, 
vomiting, fatigue, you know, the standards. And then if there is anything specific 
to the study that we need to capture or keep track of then we add those to the 
sheet. So you know if I happen not to be in one day or something then somebody 
going to see a patient for me isn’t going to miss um, you know, covering 
something so. So I guess in a sense that’s a tool that we use to, to capture AEs, 
on an ongoing basis. [okay] 
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M: So your assessment sheets [mmm hmm] that you take into every patient visit? 
 
S27: Yes, for that study, we customize them basically specific for the study. And 
then that way as I said then nothing gets overlooked if somebody else happens 
to see a patient for you. [okay, good] 
 
M: What would you say are some of the challenges associated with assigning 
causality? 
 
S27: I think the challenges would definitely be if there are multiple drugs involved 
if there is more then one chemo, certainly pre-existing conditions in a patient. 
 
M: When you say multiple drugs involved, why is that a challenge? 
 
S27: Well I guess just trying to determine which drug could be causing the 
adverse event, you know if it’s, you know they could both be causing it, it could 
be one or the other so you need to do. 
 
M: Now can you think of a time when that was the case when you needed to… 
 
S27: Not particularly for myself because again head and neck patients don’t get 
chemo very often [yeah] and if they do it’s a single agent. With the brain tumor 
patients, again they get single agents so. But I do know with helping my 
colleagues troubleshoot when they have you know, chemo trials, particularly in 
lung patients, they would have you know, more than one agent that their patients 
are being treated with. And what they do again, with the assessment sheet is 
they, they would put the two drugs and have columns for each one so that they 
can, they can sort through it a little bit easier. [yeah] But unfortunately I guess I’m 
not a great candidate to be interviewing [oh no] because I don’t do a lot of chemo 
so. [yeah] 
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M: That’s okay, you’re an experienced CRA that’s exactly what we’re looking for. 
Okay, so if there’s multiple drugs involved [mmm hmm] sometimes that’s a 
challenge, trying to tease out [yeah, yeah] which drug has caused it. [yeah] 
 
S27: And pre-existing conditions in the patient if they have you know, other 
health problems that could be contributory to some symptoms. You know, and 
sometimes it can be as easy as just the person themselves, some people will say 
they’re perfectly fine when they’re not. And other patients will elaborate on you 
know, how they’re feeling and might be exaggerating a little bit. So you know you 
have to try and understand the patient themselves as well. 
 
M: How do you, well can you give me an example of maybe a time when that’s 
happened in the case of an adverse event? 
 
S27: Well even if you just say like, fatigue for instance, if you say are you feeling 
fatigued?, oh, oh yes I’m so fatigued. Are you having to take naps every day?, oh 
no, no, no. So you’re getting, on the one hand they sound like they’re flat out all 
day and then when you kind of guide, not guide them but you know you pursue it 
a little bit further then they end up saying oh no, I don’t need to take a nap. 
[laughter] So you know, that’s a pretty simplistic example but that kind of thing. 
(patient’s view is also subjective, need to investigate patient claims) 
 
M: Yeah, that’s a good example, okay. So yeah just trying to deal with those 
sometimes unreliable patient reports and I guess it’s all based on… 
 
S27: Yeah because for us, I’m not a nurse and when we go down to see the 
patients we’re recording what they’re telling us. So we’re saying first of all, how 
have you been feeling in the last week? and some of them say ‘oh feeling great 
you know, pretty good’. And then you look and see what they have commented 
on in the past and say well how are you doing as far as, last time we met you 
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said that you had this and this and this, how’s that doing? Oh, it’s the same, so 
then you’re going okay, it’s the same [laughter] and then when you read the 
doctor’s progress note, all of a sudden they’ve divulged all this other information. 
You know, and some of those things, you know, could definitely be related to 
treatment that they haven’t really, the patient really didn’t comment you know, to 
you about because they didn’t really think it was that important or significant or 
you know. [yeah, yeah] So just getting the right AEs down and I think the 
language of the AEs as well, you know, especially with brain tumor patients when 
you’re looking at the neuropathies and whether they’re like you know, you need 
to kind of break it down and make sure that you’re all talking the same language. 
[okay] 
 
M: So are there different terms for neuropathies? 
 
S27: Well, you can have neuropathy or myopathies or there are sensory 
neuropathies so you know, there’s different ways of, they’re all very slight 
differences sometimes in, in the terminology. 
 
M: Okay, so you just have to break them down to be more specific? 
 
S27: Yeah, like if the physician calls it one thing and you’re calling it something 
else but basically you’re talking about the same thing you really need to pinpoint 
what terminology you’re going to use so that there’s consistency. 
 
M: And do you use a tool to keep that terminology consistent? 
 
S27: Um, not really, usually when I review the progress notes if he’s calling it 
something different than I have then I’ll go to him and say okay, what are we 
talking about here? [yeah, yeah] So they’re very involved with us and they’re 
really great about you know, clarifying different things. [okay, alright] 
(unclear/inconsistent terminology) 
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M: Any other problems or challenges you’ve encountered when assigning 
causality? 
 
S27: Um, I can’t think off the top of my head. 
 
M: Have you got any concerns about the way causality is being assigned by 
clinicians? 
 
S27: Um, well I don’t think there is ever going to be anything that’s going to be 
black and white. (grey area) I mean I think that’s, that’s something that we have 
to live with. (understands grey area is inevitable, copes with it) And I think as 
long as you know, you’re able to have those discussions with your PIs and, and 
make sure that again, you know, you’re both involved in discussing the same 
points and talking the same language, then you know you can usually come to 
the conclusion. [okay] But sometimes it’s never that easy, even for the 
investigators, sometimes they’ll say, I don’t know, and I’ll say well you have to 
give me something, I have to report this you know, so, anyways. 
 
M: What happens in that case when you don’t know, is there a sort of general 
guideline that you follow? 
 
S27: Well, we usually go back to, sometimes we’ll go to the sponsor and say, this 
is the situation with this patient and this is what’s happened and we’re having 
difficulty determining. What do you want us to do? [right] And see what they [what 
do they usually say] well, if the investigator feels that it’s this, that and the next 
thing, then that’s fine, it’s whatever the investigator says. That’s usually their 
answer. [right, throw it back in your court] [laughter] Yeah. 
 
M: And if you’re really just not certain is there a category for that on the causality 
scale? 
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S27: Well yeah I guess, because I think they have probably, or possibly or so 
sometimes you’re stuck between possible or probable you know [and you’re just 
not sure] you’re stuck. 
 
M: Now how do you determine if you’re going to call it probable or possible, like 
what’s the tipping point? 
 
S27: I think again going back to the protocol or the investigator brochure and, 
and you know discussing it with the investigator and putting all the pieces 
together and seeing which category it fits into better. 
 
M: Let’s say it’s not an expected event, let’s say a patient has a serious adverse 
event that just isn’t expected for this fairly new drug [mmm hmm] what do you 
guys do in that case? Then I guess the IB isn’t very much help. [no] 
 
S27: Um, well I, I think what, I’m just trying to think if I’ve had an occasion for 
that, um, hmm, I don’t really know that I’ve had anything that hasn’t been you 
know specifically a disease related event. Um, you know, as opposed to an 
unexpected, like if the patient developed neutropenia and it’s not something that, 
that you’re expecting. I don’t think that I’ve come across that. [okay, alright] 
 
M: I’ve done quite a few interviews now and one of the things that’s come out is it 
is kind of difficult to make that distinction between probable and possible and 
how do you determine you know and I guess, that’s sort of part of the difficulty. 
[yeah, yeah] 
 
S27: And it will never be black and white, you just can’t [no] you know, 
sometimes you just go with what fits best. And I certainly, you know, wouldn’t 
make that determination on my own if it’s something, you know, if they’ve got 
something like that where they’ve developed neutropenia where the drug isn’t 
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going to give them that. Then that’s something I would definitely go to the 
investigator and say how do you want to address this you know. [yeah, okay] 
 
M: Now have you ever felt any external influences or pressures with regard to 
your causality assessments? 
 
S27: No, you mean with sponsors or? 
 
M: Just third parties, any pressures from? 
 
S27: No, no, [no eh, okay]. I mean we have lots of discussions amongst our 
group if we’re struggling with something like that we usually seek out you know, 
our colleagues opinions. But no, I wouldn’t say I’ve ever had any pressure to, to 
call it one way or the other. 
 
M: Or to change your causality assessment once you’ve made it? 
 
S27: No. [no okay, good] 
 
M: So from your perspective then what would make assigning causality easier? 
 
S27: That’s a very good question. [laughter] I, I don’t really know, I think just, just 
having, like making sure that you know everything, you know, if you have a list of 
everything that is potentially um, likely to cause an AE or can cause an AE for 
that particular drug then you know, it’s certainly a good tool to just have a look at 
and say okay, they could develop this, this and this. But again, we do have that 
information provided to us so [in the IB] mmm hmm. [yeah] So I don’t really know, 
I don’t know if there’s kind of like, you know, those [algorithm?] algorithms that 
you can look at. I know, they do provide those too with some of the protocols, not 
usually specific to, well some of them are specific to their counts and different 
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things. If their blood counts are low, go here and do this and do that you know. 
[laughter] But I don’t know, I mean the studies are becoming so complex. 
 
M: Why? 
 
S27: Well it’s just the future, they’re, they’re looking, I think they’re fine tuning 
research a little bit more now and they’re um, you know, they’re looking at, 
they’re doing more testing on patients during the course of their treatments. And 
they’re capturing more data during the course of the study and the demands are 
a lot more than they were before. And I think that it’s um, I don’t know it’s just 
becoming a little bit more complex. (a lot of content to report, assigning 
causality is becoming more difficult) 
 
M: Can you give me an example of some of the demands that have increased, do 
you mean for you? 
 
S27: Well I think for all of us, um, I think the, well the number of tests and 
timelines and everything that need to, you know, you’ve got to meet, so many 
different timelines and um. [for what?] For eligibility for patients, um, like you 
might have, a patient might have to start treatment within 5 weeks of surgery but 
they only come to the centre their second week after surgery so now you’re down 
to 3 weeks [right] to get them on. But you have to send tissue, pathology tissue 
off to Texas or something to be reviewed before you can put them on study [right] 
so there goes another, at least a week. And just with imaging, imaging is always 
an issue, trying to get imaging done in a timely manner. Um, but I mean I digress, 
that’s not really the topic that we’re on. 
 
M: Yeah, but that’s part of it isn’t it? If there’s anyway that you know, causality 
can be made simpler [yeah] then that allows you to focus more of your energy 
[mmm hmm] on the other increased demands. [yeah] 
 
! &"&
S27: I guess because the studies that I do, it hasn’t really been, um, that, you 
know, that difficult for me, which thankfully. [laughter] But I know some people 
have a more difficult time. [yeah, good, well not good but] [laughter] 
 
M: So when you say increased testing, like even before you know whether they 
are eligible [mmm hmm, all the pre-screening] pre-screening tests. 
 
S27: So it could be blood work, MUGA scans, ECGs, um, CT scan, pulmonary 
function tests, you know, they’re requiring a lot more up front now. And also 
specific imaging parameters, so if your patient, particularly with the brain tumor 
patients if they’re required to get MRIs on a regular basis which they do anyway. 
But they want to have certain slice thickness of the image so they’ve got to, that 
has to be set up with the department. So there’s a lot more you know, [right] 
they’re getting really nitty gritty with the details, which is good. I mean now you’re 
comparing apples with apples [yeah] because it’s, it’s, they’re fine tuning it a lot 
more. [good, alright] 
 
M:  I’m just wondering if you would do an exercise for me and read over these 10 
questions [mmm hmm]. This was an algorithm that was developed by a 
researcher named Naranjo. And if you could just read through those questions 
and cross out any that you feel are not relevant to the early phase oncology 
clinical trial setting. You think they’re all pretty good. 
 
S27: I think they are all pretty good, um. [okay] 
 
M: So now if you wouldn’t mind just ranking them in order of importance. So 10 
would be most important [mmm hmm] and least would be and 1 would be least 
important. Just to get an idea of you know, which factors are… 
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S27: The only one that doesn’t make a lot of sense to me is because you 
wouldn’t know if the patient is getting a placebo, well I guess in some instances 
you might. 
 
M: Right, just cross it out if you don’t feel it’s relevant. 
 
S27: Well I guess it depends if you know if the patient has been given a placebo 
or not. 
 
M: Yeah, and this is specific to early Phase, like Phase I oncology where patients 
aren’t usually getting a placebo. [yeah] So, others have crossed that one out. 
 
S27: Well this is, the drug, the toxicity one for the drug is important but a lot of 
times you don’t have a blood test that would detect it. 
 
M: I’m sorry number 7 [yeah] a lot of times you don’t have? 
 
S27: You wouldn’t have a blood test to detect the drugs that are being given 
[okay] like was the drug detected in the blood?, well they don’t have a test to 
detect it a lot of times [okay] you know what I mean. 
 
M: Yeah, so you might want to cross that one out too I guess, I don’t know. 
 
S27: Yeah, probably because they don’t have like. Well hopefully we wouldn’t be 
increasing the dose if the patient had some kind of an adverse reaction [right]. I 
agree with the, if the dose, [the last part] yeah. 
 
M: Okay, you can just cross out that part of it then if you like. Okay, so the one 
you ranked the lowest, was the adverse event confirmed by any object 
evidence?, [mmm hmm] and what did you interpret that to mean? 
 
! &"(
S27:  Well I wasn’t really quite, I was trying to think of, like putting that into um, a 
previous experience but I couldn’t really think of anything that, that would really 
fit, so I’m not sure it that would fit for other. 
 
M: So what did you understand objective evidence meant? 
 
S27: Well if the patient had a rash or has something that you can measure, you 
know, something visible. [right, okay] 
 
M: But that’s not really too important to assigning causality? 
 
S27: Well it’s important but I don’t know if it’s, like something like that would be 
difficult because they could be getting a rash for a lot of reasons. [okay] But I 
don’t know. 
 
M: Great, and then all the others you felt were pretty important. [mmm hmm] Was 
there anything here that you felt was sort of missing, um, should have been 
included? 
 
S27: Nothing really jumped out [no] I mean it covered a lot of bases, you know, if 
there was any history of any kind of reaction. That it was previously documented, 
that’s important to know, like if it’s in the IB. Um, and then the timing whether the 
event stopped after administration of the drug and that kind of thing. Am I missing 
something? 
 
M: No, no, what did you think of this tool did you think it was? 
 
S27: I thought it was good. 
 
M: Do you think something like that would be helpful? [mmm hmm] What sort of, 
how would it be most helpful to you? 
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S27: Well just, you know just answering some of the questions that you, you 
know, sometimes you just get blinded by your tunnel vision you know, when 
you’re looking at these things and, and it just brings things to the forefront that 
you might not think off the top of your head. [hmm okay] Makes you think. 
[laughter] [okay great] 
 
M: So this, this was one thought was to just try to modify this Naranjo scale to 
incorporate you know, make it more relevant to the early phase oncology clinical 
trial setting. And um, yeah, okay, great. 
 
M: And lastly I would just like to ask you about the education or the training that 
you’ve received with respect to assigning causality. [mmm hmm] So how did you 
learn how to do it? 
 
S27: Let me see, um, I think just basically, you know, I was asked to do what I’ve 
been doing. You know, when you’re developing, when you’re starting a new 
study and you’re developing your own tools, when you go to see the patient the 
adverse event page to include what the expected things are. And um, you know, 
certainly to review the protocol and usually I don’t read through the IB unless I’m 
looking for, unless it’s something that I’ve never dealt with before then sometimes 
I’ll have a quick look at it to see if there’s anything [unusual] yeah, unusual that I 
haven’t come across. Um, and basically that’s been you know, the rule of thumb, 
just to basically know your protocol and ah. (knowing your protocol is key to 
feeling confident on the job) 
 
M: So who taught you how to do all that, or you know, did you take some 
courses? 
 
S27: Well over the years I’ve gone to lots of conferences and things, but um, my, 
my supervisor when I first started you know, just in the, because I hadn’t worked 
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in clinical trials prior to being here. So this was um, [sort of on the job training] on 
the job yeah. [okay] 
 
M: Now thinking back to that time do you think it might have been good to have 
some sort of education around how to assign causality? 
 
S27: I think so, I think that a lot of centers are um, lacking good training tools for 
new people coming in. For sure, I mean, because it is so important in research, 
you really do need to know what the causality is and um, I think that, yeah. I 
mean, I’d love to see real training programs throughout, like across Canada. And 
I hope NCIC will take something like that up. I know that they do, they’re, they 
have good workshops you know at their Spring meetings and things. That would 
be an excellent place to present. [okay] 
 
M: Alright, now if we were to provide some sort of training around assigning 
causality and that sort of thing, would it, do you think it would be best done in 
person, or over the Internet, as a CD Rom or at a workshop or a conference. Like 
what, what’s your feeling? 
 
S27: I think you would reach more people if it was, you know, if we could go to a 
Web to do it, um, the, the conferences are great but you only get you know, a 
small amount of people. Unless you have the CD to provide to them to take back 
to their centre, which is another option. Yeah, to maximize the number of people 
that you’ll reach, I think it’s best to do the Web thing. [okay, great] 
 
M: As you know I’m here for a short time and today is my last day. Is there 
anybody else that you recommend that I speak to while I’m here? 
 
S27: Who have you talked to already? I know you talked to M. 
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M: M, SG, yourself, I’m meeting with M this afternoon [okay]. If there are any 
other CRAs that you think might be interested and have a few minutes. 
 
S27: I’ll ask, I mean some of our more senior CRAs um, I will have to make sure 
they’re here. I mean some of them just aren’t, there’s holidays going on but I’ll 
certainly um, see. [okay great] 
 
M: Thank you very much N that was wonderful. 
Subject 28 
M: I’ll just give you a little bit of a background about what we’re doing. I’m working 
with some researchers at the Juravinski Cancer Centre in Hamilton and what 
we’re interested in is how investigators assign causality to adverse events in 
clinical trials, specifically early phase oncology clinical trials. And the idea is, if we 
can get a better understanding of how that’s done and some of the challenges 
involved in that, that we can try and make that process a little bit better. And 
develop a tool to help make that, those causality assessments a little bit more 
reliable and consistent. And um, and so we feel that by getting this better 
understanding of the needs of medical oncologists and clinical trials associates 
like yourself we can make that tool more relevant to the people who will be using 
it. [mmm hmm] So do you have any questions then  [no] before we get started?  
First I would like to ask you if you wouldn’t mind, I don’t know if this will be 
possible but if you could try and recall a serious adverse event that has 
happened recently and how causality was assigned to that event. 
 
 S28: I had a patient who, oh actually it’s not even a GYNE study, okay so that 
won’t work. [laughter] 
 
M: It really doesn’t matter what kind of study it was. 
 
S28: It’s a primary lung PET scan study that I’m doing and a patient, um, when 
they were brought into the recovery room after his surgery he had a stroke. 
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[okay] Um, so causality was, because the study was comparing PET scan for 
staging for surgical candidates for lung cancer, compared to conventional staging 
it was not related to, the causality was not related to the PET scan because it 
happened right after the surgery. [um] Is that what you’re looking for? 
 
M: Sure, it sounds like an interesting, because it’s not a drug study [no it’s not a 
drug study] so it confused me a bit. So I guess we’re [you’re looking for more 
drug studies] yeah, can you give me an example of a serious adverse event 
where a patient was treated with a drug, like an investigational drug? 
 
S28: Um, okay, I had to go back a bit. [laughter] This lady was in a local study 
that we are doing for a medication and she started on the medication, I can’t 
remember what day it was. But it was three days prior to being admitted to the 
hospital with a DVT, so of course it was temporally related so the causality ended 
up being probable. 
 
M: Okay, and so that was based on the temporal relationship. [mmm hmm] Um,  
 
S28: And the fact that there was no prior history of DVTs. [okay] 
 
M: And now was that you that assigned the causality or um, or how did that go? 
 
S28: When it comes to SAEs, I’ve always got in my head what I think it’s 
probably going to be but I leave it up to the investigator to assign causality. [okay, 
great] (doesn’t mention collaborating with investigator to make a decision) 
 
M: So in that case, you were looking, you said there was a temporal relationship 
and you said the patient didn’t have a prior history of DVT. Were there any other 
things that you considered when you, when you were assigning causality? 
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S28: Well those are the two big ones really. Um, of course you have the 
investigator brochure which gives you a hint of what to be aware of. And um, this 
was for an ovarian cancer study so sometimes they are a little more likely to 
develop DVT and thrombus. Um, so yeah, those were other things that were 
looked at but those were the two big ones were the temporal relationship of 
course and her past history. [okay] (temporal relationship- theme for coping 
with uncertainty) 
 
M: So you mentioned you do refer back to the IB, are there any other resources 
that you look to? 
 
S28: Um, the protocol will sometimes give you an idea, but not usually. Um, I like 
to have a look at the IB and of course the science reports and everything that 
comes in, the adverse events reports that we do get [safety letters] safety letters 
yeah. I look at those and make sure that everybody, like all the investigators have 
a look at them as well. But um, I usually go by the IB and the letters. [okay] mmm 
hmm 
 
M: Do you keep those safety letters in a database at all or you just, how do you 
look them up? 
 
S28: How do I look them up? [yeah] Well for my GYNE studies they come to the 
principal investigator and he is very good about making sure that the other 
investigators see them and then they come to me. And then they’re forwarded to 
ethics to do their thing with them and then they come back to me. So they’re all 
filed in my office. [okay, that’s good] 
 
M: And that system seems to work for you? 
 
S28: It seems to work yeah. They weren’t really doing that as diligently when I 
first started, but um, they do now. [laughter] [that’s good] 
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M: Do you use any other tools to help you when you’re assigning causality, flow 
sheets or decision trees? 
 
S28: With the GYNE studies no. With my PET scan study, the other one we were 
talking about briefly does have a decision-tree, so I find that helpful. (would 
consider an algorithm helpful) 
 
M: And what is the decision tree for? 
 
S28: Um, for assigning causality and if they want it reported as an AE or an SAE 
and how quickly they want it reported. [oh I see] Because it’s very odd the way 
that study is working in my head, so I follow their tree that they provided because 
it doesn’t seem as logical to me they want it done. (lack of understanding 
between parties) 
 
M: So that has more to do with how quickly to report and where to report, that 
kind of thing? 
 
S28: And what to report, what to report as adverse events, AEs and SAEs, yeah. 
But no, none of the GYNE studies have any aids. [okay] 
 
M: What are some of the challenges you’ve encountered when assigning 
causality? 
 
S28: Well, most of my studies are also sponsor studies and they tend to make 
the wording vague on purpose. (big statement) [laughter] Probable, possible 
[the wording of what] probable, possible, definitely related, possibly related all 
the, so sometimes that can be a challenge if it’s something you haven’t 
encountered before. [mmm hmm] Um, but as I say it, anything, if I’m assigning a 
causality to something I’m making sure the investigator knows what I’m doing. 
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And if I have any questions about it then the final decision is always up to the 
investigator about the causality. 
 
M: So you said the wording of those terms on the causality scale are vague 
[mmm hmm] and that’s sometimes a challenge when it’s something new that you 
haven’t seen before. [mmm hmm] 
 
S28: Yeah, something unusual. 
 
M: Why is the wording, like can you tell me? 
 
S28: Well usually the wording is not related, possibly related, definitely related, 
are usually the four main ones that they use, so it depends how much you read 
into these things too sometimes, how you’re going to interpret them. So I find 
sometimes that wording can be tricky, especially possible, probable when you’re 
going into that area. (need for a standardized scale) 
 
M: Do you have any general guidelines that you follow, you know, what’s a 
possible and what’s a probable? 
 
S28: Um, of course the temporal relationships and the past medical history are 
the two big ones that I look at. Also again, back to the investigator brochure and 
what’s been reported before will help um, determine if it’s possible or probable if 
other areas, other centers have seen it happen before or if it’s already a known in 
the IB. [okay] 
 
M: So if it’s known, then it would be a probable, is that how you do it? 
 
S28: Yeah. If it’s known that it’s happened before, um, especially with um, things 
a patient hasn’t had before, it wasn’t pre-existing then it’s probably related, yeah, 
if it’s already been reported elsewhere. [yeah] 
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M: Yeah, other people have told me that they find the wording pretty difficult to 
wrap their head around and not really sure what the meaning of those terms are 
and, yeah I think there’s room for improvement there, maybe even just to define 
those terms a little bit better. Or you know, here’s when you use possible and 
here’s when you use probable. [mmm hmm] 
 
S28: But then even doing that, because you’re looking at such a broad category 
of what needs to be reported, that’s not even going to be easy to work. Like good 
luck coming up with something like that. [laughter] [thank you, well we’ll try] 
Because it’s hard to pigeon hole and that’s exactly what we’re supposed to be 
doing and you’re always going to come up with situations that aren’t going to 
quite fit and then what do you do? And that’s why I think it was designed a little 
on the vague side is to take into consideration those things. And I haven’t had it 
happen here, but in my past life as a coordinator before I came here, um, I would 
often get um, queries back from sponsors about AEs. Saying well you’ve marked 
this at possible but we think it should be probable, what do you think about 
changing this? and vice versa we think it should not be related because it’s not 
here dah, dah dah. Like I’ve had that happen in other areas of research where 
I’ve worked, I haven’t had that happen here yet. [yeah] But so they end up, you 
don’t know if they’re doing this, the sponsor is doing this because they have 
better information or they’re trying to um, I hate to say manipulate the data or the 
outcome. But you know, that’s kind of in the back of your head too. (unsure of 
investigator’s intentions at time, perhaps a lack of cimmunication) [yeah] 
But as I said, I haven’t had that happen with oncology but I’ve had it happen in 
other areas. 
 
M: Where they’ve asked you to change your causality assessment. [mmm hmm] 
What did you do in that situation? 
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S28: Well where, when I worked there I didn’t touch causality, that was the 
investigators job. So we would discuss this patient had this and, dah, dah, dah 
and that’s what happened and what do you think? and I would have him do it. 
[yeah] So anytime they asked for anything to be changed I would leave those 
queries up to him and 9 times out of 10 he would not change them. [oh that’s 
good] Because, but then it gets annoying and then you start to second guess and 
wonder why are they even asking if the investigator is ultimately responsible for 
the data and not some data entry person a million miles away who has no idea 
what is really going on. Why are they second guessing this, what are they really 
after? [yeah] (uses the term annoying, again feels disconnection with 
sponsors) 
 
M: Have you felt any other pressures or influences [nothing] from third parties. 
 
S28: No, and as I said this wasn’t in oncology these were in other areas of 
research. 
 
M: What are your concerns about how causality is being assigned now? 
 
S28: Well other than the wording, I think that was the big one and off the top of 
my head can’t think of anything else. [okay, okay] (issues with terminology) 
 
M: And from your perspective what would make assigning causality easier? 
 
S28: Better guidelines if they can be developed. [for what?] As you mentioned 
before, about what exactly do you mean by possible, probable. Um, a decision 
tree that would be followed when a patient reports, although that would be a 
forest not a tree. [laughter] Some, just a better definition of exactly what the 
sponsor means by those terms would be helpful. [okay] Because even if you 
have questions about it, um and you try and talk to your monitor, it’s not their 
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decision either, so they don’t help you. [yeah] Because they can’t be influential in 
that regard. [yeah, okay] 
 
M:  What I’d like to do now is just ask you to read over the following questions. 
These 10 questions were developed by a researcher named Naranjo and it’s an 
algorithm to help in assigning causality. What I would like you to do is first just 
read them over and cross out any that you feel are not relevant to the early 
Phase, specifically Phase I oncology clinical trial setting. 
 
S28: I’ve never done Phase I.  
 
M: So you’ve never done a Phase I? [no] Just early Phase, Phase I, Phase II, 
when you read it you’ll [okay] it should be okay for you to do. Are there any that 
you would cross out? 
 
S28: No. [no okay] 
 
M: So then now would you um, 
 
S28: See this is how it gets confusing. [laughter] 
 
M: So now then if you could just rank them in order of importance. So 10 would 
be most important and 1 would be least important. Just to get an idea of what 
factors you feel are more important than others. Okay, [mmm hmm] great, that 
wasn’t too hard was it, no, okay. 
 
M: So least important was number 1, did the adverse event appear [oh, oh oh, I 
did it wrong] did it backwards, okay. That should be easy to fix. Perfect. Yeah, 
okay, so did the adverse event appear after, so that was most important to you 
then. And least important was did the reaction reappear when a placebo was 
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given. Um, good. Now what did you understand objective evidence to be, to 
mean? 
 
S28: Um, objective evidence to me would be the blood work, um, that would be 
the big one. And if, [blood works showing?] yeah and what type of reaction did 
the patient have, did they break out in a rash, did they swell, did they have 
shortness of breath, did they have trouble breathing, like what, what happened, 
did blood pressure go up? Things like that.  
 
M: Alright great, good stuff. Now was there anything here that you felt was 
missing that should have been included?  What did you think of it overall as a 
tool? 
 
S28: It didn’t take anything subjective into consideration. Um, now you were 
looking mostly for SAEs, see SAEs are much easier than AEs to assess. (tools 
can be too objective) 
 
M: Okay, why is that? 
 
S28: Well because AEs it depends on what the patient tells you and it depends 
on the patient what they’re going to tell you. [right] And you know if it’s, it really 
depends on the patient, what they’re going to tell you. But um, that can have a 
big factor too in collecting information is what the patient tells you and if it’s AEs. 
(patient variation can alter causality attributions) 
 
M: So, so some patients tell you more than others or? 
 
S28: Oh yeah [laughter] 
 
M: Why do you think that is? 
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S28: No idea. 
 
M: Can you give me an example of a case where that has happened? 
 
S28: I had one patient, again, this is in my past life as a researcher, filling out a 
diary card for a once a day allergy medication and come back in a week with your 
diary card. And he came back with an itemized daily list by time of what he did 
[oh my gosh] for his entire day. We took the dog for a walk, we walked this far, 
turned at this time, had breakfast, this is what I had for breakfast, this was when I 
finished breakfast. [laughter] It was unbelievable. [he did that for a whole week?] 
Oh he did that for the entire six weeks of the study. [oh wow] Yeah [that would 
have been a lot to read] It’s a lot to read and then of course you know, he said 
that you know this day he got up and he stretched and felt a pain in his back so 
that’s an AE, you know and it’s just, some people can be a little nutty. 
 
M: So some patients tell you absolutely everything. [and others tell you nothing] 
Right, okay. So that’s what makes it difficult I guess. So you said that is tool 
doesn’t include anything subjective, so what do you mean by that? 
 
S28: Well from the patients point of view, you’re not, you’re not asking the 
patient. But I understand you’re looking at an acute event here, not um, like the 
patient goes home and 6 hours later develops a rash, that kind of thing and 
doesn’t tell you. Or you know, develops abdominal upsets, nausea, vomiting or 
anything like that, which can happen after a drug administration but not possibly 
within the timeframes you were looking at in this tool. You are looking more at the 
AEs that can later develop to an SAE if they become dehydrated and have to be 
admitted. 
 
M: So you think this tool would work better in the serious adverse event rather 
than the adverse event setting. [mmm hmm] Okay, yeah, that’s a good point. 
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S28: With the GYNE trials you are giving chemo meds, the patient is here for 3 
hours, they go home. The next day they start to feel really nauseous, start 
vomiting, stay at home, don’t tell anybody, just take the medications you give 
them, the medications aren’t working, they stop drinking. Three or four days later 
they end up going into emergency, being put on IV fluids and admitted, that 
happens, that happens. [right] So that wouldn’t capture that situation at the time, 
because this to me when I read this was okay, you’re talking mostly in the 
timeframe when the drug was given. [mmm hmm] So, you know, things happen 
later that start out as adverse events then become SAEs and that, that didn’t 
seem to fit here. [okay] 
 
M: Now do you think something like this would be useful? 
 
S28: Yeah. [laughter] 
 
M: You don’t sound too convincing. 
 
S28: No. It would be useful but um, some of it’s kind of redundant and it’s a little 
too wordy to be really time efficient useful. 
 
M: What’s redundant about it? 
 
S28: Um, well how many times are you going to have a reaction and then give a 
placebo? Like you’re not going to be switching arms if they’re in a study. So I 
didn’t think that really applied. Um, this here was the reaction more severe when 
the dose was increased, or less severe when the dose was decreased, ah when 
the dose was discontinued, so these are very close. [number 3 and 8] And 4 
when the drug was readministered, so these are all very similar. [mmm hmm] 
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M: So if it could be shortened up [mmm hmm] and made a little less wordy it 
might be more useful. [mmm hmm] Do you think you would use something like 
this? 
 
S28: Possibly. [laughter] 
 
M: You don’t have to be kind, you can tell me “I would never use this”. 
 
S28: Well I wouldn’t use it in this form, definitely not, it wouldn’t be worth my time. 
But if it was shorten up, more concise and possibly covered later Phase SAEs 
then yes it would be more useful than the way it appears here. [okay good] 
 
M: The last thing I want to ask you then is a little bit about your background in 
terms of how you learned how to assign causality to adverse events. So can you 
tell me about any training that you received. 
 
S28: I guess most of the training was at investigator meetings [yeah] yeah. 
 
M: Okay, and what did they teach you? 
 
S28: And I think nursing background, it’s something you just kind of learn after 
nursing for years. 
 
M: And what did you learn at the investigator, what did they teach you about at 
the investigator meetings? 
 
S28: Well they go over um, SAE reporting and that kind of thing. So I found that a 
little helpful when I first started doing clinical trials. But now it’s the same stuff 
every week, it’s redundant. [yeah] Yeah, but I think most of it was just nursing 
background. 
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M: What additional education about assigning causality do you feel needs to be 
made available? 
 
S28: Well, honestly, I don’t think we should be doing it at all, I think that is the 
investigator, they’re ultimately responsible, so I don’t think coordinators should be 
assigning causality at all. [okay] Um, but that’s just my opinion. 
 
M: So then, so that means that there shouldn’t be any education about assigning 
causality is that what you’re saying? 
 
S28: Well I think the investigators should be educated [yeah] on a lot of things. 
[laughter] So if you’re looking at education, my point of view is that coordinators 
shouldn’t be assigning causality. Um, but the investigators should definitely be 
educated in how to do it. Does that answer your question? 
 
M: Yeah, great, I think that’s a good answer. Well I think those are all the 
questions I have for you today. [okay] Thank you very much [no problem] I really 
appreciate the time because I know you are very busy. 
 
Subject 29 
M: I’ll just explain a little bit about what is that we’re doing. [mmm hmm] As I 
mentioned I’m working with Dr. AA and B who is the manager of clinical trials at 
JCC and with two other investigators in Hamilton. And we’re quite interested in 
how causality is assigned to adverse events in early Phase oncology clinical trials 
specifically. [okay] And our interest is in this because we would like to eventually 
develop a tool to help make it a little bit easier. [okay] So as I’m sure you know, 
even the most experienced clinicians find assigning causality [difficult] difficult. 
And many groups such as industry sponsors, clinical trial cooperative groups, 
research ethics boards, they all expect prompt and sensible causality 
assessments. [mmm hmm] But it’s not always that straightforward and if done 
poorly there are some implications. [right] So as I mentioned, we’re interested in 
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developing a tool to help clinicians make it more reliable and efficient. And we 
feel that by better understanding your needs we can make the tool more relevant 
to you.  [okay] So do you have any questions about what we’re doing [no] before 
we start?  First I’d like to start by just asking you if you could recall a serious 
adverse event that occurred with a patient where assigning causality was fairly 
straightforward. 
 
S29: Well it’s, I mean we see many patients who develop febrile neutropenia for 
instance from a chemotherapy drug and in that case it’s fairly straightforward. 
That’s an expected adverse event in many of the chemotherapy drugs that we 
use. Another one that would be a good example is if someone develops a blood 
clot and they’re on tamoxifen or that class of drugs in a study, that also um, is a 
well-known toxicity or side effect from that drug. So those would be two 
examples. [okay] 
 
M: What about, can you give me an example of a serious adverse event that 
happened recently that you can recall and you know, assigning causality wasn’t 
that straightforward, wasn’t that easy. 
 
S29: Um, I think, when we look at the reason why people are admitted to 
hospital, probably one of the ones that we get stuck on are, um, people who may 
have neurological types of events. Such they may um, be admitted to hospital 
with, not exactly, not stroke like symptoms but um, well for instance if they came 
into hospital, and this isn’t an example I’ve seen recently, but if they came into 
hospital with meningitis-type symptoms and you’re wondering whether it’s entirely 
meningitis or could it be leptomeningial disease from their cancer and so on. And 
so for instance in the breast and lung cancer population we do see people who 
um, present with neurological symptoms that could be part of their disease and/or 
outside of their disease it could be an infection. Or are those symptoms related to 
the study drug? Particularly if you can’t prove that it’s related to the, it’s related to 
the disease. So if you, if they had these symptoms and you do imaging such as 
! &$%
an MRI and it’s not positive and if you do all the normal tests and they’re 
negative, sometimes it can be hard to assign a causality particularly if you’re 
using a newer drug, so neurological type presentations. (newer drugs- harder to 
assign causality) Um, another sort of classic one that we see in a lot of cancer 
patients is weight loss, you know, weight loss, low grade fevers, fatigue. These 
ones are really difficult, because if they’re admitted with a generalized um, 
decline in their performance status, so they’re weak, they’re dizzy, they’ve lost 
weight, they have poor appetite and they’re on a study. Is that part of the disease 
or is that part of the treatment that they’re getting? And I have an example, this 
person wasn’t on a study but he had lung cancer and was getting gemcitabine 
and carboplatinum and he was very weak and dizzy and losing weight and so on. 
And the question was, was that his treatment or his disease? and when we 
stopped his treatment he actually got a lot better.  So by stopping the treatment 
we sort of defined that it was the treatment and not his disease. But I think those 
constitutional symptoms that cancer patients get are the hardest ones to try and 
delineate disease versus, versus drug. (confounding variables) [right] Another 
one of course that I can think of would be pain, different types of pain, whether it 
be visceral type pain or neuropathic type pain um, that someone ends up in the 
hospital with for instance a pain crisis and is that pain crisis related to their 
cancer? and sometimes that can be hard to sort out. Or is it something that the 
cancer drug that you have given them has done to increase the pain? For 
instance what happens if the cancer drug has caused them to bleed into a tumor 
and that, that has actually caused pain, for instance if they’ve bled into liver 
metastasis and that has stretched the liver is that what is causing pain, those 
types of things. So I think pain is a common thing that we see that can cause 
people to be admitted to hospital for which who knows? (very complex, left with 
uncertainty) 
 
M: That’s interesting because some people have given me an example of pain as 
something that’s clearly not related to a drug. But maybe if you took it back a few 
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more steps you would see that the drug is a [mmm hmm] more proximal cause 
and the pain is more of a distal outcome. [yeah] 
 
S29: I mean, you could go both ways with pain, I agree sometimes it’s clearly, but 
I, I guess I’m thinking of some of the newer drugs like Avastin which we know can 
cause bleeding and if it causes bleeding or some of these other drugs cause an 
infarct of the bowel because of the clot, or bleeding into an organ, then that 
certainly can cause pain.  So I don’t always think it’s that clear-cut. [no] 
(uncertainty) 
 
M: Other people I have spoken to too have said it’s pretty subjective and there’s 
a lot of interpretation involved. And do you think that’s because of the complexity 
of it? [yes] And what’s your reason why? 
 
S29: I think because there can be a component of the cancer and there can be a 
component of the treatment. [mmm hmm] And is it if they’re on the drug have 
they had recent radiation you know, what are the other things that are going, are 
there other medications that they’re on? So quite often I think it can be multi-
factorial, it may not be just due to the one thing [yeah] so it’s complex, pain is 
complex. So I don’t think you can, sometimes it might be obvious, I mean if 
someone has bone mets and they come in and they have a fracture. That’s pretty 
straightforward, it’s their disease, but it may not always be that straightforward. 
(very complex, a lot of variables to take into account) 
 
M: Are you aware of any tools to help you in making these causality decisions? 
 
S29: No. [no eh, you don’t use any?] No, in fact I think people tend to lean 
towards putting it, like when they’re not sure, and most people are never 100% 
sure, they’ll say you know either probable or could be. (err on the side of 
caution- method of coping with uncertainty) And I think we see a lot of “could 
bes” more than any other category because people don’t want to say, rule it out 
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100% that it’s not. I mean the very straightforward ones, people will say it’s most 
likely not, but if you’re not sure people will often put could be you know. [yeah so 
more of a] There’s a very grey zone and I think most people will tick off the grey 
zone. (finds comfort in having a grey area) 
 
M: So the grey zone in the scale, is that what you mean when you say the grey 
zone? 
 
S29: Yeah, because people it can either be, definite, you know what’s the 
relationship to study drug, definite, um, very likely, unlikely or probable? So I 
think a lot of people will take the could be category, I can’t remember the exact 
words but you know could be [possible] possible category because they don’t 
know for sure. [yeah okay] Because there are so many things going on with these 
patients besides that one aspect of the care. [yeah, yeah] Now I think there are 
some definite things, like we know with some of the newer drugs like Iressa and 
Tarceva, a rash is common and diarrhea is common and so when you see those 
things if someone is admitted for diarrhea because they’re on Tarceva then I 
think those are very straightforward. But I think we also, when you start putting 
these drugs out into the clinic that’s when you start to see some things that might 
not have been quite so obvious in the studies. 
 
M: Right, and why is that? 
 
S29: Just because you’re there, you’re taking a drug that was used in a very 
specific population and you’re giving that drug now to a broad, to a broader 
population that’s not as highly selected. So I think that with any study drug, with 
any drug that goes from research into the clinic will often pick up on issues that 
weren’t relevant or weren’t obvious when they were in the study phase. [yeah] 
Yeah, that’s pretty common. [yeah] 
 
M: It’s a smaller more select population. [that’s right, that’s right] Yeah. 
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S29: And then when you put it out to all broadly things start to come up, common 
things start to appear.  
 
M: Especially if it’s a rare event [mmm hmm] you just might not see it in such a 
small study. [that’s right, that’s right] It might only become apparent [when it’s 
been used extensively] yeah. 
 
M: Talking about that grey zone in the causality scale [mmm hmm] I’m just 
wondering if I could ask you to consider a scenario for me. Let’s say you’re 
treating a 65-year old female patient [mmm hmm] with a confirmed diagnosis of 
metastatic breast cancer. [mmm hmm] And she is in a Phase I clinical trial with 
an investigational drug [mmm hmm] and she experiences a pulmonary embolism. 
How would you assign causality to the study drug if there was a 75% chance that 
the adverse event was due to the study drug and a 25% chance it was due to all 
other factors. Keeping in mind this is a very hypothetical scenario and you don’t 
know much about the study drug other than what I just told you. And the scale is 
certain, probable, possible or unlikely. 
 
S29: That’s a hard one and I think it depends on what your cutoff is and um, I 
think if someone told you that there is a 75% probability that it was due to the 
study drug I would probably put probable. I don’t think I could put definite 
because it’s not a 100% so I would probably put probable. [okay] (subjectivity in 
cutoff ratios) 
 
M: And now what if there was a 50% chance it was due to the study drug and a 
50% chance it was due to all other factors? 
 
S29: Then I would go, what was the category below probable [possible] possible. 
[yeah, okay] 
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M: And what if there was a 20% chance it was due to the study drug and an 80% 
chance it was due to all other factors? 
 
S29: Then I’d put unlikely. 
 
M: Unlikely. [mmm hmm] So a 20% chance you would still say that was unlikely. 
 
S29: What was the one above that, I can’t remember? [possible] 
 
M: And it’s a 20% chance it’s due to the study drug and an 80% chance it’s due 
to all other factors. I’m not asking you to change it [no I know] I’m just trying to 
get a sense of where you’re cutoff is between unlikely and possible. 
 
S29: Yeah, 80 versus 20, yeah, I mean you could almost put in a less likely 
category in there, probable and unlikely. Sure it’s still probable but the probability 
is now swaying towards the other arm. So I would almost like to say less likely 
rather then unlikely [yeah] which is not even a category. [so somewhere in 
between possible and unlikely?] Yeah, but you have no category for that. 
[laughter] So maybe I would put it then, I would probably put probable but qualify 
it as less likely which is kind of a [you mean possible?] yeah [but less on the 
possible side] yeah. In other words, there’s sort of, yeah, I think you almost need, 
because you know, what if it’s 20 versus 40? So you’re still at less then 50% but 
40% is a lot different then 20 [yeah]. And so 40% you could say it’s still possible 
but at 20% it’s possible, but less likely than 40%, yeah it gets difficult. 
 
M: And of course we’re never faced with these, we don’t have these probabilities 
at the time when we’re assigning causality. [right] But would you say you do 
prefer to have a scale rather than the yes related to the study drug or no not 
related to the study drug? 
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S29: Oh, definitely, yes, yes. [why is that] Because then I think you’re going to 
get yes’s for everything. If you just say yes or no, people unless they’re 
absolutely 100% sure are always going to put yes, could be. And that doesn’t 
really give you very much information [mmm hmm] because then you’re going to 
get everyone saying yes except for the rare circumstances where it’s obviously 
no. [yeah] 
 
M: What are your concerns about how clinicians currently assign causality? 
 
S29: Well we probably don’t pay as much attention to it as we should. (feels they 
do not pay enough attention to assigning causality) I mean a lot of the initial 
information is prepared by the CRAs or the study nurses and I think in a practical 
everyday busy clinical environment we have these things coming across our 
desks to be signed almost on a daily basis. And I’m not sure if we think about it 
as much as we should, if we give it as much attention as we should, because it’s 
just another thing to be signed. [mmm hmm, yeah] And there’s been sort of very 
little attention paid to it in sort of the clinical research area. 
 
M: What do you think the implications are with that? 
 
S29: Well it means then that the information that the companies or the 
cooperative groups are getting is not going to be as accurate as they had hoped. 
(feels lack of attention to causality assessment leads to inaccurate 
decisions) I mean, what might be interesting is, even within the context of some 
of our meetings, like at the NCIC meeting if there was ever a workshop. It would 
be interesting to see, people would come and they could just give a few case 
scenarios and see how many people, like you have just done for me, rated those, 
and I bet you would get a very heterogeneous response [yeah] very 
heterogeneous. Well you’ll be able to tell from these surveys as well, but I think 
people’s understanding and their appreciation for the significance of it may be 
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there but I’m not sure if that’s reflected in how people deal with these on a day-to-
day basis. [okay] 
 
M: Yeah, so that’s, that a good idea, an NCIC workshop just getting people 
together and trying to understand how they are interpreting these. 
 
S29: I think you could just sort of look at it as a CME type of workshop and put up 
a few scenarios and say look at the diversity and you know, that type of thing. I 
think any type of tool or anything that makes it easier for people would be 
appreciated.  
 
M: What would make it easier for you? 
 
S29: I think if you had those scales and you gave parameters to each scale you 
know [to each of the definitions [that’s right, that’s right]. 
 
M: Can you give me an example of that sort of, I know it’s tough. 
 
S29: For instance you say 100% you know, and you can have what you mean by 
100%, absolutely, no question, this is related to the study drug. And then 
probable, you know 80 to 100% likely related to the study drug type thing. You 
could sort of break it down into the different, you know, 0 to 20% you could say, 
for 0% obviously not at all related [yeah] and then you would have a category 
above that. Um, possibly related but less likely, you know sort of 5 to 20% and 
sort of categorize it like that. 
 
M: So you think putting numerical ranges. 
 
S29: That might help because if you have a brochure and it says, with this drug, 
the possibility of having this event is 20% and then you have that event or around 
that then you can say okay where does that fit into this scale? [yeah] 
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M: And they do that in the consent form don’t they? 
 
S29: Yeah, they do. In the consent form they always tell the patient’s the less 
likely and then they give a percentage range and then they give the adverse 
event. [mmm hmm] So if we could have the percent and then the descriptor and 
a little description behind it that would give you the complete sort of 
categorization. [yeah] It still wouldn’t be perfect but it would be, it might be 
helpful. [mmm hmm] 
 
M: That’s a good idea, others have mentioned that too actually. 
 
M: What external pressures or influences have you felt from third parties when 
assigning causality? 
 
S29: I don’t really, because there’s really no sort of, I can say having done a lot 
of pharmaceutical studies really there’s not been a great deal of pressure. I have 
not felt pressure to say this is definitely or this is not. No they’re pretty well hands 
off. [good, okay] (Doesn’t feel pressured by external sources when assigning 
causality) 
 
M:  Now I’d just like to ask you if you wouldn’t mind reading over these questions. 
This is an algorithm that was developed by a researcher named Naranjo. If you 
could just read over those questions and cross out any that you don’t feel are 
relevant to the early Phase oncology clinical trial setting and then um. 
 
S29: Some of these are very [very what?] was the adverse event confirmed by 
any objective evidence. Um, we usually if it’s anything, an unusual adverse event 
it doesn’t necessarily have to be confirmed by um [by objective evidence] yeah. 
So we have to rank the remaining questions. 
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M: Yeah, so now of the ones that are remaining, [oh okay] yeah if you could just 
rank them from most important to least important. So 1 is least important, 10 is 
most important.  
 
S29: But there won’t be, okay there won’t be 10 but. [okay] 
 
M: So you can just start and then work your way down, however you want to do it 
or work your way up from the bottom. 
 
S29: This isn’t easy to do actually. [I know, it’s a tough task] Did the reaction 
appear when the placebo was given, but most Phase I studies don’t have a 
placebo in them. [you can cross it out if you like] Unless it’s going to be, I mean, 
this is specific to Phase I right? 
 
M: Yeah, we’re sort of, we’re focusing on that to start. So if I only have [yeah, 
perfect] 1, 2, 3, 4, 5, 6. [super] 
 
M: Now um, you crossed out 6, 7, 8 and 10. And so, what was your thinking of 
crossing out number 10 just that it’s not necessary to have objective evidence? 
 
S29: Well that’s the only one I was thinking of, if anything I would put that 4, no I 
don’t think you have to have objective evidence. [okay] Because an adverse 
event is an adverse event, you could have objective evidence but um, let me just 
try and think of a scenario. 
 
M: It wouldn’t necessarily affect your causality assessment though would it? [no] 
if you had it or not. [no] 
 
S29: Like pain, pain is subjective, fatigue is subjective, I mean you can try and 
quantify it but if you think that the study, that the causality, that fatigue is due to 
the study drug you’re not going to have objective evidence. [true] Weight loss, 
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well I guess if you have weight loss you can measure them in pounds but it’s not 
always going to be there. 
 
M: No, those are good examples okay. And then, why did you cross out number 
8, was the reaction more severe when the dose was increased, or less severe 
when the dose was decreased? 
 
S29: I don’t think again that is going to affect causality, I think again if you have a 
reaction, first of all you may not have that, in a patient you may not have an 
increase in dose for a Phase I study. But I don’t think that, you have to assess an 
adverse event at the time and usually you have to assign causality at the time 
and you don’t wait until the next cycle um, if their dose is reduced or, or 
increased. Then essentially what you would be doing is backtracking and saying 
okay based on this cycle I’m going to go back and try to assign causality based 
on this backwards. So I think when we look at SAEs in these new drugs we look 
at the present and what’s happening at that time. And we look at what’s the event 
and what’s the causality so you have an event and you have to say could it be or 
could it not be? [yeah] I wouldn’t necessarily, if you’re going to escalate or de-
escalate the dose that would be another cycle and so that wouldn’t necessarily 
influence how I assign causality on that cycle [at the time] mmm hmm. 
 
M: And number 7 you crossed out was it detected in the blood in concentrations 
known to be toxic, what was your reasoning for that. Just again, you wouldn’t 
have that at the time or. 
 
S29: No, and I think again whether you have, you could have an SAE with 
normal non-toxic levels of the drug in your blood. So I don’t think, that information 
is important to look at distribution of study drug and elimination of study drug. But 
again, as this is a Phase I you do not know if someone with normal blood levels 
for that drug will have an adverse event or not. It’s not going to influence your 
causality. [okay, right] 
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M: What’s toxic to one may not be toxic to another, is that what you mean? 
[mmm hmm] 
 
S29: For a given dose, for a given serum level in their blood. You could say 
someone could have an SAE with normal levels and someone could have no 
SAE with a toxic level in their blood. 
 
M: So the two most important things to you were whether this was an expected 
event [mmm hmm] and whether um, you know, the timing [right] the time 
relationships. So did the adverse event reappear after the drug was re-
administered? [mmm hmm] Okay, good, very good. What did you think of this? 
 
S29: Um, it’s somewhat, I think most people would struggle a little bit with picking 
what to put down and what to take out. 
 
M: But if we were to modify this and say just leave the ones that you thought 
were most important [right] and kind of weight them according to how you think 
they should be weighted. 
 
S29: I think it would be helpful, yeah. (feels a tool would be helpful) 
 
M: Would you use something like this? 
 
S29: I still think I would use something similar to what we talked about before. 
You know the um, and what would really help of course is if you have the 
information about the study drug and you have the toxicities and the likelihood of 
them occurring. And if you had then the event that occurred and that scale then 
you could sort of cross reference. So it’s less likely this is going to be an adverse, 
you know, the expectation there’s going to be a 20% chance of this adverse 
event occurring, this is the event that occurred and here are the scores and 
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here’s the, the scale, then I think that would help. [yeah] Have them all sort of 
together. Which right now we never do, right now we get this piece of paper that 
comes to us from the clinical trials office and it says you know, it’s in a little box 
and it says SAE, this is the event, tick off a box and that’s it. [right, yeah] 
 
M: Without really knowing what the probability of that event really is. [that’s right] 
 
S29: Unless you’ve had a lot of experience with the drug you know, but if you are 
in a Phase I study and you know, you may put three patients on it and that’s it in 
your centre. [right] You don’t have a broad experience with it. [no] 
 
M: Now, I’ve done a few interviews and one of the things that’s come out is that 
people have said that sometimes the communication is kind of poor among 
investigators in Phase I trials because you know, you only are dealing with one or 
two patients at your centre so it would be nice to have better communication. 
Would you agree with that? 
 
S29: Yeah, I think that if you have just a few centers, some, one thing that might 
be helpful is if there was almost a site, an electronic site that you could access to 
sort of see what is happening in terms of adverse events with those patients at 
other sites. So that you, you know, because right now you’re kind of in the dark 
when you’re filling out those forms. [safety letters] You get the safety letters, 
that’s true, problem is you get so many of them, some of them you look at very 
briefly. We get way too many safety, I mean we get, we get tons of them, we get 
piles this high every week from all the studies. 
 
M: It’s a bit unmanageable isn’t it? [mmm hmm] So if they were summarized in a 
database that was accessible through your computers [mmm hmm] do you think 
that might be better? 
 
S29: Because then you could access it at your leisure. [yeah] 
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M: And then lastly I’d just like to ask a little bit about your education in terms of 
the training you received, specifically with respect to assigning causality. How did 
you learn how to do it? 
 
S29: Oh I think it’s on the job training. [yeah] Um, I think most of us learn it 
through our experiences in the clinic. I mean I did have some time, I spent a year, 
did my fellowship at NCIC. Although you know, I really didn’t, there was no 
specific component in my fellowship that dealt with assigning causality. I wrote 
protocols and learned about clinical trial design and methodology but not 
specifically causality. I’ve not really seen any specific courses or symposium, or 
CME events that have dealt with that. So I think that’s, most people, most people 
really learn as they go through experience. [mmm hmm] (no formal training) 
 
M: Do you think some additional education about assigning causality would be 
worthwhile? 
 
S29: I think I mentioned this previously, something that would be interesting 
would be just a very short, you know, one hour event at something like a meeting 
at NCIC or you know, would be helpful. To make it in the context of a) being non-
threatening b) not being boring, so make it a bit fun with some cases or some 
information and data. I think, they already do a new investigator training 
workshop at NCIC so it could become, it would be interesting to see if they could 
incorporate it into that workshop. [okay] But for the veterans, a little sort of a little 
CME update, that would be an interesting symposium. 
 
M: Okay, that’s great. Those are all the questions I have for you [okay] do you 
have any questions for me? [no] Any final comments or thoughts or? 
 
S29: No, just whenever you know, the results of it are [yeah] I’d be interested in 
hearing the outcome. 
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M: Yeah, definitely, that’s the idea, we’re going to summarize all this interview 
data and put together a nice little executive summary [great] and send it out to all 
of the participants [great] and of course we’ll keep you posted if anything more 
comes out of it. We’re hoping to maybe present at the Fall NCIC meeting [okay] 
and if not then, then in the Spring. And then you know, we’re going to start to 
develop our tool [right] and we might need to get your thoughts on that later 
[okay] if that’s alright. [yeah, that’s good] But yeah, thanks very much, I really 
appreciate your time, I know how busy you are. 
Subject 30 
M: So just to give you a little background about what it is that we’re doing.  I’m 
working with Dr. AA at the JCC and a few other investigators there, B is the 
manager of the clinical trials department. And I don’t know if you’re familiar with 
ML, he works for the Centre for Evaluations of Medicines at, it’s through 
McMaster and St. Joseph’s Hospital, he’s a pharmacoepidemiologist. And so 
we’ve got a good group of researchers and I just joined on in March, I’m a 
Master’s level trained epidemiologist. And so we’re very interested in how 
investigators assign causality to adverse events that occur during early Phase, 
specifically Phase I oncology clinical trials. We understand that it’s challenging, 
even for the most experienced clinicians. And that many groups expect prompt 
and sensible causality assessments. But that it’s not always that straightforward 
and if it’s done poorly there are definitely implications. So we’re interested in 
developing a tool to help clinicians more efficiently and reliably assign causality to 
adverse events. And we feel that by better understanding your needs we can 
make the tool more relevant to you. So do you have any questions [no that’s fine] 
before we start? Okay, great. And um, so first I guess, I’d just like to ask if you 
could recall a serious adverse event that occurred where you had to assign 
causality and it was fairly straightforward. Can you give me an example?  
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S30:  Right, okay, somebody ah, was receiving cetuximab and had a, had a 
severe hypersensitivity reaction immediately during the infusion and it was 
attributed as definitely related. [okay, good] 
 
M: And so it was that whole temporal relationship that led you to say it was 
definitely related? 
 
S30: Temporal relation, known history of cetuximab causing hypersensitivity 
reactions, um, the absence of other probable or possible causes of that 
hypersensitivity reaction. It was a single-agent trial. [okay, that made it a little 
simpler?] There was nothing else that could have caused it. [okay] (process of 
elimination) 
 
M: Now can you think back to a serious adverse event where assigning causality 
wasn’t that straightforward? [um] Is there an example recently you can think of? 
 
S30: Yes, okay, I can think of one. [can you tell me about it?] Okay, a patient was 
receiving an oral VEGF receptor antagonist and um, received ah, had been 
treated for about an 8-day period and had become very unwell while on 
treatment. We’d stopped the drugs and he had recovered, we dose-reduced him 
and gave him a single dose at the reduced level. And the patient within a hour 
had fever and chills, [mmm hmm] I can’t remember all the details, I’d have to look 
at the chart. But had some, some possible urinary um findings on urine dip that 
suggested that there were, you know could have either been the drug or maybe 
this was just a coincidence and the patient actually had a urinary tract infection 
and had developed, developed urosepsis. So at the time of the event there was 
some uncertainly in my mind whether this could have been caused by infection, 
tumor fever or the drug itself. Because he had previously been been treated with 
the drug and he hadn’t had fever and chills, but had been unwell, but not fevers 
and chills. So there was some uncertainty. 
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M: When you said he was unwell after being treated for 8 days, what do you 
mean? 
 
S30: Fatigue and even some mild cognitive difficulties um, grade 3 weakness, 
anorexia, some nausea, um, a variety of symptoms. [okay, alright] 
 
M: So what led you to, how did you assign causality in that case? 
 
S30: Well in that case I felt that the event was ah, I’ll have to see actually how I 
graded it, but I believe I said it was, it was probably related but I wasn’t absolutely 
certain given that there were, there were other possible causes. (it is hard to be 
certain even with very slim possibilities of other causes) So if you have 
another possible cause or at least at that point, at the point where it was 
attributed we felt there were other possible causes. So I didn’t want to say it was 
definitely related um, and ah, but temporally it was associated with it and the 
patient had been unwell on the same drug before. So there was, there were 
enough um, both temporal and ah, and previous experience with this patient, 
reasons why we believe that it might have been related. However, in terms of 
experience with the drug, it’s a relatively new drug and um, hypersensitivity 
reactions, it’s an oral drug, had not particularly been described. (strong 
emphasis on temporal relations) Um, so there wasn’t a lot of data to go on in 
terms of, in terms of background data for the drug with this particular event. 
[mmm hmm] so there remained some uncertainty from that point of view. And 
also there was no, there was no um, biologic, particular biologic reason why this 
drug might cause um, in terms of mechanism of action. So we didn’t know any 
mechanism of action why a patient might develop fevers and chills with this drug. 
So, some uncertainty and it was, it was, you know there was some debate 
between possibly related versus probably related and I said probably related. 
(debate between causality scale measures seems to be quite common) 
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M: That seems to be the difficulty determining, whether it’s possibly or probably, 
and how do you differentiate. 
 
S30: Well in the end it doesn’t matter because these things are all dichotomized 
generally in trials. If it’s possible, probable or definite it’s considered to be 
attributed to the drug and it’s unlikely or definitely not attributed, or definitely not 
attributed then it’s considered no. So when you look at how, how these things 
that are eventually graded, anything that’s possibly, probably or definitely related 
is still attributed to the drug [mmm hmm] for the purposes of these studies. So in 
some ways possible versus probable doesn’t matter, it’s more important the 
definition of possible versus unlikely [mmm hmm], that’s, that’s really where the, 
the, it’s important that the correct, the correct side of the fence is chosen as much 
as can be done. [okay] (greater standardization of causality scale measures 
is needed and regarded as highly important) 
 
M: And how do you differentiate between possible or unlikely? Do you have sort 
of a? 
 
S30: Well again, you use all of the factors, you use whether this is the first event, 
or whether this has repeatedly happened in this particular patient, so the 
individual patient experience. You use the information from the investigator 
brochure and information that you are receiving in an ongoing mechanism, 
feedback from other patients that are receiving the drug. (new idea- using 
feedback from other patients to assign causality- although probably self 
implied) You look at the biology of the drug and say are there, are there 
probable causes, are there theoretical reasons why the drug would cause this 
particular side effect. So you know, if you’re looking a drug that affects the VEGF 
system and they get hypertension well there is, there’s a good theoretical reason 
why that would be the case, or wound healing problems. So if you know the 
biology of the, the mechanism of the drug you can look for associations for that 
reason. And then there’s the temporal association [mmm hmm] and um, I’m sure 
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I’m forgetting something. (forgets some components of causality attributions- 
may suggest that a tool would be a helpful reminder) 
 
M: So are there some general guidelines that you tend to follow then to say ok 
well I’m going to say possible this time or no I’m going to say unlikely this time? 
 
S30: Well I think in the early development of a drug if there are other, if there are 
other, let’s say the very first few patients that are being treated with the drug. Um, 
if there are other reasonable causes then I’m not overly quick to attribute them to 
the drug. Because I think you can falsely label a drug with all sorts of um, 
toxicities that have nothing to do with it. So if I’m treating patients with colorectal 
cancer and they elevate, there’s a little bit of elevation of liver enzymes um, then, 
and we know the patient has liver metastasis then I’m not quick to say this, this is 
attributed to the drug. My leaning in that case would be unlikely because we 
know that patients with colorectal cancer develop elevations of their liver 
enzymes whether you do nothing to them or treat them with any treatment. So if, 
if there’s another probable explanation then I’m going to say unlikely. If there’s no 
other probable explanation [mmm hmm] there are only possible explanations. So 
some, a patient develops um, low platelets and there’s no, you know slightly low 
platelets and there’s no other obvious cause, there’s no other probable cause 
[mmm hmm] outside of the study drug then I’m more likely to say possible. Or if 
there is, even if there’s no track record I’d say possible, if there is any track 
record at all of thrombocytopenia I would more likely say possible, you know 
probable or definite. Again depending on temporal association and if it’s the first 
time it’s happened. [all those factors okay] So it’s really, it’s, there’s, it’s a 
combination of factors when you’re making decisions, when you’re designating 
causality. (multiple factors make the decision making process very 
complex; they err on the side of caution by attributing the toxicity to the 
drug, in instances when they are uncertain) 
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M: So that’s sort of a less conservative approach really, um, erring on the side of, 
sort of protecting the drug I guess right? 
 
S30: Well um, it’s, I don’t know it’s less conservative, I don’t think it’s right to say 
that every bad thing that happens to a patient, every abnormal blood parameter, 
every um, you know, every time the patient gets a cold or whatever that it could 
be attributed to the drug. I don’t think that would be right, I don’t think that would 
be right or fair for the development of the drug. Um, so again, it’s, I don’t think it’s 
conservative or liberal [mmm hmm] or whatever, it’s a question, I think it has to 
be a balanced approach [yeah] every time you make an attribution. (tries to be 
balanced, unbiased when making an attribution) Particularly in the early 
development of a drug it’s important that those are as accurate as possible. And 
sometimes you’ll make mistakes, sometimes you’ll have, the first time a toxicity 
comes up you say, well how could that be related you know, or could that be 
related? And you might, you might say possible or you might say unlikely. And 
then when the third patient develops the same symptom which you thought could 
be from some other cause, you say wait a minute there’s a pattern developing 
here. From now on I’m going to put all these as probable or definite so I think 
that’s where the advantage of seeing many patients on the same trial. I think the 
danger when you have, when you have a trial with 40 centimeters, 40 centres 
involved and all of them put on two or three patients that nobody has an 
opportunity except for maybe the people at the central office. Nobody has the 
opportunity to recognize those patterns. So it’s better to have a centre and put 10 
or 12 patients on, on a Phase I study or an early Phase II study [yeah] to be able 
to identify what these, what these patterns are. (hard to find a balance between 
the safety of patients in early phase clinical trials and the number of 
patients you can recruit- the more patients the easier causality attribution 
is) 
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M: So that would certainly make it easier for assigning causality then is having 
more patients [per centre yeah] per centre. Is there anything else that would 
make assigning causality easier? 
 
S30: Um, well, you can imagine, you have the investigator brochures and you 
have databases from drug companies. But it would, you know, in this modern day 
of computer technology it would be nice to be able to type in, type in a toxicity for 
a particular drug you know, it would have to be obviously a secured database. 
But if drug companies would make available these databases, you could type in 
a toxicity and get an instant idea of how many other patients had this toxicity 
regardless of whether other investigators felt it was associated or not and it might 
give you some idea whether this was an unexpected percentage or an expected 
percentage in a population. [right] So that, that kind of information could be 
helpful. I suppose drug companies could make that available although they may 
be reluctant to do so. [yeah] (feels disconnect with other trial sites) 
 
M: But you do receive those safety letters, the CIOMS reports right. [mmm hmm] 
 
S30: An overwhelming number of them yeah. 
 
M: So in the form that you’re receiving them now it’s not a very useful tool. 
 
S30: Unless you can retain, like I must receive, I don’t know, 30 a week for 
different drugs and you look at them but ah, to know the, you don’t know the 
denominator right. When you find out that Oxaliplatin has caused, I don’t know, 
whatever, some eye problem or something like that, has been reported may be to 
cause some eye problem. Um, how do you know that that’s one in a million or 
one in a hundred or one in ten thousand? Like how many, how many events 
does this represent, is this a pattern, is this just a one-time thing? [yeah] So 
these, this kind of data, those reports are helpful in that you know, it, it twigs your 
memory and imagination and you put it into your database but is it, is it accurate 
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enough to help you with attributions? Not necessarily. [mmm hmm] Obviously if 
important things come up, they are supposed to be put into the, not just come up 
on adverse event reports. But they’re supposed to eventually come in through 
amendments into the consent forms and at least that is a standing record of 
existing reported attributable toxicities. [right] So that’s an important, obviously 
another important source for. [the consent form] The consent form, I mean the 
consent form documents everything that’s been reported as attributable to the 
drug. 
 
M: Are you aware of any decision-making tools to help you in attributing 
causality? 
 
S30: No, and I would be hard pressed to imagine that, well there are in many 
protocols, there are rules for attributions of, of toxicities so I guess those are 
tools. 
 
M: What are the, so they actually 
 
S30: They’ll talk about, yeah, in some protocols they’ll talk about when, when it’s 
to be attributed and not. Can’t say I’ve seen it in a protocol recently but I know I 
have seen it in protocols before, they talk about under what circumstances things 
should be attributable. 
 
M: And is that helpful? [yeah, sure] Is there anything else you can think of that 
would make assigning causality easier? 
 
S30: No [no okay] 
 
M: Do you have any concerns about the way causality is currently being 
assigned? 
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S30: Well again, if you’re only seeing a very small number of patients it’s difficult 
to recognize patterns. Um, and it can go both ways, if you only see a very small 
number of patients you may underestimate or under-relate particular symptoms 
to, to the drug. And the same thing can also happen where if, if you just decide 
that every bad thing that happens to a patient is going to be possibly attributable 
then, then not only do you jeopardize the development of a drug but you also, 
those things all get added to patient consent forms and they muddy the waters 
for patients. Patients should be, shouldn’t be told all of these possible things that 
can happen if indeed most of these things were in fact related to their underlying 
diseases. So I think it’s misinformation for patients as well as for, as well as for 
development of the drug. So it’s, you know, it’s not just a question of patient 
safety, it’s also a question of, of adequately informing patients and not clouding 
their perception of an agent. [okay] (feels patients are ill-informed)  
 
M: What external influences or pressures have you found or felt when assigning 
causality? 
 
S30: Well with smaller drug companies you tend to get more queries about why 
did you assign this as attributed or not attributed? You know, what do you think 
the underlying pathophysiology is? and so you know, smaller drug companies 
particularly when their entire livelihood depends on, on a single agent will, will be, 
will, I don’t know if pressure is the right word but they will definitely discuss 
extensively how and why you’ve chosen that something is related. (feels more 
pressure is felt by smaller drug companies) Typically if I have something that 
I, if I see that there may be a pattern emerging and I’ve started attributing a 
particular event to a drug. I also start doing extra safety checks, or extra 
evaluations of that, or looking more careful in individual or subsequent patients 
that I treat and in that particular patient to see if we can find temporal 
associations etc. So again, seeing several patients can be helpful in, in 
evaluating and identifying um. I have an example of, I saw thrombocytopenia in a 
patient on a new drug and it had not been reported and it was not in the consent 
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form. And on re-challenging the patient I made sure that we checked the platelets 
a little more frequently and indeed it happened again and it happened a third 
time. And we checked it in several of our other patients and it was happening in 
several of our patients so we were able to identify based on volume of patients 
and careful evaluation that ah, that the drug did indeed cause this toxicity. And 
whereas others hadn’t reported it at that point [good for you] so it happens. [okay] 
 
M: I saw you looking at your watch, you’ve got to go. 
 
S30: Well soon. [yeah] 
 
M:  The last thing I would like you to do then is if you wouldn’t mind reading over 
this algorithm. The questions were developed by a researcher named Naranjo. If 
you could just cross out any that you don’t feel are relevant to the early Phase I 
oncology clinical trial setting. 
 
S30: That are not relevant. [no] Are there previous conclusive reports on this 
reaction? Did the adverse event appear after the suspected drug was 
administered? Did the adverse reaction improve when the drug was 
discontinued. Did the adverse reaction reappear when the drug was re-
administered? Are there alternative causes? Did the reaction reappear when a 
placebo? Well we don’t do that [alright cross it out] so cross it out? I mean yes, I 
suppose that would be, that would be interesting information but it’s not 
practically important in a Phase I study. Was the drug detected in the blood in 
concentrations known to be toxic? Well I suppose that would be relevant if one 
had the information. Was the reaction more severe when the dose was 
increased? So dose relationship yes, although we don’t usually know that in 
single patients, although there can be inter-patient dose escalation. Did the 
patient have a similar reaction to the same or similar drugs in any previous 
exposure? That’s, sure. Was the adverse event confirmed by any objective 
evidence? Okay [okay] sure, those all look reasonable to me. 
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M: Okay, now could you rank them in order of importance, so 10 would be most 
important and 1 would be least important. Well I guess you would have 9, so 9 
would be most important and 1 would be least important. 
 
S30: I should say the placebo, this is an issue for Phase III obviously. [mmm 
hmm] Like if you see the same incidence of a toxicity in the placebo arm as you 
do in the treatment arm, that suggests that if anybody was attributed to the drug 
they probably were wrong. Okay, so what are the most important, this is, this is 
just, I don’t think there’s a right or wrong answer here but um. Well I think 
recurrence on re-administration is very important, so that’s a big one. Temporal 
association is pretty key, if it happened beforehand then, I mean these are all 
important. Did the adverse reaction improve when the drug was discontinued, 
that’s also important. That’s less important. Was the reaction more severe, that’s 
somewhat important, previous reports is important, reasonably, alternative 
causes is important. Um, previous similar reaction to the same drug, that’s the 
same thing as it occurred with re-administration, these are both the same, to a 
large extent, the same question. Did the patient have a similar reaction to the 
same or similar drugs? Did the reaction reappear when the drug was re-
administered? This is the same. Was the adverse event confirmed by any 
objective evidence, somewhat important. So the number one, well it had to occur 
after, I think that’s got to be number one, if it occurred before then it was not. 
 
M: Oh, you mean 10 is most important. 
 
S30: Oh, 10 is most important? [yeah] 10 okay. So yeah, sorry I should look at 
your scale here. So yeah, the temporal is key. Recurrence with repeated 
administration is also very important, if you have that information, you don’t 
always have that but if it happens repeatedly after each dose that’s important. Oh 
I can’t write, okay I’ll go to 8 here, and then this will be 7 [beeper goes off]. The 
side effect disappearing obviously that can’t always happen, it depends on what, 
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you know, sometimes side effects can take time to resolve [right] if there’s 
inflammation. So that’s important but, but not as important so I’m going to say 
this is, I’m going to say this is, 6, I don’t know maybe that should be 7. And this is 
going to be 5, this is going to be 4. Yeah, in a Phase I study this is important but 
in a single patient this is less of an issue [what’s that number what?] number 8. 
So number 8 says was the reaction more severe when the dose was increased?, 
a dose response curve is very important but in a single patient you often don’t 
have, you’re not going to be treating a single patient with multiple doses. [right] 
So if you’ve seen 10 patients and you notice that at dose level 4 there is more of 
a particular thing that is very helpful, so it’s not unimportant but it’s. And then this 
would be 2 I guess, was the drug detected in the blood at a toxic level?, that’s 
important, but less important maybe. [alright, great] 
 
M: I know that was a tricky exercise, thank you. It’s a, yeah, it’s tough. What did 
you think of this? Do you think if we were to sort of modify this based on what 
you’ve suggested here based on. 
 
S30: Well this is exactly that you, this is exactly the kind of thing that I’ve seen 
written into, into protocols. You know, just temporal association, dose response, 
you know all of these issues, temporal association, dose response, recurrence 
with re-administration, resolution when the drug is discontinued. These are all, 
these are all things that are important and ah. 
 
M: So do you think that if we were to, you know, do you think this would be a 
helpful tool in assigning causality if we were to [to] encourage people to think 
these things through before they. 
 
S30: Again, there’s, there are many factors here and um, um, and when you’re 
looking at alternative causes, that’s generally where it comes down to an 
uncertainty. It’s not the temporal association it’s not the, it’s not, when you’re 
doing it for the first time like the first cycle with a patient it’s not a question of how 
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many cycles have you given and has it come back repeatedly after? After it’s 
come back repeatedly it becomes a lot less of an issue, you know it’s related. But 
it’s really, when you’re giving a drug to a patient for the first time it’s looking at all 
the existing factors. Um, the patient’s underlying condition, other things that might 
have been causing it and that’s where, that’s where there’s uncertainty as 
whether it should be unlikely or possibly related. So that’s, my guess is that most 
people are familiar with these um sort of rules for causation [yeah] I would guess. 
(assumes everyone follows the same procedures for assigning causality)  
 
M: Well thank you, I really appreciate the time you took to spend with me today, I 
know how busy you are.  
Subject 31 
ntioned even the most experienced clinicians find assigning causality to adverse 
events challenging. But many groups such as industry sponsors, clinical trial 
cooperative groups and research ethics boards they all expect prompt and 
sensible causality assessments. But it’s not always that straightforward and if 
done poorly it can have implications. So we’re interested in developing a tool to 
help in efficiently and reliably assigning causality during Phase I oncology clinical 
trials in particular. And we feel that by better understanding your needs we can 
make this tool more relevant to you. So do you have any questions before we 
start?  [no] Okay, great. So, I guess, I’d just like to start by asking you if you can 
recall a serious adverse event that was fairly easy to attribute the causality to, 
can you think of an example?  
 
S31: Well with chemotherapy, nausea and vomiting are pretty well, you do know 
that is related to chemotherapy. And I think most of us are in the practice of 
reading our protocols and even the patient consent that states that side effects 
that are more likely, less likely and rare. So that if a patient experiences them 
then you, you can either refer back to the protocol or you remember reading that 
yes, that is a side effect of your therapy. Like, for example, taxanes we know that 
peripheral neuropathy, and bony pain or myalgias and arthralgias are, if they 
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start to experience something like that, it is the taxane that is causing that. So I 
guess being familiar with the side effects of the chemotherapy you’re giving is 
really important so that if the patient experiences them you can go back and say 
we know for sure that, that is. Another thing is to establish a baseline with your 
patient, so if they’ve had a back injury and they experience lower back pain 
before they even start chemotherapy. And then they say to you well I have lower 
back pain but it’s the same as it always has been. Well then you say well it’s not 
related to your chemotherapy then because it’s the same pain that was 
happening before. So I think it’s important to know your patients from a baseline 
perspective and asking baseline toxicities that are relevant to your particular 
therapy or your Phase I study tools. So that you know whether or not it’s 
attributed or if the patient had this prior to then you know it would not be related 
so. [mmm hmm] We commonly, or I commonly use the CTCAE version 3, some 
studies I still use version 2. And I like the way those are set up because I can 
keep in my mind when the patient’s explaining the severity, then I can say well 
I’ve had slight nausea on day 3 to day 7 and my appetite was kind of lousy those 
days so I think okay that was a 1 and that was a 1. If it’s nausea you know, where 
I couldn’t eat for a couple of days and you know the severity is increasing 
because of the amount of impact it’s having. So having a grading scale that puts 
into perspective, well it has, it’s present but it’s not affecting their activities of daily 
living or they’re not requiring medication then you know sort of. So those things 
really help because if you get to a grade 3 and you need analgesia or if you get 
to a grade 3 and they’re needing intravenous parental support then oh yeah, 
that’s where they’re at then you know exactly what grade they’re at. If it’s not to 
that point but it’s more severe and affecting their appetite and ability to eat then 
you know it’s a 2. So, ques like that really help [mmm hmm] to put into 
perspective just what grade you’re at. And it’s also important because if you need 
a dose reduction based on a toxicity level then you’re making the right, the right 
assessment. [right] 
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M: Now can you think back to a patient that had an SAE and assigning causality 
wasn’t that straightforward, can you give me an example? 
 
S31: Um, yes, I had a patient who ah, developed a pulmonary embolism and we 
couldn’t say for certain it was the chemotherapy she was on. It could have been 
disease related, it could have been disease progression. There was a number of 
issues but we weren’t clear um, and yeah, we weren’t able to assign. So the 
study gave us the option of probably or possibly and you know, or could be. So 
that’s where we ended up, we weren’t able to definitely say that it was related. 
[mmm hmm] Now they always ask, they always continue to ask for clarification 
after that to try and establish if it definitely is or definitely wasn’t. (pressure 
mainly lie on possible and probable decision outcomes, not so much 
related or not) But um, the patient passed away so we didn’t, we didn’t have 
resolution, except death was our resolution. Sometimes I think that is a way to 
eventually, as it progresses and as it resolves you can sort of maybe after the 
fact like retrospectively say like well yeah it probably was or it was definitely. So 
sometimes there are grey areas and at the time it might be difficult but 
retrospectively by continuing to look at data after the fact then you’re able to um, 
to decide at a later date. 
 
M: So when you say it’s grey, what do you mean exactly? 
 
S31: Well that you’re not, you have your treatment but you’re not sure that this is 
definitely related to their treatment and it may be related to other, like it might be 
disease progression or the nature of the disease. Or maybe the patient becomes 
more inactive because they’re fatigued or anemic from chemotherapy. Like, 
there’s other issues that could cause a pulmonary embolism and it’s not directly a 
side effect of the medication but secondarily to. [mmm hmm] So then it’s, it’s well 
it’s not directly the medication it’s, you know, medication may have caused this, it 
may have caused this and as a result here we are but. So then it’s, you can’t 
really say it’s definitely 
! &'#
 
M: So that patient who experienced a pulmonary embolism was that patient on a 
trial? [yes she was] and was she, what kind of cancer did she have? 
 
S31: She had brain cancer and she had metastatic disease to liver and bone and 
later brain, but she never had pulmonary disease. So that’s, I think you know it’s, 
I mean, I remember speaking to the physician and he said I can’t say this is 
directly related. I mean if the patient received chemotherapy and develops a rash 
with 5 minutes of infusion you know, because that’s tangible that that’s, because 
something is going in and the body is not agreeing. It’s tangible evidence that 
there is a toxicity. But something that is not a direct result but could subsequently 
happen is I think a grey area, and it could probably, it might have been, we don’t 
know for sure. [yeah] So that’s why I say it’s kind of a grey [yeah] a grey area. 
[yeah] (takes comfort in accepting a grey area of causality) But she was on a 
clinical trial and they did request, subsequent to even her, her death, any other 
information that could have been brought forward to help them. And I think it was 
decided at the end that it wasn’t certain what the causality was so. Sometimes I 
think they end up being grey [yeah] there’s no definite causality relation so. 
[yeah] 
 
M: Are you aware of any tools to help you in making that decision a bit easier? 
 
S31: Um, [you mentioned the CTCAE] yeah, but again with that, is it present, or 
is the patient on um, anticoagulant therapy, are they on oxygen therapy? But it 
assigns a grading for toxicity but not causality, so no there really is not. Again, if I 
were to look to my protocol and it was maybe even a rare side effect but it wasn’t 
one of the ones listed. [mmm hmm] So again, we thought well it’s always 
possible this could be the one out of a thousand that experiences this as toxicity 
but um. Yeah it would be difficult to figure out what tool would be, I mean that’s 
sort of a very extreme I think. I think you’re probably looking at more common 
issues to assign causality. So I’m not sure what tool would be handy, I mean 
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because we do have you know, the companies do provide us with the list of 
common side effects but um. [in the protocol?] Yes, and in our investigator 
brochures and product monograph and things like that. So we have some tools in 
place, I mean sometimes it is time consuming to go back and look through 
product monographs, read through pages and pages of very complicated 
information and also chemistry associated with it but. (feels time pressures) 
Um, so maybe simplifying something like that would be useful because it’s, I 
mean, I admit I don’t often read my product monographs and my investigator 
brochures because there’s so much literature in there and I just don’t have time 
to wade through. [yeah] So maybe a more simplified version of something like 
that, this is the drug, this is how it’s been used, these are the common side 
effects. And then you could have a quick reference, oh yeah, this is something 
we see all the time with gemcitabine or whatever the agent is. [yeah, okay] 
 
M: Are there any general guidelines that you follow when you’re assigning 
causality? 
 
S31: Um, again with seeing patients on a particular study and using drugs that 
you’ve um, experienced in the past. Or you know, you’ve spoken to patients in 
the past and they’re all, there are always common side effects that you know are 
common to these drugs. So I guess with experience you know again, if a patient 
is having peripheral neuropathy that it is the taxane, that is one of the issues with 
a taxane. So it’s very, not easy, but it’s almost you know, this is, it’s fairly black 
and white that you know, if you look it up that is a common side effect. As is you 
know, musculoskeletal pain. So the more you hear patients experiencing those 
when you get to the taxane then the more you realize that yeah this is, it is, the 
causality is definitely there. Um, so other than that, I can’t think of a particular 
guideline that, I guess, and again knowing your patient’s baseline, is this 
something new for them? If they haven’t experienced it before and they’re on 
new agents then, then it leads you to believe that the causality probably would be 
the new agents you know. Like I said if they had runny nose and teary eyes prior 
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because of allergies then if they experience them after, then it’s probably not 
your agents that are causing them but it’s probably the patient had a pre-existing 
condition. Then you would know, well it’s probably not the agents that we’re 
using then. So to establish a baseline again but you know, I mean if they had hot 
flashes before and we’re giving them a taxane that’s going to cause them, well 
they had them before [yeah] so you know, maybe not and it’s just them, and their 
condition. [yeah, okay] 
 
M: What would you say are some of the problems or challenges when assigning 
causality? 
 
S31: Um, I think while they are on active treatment it’s much simpler because as 
they are experiencing, as the agents go in and create more side effects it’s easier 
to relate causality. When toxicities linger into the follow-up phase and they go 
onto, for example our breast patients will go onto a hormone. Chemotherapy 
agents will cause for them hot flashes sometimes if they are putting women that 
are close to menopause they will begin to experience symptoms of menopause. 
Then you put them on a hormone which also causes hot flashes and bony pain 
and is it left over from our chemo or is it something attributing to the hormone that 
we are now giving? And when does one end and the other begin? Because we 
haven’t really given a fair amount of time in between. So I find sometimes I can’t 
really say this is chemo anymore. Is it the tamoxifen or gee wiz is this the chemo 
still and we’re adding to that effect with an agent that also causes hot flashes and 
the tamoxifen is also? You know, so that for me is like when do I say ‘no, it’s six 
months and it probably can’t be chemo anymore’? There is no guideline to say 
you know, it should be out of their system at this certain time and if they 
experience these side effects or toxicities, it’s probably, the causality is probably 
something else now because after this length of time it can’t be your 
chemotherapy agents any more if they’ve been on them for say six months or a 
year. Or when is it, when is it finite that we can no longer say, we can no longer 
assign causality? That, that for me is a struggle. 
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M: Yeah, I would say that certainly makes it, and have you had an example for 
me, can you? 
 
S31: Often, often. [yeah] Because these ladies, for example on a study I have 
right now, they have between 3 and 5 weeks to go onto a hormone when they 
finish their last dose of chemotherapy, they’re also receiving radiation. Well all of 
those agents will cause fatigue, radiation can cause fatigue, hormones can cause 
fatigue and chemotherapy agents you know, can cause fatigue. I mean 
secondary to anemia or you know, if their white cells are dropping or for whatever 
reason. [mmm hmm] So when they’re continued to be fatigued post-chemo, 
excuse me, but then you look and see oh they’re receiving radiation treatments 
every day for 5 weeks and no wonder they’re tired. Well which is, where is the 
causality, is it both, is it no longer chemo but now it’s radiation? So often I 
struggle with, with when to say it’s one treatment versus the other that’s, that I 
should assign causality to. [yeah] I don’t know how we would, how we would get 
around that. Maybe there is a guideline you know that says most people at the 
end of this period of time should have metabolized these agents and should no 
longer be experiencing these effects. So causality is probably not, you know, not 
with this agent so look at what else is going on so, maybe something like that 
would be helpful. (they do not feel as through they have adequate resources 
to make the most informed decision they can) 
 
M: Yeah, so like guidelines with respect to [maybe timelines] yeah, elimination of 
the drug. [mmm hmm] Okay. 
 
M: What are your concerns about how causality is currently being assigned? 
 
S31: Well for example when you have three different treatments that could 
possibly, then is it accurate? You’re assigning causality to an agent that may not 
be responsible, it maybe left over chemo toxicity and then you’re saying well 
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perhaps it’s tamoxifen. Maybe it’s not the tamoxifen maybe it’s the fact that the 
patient is coming in every day for 5 weeks to receive radiation and they’re worn 
out from that. [yeah] So you may not be accurately assigning causality in that 
instance. So um, you know when they, I don’t know if it impacts marketing they’re 
having to state that fatigue is an issue when perhaps it’s not. (feels concerned 
about the impact of their attributions) So I wonder about the accuracy of 
assigning causality when there’s multiple agents involved, or multiple therapies 
involved and they may share common toxicities. [mmm hmm] 
 
M: So you said you worry about the marketing, what do you mean? 
 
S31: Well I, you know if they’re looking at patients in long term and saying, well 
you can have fatigue for up to 2 years after chemotherapy. So when they put out 
the, the common um, toxicities, less common and rare, would that be in there? 
Because a lot of these women are experiencing these toxicities. But yet, causality 
may not be, may not have been an issue with the particular agent but it’s there, 
we said well yes they’re still having, this um, toxicity and perhaps it’s this agent. 
So you’re assigning causation when maybe it’s not it may be something else. So 
as a company I think they’re obligated to list that as a part of their um, their 
package. Maybe not, maybe they don’t take into account certain timeframes. 
(disconnect from company sponsors) Maybe they have a tool. [laughter] 
 
M: Okay, do you have any other concerns, about how it’s being assigned? 
 
S31: Um, I think with experience you get better at knowing what regimes and 
what therapies cause, what are common to certain things so that you’re more 
comfortable saying you know, if you’re on this chemotherapy and you’re having 
nausea and vomiting we’re pretty certain it’s the chemotherapy. So you get more 
confident saying yes, it’s definitely related. Um, there are still some grey areas 
where I say well it could possibly be, I’m not really sure but I’m saying it’s 
possible. So I guess, yeah, that comes with experience and you know, talking to 
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patients, doing our interviews with them through each cycle and, and you get 
more comfortable saying to them you know, ‘don’t worry you’re not falling apart, 
that’s your chemotherapy that’s causing all that, so once you’re done it will get 
better. And yes that is what’s causing you to feel this way now but you know, 
later on it will subside as you excrete all that agent’. So use your confidence to 
reassure your patients that it is, the cause is there now but it will. So that’s 
experience I guess as I get you know, better at it. [right] I definitely, when I was 
new, definitely it was a struggle to decide but again I know now if I know my 
patient’s baseline and I know what’s common to this regime then I can safely say 
this, this is probably, not probably. (a get a sense that they have a strong 
connection with their patients, they care deeply about their safety and 
outcome of the trial) This is your chemo, remember you said you had a back 
problem prior to chemo?, so it’s probably your back. Because we’re making you 
lie for five hours to receive your treatment and you know, that type of thing so. 
[yeah] 
 
M: Now you said you’ve been here for a year in this position. [yeah, a year in 
April] How did you learn how to assign causality at the start? You said it was 
pretty hard, did you have any training? 
 
S31: No. [no] 
 
M: So how did you figure it out? 
 
S31: Well we have our tools, the CTCAE, versions 2 and 3. Again, making sure 
that, I would look back and know my patient’s baseline. Reading the protocol and 
the patient consent that the patient gets that explains what are common 
toxicities. And you know, referring back to that, you  know, certain things they are 
experiencing are definitely related and the cause is definitely this regime. [mmm 
hmm] So using the tools, so yes if we had more tools it definitely would make life 
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easier. (feels tools would be beneficial) Um, I guess with this job, a lot of it is 
just on the job training, you learn as you go. [okay] 
 
M: A lot of people have said that, that there really isn’t much training out there 
and that’s kind of surprising. [it’s scary isn’t it?] What additional education about 
assigning causality do you feel needs to be made available? Because you’re 
fairly new to this [yeah] so can you think about what might have helped you a 
year ago when you were starting? 
 
S31: Um, I don’t know, I mean, a lot of the agents we give, even in breast, there 
are so many different agents and so many, I mean they do have their unique 
issues that are definitely a cause of their, their regime. So um, I mean right now 
we go to in-services whenever we can, that the drug companies often, they will 
offer them and we go and they talk about their new, their new therapies and 
what. They’ll talk about what they’re designed to do and what the side effects 
are. So that when you get involved with a lot of these new therapies you 
remember what the sort of common issues are so that you can assign causality. 
(can feel deeply involved with agents) 
 
M: Do you mean like the investigator meetings? 
 
S31: Yes and in-services that companies come to and they will talk about specific 
agents. Like we have a lot of that on um, anemia and talking about what anemia 
is, chemotherapy induced anemia, when to treat it, what sort of are common um, 
issues with anemia. And then the drugs we can use and what the side effects of 
those are. So it’s like a package and you have all your information with 
everything involved so going to those has helped. But um, I’m, I’m not really sure, 
I mean what? 
 
M: Do you think, I guess, you know, others have said maybe sort of a workshop 
or um. 
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S31: But do you do a general presentation as to 
 
M: Well, what would you like? If you had your, if it was up to you [mmm hmm] 
what would work best for you just starting out? 
 
S31: I guess, I guess it would have to be general initially because after that you 
do work with specific agents and but is it, you’re talking specifically about not 
what the toxicities are but how you decide whether or not it’s your agent [yeah] 
that’s related or if it’s not. [mmm hmm] So yeah, a general workshop that would 
definitely say here’s some of the tips that may help you to decide, you know, 
remember to use the criteria or guidelines that are associated with your protocol 
to help you to decide whether or not these are. And how to grade them because 
that’s always important. Um, yeah actually it would have been very helpful to 
have a workshop. And then probably hands on, like you’re given an exercise 
where you have, and you know, we’ve done that before and those really help. 
You know, you have a scenario and you’re given a worksheet and you have to 
decide you know, how do you, is this related or is this not related? [yeah] Yeah, 
definitely, that probably would have been, even just to, because it would be 
general, even just to be an eye opener or even just um, open the mind to this is 
what you’re getting into and this is what you’re going to have to do and you will 
have to decide, you know, to assign causality and to grade it and yeah, yeah it 
would have been helpful. [laughter] [okay, great] 
 
M: One of the things that, oh I know what I wanted to ask you, have you ever felt 
any external influences or pressures from third parties when assigning causality? 
 
S31: No, I can’t say I have. Often I will confer with the physician because we 
interview the patients and then the physicians interview the patients. Um, 
sometimes I, I really prefer when we do it together because we both hear the 
same story. (feels there are benefits to assigning causality as a team) And 
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sometimes the patients will tell the physicians one version and then we’ll get 
either a more detailed or a less detailed. Or there will be some components 
missing. But often if I am not sure I will go to the physician and say did she tell 
you about that um, um, back pain that she had and she had to take Tylenol #3 
before she had some relief? And what do you think? Do you think it’s related or 
um? Actually I had a situation recently where a patient received Eprex and yet I 
was certain it was the agent, it was the first time that she received the 
gemcitabine. And one of the common side effects of gemcitabine is a rash, and 
she developed a rash, a grade 3 rash which is quite severe. And um, um, there 
were two physicians involved, one that had seen her with the physician being 
away and then he came back and saw her. And he admitted to me that he 
believed it was the gemcitabine but she, the initial physician thought it was the 
Eprex because it was the first time for both agents. [right] So they stopped the 
Eprex even though the patient was anemic and did not offer any other support. 
And um, just added other agents to help buffer the effects from the gemcitabine 
and the patient did not have any further rashes but sort of had to continue with an 
anemia that was you know, causing her some,  some issues with her quality of 
life. [right] It would have been nice if we could have established causality 
unanimously but. [yeah] (further exemplifies the need for a standardized 
approach) So I say going to the physician but if there is more than one involved 
there can be more than one opinion. [yes, okay] But generally getting a 
consensus is helpful if you can go to your physicians and they often are very 
good at saying well. Even when I don’t think it is, they’ll say no I think it was you 
know, the agent that caused this, this is definitely associated and yes we’ll say 
it’s, we’ll assign causality to that. So I don’t try to decide on my own, if I’m not 
sure I will go and ask [yeah] for other input and then we’ll try to make a decision. 
And then we’ll all have the same version, the same story. [yeah] 
 
M:  What I’d like to do now, I’d just like to ask you if you wouldn’t mind reading 
over the following questions. This was an algorithm that was designed by a 
researcher named Nar, Naranjo. Sorry getting all tongue-tied. If you could cross 
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out any questions that you feel are not relevant to the Phase I oncology clinical 
trial setting [mmm hmm] we can start with that, that would be great. [okay] 
 
S31: I don’t know, I haven’t done Phase I [okay] so I’m not that familiar or 
comfortable with Phase I, but I um, from reading I think that Phase I is to 
establish reactions in the patient that has been used in a clinical setting and they 
want to see how patients react. [yes, yeah] Okay 
 
M: Primarily to look at the safety of the drug. [okay] 
 
S31: Okay, so there probably wouldn’t have been previous conclusive report on a 
reaction. So just cross them out. [yeah] Did it appear after the suspected drug 
was administered? I think all of these would be important [okay] except for I don’t 
know how much previous. Although this is something I use a lot is looking back 
and see what’s previously stated. [yeah] But in Phase I you probably wouldn’t 
have a lot of [yeah] conclusive reports. 
 
M: Yeah, you would have an IB but it probably wouldn’t be as comprehensive as 
say in a Phase III trial. [mmm hmm] So now with the remaining ones could you 
just rank them in order of importance? So you know, 10 would be most important 
[okay] and 1 would be, well I guess you could start from 10 and work your way 
down. [so just number them] Yeah, you could just write beside them [oh on here] 
yeah, just whatever rank you want to give them. 
 
S31: Was the adverse event confirmed by any objective evidence? [is that 
confusing?] Well objective, are we able to tell, I mean is it objective, I mean when 
a patient tells you it’s, hmm. Okay, I don’t know. 
 
M: It’s a difficult exercise, but I guess we just want to get a sense of you know 
what people feel are the most important issues [okay] most important factors 
when attributing causality, in assigning causality. So least important was, was the 
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drug detected in the blood in concentrations known to be toxic, why did you rate 
that one so low? 
 
S31: I don’t know, it was just sort of from what numbers I had left to assign 
[laughter] I did find it difficult. I mean every one of those would be really important 
issues. If I could I would probably give them all a 10. So I found that even 
something that’s a 2, well I think that could be a 10 if you look at well, is there 
something else that you could assign causality to, that would probably be quite 
high. And again, if you did blood work and saw that maybe the dose you are 
giving is too high and if you lower the dose it would still be effective but not have 
as much side effect, that could also be a 10. So I found it difficult, so it was 
basically what numbers do I have left to assign. [yeah] They would probably all 
be, if I could I would give, they would all be important. [okay, good] 
 
M: What did you think of this as a tool if we were to you know, if we were to 
remove this question and weight them accordingly and then somehow link that to 
a causality assessment. Do you think that would be useful? 
 
S31: I think if you were to say are any of these, do you think any of these are 
important in how you would determine causality or assign causality? Then I 
would have replied yes, I think they’re all, you know, maybe some more so than 
others but assigning a 1 or 2 means well maybe it’s not that important when 
probably it would be. 
 
M: Okay, but let’s say we design a tool and you know, you have to answer these 
questions with yes or no and at the end it produces a score [mmm hmm] and 
then based on that score you would know yeah, we’ll assign it a possible or a 
probable [mmm hmm] or a definitely or what have you. Do you think that’s a tool 
that you might use? 
 
S31: Mmm hmm. 
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M: What sort of, what other features would it need to so that it would be useful to 
you? Is it too long, is it too time consuming, takes too much brainpower, is it 
something that you do anyway and it’s not useful? 
 
S31: Um, I don’t think it’s time consuming, I think any tool that you have that 
helps you to establish causality or not would be useful. (time seems to be a 
large barrier) So I don’t, I wouldn’t consider the time factor, I don’t think, you 
know, something like this is definitely not time consuming. It would probably be 
best to spend an extra few minutes doing this to help you if you found it would 
than to not do it at all. Because then, like I said, later on you are trying to 
retrospectively figure out was it or was it not. So if we could determine it sooner 
with a tool then I think it would be worth the time. So time wouldn’t be an issue for 
me. Um, I don’t think it uses brainpower, if it’s a tool that’s assisting you then it 
wouldn’t be using brainpower, in fact it’s helping you relieve that stress. [laughter] 
And what was the other issue you were saying? 
 
M: Oh, I was just wanting to know how we could make this useful and practical 
for you in your work, in your everyday working environment. Is it best on paper or 
on a computer or? 
 
S31: Um, I like paper because you can pick it up and refer to it without having to 
log in and find the site and you know, bring it up on your screen and, and then 
you know. [yeah] So I like a tool on paper, it’s tangible, it’s quick [yeah] probably 
less time consuming than trying to search for it. [yeah] 
 
M: Okay, good, thanks for doing that. [okay] Let me just see, I think that’s, I think 
those are all the questions actually that I have for you. [okay] Do you have any 
final comments or questions you’d like to ask me? [no] Okay, great. Well thank 
you very much, I really appreciate this time, I know how busy you guys are. 
Subject 32 
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M: As I mentioned we’re interested in how causality is assigned to adverse 
events [mmm hmm] serious adverse events in early phase clinical trials. [right] 
Even the most experienced find assigning causality challenging. [mmm hmm] 
And many groups such as industry sponsors, clinical trial cooperative groups and 
research ethics boards they all expect prompt and sensible causality 
assessments. [mmm hmm] But as you know, it’s not always that straightforward 
and if done poorly there are some implications. [mmm hmm] So we’re interested 
in developing a tool to help efficiently and reliably assign causality [okay] and as I 
mentioned earlier, we feel that by better understanding your needs we can help 
make this tool more relevant to you. [okay] So do you have any questions before 
we start?  [no] Okay. So first of all, I’d just like to ask you if you can recall recently 
a serious adverse event that happened with one of your patients that was pretty 
straightforward in terms of assigning causality [okay] can you think of an 
example?  
 
S32: I just had two, febrile neutropenia which is pretty common in our 
 
M: So what patient, the patient was on a trial? 
 
S32: She was on a clinical, both of them were on a clinical trial yeah, with 
docetaxel and then the clinical trial study drug. 
 
M: Okay so it was a combination of docetaxel plus [Avastin] okay yeah. And um, 
that patient experienced febrile neutropenia 
 
S32: Both were admitted to hospital with febrile neutropenia. [okay] 
 
M: And how did you assign causality in that case? 
 
S32: Well for me it’s the principal investigator that assigns the causality. But we 
just know that one of the toxicities of docetaxel is um, low counts and fatigue and 
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you know, just by knowing the toxicities of the specific chemo we could relate it 
probably to the docetaxel, but not 100%. [okay] Because the Avastin may be a 
factor in that, so it was primarily docetaxel and then a question of whether or not 
it might be the Avastin as well. [okay] 
 
M: But for the most part that was pretty straightforward? 
 
S32: Yeah, for me because I’ve dealt with docetaxel quite a bit so I know a lot of 
the toxicities and we see that frequently. (experience is key) Not always to the 
point that they’re hospitalized, their counts, their neuts fall sometimes to zero, so 
obviously they’re open to infection and that’s usually what lands them with a fever 
and then in the hospital. But um, yeah, docetaxel is one that I know is going to 
cause that in most patients to some degree. [yeah] So that’s how I know that, to 
assign that causality to it. [okay] When you’re using a drug like Avastin or 
something that’s new they do have their list of toxicities that come with that 
specific drug so you can kind of correlate it and look at it and say well it’s not 
really a toxicity that they specify. It might be a minute percentage that get it but 
um, so we don’t, we don’t say 100% that it’s the docetaxel, we have to sort of 
look at possibly the Avastin or the combination of the two. I don’t know if that 
helps at all. [yeah] 
 
M: Okay, can you give me an example of a serious adverse event that has 
occurred and it maybe wasn’t as easy to attribute causality. 
 
S32: Oh God, let me think, yeah we had one last year, what was she admitted 
for? God I can’t remember now. I’m trying to remember what she was specifically 
admitted for, I think it was more depression. And um, what did they classified it 
as? depression and, I don’t know what the terminology was but she was 
hospitalized for a few days, she just couldn’t cope anymore. And I think it was, 
she obviously, a lot of it was due to the stress, having cancer and being fairly 
young and having kids at home. So we couldn’t really attribute it to a study 
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medication. Um, I spoke to the doctor, the PI that was working with me on that 
trial and I said would you specifically think that that was a reaction from a study 
drug? and he said no. So I mean, I kind of rely on the investigator to know where 
the symptoms are coming from and if they could be attributed to a certain 
medication they’re on. So I really rely on their expertise to know whether or not 
it’s something I can relate to the study drug. I wish I could remember specifically 
what it was that they admitted her with. [that’s okay, close enough] Fatigue or 
something like that, depression, she wasn’t in very long. [okay] 
 
M: So in that case it was a bit challenging because you weren’t sure if it was due 
to um, just the normal stress of having a [cancer yeah] cancer diagnosis. 
 
S32: Sometimes it’s not black and white because it could be a number of factors. 
(grey area again) And when you factor in the fact that they’re on chemotherapy 
and they’re on study medication, and they’re on pre-medication for you know, 
nausea, vomiting, whatever, they’re on growth factors, they’re on Tylenol for pain. 
So sometimes it’s hard to attribute it to exactly one specific thing. You kind of 
have to say it could be a combination of their con-meds and their study 
medication and the chemo, so it’s harder to give a causality. So usually a lot of 
times we just, we have to answer unknown because we’re not, we can’t specify 
exactly, possibly, could be related you know. And our CTO assessment sheets 
that we use um, we always like to relate the toxicity to the specific study drug that 
we’re using. So I think we have a few options, one being likely, um, possible and 
then unrelated and unknown. So you kind of have a few things you can pick from. 
[mmm hmm] That helps us to be able to sort of look at it and say okay, she didn’t 
have this at the last cycle, but she has it at this cycle, and is she still on it and 
how long? And then you can sort of get a pattern, if you have quite a few people 
on that same study you can see that maybe by cycle III they’re all starting to have 
more fatigue. Or they’re starting to have you know, changes in their fingernails, 
so you can see a pattern emerging. 
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M: Right as you have more patients enrolled you see a pattern happening. 
 
S32: Yeah, well yeah, with the sheets that we have we can sort of look back and 
quickly say oh yeah, all of these patients seem to be doing this around the same 
time. So that sometimes helps assign causality. (uses the term quickly 
suggests there is not a lot of time available to make these decisions) 
 
M: So this is sort of a baseline assessment, or it’s a an assessment page that 
you use for. 
 
S32: Yeah, we do a baseline assessment page and then we do, they’re called 
clinical trial observation, so they’re just sheets that we use that have all the 
toxicities. So each time we see a patient we review all of their toxicities since the 
last time they came in. [mmm hmm] 
 
M: Are there any other tools that you use when assigning causality? 
 
S32: Um, well of course you’re using your protocol, so each protocol is going to 
give you a list of um, possible side effects for each drug that they’re on. So that’s 
a tool that we always use, you kind of refer back to the protocol, like is this a side 
effect that we’re going to see with Avastin? Yeah, the protocol is huge, it really 
gives us, it’s sort of our bible to work from when we start because that will give us 
an idea of what we’re, what to expect. You know they may say that a certain 
percentage of patients on drug x are going to experience bleeding or gum 
soreness or. So we know right away if we see a patient we can say yeah that’s, 
we’re pretty sure that’s related to the study medication because that’s a side 
effect that they’ve noted in the protocol. [okay] 
 
M: Are you aware of any other decision-making tools in helping you assign 
causality? 
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S32: Not that I know of. [okay] (not aware of the tools that exist) 
 
M: What would you say are some of the challenges with assigning causality? 
 
S32: Well I think I mentioned it before, you’re going to get some toxicities that 
kind of overflow into you know, it could be a couple of different categories. It 
could be your study medication as well as your, your chemotherapy. So you’re 
getting, I don’t know, something like, I don’t know, say neuropathy of the hands 
and feet, well they’re, there’s different drugs that will cause that. We know 
docetaxel will cause that, but then you’ll get a study drug that may have that 
same adverse effect. So trying to directly relate causality to that sometimes is 
difficult when you know that it could be experienced in two, two different, or three 
different medications. [yeah, okay] (so many confounded variables really 
impedes decision making confidence) 
 
M: Any other challenges that you’ve encountered? 
 
S32: In causality [yeah, assigning causality] well I mean, I think, I find it difficult 
because I don’t, I mean I have a bit of a medical background but I’m not a doctor 
so I don’t know. When somebody comes in with something that’s not common, 
you know, how do you rate that. If it’s not on the list in the protocol and it’s 
something you haven’t experienced, sometimes that’s difficult [mmm hmm] to 
make that judgment. Is this just a specific case with that patient or is it possible 
that it’s a reaction or a side effect or toxicity of the medication? So that’s 
sometimes is hard, something that you don’t see frequently, how to grade that or 
you know, the causality of that sometimes is difficult for, for somebody who is not 
a doctor to pick that up and say this is definitely, and we don’t really have a tool 
for that because there’s nothing that you can really refer to. You have your 
protocol and you know, you have your list of side effects from the chemo drug so 
you kind of go by that and if you don’t see it in there, it’s hard to grade it, like 
where do you put that? you’re not quite sure you know. [yeah] So unless it’s in 
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your protocol it’s hard to find out where that comes from. [yeah, okay] (protocol 
is a commonly used and heavily waited resource when assigning causality) 
 
M: What do you do in that case? 
 
S32: Go to the PI, you go to the principal investigator and say, you know, do you 
relate this to the study medication? And they’re good to tell us whether or not it’s 
related. 
 
M:  Do you have any concerns about how causality is being assigned? 
 
S32: I wouldn’t say I have any concerns about it really, I mean, it’s pretty 
straightforward, I mean if you don’t know where the causality is coming from you, 
you go to your PI. Because ultimately they’re the responsible person and they’re 
the ones that should be able to tell you that it’s either related or not related or 
where, what the causality is so. [mmm hmm] I count on them. 
 
M: Do you have any concerns about their causality assessments? 
 
S32: Sometimes. We have to, I mean you have to be able to trust them, 
hopefully, they’re taking on the study, they’re responsible for it. I mean you can 
go to the sponsor and actually I do that a lot too, you know. Just call up the 
sponsor company and say, you know, I’m kind of stuck here, I’m not sure if this 
is, you know, could this be a toxicity of your study drug, do you think there’s a 
possibility. And we’ve done that too where you know, you’ll just email them or call 
them. [okay] And they have a pretty, I mean they have a very broad knowledge of 
the drug that they’re putting out there and what they’ve seen. And of course 
they’re getting data from everywhere so they should be able to tell us you know, 
if that’s something they’ve seen before. [okay, good] 
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M: What external influences or pressures from third parties have you felt when 
assigning causality? 
 
S32: Hmm, not too much. Sometimes you’ll have a patient on a study where the 
oncologist would like them off and for whatever specific reason or on, you know, 
they maybe say that ah, it’s not a cause of the study medication. Where you’re 
kind of thinking oh I don’t know, I’ve seen this a few times and it seems pretty 
clear to me. But they’re sort of saying ‘no it’s not a cause’. So I mean to say 
there’s never been an issue around that. 
 
M: And that’s from the physician? 
 
S32: Yeah, because they want to, sometimes they will part the sea to keep their 
patients on the study. [really?] Sometimes. [why do you think that is?] I don’t 
know, because obviously when they’re affiliated with a study and if the study is 
doing well, they want to you know, have their name affiliated with that study and 
the more patients they have on the better it looks for them and our site too so. 
(feels some physicians are biased, may be more focused on the appraisal 
of marketing a drug, then true concern for the patient-however there are 
severe consequences) But I think they’re all pretty good at, I mean we have to 
report all SAEs there’s no way around that, you have to do that, we report it to 
our ethics and our report goes out to the sponsor so. If it’s something that’s 
causing the patient to be hospitalized or it’s harming the patient there’s no way 
around it. But I don’t think, I have never personally had any major issues over 
that. [okay] 
 
M: So from your perspective then what would make assigning causality easier? 
 
S32: I guess, I don’t know, that’s a good question, what would make it easier. I 
mean obviously a book that said all the possibilities of side effects and, and then 
how to relate them. Like yes this is related to drug x or this is related to chemo 
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whatever. It would be nice to have a tool that told you directly whether there was 
a possibility of causality. Maybe the Internet tells us that I don’t know, I don’t have 
time to run back up every time. But yeah, it would be nice to have some kind of 
manual that said you know, this side effect is the causality of from whatever. It’s 
not possible though. 
 
M: That might be asking a little much. What I’d like to do now is I’d just like to ask 
you to do a little exercise for me. This was an algorithm that was designed by a 
researcher [mmm] to help in assigning causality. Our thought is that if we can 
modify this a little bit to suit our needs for the early Phase oncology clinical trials 
study that that might help make things a little easier in terms of thinking it 
through. So I’m just wondering if you wouldn’t mind reading over those 10 
questions and crossing out any that you do not feel are not relevant to the 
oncology, early Phase oncology clinical trial setting. 
 
S32:  I don’t quite understand this one, was the drug detected in the blood or 
other fluids in concentrations known to be toxic? [mmm hmm, what’s confusing 
about that one?] You’re talking about the study drug I’m assuming. [yes, yes] So 
was the study drug detected in the blood in concentrations known to be toxic? [is 
that something you would normally have or?] No because I mean you wouldn’t 
administer a level of drug that would be toxic for one, I would hope. [yeah, well I 
guess] If it was known to be toxic, I don’t, that question is just confusing for me so 
maybe it’s just me. [cross it out then, go for it] 
 
M: Okay [you want these ranked] Yeah, so now if you could just rank the 
remaining ones in order of importance, so which ones do you think are most 
important. So most important would be 10 and you could just kind of work your 
way down from there I guess. 
 
M: Okay, great, thanks. Most important was did the adverse event appear after 
the suspected drug was administered, that makes sense [mmm hmm] that’s 
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pretty important yeah. Did the reaction improve when the drug was discontinued, 
good yeah. Um, there are no right or wrong answers here, it’s just interesting to 
see what people have done and we’re going to try and summarize it all. Least 
important, was the reaction more severe when the dose was increased, or less 
severe when the dose was decreased, why did you rank that so low? 
 
S32: Well to me if you answer these questions that automatically is answered. 
[okay] And the severity is very hard to rate in some cases because if you we’re 
some things are, like if you’re grading something that has a value to it, you can 
easily assign severity to it. But when it’s subjective, like how a patient is feeling or 
how sore their mouth is or you know, how much pain they might be experiencing, 
it’s all very subjective to each patient. So severe to one person might be you 
know, moderate to another. So those kinds of things I find, unless you can assign 
a number value to it I find that hard to grade. Because some things are very 
subjective, pain, those things are, in my, I find personally hard to grade. [okay] 
 
M: That’s actually a really good point yeah, okay. So what did you think about 
this, so if we were to, never mind the fact they are ranked now. But if we were to 
give this to you as a tool to think about when you’re assigning causality do you 
think that would be useful. 
 
S32: It would be useful, I would like it smaller, I don’t want to have too big a form 
to have to peruse to go through it to figure out. It should have you know, a few 
very pertinent points that should get you right to the causality of it. One of them 
being, did it start after the drug was administered? When you stopped the drug 
did the reaction go away? Like very specific questions that don’t get too wordy 
and don’t try to get into too much of the detail right away that can give you an 
idea of how you’re going to assign the causality. (simplicity is key) I wouldn’t 
want that many points on it I think [yeah] I think I would want less [fewer] yeah. A 
lot of those are sort of repetitive, but just in a different way. 
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M: Yeah, they overlap a bit yeah, a lot of people have said that. Okay, great. 
 
M: And then lastly I would just like to ask you a little bit about the training that 
you’ve received. [mmm hmm] So um, can you tell me about how you learned how 
to assign causality to adverse events, what kind of training did you have? 
 
S32: There’s no formal training really, you just kind of got thrown into the 
position. I mean, the training is really on the job training. It’s the more patients 
you see, the more that you start to understand that there’s going to be certain 
side effects and toxicities that you’re going to see in cancer patients. And then 
you start seeing them specific to a specific drug and you  just, it’s really learn as 
you go. [and what about yeah, yeah] Training, specific training comes with each 
new study that we open. So when you open up a new clinical trial you attend 
investigator meetings where they explain everything you know. How, what drug, 
this is the drug we’re using, this is how the drug works, this is how the drug is you 
know, produced, this is how it’s going to work in the body, this is what we’re 
hoping it’s going to you know, achieve. So you learn all that from the sponsor that 
is opening the study. So a lot of what you’re going to be taking back is stuff that 
you learn from them. 
 
M: And do you usually learn how to assign causality at those investigator 
meetings? 
 
S32: Yeah, they do, they talk about how you’re going to report adverse events 
and what to look for. They usually have a book, we usually have a book that lists 
adverse events. Possible side effects and then it’ll have you know, the very, the 
common ones, the not so common, the almost never seen, highly unlikely, so 
they’re sort of 
 
M: Is that something separate from the IB or? 
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S32: It’s in the, each specific protocol. The investigator brochure has that too but 
the protocol will have it in it. And it’s usually, when we give patient’s consent it will 
also be in there. We’ll have categories that will say these are the side effects that 
you might experience or are likely to experience. And then it sort of goes down 
the list and it breaks it to likely, less likely, highly unlikely you know [mmm hmm] 
so they know what to look for. So that’s a good tool for us if we want to quickly, 
you know if you get called down and it’s not your study and you know, well the 
doctor is saying well this patient and it’s not a study you’ve done. You can quickly 
look at the, the protocol and say, oh yeah, it’s, it’s you know it’s in there but, so 
that will give you a quick idea. [right] If you don’t know the study very well or if 
you’re not sure which drug they’re using. 
 
M: So those investigator meetings are pretty, pretty important. 
 
S32: For us they are, I mean, that’s what 
 
M: Do you get to go to them or is it usually the PI? 
 
S32: No we do, the study coordinator goes and the PI, because we’re 
coordinating the whole study and we’re the ones that usually are telling the PIs 
the stuff you need to look for, they come to us. So I think it’s really important that 
CRAs go to that because we’re the ones coordinating the study, we know that 
study inside and out. We know what patients are eligible, what makes them not 
eligible. You know, there are points were we need to go to the PI and say you 
know, we need to stop this patient because we’re seeing this or. So yeah, it’s 
really important, it’s huge. [yeah] 
 
M: What additional education about assigning causality do you feel needs to be 
made available? 
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S32: Um, be nice if the site would give you that kind of training, but it would be 
really hard to do I think because we all have different studies that are all, mind 
you, each area seems to see the same. (feels education on assigning 
causality would create greater consistency between professionals) I mean if 
you’re working in lung, or if you’re working with GI or whatever, you tend to see 
the same drugs over and over again. [yeah] So you know a lot of the causality 
just from you know, repetition. But if you kind of, you know, as a, as a breast 
study coordinator for the breast site, I don’t see a lot of the drugs they use say in 
GI. [yeah] So when I get a GI drug I really, I don’t know how to assign causality to 
something. So, it would be helpful if the site did on site training [what do you 
mean the site, your] our site here. Like our clinical trials office if they had, I don’t 
know, one or two days a year, like a workshop that helped with that. I don’t even 
know if it would be possible. [I think anything is possible] Yeah well. 
 
M: So like a one-day workshop you think would work well? 
 
S32: Yeah something like that. 
 
M: What would be included in the workshop if you could have, if you could design 
it yourself what would you do? 
 
S32: Well I mean, obviously it would be nice to have um, you know the scientists 
or the doctors that work with these and have, you know, the ones that come up 
with these study drugs and know what causalities may come up. Or what 
toxicities may come up and what causes them. And it would be nice for us to 
learn what actually causes them, like what’s actually happening when a patient is 
having this type of side effect. Like what’s going on with the body and how it’s 
reacting with the specific drug that could be causing that causality. [yeah, okay] I 
don’t know [yeah that’s good] (a more biological approach to understand 
toxicities could aid in causality assessment) 
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M: I think that’s all the questions that I have then, do you have any final thoughts 
or comments or questions? 
 
S32: No, sorry it’s after 2:00. 
 
M: I know, it’s getting on in the afternoon and people are tired. Well thank you 
very much.  
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Appendix 10: Themes 
Theme 1: Coping with Uncertainty 
Definition: These professionals use a variety of methods to cope with the 
uncertainty of causality attribution. 
Subthemes: 
! Consider protocol drug 
! Consider other drugs 
! Cognitive Approach of considering all variables 
! Take comfort in recognizing grey area 
! Temporal association 
! Erring on the side of caution 
! Rely on their experience 
Quotations: 
! Certainty is very difficult to achieve- S01 
! I think that the probable, possible, etc scale is better, it just gives more 
room for interpretation of the interpretation.- S01 
! Yeah and yes and no is desperately frustrating sometimes because things 
are grey like, you know, if it’s unlikely but it’s still possible then saying you 
know, is that yes or no because that’s hard.- S01 
! There is a lot of background noise in side effects, what side effects may be 
caused by other drugs, disease.- S01 
! But we’re still stuck with you know, these vague situations with the 
problems we’ve discussed and I don’t, it’s not clear.- S01 
! Most of it is kind of intuitive you know, so I’m not sure.- S01 
! Um, sometimes it’s grey, you know, maybe could be and that’s the 
difficulty.-  S03 
! And I think a lot, a lot of that has to do with you know, how do you make 
the decision, it’s difficult sometimes, sometimes it’s pretty straight forward 
that they’re experiencing an adverse event that is know to occur with the 
study medication.- S04 
! I think yes or no becomes very hard and we’re not always sure you know. 
And there’s always that element of doubt about it. But I think you have to 
be able to say how strong or weak your doubt is and when you have the 
graded scale it just gives you some flexibility to do that.- S05 
! That is a challenge in that typically when patients go in to clinical Phase 1 
trials they have advanced, often refractory cancers and ah, needless to 
say, significant ah, medical problems at the beginning and throughout the 
clinical trial.- S06 
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! I think it’s better to maintain a sort of a graded scale because I don’t think 
one can be that definitive. With the number of resources you have, it’s only 
a matter of being able to document and have there as a possibility.- S06 
! Problems, first of all you’re never definite, definite, hindsight’s always 
20/20, so looking back a few months later you can sometimes get a more 
clearer picture of what, like analyze the situation a little bit more.  
Sometimes when you’re right in the situation and you have to, you have 
that responsibility of assigning it right then and there, you don’t have all 
the information right? You don’t know how it’s going to end, you don’t 
know, um, if, if, why it happened or anything. You can analyze the 
situation after it occurred and everything has evolved then it’s sometimes 
easier to go back and go well this and this happened we can do that. So 
assigning causality sometimes at the time is sometimes clear cut and 
sometimes very difficult.- S07  
! Oh, who knows, whenever you get an algorithm it’s always like the 
yes/no’s sorts of things and sometimes there’s a grey in-between. So 
sometimes you have to kind of think differently.- S07 
! You always look at, I mean there are always so many other confounding 
variables in this population, especially if their disease is starting to get a bit 
worse.  They go on other medication, right which can impact, you don’t 
know what these newer agents do with any of the other medications that 
are out there. There are just so many variables that can [yeah] affect,  
drug-drug interaction you know and drug-disease interaction, drug-foods. I 
always make a point of asking patients are they on any over the counter or 
complimentary therapies because they may not think, well I’m not taking 
any medication but they’re on all these herbal or [yeah] just lots [lots of 
unknowns right?].- S09 
! I like the scale because yes/no is pretty black and white and often there 
are many scenarios where you’re just not sure.- S10 
! Often these patients are just, have such complicated histories, you know, 
they’re prone to other medical problems.- S10 
! The challenges are particularly in Phase I trials these are, these, they all 
have their advanced disease, they often all have been through numerous 
other treatments, some of them have been heavily pretreated. Many of 
them are not of the greatest performance status and so they have a lot of 
other co morbidities or symptoms that can merge and        play a role. 
Sometimes these brand new drugs we really don’t know. We don’t have a 
lot of information, that’s why we do the Phase Is. And how much weight 
we put on what is seen or not seen in dogs or monkeys or whichever 
animal work they have done it on, large animal work done, kind of you 
know, there’s not a lot of data there, so in the end if you don’t have a lot of 
data to work with and you have patients, it does become very hard.- S13 
! Yeah, [yeah] yeah I think so. [okay why?] Well because there’s a, it may 
help you sometimes in the dilemma where you in this grey zone of serious 
adverse event where you think about what to, what to assign to this SAE. 
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If you have a clearly unrelated or clearly related SAE that’s easy but the, 
the vast majority of SAE’s is probably somewhere in between..- S14 
! That’s where I think issues of attribution become very difficult.- S19 
! But you have to, I think you have to assume that you don’t know enough 
about the drug that it could be drug related.- S20 
! I think a lot of it sometimes is the background noise from patient or the 
disease. And how do you know the symptoms are not related to the 
cancer or to underlying symptoms from other comorbidities from other 
chronic diseases the patient may have? - S20 
! Well sometimes it’s difficult, somebody, say somebody with chest pain 
who has plural metastasis it’s really hard sometimes to know whether this 
is related to pulmonary embolism. Then basically have to do the 
appropriate diagnostic imaging which in that case would probably be a 
spiral CT scan to try and sort some of that out. Um, what other symptoms? 
say patient fatigue, ah, well that can be really difficult for instance, it could 
be related to disease, study drug, could be related to psychologic factors, 
some change in the patient’s environment, who knows? And that could be, 
and you have to look at all those and figure out which is most likely and 
then it’s you know, and have there been changes in those areas that might 
explain it? Um, and if there’s more than a couple of possibilities you have 
to kind of use your judgment which is more likely.- S20 
! Just that there’s more than one possible explanation for a lot of toxicities 
that you see. So as you say, PE can be due to the drug or it could be due 
to the cancer and maybe they would have had that PE even if they weren’t 
on the drug or because they’re immobile or any number of factors. I guess 
it’s just that there are multiple factors at play. I’d say that’s the most 
difficult aspect of it. And plus the fact that they may be on other 
treatments, like they may be on something for their hypertension or their 
diabetes [yeah], they’ve got often multiple medical problems aside from 
the cancer.- S21 
! And then it becomes difficult for me, but then you’re forced to make some 
kind of a decision.- S22 
! To the causality [oh the causality yeah] because you have to react in some 
way. So I had to think this morning for example this ocular side effect, was 
it due to you know, drug A or drug B or the combination. Or was it due to 
something incidental like you know conjunctivitis or something. So you 
have to think about alternative causes, alternative explanations. I mean 
people with cancer get many symptoms from the cancer that are not 
necessarily due to the drug, they may just be due to the underlying 
disease. And of course a lot of people have comorbidities because they’re 
elderly and have a 101,000 things wrong with them. And you know, is it 
just something incidental. So I think one of the important things in the 
causal reasoning is, is to be aware of what the possible causes could be. 
You know, it’s due to the experimental drug, it’s due to some other drug 
the patient may be taking or may have just started taking. It could be due 
to the underlying cancer, it could be due to some other illness that may 
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have occurred or that may have already existed like diabetes or angina or 
something you know. So I think critical in the sort of, the kind of cognitive 
approach is the realization that there’s a whole slate of things which could 
possibly either alone or in combination have resulted in this phenomena.- 
S22 
! But every now and then it’s tough, like what happened this morning for 
example, it was difficult, it wasn’t clearly obvious to me what was going 
on.- S22 
! You might argue you know, causality is difficult, causality is not simple. 
[no] You know, there’s different kinds of causality, there’s the kind of 
relationship where something is sufficient on it’s own. [right] There’s 
another kind of relationship where something by itself is not sufficient on 
it’s own but it’s necessary. [and then there’s] And there’s relationships that 
are where you have it’s neither sufficient nor necessary but it nonetheless 
contributes. So it’s actually, on the one hand you’re saying well just 
attribute causality but there’s actually a more profound and fundamental 
understanding of causality with respect to well what type of causality? Um, 
which is important I think because it does help you manage the situation 
you know, so sometimes I don’t think it’s possible to be 100% sure.- S22 
! You know, this is caused by drug X or it’s not. And in a sense I don’t like 
that because, I know, I just don’t think it represents the reality and the 
reality is sometimes there is an element of uncertainty.- S22 
! But, but even if you stumble on a strategy that’s effective it doesn’t 
necessarily mean that there aren’t other strategies that are also effective. 
[sure, yeah] So this just speaks to the complexity of this, especially when 
you’re dealing with two drugs.- S22 
! M: So definitely dealing with two or more drugs in combination is a 
challenge [yeah] in terms of assigning causality, are there any other 
challenges? - S22 
! So it’s, you know, these things are in a way matters of life and death, they 
can be.- S22 
! And I think a lot of things can happen under the, under the banner of 
uncertainty. You know, you can be forced to under, I think that uncertainty 
is at the heart of this, its at the heart of this. And I don’t think it’s a matter 
of honesty or dis, I think it’s uncertainty and how do people cope with 
uncertainty? And I think that this actually is the measure of whether 
enterprises succeed or fail. You know, it’s how they deal with uncertainty. 
So I think for example one of the differences between successful 
businessmen and unsuccessful people in business is that the 
unsuccessful people don’t know how to deal with uncertainty. Um, 
because life is full of uncertainty and you know, it’s possible to be 
panicked into, into making a wrong decision. On the other hand it’s also 
possible to be paralyzed into not making any decision at all. [yeah] So 
when you see these kind of little human dramas played out in this situation 
as well because, but I think it’s a mistake to not allow the physician to be 
uncertain when he or she is genuinely uncertain.- S22 
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! Well more so but there was a lot of problems with some of the toxicities as 
well, all the patients were having serious adverse events. But they were 
also very ill patients and it’s very hard to separate that out at times.- S23 
! Nothing in particular pops up, I mean I can see there are some areas that 
obviously are a little grey as to which way the assignment should go, 
whether it’s definitely related or somewhat related. - S24 
! Um, ah, well just that, that, it’s always, you never know whether 
something, there could be that chance that you don’t know whether 
something could be related if it’s a new event if it’s happening with our 
patients.- S25 
! Well I guess just trying to determine which drug could be causing the 
adverse event, you know if it’s, you know they could both be causing it, it 
could be one or the other so you need to do.- S27 
! And pre-existing conditions in the patient if they have you know, other 
health problems that could be contributory to some symptoms. You know, 
and sometimes it can be as easy as just the person themselves, some 
people will say they’re perfectly fine when they’re not. And other patients 
will elaborate on you know, how they’re feeling and might be exaggerating 
a little bit. So you know you have to try and understand the patient 
themselves as well.- S27 
! So quite often I think it can be multi-factorial, it may not be just due to the 
one thing [yeah] so it’s complex, pain is complex. So I don’t think you can, 
sometimes it might be obvious, I mean if someone has bone mets and 
they come in and they have a fracture. That’s pretty straightforward, it’s 
their disease, but it may not always be that straightforward.- S29 
! So it’s really, it’s, there’s, it’s a combination of factors when you’re making 
decisions, when you’re designating causality.- S30 
! So sometimes there are grey areas and at the time it might be difficult but 
retrospectively by continuing to look at data after the fact then you’re able 
to um, to decide at a later date.- S31 
! It’s tangible evidence that there is a toxicity. But something that is not a 
direct result but could subsequently happen is I think a grey area, and it 
could probably, it might have been, we don’t know for sure. [yeah] So 
that’s why I say it’s kind of a grey [yeah] a grey area.- S31 
! So sometimes it’s hard to attribute it to exactly one specific thing. You kind 
of have to say it could be a combination of their con-meds and their study 
medication and the chemo, so it’s harder to give a causality. So usually a 
lot of times we just, we have to answer unknown because we’re not, we 
can’t specify exactly, possibly, could be related you know.- S32 
! A study drug that may have that same adverse effect. So trying to directly 
relate causality to that sometimes is difficult when you know that it could 
be experienced in two, two different, or three different medications.- S32 
 
Theme 2: Subjective Judgments 
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Definition: There is rarely objective evidence when assigning causality, making it 
a very subjective process, full of inconsistency. 
Subthemes: 
! Variations in experience level 
! Variations in work ethic 
! Patient subjectivity 
! Lack of standardized tool 
Quotations: 
! I don’t know that I have, I think, I can certainly imagine however, in one’s 
own trial whether there’s going to be a bias and you don’t want side effects 
to be attributable to your drug, um. [like if you were the PI] Right, if you 
were the PI easy to imagine and it may or may not be conscious though. 
And on the flip side is you may have a prejudice against the drug because 
it is prior reputation, or difficulty of administration or something which you 
know. I can’t say that personally in short I’ve felt anything in particular, but 
it may be lack of experience to date.- S01 
! And, and ah, um, what really annoys me is when investigators at other 
sites don’t pay attention to this and let’s say there’s an SAE they attribute 
it to you know, very likely study drug.-  S03 
! My head.-  S03 
! Just my clinical judgment.-  S03 
! My common sense.-  S03 
! I mean it’s almost from the experience we’ve had with drugs.- S03 
! So I think, those ones are okay because you’re basing it a bit on personal 
experience [yeah] and a little bit on what’s published.- S04 
! So it’s more like each case, hopefully, you know, the fear is that you’re not 
consistent I guess, that you know, you’re scoring a patient differently, 
that’s, that’s the fear.- S04 
! Basically all one can really do is, based on experience of managing these 
people sort of know what to expect as their cancers progress and as their 
regional stages of life, as in previous experience in managing.- S06 
! It’s really based on experience at this, at this stage. So really it would 
depend on a, an experienced investigator who has managed a lot of the 
specific patient population to in my opinion, accurately determine if this is 
something that’s related.- S06 
! That’s a clinical judgment based on what’s happened to the patient.- S06 
! So it is experience.- S06 
! Yeah, I mean you use your clinical assessment and um, and it’s really 
process of elimination and if nothing else comes out.- S09 
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! Well I think just the fact that there, there isn’t a systematic way to do it, 
that it often is based on hunches and feelings as opposed to a rigorous 
method or measurement tool.- S10 
! So I think it definitely depends, again, very individual, depends on the 
patient, depends on your personality, what you’re asking. If you’re asking 
the appropriate questions or not, I think that that makes a big, a big 
difference too.- S11 
! Oh gosh, it’s hard to say, again, every patient is different. Some patients, 
um, some patients I think it’s easier to leave everything open and let, just 
leave it as a blank slate, let them tell you everything that’s been 
happening. Um, some patients if you do that won’t tell you anything. So 
some patients, not prompting but some patients you need to I think go 
through a list of questions and ask them about specific side effects, 
problems, even possibly body systems and leave it open that way for them 
to suggest things to you. Um, again, um, I find it’s, again reporting is very 
different from person to person in terms of the clinicians.- S11 
! Um, and again I think that’s very subjective for the clinician also the way 
the patient describes things. I could consider it a grade 2 whereas the 
physician could consider it grade 3. - S11 
! I have to admit that is very subjective at times.- S13 
! Um, well to be honest, not really I think you just go on what your best 
clinical judgment is or what your patient’s status is.- S13 
! But ah, um, you know, I think it’s a very subjective process, that’s the 
problem. And subjective in terms of ranking them or associating but also 
subjective in how much effort people actually put into the work. And I won’t 
say I do it all the time but you know, I think in terms of how much 
background work one does in trying to understand the causality with each 
one trying, if you’re not certain, if you are certain it’s very easy. Perhaps, if 
you’re not certain are you going to spend that extra time to pull out the IB 
or talk to you’re you know, pull out the protocol and actually do the best.- 
S13 
! So unrelated, definite, possible. Like what’s the unlikely and probable 
versus possible versus probable, you know, where do you draw the line? 
Again, it’s very subjective.- S13  
! But ah, um, you know, I think it’s a very subjective process, that’s the 
problem. And subjective in terms of ranking them or associating but also 
subjective in how much effort people actually put into the work. And I won’t 
say I do it all the time but you know, I think in terms of how much 
background work one does in trying to understand the causality with each 
one trying, if you’re not certain, if you are certain it’s very easy. Perhaps, if 
you’re not certain are you going to spend that extra time how much 
background work one doesto pull out the IB or talk to you’re you know, pull 
out the protocol and actually do the best [7:30].- S13 
! But that is basically based on, on the situation and your experience and 
not on any formal rules or algorithms or whatever.- S14 
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! Well it’s so subjective, in the end, for the majority of SAEs which are in this 
grey zone of possibly or likely or unlikely related, it’s a very subjective, a 
very subjective thing.- S14  
! You know, where the same event can be attributed differently because a 
lot of things, it’s a subjective assessment. It’s not as objective as it should 
be, I think that’s what makes it a challenge.- S18 
! No. I think we basically use our medical judgment and the sources of 
information.- S20 
! No, it’s kind of, for me it’s like an intuitive process, and I should also say 
that sometimes the CRA’s do it.- S21 
! Um, I think it’s a long way from engineering right now and I think a lot of it 
is gut feeling and kind of intuition.- S22 
! Well I guess one of the things that I’ve always had a difficult um, thing to 
grapple with is that there are too many, often there are too many 
categories of relatedness. [okay] You know, like definite, probable, 
possible, unlikely or not, do you see what I mean? [yeah] And I think that 
those are fairly subjective definitions that will vary from person-person. 
You know, what I think is unlikely is not necessarily what you might think 
to be unlikely [mmm hmm] and so um, again the assigning of causality 
there could be sort of chance depending on the interpretation of the 
definition by the individual physician.- S26 
! Well as I said I think sometimes it’s arbitrary and it depends upon the 
physician’s interpretations of the definitions of you know, these different 
things. I think it depends a little bit on the physician’s past experiences, 
expectations and biases with respect to the class of agents and so on.- 
S26 
! Well we probably don’t pay as much attention to it as we should. I mean a 
lot of the initial information is prepared by the CRAs or the study nurses 
and I think in a practical everyday busy clinical environment we have these 
things coming across our desks to be signed almost on a daily basis. And 
I’m not sure if we think about it as much as we should, if we give it as 
much attention as we should, because it’s just another thing to be signed. 
[mmm hmm, yeah] And there’s been sort of very little attention paid to it in 
sort of the clinical research area.- S29 
! Like pain, pain is subjective, fatigue is subjective, I mean you can try and 
quantify it but if you think that the study, that the causality, that fatigue is 
due to the study drug you’re not going to have objective evidence. [true] 
Weight loss, well I guess if you have weight loss you can measure them in 
pounds but it’s not always going to be there.- S29 
! It would have been nice if we could have established causality 
unanimously but. [yeah]  So I say going to the physician but if there is 
more than one involved there can be more than one opinion.- S31 
! But when it’s subjective, like how a patient is feeling or how sore their 
mouth is or you know, how much pain they might be experiencing, it’s all 
very subjective to each patient. So severe to one person might be you 
know, moderate to another. So those kinds of things I find, unless you can 
! &*&
assign a number value to it I find that hard to grade. Because some things 
are very subjective, pain, those things are, in my, I find personally hard to 
grade.- S32 
 
 
 
 
 
Theme 3: Insufficient Resources 
Definition: There are a lack of resources available, or made known, to assist 
these professionals in assigning causality. 
Subthemes: 
! No causality tool 
! Lack of detail 
! Communication issues 
o Sponsor and interviewees 
o Patient and interviewees 
Quotations: 
! So there’s often not a lot of guidance it’s more winging it.- S01 
! Yeah, and I would say timing is the most important factor. I mean, other 
factors, we don’t usually have dose as a, as a ah, we don’t usually have 
doses in the same, different doses in the same patient to be able to judge 
a dosing relationship- S01 
! As previously mentioned dose, you know, often we don’t have a dose 
relationship that we can look at.- S01 
! Supposedly one of the criteria for causality is something like a dose 
response relationship whereby more of something causes more of an 
effect. And a patient typically, although we may have that in a cumulative 
dose, we don’t have different doses from cycle to cycle necessarily. So 
you can’t say when you had a little bit of this you felt a little nauseated, 
now that we’re giving you 10 times more you’re feeling really nauseated. 
So we wouldn’t have that information typically. - S01 
! Actually not any that I know of.- S04 
! I can’t say that there any actual guidelines that I know of or that I 
specifically follow.- S04 
! Oh, very little, I mean I think um, a lot of the pharmaceutical sponsors that 
we did some studies with, had some training modules but not necessarily 
for causality mostly for adverse event reporting- S04 
! I normally don’t use anything particularly that formal.- S05 
! &*'
! There hasn’t been any formal training, yeah, there’s hasn’t been anything 
formal.- S05 
! No I’m not aware of any.- S06 
! Um, I would say that more resources would be good for investigators, 
more resources at their disposal. [what sort of resources] Well, resources 
through the sponsor [for what] for information [oh okay] more information 
as to whether, you know, if you have questions about a certain event. And 
for example you wanted to understand the drug’s pharmacology better and 
try and determine you know, in some way could there be access to that 
information beyond the IB. The opportunity to discuss on a regular basis 
with other investigators, how the trial is going, um, through conference 
calls is a good idea.- S06 
! Lack of appropriate information.- S06 
! Well I think if there’s a, I think there is a certain distance often between the 
clinical trials nurse and the physician.- S06 
! No not really, using just yeah, anything.- S07 
! Well usually there’s teleconferences and other meetings to discuss what’s 
happening with other patients. But a lot of times communication isn’t as 
good as it could be.- S07 
! We should be involved in as much of those discussions just so everybody 
is informed. I haven’t done a lot of, so I don’t know what they do to keep it 
up but sometimes you do feel a little bit, you have no idea what the other 
people are doing. And it would be a little insightful as to how they’re doing 
it, yeah.- S07 
! Nothing formal. Sometimes in start up meetings or something like that 
they’ll, they’ll say a little blurb about assigning causality but they won’t 
really give like formal education as to what, we should use this tool or 
anything like that. It’s mostly a set reaction sort of.- S07 
! Imprecise science! I am not, I mean I guess to have definition, I mean 
more clearly defined sorts of definitions of the terminology would be most, 
would be the thing that would be most helpful. [which terminology?] You 
know, in terms of the causality terminology, so more clearly define what 
people mean by unlikely, possibly, probably, you know definitely related. 
And at least people are using the terminology you know, in a similar 
fashion. - S08 
! No, no I’m not aware of any.- S09 
! I think it would be beneficial for all of us maybe to spend a bit a time with 
them and see. Or even with the data management, I don’t know what they 
do with the data management part of it. [yeah] And I think it would help us 
understand part of what we’re doing too when you see how companies or 
CRO’s try to collate the information we send to them. And then what it can 
do in terms of, you know analyzing the study or.- S09 
! I’ll be honest and say I don’t really have any [really]. I don’t have any tools 
that I use.- S10 
! M: And then um, do you know of any tools that are available to help in 
assigning causality? Have you every used any sort of a decision tree or an 
! &*(
algorithm or [no] something like that? No. [no] Do you think that would be 
useful? 
S11: I do think that would be useful um.- S11 
! A lot of the times I find it’s hard and I don’t think it’s an on purpose thing 
from patients, but I don’t necessarily think that we do get every single bit of 
information all the time.- S11 [yeah] I think different things are reported to 
different people, depending on your position, whether that be chemo 
nurse, clinical trials nurse or the physician.- S11 
! I’ve had no formal training [no] actually.- S11 
! None. [no] No, well I mean, I guess I shouldn’t say that, none in terms of 
standardized criteria that’s for sure. Resources, unless you mean basically 
going back to see maybe the investigator brochure and trying to 
understand some of the toxicities.- S13 
! No, not that I’m aware of, not that we use here that I’m aware of. 
! Um, more information from the sponsor I guess in terms of um, side 
effects of the drug.- S15 
! Are there tools out there? [laughter] no I don’t. [okay].- S18 
! I think it’s human nature to forget things [okay, forget] and obviously if it’s 
a very serious event, it’s going to be recorded and you’re likely going to 
hear about it in some way. But not all patients understand that in a clinical 
trial that we’re also interested in the side effects of the treatment. And in a 
Phase I actually toxicity is your primary endpoint. [mmm hmm] But the 
patients of course feel that they’re on the treatment to help their cancer 
[yeah] so there’s a little bit of a disconnect there. So they’re more 
interested in what the drug is doing for their cancer and they kind of are 
hunkered down with the idea, many of them are very stoical right [yeah] 
they say I’m going to put up with whatever side effects I have to put up 
with um, to get through this treatment because it’s going to help my 
cancer. And I think that’s, that translates sometimes to a lack of reporting 
of events. I think that some patients may also perceive that you know, the 
doctors or nurses don’t want to hear them complaining right, they just feel 
that they’ll sound like whiners right.- S19 
! Besides the patient, family members, maybe differences in behaviour, 
maybe some psychologic or neurologic issues associated with the 
medication because we just don’t know enough about them, ah lab work, 
imaging results sometimes [okay] and the physical examination.- S20 
! Nothing formal.- S20 
! Minimal at best [okay] basically on-the-job training. I think all the CRAs we 
basically self-train or train each other as we go.- S23 
! Yeah, um, yeah, obviously we haven’t received any training for it but um, 
I’m not sure that we’re the ones who are actually expected to come up 
with that determination. - S24 
! So the physician meets with the patient [mmm hmm] and afterwards they 
come out and they dictate what sort of went on. [mmm hmm] And often 
times it’s not extremely detailed, is that what you’re saying? - S24 
! &*)
! Yeah, more detailed information I guess, other than what’s in the consent 
form, having a list of expected events and maybe, some of them put in the 
percentages of what the patients have already experienced. So yeah, I 
guess that, just a more detailed sort of, um, like I was saying we go to the 
dose modification and it will list sort of what the expected toxicities are and 
the rules to follow. So maybe to have some kind of I don’t know, chart or 
information in that area to go to, to see what we’re looking for and how 
they expect us to assign the causality.- S25 
! But other than that um, as far as education as to how to assess the 
causality [yeah] I would say that’s really minimal to none.- S25 
! Trial and error I guess. I mean the only, the only lecture I’ve ever heard 
about is, I’ve heard A speak once, but other than that you know, really 
nothing. I mean you’d ask other more senior investigators what they would 
say for this particular event and so on. But otherwise, there was no formal 
training.- S26 
! Well, most of my studies are also sponsor studies and they tend to make 
the wording vague on purpose. [laughter] Probable, possible [the wording 
of what] probable, possible, definitely related, possibly related all the, so 
sometimes that can be a challenge if it’s something you haven’t 
encountered before.- S28 
! No. [no eh, you don’t use any?] No, in fact I think people tend to lean 
towards putting it, like when they’re not sure, and most people are never 
100% sure, they’ll say you know either probable or could be. And I think 
we see a lot of “could bes” more than any other.- S29 
! There’s no formal training really, you just kind of got thrown into the 
position.- S32 
 
Theme 4: Apprehensive Causality Attributions 
Definition: There is a general fear of making an incorrect causality attribution that 
may result in rather severe consequences. 
Subthemes: 
! Fear of under attributing causality to the drug being tested 
! Fear of over attributing causality to the drug being tested  
Quotations: 
! I think it can interfere, the inaccuracy of it can interfere with drug 
development and can potentially in the most extreme case, kill a drug. Or I 
suppose on the other side allow a drug to go ahead when side effects are 
overlooked. Although if, if you have a bunch of us who are calling unlikely 
things possible, because you know, we’re not really sure because it’s just 
subjective. And the FDA looks at that or the investigators look at that and 
decide, you know we just have too many pulmonary embolisms and 
they’re all possible, as opposed to unlikely, you know, it can impact what 
! &**
they do with that drug. They may change the dose and lose effect or they 
may stop the trial or whatever. So there’s risk to the drug and to the 
patient.- S01  
! If it’s done incorrectly, it’s a pain in the ass for all the trial nurses and all 
the invest, all the trial doctors all over the world because it takes time to 
sort out.-  S03 
! There’s, there’s two concerns, I think one concern is you know, over 
assigning causality. Because patients are, they can get sick, morbidities, 
multiple medications, actually a lot of reasons and it sometimes it’s easier 
to blame it on the drug. But I think my fear is that if you, if you do that 
liberally you’d be, not discrediting the drug but you’re not um, it could lead 
to dose reductions, could eventually work their way into an ineffective 
treatment schedule for that. If you saw a whole bunch of side effects that 
you thought were you know not really related to the drug and that led to 
that drug being less developed in a certain disease. Maybe you’re doing a 
dis-service to that patient population, so that’s one, that’s one concern I 
have. Perhaps over-assigning causality just because of the complications 
of some of the patients on the program is my biggest concern. And the 
other concern is, the other, completely opposite really is the not assigning 
causality and then drugs are allowed to develop. And then it’s only when 
you start getting into Phase 2, Phase 3 studies that you really, adverse 
events really show themselves. And you’re thinking well why wasn’t this 
picked up in the Phase 1 or 2 studies? [yeah] So I think you can go either 
way, you can make errors on either way, one way you might kill a drug 
that might be successful and on the other way you might let a drug 
develop not carefully enough.- S04 
! I mean the biggest stress, not that I’ve had any stress about it, but the 
biggest issue is assigning causality that could result in a Phase 2 program 
going to a lower dose or something like that or you know a ineffective dose 
for a given cohort of patients is a concern, whether you’re doing the, you 
made the call because that’s often a critical step in a clinical trial.- S04 
! There you’re getting, you’re, you know it’s hard to, to, how, how strongly 
are you going to implicate the study on the side of implicating the study 
drug just from these issues.- S05 
! Yeah, they are really, I think in some cases we have to be, make sure that 
well, is there an element of doubt but clearly that’s where the unlikely 
category comes in and these are patients who are being said, well it’s 
probably related to their targeted agent and you know, clearly that’s 
probably likely not the case. But what that does is it really contaminates 
the whole database in terms of what is the causality of these toxicities. It’s 
a huge problem worldwide and we certainly see that when we’re having to 
look at data from large international studies where you have groups who 
probably don’t have a lot of experience with either the chemo or the 
targeted agent. And making these attributions it really kind of make a 
mess of the database.- S05 
! '++
! Mostly I find you know I tend, I agree with, with the conclusions they come 
to and sometimes um, I think there’s a tendency to over report disease-
related symptoms as being related to the investigational agent by the 
invest, you know, to be reported by the investigator. - S08 
! And so in that setting there’s a discrepancy between what the investigator 
feels and what the medical monitor feels. - S08 
! Well I think that there are, I mean I think you know, if you start sort of 
labeling a drug as having you know x, y and z side effects and in fact 
they’re in fact they’re side effects related to the disease then you know, 
um that’s a problem. But on the other hand does it, how does it limit 
development of the, the agents. I’m not certain, well I’m not less certain 
that it’s going to limit development of the agent. - S08 
! Well, I think you can overcall things that, and say that they’re related when 
they’re not. [mmm hmm] Um, and then that leads to for the drug 
companies to sort out or, or you know, whoever the sponsor is in 
determining are these or are they not? And I think um, it would be 
beneficial at some point to follow through on the other end of things to see 
what it means when you’re on that end. [what do you mean on the other 
end?] Like a CRO getting this information in and saying now, you know, oh 
well what does that mean, the word, how you take it and what did they do 
with it from that point. Because I mean we submit the information but what 
happens on that side, but I think.- S09 
! I think the biggest implication would be that if a drug gets attributed to 
have a set of adverse events that are quite serious then that may preclude 
further study of that drug, that might stop the trial.  And if you’re looking at 
a dose escalation study where you’re escalating to your next dose based 
on the tolerated dose, you’re now saying that there’s some side effects. 
Well you might not go to the next dose level, or you’re recruiting more 
patients to that particular cohort level so subjecting more people to the 
drug than may be necessary in a clinical trial. So the issue of not, of a 
potentially very good drug not being taken further because of the concerns 
of the adverse events, that’s going one way. And the other way if you don’t 
attribute the causality, a potentially dangerous drug could come to market 
without the proper, or with concerns about adverse events.- S10 
! Um, an implication could be the fact that drugs aren’t being marketed or 
aren’t moving on to different phases of trial because causality has been 
improperly assigned. It could also on the very opposite side of the 
spectrum, it could also lead to harmed patients, it could lead to death in 
patients. A whole array of things, I mean it could obviously affect the 
statistical analysis of the study, it can affect everything.- S11 
! So you could in one situation attribute something to an entire one set of 
the, the most serious and if it’s this and you don’t acknowledge it, that’s 
dangerous for future patients in the study. [right] If it’s, if it’s you know, this 
and you label it as this, you could be potentially closing a trial that 
presumably was well thought out and had a good hypothesis and the 
hypothesis could end up being rejected. [implications] Potentially [yeah] I 
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mean if you polarize the extremities yeah, most of the stuff is not going to 
end up being that extreme, it’s going to be in the middle but.- S12  
! Well there’s definitely implications in serious adverse events, and, and 
association, obviously if you put it wrong then there’s misinformation. If it is 
associated and you don’t think it is then that, that’s probably the more 
harm there because we need to be aware, particularly in Phase Is that we 
need to be aware of and people think oh it’s very unlikely I’m going to put it 
not related but then obviously that’s information that the physicians and 
the patients in particular need to know about. So I think the worst is an 
association that is there but one grades as not associated and, and harm 
could be done to patients. The other extreme is people, and I see this a, a 
lot because you have to, as the PI on the trials you have to signoff on all 
the REB submissions to the REB. People that put everything is associated 
creates lots of paperwork. Where its very clear in reading through their 
SAE this was not drug related, this was disease related. And to me that 
doesn’t do any harm to patients which is good but it creates extra 
paperwork for the CRAs, for the nurse, for us, for the REBs and to me 
that’s more irritating when it comes from all around the world, you know 
you get. [yeah] People could be, could think a little I think, I don’t know, 
think a little bit more clearer in terms of what they think is associated and 
perhaps those that are not associated would save the.- S13 
! Well you can clearly overlook, worst possible thing would be that you 
actually don’t report a side effect which is actually a side effect, from, from 
the drug. That may really happen, but I think one of the existing problems 
is that the frequency of those side effects maybe under reported.- S14 
! Overlooking it altogether is certainly worse [yeah] but I think [it’s also 
important] a serious adverse event, if a serious adverse event is seen in 
relationship to this more often then at some point we, we report it. But I 
think the frequency may then be under reported. But the key, overlooking 
a side effect or not reporting a serious adverse event which is actually part 
of the side effect profile, that’s probably the worst, the worst thing.- S14 
! The opposite is true too, if you , if you report an SAE which is not related 
to the drug [mmm hmm] then that can cause a considerable, can have 
considerable sincere consequences for the, for the drug and the 
development of the drug.- S14 
! Worse case scenario that you delay or you stop the development of the 
drug. I mean imagine that a patient dies on a Phase I study and you 
assign the death as possibly related to the study drug and it wasn’t. 
Something like this can kill, kill a drug in the development or at least 
considerably delay it or cause a lot more costs for the, for the company or 
whoever develops the drug to do additional testing and stuff like this.- S14 
! Um, well, of assigning them poorly? It’s either you under, or whatever 
event it was so you’re compromising safety of future patients who might go 
on this treatment if you um, rule that it wasn’t related to the drug. Or you 
might over, you know if you say that everything is related to the um, to the 
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investigational drug then you’re over, over rating it as to whether the drug 
is causing problems. So it’s pretty serious.- S15 
! Well the potential ramifications of that is the drug might not go out to 
market and it might be a potentially legitimate drug. [okay] Because 
describe SAEs or have SAEs that might not really, that are manageable or 
might not really be 100% related to the drug. Especially if you pick a poor 
group of people who you know always get admitted for nausea and 
vomiting because they have a poor ECOG status. And it could be that they 
were just very poor patients initially to put on treatment.- S15 
! I think there’s two big concerns. One is if you assign causality and say it’s 
related improperly then it might tarnish a good drug and stop dose 
escalation in a way that wouldn’t be appropriate. Alternatively if you ignore 
it, it might cause further toxicities in others and be potentially dangerous to 
other patients. I think it’s a very dangerous thing. I also think that 
sometimes as oncologists we tend to minimize rather then maximize 
because we’re used to toxicity with drugs and that can be dangerous.- S16 
! I think most of the doctors who do a lot of clinical research are aware of 
the fact that you don’t want to underestimate the toxicity of a drug. But at 
the same time you don’t want to assign every single adverse event to the 
drug some will not be due to the drug. So you usually end up in the, this is 
a possible to probable consequence of the drug if it’s in the grey area 
where there could be many reasons why the patient had an adverse 
event.- S17 
! One always worries if an investigator who is on, perhaps working with a 
drug company may wish to minimize adverse events because they really 
want this drug to be a success or acceptable. And it need not necessarily 
be driven by egregious opportunities around receipt of research funds, it 
may be because they get sort of um, too invested in the drug itself and 
wanting it to succeed or wanting their career to succeed or something of 
that nature. But that can induce investigator bias. Um, on the other hand 
you can have some investigators who um, will always attribute causality to 
the drug because they rather simplistically think if anything bad happens it 
must be the drug.- S17 
! Um, I think any time with an investigational agent, like I said your antenna 
are fairly high up and you probably are more likely to ah, to lean on the 
side of, you don’t want to harm a patient or subject to harm to assign 
causality where it may not have. Like assign a higher level of attribution 
even if it may not have been. So you know, when in doubt the diagnosis of 
exclusion is going to be that it’s, it’s the investigational agent. [yeah] So, 
and that may be unfair to the agent under development right. [mmm hmm] 
So it’s just your level of, you scrutinize it more, like I said a more 
conservative approach to when in doubt, better to say it’s possibly related 
than not. Those are, and no tool.- S18 
! I probably don’t give it as much thought as, as I should. I mean, I guess 
the real risk is that if people are falsely ascribing SAEs to the drug when 
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it’s really the cancer then you could potentially throw out a good drug.- 
S21 
! And I guess the converse is true too that if you don’t, if you don’t 
adequately report the toxicities then you might be introducing a drug to the 
market that is dangerous.- S21 
! But it may not be quite that easy to do with chemotherapy, even in the, 
even off trial, but it’s particularly difficult to do that on a trial because you 
know that you might sabotage you know, the intent of the study by just 
unnecessarily stopping. You know, I think the onus on an investigator and 
somebody who’s responsible for treating the patient on a trial is quite high 
really because they have the ability to undermine the trial by making a 
fallacious attribution. You know because something might have happened 
you know, they got gastro because they ate something at some restaurant 
or something and then you say well it’s the drug and you take them off the 
drug. Well then you undermine the whole enterprise you know which isn’t 
just that trial, it stretches back over probably 15 years of work and money 
and investment. And it’s so easy to undermine it by making, by casually 
making the wrong attribution.- S22 
! So there’s two kinds of mistakes you can make. You can make a false 
positive attribution or you can make a false negative lack of attribution, 
when in fact you should have.- S22 
! The real, the really difficult issue is where you would have a situation 
where you would have to stop the study drug or reduce the dose of the 
study drug. There I think it becomes particularly difficult and particularly 
important that the correct decision is made. If you’re simply going to say 
well you can treat this with a bit of Imodium or some heparin or something 
it doesn’t really matter. But where you’re forced to interfere with the 
conduct of the study and the administration of the new drug that’s where it 
becomes acutely important to do the right thing.- S22 
! Because I think you can falsely label a drug with all sorts of um, toxicities 
that have nothing to do with it.- S30 
! Um, and it can go both ways, if you only see a very small number of 
patients you may underestimate or under-relate particular symptoms to, to 
the drug. And the same thing can also happen where if, if you just decide 
that every bad thing that happens to a patient is going to be possibly 
attributable then, then not only do you jeopardize the development of a 
drug but you also, those things all get added to patient consent forms and 
they muddy the waters for patients.- S30 
! So you’re assigning causation when maybe it’s not it may be something 
else. So as a company I think they’re obligated to list that as a part of their 
um, their package. Maybe not, maybe they don’t take into account certain 
timeframes. Maybe they have a tool.- S31 
 
Theme 5: Competing Goals 
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Definition: Within the process of assigning causality these professionals’ primary 
interest is to be as accurate as possible and while considering the safety of their 
patient. However their goals compete against other goals of the trial whether it be 
the workload, time, or the development of an agent. 
Subthemes: 
! Patient safety vs. drug development 
! Accuracy vs. extreme workload and drastic timelines 
! Financial pressures 
! Patient vs. physician 
 
 
 
Quotations: 
! Well if you have, ah, ah following the patients with this and it takes how 
many minutes or hours to do it, it’s very costly [it adds up] it’s very labour 
intensive.-  S03 
! And the ICH/GCP guidelines which this is part of is, is, ah, is making it 
very, very difficult to do this sort of research and it’s unfortunate because 
you know, we need to study new drugs, we need to, yeah.- S03 
! Yeah, you know, my concern is sometimes not enough attention is paid or 
they don’t understand sometimes what the implications are so they don’t 
give it enough time, they don’t understand it.-  S03 
! From a causality point of view, I mean there’s more stress if the adverse 
event is of a more serious magnitude in terms of determining how related 
it is to the trial medication.- S04 
! There’s an awful lot of pressure when you’re doing early phase studies 
with a small biotech company. They, there’s a lot riding on, on, you know, 
there are the issues of well are you going to torpedo their only drug or just 
from a financial point of view, with toxicities that are going to expand the 
dose level. That’s gets in and take longer for the study to complete, those 
have big financial implications. On the other hand our, our first 
responsibility is to the patient and if not I think making sure, a lot of 
pressure from the smaller companies. And I think the other pressure is just 
the sheer volume of the adverse events you know, here are the ones from 
the last couple of weeks. So it’s just huge volumes and they all, and 
everybody wants them done within kind of 24/48 hours and it just becomes 
impossible to do. On some level there needs to be, and a lot of these are 
these ones that you know it’s clearly the chemo drug and probably really 
isn’t related to the study drug. But there’s, probably half of those are those 
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kind of things that have been generated, probably inappropriately because 
of the experience of the people who, it’s a problem. It’s a huge workload 
and unless we’re handling them consistently I’m not sure we’re going to be 
any further ahead.- S05 
! Um, well there, you know, there, I think one has to fight, now this is a more 
of a perception, I don’t have any examples. But there’s a risk that the 
sponsor may want, may prefer you to go to an unlikely conclusion. That I 
disagree with.- S06  
! No I haven’t because I’ve stubbornly just said well that’s my final answer, 
so I’ve never felt any, any sense of coercion. Obviously, you know, 
inherently results in more work for somebody but ah, in the Phase 1 
setting I, I, I think ultimately it’s the sponsor’s in their best interest to fully 
understand what their drug is doing and what it’s potential effects are. But 
one does have to be fairly stubborn in that regard.- S06 
! The challenge is that the good Epi group who can run trials in an 
academic setting are going to be approached by drug companies. And you 
need a lot of money, those staff have to be paid and there are costs to the 
clin epi group and that’s a lot better then a local academic.- S07  
investigator say getting a grant for 100,000 bucks and he can give you a  
$1000 bucks. I think they’re, they’re, the risk I think comes in the academic 
setting when the institute needs to kind of step up I mean today that’s 
being done, certainly here’s its done so it’s, but I don’t know about other 
centres across the country.- S06 
! Not too much, but then again I’m not the one that the sponsors contacting 
when they call you and go are you sure that this is what you think it is? 
and stuff like that. I’ve had one of those calls where they’ll call back and 
they’ll say is this the way you want it? And you just go back to the 
physician and tell them they want to reconsider. And sometimes the 
physician is, will stick to their guns and sometimes they will re-think it or 
whatever.- S07 
! Well I think it’s based on what’s been listed in the protocol and possibly 
the investigator brochure. But really do you have time to look at an 
investigator brochure every time? No.- S08 
! And then you have, because different companies will approach it 
differently and so then you have AstraZeneca with their reports. The 
company sort of reports basically they, they want to downplay um, these 
and so their stock standard line is that you know, such and such a side 
effect is not listed in the investigator brochure, the implication being well it 
can’t be related. So you know they take the, so you’ve got to look at it with, 
it’s somewhat helpful but somewhat tedious. - S08 
! No, cause what happens, they’ll send us the report and then it’s up to us 
to how we deal with it. I mean they have to be forwarded to the REB and 
the internal documentation that we do is more about sort of thinking for 
ourselves whether we want to make consent changes. Whether we see 
something which is happening you know, with um, severity or a frequency 
that would justify making a change to the consent form. And that doesn’t 
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happen very often, in part because you know, we tend to wait for, because 
periodically there will be an update to the investigator brochures and then 
they’ll considered if the consents need to be updated. - S08 
! Sometimes in some places for some companies you know the serious 
adverse event would be mucusitis, diarrhea and dehydration. And other 
places and I guess the NCIC in particular, I mean our recent experience, is 
that they say well the drug doesn’t cause dehydration, the diarrhea and 
the mucacitis does. So you have primary adverse event and then you 
have secondary effects from that [right]. And then really only want the 
primary event reported as the serious adverse event and then what’s 
secondary to that is covered in the description of the serious adverse 
event. - S08 
! S08: [that’s a bit of a challenge] It is and some of that is sort of developing 
a better understanding of what individual sponsors want or expect. But on 
the other hand maybe there should be you know, greater consistency. - 
S08 
M: You find that there is variation among the sponsors as to what it is that 
they want and expect.  
S08: Yeah. 
! Um, well they come back and say well are you sure that’s related? [mmm 
hmm] right [yeah] you know. No I’m not sure but I’m not willing to say it’s 
not, you know.- S09 
! M: Sort of the pressure to keep the drug development process moving I 
guess. 
S09: Um, hmm, um, hmm. Yeah, very much so. And, and I think some of 
the pressures come around too is you know to put patients on study and 
sometimes that feels more, that’s more the goal rather than the safety of 
the patient. I think we rely on the companies to monitor these studies and 
when they don’t, especially the early phase studies, and when they don’t 
there’s a huge problem with that. I’m not perfect, and they’re not either but 
I think they then have the responsibility to monitor those studies and get 
those forms back into data management so they can make the proper 
queries that will probably, that could correct anything that you’re not even 
aware of.- S09 
! Well if you’re involved in industry studies then certainly there’s some 
pressure from, not so much for assigning causality but continuing. So if 
you’ve had someone who has had an adverse event and you want to dose 
reduce them or hold off treatment for a little while sometimes there is that 
pressure to continue with the study. So in that sense you could think well 
maybe if you had assigned them a possible as opposed to a probable 
relationship then you could, you could be pushed to continue with the 
study. But you always have to keep the patient’s safety in mind [right] at 
the end of the day so, so that’s what you go by.- S10 
! But I must admit I really haven’t had that much pressure in terms of 
treating the patient. It always comes down to the patient’s safety and that’s 
what you go by.- S10 
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! Again, I’m not really sure that’s optimal especially considering how, you 
know, little time everybody has these days.- S11 
! Um, I mean to start out with the very basics, a lot of, a huge workload 
involved, um, in doing it poorly and that, I mean it could be anything. Just 
from the workload involved in SAE’s, even the reporting, all the different 
avenues it needs to go through.- S11 
! Who’s kidding who, they’re busy and overworked, um, and trials are a lot 
of paper work. So I think that’s possible, I certainly don’t think there would 
be malicious intent [no] but I, but I do think that you know, even time 
constraints that sort of thing could have, play a factor in that.- S11 
! So if, if, there’s an SAE that, that comes out of that, that has So if, if, 
there’s an SAE that, that comes out of that, that has implications for 
notifying sponsors, the sponsor notifying the regulatory agencies and the 
company, there’s timelines for doing so. The nature of enough AEs may 
influence the conduct of the study [how does it influence?] so 
misrepresent, well a series of SAEs may [9:51].- S12  
! It’s just very practical and if ah, I mean there is a bureaucratic process that 
is time consuming that if you assign an SAE versus not that somebody’s 
going to have to do a lot of work and meet timelines and set a whole ball 
rolling.- S12  
! I think you then have the issue of the sponsor, and sponsors, sponsor may 
influence. [okay, how so?] I think in general from what I’ve seen, sponsors 
will tend to, tend to things that are expected, the, if the consequence is an 
expected one and it’s tended less to be labeled serious adverse event 
even if it’s expected but the degree and the severity wasn’t, that’s a tricky 
one, you give an agent.- S12  
! I mean I think um, basically um, if we all had more time in our day it would 
probably be easier to do it. The SAE has to be filled in within 24 hours. I 
mean that’s another issue, why 24 hours? what’s the urgency? By the time 
we receive it, we send it off to the sponsor, it goes to REB, there’s going to 
be a lag time anyways. And you don’t expect things to, you know, maybe 
grade 5 toxicities where you have a death, maybe that should be 24 
hours. But I, I don’t know why an SAE can’t be 48, so you don’t feel that 
pressure to have to. Not that, I think we do it just because we feel a 
pressure, but again I think we just said 24 hours and that’s just been the 
rule that’s been adopted all along right. [right] I actually don’t see the 
rationale of 24 versus 48.- S13 
! Well I think the only external pressures is obviously be accurate as 
possible. And so you know we’re part of the, part of the Princess Margaret 
Consortium and you know a couple of the NCI trials, you know the NCI 
physician from the US is emailing me in terms of causality, so obviously 
there are pressures to be as accurate as possible. But sometimes you 
really don’t know if it’s associated or not.- S13 
! Um, probably the sponsor wanting an answer right away of what the 
cause, because sometimes you don’t know, it’s hard to make a decision 
on one patient, like the first patient that presents. Especially if that 
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particular patient has multiple problems and it’s possible that it could be 
their disease or a component of their disease that’s causing the symptom 
or the, the abnormal lab result.- S15 
! The first issue is how quickly can you really assign it? Often you know, you 
need to report within 24 hours. Within 24 hours you may report, the person 
came in with chest pain, da, da, da, and you don’t have any real idea if it’s 
related or not.- S16 
! I think sometimes, sometimes you’re in such a rush to get the CRF done 
that I think you don’t necessarily spend enough time. And I think one of 
the other problems is we get so many reports about drugs, you know like 
alerts [safety letters?] safety letters that sometimes everybody doesn’t 
know these things and may not know if it’s related or not. I think keeping 
up with the safety letters is hard, [just because you get so many of them?] 
mmm hmm and not really knowing the drug well.- S16 
! The timeline, it’s mainly the timeline and the pharmaceutical company.- 
S16 
! And if you’re so busy or have not done your homework in terms of reading 
about the drug, or don’t have the time to go look it up. So you know, 
basically just having a busy clinic and being busy at work can lead you to 
mis-attribute these things right.- S19 
! Third parties, um, our CRA’s sometimes want things attributed in a certain 
way.- S19 
! Yeah, I was just thinking they’re, when you look at attribution of adverse 
events, I mean they’re basically the people you’re working with [yeah and 
they want] you think you’re filling out a CRF and then um [they] they want 
an attribution level. And ah, sometimes they have their opinions about 
what the attribution is and they’re different from [yours] mine. You know, 
not a lot but um, that just in terms of explaining to them and then they 
have to change their forms [yeah, yeah] and if they’ve already submitted 
the forms a certain way. Ah, in affect you’re creating more work for them, 
ah, so that does, I don’t like to create more work for the people I work with. 
So I do feel a little but of pressure there, but ah.- S19 
! I guess, I guess one of the biggest challenges these days is that if we, 
people have enough time to rigorously evaluate all the possibilities in a 
very busy clinic setting. [yeah so] The time to sit down and really fully go 
over everything with the patient in terms of  what’s new by history and do a 
good physical examination.- S20 
! Um, I think everybody’s under severe time pressures these days and it 
makes it, it’s um, you need to have a dedicated infrastructure to do good 
Phase I and II studies.- S20 
! Yeah, that’s a very valid question, sometimes I will have a patient who is 
having a serious toxicity and I want to stop the drug and the patient is 
pressuring me to keep on the drug. And you know, if you are going to keep 
them on the drug then maybe you have to under report the toxicity.- S21 
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! No, I don’t, I don’t think so, no, it’s mainly the example I can think of is 
patient’s pressuring me to keep them on a drug when I’m not sure that’s to 
their, you know in their best interest.- S21 
! I guess, I keep coming back to this, but keeping it simple and brief 
because there are a lot of competitors for a trialist’s attention, you know, 
like there are a lot of time constraints and something more simple that 
would be best.- S21 
! On the other hand you don’t want to be paralyzed by uncertainty because 
if you’re in a busy clinic you can only tolerate paralysis for so long [right] 
you have to make some kind of a decision.- S22 
! Well I think you know, they have to make a judgment in a hurry, so there’s 
a concern straight away, they’re on the busy machine in the clinic and they 
have to, you know, somebody puts some form in front of them and they 
kind of, you know, they’ve got two pens, one pen in their left hand and one 
pen in their right hand and they’re hitting the typewriter with their nose and 
looking at the screen and trying to do four things at once and the 
telephone is ringing and so on. It really is a zoo as you know, so they have 
to make hurried decisions, so that’s my one, that’s my number one 
concern.- S22 
! I have seen situations where some pressure, let’s say that the 
pharmaceutical company maybe had a different viewpoint about what was 
said, you know without being specific I’ve certainly seen that. I think most 
people have, most people that deal with pharmaceutical companies realize 
that they’re obviously coming from a certain angle. And that they may 
have a different interpretation, sometimes, I think sometimes they’re right. 
I think, I’m not saying they’re always wrong but certainly they have a 
viewpoint [sure] which they express you know.- S22 
! I think you know, if a patient is sick in a way that taxes the resources of the 
cancer center and the hospital, I think you know, there’s certainly pressure 
not to carry this on beyond what’s reasonable. And you know, that’s, that’s 
understandable and inevitable.- S22 
! Time, the physician’s time.- S23 
! Well it’s the companies they want to get their drugs to market and 
sometimes you get a little pressure from them you know? [to do what?]  
Well to just to confirm yes this is related particularly if it’s nasty, nasty stuff. 
There’s a couple of companies out there that don’t think twice about 
picking up the phone, you know, asking you to review with the physician, 
that’s fine we’ll review it but ultimately we’re not here for the trial. Well 
we’re here for the trials, but we’re here for the patients and so we’re not 
going to cause them any harm if we can help it.- S23 
! Lack of time probably. [just time pressures, yeah, okay that would seem 
reasonable].- S24 
! Yes I guess, um, I was going to say something similar to that, that they 
might be making decisions quickly without really going to source, some 
sort of source or really knowing.- S25 
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! Um, well I find the companies, well they don’t always agree and then ah, 
[with your assessment?] with our assessments. And you see that often in 
safety reports that come through, it’s tends to be always a possible or 
probable assessment when it really may not be necessary. But not a major 
pressure other than they want to know what the causality is you know, with 
that initial, if it’s an SAE for example [yeah] they want to know that right 
away because they have to send that out to other sites. [yeah] So you 
know, that’s the pressure there to sort of um, get that answer quickly. And 
because we don’t want to make that ultimate decision they may be getting 
our assessment initially that might not be the correct one so I guess that 
would be a concern or a pressure for me [yeah] to get the physicians 
ultimate decision on [right]. Because they want the information quickly 
right with an SAE so.- S25 
! Ah, yeah, they could do that for sure, they might phone us, or during 
monitor visit they might um, sort of query it and ask questions about why 
we, thought it was related or not. And then give us their reasons why they 
think it should be different and want us to change it and we might not 
always want to. So there’s, there’s always that happens, usually they 
would speak with the physician, we’d have them speak directly with them 
so they would discuss their reasons for their assessment. But it does 
happen.- S25 
! Ah, none [can you recall a time?] none really, I mean there’s, the only 
pressure that you feel um, is the sort of sense of urgency of, because you 
know you have to fill out the SAE report within 24 hours and all this sort of 
stuff. You may not have all the information and you may make an original, 
you may make an assessment that subsequently you change or becomes 
clearer as time goes on that something else is in fact happening and you 
want to change your mind about something. Which is, which is fine and 
you do, do that but I think that sometimes, I don’t know that you should 
necessarily have to assign the causality right away. I mean I think 
reporting the SAE right away and saying this is what’s happening and 
we’re monitoring the patient and these are the steps we’ve taken. And 
we’ll, you know, as things evolve we’ll let you know what we think actually 
happened, rather than saying yes we think this is study drug related within 
the first 18 hours when you don’t, you may not necessarily have all the 
facts yet.- S26 
! Like I think that whole 24-hour, like I understand that we need to report the 
event but I think the causality part of it should be delayed until after you 
have the facts. And then you can say okay really I think this is you know.- 
S26 
! So anytime they asked for anything to be changed I would leave those 
queries up to him and 9 times out of 10 he would not change them. [oh 
that’s good] Because, but then it gets annoying and then you start to 
second guess and wonder why are they even asking if the investigator is 
ultimately responsible for the data and not some data entry person a 
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million miles away who has no idea what is really going on. Why are they 
second guessing this, what are they really after?- S28 
! Well with smaller drug companies you tend to get more queries about why 
did you assign this as attributed or not attributed? You know, what do you 
think the underlying pathophysiology is? and so you know, smaller drug 
companies particularly when their entire livelihood depends on, on a single 
agent will, will be, will, I don’t know if pressure is the right word but they 
will definitely discuss extensively how and why you’ve chosen that 
something is related.- S30 
 
